

```
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 234733 for detecting SNP TSC0057297.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 234733; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 734 AGAAACAGACACA 745
Db 13 ATAAACATAACA 2
RESULT 564
ABC94294/C
ID ABC94294 standard; DNA; 13 BP.
XX
AC ABC94294;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 94311 for detecting SNP TSC0023541.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 94311; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 734 AGAAACAGACACA 745
Db 13 ATAAACATAACA 2
RESULT 565
ABC06155
ID ABC06155 standard; DNA; 13 BP.
XX
AC ABC06155;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 6146 for detecting SNP TSC0001931.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
```

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 6146; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 10 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGACACA 745

Db 1 AAAAAACATAACA 12

RESULT 566

ABC37605
 ID ABC37605 standard; DNA; 13 BP.

XX AC ABC37605;

XX 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 37622 for detecting SNP TSC0011703.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 37622; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 10 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGACACA 745

Db 1 AAAAAACATAACA 12

RESULT 567

ABF24592
 ID ABF24592 standard; DNA; 13 BP.

XX AC ABF24592;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 124589 for detecting SNP TSC0031161.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 124589; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 0 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACACA 742


```

Db      2 AGGAGAAAGATA 13
RESULT 568
ABF41880/c
ID ABF41880 standard; DNA; 13 BP.
XX AC ABF41880;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 141877 for detecting SNP TSC0035552.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX CS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 141877; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 736 AAACAGAACACC 747
Db 13 AAAAACAACACC 2
RESULT 569
ABF41881
ID ABF41881 standard; DNA; 13 BP.
XX AC ABF41881;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 141878 for detecting SNP TSC0035552.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX CS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 141877; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 736 AAACAGAACACC 747
Db 13 AAAAACAACACC 2

```

```

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 141878; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 736 AAACAGAACACC 747
Db 1 AAAAACAACACC 12
RESULT 570
ABC27868
ID ABC27868 standard; DNA; 13 BP.
XX AC ABC27868;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 27885 for detecting SNP TSC0007856.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.

```


ID	ABF27768 standard; DNA; 13 BP.
XX	
AC	ABF27768;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 127765 for detecting SNP TSC0031989.
XX	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WFI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 127765; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 0 A; 2 C; 4 G; 7 T; 0 U; 0 Other;
Query Match	40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity	83.3%; Pred. No. 5e+02;
Matches 10; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	735 GAAACAGAAAC 746
DB	12 GAAACCGAAAC 1
RESULT 575	
ABF48665	
ID	ABF48665 standard; DNA; 13 BP.
XX	
AC	ABF48665;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 148662 for detecting SNP TSC0037536.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 7 A; 6 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAGACAGAACACC 747
Db 2 AAGACAGAACACC 13

RESULT 578
ABH41119/c
ID ABH41119 standard; DNA; 13 BP.
XX
AC ABH41119;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 241096 for detecting SNP TSC0058805.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 241096; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 4 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAGA 742
Db 12 AAGAGAAAGAGA 1

RESULT 579
ABC67855
ID ABC67855 standard; DNA; 13 BP.
XX
AC ABC67855;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 67872 for detecting SNP TSC0017721.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 67872; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 10 A; 3 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAACCA 745
Db 2 AAAAAACAAACCA 13

RESULT 580
ABC94296/c
ID ABC94296 standard; DNA; 13 BP.
XX
AC ABC94296;
XX
DT 21-FEB-2002 (first entry)

XX PS Claim 1; SEQ ID NO 76072; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAGACAGACACC 747
Db 2 AAGACCTAACACC 13
|||||
|||||

RESULT 583
ABC55567
ID ABC55567 standard; DNA; 13 BP.
XX AC ABC55567;
XX AC ABC55567;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 55584 for detecting SNP TSC0015160.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WC200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 55584; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX CC

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Sequence 13 BP; 11 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACACAGACA 745
Db 1 AAAAAACAAACA 12
|||||
|||||

RESULT 584
ABC07302/c
ID ABC07302 standard; DNA; 13 BP.
XX AC ABC07302;
XX AC ABC07302;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 7293 for detecting SNP TSC0002134.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WC200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 7293; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Sequence 13 BP; 0 A; 0 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACACAGACA 745
Db 12 AAAAAACAAACA 1
|||||
|||||

```

RESULT 585
ABC88808/c
ID ABC88808 standard; DNA; 13 BP.
XX
AC ABC88808;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 88825 for detecting SNP TSC0022318.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 88825; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99889, ABF00010-ABF99889, ABH00010-ABH99889 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 1 C; 4 G; 8 T; 0 U; 0 Other;
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99889, ABF00010-ABF99889, ABH00010-ABH99889 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 1 C; 4 G; 8 T; 0 U; 0 Other;
XX
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred.No.5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACCG 748
Db 12 AACAAAAAACCG 1

RESULT 586
ABF24593/c
ID ABF24593 standard; DNA; 13 BP.
XX
AC ABF24593;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 124590 for detecting SNP TSC0031161.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.

```

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 124590; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99889, ABF00010-ABF99889, ABH00010-ABH99889 and ABT00010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 5 C; 0 G; 7 T; 0 U; 0 Other;
XX
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred.No.5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAGA 742
Db 12 AGGAGAAACAGA 1

RESULT 587
ABF73773/c
ID ABF73773 standard; DNA; 13 BP.
XX
AC ABF73773;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 173770 for detecting SNP TSC0043273.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.

```


XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 173770; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABEC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 13 BP; 2 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
SQ Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 734 AGAAACAGAACCA 745
DB 13 AGAAATAGAAAA 2
RESULT 588
ABH25373
ID ABH25373 standard; DNA; 13 BP.
XX AC ABH25373;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 225350 for detecting SNP TSC0054939.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 225350; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABEC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 13 BP; 10 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
SQ Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 734 AGAAACAGAACCA 745
DB 1 ATAAACAAACCA 12
RESULT 589
ABF56044
ID ABF56044 standard; DNA; 13 BP.
XX AC ABF56044;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 156041 for detecting SNP TSC0039372.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 156041; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABEC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 13 BP; 7 A; 0 C; 5 G; 1 T; 0 U; 0 Other;


```

XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 240237; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABT0010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AACACAGAACACC 747
XX 12 AACACCAATACC 1
XX
XX RESULT 593
XX ABH42948/c
XX ID ABH42948 standard; DNA; 13 BP.
XX
XX AC ABH42948;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 242925 for detecting SNP TSC0000966.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX Oligonucleotide SEQ ID NO 242925 for detecting SNP TSC0000966.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 242925; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABT0010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AACACAGAACACC 747
XX 13 AACACCAATACC 2
XX
XX RESULT 594
XX ABC39716/c
XX ID ABC39716 standard; DNA; 13 BP.
XX
XX AC ABC39716;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 39733 for detecting SNP TSC0012134.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 39733; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010

```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 0 A; 0 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AACAGAACACC 747
 13 AACACAAACCC 2
 Db
 RESULT 595
 ABC64867
 ID ABC64867 standard; DNA; 13 BP.
 AC
 AC ABC64867;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 64884 for detecting SNP TSC0017098.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 64884; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AACAGAACACC 747

Db
 RESULT 596
 ABH29484/c
 ID ABH29484 standard; DNA; 13 BP.
 XX
 AC ABH29484;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 229461 for detecting SNP TSC0055973.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 229461; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 0 A; 1 C; 5 G; 7 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCAGAGAAACA 740
 13 CCAGAGAAACA 2
 Db
 RESULT 597
 ABF82672/c
 ID ABF82672 standard; DNA; 13 BP.
 XX
 AC ABF82672;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 182669 for detecting SNP TSC0045147.

```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 182669; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 736 AAACAGAACACC 747
Db ||||| |||||
12 AAACATAAAACC 1
RESULT 598
ABH40318/c
XX ID ABH40318 standard; DNA; 13 BP.
XX AC ABH40318;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 240295 for detecting SNP TSC0058607.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 182669; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 736 AAACAGAACACC 747
Db ||||| |||||
12 AAACATAAAACC 1
RESULT 598
ABH40318/c
XX ID ABH40318 standard; DNA; 13 BP.
XX AC ABH40318;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 240295 for detecting SNP TSC0058607.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 240296; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 3 G; 10 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 734 AGAAACAGAACCA 745
Db ||||| |||||
13 ACAACAAACAAACA 2
RESULT 599
ABH40319
XX ID ABH40319 standard; DNA; 13 BP.
XX AC ABH40319;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 240296 for detecting SNP TSC0058607.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 240296; 29pp + Sequence Listing; German.
```

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 10 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAACAAGACCA 745
 Db 1 ACAACAAGACCA 12
 RESULT 600
 ABH49233/C
 ID ABH49233 standard; DNA; 13 BP.
 AC ABH49233;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 249210 for detecting SNP TSC0010445.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 249210; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 2 A; 5 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 731 AGGAGAAACACA 742
 Db 13 AGGAGTAATAGA 2
 RESULT 601
 ABH53840/C
 ID ABH53840 standard; DNA; 13 BP.
 XX
 AC ABH53840;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 253817 for detecting SNP TSC0061883.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 253817; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 0 A; 0 C; 3 G; 10 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGAACACC 747
 Db 13 AAACAAACACC 2
 RESULT 602

```
ABC67854/C
ID ABC67854 standard; DNA; 13 BP.
XX AC
XX ABC67854;
XX AC
XX 21-FEB-2002 (first entry)
XX DT
XX 21-FEB-2002 (first entry)
XX DT
XX Oligonucleotide SEQ ID NO 67871 for detecting SNP TSC0017721.
XX DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX KW
XX OS Homo sapiens.
XX OS
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX Claim 1; SEQ ID NO 67871; 29pp + Sequence Listing; German.
XX PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Sequence 13 BP; 0 A; 0 C; 3 G; 10 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 2; Gaps 0;
XX
XX QY 734 AGAACGACGACA 745
XX Db 12 AAAACAAACAA 1
XX
XX RESULT 603
XX ABH19405
XX ID ABH19405 standard; DNA; 13 BP.
XX AC
XX ABH19405;
XX AC
XX 22-FEB-2002 (first entry)
XX DT
XX Oligonucleotide SEQ ID NO 219382 for detecting SNP TSC0008134.
XX DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX KW
XX OS Homo sapiens.
XX OS
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX Claim 1; SEQ ID NO 67871; 29pp + Sequence Listing; German.
XX PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 2; Gaps 0;
XX
XX QY 734 AGAACGACGACA 745
XX Db 12 AAAACAAACAA 1
XX
XX RESULT 603
XX ABH19405
XX ID ABH19405 standard; DNA; 13 BP.
XX AC
XX ABH19405;
XX AC
XX 22-FEB-2002 (first entry)
XX DT
XX Oligonucleotide SEQ ID NO 219382 for detecting SNP TSC0008134.
XX DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX KW
XX OS Homo sapiens.
XX OS
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
```

```
OS Homo sapiens.
XX WO200177384-A2.
XX AC
XX 18-OCT-2001.
XX PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX Claim 1; SEQ ID NO 219382; 29pp + Sequence Listing; German.
XX PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC
XX SQ Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 2; Gaps 0;
XX
XX QY 736 AAACGACGACAC 747
XX Db 2 AAACATAAACCC 13
XX
XX RESULT 604
XX ABH42799
XX ID ABH42799 standard; DNA; 13 BP.
XX AC
XX ABH42799;
XX AC
XX 22-FEB-2002 (first entry)
XX DT
XX Oligonucleotide SEQ ID NO 242776 for detecting SNP TSC0059232.
XX DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX KW
XX OS Homo sapiens.
XX OS
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
```

```

XX DR WPI; 2001-657177/75.
XX CC
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 242776; 29pp + Sequence Listing; German.
XX CC
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AAACAGAACACC 747
XX Db 2 AAACAAAAAACCC 13
XX
XX RESULT 605
XX ABH42949
XX ID ABH42949 standard; DNA; 13 BP.
XX AC
XX AC ABH42949;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 242926 for detecting SNP TSC0000966.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX CC
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
XX CC designed to detect single-nucleotide polymorphisms and cytosine
XX CC methylation status.
XX PS Claim 1; SEQ ID NO 242926; 29pp + Sequence Listing; German.
XX CC
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;
XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AAACAGAACACC 747
XX Db 2 AAACAAAAAACCC 13
XX
XX RESULT 606
XX ABC76053
XX ID ABC76053 standard; DNA; 13 BP.
XX AC
XX AC ABC76053;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 76070 for detecting SNP TSC0019478.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX CC
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
XX CC designed to detect single-nucleotide polymorphisms and cytosine
XX CC methylation status.
XX PS Claim 1; SEQ ID NO 76070; 29pp + Sequence Listing; German.
XX CC
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 5e+02;

```


Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACACAGAACCC 747
|||||
Db 2 AACCCGACACC 13

RESULT 607
ABCS9861
ID ABCS9861 standard; DNA; 13 BP.
XX
AC ABCS9861;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 59878 for detecting SNP TSC0016011.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 59878; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 728 GCCAGGAGAAC 739
|||||
Db 2 GCCACGAAAC 13

RESULT 608
ABC39717
ID ABC39717 standard; DNA; 13 BP.
XX
AC ABC39717;
XX

DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 39734 for detecting SNP TSC0012134.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 39734; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACACAGAACCC 747
|||||
Db 1 AACACAAACC 12

RESULT 609
ABF24768/c
ID ABF24768 standard; DNA; 13 BP.
XX
AC ABF24768;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 124765 for detecting SNP TSC0031132.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.

```

XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 124765; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 2 G; 10 T; 0 U; 0 Other;
XX CC Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX CC Best Local Similarity 83.3%; Pred. No. 5e+02;
XX CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 734 AGAAACAGACCA 745
DB 12 ATAAACAAACA 1
|||||
RESULT 610
ABH19991
ID ABH19991 standard; DNA; 13 BP.
XX AC ABH19991;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 219968 for detecting SNP TSC0053525.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 149922; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
XX CC Query Match 40.0%; Score 8.8; DB 1; Length 13;
XX CC Best Local Similarity 83.3%; Pred. No. 5e+02;
XX CC Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 737 AACGACACCG 748
DB 2 AACACAACTCCG 13
|||||
RESULT 611
ABF49925
ID ABF49925 standard; DNA; 13 BP.
XX AC ABF49925;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 149922 for detecting SNP TSC0037827.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 149922; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

```

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACAGAACACC 747
|||||
Db 1 AAAAAAACATC 12

RESULT 612
ABH29483
ID ABH29483 standard; DNA; 13 BP.
XX AC
XX ABH29483;
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 229460 for detecting SNP TSC0055973.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 229460; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 4 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 729 CCAGGAGAACCA 740
|||||
Db 1 CCACGATAAACCA 12

RESULT 613
ABF59007
ID ABF59007 standard; DNA; 13 BP.

XX AC
XX ABF59007;
XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 159004 for detecting SNP TSC0040037.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 159004; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 8 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAACAGAACCA 745
|||||
Db 1 AAAAAACCGAACCA 12

RESULT 614
ABH36001/C
ID ABH36001 standard; DNA; 13 BP.

XX AC
XX ABH36001;
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 235978 for detecting SNP TSC0005750.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 235978; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 0 A; 7 C; 0 G; 6 T; 0 U; 0 Other;
 XX Query Match 40.0%; Score 8.8; DB 1; Length 13;
 XX Best Local Similarity 83.3%; Pred. No. 5e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 731 AGGAGAACACAGA 742
 DB 13 AGGAGGAAGAGA 2
 RESULT 615
 ABC69696
 ID ABC69696 standard; DNA; 13 BP.
 XX AC ABC69696;
 XX 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 69713 for detecting SNP TSC0018143.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 69713; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 8 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
 XX Query Match 40.0%; Score 8.8; DB 1; Length 13;
 XX Best Local Similarity 83.3%; Pred. No. 5e+02;
 XX Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 731 AGGAGAACACAGA 742
 DB 2 AGGAGGAAGAGA 13
 RESULT 616
 ABC55566/C
 ID ABC55566 standard; DNA; 13 BP.
 XX AC ABC55566;
 XX 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 55583 for detecting SNP TSC0015160.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 55583; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 0 A; 0 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 10; Conservative 0; Indels 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAACCA 745
Db 13 AAAAAACAAACCA 2
|||||

RESULT 617

ABC31753
ID ABC31753 standard; DNA; 13 BP.

XX AC ABC31753;

XX DT 20-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 31770 for detecting SNP TSC0009898.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 31770; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 10; Conservative 0; Indels 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAACCA 745
Db 2 AAAAAACAAACCA 13
|||||

RESULT 618
ABH02514/c
ID ABH02514 standard; DNA; 13 BP.

XX AC ABH02514;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 202491 for detecting SNP TSC0049770.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 202491; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 10; Conservative 0; Indels 2; Indels 0; Gaps 0;

QY 736 AAACAGAACACC 747
Db 12 AAAAAACAAACACC 1
|||||

RESULT 619

ABF82675
ID ABF82675 standard; DNA; 13 BP.

XX ABF82675;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 182672 for detecting SNP TSC0045147.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 182672; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 9 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGACACACC 747
 Db 2 AAACAGACACACC 13
 RESULT 620
 ABH49232
 ID ABH49232 standard; DNA; 13 BP.
 XX
 AC ABH49232;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 249209 for detecting SNP TSC0010445.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX

PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 249209; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 731 AGGAGAAACAGA 742
 Db 1 AGGAGTAATAGA 12
 RESULT 621
 ABC23144/c
 ID ABC23144 standard; DNA; 13 BP.
 XX
 AC ABC23144;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 23161 for detecting SNP TSC0004665.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX

QY 736 AACACAGACACC 747
 Db 12 AACACACATC 1
 RESULT 624
 ABH42936/c
 ID ABH42936 standard; DNA; 13 BP.
 XX
 AC ABH42936;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 242913 for detecting SNP TSC0000966.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 242913; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACAGACACC 747
 Db 13 AACACACTAC 2
 RESULT 625
 ABC94295
 ID ABC94295 standard; DNA; 13 BP.
 XX
 AC ABC94295;
 XX
 DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 94312 for detecting SNP TSC0023541.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 94312; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACAGACACC 747
 Db 2 AACACATACACC 13
 RESULT 626
 ABC27869/c
 ID ABC27869 standard; DNA; 13 BP.
 XX
 AC ABC27869;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 27866 for detecting SNP TSC0007856.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 27886; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
CC
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 727 TGCACGAGAGA 738
DB 13 TGGTAGAGAAA 2
RESULT 627
ABC31752/c
ID ABC31752 standard; DNA; 13 BP.
XX ABC31752;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 31769 for detecting SNP TSC0009898.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 31769; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
CC
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 734 AGAAACAGAAC 745
DB 12 AAAACATAC 1
RESULT 628
ABC32872/c
ID ABC32872 standard; DNA; 13 BP.
XX ABC32872;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 32889 for detecting SNP TSC0010331.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 32889; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 2 G; 10 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAACAAGAACCA 745

Db 12 AAAAAAACAACA 1

RESULT 629

ABC88809
ID ABC88809 standard; DNA; 13 BP.

XX AC ABC88809;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 88826 for detecting SNP TSC0022318.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 88826; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 8 A; 4 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACAGAACACCG 746

Db 2 AAAAAAACCAG 13

RESULT 630

ABF30659
ID ABF30659 standard; DNA; 13 BP.

XX AC ABF30659;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 130656 for detecting SNP TSC0032625.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 130656; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAACAAGAACCA 745

Db 2 AAAAAAACAACA 13

RESULT 631

ABF39593
ID ABF39593 standard; DNA; 13 BP.

XX AC ABF39593;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 139590 for detecting SNP TSC0034952.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 139590; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, AEF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 5 C; 2 G; 0 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCAGCGGAGAACCA 740
DB 1 CCAGCGGAGAACCA 12
RESULT 632
ABH19404/C
ID ABH19404 standard; DNA; 13 BP.
AC ABH19404;
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 219381 for detecting SNP TSC0008134.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 219381; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, AEF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 736 AAACAGAACACC 747
DB 12 AAACATATAAAC 1
RESULT 633
ABH19406/C
ID ABH19406 standard; DNA; 13 BP.
AC ABH19406;
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 219383 for detecting SNP TSC0008134.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 219383; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AAACAGAACACC 747
 Db 12 AAACACAAACC 1
 ||||| |||||
 ||||| |||||

RESULT 634
 ABH33791/C
 ID ABH33791 standard; DNA; 13 BP.
 XX AC ABH33791;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 233768 for detecting SNP TSC0057055.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 233768; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 1 A; 4 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;

Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAACAGAACCA 745
 Db 12 AGAACGGAAGA 1
 ||||| |||||
 ||||| |||||

RESULT 635
 ABH10381/C
 ID ABH10381 standard; DNA; 13 BP.
 XX AC ABH10381;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 210358 for detecting SNP TSC0051372.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 210358; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAACAGAACCA 745
 Db 13 AGAAAAAGAAAA 2
 ||||| |||||
 ||||| |||||

RESULT 636
 ABH43253
 ID ABH43253 standard; DNA; 13 BP.
 XX AC ABH43253;

XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 243230 for detecting SNP TSC0059331.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PS WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 243230; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -REC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SE Sequence 13 BP; 8 A; 4 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACAGACACACC 747
DB 2 AACCCGACCAAC 13
RESULT 637
ID AAF92654 standard; DNA; 13 BP.
AC AAF92654;
XX DT 16-MAY-2001 (first entry)
XX DE HLA-DR typing probe #34.
XX KW Human; leukocyte antigen; HLA; typing; sequence specific probe; SSOPH;
XX KW ss.
XX OS Homo sapiens.
XX PN US6194147-B1.
XX PD 27-FEB-2001.

XX PF 30-DEC-1997; 97US-00000805.
XX PR 27-JUN-1990; 90US-00544218.
XX PR 08-APR-1993; 93US-00057957.
XX PA (BLOO-) BLOOD CENT RES FOUND INC.
XX PI Baxter-Lowe LA, Gorski JA;
XX PS WPI; 2001-217923/22.
XX PT Human leukocyte antigen typing by amplifying a sample followed by
XX PT sequence specific oligonucleotide hybridization with labeled
XX PT oligonucleotide probes that hybridize with a series of known control DNA
XX PT sequences.
XX PS Disclosure; Col 11-14; 16pp; English.
XX CC The present invention relates to human leukocyte antigen (HLA) typing.
XX CC The method involves detecting polymorphic residues by sequence specific
XX CC oligonucleotide probe hybridization (SSOPH) with labeled oligonucleotide
XX CC probes
XX SE Sequence 13 BP; 4 A; 3 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 40.0%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 729 CCAGGAGAAACA 740
DB 2 CCTGGAGAGACA 13
RESULT 638
ID AAS17271/c standard; cDNA; 13 BP.
XX AC AAS17271;
XX DT 25-FEB-2002 (first entry)
XX DE Exon1-exon2 junction of wild type mouse agouti cDNA clone.
XX KW Murine; agouti; fatty acid synthetase; intracellular calcium level;
XX KW diabetes; neoplasm; hyperinsulinaemia; obesity; cancer; tumour;
XX KW anorectic; antidiabetic; cytostatic; mouse; ss.
XX OS Mus musculus.
XX PN US6310034-B1.
XX PD 30-OCT-2001.
XX PF 03-MAR-1998; 98US-00034088.
XX PR 21-MAY-1993; 93US-00064385.
XX PA (UTBA-) UT-BAITELLE LLC.
XX PI Woychik RP, Bultman SJ, Michaud EJ;
XX PS WPI; 2002-040243/05.
XX PT New mammalian agouti polypeptide useful to identify molecules that
XX PT control agouti polypeptide and as immunogen to produce antibodies useful
XX PT for treating, preventing diabetes, hyperamylinemia, neoplasms, obesity.
XX PS Example 1; Fig 9B; 140pp; English.
XX CC The present invention relates to the isolation of murine and human agouti
XX CC polypeptides and the polynucleotides encoding them. Also given are

CC methods, compositions and kits for identifying compounds which are
 CC inhibitors of agouti activity, and for altering fatty acid synthetase
 CC activity and intracellular calcium levels in transformed cells. The
 CC sequences and methods of the invention are useful in the detection and
 CC treatment of diabetes, neoplasms, hyperinsulinaemia, obesity, and various
 CC forms of cancer including tumours. The present sequence representing the
 CC exon1-exon2 junction of the wild type mouse agouti cDNA clone is compared
 CC to the same junction in the agouti Ay (lethal yellow) cDNA clone
 XX
 SQ Sequence 13 BP; 0 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAGCAGACCA 745
 DB 13 AGAAGCAGACCA 2
 ||||| |||||
 30-APR-2003 (first entry)
 XX Wild-type human agouti cDNA fragment.
 XX Human; ss; agouti; chromosome 20; black pigment; yellow pigment;
 KW agouti coat colour; obesity; non-insulin dependent diabetes;
 KW obesity-associated diabetes; intracellular calcium level;
 KW hyperinsulinaemia; hyperglycaemia; fatty acid synthetase; metabolism;
 KW adipocyte cell; diabetes; hyperamylinemia; cancer; gene therapy;
 KW cycostatic; antidiabetic; anorectic; intron/exon structure; Ay.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT misc_feature 7..8
 FT /tag= a
 FT /note= "DNA break point"
 XX
 XX US2002151463-A1.
 XX
 XX 17-OCT-2002.
 XX
 XX 12-FEB-2001; 2001US-00781811.
 XX
 XX 21-MAY-1993; 93US-00064385.
 XX
 XX 03-MAR-1998; 98US-00034088.
 XX
 XX (WOYC/) WOYCHIK R P.
 XX (BULT/) BULTMAN S J.
 XX (MICH/) MICHAUD E J.
 XX
 XX Woychik RP, Bultman SJ, Michaud EJ;
 XX
 XX WPI; 2003-198329/19.
 XX
 XX New polynucleotide comprising an isolated agouti gene, useful for
 PT diagnosing, preventing and/or treating diabetes, hyperamylinemia, cancer
 PT or obesity.
 XX
 XX Example 1; Fig 9B; 152pp; English.
 XX
 XX The invention discloses a polynucleotide comprising an isolated agouti
 CC gene and the polypeptide it encodes. The agouti locus, in chromosome 20,
 CC regulates the differential production of black and yellow pigment
 CC granules that give rise to the agouti coat colour of mice. Obesity and
 CC non-insulin dependent diabetes are genetically inherited disorders in
 CC humans and mice. The obesity-associated diabetes of the mutant agouti

CC alleles bear a similarity to non-insulin dependent diabetes in obese
 CC humans. Also disclosed are methods for detecting proteins which interact
 CC with the agouti polypeptide, for generating an immune response, for
 CC increasing or decreasing the intracellular calcium level in a cell, for
 CC promoting obesity, hyperinsulinaemia or hyperglycaemia in an animal and
 CC for altering fatty acid synthetase activity in a cell or increasing the
 CC metabolism in an adipocyte cell. The polynucleotide is useful in
 CC detecting and cloning of the gene in which expression of the gene product
 CC correlates with the development of diabetes, hyperamylinemia, cancer and
 CC obesity in animals, in detecting the agouti gene and homologous DNA
 CC sequences, in detecting mutations in the gene, in early detection of
 CC animals at risk of developing the diseases and in early treatment (e.g.
 CC gene therapy) of afflicted animals. The antibody is used in isolating and
 CC regulating the activity of agouti proteins. The sequence presented is the
 CC wild-type human agouti cDNA fragment showing the DNA break point at the
 CC exon 1/exon 2 boundary compared to the agouti Ay mutation cDNA sequence
 CC (ABX11333) and the Ay mutation genomic DNA sequence (ABX11334)
 XX
 SQ Sequence 13 BP; 0 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 40.0%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 5e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAGCAGACCA 745
 DB 13 AGAAGCAGACCA 2
 ||||| |||||
 RESULT 640
 ADE14088
 ID ADE14088 standard; DNA; 13 BP.
 XX
 AC ADE14088;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Optineurin promoter motif, repeat element or regulatory region #197.
 XX
 XX Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
 KW SNP; glaucoma; progressive ocular hypertensive disorder;
 KW glaucoma related disorder; motif; repeat element; regulatory region.
 XX
 OS Homo sapiens.
 XX
 XX US2003190617-A1.
 XX
 XX 09-OCT-2003.
 XX
 XX 06-MAR-2002; 2002US-00091281.
 XX
 XX 06-MAR-2002; 2002US-00091281.
 XX
 XX (SIEE/) SI E.
 XX (RAYM/) RAYMOND V.
 XX (MORI/) MORISSETTE J.
 XX
 XX Raymond V, Morissette J, Si E;
 XX
 XX WPI; 2003-864168/80.
 XX
 XX New nucleic acid sequences of the optineurin gene are useful to detect
 PT polymorphisms particularly single nucleotide polymorphisms in the
 PT optineurin promoter to diagnose, prognose and treat glaucoma and related
 PT disorders.
 XX
 XX Claim 11; SEQ ID NO 199; 159pp; English.
 XX
 XX The invention relates to an isolated nucleic acid (N1) comprising at
 CC least 20 but not more than 1500 consecutive nucleotides of the optineurin
 CC promoter appearing as ADE13890. Also included are the optineurin promoter
 CC operably linked to a heterologous nucleic acid, a nucleic acid capable of
 CC detecting a single nucleotide polymorphism (SNP) in the optineurin

CC promoter, a host cell comprising the promoter operably linked to a
CC heterologous sequence, diagnosing or prognosing glaucoma in a sample
CC obtained from a cell or bodily fluid (comprising detecting a polymorphism
CC in a promoter region of the optineurin gene, associated with a glaucoma
CC phenotype), detecting a SNP sequence variation in a sample containing
CC DNA, detecting the presence of an optineurin promoter sequence variation
CC in a sample containing DNA, determining the presence or increased
CC susceptibility to glaucoma or to a progressive ocular hypertensive
CC disorder resulting in loss of visual field in a patient (or the severity
CC or progression of glaucoma in a patient, comprising providing
CC amplification reaction primers that direct amplification of a selected
CC nucleic acid region containing the variation within the optineurin
CC promoter and amplifying the DNA) and detecting a polymorphism (comprising
CC obtaining a sample containing human genomic DNA, providing a nucleic acid
CC capable of detecting a SNP located within an optineurin promoter, and
CC detecting the polymorphism). The invention is used to diagnose and
CC prognose glaucoma and also to treat glaucoma related disorders. The
CC present sequence is an optineurin promoter motif, repeat element or
CC putative regulatory region.
XX
SQ Sequence 13 BP; 6 A; 2 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 40.0%; Score 9.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 5e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAACAGACAC 746
Db 2 GAAGGGAACAC 13

RESULT 641
ABF45517/G
ID ABF45517 standard; DNA; 13 BP.
XX
AC ABF45517;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 145514 for detecting SNP TSC0036638.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 145514; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and AB10010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and AB10010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 1 Other;

Query Match 39.1%; Score 8.6; DB 1; Length 13;
Best Local Similarity 88.9%; Pred. No. 5.4e+02;
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAAC 739
Db 9 AGGAGAAAY 1

RESULT 642
ABF45516
ID ABF45516 standard; DNA; 13 BP.
XX
AC ABF45516;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 145513 for detecting SNP TSC0036638.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 145513; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and AB10010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 1 Other;

Query Match 39.1%; Score 8.6; DB 1; Length 13;
Best Local Similarity 88.9%; Pred. No. 5.4e+02;
Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAC 739
 Db 5 AGGAGAAAY 13

RESULT 643
 ID ABF48268 standard; DNA; 13 BP.
 XX AC ABF48268;
 XX DT 21-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 148265 for detecting SNP TSC0037435.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX DT 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 148265; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 1 Other;
 Query Match 39.1%; Score 8.6; DB 1; Length 13;
 Best Local Similarity 88.9%; Pred. No. 5.4e+02;
 Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAC 739
 Db 5 AGGAGAAAY 13

RESULT 644
 ID ABF16962 standard; DNA; 13 BP.
 XX AC ABF16962;
 XX DT 21-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 148266 for detecting SNP TSC0037435.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PR 06-APR-2001; 2001WO-IB000713.

DE Oligonucleotide SEQ ID NO 116959 for detecting SNP TSC0029279.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX DT 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 116959; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 1 Other;
 Query Match 39.1%; Score 8.6; DB 1; Length 13;
 Best Local Similarity 88.9%; Pred. No. 5.4e+02;
 Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAC 739
 Db 5 AGGAGAAAY 13

RESULT 645
 ID ABF48269 standard; DNA; 13 BP.
 XX AC ABF48269;
 XX DT 21-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 148266 for detecting SNP TSC0037435.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PR 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PR Claim 1; SEQ ID NO 148266; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 1 Other;
XX
XX Query Match 39.1%; Score 8.6; DB 1; Length 13;
XX Best Local Similarity 88.9%; Pred. No. 5.4e+02;
XX Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 731 AGGAGAAAC 739
XX Db | | | | | | | | | |
XX 9 AGGAGAAAY 1
XX
XX RESULT 646
XX ABF16963/C
XX ID ABF16963 standard; DNA; 13 BP.
XX AC ABF16963;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 116960 for detecting SNP TSC0029279.
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 116960; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 1 Other;
XX
XX Query Match 39.1%; Score 8.6; DB 1; Length 13;
XX Best Local Similarity 88.9%; Pred. No. 5.4e+02;
XX Matches 8; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 731 AGGAGAAAC 739
XX Db | | | | | | | | | |
XX 9 AGGAGAAAY 1
XX
XX RESULT 647
XX AAL37783
XX ID AAL37783 standard; RNA; 13 BP.
XX AC AAL37783;
XX DT 05-AUG-2002 (first entry)
XX DE 5' conserved RNA region of wild-type influenza B virus.
XX CYTOSTATIC; antiviral; tumour associated antigen; TAA; dendritic cell;
XX virus-associated antigen; VAA; recombinant influenza virus; vaccine;
XX viral infection; immune; wild-type; influenza B virus; ss.
XX OS Influenza virus.
XX PN EP1201760-A1.
XX PD 02-MAY-2002.
XX PF 30-OCT-2000; 2000EP-00123687.
XX PR 30-OCT-2000; 2000EP-00123687.
XX PA (ARTE-) ARTEMIS PHARM GMBH.
XX PI Schuler G, Hobom G, Steinkasserer A, Strobel I, Grassmann R;
XX WPI; 2002-418777/45.
XX PT Expressing tumor or viral associated antigens by dendritic cells, used
XX for treating tumors or viral infections, comprises using recombinant
XX influenza virus containing nucleic acid encoding the antigens.
XX PS Disclosure; Page 6; 33pp; English.
XX
XX The invention relates to a method for the expression of tumour associated
CC antigens (TAA) or virus-associated antigens (VAA) by dendritic cells
CC comprising: preparing a recombinant influenza virus containing a
CC nucleotide sequence coding for the TAA or VAA; and infecting dendritic
CC cells with the recombinant virus. The method is used for expressing TAA
CC or VAA in dendritic cells. The cells are used for preparing a medicament
CC for treating tumours or viral infections. A vaccine can be created by
CC using dendritic cells presenting tumour antigens to induce an immune
CC response. This polynucleotide sequence represents a 5' conserved RNA
CC region of the wild-type influenza B virus of the invention
XX

SQ Sequence 13 BP; 5 A; 1 C; 2 G; 0 T; 1 U; 4 Other;
Query Match 39.1%; Score 8.6; DB 1; Length 13;
Best Local Similarity 72.7%; Pred. No. 5.4e+02;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
|||:||||:
Db 1 AGUAGWAACAR 11

RESULT 648
ID ABQ75466 standard; RNA; 13 BP.
XX AC ABQ75466;
XX 07-NOV-2002 (first entry)
XX Influenza virus B 5' conserved region SEQ ID NO:8.
XX Influenza virus; transcription; replication; RNA polymerase; vaccine;
KW gene therapy; cytostatic; anti-HIV; hepatotropic; antiinflammatory;
KW immunomodulator; virucide; infectious disease; ss.
XX Influenza virus.
XX WO200264757-A2.
XX 22-AUG-2002.
XX 07-FEB-2002; 2002WO-EP001257.
XX 09-FEB-2001; 2001EP-00103060.
XX (ARTE-) ARTEMIS PHARM GMBH.
XX Hobom G, Menke A;
XX WPI; 2002-657594/70.
XX New human influenza virus comprising an RNA-sequence encoding a modified
PT RNA-polymerase, useful for preparing agents for therapeutic and
PT prophylactic vaccination, or treating a growing tumor or a chronic
PT infectious disease.
XX Disclosure; Page 16; 172pp; English.

CC The present invention describes a human influenza virus (I) comprising an
CC RNA-sequence encoding a modified RNA-polymerase that differs from the
CC wild-type RNA-polymerase of the human influenza virus in that at least 1
CC of the amino acid residues distinguishing the wild-type RNA-polymerase of
CC the human influenza virus from FV Bratislava RNA-polymerase has been
CC replaced with the corresponding amino acid residue(s) as present in FV
CC Bratislava RNA-polymerase. (I) has virucide, cytostatic, anti-HIV,
CC hepatotropic, antiinflammatory and immunomodulator activities and can be
CC used in gene therapy and vaccines. The influenza virus is useful for
CC preparing agents for: (a) gene transfer into cells, preferably into
CC mammalian cells, particularly into human cells, by viral infection; (b)
CC gene transfer into antigen-presenting cells, and the use of the obtained
CC product for ex vivo immunotherapy; in vivo somatic gene therapy; (c)
CC vaccination, including therapeutic and prophylactic vaccination; (c)
CC eliciting an immune response, including the induction of a T-cell
CC response; (d) treating a growing tumour or a chronic infectious disease;
CC (e) immunotherapy, preferably for autologous immunotherapy; (f) transfer
CC and expression of foreign genes into cells infected by such viruses; or
CC (g) transfer and expression of RNA molecules into cells infected by such
CC viruses, preferably the RNA molecules to be expressed are antisense
CC sequences or double-strand sequences relative to the target cellular mRNA
CC molecules, and/or the agent is suitable for sequence-specific gene
CC silencing, preferably by antisense RNA or RNA interference mechanisms
CC such as ribozyme cleavages of target RNAs. The recombinant viruses can be
CC made for use in vaccines against HIV, hepatitis B or C virus, herpes

CC viruses or papilloma viruses. The present sequence represents a 5'
CC conserved region of a wild type influenza virus, given in the
CC exemplification of the present invention
XX Sequence 13 BP; 5 A; 1 C; 2 G; 0 T; 1 U; 4 Other;
SQ Query Match 39.1%; Score 8.6; DB 1; Length 13;
Best Local Similarity 72.7%; Pred. No. 5.4e+02;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
|||:||||:
Db 1 AGUAGWAACAR 11

RESULT 649
ID ABK15502 standard; RNA; 13 BP.
XX AC ABK15502;
XX 08-MAY-2002 (first entry)
XX Wild type influenza B, 5' conserved region.
XX Influenza B; tandem RNA segment; TRS; gene expression; influenza;
KW vaccine; somatic gene therapy; expression vector; immunotherapy;
KW autologous immunotherapy; gene silencing; ss.
XX Influenza virus.
XX EP1174514-A1.
XX 23-JAN-2002.
XX 20-JUL-2000; 2000EP-00115626.
XX 20-JUL-2000; 2000EP-00115626.
XX (ARTE-) ARTEMIS PHARM GMBH.
XX Hobom G, Menke A, Meyer-Rogge S;
XX WPI; 2002-156694/21.
XX Recombinant influenza virus for transfer and expression of foreign genes
PT and RNA molecules into cells and for preventing, treating influenza, has
PT bisclonronic viral RNAs coding for two genes in tandem arrangement.
XX Disclosure; Page 6; 39pp; English.

CC The invention describes a recombinant influenza virus (I), stable in the
CC absence of any helper virus, that has a viral RNA segment being a
CC bisclonronic RNA molecule coding for two genes in tandem arrangement
CC (tandem RNA segment, TRS). (I) is useful for expression of incorporated
CC foreign gene(s) and RNA molecules in cells. (I), preferably a recombinant
CC influenza A virus is useful for: preventing and/or treating influenza,
CC and for preparing a medicament for vaccination purposes; somatic gene
CC therapy, and as immunogen for inducing antibodies; as an expression
CC vector for producing proteins or glycoproteins; preparing agents for
CC somatic gene therapy; immunotherapy, preferably autologous immunotherapy;
CC transfer and expression of foreign genes and RNA molecules into cells
CC infected by such viruses, where the RNA molecules to be expressed include
CC antisense or double-stranded sequences relative to the target cell
CC cellular mRNA molecules, and/or the agent is suitable for sequence-
CC specific gene silencing, preferably by antisense RNA or RNA interference
CC mechanisms. (I) gives high-yield expression for foreign genes. This
CC sequence represents the 5' conserved region of influenza B virus,
CC described in the method of the invention
XX Sequence 13 BP; 5 A; 1 C; 2 G; 0 T; 1 U; 4 Other;
SQ Query Match 39.1%; Score 8.6; DB 1; Length 13;

DT 10-APR-2000 (first entry)
XX Human dendritic cell SAGE tag, SEQ ID NO:331.
DE
XX
XX SAGE tag; serial analysis of gene expression; antigen-presenting cell;
KW APC; monocyte-derived dendritic cell; differential gene expression;
KW immunostimulatory cofactor; costimulatory factor; CTL;
KW cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.
XX
XX Homo sapiens.
XX
XX WO9965924-A2.
XX
XX 23-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US013800.
XX
XX 19-JUN-1998; 98US-0089833P.
XX 19-JUN-1998; 98US-0089844P.
XX 19-JUN-1998; 98US-0089853P.
XX 19-JUN-1998; 98US-0089878P.
XX 19-JUN-1998; 98US-0089991P.
XX 19-JUN-1998; 98US-0089992P.
XX 19-JUN-1998; 98US-0089993P.
XX 19-JUN-1998; 98US-0089994P.
XX 19-JUN-1998; 98US-0089997P.
XX 19-JUN-1998; 98US-0089999P.
XX 19-JUN-1998; 98US-0090000P.
XX 19-JUN-1998; 98US-0090003P.
XX 19-JUN-1998; 98US-0090006P.
XX 19-JUN-1998; 98US-0090009P.
XX 19-JUN-1998; 98US-0090040P.
XX 19-JUN-1998; 98US-0090041P.
XX 19-JUN-1998; 98US-0090042P.
XX 19-JUN-1998; 98US-0090043P.
XX 19-JUN-1998; 98US-0090044P.
XX 19-JUN-1998; 98US-0090045P.
XX 19-JUN-1998; 98US-0090047P.
XX 19-JUN-1998; 98US-0090048P.
XX 19-JUN-1998; 98US-0090072P.
XX 19-JUN-1998; 98US-0090076P.
XX 19-JUN-1998; 98US-0090077P.
XX 19-JUN-1998; 98US-0090078P.
XX 19-JUN-1998; 98US-0090079P.
XX 19-JUN-1998; 98US-0090080P.
XX 08-DEC-1998; 98US-0111715P.
XX
XX (GENZ) GENZYME CORP.
XX (ROBE/) ROBERTS B L.
XX (SHAN/) SHANKARA S.
XX
XX Roberts BL, Shankara S;
XX
XX WPI; 2000-106077/09.
XX
XX Isolated polynucleotides differentially expressed in antigen-presenting
XX cells, useful in gene vaccines against cancer.
XX
XX Claim 1; Page 73; 130pp; English.
XX
XX Sequences AA277573-279709 represent SAGE (serial analysis of gene
XX expression) tags used to identify mRNA transcripts encoding
XX immunostimulatory cofactor proteins which are preferentially or
XX differentially expressed in monocyte-derived dendritic cells compared
XX with monocytes. Some of the transcripts correspond to known genes or ESTs
XX (expressed sequence tags) which were previously unknown to be
XX preferentially or differentially expressed in dendritic cells, while
XX other transcripts correspond to novel genes. Antigen-presenting cell
XX (APC)-associated costimulatory factors play an important role in the
XX activation of the cytotoxic immune response, particularly against tumour
XX cells. Tumour antigen presentation via the MHC (major histocompatibility
XX complex) and subsequent recognition by T-cell receptors is alone
XX insufficient to activate a robust cytotoxic immune response that can lyse

CC the tumour cells, immunostimulatory cofactors also being required for
CC efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid
CC sequences identified using the SAGE tags have several potential uses.
CC They may be used in vaccines to induce an immune response, particularly
CC against a tumour antigen; to modulate the genotype of an APC; to screen
CC for agents that modulate expression of differentially expressed genes in
CC an APC; and as hybridisation probes/amplification primers for the
CC diagnosis, prognosis and monitoring of diseases related to abnormal
CC expression of these genes. Detection of the dendritic cell differentially
CC expressed genes, or of their encoded proteins, can be used to identify
CC cells as belonging to the monocyte lineage. Cells containing these genes
CC can be used in active immunotherapy (or to stimulate production of a
CC population of antigen-specific effector cells) and vectors containing
CC them are used in gene therapy. Co-administration of tumour antigens and
CC APC-associated costimulatory factors ensures adequate antigen
CC presentation to endogenous APCs and upregulates the APCs for the
CC presentation of co-stimulatory signals, migration to T cell-rich sites,
CC secretion of T cell growth factors and secretion of chemokines for
CC recruitment of immune effector cells
XX
XX Sequence 10 BP; 1 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 731 AGGAGAAACA 740
Db 10 AGGATAAACA 1
|||||
RESULT 654
AAZ81993
ID AAZ81993 standard; DNA; 10 BP.
XX
XX AAZ81993;
XX
XX 07-APR-2000 (first entry)
XX
XX Metastatic breast tumour cell upregulated transcript tag #1227.
XX
XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
KW antimetastatic; vaccine; diagnosis; ss.
XX
XX Homo sapiens.
XX
XX WO9965928-A2.
XX
XX 23-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US013647.
XX
XX 19-JUN-1998; 98US-0089853P.
XX 19-JUN-1998; 98US-0089997P.
XX 19-JUN-1998; 98US-0090039P.
XX 19-JUN-1998; 98US-0090040P.
XX 19-JUN-1998; 98US-0090041P.
XX
XX (GENZ) GENZYME CORP.
XX (ROBE/) ROBERTS B L.
XX (SHAN/) SHANKARA S.
XX
XX Roberts BL, Shankara S;
XX
XX WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic and
XX non-metastatic breast cancer cells, useful for diagnosis, prevention and
XX treatment of cancer.
XX
XX Claim 1; Page 91; 219pp; English.
XX

AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts that are preferentially transcribed in the metastatic breast tumour tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942 to AAZ86677 represent tags corresponding to distinct transcripts that are preferentially transcribed in the primary or non-metastatic breast tumour tissue (i.e. are downregulated in metastatic breast tumour cells). These transcripts can be used for diagnosis, prognosis, monitoring and treatment of breast cancer, particularly where metastatic. Diagnosis is by standard immunoassays or hybridisation/amplification reactions. Compounds that modulate expression of the transcripts are potentially useful for treatment of (metastatic) breast cancer, while promoters from the transcripts are used to direct expression, in selected cell types, of e.g. therapeutic genes (also ribozymes or antisense sequences), particularly an antigen-encoding sequence for use in gene or cell-based vaccines. Polypeptides encoded by the transcripts are also useful in vaccines; for diagnosing breast cancer and for raising specific antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic agents. Host cells that produce the polypeptides can be used to expand and isolate populations of educated, antigen-specific immune effector cells, e.g. cytotoxic T lymphocytes, and these used for adoptive immunotherapy.

Sequence 10 BP; 3 A; 3 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 727 TGCCAGGAGCA 736
|||||
DB 1 TGCCAGGACA 10

RESULT 655
AAZ80828/c
ID AAZ80828 standard; DNA; 10 BP.

AC AAZ80828;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #62.

KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;

KW non-metastatic breast tumour tissue; gene therapy; anticancer;

KW antimetastatic; vaccine; diagnosis; ss.

OS Homo sapiens.

PN WO9965928-A2.

PD 23-DEC-1999.

PF 18-JUN-1999; 99WO-US013647.

PR 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089997P.

PR 19-JUN-1998; 98US-0090039P.

PR 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.

PA (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.

PA (SHAN/) SHANKARA S.

PI Roberts BL, Shankara S;

XX WPI; 2000-106079/09.

Isolated polynucleotides differentially expressed between metastatic and non-metastatic breast cancer cells, useful for diagnosis, prevention and treatment of cancer.

PS Claim 1; Page 59; 219pp; English.
XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts that are preferentially transcribed in the metastatic breast tumour tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942 to AAZ86677 represent tags corresponding to distinct transcripts that are preferentially transcribed in the primary or non-metastatic breast tumour tissue (i.e. are downregulated in metastatic breast tumour cells). These transcripts can be used for diagnosis, prognosis, monitoring and treatment of breast cancer, particularly where metastatic. Diagnosis is by standard immunoassays or hybridisation/amplification reactions. Compounds that modulate expression of the transcripts are potentially useful for treatment of (metastatic) breast cancer, while promoters from the transcripts are used to direct expression, in selected cell types, of e.g. therapeutic genes (also ribozymes or antisense sequences), particularly an antigen-encoding sequence for use in gene or cell-based vaccines. Polypeptides encoded by the transcripts are also useful in vaccines; for diagnosing breast cancer and for raising specific antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic agents. Host cells that produce the polypeptides can be used to expand and isolate populations of educated, antigen-specific immune effector cells, e.g. cytotoxic T lymphocytes, and these used for adoptive immunotherapy.

Sequence 10 BP; 0 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 734 AGAAACAGAA 743
|||||
DB 10 AGAAACGGAA 1

RESULT 656
AAZ83448

ID AAZ83448 standard; DNA; 10 BP.

AC AAZ83448;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #2682.

XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;

KW non-metastatic breast tumour tissue; gene therapy; anticancer;

KW antimetastatic; vaccine; diagnosis; ss.

OS Homo sapiens.

PN WO9965928-A2.

PD 23-DEC-1999.

PF 18-JUN-1999; 99WO-US013647.

PR 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089997P.

PR 19-JUN-1998; 98US-0090039P.

PR 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.

PA (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.

PA (SHAN/) SHANKARA S.

PI Roberts BL, Shankara S;

XX WPI; 2000-106079/09.

Isolated polynucleotides differentially expressed between metastatic and non-metastatic breast cancer cells, useful for diagnosis, prevention and

```

PT treatment of cancer.
XX
PS Claim 1; Page 131; 219pp; English.
XX
CC AA280767 to AA283941 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the metastatic breast tumour
CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
CC to AA286677 represent tags corresponding to distinct transcripts that are
CC preferentially transcribed in the primary or non-metastatic breast tumour
CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC transcripts can be used for diagnosis, prognosis, monitoring and
CC treatment of breast cancer, particularly where metastatic. Diagnosis is
CC by standard immunoassays or hybridisation/amplification reactions.
CC Compounds that modulate expression of the transcripts are potentially
CC useful for treatment of (metastatic) breast cancer, while promoters from
CC the transcripts are used to direct expression, in selected cell types, of
CC e.g. therapeutic genes (also ribozymes or antisense sequences),
CC particularly an antigen-encoding sequence for use in gene or cell-based
CC vaccines. Polypeptides encoded by the transcripts are also useful in
CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC agents. Host cells that produce the polypeptides can be used to expand
CC and isolate populations of educated, antigen-specific immune effector
CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC immunotherapy
XX
SQ Sequence 10 BP; 3 A; 4 C; 3 G; 0 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 739 CAGAACACCG 748
Db 1 CGGAACACCG 10
RESULT 657
AAZ81077/C
ID AAZ81077 standard; DNA; 10 BP.
XX
AC AAZ81077;
XX
DT 07-APR-2000 (first entry)
XX
DE Metastatic breast tumour cell upregulated transcript tag #311.
XX
KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
KW antimetastatic; vaccine; diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9965928-A2.
XX
PD 23-DEC-1999.
XX
PF 18-JUN-1999; 99WO-US013647.
XX
PR 19-JUN-1998; 98US-0089853P.
XX
PR 19-JUN-1998; 98US-0089997P.
XX
PR 19-JUN-1998; 98US-0090039P.
XX
PR 19-JUN-1998; 98US-0090040P.
XX
XX (GENZ ) GENZYME CORP.
PA (ROBE/) ROBERTS B L.
PA (SHAN/) SHANKARA S.
XX
PI Roberts BL, Shankara S;
XX
DR WPI; 2000-106079/09.

```

```

PT Isolated polynucleotides differentially expressed between metastatic and
PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
PT treatment of cancer.
XX
PS Claim 1; Page 66; 219pp; English.
XX
CC AA280767 to AA283941 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the metastatic breast tumour
CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
CC to AA286677 represent tags corresponding to distinct transcripts that are
CC preferentially transcribed in the primary or non-metastatic breast tumour
CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC transcripts can be used for diagnosis, prognosis, monitoring and
CC treatment of breast cancer, particularly where metastatic. Diagnosis is
CC by standard immunoassays or hybridisation/amplification reactions.
CC Compounds that modulate expression of the transcripts are potentially
CC useful for treatment of (metastatic) breast cancer, while promoters from
CC the transcripts are used to direct expression, in selected cell types, of
CC e.g. therapeutic genes (also ribozymes or antisense sequences),
CC particularly an antigen-encoding sequence for use in gene or cell-based
CC vaccines. Polypeptides encoded by the transcripts are also useful in
CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC agents. Host cells that produce the polypeptides can be used to expand
CC and isolate populations of educated, antigen-specific immune effector
CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC immunotherapy
XX
SQ Sequence 10 BP; 1 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 731 AGGAGAAACA 740
Db 10 AGGATAAACA 1
RESULT 658
AAZ81577
ID AAZ81577 standard; DNA; 10 BP.
XX
AC AAZ81577;
XX
DT 07-APR-2000 (first entry)
XX
DE Metastatic breast tumour cell upregulated transcript tag #811.
XX
KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
KW antimetastatic; vaccine; diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9965928-A2.
XX
PD 23-DEC-1999.
XX
PF 18-JUN-1999; 99WO-US013647.
XX
PR 19-JUN-1998; 98US-0089853P.
XX
PR 19-JUN-1998; 98US-0089997P.
XX
PR 19-JUN-1998; 98US-0090039P.
XX
PR 19-JUN-1998; 98US-0090040P.
XX
XX (GENZ ) GENZYME CORP.
PA (ROBE/) ROBERTS B L.
PA (SHAN/) SHANKARA S.
XX
PI Roberts BL, Shankara S;
XX

```

```

DR WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic and
PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
PT treatment of cancer.
XX
XX Claim 1; Page 80; 219pp; English.
XX
XX AA280767 to AA283941 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the metastatic breast tumour
CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
CC to AA286677 represent tags corresponding to distinct transcripts that are
CC preferentially transcribed in the primary or non-metastatic breast tumour
CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC transcripts can be used for diagnosis, prognosis, monitoring and
CC treatment of breast cancer, particularly where metastatic. Diagnosis is
CC by standard immunoassays or hybridisation/amplification reactions.
CC Compounds that modulate expression of the transcripts are potentially
CC useful for treatment of (metastatic) breast cancer, while promoters from
CC the transcripts are used to direct expression, in selected cell types, of
CC e.g. therapeutic genes (also ribozymes or antisense sequences),
CC particularly an antigen-encoding sequence for use in gene or cell-based
CC vaccines. Polypeptides encoded by the transcripts are also useful in
CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC agents. Host cells that produce the polypeptides can be used to expand
CC and isolate populations of educated, antigen-specific immune effector
CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC immunotherapy
XX
XX Sequence 10 BP; 4 A; 2 C; 4 G; 0 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 729 CCAGGAGAAA 738
Db |||||
1 CCAGGAGGAA 10
RESULT 659
AA281330/c
ID AA281330 standard; DNA; 10 BP.
AC AA281330;
XX
XX 07-APR-2000 (first entry)
XX
XX Metastatic breast tumour cell upregulated transcript tag #564.
DE
XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
KW antimetastatic; vaccine; diagnosis; ss.
XX
XX Homo sapiens.
OS
XX WO9965928-A2.
PN
XX 23-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US013647.
PF
XX 19-JUN-1998; 98US-0089853P.
PR
XX 19-JUN-1998; 98US-0089937P.
PR
XX 19-JUN-1998; 98US-0090039P.
PR
XX 19-JUN-1998; 98US-0090040P.
PR
XX 19-JUN-1998; 98US-0090041P.
XX
XX (GENZ ) GENZYME CORP.
PA (ROBE/) ROBERTS B L.
PA (SHAN/) SHANKARA S.
XX

```

```

PI Roberts BL, Shankara S;
XX
XX WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic and
PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
PT treatment of cancer.
XX
XX Claim 1; Page 73; 219pp; English.
XX
XX AA280767 to AA283941 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the metastatic breast tumour
CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
CC to AA286677 represent tags corresponding to distinct transcripts that are
CC preferentially transcribed in the primary or non-metastatic breast tumour
CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC transcripts can be used for diagnosis, prognosis, monitoring and
CC treatment of breast cancer, particularly where metastatic. Diagnosis is
CC by standard immunoassays or hybridisation/amplification reactions.
CC Compounds that modulate expression of the transcripts are potentially
CC useful for treatment of (metastatic) breast cancer, while promoters from
CC the transcripts are used to direct expression, in selected cell types, of
CC e.g. therapeutic genes (also ribozymes or antisense sequences),
CC particularly an antigen-encoding sequence for use in gene or cell-based
CC vaccines. Polypeptides encoded by the transcripts are also useful in
CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC agents. Host cells that produce the polypeptides can be used to expand
CC and isolate populations of educated, antigen-specific immune effector
CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC immunotherapy
XX
XX Sequence 10 BP; 0 A; 2 C; 0 G; 8 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 734 AGAAGACAGAA 743
Db |||||
10 AGAAGACAGAA 1
RESULT 660
AA281855/c
ID AA281855 standard; DNA; 10 BP.
AC AA281855;
XX
XX 07-APR-2000 (first entry)
XX
XX Metastatic breast tumour cell upregulated transcript tag #1089.
DE
XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
KW antimetastatic; vaccine; diagnosis; ss.
XX
XX Homo sapiens.
OS
XX WO9965928-A2.
PN
XX 23-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US013647.
PF
XX 19-JUN-1998; 98US-0089853P.
PR
XX 19-JUN-1998; 98US-0089937P.
PR
XX 19-JUN-1998; 98US-0090039P.
PR
XX 19-JUN-1998; 98US-0090040P.
PR
XX 19-JUN-1998; 98US-0090041P.
XX
XX (GENZ ) GENZYME CORP.
PA (ROBE/) ROBERTS B L.
PA (SHAN/) SHANKARA S.
XX

```


PA (SHAN/) SHANKARA S.
 XX Roberts BL, Shankara S;
 XX WPI; 2000-106079/09.
 XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX Claim 1; Page 87; 219pp; English.
 XX
 CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 2 A; 3 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 727 TGCCAGGAGA 736
 DB 10 TTCCAGGAGA 1
 RESULT 661
 AAZ82611/c
 ID AAZ82611 standard; DNA; 10 BP.
 XX AAZ82611;
 XX 07-APR-2000 (first entry)
 XX Metastatic breast tumour cell upregulated transcript tag #1845.
 XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 XX non-metastatic breast tumour tissue; Gene therapy; anticancer;
 XX antimetastatic; vaccine; diagnosis; ss.
 XX Homo sapiens.
 XX WO9965928-A2.
 XX 23-DEC-1999.
 XX 18-JUN-1999; 99WO-US013647.
 XX 19-JUN-1998; 98US-0089853P.
 XX 19-JUN-1998; 98US-008997P.
 XX 19-JUN-1998; 98US-0090039P.
 XX 19-JUN-1998; 98US-0090040P.
 XX 19-JUN-1998; 98US-0090041P.

PA (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 XX (SHAN/) SHANKARA S.
 XX Roberts BL, Shankara S;
 XX WPI; 2000-106079/09.
 XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX Claim 1; Page 108; 219pp; English.
 XX
 CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 0 A; 2 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 729 CCAGGAGAAA 738
 DB 10 CCAGGACAAA 1
 RESULT 662
 AAZ82802/c
 ID AAZ82802 standard; DNA; 10 BP.
 XX AAZ82802;
 XX 07-APR-2000 (first entry)
 XX Metastatic breast tumour cell upregulated transcript tag #2036.
 XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 XX non-metastatic breast tumour tissue; Gene therapy; anticancer;
 XX antimetastatic; vaccine; diagnosis; ss.
 XX Homo sapiens.
 XX WO9965928-A2.
 XX 23-DEC-1999.
 XX 18-JUN-1999; 99WO-US013647.
 XX 19-JUN-1998; 98US-0089853P.
 XX 19-JUN-1998; 98US-008997P.
 XX 19-JUN-1998; 98US-0090039P.
 XX 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.
XX (GENZ) GENZYME CORP.
PA (ROBE/) ROBERTS B L.
FA (SHAN/) SHANKARA S.
XX
PI Roberts BL, Shankara S;
XX
XX WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic and
PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
PT treatment of cancer.
XX
XX Claim 1; Page 114; 219pp; English.
XX
XX AA280767 to AA283941 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the metastatic breast tumour
CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
CC to AA286677 represent tags corresponding to distinct transcripts that are
CC preferentially transcribed in the primary or non-metastatic breast tumour
CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC transcripts can be used for diagnosis, prognosis, monitoring and
CC treatment of breast cancer, particularly where metastatic. Diagnosis is
CC by standard immunoassays or hybridisation/amplification reactions.
CC Compounds that modulate expression of the transcripts are potentially
CC useful for treatment of (metastatic) breast cancer, while promoters from
CC the transcripts are used to direct expression, in selected cell types, of
CC e.g. therapeutic genes (also ribozymes or antisense sequences),
CC particularly an antigen-encoding sequence for use in gene or cell-based
CC vaccines. Polypeptides encoded by the transcripts are also useful in
CC vaccines; for diagnosing breast cancer and for raising specific
CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC agents. Host cells that produce the polypeptides can be used to expand
CC and isolate populations of educated, antigen-specific immune effector
CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC immunotherapy
XX
SQ Sequence 10 BP; 1 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 733 GAGAACAGCA 742
Db ||| |||||
10 GATAAACAGA 1
RESULT 663
AA286557/C
ID AA286557 standard; DNA; 10 BP.
AC AA286557;
XX
XX 07-APR-2000 (first entry)
XX
XX Metastatic breast tumour cell downregulated transcript tag #5791.
XX
XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
XX non-metastatic breast tumour tissue; Gene therapy; anticancer;
XX antimetastatic; vaccine; diagnosis; ss.
XX
XX Homo sapiens.
XX
XX WO9365928-A2.
XX
XX 23-DEC-1999.
XX
XX 18-JUN-1999; 99WO-US013647.
XX
XX 19-JUN-1998; 98US-0089853P.
XX 19-JUN-1998; 98US-0089937P.

PR 19-JUN-1998; 98US-0090039P.
PR 19-JUN-1998; 98US-0090040P.
PR 19-JUN-1998; 98US-0090041P.
XX
XX (GENZ) GENZYME CORP.
PA (ROBE/) ROBERTS B L.
FA (SHAN/) SHANKARA S.
XX
XX Roberts BL, Shankara S;
XX
XX WPI; 2000-106079/09.
XX
XX Isolated polynucleotides differentially expressed between metastatic and
PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
PT treatment of cancer.
XX
XX Claim 1; Page 211; 219pp; English.
XX
XX AA280767 to AA283941 represent tags corresponding to distinct transcripts
CC that are preferentially transcribed in the metastatic breast tumour
CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
CC to AA286677 represent tags corresponding to distinct transcripts that are
CC preferentially transcribed in the primary or non-metastatic breast tumour
CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
CC transcripts can be used for diagnosis, prognosis, monitoring and
CC treatment of breast cancer, particularly where metastatic. Diagnosis is
CC by standard immunoassays or hybridisation/amplification reactions.
CC Compounds that modulate expression of the transcripts are potentially
CC useful for treatment of (metastatic) breast cancer, while promoters from
CC the transcripts are used to direct expression, in selected cell types, of
CC e.g. therapeutic genes (also ribozymes or antisense sequences),
CC particularly an antigen-encoding sequence for use in gene or cell-based
CC vaccines. Polypeptides encoded by the transcripts are also useful in
CC vaccines; for diagnosing breast cancer and for raising specific
CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
CC agents. Host cells that produce the polypeptides can be used to expand
CC and isolate populations of educated, antigen-specific immune effector
CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
CC immunotherapy
XX
SQ Sequence 10 BP; 0 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 736 AAACAGACCA 745
Db ||| |||||
10 AAACAGACCA 1
RESULT 664
AAC74106/C
ID AAC74106 standard; cDNA; 10 BP.
AC AAC74106;
XX
XX 02-FEB-2001 (first entry)
XX
XX Human dendritic cell and monocyte expressed gene oligonucleotide #193.
XX Human; dendritic cell; monocyte; immune system; diagnosis; cancer;
XX autoimmune disease; tumour; ss.
XX
XX Homo sapiens.
XX
XX WO200060074-A1.
XX
XX 12-OCT-2000.
XX
XX 30-MAR-2000; 2000WO-JP002019.
XX
XX 01-APR-1999; 99JP-00095481.

XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 XX Hashimoto S, Matsushima K, Suzuki T;
 PI WPI; 2000-619172/59.
 DR Groups of genes expressed in human dendritic cells at a greater or lesser
 PT extent than in monocytes for investigation and diagnosis of autoimmune
 PT disease and tumors.
 XX
 PS Claim 10; Page 13; 95pp; Japanese.
 XX
 CC The present invention describes a group of genes consisting of 100 genes
 CC which are highly expressed in human dendritic cells; a group of genes
 CC which are expressed at a higher frequency in human dendritic cells than
 CC in human monocytes; and a group of genes which are expressed at lower
 CC frequency in human dendritic cells than in human monocytes. Each group of
 CC genes are characterised in that cDNAs of these genes respectively have
 CC the base sequences of SEQ ID NO:1 to 100 (AAC73914 to AAC74013), SEQ ID
 CC NO:101 to 200 (AAC74014 to AAC74113) and SEQ ID NO:201 to 300 (AAC74114
 CC to AAC74213), each is continuous with the base sequence 5'-CATG-3',
 CC located most closely to the poly-A region. The sequences can be used for
 CC the investigation of the role and mechanism of the involvement of
 CC dendritic cells in the immune system and for the study and diagnosis of
 CC diseases in which dendritic cells play a significant role, e.g. cancers
 CC and autoimmune diseases
 XX
 SQ Sequence 10 BP; 1 A; 2 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 AGGAGAAACA 740
 |||||
 DB 10 AGGATAACA 1
 |||||

RESULT 665
 AAH63994
 ID AAH63994 standard; cDNA; 10 BP.
 XX
 AC AAH63994;
 XX
 XX 20-SEP-2001 (first entry)
 XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 834.
 XX
 DE Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW Cancer diagnosis; cell specific gene expression; ss.
 KW
 OS Homo sapiens.
 XX
 XX WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 XX WPI; 2001-367706/38.
 XX
 PS Claim 13; Page 58; 94pp; English.

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 GAGAAACAGA 742
 |||||

RESULT 666
 AAH64523/c
 ID AAH64523 standard; cDNA; 10 BP.
 XX
 AC AAH64523;
 XX
 XX 20-SEP-2001 (first entry)
 XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 1363.
 XX
 DE Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW Cancer diagnosis; cell specific gene expression; ss.
 KW
 OS Homo sapiens.
 XX
 XX WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 XX WPI; 2001-367706/38.
 XX
 PS Claim 13; Page 70; 94pp; English.

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 729 CCAGGAGAAA 738
 |||||
 DB 1 CCAGGAGGAA 10
 |||||

RESULT 666
 AAH64523/c
 ID AAH64523 standard; cDNA; 10 BP.
 XX
 AC AAH64523;
 XX
 XX 20-SEP-2001 (first entry)
 XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 1363.
 XX
 DE Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW Cancer diagnosis; cell specific gene expression; ss.
 KW
 OS Homo sapiens.
 XX
 XX WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 XX WPI; 2001-367706/38.
 XX
 PS Claim 13; Page 70; 94pp; English.

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 GAGAAACAGA 742
 |||||

RESULT 666
 AAH64523/c
 ID AAH64523 standard; cDNA; 10 BP.
 XX
 AC AAH64523;
 XX
 XX 20-SEP-2001 (first entry)
 XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 1363.
 XX
 DE Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW Cancer diagnosis; cell specific gene expression; ss.
 KW
 OS Homo sapiens.
 XX
 XX WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 XX WPI; 2001-367706/38.
 XX
 PS Claim 13; Page 70; 94pp; English.

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 GAGAAACAGA 742
 |||||

XX The present invention describes a method of identifying the type of cell
 CC in a sample, involving determining which of the sequences AAH63161-
 CC AAH64724 is expressed by the cell. The transcriptomes described in the
 CC invention are cell-type specific, cancer specific or ubiquitously
 CC expressed in humans. They can also be used to screen for drugs, reduce
 CC cancer specific gene expression, standardise expression and restore the
 CC function of a diseased cell or tissue. The present sequence is one of the
 CC transcriptomes described in the exemplification of the invention
 XX

SQ Sequence 10 BP; 4 A; 2 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 729 CCAGGAGAAA 738
 |||||
 DB 1 CCAGGAGGAA 10
 |||||

RESULT 666
 AAH64523/c
 ID AAH64523 standard; cDNA; 10 BP.
 XX
 AC AAH64523;
 XX
 XX 20-SEP-2001 (first entry)
 XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 1363.
 XX
 DE Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW Cancer diagnosis; cell specific gene expression; ss.
 KW
 OS Homo sapiens.
 XX
 XX WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 XX WPI; 2001-367706/38.
 XX
 PS Claim 13; Page 70; 94pp; English.

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 729 CCAGGAGAAA 738
 |||||
 DB 1 CCAGGAGGAA 10
 |||||

RESULT 666
 AAH64523/c
 ID AAH64523 standard; cDNA; 10 BP.
 XX
 AC AAH64523;
 XX
 XX 20-SEP-2001 (first entry)
 XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 1363.
 XX
 DE Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW Cancer diagnosis; cell specific gene expression; ss.
 KW
 OS Homo sapiens.
 XX
 XX WO200138577-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 21-NOV-2000; 2000WO-US031922.
 XX
 PR 24-NOV-1999; 99US-00448480.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX
 XX WPI; 2001-367706/38.
 XX
 PS Claim 13; Page 70; 94pp; English.

Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 GAGAAACAGA 742
 |||||

Db 10 GATAACAGCA 1

RESULT 667
AAH64453/C
ID AAH64453 standard; cDNA; 10 BP.

XX AC AAH64453;
XX 20-SEP-2001 (first entry)
XX Human ubiquitously expressed transcriptome sequence SEQ ID NO: 1293.
XX Human; transcriptome; gene expression pattern; cancer; drug screening;
XX cancer diagnosis; cell specific gene expression; ss.
XX Homo sapiens.
XX WO200138577-A2.
XX 31-MAY-2001.
XX 21-NOV-2000; 2000WO-US031922.
XX 24-NOV-1999; 99US-00448480.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Velculescu VE, Vogelstein B, Kinzler KW;
XX WPI; 2001-367706/38.
XX New isolated polynucleotides, useful for identifying specific cell type,
XX such as cancer cell, comprises transcriptomes expressed in particular
XX cell types.
XX Claim 11; Page 68; 94pp; English.
XX The present invention describes a method of identifying the type of cell
XX in a sample, involving determining which of the sequences AAH63161-
XX AAH64724 is expressed by the cell. The transcriptomes described in the
XX invention are cell-type specific, cancer specific or ubiquitously
XX expressed in humans. They can also be used to screen for drugs, reduce
XX cancer specific gene expression, standardise expression and restore the
XX function of a diseased cell or tissue. The present sequence is one of the
XX transcriptomes described in the exemplification of the invention

XX SQ Sequence 10 BP; 1 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 AGGAGAAACA 740
Db 10 AGGATAACA 1
|||||
RESULT 668
AAF74014/C
ID AAF74014 standard; DNA; 10 BP.
XX AC AAF74014;
XX 30-APR-2001 (first entry)
XX Human SLC6A4 allele-specific oligonucleotide primer #134.
XX Solute carrier family 6 neurotransmitter transporter; seotonin 4; SLC6A4;
XX genotyping; allele specific oligonucleotide; ss.
XX Homo sapiens.

XX OS

PN WO200109161-A1.
XX 08-FEB-2001.
XX 31-JUL-2000; 2000WO-US020638.
XX 29-JUL-1999; 99US-0146290P.
XX (GENA-) GENAISSANCE PHARM INC.
XX Denton RR, Duda A, Nandabalan K, Sanchis A, Stephens JC;
XX WPI; 2001-123317/13.
XX New isolated polynucleotide comprising a polymorphic variant for the
XX solute carrier family 6 neurotransmitter transporter, serotonin member 4
XX gene for identifying drugs for treating disorders related to expression
XX of the protein.
XX Claim 12; Page 22; 152pp; English.
XX The present invention relates to a polymorphic variant of a reference
XX sequence for the solute carrier family 6 neurotransmitter transporter,
XX serotonin member 4 (SLC6A4) gene or a fragment of it or a sequence
XX complementary to the first sequence. The invention is used in producing a
XX recombinant organism that can be used to express SLC6A4 for protein
XX structure analysis and binding studies. A composition comprising a
XX genotyping oligonucleotide is used to detect a polymorphism in the SLC6A4
XX gene
XX SQ Sequence 10 BP; 0 A; 2 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 729 CCAGGAGAAA 738
Db 10 CCAGAGAGAAA 1
|||||
RESULT 669
ABA83142
ID ABA83142 standard; cDNA; 10 BP.
XX AC ABA83142;
XX 08-FEB-2002 (first entry)
XX eIF-2-associated p67 ovarian tumour marker gene SAGE tag, SEQ ID NO:102.
XX Ovarian tumour marker gene; human; overexpression; upregulation;
XX epithelial tumor; cancer; diagnosis; prognosis; disease monitoring;
XX identification; serous cystadenoma; borderline serous tumour;
XX serous cystadenocarcinoma; mucinous cystadenocarcinoma;
XX mucinous cystadenoma; borderline mucinous tumour; endometrioid carcinoma;
XX undifferentiated carcinoma; clear cell adenocarcinoma; cystadenofibroma;
XX adenofibroma; Brenner tumour; serial analysis of gene expression;
XX immune response pathway; cell proliferation regulation; protein folding;
XX membrane localised; secreted; therapeutic target; cytostatic;
XX Gene therapy; vaccine; SAGE tag; ss.
XX Homo sapiens.
XX WO200175177-A2.
XX 11-OCT-2001.
XX 03-APR-2001; 2001WO-US010947.
XX 03-APR-2000; 2000US-0194336P.
XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

```

XX PI Morin PJ, Sherman-Baust CA, Pizer ES, Hough CD;
XX DR WPI; 2001-626450/72.
XX PT Detecting and identifying ovarian tumor, identifying increased risk for
XX PT developing ovarian cancer, and determining effectiveness of ovarian
XX PT cancer treatment, by measuring expression level of ovarian tumor marker
XX PT gene.
XX PS Claim 25; Page 31; 140pp; English.
XX CC The invention relates to methods for diagnosing and prognosing ovarian
XX CC tumors in an individual via the detection and measurement of the
XX CC expression of ovarian tumor marker genes (ABA83081-ABA83122, ABA83180,
XX CC ABA83182 and ABA83184) or segments thereof (ABA83123-ABA83169, ABA83179,
XX CC ABA83181 and ABA83183). The methods of the invention are useful for
XX CC detecting an ovarian tumor in a patient, for identifying an individual
XX CC at increased risk for developing ovarian cancer, in prognostic tests for
XX CC assessing the relative severity of ovarian cancer, in tests for
XX CC monitoring a patient in remission from ovarian cancer, in tests for
XX CC monitoring disease status in a patient being treated for ovarian cancer.
XX CC The methods can additionally be used to identify a particular tumor as
XX CC being an ovarian tumor (i.e., an epithelial ovarian tumor selected from
XX CC serous cystadenoma, borderline serous tumor, serous cystadenocarcinoma,
XX CC mucinous cystadenoma, borderline mucinous tumor, mucinous
XX CC cystadenocarcinoma, endometrioid carcinoma, undifferentiated carcinoma,
XX CC clear cell adenocarcinoma, cystadenofibroma, adenofibroma and Brenner
XX CC tumor. The ovarian tumor marker genes of the invention were identified
XX CC using SAGE (serial analysis of gene expression) and were found to be
XX CC overexpressed in a broad variety of ovarian epithelial tumor cells
XX CC relative to normal ovarian epithelial cells. The marker genes are
XX CC implicated in immune response pathways, in the regulation of cell
XX CC proliferation and in protein folding, and many of these are membrane-
XX CC localised or secreted. In addition to their use as diagnostic and
XX CC prognostic markers, the ovarian tumor marker genes or their encoded
XX CC proteins may be used as therapeutic targets for the treatment and
XX CC prevention of ovarian cancer. Sequences ABA83123-ABA83169, ABA83179,
XX CC ABA83181 and ABA83183 represent SAGE tags derived from the ovarian tumor
XX CC marker genes of the invention
XX SQ Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 735 GAACAGAAC 744
Db 1 GAAACTGAAC 10
RESULT 670
AAF35790
ID AAF35790 standard; DNA; 10 BP.
XX AC AAF35790;
XX DT 23-MAR-2001 (first entry)
XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2529.
XX KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
XX KW serial analysis of gene expression; antifungal; tag; identification;
XX KW linker; PCR primer; ds.
XX OS Saccharomyces cerevisiae.
XX PN WO200077214-A2.
XX PD 21-DEC-2000.
XX PN

```

```

PF 14-JUN-2000; 2000WO-US016223.
XX PR 16-JUN-1999; 99US-00335032.
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX PI Velculescu V, Vogelstein B, Kinzler K;
XX DR WPI; 2001-061874/07.
XX PS Yeast gene coding sequences comprising NORF genes with serial analysis of
XX PT gene expression (SAGE) tags; useful for studying, monitoring and
XX PT affecting phases of the cell cycle.
XX CC Example; Page 90; 419pp; English.
XX CC The present invention describes an isolated DNA molecule comprising a
XX CC coding sequence of a yeast gene selected from a group of 745 NORF (not
XX CC previously assigned open reading frame; or nonannotated ORF) genes
XX CC comprising a SAGE (serial analysis of gene expression) tag. Also
XX CC described are: (1) a method (M1) of using NORF genes to affect the cell
XX CC cycle comprising administering a NORF gene whose expression varies by at
XX CC least 10% between any two phases of the cell cycle selected from log
XX CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX CC antifungal drugs comprising: (a) contacting a test substance with a yeast
XX CC cell; and (b) monitoring expression of a NORF gene whose expression
XX CC varies as in M1, where a test substance which modifies the expression of
XX CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
XX CC identifying human genes which are involved in cell cycle progression
XX CC comprising contacting human DNA with a probe which comprises at least 10
XX CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
XX CC and (4) a method (M4) for identifying a candidate drug as a member of a
XX CC class of drugs having a characteristic effect on gene expression in a
XX CC yeast cell comprising contacting a yeast cell with a candidate drug and
XX CC monitoring expression in the yeast cell of at least 1 NORF gene whose
XX CC expression is affected by the class of drugs. The NORF genes may be used
XX CC to study, monitor and affect phases of the cell cycle, the differentially
XX CC expressed genes may be used as markers of phases of the cell cycle. The
XX CC methods may be used to identify candidate drugs which affect the cell
XX CC cycle and for identification of antifungal drugs. AAF33286 to AAF4064
XX CC represent SAGE tags used in the exemplification of the present invention.
XX CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
XX CC method, in the exemplification of the present invention
XX SQ Sequence 10 BP; 6 A; 1 C; 3 G; 0 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 734 AGAAACAGAA 743
Db 1 AGAAACAGAA 10
RESULT 671
AAF43163
ID AAF43163 standard; DNA; 10 BP.
XX AC AAF43163;
XX DT 23-MAR-2001 (first entry)
XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:11302.
XX KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
XX KW serial analysis of gene expression; antifungal; tag; identification;
XX KW linker; PCR primer; ds.
XX OS Saccharomyces cerevisiae.
XX PN WO200077214-A2.
XX PD
XX PN

```

```

XX PD 21-DEC-2000.
XX PN
XX PP 14-JUN-2000; 2000WO-US016223.
XX PR 16-JUN-1999; 99US-00335032.
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX PI Velculescu V, Vogelstein B, Kinzler K;
XX DR WPI; 2001-061874/07.
XX PT Yeast gene coding sequences comprising NORF genes with serial analysis of
XX PT gene expression (SAGE) tags, useful for studying, monitoring and
XX PT affecting phases of the cell cycle.
XX PS Example; Page 353; 419pp; English.
XX CC The present invention describes an isolated DNA molecule comprising a
XX CC coding sequence of a yeast gene selected from a group of 745 NORF (not
XX CC previously assigned open reading frame; or nonannotated ORF) genes
XX CC comprising a SAGE (serial analysis of gene expression) tag. Also
XX CC described are: (1) a method (M1) of using NORF genes to affect the cell
XX CC cycle comprising administering a NORF gene whose expression varies by at
XX CC least 10% between any two phases of the cell cycle selected from log
XX CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX CC antifungal drugs comprising: (a) contacting a test substance with a yeast
XX CC cell; and (b) monitoring expression of a NORF gene whose expression
XX CC varies as in M1, where a test substance which modifies the expression of
XX CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
XX CC identifying human genes which are involved in cell cycle progression
XX CC comprising contacting human DNA with a probe which comprises at least 10
XX CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
XX CC and (4) a method (M4) for identifying a candidate drug as a member of a
XX CC class of drugs having a characteristic effect on gene expression in a
XX CC yeast cell comprising contacting a yeast cell with a candidate drug and
XX CC monitoring expression in the yeast cell of at least 1 NORF gene whose
XX CC expression is affected by the class of drugs. The NORF genes may be used
XX CC to study, monitor and affect phases of the cell cycle, the differentially
XX CC expressed genes may be used as markers of phases of the cell cycle. The
XX CC methods may be used to identify candidate drugs which affect the cell
XX CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
XX CC represent SAGE tags used in the exemplification of the present invention.
XX CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
XX CC method, in the exemplification of the present invention.
XX SQ Sequence 10 BP; 3 A; 3 C; 3 G; 1 T; 0 U; 0 Other;
      Query Match      38.2%; Score 8.4; DB 1; Length 10;
      Best Local Similarity 90.0%; Pred. No. 5.2e+02;
      Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 727 TCCACGAGAGA 736
DB 1 TCCACGAGAGA 10
      |||||
      |||||

RESULT 672
AAF43935/C
ID AAF43935 standard; DNA; 10 BP.
XX AC AAF43935;
XX DT 23-MAR-2001 (first entry)
XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:12074.
XX KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
XX KW serial analysis of gene expression; antifungal; tag; identification;
XX KW linker; PCR primer; ds.

```

```

OS Saccharomyces cerevisiae.
XX WO200077214-A2.
XX PD 21-DEC-2000.
XX PP 14-JUN-2000; 2000WO-US016223.
XX PR 16-JUN-1999; 99US-00335032.
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX PI Velculescu V, Vogelstein B, Kinzler K;
XX DR WPI; 2001-061874/07.
XX PT Yeast gene coding sequences comprising NORF genes with serial analysis of
XX PT gene expression (SAGE) tags, useful for studying, monitoring and
XX PT affecting phases of the cell cycle.
XX PS Example; Page 381; 419pp; English.
XX CC The present invention describes an isolated DNA molecule comprising a
XX CC coding sequence of a yeast gene selected from a group of 745 NORF (not
XX CC previously assigned open reading frame; or nonannotated ORF) genes
XX CC comprising a SAGE (serial analysis of gene expression) tag. Also
XX CC described are: (1) a method (M1) of using NORF genes to affect the cell
XX CC cycle comprising administering a NORF gene whose expression varies by at
XX CC least 10% between any two phases of the cell cycle selected from log
XX CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX CC antifungal drugs comprising: (a) contacting a test substance with a yeast
XX CC cell; and (b) monitoring expression of a NORF gene whose expression
XX CC varies as in M1, where a test substance which modifies the expression of
XX CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
XX CC identifying human genes which are involved in cell cycle progression
XX CC comprising contacting human DNA with a probe which comprises at least 10
XX CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
XX CC and (4) a method (M4) for identifying a candidate drug as a member of a
XX CC class of drugs having a characteristic effect on gene expression in a
XX CC yeast cell comprising contacting a yeast cell with a candidate drug and
XX CC monitoring expression in the yeast cell of at least 1 NORF gene whose
XX CC expression is affected by the class of drugs. The NORF genes may be used
XX CC to study, monitor and affect phases of the cell cycle, the differentially
XX CC expressed genes may be used as markers of phases of the cell cycle. The
XX CC methods may be used to identify candidate drugs which affect the cell
XX CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
XX CC represent SAGE tags used in the exemplification of the present invention.
XX CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
XX CC method, in the exemplification of the present invention.
XX SQ Sequence 10 BP; 1 A; 2 C; 2 G; 5 T; 0 U; 0 Other;
      Query Match      38.2%; Score 8.4; DB 1; Length 10;
      Best Local Similarity 90.0%; Pred. No. 5.2e+02;
      Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 729 CCACGAGAAA 738
DB 10 CCACGAGAAA 1
      |||||
      |||||

RESULT 673
AAF37363
ID AAF37363 standard; DNA; 10 BP.
XX AC AAF37363;
XX DT 23-MAR-2001 (first entry)
XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:4102.
XX KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX KW nor previously assigned open reading frame; nonannotated ORF; SAGE;

```

KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
XX 14-JUN-2000; 2000WO-US016223.
XX PF
XX 16-JUN-1999; 99US-00335032.
XX PR
XX (UYJO) UNIV JOHNS HOPKINS.
XX PA
XX Velulescu V, Vogelstein B, Kinzler K;
XX PI
XX WPI; 2001-061874/07.
XX DR
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
XX Example; Page 146; 419pp; English.
XX
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
XX Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 730 CAGGAGAAC 739
Db 1 CAGGATTAAC 10
RESULT 674
AAF40688
ID AAF40688 standard; DNA; 10 BP.
XX AAF40688;
AC
XX 23-MAR-2001 (first entry)
DT
XX
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7427.
DE

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.
XX
XX WO200077214-A2.
XX PN
XX 21-DEC-2000.
XX PD
XX 14-JUN-2000; 2000WO-US016223.
XX PF
XX 16-JUN-1999; 99US-00335032.
XX PR
XX (UYJO) UNIV JOHNS HOPKINS.
XX PA
XX Velulescu V, Vogelstein B, Kinzler K;
XX PI
XX WPI; 2001-061874/07.
XX DR
XX
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
XX Example; Page 265; 419pp; English.
XX
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
XX Sequence 10 BP; 3 A; 4 C; 2 G; 1 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 739 CAGAACACCG 748
Db 1 CAGTACACCG 10
RESULT 675
AAF38499
ID AAF38499 standard; DNA; 10 BP.
XX AAF38499;
AC
XX

DT XX 23-MAR-2001 (first entry)

DE XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5238.

KW XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;

KW DE nor previously assigned open reading frame; nonannotated ORF; SAGE;

KW KW serial analysis of gene expression; antifungal; tag; identification;

KW KW linker; PCR primer; ds.

XX OS Saccharomyces cerevisiae.

XX XX WO200077214-A2.

PN XX 21-DEC-2000.

PD XX 14-JUN-2000; 2000WO-US016223.

XX PF 16-JUN-1999; 99US-00335032.

XX PR (UYJO) UNIV JOHNS HOPKINS.

XX PA Velulescu V, Vogelstein B, Kinzler K;

XX PI WPI; 2001-061874/07.

XX DR Yeast gene coding sequences comprising NORF genes with serial analysis of

XX PT gene expression (SAGE) tags, useful for studying, monitoring and

XX PT affecting phases of the cell cycle.

XX PS Example; Page 187; 419pp; English.

XX CC The present invention describes an isolated DNA molecule comprising a

CC CC coding sequence of a yeast gene selected from a group of 745 NORF (not

CC CC previously assigned open reading frame; or nonannotated ORF) genes

CC CC comprising a SAGE (serial analysis of gene expression) tag. Also

CC CC described are: (1) a method (M1) of using NORF genes to affect the cell

CC CC cycle comprising administering a NORF gene whose expression varies by at

CC CC least 10% between any two phases of the cell cycle selected from log

CC CC phase, S phase and G2/M; (2) a method (M2) for screening candidate

CC CC antifungal drugs comprising: (a) contacting a test substance with a yeast

CC CC cell; and (b) monitoring expression of a NORF gene whose expression

CC CC varies as in M1, where a test substance which modifies the expression of

CC CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for

CC CC identifying human genes which are involved in cell cycle progression

CC CC comprising contacting human DNA with a probe which comprises at least 10

CC CC contiguous nucleotides of a NORF gene whose expression varies as in M1;

CC CC and (4) a method (M4) for identifying a candidate drug as a member of a

CC CC class of drugs having a characteristic effect on gene expression in a

CC CC yeast cell comprising contacting a yeast cell with a candidate drug and

CC CC monitoring expression in the yeast cell of at least 1 NORF gene whose

CC CC expression is affected by the class of drugs. The NORF genes may be used

CC CC to study, monitor and affect phases of the cell cycle, the differentially

CC CC expressed genes may be used as markers of phases of the cell cycle. The

CC CC methods may be used to identify candidate drugs which affect the cell

CC CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064

CC CC represent SAGE tags used in the exemplification of the present invention.

CC CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE

CC CC method, in the exemplification of the present invention

XX SQ Sequence 10 BP; 6 A; 2 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 5.2e-02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AAACAGACCA 745

DB 1 AAACAGACCA 10

|||||

RESULT 676

AAF37393

ID AAF37393 standard; DNA; 10 BP.

XX AAF37393;

AC 23-MAR-2001 (first entry)

DT XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:4132.

DE XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;

XX KW nor previously assigned open reading frame; nonannotated ORF; SAGE;

XX KW serial analysis of gene expression; antifungal; tag; identification;

XX KW linker; PCR primer; ds.

XX OS Saccharomyces cerevisiae.

XX XX WO200077214-A2.

PN XX 21-DEC-2000.

PD XX 14-JUN-2000; 2000WO-US016223.

XX PF 16-JUN-1999; 99US-00335032.

XX PR (UYJO) UNIV JOHNS HOPKINS.

XX PA Velulescu V, Vogelstein B, Kinzler K;

XX PI WPI; 2001-061874/07.

XX DR Yeast gene coding sequences comprising NORF genes with serial analysis of

XX PT gene expression (SAGE) tags, useful for studying, monitoring and

XX PT affecting phases of the cell cycle.

XX PS Example; Page 147; 419pp; English.

XX CC The present invention describes an isolated DNA molecule comprising a

CC CC coding sequence of a yeast gene selected from a group of 745 NORF (not

CC CC previously assigned open reading frame; or nonannotated ORF) genes

CC CC comprising a SAGE (serial analysis of gene expression) tag. Also

CC CC described are: (1) a method (M1) of using NORF genes to affect the cell

CC CC cycle comprising administering a NORF gene whose expression varies by at

CC CC least 10% between any two phases of the cell cycle selected from log

CC CC phase, S phase and G2/M; (2) a method (M2) for screening candidate

CC CC antifungal drugs comprising: (a) contacting a test substance with a yeast

CC CC cell; and (b) monitoring expression of a NORF gene whose expression

CC CC varies as in M1, where a test substance which modifies the expression of

CC CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for

CC CC identifying human genes which are involved in cell cycle progression

CC CC comprising contacting human DNA with a probe which comprises at least 10

CC CC contiguous nucleotides of a NORF gene whose expression varies as in M1;

CC CC and (4) a method (M4) for identifying a candidate drug as a member of a

CC CC class of drugs having a characteristic effect on gene expression in a

CC CC yeast cell comprising contacting a yeast cell with a candidate drug and

CC CC monitoring expression in the yeast cell of at least 1 NORF gene whose

CC CC expression is affected by the class of drugs. The NORF genes may be used

CC CC to study, monitor and affect phases of the cell cycle, the differentially

CC CC expressed genes may be used as markers of phases of the cell cycle. The

CC CC methods may be used to identify candidate drugs which affect the cell

CC CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064

CC CC represent SAGE tags used in the exemplification of the present invention.

CC CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE

CC CC method, in the exemplification of the present invention

XX SQ Sequence 10 BP; 6 A; 2 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 5.2e-02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 729 CCAGAGAGAAA 738

DB 1 CCAGAGAGAAA 10

|||||

Db 1 TGCAGGAAA 10

RESULT 678
AAF42636/c
ID AAF42636 standard; DNA; 10 BP.
XX AC AAF42636;
XX DT 23-MAR-2001 (first entry)
XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:10775.
XX KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
XX KW serial analysis of gene expression; antifungal; tag; identification;
XX KW linker; PCR primer; ds.
XX OS Saccharomyces cerevisiae.
XX PN WO200077214-A2.
XX PD 21-DEC-2000.
XX PF 14-JUN-2000; 2000WO-US016223.
XX PR 16-JUN-1999; 99US-00335032.
XX PA (UYJO) UNIV JOHNS HOPKINS.
XX PI Velulescu V, Vogelstein B, Kinzler K;
XX DR WPI; 2001-061874/07.
XX PT Yeast gene coding sequences comprising NORF genes with serial analysis of
XX PT gene expression (SAGE) tags, useful for studying, monitoring and
XX PT affecting phases of the cell cycle.
XX PS Example; Page 334; 419pp; English.
XX CC The present invention describes an isolated DNA molecule comprising a
XX CC coding sequence of a yeast gene selected from a group of 745 NORF (not
XX CC previously assigned open reading frame; or nonannotated ORF) genes
XX CC comprising a SAGE (serial analysis of gene expression) tag. Also
XX CC described are: (1) a method (M1) of using NORF genes to affect the cell
XX CC cycle comprising administering a NORF gene whose expression varies by at
XX CC least 10% between any two phases of the cell cycle selected from log
XX CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX CC cell; and (b) monitoring expression of a NORF gene whose expression
XX CC varies as in M1, where a test substance which modifies the expression of
XX CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
XX CC identifying human genes which are involved in cell cycle progression
XX CC comprising contacting human DNA with a probe which comprises at least 10
XX CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
XX CC and (4) a method (M4) for identifying a candidate drug as a member of a
XX CC class of drugs having a characteristic effect on gene expression in a
XX CC yeast cell comprising contacting a yeast cell with a candidate drug and
XX CC monitoring expression in the yeast cell of at least 1 NORF gene whose
XX CC expression is affected by the class of drugs. The NORF genes may be used
XX CC to study, monitor and affect phases of the cell cycle, the differentially
XX CC expressed genes may be used to identify candidate drugs which affect the cell
XX CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
XX CC represent SAGE tags used in the exemplification of the present invention.
XX CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
XX CC method, in the exemplification of the present invention
XX SQ Sequence 10 BP; 1 A; 1 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 677
AAF38223
ID AAF38223 standard; DNA; 10 BP.
XX AC AAF38223;
XX DT 23-MAR-2001 (first entry)
XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:4962.
XX KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
XX KW serial analysis of gene expression; antifungal; tag; identification;
XX KW linker; PCR primer; ds.
XX OS Saccharomyces cerevisiae.
XX PN WO200077214-A2.
XX PD 21-DEC-2000.
XX PF 14-JUN-2000; 2000WO-US016223.
XX PR 16-JUN-1999; 99US-00335032.
XX PA (UYJO) UNIV JOHNS HOPKINS.
XX PI Velulescu V, Vogelstein B, Kinzler K;
XX DR WPI; 2001-061874/07.
XX PT Yeast gene coding sequences comprising NORF genes with serial analysis of
XX PT gene expression (SAGE) tags, useful for studying, monitoring and
XX PT affecting phases of the cell cycle.
XX PS Example; Page 177; 419pp; English.
XX CC The present invention describes an isolated DNA molecule comprising a
XX CC coding sequence of a yeast gene selected from a group of 745 NORF (not
XX CC previously assigned open reading frame; or nonannotated ORF) genes
XX CC comprising a SAGE (serial analysis of gene expression) tag. Also
XX CC described are: (1) a method (M1) of using NORF genes to affect the cell
XX CC cycle comprising administering a NORF gene whose expression varies by at
XX CC least 10% between any two phases of the cell cycle selected from log
XX CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX CC antifungal drugs comprising: (a) contacting a test substance with a yeast
XX CC cell; and (b) monitoring expression of a NORF gene whose expression
XX CC varies as in M1, where a test substance which modifies the expression of
XX CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
XX CC identifying human genes which are involved in cell cycle progression
XX CC comprising contacting human DNA with a probe which comprises at least 10
XX CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
XX CC and (4) a method (M4) for identifying a candidate drug as a member of a
XX CC class of drugs having a characteristic effect on gene expression in a
XX CC yeast cell comprising contacting a yeast cell with a candidate drug and
XX CC monitoring expression in the yeast cell of at least 1 NORF gene whose
XX CC expression is affected by the class of drugs. The NORF genes may be used
XX CC to study, monitor and affect phases of the cell cycle, the differentially
XX CC expressed genes may be used to identify candidate phases of the cell cycle. The
XX CC methods may be used to identify candidate drugs which affect the cell
XX CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
XX CC represent SAGE tags used in the exemplification of the present invention.
XX CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
XX CC method, in the exemplification of the present invention
XX SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

727 TGCAGGAGA 736
|||||||

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 728 GCCAGGAGAA 737
| | | | | | | | | |
Db 1 GCCAGGAGAA 10

RESULT 679
AAF42385
ID AAF42385 standard; DNA; 10 BP.
XX AAF42385;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:9124.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000WO-US016223.
XX
PR 16-JUN-1999; 99US-00335032.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Velulescu V, Vogelstein B, Kinzler K;
XX
PI MPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
PS Example; Page 325; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33282 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
SQ Sequence 10 BP; 4 A; 3 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 728 GCCAGGAGAA 737
| | | | | | | | | |
Db 1 GCCAGGAGAA 10

RESULT 680
AAF35570
ID AAF35570 standard; DNA; 10 BP.
XX AAF35570;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2309.
XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000WO-US016223.
XX
PR 16-JUN-1999; 99US-00335032.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Velulescu V, Vogelstein B, Kinzler K;
XX
PI MPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
PS Example; Page 82; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33282 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
SQ Sequence 10 BP; 4 A; 3 C; 3 G; 0 T; 0 U; 0 Other;

XX Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;
SQ Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 735 GAAACAGAAC 744
DB 1 GAACTGAAC 10
RESULT 681
ID AAF41687 standard; DNA; 10 BP.
XX AAF41687;
AC AAF41687;
DT 23-MAR-2001 (first entry)
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:8426.
DE Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX Saccharomyces cerevisiae.
OS WO200077214-A2.
PN WO200077214-A2.
XX 21-DEC-2000.
XX 14-JUN-2000; 2000WO-US016223.
PF 16-JUN-1999; 99US-00335032.
PR (UYCO) UNIV JOHNS HOPKINS.
XX Velculescu V, Vogelstein B, Kinzler K;
PI WPI; 2001-061874/07.
DR Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
PS Example; Page 300; 419pp; English.
XX The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064

CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX Sequence 10 BP; 7 A; 2 C; 1 G; 0 T; 0 U; 0 Other;
SQ Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 735 GAAACAGAAC 744
DB 1 GAAACAAAC 10
RESULT 682
ID ABL01295 standard; DNA; 10 BP.
XX ABL01295;
AC ABL01295;
DT 12-MAR-2002 (first entry)
XX Human MMP3 gene polymorphism detection primer SEQ ID NO:74.
DE Human; matrix metalloproteinase 3; MMP3; chromosome 11q22.3; SNP;
KW haplotype; polymorphism; polymorphic; single nucleotide polymorphism;
KW probe; primer; detection; genotyping; vulnery; cyostatic; cancer;
KW antiarteriosclerotic; gene therapy; coronary atherosclerosis;
KW wound healing; ss.
XX Homo sapiens.
OS WO200179238-A2.
PN WO200179238-A2.
XX 25-OCT-2001.
PD 17-APR-2001; 2001WO-US012452.
PF 17-APR-2000; 2000US-0197911P.
PR 13-JUL-2000; 2000US-0218092P.
XX (GENA-) GENAISANCE PHARM INC.
XX Bentivegna SC, Chew A, Choi JY, Koshiy B, Stephens JC;
PI WPI; 2002-075067/10.
DR Genotyping human matrix metalloproteinase 3 gene of an individual for
PT determining the haplotype of the individual, comprises determining the
PT identity of a nucleotide pair at specific polymorphic sites for two
PT copies of the gene.
XX Claim 17; Page 15; 83pp; English.
XX The present invention describes a method for genotyping a human matrix
CC metalloproteinase 3 (MMP3) gene of an individual. MMP3 has vulnery,
CC cyostatic and antiarteriosclerotic activity, and can be used in gene
CC therapy. The method can be used for improving the efficacy and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with MMP3 activity, e.g., wound healing,
CC cancer and coronary atherosclerosis; to validate MMP3 as a candidate
CC agent for treating a specific condition or disease predicted to be
CC associated with MMP3 activity; and in the design of clinical trials of
CC candidate drugs for treating a specific condition or disease predicted to
CC be associated with MMP3 activity. Polymorphic variants of a reference
CC sequence for MMP3 (see ABL01223) are useful in studying the expression
CC and function of MMP3, and in expressing MMP3 protein for use in screening
CC for candidate drugs to treat diseases related to MMP3 activity. ABL01225
CC to ABL01246 and ABL01247 to ABL01290 represent allele-specific
CC oligonucleotide (ASO) probes and primers used in the detection of
CC polymorphisms in the human MMP3 gene. ABL01291 to ABL01334 represent
CC preferred primers used in the detection of polymorphisms in the human

CC MMP3 gene
 XX
 SQ Sequence 10 BP; 6 A; 2 C; 2 G; 0 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 731 AGGAGAAACA 740
 |||||
 Db 1 AGGAGAAACA 10
 RESULT 683
 ABL01310
 ID ABL01310 standard; DNA; 10 BP.
 XX
 AC ABL01310;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human MMP3 gene polymorphism detection primer SEQ ID NO:89.
 XX
 KW Human; matrix metalloproteinase 3; MMP3; chromosome 11q22.3; SNP;
 KW haplotype; polymorphism; polymorphic; single nucleotide polymorphism;
 KW probe; primer; detection; genotyping; vulnerability; cytostatic; cancer;
 KW antiarteriosclerotic; gene therapy; coronary atherosclerosis;
 KW wound healing; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200179238-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012452.
 XX
 PR 17-APR-2000; 2000US-0197911P.
 PR 13-JUL-2000; 2000US-0218092P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
 XX
 DR WPI; 2002-075067/10.
 XX
 PT Genotyping human matrix metalloproteinase 3 gene of an individual for
 PT determining the haplotype of the individual, comprises determining the
 PT identity of a nucleotide pair at specific polymorphic sites for two
 PT copies of the gene.
 XX
 PS Claim 17; Page 15; 83pp; English.
 XX
 CC The present invention describes a method for genotyping a human matrix
 CC metalloproteinase 3 (MMP3) gene of an individual. MMP3 has vulnerary,
 CC cytostatic and antiarteriosclerotic activity, and can be used in gene
 CC therapy. The method can be used for improving the efficacy and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with MMP3 activity, e.g., wound healing,
 CC cancer and coronary atherosclerosis; to validate MMP3 as a candidate
 CC agent for treating a specific condition or disease predicted to be
 CC associated with MMP3 activity; and in the design of clinical trials of
 CC candidate drugs for treating a specific condition or disease predicted to
 CC be associated with MMP3 activity. Polymorphic variants of a reference
 CC sequence for MMP3 (see ABL01223) are useful in studying the expression
 CC and function of MMP3, and in expressing MMP3 protein for use in screening
 CC for candidate drugs to treat diseases related to MMP3 activity. ABL01225
 CC to ABL01246 and ABL01247 to ABL01290 represent allele-specific
 CC oligonucleotide (ASO) probes and primers used in the detection of
 CC polymorphisms in the human MMP3 gene. ABL01291 to ABL01334 represent
 CC preferred primers used in the detection of polymorphisms in the human
 CC MMP3 gene
 XX

SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 727 TGCAGGAGA 736
 |||||
 Db 1 TGCAGGAGAA 10
 RESULT 684
 ABL42763
 ID ABL42763 standard; cDNA; 10 BP.
 XX
 AC ABL42763;
 XX
 DT 12-APR-2002 (first entry)
 XX
 DE Human maturation/activation dendritic cell expression gene tag #137.
 XX
 KW Human; maturation/activation dendritic cell expression gene; tag;
 KW maturation; activation; dendritic cell; ss.
 XX
 OS Homo sapiens.
 XX
 PN JP2001327293-A.
 XX
 PD 27-NOV-2001.
 XX
 PF 22-MAY-2000; 2000JP-00150562.
 XX
 PR 22-MAY-2000; 2000JP-00150562.
 XX
 PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
 XX
 DR WPI; 2002-127070/17.
 XX
 PT Human maturation/activation dendritic cell expression gene group.
 XX
 PS Claim 10; Page 13; 41pp; Japanese.
 XX
 CC The present invention describes a human maturation/activation dendritic
 CC cell (DC) expression gene group consisting of 100 genes which show the
 CC highest expression among the genes expressed in human maturation/
 CC activation DC. Also described are: (1) a protein expressed by the above
 CC human maturation/activation DC expression gene; (2) an antibody against
 CC the protein; and (3) an antagonist against the expression of each gene
 CC belonging to the above gene group. The gene group is useful for the
 CC treatment and the diagnosis of various human diseases related to human
 CC DC. ABL42627 to ABL42926 represent specifically claimed human
 CC maturation/activation DC expression gene tags from the present invention
 XX
 SQ Sequence 10 BP; 4 A; 2 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 10;
 Best Local Similarity 90.0%; Pred. No. 5.2e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 730 CAGGAGAAAC 739
 |||||
 Db 1 CAGGAGAAAC 10
 RESULT 685
 AAS14466
 ID AAS14466 standard; DNA; 10 BP.
 XX
 AC AAS14466;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Primer-extension oligonucleotide #11 to detect human SCY11 polymorphisms.

```

XX KW Human; single nucleotide polymorphism; SNP; SCYA1; chromosome 17;
XX KW small inducible cytokine A1-I-309; haplotyping; genotyping; gene;
XX KW atherosclerosis; human immunodeficiency virus; HIV infection; primer; ss.
XX OS Homo sapiens.
XX PN WO200179236-A2.
XX PD 25-OCT-2001.
XX PF 16-APR-2001; 2001WO-US012305.
XX PR 14-APR-2000; 2000US-0197119P.
XX PA (GENA-) GENAISSANCE PHARM INC.
XX PI Choi JY, Klem SE, Koshy B, Sausker EA, Stephens JC;
XX WPI; 2002-075066/10.
XX DR Genotyping human small inducible cytokine A1-I-309, homologous to mouse
XX PT Tca-3 gene of individual, involves determining identity of nucleotide
XX PT pair at specific polymorphic sites for two copies of the gene.
XX PS Claim 17; Page 13; 58pp; English.
XX CC The present invention relates to novel single nucleotide polymorphisms
XX CC (SNPs) in the human small inducible cytokine A1-I-309 (SCYA1) gene
XX CC located on chromosome 17, and methods for haplotyping and/or genotyping
XX CC the SCYA1 gene. The methods of the invention make use of allele-specific
XX CC oligonucleotides (ASOs) as probes and primers and/or primer-extension
XX CC oligonucleotides for detecting the SCYA1 gene polymorphisms. The
XX CC polynucleotides and screened compounds are useful for the treatment of
XX CC diseases associated with SCYA1 activity, such as atherosclerosis, human
XX CC immunodeficiency virus (HIV) infection, and other inflammatory disorders.
XX CC AAS14456-AAS14473 represent primer-extension oligonucleotides for
XX CC detecting human SCYA1 gene polymorphisms
XX SQ Sequence 10 BP; 5 A; 4 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 737 AACAGAACAC 746
DB 1 AACAGAACCC 10

RESULT 686
ABV84410
ID ABV84410 standard; cDNA; 10 BP.
XX AC ABV84410;
XX DT 12-DEC-2002 (first entry)
XX DE Human methionine aminopeptidase/eIF-2-associated p67 SAGE tag #220.
XX KW SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
XX KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
XX KW expression pattern; differential expression; ss.
XX OS Homo sapiens.
XX PN JP2002209591-A.
XX PD 30-JUL-2002.
XX PF 19-JAN-2001; 2001JP-00012328.
XX PR 19-JAN-2001; 2001JP-00012328.

```

```

XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX WPI; 2002-631294/68.
XX DR Human chronic hepatitis C tissue expression exasperating gene group
XX PT comprises 100 high-ranking genes.
XX PS Claim 19; Page 16; 139pp; Japanese.
XX CC The invention relates to SAGE (serial analysis of gene expression) tags
XX CC representing groups of genes which are differentially expressed in human
XX CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
XX CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
XX CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
XX CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
XX CC polyA region of cDNAs derived from a variety of genes. These tags serve
XX CC to uniquely identify each transcript and can thus be used to analyse the
XX CC pattern of gene expression in particular cell types. The invention also
XX CC relates to proteins encoded by the genes expressed in chronic hepatitis C
XX CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
XX CC the expression of groups of genes that are overexpressed in chronic
XX CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
XX CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
XX CC treatment of these diseases. Such genes, inhibitors of their expression
XX CC or activity, and antibodies against the gene products may be used in the
XX CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
XX CC ABV84391-ABV84490 are SAGE tags representing the 100 most highly
XX CC expressed genes out of those genes which are overexpressed in
XX CC hepatocellular carcinoma compared with normal liver tissue
XX SQ Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 5.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 735 GAAACAGAAC 744
DB 1 GAAACAGAAC 10

RESULT 687
ABV84609
ID ABV84609 standard; cDNA; 10 BP.
XX AC ABV84609;
XX DT 12-DEC-2002 (first entry)
XX DE Human methionine aminopeptidase/eIF-2-associated p67 SAGE tag #419.
XX KW SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
XX KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
XX KW expression pattern; differential expression; ss.
XX OS Homo sapiens.
XX PN JP2002209591-A.
XX PD 30-JUL-2002.
XX PF 19-JAN-2001; 2001JP-00012328.
XX PR 19-JAN-2001; 2001JP-00012328.
XX PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX WPI; 2002-631294/68.
XX DR Human chronic hepatitis C tissue expression exasperating gene group
XX PT comprises 100 high-ranking genes.
XX

```

PS Claim 37; Page 22; 139pp; Japanese.

XX The invention relates to SAGE (serial analysis of gene expression) tags

CC representing groups of genes which are differentially expressed in human

CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced

CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.

CC The SAGE tags of this invention consist of a sequence of 10 nucleotides

CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the

CC polyA region of cDNAs derived from a variety of genes. These tags serve

CC to uniquely identify each transcript and can thus be used to analyse the

CC pattern of gene expression in particular cell types. The invention also

CC relates to proteins encoded by the genes expressed in chronic hepatitis C

CC liver tissue or HCC, antibodies against these proteins, and inhibitors of

CC the expression of groups of genes that are overexpressed in chronic

CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed

CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and

CC treatment of these diseases. Such genes, inhibitors of their expression

CC or activity, and antibodies against the gene products may be used in the

CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences

CC ABV84591-ABV84690 are SAGE tags representing the 100 most highly

CC expressed genes out of those genes which are overexpressed in

CC hepatocellular carcinoma compared with chronic hepatitis C liver tissue

XX

SQ Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 5.2e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 735 GAACAGAAC 744

DB 1 GAACAGAAC 10

RESULT 688

ABV84344

ID ABV84344 standard; cDNA; 10 BP.

XX

AC ABV84344;

XX

DT 12-DEC-2002 (first entry)

XX

DE Human DKFZP586I1023 protein-like EST SAGE tag #154.

XX

XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;

KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;

KW expression pattern; differential expression; EST; expressed sequence tag;

KW ss.

XX

OS Homo sapiens.

XX

XX JP2002209591-A.

XX

PN 30-JUL-2002.

XX

XX 19-JAN-2001; 2001JP-00012328.

XX

XX 19-JAN-2001; 2001JP-00012328.

PR

XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

PA

XX WPI; 2002-631294/68.

DR

XX

XX Human chronic hepatitis C tissue expression exasperating gene group

PT comprises 100 high-ranking genes.

XX

XX Claim 10; Page 14; 139pp; Japanese.

PS

XX The invention relates to SAGE (serial analysis of gene expression) tags

CC representing groups of genes which are differentially expressed in human

CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced

CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.

CC The SAGE tags of this invention consist of a sequence of 10 nucleotides

CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the

CC polyA region of cDNAs derived from a variety of genes. These tags serve

CC to uniquely identify each transcript and can thus be used to analyse the

CC pattern of gene expression in particular cell types. The invention also

CC relates to proteins encoded by the genes expressed in chronic hepatitis C

CC liver tissue or HCC, antibodies against these proteins, and inhibitors of

CC the expression of groups of genes that are overexpressed in chronic

CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed

CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and

CC treatment of these diseases. Such genes, inhibitors of their expression

CC or activity, and antibodies against the gene products may be used in the

CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences

CC ABV84591-ABV84690 are SAGE tags representing the 100 most highly

CC expressed genes out of those genes which are overexpressed in

CC hepatocellular carcinoma compared with chronic hepatitis C liver tissue

XX

SQ Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 5.2e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 735 GAACAGAAC 744

DB 1 GAACAGAAC 10

RESULT 688

ABV84344

ID ABV84344 standard; cDNA; 10 BP.

XX

AC ABV84344;

XX

DT 12-DEC-2002 (first entry)

XX

DE Human DKFZP586I1023 protein-like EST SAGE tag #154.

XX

XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;

KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;

KW expression pattern; differential expression; EST; expressed sequence tag;

KW ss.

XX

OS Homo sapiens.

XX

XX JP2002209591-A.

XX

PN 30-JUL-2002.

XX

XX 19-JAN-2001; 2001JP-00012328.

XX

XX 19-JAN-2001; 2001JP-00012328.

PR

XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

PA

XX WPI; 2002-631294/68.

DR

XX

XX Human chronic hepatitis C tissue expression exasperating gene group

PT comprises 100 high-ranking genes.

XX

XX Claim 10; Page 14; 139pp; Japanese.

PS

XX The invention relates to SAGE (serial analysis of gene expression) tags

CC representing groups of genes which are differentially expressed in human

CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced

CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.

CC The SAGE tags of this invention consist of a sequence of 10 nucleotides

CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the

CC polyA region of cDNAs derived from a variety of genes. These tags serve

CC to uniquely identify each transcript and can thus be used to analyse the

CC pattern of gene expression in particular cell types. The invention also

CC relates to proteins encoded by the genes expressed in chronic hepatitis C

CC liver tissue or HCC, antibodies against these proteins, and inhibitors of

CC the expression of groups of genes that are overexpressed in chronic

CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed

CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and

CC treatment of these diseases. Such genes, inhibitors of their expression

CC or activity, and antibodies against the gene products may be used in the

CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences

CC ABV84291-ABV84390 are SAGE tags representing the 100 least highly

CC expressed genes out of those genes which are underexpressed in chronic

CC hepatitis C liver tissue compared with normal liver tissue

XX

SQ Sequence 10 BP; 3 A; 3 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 5.2e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 727 TGCCAGGACA 736

DB 1 TGCCAGGACA 10

RESULT 689

AAD60146/c

ID AAD60146 standard; DNA; 10 BP.

XX

AC AAD60146;

XX

DT 18-DEC-2003 (first entry)

XX

XX Human ARG energy metabolism, apoptosis and redox regulator #1.

XX Human; androgen-regulated gene; ARG; PMEPAL; prostate cancer; ss.

XX

OS Homo sapiens.

XX

XX US6566130-B1.

XX

XX 20-MAY-2003.

PD

XX 26-JAN-2001; 2001US-00769482.

PF

XX 28-JAN-2000; 2000US-0178772P.

XX

XX 31-JAN-2000; 2000US-0179045P.

XX

XX (JACK-) JACKSON FOUND ADVANCEMENT MILITARY MED.

PA

XX Srivastava S, Moul JW, Xu LL, Segawa T;

XX

XX WPI; 2003-719644/68.

DR

XX

XX Novel isolated androgen-regulated gene designated as PMEPAL useful for

PT selecting primers and probes for detecting prostate cancer cells in

PT biological samples by nucleic acid amplification techniques.

XX

XX Example 7; Col 69; 58pp; English.

PS

XX The invention relates to an isolated androgen-regulated gene (ARG)

CC designated as PMEPAL. The invention is useful for selecting primers and

CC probes for detecting prostate cancer cells in a biological sample by

CC using nucleic acid amplification techniques. The present sequence is

CC human ARG energy metabolism, apoptosis and redox regulator

CC oligonucleotide

XX

SQ Sequence 10 BP; 1 A; 2 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 5.2e+02;

```
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 731 AGGAGAACACA 740
Db 10 AGGATTAACA 1

RESULT 690
ABQ86777/c
ID ABQ86777 standard; cDNA; 11 BP.
AC ABQ86777;
XX 10-SEP-2002 (first entry)
DT Human skin stress/ageing related EST SEQ ID NO 532.
DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
KW Homo sapiens.
XX WO200253773-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015178.
XX 03-JAN-2001; 2001DE-01000121.
XX (HENK ) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-528865/56.
XX Identifying genes involved in skin stress and aging, useful e.g. in
XX screening for cosmetic or therapeutic agents, based on differential gene
XX expression.
XX Claim 8; Page 59; 325pp; German.
XX The invention relates to identifying (M1) genes in vitro that, in humans
XX or animals, are important for skin ageing and/or skin stress by serial
XX analysis of gene expression between mixtures of transcribed and
XX optionally translated, genetically encoded factors (A) obtained from
XX young and aged skin, to identify that genes that show strong differential
XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX useful for: identifying markers of skin ageing and/or stress; determining
XX skin ageing and/or stress; and identifying or determining the effects of
XX pharmaceutical or cosmetic agents for control of skin ageing. The present
XX sequence is one of a group of human skin ageing/stress related expressed
XX sequence tags (ABQ86246-ABQ87680) of the invention
XX Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
PS Claim 8; Page 59; 325pp; German.
XX The invention relates to identifying (M1) genes in vitro that, in humans
XX or animals, are important for skin ageing and/or skin stress by serial
XX analysis of gene expression between mixtures of transcribed and
XX optionally translated, genetically encoded factors (A) obtained from
XX young and aged skin, to identify that genes that show strong differential
XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX useful for: identifying markers of skin ageing and/or stress; determining
XX skin ageing and/or stress; and identifying or determining the effects of
XX pharmaceutical or cosmetic agents for control of skin ageing. The present
XX sequence is one of a group of human skin ageing/stress related expressed
XX sequence tags (ABQ86246-ABQ87680) of the invention
XX Query Match 38.2%; Score 8.4; DB 1; Length 11;
XX Best Local Similarity 90.0%; Pred. No. 5.4e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 736 AAACAGAACACA 745
Db 10 AATCAGAACACA 1

RESULT 691
ABQ86292/c
ID ABQ86292 standard; cDNA; 11 BP.
XX AC ABQ86292;
XX 10-SEP-2002 (first entry)
DT Human skin stress/ageing related EST SEQ ID NO 47.
DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
```

```
XX Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253773-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015178.
XX 03-JAN-2001; 2001DE-01000121.
XX (HENK ) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-528865/56.
XX Identifying genes involved in skin stress and aging, useful e.g. in
XX screening for cosmetic or therapeutic agents, based on differential gene
XX expression.
XX Claim 8; Page 39; 325pp; German.
XX The invention relates to identifying (M1) genes in vitro that, in humans
XX or animals, are important for skin ageing and/or skin stress by serial
XX analysis of gene expression between mixtures of transcribed and
XX optionally translated, genetically encoded factors (A) obtained from
XX young and aged skin, to identify that genes that show strong differential
XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX useful for: identifying markers of skin ageing and/or stress; determining
XX skin ageing and/or stress; and identifying or determining the effects of
XX pharmaceutical or cosmetic agents for control of skin ageing. The present
XX sequence is one of a group of human skin ageing/stress related expressed
XX sequence tags (ABQ86246-ABQ87680) of the invention
XX Query Match 38.2%; Score 8.4; DB 1; Length 11;
XX Best Local Similarity 90.0%; Pred. No. 5.4e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 733 GAGAAACAGACA 742
Db 10 GATTAACAGACA 1

RESULT 692
ABQ86858/c
ID ABQ86858 standard; cDNA; 11 BP.
XX AC ABQ86858;
XX 10-SEP-2002 (first entry)
DT Human skin stress/ageing related EST SEQ ID NO 613.
DE Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253773-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015178.
XX 03-JAN-2001; 2001DE-01000121.
XX (HENK ) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
```

```

XX WPI; 2002-528865/56.
XX Identifying genes involved in skin stress and aging, useful e.g. in
XX screening for cosmetic or therapeutic agents, based on differential gene
XX expression.
XX Claim 8; Page 62; 325pp; German.
XX The invention relates to identifying (M1) genes in vitro that, in humans
XX or animals, are important for skin ageing and/or skin stress by serial
XX analysis of gene expression between mixtures of transcribed and
XX optionally translated, genetically encoded factors (A) obtained from
XX young and aged skin, to identify that genes that show strong differential
XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX useful for: identifying markers of skin ageing and/or stress; determining
XX skin ageing and/or stress; and identifying or determining the effects of
XX pharmaceutical or cosmetic agents for control of skin ageing. The present
XX sequence is one of a group of human skin ageing/stress related expressed
XX sequence tags (ABQ86246-ABQ87680) of the invention
XX Sequence 11 BP; 0 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 734 AGAAGACAGAA 743
DB 10 AGAAGACAGAA 1
RESULT 693
ABQ86986
ID ABQ86986 standard; cDNA; 11 BP.
XX
XX ABQ86986;
XX
XX 10-SEP-2002 (first entry)
XX Human skin stress/ageing related EST SEQ ID NO 741.
XX Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253773-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015178.
XX 03-JAN-2001; 2001DE-01000121.
XX (HENK ) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-528865/56.
XX Identifying genes involved in skin stress and aging, useful e.g. in
XX screening for cosmetic or therapeutic agents, based on differential gene
XX expression.
XX Claim 8; Page 68; 325pp; German.
XX The invention relates to identifying (M1) genes in vitro that, in humans
XX or animals, are important for skin ageing and/or skin stress by serial
XX analysis of gene expression between mixtures of transcribed and
XX optionally translated, genetically encoded factors (A) obtained from
XX young and aged skin, to identify that genes that show strong differential
XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX useful for: identifying markers of skin ageing and/or stress; determining

```

```

CC skin ageing and/or stress; and identifying or determining the effects of
CC pharmaceutical or cosmetic agents for control of skin ageing. The present
CC sequence is one of a group of human skin ageing/stress related expressed
CC sequence tags (ABQ86246-ABQ87680) of the invention
XX
XX Sequence 11 BP; 4 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 729 CCAGGAGGAA 738
DB 1 CCAGGAGGAA 10
RESULT 694
ABQ86782
ID ABQ86782 standard; cDNA; 11 BP.
XX
XX ABQ86782;
XX
XX 10-SEP-2002 (first entry)
XX Human skin stress/ageing related EST SEQ ID NO 537.
XX Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253773-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015178.
XX 03-JAN-2001; 2001DE-01000121.
XX (HENK ) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-528865/56.
XX Identifying genes involved in skin stress and aging, useful e.g. in
XX screening for cosmetic or therapeutic agents, based on differential gene
XX expression.
XX Claim 8; Page 59; 325pp; German.
XX The invention relates to identifying (M1) genes in vitro that, in humans
XX or animals, are important for skin ageing and/or skin stress by serial
XX analysis of gene expression between mixtures of transcribed and
XX optionally translated, genetically encoded factors (A) obtained from
XX young and aged skin, to identify that genes that show strong differential
XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
XX useful for: identifying markers of skin ageing and/or stress; determining
XX skin ageing and/or stress; and identifying or determining the effects of
XX pharmaceutical or cosmetic agents for control of skin ageing. The present
XX sequence is one of a group of human skin ageing/stress related expressed
XX sequence tags (ABQ86246-ABQ87680) of the invention
XX Sequence 11 BP; 3 A; 4 C; 3 G; 1 T; 0 U; 0 Other;
SQ
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 739 CAGAACACCG 748
DB 1 CAGAACACCG 10

```



```

RESULT 695
ABV68185/c
ID ABV68185 standard; cDNA; 11 BP.
XX
AC ABV68185;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 5971.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 112; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 2 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
XX
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 733 GAGAAACAGA 742
Db 10 GATTAACAGA 1
XX
RESULT 696
ABV65377
ID ABV65377 standard; cDNA; 11 BP.
XX
AC ABV65377;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 3163.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX
RESULT 697
ABV71340/c
ID ABV71340 standard; cDNA; 11 BP.
XX
AC ABV71340;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 9126.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 112; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 3 A; 4 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 739 CAGAACACCG 748
Db 1 CGGAACACCG 10
XX

```



```
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AAACAGAAC 745
DB 10 AATCAGAAC 1
|||||
|

RESULT 700
ABV67021/c
ID ABV67021 standard; cDNA; 11 BP.
XX
AC ABV67021;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 4807.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
FN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX (HENKEL KGAA.
XX
PA Petersohn D, Conradt M, Hofmann K;
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 157; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 1 A; 2 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 729 CCAGGAGAAA 738
DB 11 CCAGGAGAAA 2
|||||
|

RESULT 701
ABV62887
ID ABV62887 standard; cDNA; 11 BP.
XX
AC ABV62887;

Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 737 AACAGAACAC 746
DB 2 AACAGAACGC 11
|||||
|

RESULT 702
ABV63919/c
ID ABV63919 standard; cDNA; 11 BP.
XX
AC ABV63919;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 1705.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
FN WO200253774-A2.
XX
```


CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus; rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the skin. The present sequence is that of a human expressed sequence tag (EST) of the invention

SQ Sequence 11 BP; 0 A; 2 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 729 CCAGAGAGAAA 738

|||||

11 CCAGCAGAAA 2

RESULT 705

ABV62842/C

ID ABV62842 standard; cDNA; 11 BP.

XX AC ABV62842;

XX AC

DT 21-OCT-2002 (first entry)

XX Human skin EST 628.

XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;

XX immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;

XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

XX Homo sapiens.

XX WO200253774-A2.

XX 11-JUL-2002.

XX 20-DEC-2001; 2001WO-EP015179.

XX 03-JAN-2001; 2001DE-01000127.

XX (HENK) HENKEL KGAA.

XX Petersohn D, Conradt M, Hofmann K;

XX WPI; 2002-590638/63.

XX In vitro identification of skin-expressed genes, useful for determining

XX homeostasis and identifying cosmetic or pharmaceutical agents against

XX e.g. skin cancer.

XX Disclosure; Page 42; 1345pp; German.

XX The invention relates to in vitro identification (M1) of genes expressed

XX in the skin of humans or animals by subjecting a mixture of genetically

XX encoded factors from skin, to serial analysis of gene expression (SAGE)

XX so as to identify skin-expressed genes and quantify their expression.

XX (M1) is useful for identifying genes involved in skin homeostasis; to

XX determine skin homeostasis and to test agent (A) that maintains or

XX promotes skin homeostasis or that can be used for treating skin

XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;

XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;

XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the

XX skin. The present sequence is that of a human expressed sequence tag

XX (EST) of the invention

XX Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

XX Query Match 38.2%; Score 8.4; DB 1; Length 11;

XX Best Local Similarity 90.0%; Pred. No. 5.4e+02;

XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 736 AACACAGAAC 745

|||||

11 CCAGCAGAAA 2

RESULT 707

ABV71647

ID ABV71647 standard; cDNA; 11 BP.

XX AC ABV71647;

XX AC

DT 21-OCT-2002 (first entry)

XX Human skin EST 9433.

XX DE

XX XX

Db 10 AATCAGAAC 1

RESULT 706

ABV67553

ID ABV67553 standard; cDNA; 11 BP.

XX AC ABV67553;

XX AC

DT 21-OCT-2002 (first entry)

XX Human skin EST 5339.

XX DE

XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;

XX immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;

XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

XX Homo sapiens.

XX WO200253774-A2.

XX 11-JUL-2002.

XX 20-DEC-2001; 2001WO-EP015179.

XX 03-JAN-2001; 2001DE-01000127.

XX (HENK) HENKEL KGAA.

XX Petersohn D, Conradt M, Hofmann K;

XX WPI; 2002-590638/63.

XX In vitro identification of skin-expressed genes, useful for determining

XX homeostasis and identifying cosmetic or pharmaceutical agents against

XX e.g. skin cancer.

XX Disclosure; Page 172; 1345pp; German.

XX The invention relates to in vitro identification (M1) of genes expressed

XX in the skin of humans or animals by subjecting a mixture of genetically

XX encoded factors from skin, to serial analysis of gene expression (SAGE)

XX so as to identify skin-expressed genes and quantify their expression.

XX (M1) is useful for identifying genes involved in skin homeostasis; to

XX determine skin homeostasis and to test agent (A) that maintains or

XX promotes skin homeostasis or that can be used for treating skin

XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;

XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;

XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the

XX skin. The present sequence is that of a human expressed sequence tag

XX (EST) of the invention

XX Sequence 11 BP; 4 A; 1 C; 6 G; 0 T; 0 U; 0 Other;

XX Query Match 38.2%; Score 8.4; DB 1; Length 11;

XX Best Local Similarity 90.0%; Pred. No. 5.4e+02;

XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 732 GGAGAGAACAG 741

|||||

1 GGAGAGACAG 10

RESULT 707

ABV71647

ID ABV71647 standard; cDNA; 11 BP.

XX AC ABV71647;

XX AC

DT 21-OCT-2002 (first entry)

XX Human skin EST 9433.

XX DE

XX XX

KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX Claim 24; Page 304; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX Sequence 11 BP; 9 A; 2 C; 0 G; 0 T; 0 U; 0 Other;
 SQ Query Match 38.2%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 5.4e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AACACAGACA 745
 DB 2 AACACAAACA 11
 RESULT 708
 ABV68446/C
 ID ABV68446 standard; cDNA; 11 BP.
 XX AC ABV68446;
 XX 21-OCT-2002 (first entry)
 XX Human skin EST 6232.
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.

XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX Disclosure; Page 198; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX Sequence 11 BP; 0 A; 2 C; 1 G; 8 T; 0 U; 0 Other;
 SQ Query Match 38.2%; Score 8.4; DB 1; Length 11;
 Best Local Similarity 90.0%; Pred. No. 5.4e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 734 AGAAACAGAA 743
 DB 11 AAAAACAGAA 2
 RESULT 709
 ABV66482
 ID ABV66482 standard; cDNA; 11 BP.
 XX AC ABV66482;
 XX 21-OCT-2002 (first entry)
 XX Human skin EST 4268.
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX Disclosure; Page 143; 1345pp; German.

CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 4 A; 3 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 729 CCAGGAGAAA 738
Db 2 CCAGGGGAAA 11
|||||
RESULT 710
ABV69554
ID ABV69554 standard; cDNA; 11 BP.
XX
AC ABV69554;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 7340.
XX
XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Disclosure; Page 230; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention

SQ Sequence 11 BP; 4 A; 2 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 729 CCAGGAGAAA 738
Db 1 CCAGGGGAAA 10
|||||
RESULT 711
ABV70308
ID ABV70308 standard; cDNA; 11 BP.
XX
XX AC ABV70308;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 8094.
XX
XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Claim 24; Page 259; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
SQ Sequence 11 BP; 5 A; 3 C; 3 G; 0 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 5.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 737 AACAGAACAC 746
Db 2 AACAGAACAC 11
|||||
RESULT 712
AAV39563

```

ID AAV39563 standard; cDNA; 12 BP.
XX AC AAV39563;
XX DT 28-SEP-1998 (first entry)
XX DE Mass spectrometric analysis primer SEQ ID NO:86.
XX KW Mass spectrometry; diagnosis; detection; biological sample; infection;
XX KW genetic disease; chromosomal abnormality; identification; heredity;
XX KW pathogenic organism; telomerase activity; oncogene mutation;
XX KW cancer-specific sequence; primer; ss.
XX OS Synthetic.
XX PN WO9820166-A2.
XX PD 14-MAY-1998.
XX PF 06-NOV-1997; 97WO-US020444.
XX PR 06-NOV-1996; 96US-00744481.
XX PR 06-NOV-1996; 96US-00744590.
XX PR 06-NOV-1996; 96US-00746036.
XX PR 06-NOV-1996; 96US-00746055.
XX PR 23-JAN-1997; 97US-00786988.
XX PR 23-JAN-1997; 97US-00787639.
XX PR 19-SEP-1997; 97US-00933792.
XX PR 08-OCT-1997; 97US-00947801.
XX PA (SEQU-) SEQUENOM INC.
XX PI Koster H, Tang X, Fu D, Siebert CW, Little DP, Higgins GS;
XX PI Braun A, Damhoffer-Demar B, Jurinke C, Van Den Boom D, Xiang G;
XX PI Lough DM;
XX DR WPI; 1998-286975/25.
XX PT Sequencing nucleic acid by mass spectrometric analysis - for detecting
XX PT nucleic acids, telomerase activity, oncogene mutations, or cancer-
XX PT specific sequences, for diagnosis of disease.
XX PS Claim 48; Page 266; 478pp; English.
XX CC A process has been developed for determining the sequence of a target
XX CC nucleic acid. The process comprises: (i) generating at least two
XX CC fragments (F) from the target nucleic acid; and (ii) analysing F by mass
XX CC spectrometry (MS). The sequences in AAV39563 to AAV39592 are specifically
XX CC claimed primers for use in the mass spectrometric analysis of the above
XX CC process. The process is used to detect genetic diseases (e.g.
XX CC haemophilia, thalassemia, Duchenne muscular dystrophy, Alzheimer's
XX CC disease, cystic fibrosis and many others) or chromosomal abnormalities
XX CC (or predisposition); infections and cancers; also for establishing
XX CC identity and heredity. Particular applications are diagnosis of
XX CC neuroblastoma, detecting telomerase, determining family relationships and
XX CC HLA compatibility, and in genetic fingerprinting. Compared with known
XX CC methods using MS, this process requires fewer specific reagents and is
XX CC better suited to automation. Extended primers are shorter; primer
XX CC annealing is more efficient and the process allows detection of many
XX CC sequences simultaneously
XX SQ Sequence 12 BP; 5 A; 3 C; 4 G; 0 T; 0 U; 0 Other;
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 728 GCCAGGAGAA 737
DB 2 GCCAGGACAA 11

```

AAV39558
ID AAV39558 standard; cDNA; 12 BP.
XX AC AAV39558;
XX DT 28-SEP-1998 (first entry)
XX DE Mass spectrometric analysis primer SEQ ID NO:81.
XX KW Mass spectrometry; diagnosis; detection; biological sample; infection;
XX KW genetic disease; chromosomal abnormality; identification; heredity;
XX KW pathogenic organism; telomerase activity; oncogene mutation;
XX KW cancer-specific sequence; primer; ss.
XX OS Synthetic.
XX PN WO9820166-A2.
XX PD 14-MAY-1998.
XX PF 06-NOV-1997; 97WO-US020444.
XX PR 06-NOV-1996; 96US-00744481.
XX PR 06-NOV-1996; 96US-00744590.
XX PR 06-NOV-1996; 96US-00746036.
XX PR 06-NOV-1996; 96US-00746055.
XX PR 23-JAN-1997; 97US-00786988.
XX PR 23-JAN-1997; 97US-00787639.
XX PR 19-SEP-1997; 97US-00933792.
XX PR 08-OCT-1997; 97US-00947801.
XX PA (SEQU-) SEQUENOM INC.
XX PI Koster H, Tang X, Fu D, Siebert CW, Little DP, Higgins GS;
XX PI Braun A, Damhoffer-Demar B, Jurinke C, Van Den Boom D, Xiang G;
XX PI Lough DM;
XX DR WPI; 1998-286975/25.
XX PT Sequencing nucleic acid by mass spectrometric analysis - for detecting
XX PT nucleic acids, telomerase activity, oncogene mutations, or cancer-
XX PT specific sequences, for diagnosis of disease.
XX PS Claim 48; Page 264; 478pp; English.
XX CC A process has been developed for determining the sequence of a target
XX CC nucleic acid. The process comprises: (i) generating at least two
XX CC fragments (F) from the target nucleic acid; and (ii) analysing F by mass
XX CC spectrometry (MS). The sequences in AAV39483 to AAV39592 are specifically
XX CC claimed primers for use in the mass spectrometric analysis of the above
XX CC process. The process is used to detect genetic diseases (e.g.
XX CC haemophilia, thalassemia, Duchenne muscular dystrophy, Alzheimer's
XX CC disease, cystic fibrosis and many others) or chromosomal abnormalities
XX CC (or predisposition); infections and cancers; also for establishing
XX CC identity and heredity. Particular applications are diagnosis of
XX CC neuroblastoma, detecting telomerase, determining family relationships and
XX CC HLA compatibility, and in genetic fingerprinting. Compared with known
XX CC methods using MS, this process requires fewer specific reagents and is
XX CC better suited to automation. Extended primers are shorter; primer
XX CC annealing is more efficient and the process allows detection of many
XX CC sequences simultaneously
XX SQ Sequence 12 BP; 5 A; 3 C; 4 G; 0 T; 0 U; 0 Other;
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 728 GCCAGGAGAA 737
DB 2 GCCAGGACAA 11

RESULT 714
AA19666/c
ID AAX19666 standard; DNA; 12 BP.
XX
AC AAX19666;
XX
XX 03-JUN-1999 (first entry)
XX
XX Antisense 12-chain oligonucleotide.
XX
XX Cell membrane transfer; polynucleotide; polymer; polycation segment;
XX genetic disease; neoplastic disease; cardiovascular disease;
XX infectious disease; transplantation related disorder; ss.
XX
XX Synthetic.
XX
XX WO9906055-A1.
XX
XX 11-FEB-1999.
XX
XX 31-JUL-1998; 98WO-US016012.
XX
XX 01-AUG-1997; 97US-00912968.
XX
XX 30-JUL-1998; 98US-00124943.
XX
XX (SUPR-) SUPRATEK PHARMA INC.
XX
XX Kabanov AV, Alakov VY, Vinogradov SV;
XX
XX WPI; 1999-204365/17.
XX
XX New polymer compositions which include e.g. polycation segments.
XX
XX Example 9; Page 56; 94pp; English.
XX
XX The present invention describes polymer compositions comprising a
XX plurality of covalently bound polymer segments. The segments comprise:
XX (a) at least one polycation segment; and (b) at least one water-soluble
XX nonionic polymer segment. The polycation segment is a cationic homo- or
XX copolymer comprising at least three cationic amino acids or at least
XX three aminoalkylene monomers. The monomers are selected from: (i) at
XX least one tertiary amino monomer of formula (I), or a quaternary salt of
XX this; and (ii) at least one secondary amino monomer of formula (II), or
XX an acid addition or quaternary salt of this. The compositions may be used
XX for delivery of nucleic acids to cells. They may be used for treatment of
XX genetic diseases, neoplastic diseases, cardiovascular diseases,
XX infectious diseases or transplantation related disorders. Administration
XX by inhalation. The present sequence represents an oligonucleotide used in
XX an example from the present invention
XX
XX Sequence 12 BP; 0 A; 5 C; 2 G; 4 T; 1 U; 0 Other;
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 730 CAGGAGGAAC 739
XX |||||
XX Db 11 CAGGAGGAAC 2
XX
XX RESULT 715
AA19669/c
ID AAX19669 standard; DNA; 12 BP.
XX
XX AC AAX19669;
XX
XX 03-JUN-1999 (first entry)
XX
XX 12-mer oligonucleotide.
XX
XX Cell membrane transfer; polynucleotide; polymer; polycation segment;

KW Genetic disease; neoplastic disease; cardiovascular disease;
KW infectious disease; transplantation related disorder; ss.
XX
XX Synthetic.
XX
XX WO9906055-A1.
XX
XX 11-FEB-1999.
XX
XX 31-JUL-1998; 98WO-US016012.
XX
XX 01-AUG-1997; 97US-00912968.
XX
XX 30-JUL-1998; 98US-00124943.
XX
XX (SUPR-) SUPRATEK PHARMA INC.
XX
XX Kabanov AV, Alakov VY, Vinogradov SV;
XX
XX WPI; 1999-204365/17.
XX
XX New polymer compositions which include e.g. polycation segments.
XX
XX Example 21; Page 68; 94pp; English.
XX
XX The present invention describes polymer compositions comprising a
XX plurality of covalently bound polymer segments. The segments comprise:
XX (a) at least one polycation segment; and (b) at least one water-soluble
XX nonionic polymer segment. The polycation segment is a cationic homo- or
XX copolymer comprising at least three cationic amino acids or at least
XX three aminoalkylene monomers. The monomers are selected from: (i) at
XX least one tertiary amino monomer of formula (I), or a quaternary salt of
XX this; and (ii) at least one secondary amino monomer of formula (II), or
XX an acid addition or quaternary salt of this. The compositions may be used
XX for delivery of nucleic acids to cells. They may be used for treatment of
XX genetic diseases, neoplastic diseases, cardiovascular diseases,
XX infectious diseases or transplantation related disorders. Administration
XX by inhalation. The present sequence represents an oligonucleotide used in
XX an example from the present invention
XX
XX Sequence 12 BP; 0 A; 4 C; 3 G; 4 T; 1 U; 0 Other;
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 730 CAGGAGGAAC 739
XX |||||
XX Db 11 CAGGAGGAAC 2
XX
XX RESULT 716
AA87791
ID AAA87791 standard; DNA; 12 BP.
XX
XX AC AAA87791;
XX
XX 28-NOV-2000 (first entry)
XX
XX Promoter P13H2 transcription factor binding site SEQ ID #145.
XX
XX Human; secreted protein; forensic procedure; gene therapy;
XX chromosome mapping; cancer; autoimmune disease; cardiovascular disorder;
XX cystic fibrosis; hypothyroidism; immunological disorder; amyloidosis;
XX brain disorder; skeletal muscle disorder; eye disorder; obesity;
XX mitochondrial cytopathy; diabetes; atherosclerosis; Alzheimer's disease;
XX neurodegenerative disorder; graft rejection; dementia; hyperlipidaemia;
XX septic shock; impotence; promoter; P13H2; ds.
XX
XX Homo sapiens.
XX
XX WO200037491-A2.

PD 29-JUN-2000.
 XX
 PF 20-DEC-1999; 99WO-IB002058.
 XX
 PR 22-DEC-1998; 98US-0113686P.
 PR 25-JUN-1999; 99US-0141032P.
 XX
 PA (GEST) GENSET.
 XX
 PI Bougueleret L, Dumas J, Duclert A;
 PI WPI; 2000-442637/38.
 DR
 XX
 PT Polynucleotides and polypeptides encoding proteins with signal peptides,
 PT useful in diagnostic, forensic, gene therapy and chromosome mapping
 PT procedures.
 XX
 PS Example 48; Fig 5; 306pp; English.
 XX
 CC This sequence represents a transcription factor binding site identified
 CC in the human p132 promoter. The invention relates to sequences AA87725-
 CC A87774 which encode human secreted proteins AB25763-B25812. The proteins
 CC include signal peptides. The p132 promoter is used in the isolation of
 CC the cDNAs of the invention. Included in the invention are a host cell
 CC containing one of the cDNA sequences, and a purified antibody capable of
 CC binding to one of the secreted proteins. Also contained in the invention
 CC are methods for storing the sequence data on a computer system, and a
 CC method for identifying features of the cDNA sequences using a computer
 CC programme. The cDNAs are useful for expressing secreted proteins or
 CC fragments to obtain antibodies capable of specifically binding to the
 CC secreted proteins. The cDNAs may also be useful in diagnostic, forensic,
 CC gene therapy and chromosome mapping procedures and may be used to design
 CC expression vectors and secretion vectors. The proteins of the invention
 CC may be used to treat diseases including cancer, autoimmune diseases,
 CC cardiovascular disorders, cystic fibrosis, hypothyroidism, immunological
 CC disorders, amyloidosis, brain disorders, skeletal muscle disorders, eye
 CC neurodegenerative disorders, graft rejection, Alzheimer's disease,
 CC dementia, hyperlipidaemia, septic shock and impotence
 XX
 SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGACAA 745
 Db ||||| |||||
 3 AAACAGACAA 12
 RESULT 717
 AAA06954/c
 ID AAA06954 standard; RNA; 12 BP.
 XX
 AC AAA06954;
 XX
 DT 03-JUL-2000 (first entry)
 XX
 DE Human XIAP IRES mutant polypyrimidine tract, SEQ ID NO:18.
 XX
 KW X-linked inhibitor of apoptosis protein; XIAP; IRES;
 KW internal ribosome entry site; human; cap-independent translation;
 KW drug screening; cancer; autoimmune disease; degenerative disease;
 KW immunorejection; Gene therapy; mutant; polypyrimidine tract; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200005366-A2.
 XX
 PD 03-FEB-2000.
 XX

PF 22-JUL-1999; 99WO-IB001415.
 XX
 PR 24-JUL-1998; 98US-00121979.
 PR 14-JUN-1999; 99US-00332319.
 XX
 PA (UYOT-) UNIV OTTAWA.
 XX
 PI Korneluk RG, Holcik M, Liston P;
 PI WPI; 2000-338644/29.
 DR
 XX
 PT New isolated X-linked inhibitor of apoptosis internal ribosome entry
 PT site, used to develop agents for treating, e.g. cancer.
 XX
 PS Example IV; Fig 5A; 87pp; English.
 XX
 CC The invention relates to the identification of modulators of cap-
 CC independent translation and apoptosis. The method comprises exposing a
 CC test compound to an X-linked inhibitor of apoptosis protein (XIAP)
 CC internal ribosome entry site (IRES) reporter cistron, and determining the
 CC amount of translation from the XIAP IRES reporter cistron exposed to the
 CC compound relative to the translation from the unexposed XIAP IRES
 CC reporter cistron. A relative increase in translation from the exposed
 CC XIAP IRES reporter cistron indicates a compound that increases XIAP IRES-
 CC dependent (cap independent) translation. XIAP protein plays a critical
 CC role in the regulation of apoptosis by suppressing activation of
 CC downstream caspase-3 and caspase-7. Compounds identified by the method
 CC which decrease XIAP IRES-dependent translation (thus leading to reduced
 CC expression of XIAP and hence increasing apoptosis) can be used for
 CC treating cancer. The methods can also be used for the identification of
 CC agents that upregulate XIAP translation and hence inhibit apoptosis,
 CC which can be used to treat autoimmune diseases, degenerative diseases or
 CC immunorejection. Such agents may, for example, be used to inhibit
 CC apoptosis of neurons in conditions such as Alzheimer's disease; islet
 CC cells in autoimmune diabetes mellitus; photoreceptor cells in retinitis
 CC pigmentosa and diabetic retinopathy; and cardiomyocytes after myocardial
 CC infarction. They can also be used to enhance the survival of cell or
 CC organ transplants. XIAP IRES elements can also be incorporated into
 CC expression constructs which encode XIAP or other IAPs (inhibitor of
 CC apoptosis proteins, e.g., XIAP; AAY81440). Such constructs may be used in
 CC gene therapy to inhibit apoptosis in a cell. Sequences AAA06947-A06954
 CC represent the RNA sequences of mutant human XIAP IRES polypyrimidine
 CC tracts which, along with the wild-type polypyrimidine tract (AAA06946),
 CC were used in an exemplification of the present invention to determine
 CC whether the polypyrimidine tract is important for XIAP IRES function
 XX
 SQ Sequence 12 BP; 2 A; 2 C; 1 G; 0 T; 7 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGACAA 745
 Db ||||| |||||
 10 AAACAGACAA 1
 RESULT 718
 AAA91860/c
 ID AAA91860 standard; DNA; 12 BP.
 XX
 AC AAA91860;
 XX
 DT 15-SEP-2003 (revised)
 DT 05-JAN-2001 (first entry)
 XX
 DE Oligonucleotide complementary to part of Herpes Simplex Virus 1.
 XX
 KW Block copolymer; genetic; neoplastic; cardiovascular; infectious disease;
 KW HIV; AIDS; cancer; Herpes Simplex Virus 1; HSV-1; antisense;
 KW oligonucleotide; DNA-RNA hybrid; ss.
 XX
 OS Human herpesvirus 1.

```
XX Key Location/Qualifiers
FH misc_RNA 12
FT 12 /*tag= a
FT /label= RNA
XX
XX WO200047186-A1.
XX
XX 17-AUG-2000.
XX
XX 06-JAN-2000; 2000WO-US000309.
XX
XX 08-JAN-1999; 99US-00227364.
XX
XX (SUPR-) SUPRATEK PHARMA INC.
XX (KABA/) KABANOV A V.
XX
XX Kabanov AV, Lemieux PM, Vinogradov SV, Alakhov VY;
XX WPI; 2000-571847/53.
XX
XX Composition for gene therapy comprises polynucleotide and polyoxyethylene
XX -polyoxypropylene block copolymer in amounts insufficient for gel
XX formation.
XX
XX Example 9; Page 58; 112pp; English.
XX
XX The present invention relates to compositions of a polynucleotide or its
XX derivatives and at least one polyoxyethylene-polyoxypropylene block
XX copolymer. The compositions of the invention form a molecular solution or
XX colloidal dispersion. The invention is used for delivering a
XX polynucleotide to a cell for gene therapy of an animal. Diseases that may
XX be treated by the invention include genetic, neoplastic, cardiovascular
XX and infectious diseases. The use of the block copolymers reduces the
XX number of polynucleotide molecules and the time required to obtain an
XX immune response, so that a booster injection is not required.
XX Additionally, the risk of integration of polynucleotides into the
XX chromosomes of the host organism is reduced and the risk of developing
XX anti-polynucleotide antibodies is reduced. The present sequence is an
XX oligonucleotide complementary to the splicing site at 983-994 of the
XX Herpes Simplex Virus 1 (HSV-1). This antisense oligonucleotide was
XX designed to inhibit Herpes Virus. (Updated on 15-SEP-2003 to standardise
XX OS field)
XX
XX Sequence 12 BP; 0 A; 5 C; 2 G; 4 T; 1 U; 0 Other;
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 730 CAGGAGGAAC 739
XX |||||
XX 11 CAGGAGGAAC 2
XX
XX Db
XX
XX RESULT 719
XX AAA91863/c
XX ID AAA91863 standard; DNA; 12 BP.
XX
XX AC AAA91863;
XX
XX 15-SEP-2003 (revised)
XX DT 05-JAN-2001 (first entry)
XX
XX Oligonucleotide A complementary to part of Herpes Simplex Virus 1.
XX
XX Block copolymer; genetic; neoplastic; cardiovascular; infectious disease;
XX HIV; AIDS; cancer; Herpes Simplex Virus 1; HSV-1; antisense;
XX oligonucleotide; DNA-RNA hybrid; ss.
XX
XX Human herpesvirus 1.
XX
XX Key Location/Qualifiers
```

```
FT misc_RNA 12
FT 12 /*tag= a
FT /label= RNA
XX
XX WO200047186-A1.
XX
XX 17-AUG-2000.
XX
XX 06-JAN-2000; 2000WO-US000309.
XX
XX 08-JAN-1999; 99US-00227364.
XX
XX (SUPR-) SUPRATEK PHARMA INC.
XX (KABA/) KABANOV A V.
XX
XX Kabanov AV, Lemieux PM, Vinogradov SV, Alakhov VY;
XX WPI; 2000-571847/53.
XX
XX Composition for gene therapy comprises polynucleotide and polyoxyethylene
XX -polyoxypropylene block copolymer in amounts insufficient for gel
XX formation.
XX
XX Example 21; Page 68; 112pp; English.
XX
XX The present invention relates to compositions of a polynucleotide or its
XX derivatives and at least one polyoxyethylene-polyoxypropylene block
XX copolymer. The compositions of the invention form a molecular solution or
XX colloidal dispersion. The invention is used for delivering a
XX polynucleotide to a cell for gene therapy of an animal. Diseases that may
XX be treated by the invention include genetic, neoplastic, cardiovascular
XX and infectious diseases. The use of the block copolymers reduces the
XX number of polynucleotide molecules and the time required to obtain an
XX immune response, so that a booster injection is not required.
XX Additionally, the risk of integration of polynucleotides into the
XX chromosomes of the host organism is reduced and the risk of developing
XX anti-polynucleotide antibodies is reduced. The present sequence is
XX oligonucleotide A complementary to the splice site of the early mRNA of
XX Herpes Simplex Virus 1 (HSV-1). This antisense oligonucleotide was
XX designed to inhibit Herpes Virus. (Updated on 15-SEP-2003 to standardise
XX OS field)
XX
XX Sequence 12 BP; 0 A; 4 C; 3 G; 4 T; 1 U; 0 Other;
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 730 CAGGAGGAAC 739
XX |||||
XX 11 CAGGAGGAAC 2
XX
XX Db
XX
XX RESULT 720
XX ABI21106/c
XX ID ABI21106 standard; DNA; 12 BP.
XX
XX AC ABI21106;
XX
XX 22-FEB-2002 (first entry)
XX DT
XX
XX Oligonucleotide primer SEQ ID NO 321079 for detecting SNP TSC0030058.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
```


CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 737 AACAGAACAC 746
|||||
Db 11 AACACACAC 2

RESULT 723

AB114280
ID AB114280 standard; DNA; 12 BP.

XX AC AB114280;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 314253 for detecting SNP TSC0026236.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW Peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX PS Claim 1; SEQ ID NO 314253; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABIC00010-ABIC2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACAGAACAC 745
|||||
Db 1 AACACACAC 10

RESULT 724

AB116668/C

ID AB116668 standard; DNA; 12 BP.

XX AC AB116668;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 316641 for detecting SNP TSC0027537.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX PS Claim 1; SEQ ID NO 316641; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABIC00010-ABIC2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACAGAACAC 745

|||||
Db 10 AACACACAC 1

RESULT 725

AB160821

ID AB160821 standard; DNA; 12 BP.

XX AC AB160821;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 360794 for detecting SNP TSC0052235.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 360794; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP);
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAAC 745
 Db 3 AAACAGAAC 12
 RESULT 726
 ABI80715
 ID ABI80715 standard; DNA; 12 BP.
 XX AC ABI80715;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 380688 for detecting SNP TSC0008685.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 272424; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP);
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAAC 745
 Db 3 AAACAGAAC 12
 RESULT 727
 ABH72439
 ID ABH72439 standard; DNA; 12 BP.
 XX AC ABH72439;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 272424 for detecting SNP TSC0002812.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 272424; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP);
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAAC 745
 Db 3 AAACAGAAC 12

XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 380688; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP);
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAAC 745
 Db 3 AAACAGAAC 12
 RESULT 727
 ABH72439
 ID ABH72439 standard; DNA; 12 BP.
 XX AC ABH72439;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 272424 for detecting SNP TSC0002812.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 272424; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP);
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAAC 745
 Db 3 AAACAGAAC 12

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACACAGAAC 745

Db 1 AACACAGAAC 10

RESULT 728

ABH76766/c

ID ABH76766 standard; DNA; 12 BP.

AC ABH76766;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 276759 for detecting SNP TSC0004276.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 276759; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 735 GAAACAGAAC 744

Db 12 GAAACAGAAC 3

RESULT 729

ID AB104071 standard; DNA; 12 BP.

XX AB104071;

XX AC AB104071;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 304044 for detecting SNP TSC0020762.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 304044; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 734 AGAACAGAAC 743

Db 1 AGAACAGAAC 10

RESULT 730

AB159560

ID AB159560 standard; DNA; 12 BP.

XX

AC ABI59560;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 359533 for detecting SNP TSC0051639.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX Claim 1; SEQ ID NO 359533; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 0 Other;
SQ
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 731 AGGAGAAACA 740
DB 3 AGGAGAAAGA 12
RESULT 731
ABH71510/C
ID ABH71510 standard; DNA; 12 BP.
XX
XX ABH71510;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 271487 for detecting SNP TSC0002519.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN

XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX Claim 1; SEQ ID NO 271487; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
SQ
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 737 AACAGAACAC 746
DB 12 AACAAACAC 3
RESULT 732
ABI44439
ID ABI44439 standard; DNA; 12 BP.
XX
XX ABI44439;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 34412 for detecting SNP TSC0006223.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 344412; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAGACAGACA 745
 Db 1 AAGACATACA 10
 RESULT 733
 ABI51302/c
 ID ABI51302 standard; DNA; 12 BP.
 XX
 AC ABI51302;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 351275 for detecting SNP TSC0047201.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 351275; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAGACAGACA 745
 Db 1 AAGACATACA 10
 RESULT 733
 ABI51302/c
 ID ABI51302 standard; DNA; 12 BP.
 XX
 AC ABI51302;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 351275 for detecting SNP TSC0047201.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 351275; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAGACAGACA 745
 Db 1 AAGACATACA 10
 RESULT 733
 ABI51302/c
 ID ABI51302 standard; DNA; 12 BP.
 XX
 AC ABI51302;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 351275 for detecting SNP TSC0000396.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 355193; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 734 AGAAACAGAA 743

```

Db      ||||| |||||
        10 AGAAGAGAA 1
RESULT 735
ABI82023/c
XX ID   ABI82023 standard; DNA; 12 BP.
XX AC   ABI82023;
XX DT   22-FEB-2002 (first entry)
XX DE   Oligonucleotide primer SEQ ID NO 381996 for detecting SNP TSC0064673.
XX KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS   Homo sapiens.
XX PN   WO200177384-A2.
XX PD   18-OCT-2001.
XX PF   06-APR-2001; 2001WO-IB000713.
XX PR   07-APR-2000; 2000DE-01019173.
XX PA   (EPIG-) EPIGENOMICS AG.
XX PI   Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 381996; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
Query Match      38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      735 GAACAGAAC 744
        ||||| |||||
        11 GAACAGAAC 2
Db
RESULT 736
ABH71928/c
XX ID   ABH71928 standard; DNA; 12 BP.
XX AC   ABH71928;
XX DT   22-FEB-2002 (first entry)
XX DE   Oligonucleotide primer SEQ ID NO 271905 for detecting SNP TSC0002650.

```

```

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS   Homo sapiens.
XX PN   WO200177384-A2.
XX PD   18-OCT-2001.
XX PF   06-APR-2001; 2001WO-IB000713.
XX PR   07-APR-2000; 2000DE-01019173.
XX PA   (EPIG-) EPIGENOMICS AG.
XX PI   Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 271905; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match      38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      735 AAACAGAAC 745
        ||||| |||||
        10 AAACAGAAC 1
Db
RESULT 737
ABH74652
XX ID   ABH74652 standard; DNA; 12 BP.
XX AC   ABH74652;
XX DT   22-FEB-2002 (first entry)
XX DE   Oligonucleotide primer SEQ ID NO 274637 for detecting SNP TSC0003624.
XX KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS   Homo sapiens.
XX PN   WO200177384-A2.
XX PD   18-OCT-2001.
XX PF   06-APR-2001; 2001WO-IB000713.

```

```

PR 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 274637; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 736 AACAGAAACA 745
DB 2 AACAGAAACA 11
|||||
2 AACAGAAACA 11
RESULT 738
ABI00098/c
ID ABI00098 standard; DNA; 12 BP.
XX AC ABI00098;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 300071 for detecting SNP TSC0018852.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 300071; 29pp + Sequence Listing; German.

```

```

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 737 AACAGAAACA 746
DB 12 AACAGAAACA 3
|||||
12 AACAGAAACA 3
RESULT 739
ABI04241/c
ID ABI04241 standard; DNA; 12 BP.
XX AC ABI04241;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 304214 for detecting SNP TSC0020823.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 304214; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

```

```

XX SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 738 ACAGAACACC 747
Db 10 ACAAACACC 1
|||||
RESULT 740
ABI39615/C
ID ABI39615 standard; DNA; 12 BP.
XX AC ABI39615;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 339588 for detecting SNP TSC0041089.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 339588; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 2 C; 0 G; 7 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 734 AGAATAGAA 743
Db 10 AGAATAGAA 1
|||||
RESULT 741
ABI39615/C
ID ABI39615 standard; DNA; 12 BP.
XX AC ABI39615;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 339588 for detecting SNP TSC0058802.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 339588; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 736 AAACAGACA 745
Db 11 AAACAGACA 2
|||||
RESULT 742
ABI71507/C
ID ABI71507 standard; DNA; 12 BP.
XX AC ABI71507;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 371480 for detecting SNP TSC0058802.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 341601; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 736 AAACAGACA 745
Db 11 AAACAGACA 2
|||||
RESULT 742
ABI71507/C
ID ABI71507 standard; DNA; 12 BP.
XX AC ABI71507;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 371480 for detecting SNP TSC0058802.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 341601; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

```


CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 738 ACAGAACACC 747
 ||| |||||
 Db 1 ACAAACACC 10

RESULT 745
 ABH96984/c
 ID ABH96984 standard; DNA; 12 BP.

XX AC ABH96984;
 XX
 DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 296977 for detecting SNP TSC0017378.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 296977; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 0 A; 5 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 733 GAGAAACAGA 742
 ||| |||||
 Db 11 GAGAAAGAGA 2

RESULT 746
 ABH72374
 ID ABH72374 standard; DNA; 12 BP.

XX AC ABH72374;
 XX
 DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 272355 for detecting SNP TSC0002794.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 272355; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AAACAGACACA 745
 ||| |||||
 Db 2 AAACACACACA 11

RESULT 747
 ABI28308/c
 ID ABI28308 standard; DNA; 12 BP.

XX AC ABI28308;

XX

DT 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 328281 for detecting SNP TSC0034210.
DE SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 328281; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 736 AACAGAACCA 745
DB 11 AACATACCA 2
RESULT 748
ABH79310
ID ABH79310 standard; DNA; 12 BP.
XX AC ABH79310;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 279303 for detecting SNP TSC0007155.
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 279303; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
CC Query Match 38.2%; Score 8.4; DB 1; Length 12;
CC Best Local Similarity 90.0%; Pred. No. 5.6e+02;
CC Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 737 AACAGAACAC 746
DB 3 AACAAACAC 12
RESULT 749
ABH84560
ID ABH84560 standard; DNA; 12 BP.
XX AC ABH84560;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 284553 for detecting SNP TSC0011877.
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PT methylation status.
 PS Claim 1; SEQ ID NO 284553; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGACAC 746
 DB 3 AACACACAC 12
 RESULT 750
 ABH87662/C
 ID ABH87662 standard; DNA; 12 BP.
 AC ABH87662;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 287655 for detecting SNP TSC0013191.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 ER 07-APR-2000; 2000DE-01019173.
 XX
 FA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 287655; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGACAC 746
 DB 1 AACACACAC 10
 RESULT 751
 ABI20069
 ID ABI20069 standard; DNA; 12 BP.
 AC ABI20069;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 320042 for detecting SNP TSC0029553.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 ER 07-APR-2000; 2000DE-01019173.
 XX
 FA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 320042; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGACAC 746
 DB 1 AACACACAC 10

KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
PD	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	(EPIG-) EPIGENOMICS AG.
XX	Olek A, Piepenbrock C, Berlin K;
XX	WPI; 2001-657177/75.
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	Claim 1; SEQ ID NO 300072; 29pp + Sequence Listing; German.
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;
XX	Query Match 38.2%; Score 8.4; DB 1; Length 12;
XX	Best Local Similarity 90.0%; Pred. No. 5.6e+02;
XX	Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	737 AACAGAACAC 746
Db	12 AACAAACAC 3
XX	RESULT 754
XX	ABI00099/c
XX	ID ABI16680 standard; DNA; 12 BP.
XX	AC ABI16680;
XX	22-FEB-2002 (first entry)
XX	Oligonucleotide primer SEQ ID NO 316653 for detecting SNP TSC0027543.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	SNP; single nucleotide polym

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 316653; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGAACAC 746
 DB 12 AACAAACAC 3
 |||||
 |||||
 RESULT 755
 ABI43673/C
 ID ABI43673 standard; DNA; 12 BP.
 XX
 XX ABI43673;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 343646 for detecting SNP TSC0043181.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 343646; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 738 ACAGAACACC 747
 DB 10 ACAAAACACC 1
 |||||
 |||||
 RESULT 756
 ABI71048
 ID ABI71048 standard; DNA; 12 BP.
 XX
 XX ABI71048;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 371021 for detecting SNP TSC0058524.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 371021; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

PN WO200177384-A2.
 PD 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 303454; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGAACAC 746
 Db |||||
 11 AACAAACAC 2
 RESULT 760
 ID ABI05429/C
 XX ABI05429 standard; DNA; 12 BP.
 AC ABI05429;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 303454 for detecting SNP TSC0021427.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 303454; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGAACAC 746
 Db |||||
 11 AACAAACAC 2

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 305402; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGAACAC 746
 Db |||||
 11 AACAAACAC 2
 RESULT 761
 ID ABH87618
 XX ABH87618 standard; DNA; 12 BP.
 AC ABH87618;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 287611 for detecting SNP TSC0013168.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 287611; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The

DE Oligonucleotide primer SEQ ID NO 305010 for detecting SNP TSC0021207.
 XX
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 305010; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 3 C; 5 G; 0 T; 0 U; 0 Other;
 XX
 CC Query Match 38.2%; Score 8.4; DB 1; Length 12;
 CC Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 CC Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 730 CAGGAGAAAC 739
 Db 3 CCGGAGAAAC 12
 XX
 RESULT 765
 ABI07062
 ID ABI07062 standard; DNA; 12 BP.
 XX
 AC ABI07062;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 307035 for detecting SNP TSC0022307.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 307035; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;
 XX
 CC Query Match 38.2%; Score 8.4; DB 1; Length 12;
 CC Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 CC Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 733 GAGAAACAGA 742
 Db 3 GAGAAAGAGA 12
 XX
 RESULT 766
 ABH84195/c
 ID ABH84195 standard; DNA; 12 BP.
 XX
 AC ABH84195;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 284188 for detecting SNP TSC0011703.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

```

PS Claim 1; SEQ ID NO 284188; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 736 AAACAGAACCA 745
DB 12 AAACATACCA 3
RESULT 767
ABH87477
ID ABH87477 standard; DNA; 12 BP.
AC ABH87477;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 287470 for detecting SNP TSC0013106.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 287470; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 736 AAACAGAACCA 745
DB 12 AAACATACCA 3
RESULT 768
ABH13642/C
ID ABH13642 standard; DNA; 12 BP.
XX
AC ABH13642;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 313615 for detecting SNP TSC0025865.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 313615; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 2 C; 0 G; 7 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 734 AGAACAGAAC 743
DB 12 AGAAATAGAA 3

```

```
RESULT 769
ABH90374
ID ABH90374 standard; DNA; 12 BP.
XX
AC ABH90374;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 290367 for detecting SNP TSC0014319.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PD WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 290367; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and ABI0010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 736 AACACAGACA 745
DB 3 AACACAGACA 12
|||||
RESULT 770
ABI57707
ID ABI57707 standard; DNA; 12 BP.
XX
AC ABI57707;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 357680 for detecting SNP TSC0005077.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 357680; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and ABI0010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 731 AGGAGAAACA 740
DB 1 AGGAGAAATA 10
|||||
RESULT 771
ABI30960/c
ID ABI30960 standard; DNA; 12 BP.
XX
AC ABI30960;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 330933 for detecting SNP TSC0035850.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
```



```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 330933; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 737 AACGACAC 746
DB 10 AACGACAC 1
|||||

RESULT 772
ABI34691
ID ABI34691 standard; DNA; 12 BP.
XX
AC ABI34691;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 334664 for detecting SNP TSC0038335.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 334664; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 736 AACGACAC 745
DB 2 AACGACAC 11
|||||

RESULT 773
ABI11095
ID ABI11095 standard; DNA; 12 BP.
XX
AC ABI11095;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 311068 for detecting SNP TSC0024293.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 311068; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;

```

```

Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 GAGAAACAGA 742
DB 1 GAGAAAGAGA 10
|||||
RESULT 774
ABI36833
ID ABI36833 standard; DNA; 12 BP.
XX
AC ABI36833;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 336806 for detecting SNP TSC0039530.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 336806; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 737 AACAGAACAC 746
DB 1 AACAGAACAC 10
|||||
RESULT 775
ABH87388
ID ABH87388 standard; DNA; 12 BP.
XX
ABH87388;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 314228 for detecting SNP TSC0026215.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
ABH87388;

```

```

XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 287381 for detecting SNP TSC0013065.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 287381; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 6 A; 4 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACAGAACAC 745
DB 3 AACAGAACAC 12
|||||
RESULT 776
ABI14255
ID ABI14255 standard; DNA; 12 BP.
XX
ABI14255;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 314228 for detecting SNP TSC0026215.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX

```

PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 314228; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 736 AAACAGAAC 745
Db 2 AAACAGAAC 11
RESULT 777
ABI17022/c
ID ABI17022 standard; DNA; 12 BP.
XX
AC ABI17022;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 316995 for detecting SNP TSC0027741.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 316995; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 734 AGAAACAGAA 743
Db 11 AGAAACAGAA 2
RESULT 778
ABI67989/c
ID ABI67989 standard; DNA; 12 BP.
XX
AC ABI67989;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367962 for detecting SNP TSC0009109.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 367962; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 736 AACACAGAAC 745

Db 11 AACACATACA 2

RESULT 779

ABI77598

ID ABI77598 standard; DNA; 12 BP.

XX AC

ABI77598;

XX DT

22-FEB-2002 (first entry)

XX DE

Oligonucleotide primer SEQ ID NO 377571 for detecting SNP TSC0062398.

XX KW

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS

Homo sapiens.

XX FN

WO200177384-A2.

XX PD

18-OCT-2001.

XX PF

06-APR-2001; 2001WO-IB000713.

XX PR

07-APR-2000; 2000DE-01019173.

XX PA

(EPIG-) EPIGENOMICS AG.

XX PI

Olek A, Piepenbrock C, Berlin K;

XX DR

WPI; 2001-657177/75.

XX PT

Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS

Claim 1; SEQ ID NO 377571; 29pp + Sequence Listing; German.

XX CC

This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB192073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ

Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match

Best Local Similarity 38.2%; Score 8.4; DB 1; Length 12;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 738 ACAGACAC 747

|||||

Db 3 ACAAAACACC 12

RESULT 780

ABH95015/C

ID ABH95015 standard; DNA; 12 BP.

XX AC

ABH95015;

XX DT

22-FEB-2002 (first entry)

XX DE

Oligonucleotide primer SEQ ID NO 295008 for detecting SNP TSC0016398.

XX KW

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS

Homo sapiens.

XX FN

WO200177384-A2.

XX PD

18-OCT-2001.

XX PF

06-APR-2001; 2001WO-IB000713.

XX PR

07-APR-2000; 2000DE-01019173.

XX PA

(EPIG-) EPIGENOMICS AG.

XX PI

Olek A, Piepenbrock C, Berlin K;

XX DR

WPI; 2001-657177/75.

XX PT

Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS

Claim 1; SEQ ID NO 295008; 29pp + Sequence Listing; German.

XX CC

This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB192073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ

Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match

Best Local Similarity 38.2%; Score 8.4; DB 1; Length 12;

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 736 AACACAGAAC 745

|||||

12 AACACATACA 3

Db

RESULT 781

ABH80275/C

ID ABH80275 standard; DNA; 12 BP.

XX AC

ABH80275;

XX DT

22-FEB-2002 (first entry)

XX DE

Oligonucleotide primer SEQ ID NO 280268 for detecting SNP TSC0008419.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 280268; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: the sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AACAGAAACA 745
 DB 12 AACAAACA 3
 RESULT 782
 ABI13568/C
 ID ABI13568 standard; DNA; 12 BP.
 XX AC ABI13568;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 313541 for detecting SNP TSC0025831.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 313543; 29pp + Sequence Listing; German.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 313541; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGAAACA 746
 DB 11 AACAAACA 2
 RESULT 783
 ABI13570/C
 ID ABI13570 standard; DNA; 12 BP.
 XX AC ABI13570;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 313543 for detecting SNP TSC0025831.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 313543; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 0 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 737 AACAGAACAC 746
 DB 11 AACAAACAC 2
 |||||
 |||||

RESULT 784
 ABI69013
 ID ABI69013 standard; DNA; 12 BP.
 AC ABI69013;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 369986 for detecting SNP TSC0006352.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 369986; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: the sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACAGAACAC 745
 DB 1 AACACATAACA 10
 |||||
 |||||

RESULT 785
 ABI78823/c
 ID ABI78823 standard; DNA; 12 BP.
 XX
 AC ABI78823;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 378796 for detecting SNP TSC0006029.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 378796; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACAGAACAC 745
 DB 11 AACACATAACA 2
 |||||
 |||||

RESULT 786
 ABH73493/c


```

QY 736 AACAGACACA 745
ID ABI45554 standard; DNA; 12 BP.
XX
AC ABI45554;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 345527 for detecting SNP TSC0044075.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 345527; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 737 AACAGACACA 746
DB 2 AACAAACAC 11
|||||
RESULT 792
ABI70289
ID ABI70289 standard; DNA; 12 BP.
XX
AC ABI70289;
XX
DT 22-FEB-2002 (first entry)
XX

```

```

XX
DE Oligonucleotide primer SEQ ID NO 370262 for detecting SNP TSC0058079.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 370262; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 GAGAAACACA 742
DB 1 GAGAAATAGA 10
|||||
RESULT 793
ABH70967
ID ABH70967 standard; DNA; 12 BP.
XX
AC ABH70967;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 270944 for detecting SNP TSC0002334.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

```

PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 270944; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 5 A; 5 C; 1 G; 1 T; 0 U; 0 Other;
 XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGACAC 746
 DB |||||
 3 AACCGAACAC 12
 RESULT 794
 ABH97274/C
 ID ABH97274 standard; DNA; 12 BP.
 XX ABH97274;
 AC ABH97274;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 297267 for detecting SNP TSC0017501.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 297267; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
 XX Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 XX Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AACACAGAAC 745
 DB |||||
 11 AACACAGAAC 2
 RESULT 795
 ABH72613
 ID ABH72613 standard; DNA; 12 BP.
 XX ABH72613;
 AC ABH72613;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 272598 for detecting SNP TSC0002872.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 272598; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 734 AGAAGACAA 743
|||||
Db 2 AGAAGACAA 11

RESULT 796

ABI49158
ID ABI49158 standard; DNA; 12 BP.

XX AC ABI49158;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 349131 for detecting SNP TSC0045930.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX FA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 349131; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 0 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 AGGAGAAACA 740
|||||
Db 1 AGGAGAAAGA 10

RESULT 797
ABI52327/C

XX ABI52327 standard; DNA; 12 BP.

XX AC ABI52327;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 352300 for detecting SNP TSC0047801.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX FA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 352300; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 AGGAGAAACA 740
|||||
Db 11 AGGAGAAATA 2

RESULT 798
ABI70863

XX ABI70863 standard; DNA; 12 BP.

XX AC ABI70863;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 370836 for detecting SNP TSC0058425.

XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 370836; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAAC 745
 DB 3 AAACAGAAC 12
 RESULT 799
 ABI57396
 ID ABI57396 standard; DNA; 12 BP.
 XX AC ABI57396;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 357369 for detecting SNP TSC0050578.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 357369; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 8 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 734 AGAAACAGAA 743
 DB 2 AGAAACAGAA 11
 RESULT 800
 ABH92353/C
 ID ABH92353 standard; DNA; 12 BP.
 XX AC ABH92353;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 292346 for detecting SNP TSC0015179.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 292346; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 738 ACAGACACC 747
Db 12 ACATACACC 3

RESULT 801
ABH70419/C
ID ABH70419 standard; DNA; 12 BP.
XX
AC ABH70419;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 270396 for detecting SNP TSC0002115.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 270396; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 738 ACAGACACC 747
Db 12 ACATACACC 3

RESULT 803
ABH79493
ID ABH79493 standard; DNA; 12 BP.
XX

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACACAGACA 745
Db 12 AACATAACA 3

RESULT 802
ABH74364
ID ABH74364 standard; DNA; 12 BP.
XX
AC ABH74364;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 274349 for detecting SNP TSC0003519.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 274349; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 734 AGAAACAGAA 743
Db 2 AGAAACAGAA 11

RESULT 803
ABH79493
ID ABH79493 standard; DNA; 12 BP.
XX

AC ABH79493;
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 279486 for detecting SNP TSC0007399.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 279486; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 738 ACAGAACACC 747
 Db ||| |||||
 2 ACACACACC 11
 RESULT 804
 ABI32451
 ID ABI32451 standard; DNA; 12 BP.
 XX
 XX ABI32451;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 332424 for detecting SNP TSC0035902.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 PN

XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 332424; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 746
 Db ||| |||||
 2 AACAAACACC 11
 RESULT 805
 ABH89176/C
 ID ABH89176 standard; DNA; 12 BP.
 XX
 XX ABH89176;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 289169 for detecting SNP TSC0013829.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 289169; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 738 ACAGACACCC 747
Db 12 ACACACACCC 3
||| |||||

RESULT 806
ABI17825
ID ABI17825 standard; DNA; 12 BP.
XX
XX ABI17825;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 317798 for detecting SNP TSC0028282.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 317798; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 738 ACAGACACCC 747
Db 1 ACACACACCC 10
||| |||||

RESULT 807
ABI18090/c
ID ABI18090 standard; DNA; 12 BP.
XX
XX ABI18090;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 318063 for detecting SNP TSC0028421.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 318063; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 739 CAGACACCG 748

```

Db      11 CATAACACCG 2
RESULT 808
ABI23297/c
ID      ABI23297 standard; DNA; 12 BP.
XX
AC      ABI23297;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 323270 for detecting SNP TSC0031302.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 323270; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
AB000010
-AB000010-ABF99989, AB000010-ABH99989 and AB000010-AB182073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
AB000010
-AB000010-ABF99989, AB000010-ABH99989 and AB000010-AB182073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match      38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      737 AACAGACAC 746
DB      12 AACCGACAC 3
RESULT 809
ABI25971
ID      ABI25971 standard; DNA; 12 BP.
XX
AC      ABI25971;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 325944 for detecting SNP TSC0032814.
XX

```

```

XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 325944; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
AB000010
-AB000010-ABF99989, AB000010-ABH99989 and AB000010-AB182073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 10 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
XX
Query Match      38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      734 AGAAACAGAA 743
DB      2 AGAAACAGAA 11
RESULT 810
ABI10323
ID      ABI10323 standard; DNA; 12 BP.
XX
AC      ABI10323;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 310296 for detecting SNP TSC0023904.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX

```


PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 310296; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 736 AAACAGAAC 745
Db 1 AAACAAAC 10
|||||
RESULT 811
ABH88014
ID ABH88014 standard; DNA; 12 BP.
XX
XX ABH88014;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 288007 for detecting SNP TSC0013340.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 288007; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 735 GAAACAGAAC 744
Db 3 GAAACAAAC 12
|||||
RESULT 812
ABI38684/C
ID ABI38684 standard; DNA; 12 BP.
XX
XX ABI38684;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 338657 for detecting SNP TSC0040612.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 338657; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

[illegible]

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 734 AGAAACAGAA 743
 DB ||||| |||||
 2 AGAAATAGAA 11
 RESULT 818
 ABI28482
 ID ABI28482 standard; DNA; 12 BP.
 XX
 AC ABI28482;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 328455 for detecting SNP TSC0034312.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 328455; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAA 745
 DB ||||| |||||
 3 AAACAAACA 12
 RESULT 819
 ABH85326
 ID ABH85326 standard; DNA; 12 BP.
 XX
 AC ABH85326;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285319 for detecting SNP TSC0012239.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 285319; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 10 A; 2 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAA 745
 DB ||||| |||||
 2 AAACAAACA 11
 RESULT 820
 ABI15309/C
 ID ABI15309 standard; DNA; 12 BP.
 XX
 AC ABI15309;
 XX

Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAA 745
 DB ||||| |||||
 3 AAACAAACA 12
 RESULT 819
 ABH85326
 ID ABH85326 standard; DNA; 12 BP.
 XX
 AC ABH85326;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285319 for detecting SNP TSC0012239.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 285319; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 10 A; 2 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AAACAGAA 745
 DB ||||| |||||
 2 AAACAAACA 11
 RESULT 820
 ABI15309/C
 ID ABI15309 standard; DNA; 12 BP.
 XX
 AC ABI15309;
 XX

DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 315282 for detecting SNP TSC0026831.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 315282; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 738 ACAGACACCC 747
Db 11 ACAAAACACC 2
RESULT 821
ABI40624/C
ID ABI40624 standard; DNA; 12 BP.
XX
XX ABI40624;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 340597 for detecting SNP TSC0008164.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 340597; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 0 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 731 AGGAGAAACA 740
Db 10 AGGAGAAAA 1
RESULT 822
ABI42417/C
ID ABI42417 standard; DNA; 12 BP.
XX
XX ABI42417;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 342390 for detecting SNP TSC0042520.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.
WO200177384-A2.
18-OCT-2001.

06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 305009; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 4 A; 2 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 730 CAGGAGAAAC 739
Db 3 CGGAGAGAAAC 12
|||||

RESULT 827
ABI08156
ID ABI08156 standard; DNA; 12 BP.
XX
AC ABI08156;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 308129 for detecting SNP TSC0022883.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PS Claim 1; SEQ ID NO 305009; 29pp + Sequence Listing; German.
XX
SQ This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

peptide nucleic acid; cytosine methylation; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.
WO200177384-A2.
18-OCT-2001.

06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 373461; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 2 A; 2 C; 0 G; 8 T; 0 U; 0 Other;
Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 734 AGAAACAGAA 743
Db 10 AGAANTAGAA 1
|||||

RESULT 826
ABI05036
ID ABI05036 standard; DNA; 12 BP.
XX
AC ABI05036;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 305009 for detecting SNP TSC0021207.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 308129; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 737 AACAGAACAC 746
 DB 1 AACATAACAC 10
 RESULT 828
 ABI59320/C
 ID ABI59320 standard; DNA; 12 BP.
 AC ABI59320;
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 359293 for detecting SNP TSC0051542.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 PF 06-APR-2001; 2001WO-IB000713.
 PP
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 359293; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 745
 DB 10 AACACAAACA 1
 RESULT 829
 AAS07924
 ID AAS07924 standard; DNA; 12 BP.
 AC AAS07924;
 XX
 DT 23-OCT-2001 (first entry)
 DE Human transcription factor binding site from promoter P15B4 #3.
 XX
 KW Human; expressed sequence tag; EST; ds; promoter P15B4;
 KW acute myocardial infarction; acute ischaemic stroke; diabetes; anaemia;
 KW growth hormone deficiency; hepatitis; kidney carcinoma;
 KW multiple sclerosis; chemotherapy-induced neutropenia;
 KW transcription factor binding site.
 XX Homo sapiens.
 OS
 XX EF1104808-A1.
 PN
 XX 06-JUN-2001.
 PD
 PF 27-JUL-2000; 2000EP-00202699.
 PP
 XX 05-AUG-1999; 99US-0147499P.
 PR
 XX (GEST) GENSET.
 PA
 XX Dumas Milne Edwards J, Jobert S, Giordano J;
 PI
 XX WPI; 2001-357986/38.
 DR
 XX New purified 5' expressed sequence tags useful in diagnostic, forensic,
 PT gene therapy or chromosome mapping procedures, or for distinguishing
 PT human tissues or cells from non-human tissues or cells.
 XX
 XX Example 53; Fig 5; 90pp; English.
 PS
 XX The sequence represents a transcription factor binding site from human
 CC promoter P15B4, the promoter and binding site being isolated using
 CC sequence from one of the 5' expressed sequence tags (EST) of the
 CC invention, one of 15442 nucleotide sequences not given in the
 CC specification. The 5' EST may be used to efficiently identify and isolate
 CC 5'untranslated regions (UTRs) and upstream regulatory regions which
 CC control the location, developmental stage, rate and quantity of protein
 CC synthesis, as well as the stability of the mRNA. ESTs containing the 5'
 CC ends of protein genes may include sequences for chromosome mapping and
 CC identification individuals. The EST may further be used to distinguish
 CC human tissues or cells from non-human tissues or cells, to distinguish
 CC between human tissues or cells that do not and do not express

CC polynucleotides comprising the 5' EST sequences, to obtain and express
 CC cDNA clones which include full protein coding sequences of the
 CC corresponding gene products, to map and clone promoter regions, and open
 CC reading frames from a genomic sequence, and to obtain and express
 CC extended cDNAs encoding portions of the protein. EST-related nucleic
 CC acids are useful in forensic procedures or in diagnosis of genetic
 CC diseases resulting from abnormal gene expression, for constructing a high
 CC resolution map of human chromosomes, and in gene therapy to control or
 CC treat genetic diseases. Proteins expressed from the cDNAs may be used in
 CC myocardial infarction, acute ischaemic stroke, diabetes, anaemia, growth
 CC hormone deficiency, hepatitis, kidney carcinoma, multiple sclerosis,
 CC chemotherapy-induced neutropaenia
 XX
 SQ Sequence 12 BP; 9 A; 2 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACACAGAACCA 745
 ||||| |||||
 Db 3 AACACAAACCA 12

RESULT 830

AA07921
 ID AA07921 standard; DNA; 12 BP.

AC AA07921;

DT 23-OCT-2001 (first entry)

DE Human transcription factor binding site from promoter P13H2 #15.

Human; expressed sequence tag; EST; ds; promoter P13H2;
 acute myocardial infarction; acute ischaemic stroke; diabetes; anaemia;
 growth hormone deficiency; hepatitis; kidney carcinoma;
 multiple sclerosis; chemotherapy-induced neutropaenia;
 transcription factor binding site.

OS Homo sapiens.

PN EP1104808-A1.

PD 06-JUN-2001.

PF 27-JUL-2000; 2000EP-00202699.

PR 05-AUG-1999; 99US-0147499P.

XX (GSEST) GENSET.

XX Dumas Milne Edwards J, Jobert S, Giordano J;

XX WPI; 2001-357986/38.

XX New purified 5' expressed sequence tags useful in diagnostic, forensic,
 XX gene therapy or chromosome mapping procedures, or for distinguishing
 XX human tissues or cells from non-human tissues or cells.

XX Example 53; Fig 5; 90pp; English.

XX The sequence represents a transcription factor binding site from human
 XX promoter P13H2, the promoter and binding site being isolated using
 XX sequence from one of the 5' expressed sequence tags (EST) of the
 XX invention, one of 15442 nucleotide sequences not given in the
 XX specification. The 5' EST may be used to efficiently identify and isolate
 XX 5' untranslated regions (UTRs) and upstream regulatory regions which
 XX control the location, developmental stage, rate and quantity of protein
 XX synthesis, as well as the stability of the mRNA. ESTs containing the 5'
 XX ends of protein genes may include sequences for chromosome mapping and
 XX identification individuals. The EST may further be used to distinguish

CC human tissues or cells from non-human tissues or cells, to distinguish
 CC between human tissues or cells that do not and do not express
 CC polynucleotides comprising the 5' EST sequences, to obtain and express
 CC cDNA clones which include full protein coding sequences of the
 CC corresponding gene products, to map and clone promoter regions, and open
 CC reading frames from a genomic sequence, and to obtain and express
 CC extended cDNAs encoding portions of the protein. EST-related nucleic
 CC acids are useful in forensic procedures or in diagnosis of genetic
 CC diseases resulting from abnormal gene expression, for constructing a high
 CC resolution map of human chromosomes, and in gene therapy to control or
 CC treat genetic diseases. Proteins expressed from the cDNAs may be used in
 CC myocardial infarction, acute ischaemic stroke, diabetes, anaemia, growth
 CC hormone deficiency, hepatitis, kidney carcinoma, multiple sclerosis,
 CC chemotherapy-induced neutropaenia
 XX
 SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
 Best Local Similarity 90.0%; Pred. No. 5.6e+02;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 736 AACACAGAACCA 745
 ||||| |||||
 Db 3 AACACAAACCA 12

RESULT 831

ABA05981/C
 ID ABA05981 standard; DNA; 12 BP.

AC ABA05981;

DT 07-MAR-2002 (first entry)

DE HSV-1 antisense oligonucleotide 1.

Activation; dendritic cell; immune response; rheumatoid arthritis;
 Crohn's disease; ulcerative colitis; thalassemia; muscular dystrophy;
 cystic fibrosis; osteoporosis; tumour; cancer; cardiovascular disease;
 ischaemia; infectious disease; hepatitis; HIV; infection; vaccine;
 acquired immunodeficiency syndrome; AIDS; transplant rejection; malaria;
 cytostatic; antiinflammatory; antirheumatic; antiarthritic; anti-HIV;
 antiarteriosclerotic; ophthalmological; antialcoholism; osteopathic;
 dermatological; immunosuppressive; antitumor; cardiatic; protozoacide;
 cerebroprotective; vasotropic; virucide; hepatotropic; tuberculostatic;
 HSV-1; herpes simplex virus; antisense oligonucleotide; ss.

OS Synthetic.

PN WO200183698-A2.

XX 08-NOV-2001.

XX 30-APR-2001; 2001WO-US013921.

XX 28-APR-2000; 2000US-0200487P.

XX 01-JAN-2001; 2001US-0260806P.

XX (SUPR-) SUPRATEK PHARMA INC.

XX Kabanov AV, Lemieux P, Guerin N, Alakhov V, Vinogradov S;

XX WPI; 2002-097495/13.

XX Inducing activation composition for dendritic cells in human, contains
 XX polynucleotide, viral vector, or polynucleotide derivative and
 XX polyoxyethylene-polyoxypropylene block copolymer.

XX Example 9; Page 62; 126pp; English.

XX The invention relates to an activation inducing composition for dendritic
 XX cells in animals comprises a polynucleotide, viral vector or

polynucleotide derivative and polyoxyethylene-polyoxypropylene block copolymer(s). The composition has cytostatic, antiinflammatory, antirheumatic, antiarthritic, antiarteriosclerotic, ophthalmological, antiasthmatic, osteopathic, dermatological, immunosuppressive, antiulcer, cardiac, cerebroprotective, vasotropic, virucide, hepatotropic, anti-HIV, protozoacide and tuberculostatic activity. The composition is for inducing activation of dendritic cells in animals, preferably human; increasing the level of production and infiltration for dendritic cells in response to gene expression and increasing the immune response and generates large amounts of dendritic cells in vivo or in vitro. It is also used in treating genetic diseases including rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, alpha-thalassemia, beta-thalassemia, phenylketonuria, muscular dystrophy such as Duchenne Muscular Dystrophy, hypersarcosinaemia, adenomatous intestinal polyposis, arteriosclerosis and hypercholesterolaemia, cystic fibrosis, osteopetrosis, increased spontaneous tumours, T and B cell immunodeficiency, high cholesterol, arthritis, glaucoma or alcoholism. It can be also used to treat neoplastic diseases including cancer, lymphoma and melanoma, cardiovascular diseases including stroke, myocardial ischaemia, infectious diseases such as hepatitis, HIV infections and acquired immunodeficiency syndrome (AIDS) and transplantation related disorders such as renal transplant rejection. It is also used in vaccine therapies and immunisation, including melanoma vaccines, HIV vaccines, malaria or tuberculosis. The present sequence is that of a HSV-1 antisense oligonucleotide, useful to the invention

Sequence 12 BP; 0 A; 5 C; 2 G; 4 T; 1 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 730 CAGGAGAAAC 739
|||||
Db 11 CAGGAGGAAC 2

RESULT 832
ABA05984/C
ID ABA05984 standard; DNA; 12 BP.

AC ABA05984;

DT 07-MAR-2002 (first entry)

DE HSV-1 antisense oligonucleotide 2.

Activation; dendritic cell; immune response; rheumatoid arthritis; Crohn's disease; ulcerative colitis; thalassemia; muscular dystrophy; cystic fibrosis; osteopetrosis; tumour; cancer; cardiovascular disease; ischaemia; infectious disease; hepatitis; HIV; infection; vaccine; acquired immunodeficiency syndrome; AIDS; transplant rejection; malaria; cytostatic; antiinflammatory; antirheumatic; antiarthritic; anti-HIV; antiarteriosclerotic; ophthalmological; antiasthmatic; osteopathic; dermatological; immunosuppressive; antiulcer; cardiac; protozoacide; cerebroprotective; vasotropic; virucide; hepatotropic; tuberculostatic; HSV-1; herpes simplex virus; antisense oligonucleotide; ss.

OS Synthetic.

XX WO200183698-A2.

PN 08-NOV-2001.

PD 30-APR-2001; 2001WO-US013921.

PF 28-APR-2000; 2000US-0200487P.

PR 01-JAN-2001; 2001US-0260806P.

XX (SUPR-) SUPRATEK PHARMA INC.

XX Kabanov AV, Lemieux P, Guerin N, Alakhov V, Vinogradov S;

WPI; 2002-097495/13.
Inducing activation composition for dendritic cells in human, contains polynucleotide, viral vector, or polynucleotide derivative and polyoxyethylene-polyoxypropylene block copolymer.
Example 21; Page 72; 126pp; English.

The invention relates to an activation inducing composition for dendritic cells in animals comprising a polynucleotide, viral vector or polynucleotide derivative and polyoxyethylene-polyoxypropylene block copolymer(s). The composition has cytostatic, antiinflammatory, antirheumatic, antiarthritic, antiarteriosclerotic, ophthalmological, antiasthmatic, osteopathic, dermatological, immunosuppressive, antiulcer, cardiac, cerebroprotective, vasotropic, virucide, hepatotropic, anti-HIV, protozoacide and tuberculostatic activity. The composition is for inducing activation of dendritic cells in animals, preferably human; increasing the level of production and infiltration for dendritic cells in response to gene expression and increasing the immune response and generates large amounts of dendritic cells in vivo or in vitro. It is also used in treating genetic diseases including rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, alpha-thalassemia, beta-thalassemia, phenylketonuria, muscular dystrophy such as Duchenne Muscular Dystrophy, hypersarcosinaemia, adenomatous intestinal polyposis, arteriosclerosis and hypercholesterolaemia, cystic fibrosis, osteopetrosis, increased spontaneous tumours, T and B cell immunodeficiency, high cholesterol, arthritis, glaucoma or alcoholism. It can be also used to treat neoplastic diseases including cancer, lymphoma and melanoma, cardiovascular diseases including stroke, myocardial ischaemia, infectious diseases such as hepatitis, HIV infections and acquired immunodeficiency syndrome (AIDS) and transplantation related disorders such as renal transplant rejection. It is also used in vaccine therapies and immunisation, including melanoma vaccines, HIV vaccines, malaria or tuberculosis. The present sequence is that of a HSV-1 antisense oligonucleotide, useful to the invention

Sequence 12 BP; 0 A; 4 C; 3 G; 4 T; 1 U; 0 Other;

Query Match 38.2%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 5.6e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 730 CAGGAGAAAC 739
|||||
Db 11 CAGGAGGAAC 2

RESULT 833
AAK99268

ID AAK99268 standard; DNA; 12 BP.

XX AAK99268;

AC 31-MAY-2002 (first entry)

DT P15B4 promoter transcription binding site SRY_02.

XX Promoter DNA; diagnostic; forensic; gene therapy; chromosome mapping; expression vector; secretion vector; P15B4; transcription binding site; ss.

XX Homo sapiens.

OS CA2343602-A1.

PN 18-OCT-2001.

PD 17-APR-2001; 2001CA-02343602.

PF 18-APR-2000; 2000US-0197873P.

XX (GEST) GENSET.

RESULT 836
 ADE14111/c
 ID ADE14111 standard; DNA; 9 BP.
 XX AC ADE14111;
 XX DT 29-JAN-2004 (first entry)
 XX DE Optineurin promoter motif, repeat element or regulatory region #220.
 XX DT 29-JAN-2004 (first entry)
 XX DE Optineurin promoter motif, repeat element or regulatory region #220.
 XX KW Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
 XX KW SNP; glaucoma; progressive ocular hypertensive disorder;
 XX KW glaucoma related disorder; motif; repeat element; regulatory region.
 XX OS Homo sapiens.
 XX US2003190617-A1.
 XX PD 09-OCT-2003.
 XX PF 06-MAR-2002; 2002US-00091281.
 XX PR 06-MAR-2002; 2002US-00091281.
 XX PA (SIBEE/) SI E.
 XX PA (RAYM/) RAYMOND V.
 XX PA (MORI/) MORISSETTE J.
 XX PI Raymond V, Morissette J, Si E;
 XX WPI; 2003-864168/80.
 XX New nucleic acid sequences of the optineurin gene are useful to detect
 XX polymorphisms particularly single nucleotide polymorphisms in the
 XX optineurin promoter to diagnose, prognosis and treat glaucoma and related
 XX disorders.
 XX Claim 11; SEQ ID NO 222; 159pp; English.
 XX The invention relates to an isolated nucleic acid (NI) comprising at
 XX least 20 but not more than 1500 consecutive nucleotides of the optineurin
 XX promoter appearing as ADE13890. Also included are the optineurin promoter
 XX operably linked to a heterologous nucleic acid, a nucleic acid capable of
 XX detecting a single nucleotide polymorphism (SNP) in the optineurin
 XX promoter, a host cell comprising the promoter operably linked to a
 XX heterologous sequence, diagnosing or prognosing glaucoma in a sample
 XX obtained from a cell or bodily fluid (comprising detecting a polymorphism
 XX in a promoter region of the optineurin gene, associated with a glaucoma
 XX phenotype), detecting a SNP sequence variation in a sample containing
 XX DNA, detecting the presence of an optineurin promoter sequence variation
 XX in a sample containing DNA, determining the presence or increased
 XX susceptibility to glaucoma or to a progressive ocular hypertensive
 XX disorder resulting in loss of visual field in a patient (or the severity
 XX or progression of glaucoma in a patient, comprising providing
 XX amplification reaction primers that direct amplification of a selected
 XX nucleic acid region containing the variation within the optineurin
 XX promoter and amplifying the DNA) and detecting a polymorphism (comprising
 XX obtaining a sample containing human genomic DNA, providing a nucleic acid
 XX capable of detecting a SNP located within an optineurin promoter, and
 XX detecting the polymorphism). The invention is used to diagnose and
 XX prognose glaucoma and also to treat glaucoma related disorders. The
 XX present sequence is an optineurin promoter motif, repeat element or
 XX putative regulatory region.
 XX Sequence 9 BP; 0 A; 2 C; 1 G; 6 T; 0 U; 0 Other;
 XX Query Match 36.4%; Score 8; DB 1; Length 9;
 XX Best Local Similarity 100.0%; Pred.No. 4.1e+03;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 734 AGAACACAG 741

Db 8 AGAACACAG 1
 RESULT 837
 AAQ96884
 ID AAQ96884 standard; DNA; 10 BP.
 XX AC AAQ96884;
 XX DT 16-OCT-2003 (revised)
 XX DT 26-MAR-1996 (first entry)
 XX DE HIV-1 NL4-3 nef gene nucleotide deletion 479.
 XX KW HIV-1; AIDS; attenuation; vaccine; nef gene; avirulence; ss.
 XX OS Human immunodeficiency virus 1.
 XX WO9521912-A1.
 XX PD 17-AUG-1995.
 XX PF 14-FEB-1995; 95WO-AU0000063.
 XX PR 14-FEB-1994; 94AU-00003864.
 XX PR 21-FEB-1994; 94AU-00004002.
 XX PR 23-DEC-1994; 94AU-00000284.
 XX PA (MACF-) MACFARLANE BURNET CENT MEDICAL.
 XX PA (AURE-) AUSTRALIAN RED CROSS SOC.
 XX PI Deacon NJ, Learmont JC, Mcphee DA, Crowe S, Cooper D;
 XX WPI; 1995-293115/38.
 XX New non-pathogenic HIV-1 strain carrying a deletion in its nef gene or
 XX LTR region - can be used in a vaccine to inhibit/reduce productive
 XX infection in an individual by a pathogenic strain.
 XX Claim 13; Page 194; 301pp; English.
 XX Attenuation of pathogenic HIV-1 strain NL4-3 involves deletion of 1 or
 XX more decanucleotides (AAQ96406-Q97018) from the nef gene and/or 1 or more
 XX decanucleotides (AAQ97019-Q97166) from the LTR region; the sequence of
 XX AAQ96406 corresponds to nucleotides 1-10 of the nef gene (AAQ96141). The
 XX resulting avirulent HIV strains are still capable of inducing an immune
 XX response in humans, and enable the generation of therapeutic, diagnostic
 XX and targeting agents against HIV-1 infection. (Updated on 16-OCT-2003 to
 XX standardise OS field)
 XX Sequence 10 BP; 5 A; 3 C; 2 G; 0 T; 0 U; 0 Other;
 XX Query Match 36.4%; Score 8; DB 1; Length 10;
 XX Best Local Similarity 100.0%; Pred.No. 6e+02;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 740 AGAACACAC 747
 Db 1 AGAACACAC 8
 RESULT 838
 AAQ96883
 ID AAQ96883 standard; DNA; 10 BP.
 XX AC AAQ96883;
 XX DT 16-OCT-2003 (revised)
 XX DT 26-MAR-1996 (first entry)
 XX DE HIV-1 NL4-3 nef gene nucleotide deletion 478.
 XX

KW HIV-1; AIDS; attenuation; vaccine; nef gene; avirulence; ss.
 XX Human immunodeficiency virus 1.
 OS WO9521912-A1.
 PN 17-AUG-1995.
 XX 14-FEB-1995; 95WO-AU0000063.
 XX 14-FEB-1994; 94AU-00003864.
 PR 21-FEB-1994; 94AU-00004002.
 PR 23-DEC-1994; 94AU-00000284.
 XX (MACF-) MACFARLANE BURNET CENT MEDICAL.
 PA (AURE-) AUSTRALIAN RED CROSS SOC.
 XX Deacon NJ, Learmont JC, Mcphee DA, Crowe S, Cooper D;
 PI WPI; 1995-293115/38.
 XX New non-pathogenic HIV-1 strain carrying a deletion in its nef gene or
 PT LTR region - can be used in a vaccine to inhibit/reduce productive
 PT infection in an individual by a pathogenic strain.
 XX Claim 13; Page 194; 301pp; English.
 XX Attenuation of pathogenic HIV-1 strain NL4-3 involves deletion of 1 or
 CC more decaucleotides (AAQ96406-Q97018) from the nef gene and/or 1 or more
 CC decaucleotides (AAQ97019-Q97166) from the LTR region; the sequence of
 CC AAQ96406 corresponds to nucleotides 1-10 of the nef gene (AAQ96141). The
 CC resulting avirulent HIV strains are still capable of inducing an immune
 CC response in humans, and enable the generation of therapeutic, diagnostic
 CC and targeting agents against HIV-1 infection. (Updated on 16-OCT-2003 to
 CC standardise OS field)
 XX Sequence 10 BP; 5 A; 3 C; 2 G; 0 T; 0 U; 0 Other;
 SQ Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e-02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 740 AGAACACC 747
 Db 2 AGAACACC 9
 RESULT 839
 AAZ78109
 ID AAZ78109 standard; DNA; 10 BP.
 XX AAZ78109;
 XX 10-APR-2000 (first entry)
 DT Human dendritic cell SAGE tag, SEQ ID NO:537.
 DE SAGE tag; serial analysis of gene expression; antigen-presenting cell;
 KW APC; monocyte-derived dendritic cell; differential gene expression;
 KW immunostimulatory cofactor; costimulatory factor; CTL; antitumor;
 KW cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.
 XX Homo sapiens.
 OS WO9965924-A2.
 XX 23-DEC-1999.
 XX 18-JUN-1999; 99WO-US013800.
 PF 19-JUN-1998; 98US-0089833P.
 PR 19-JUN-1998; 98US-0089844P.
 PR 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089878P.
 PR 19-JUN-1998; 98US-0089991P.
 PR 19-JUN-1998; 98US-0089992P.
 PR 19-JUN-1998; 98US-0089993P.
 PR 19-JUN-1998; 98US-0089994P.
 PR 19-JUN-1998; 98US-0089997P.
 PR 19-JUN-1998; 98US-0090000P.
 PR 19-JUN-1998; 98US-0090003P.
 PR 19-JUN-1998; 98US-0090036P.
 PR 19-JUN-1998; 98US-0090039P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 PR 19-JUN-1998; 98US-0090042P.
 PR 19-JUN-1998; 98US-0090043P.
 PR 19-JUN-1998; 98US-0090044P.
 PR 19-JUN-1998; 98US-0090045P.
 PR 19-JUN-1998; 98US-0090047P.
 PR 19-JUN-1998; 98US-0090048P.
 PR 19-JUN-1998; 98US-0090072P.
 PR 19-JUN-1998; 98US-0090076P.
 PR 19-JUN-1998; 98US-0090077P.
 PR 19-JUN-1998; 98US-0090078P.
 PR 19-JUN-1998; 98US-0090079P.
 PR 19-JUN-1998; 98US-0090080P.
 PR 08-DEC-1998; 98US-0111715P.
 XX (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 XX Roberts BL, Shankara S;
 XX WPI; 2000-106077/09.
 XX Isolated polynucleotides differentially expressed in antigen-presenting
 PT cells, useful in gene vaccines against cancer.
 PT Claim 1; Page 80; 130pp; English.
 PS Sequences AAZ77573-279709 represent SAGE (serial analysis of gene
 XX expression) tags used to identify mRNA transcripts encoding
 CC immunostimulatory cofactor proteins which are preferentially or
 CC differentially expressed in monocyte-derived dendritic cells compared
 CC with monocytes. Some of the transcripts correspond to known genes or ESTs
 CC (expressed sequence tags) which were previously unknown to be
 CC preferentially or differentially expressed in dendritic cells, while
 CC other transcripts correspond to novel genes. Antigen-presenting cell
 CC (APC)-associated costimulatory factors play an important role in the
 CC activation of the cytotoxic immune response, particularly against tumour
 CC cells. Tumour antigen presentation via the MHC (major histocompatibility
 CC complex) and subsequent recognition by T-cell receptors is alone
 CC insufficient to activate a robust cytotoxic immune response that can lyse
 CC the tumour cells, immunostimulatory cofactors also being required for
 CC efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid
 CC sequences identified using the SAGE tags have several potential uses.
 CC They may be used in vaccines to induce an immune response, particularly
 CC against a tumour antigen; to modulate the genotype of an APC; to screen
 CC for agents that modulate expression of differentially expressed genes in
 CC an APC; and as hybridisation probes/amplification primers for the
 CC diagnosis, prognosis and monitoring of diseases related to abnormal
 CC expression of these genes. Detection of the dendritic cell differentially
 CC expressed genes, or of their encoded proteins, can be used to identify
 CC cells as belonging to the monocyte lineage. Cells containing these genes
 CC can be used in active immunotherapy (or to stimulate production of a
 CC population of antigen-specific effector cells) and vectors containing
 CC them are used in gene therapy. Co-administration of tumour antigens and
 CC APC-associated costimulatory factors ensures adequate antigen
 CC presentation to endogenous APCs and upregulates the APCs for the
 CC presentation of co-stimulatory signals, migration to T cell-rich sites,
 CC secretion of T cell growth factors and secretion of chemokines for
 CC recruitment of immune effector cells
 XX

SQ Sequence 10 BP; 3 A; 4 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred.No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 GAACACCG 748
 |||||
 Db 1 GAACACCG 8

RESULT 840
 AAZ80857/C
 ID AAZ80857 standard; DNA; 10 BP.
 XX AC AAZ80857;
 XX DT 07-APR-2000 (first entry)
 XX DE Metastatic breast tumour cell upregulated transcript tag #91.
 XX DE Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 XX OS Homo sapiens.
 XX PN WO9965928-A2.
 XX PD 23-DEC-1999.
 XX PF 18-JUN-1999; 95WO-US013647.
 XX PR 19-JUN-1998; 98US-0089853P.
 XX PR 19-JUN-1998; 98US-0089997P.
 XX PR 19-JUN-1998; 98US-0090039P.
 XX PR 19-JUN-1998; 98US-0090040P.
 XX PR 19-JUN-1998; 98US-0090041P.
 XX PA (GENZ) GENZYME CORP.
 XX PA (ROBE/) ROBERTS B L.
 XX PA (SHAN/) SHANKARA S.
 XX PI Roberts BL, Shankara S;
 XX WPI; 2000-106079/09.
 XX Isolated polynucleotides differentially expressed between metastatic and
 non-metastatic breast cancer cells, useful for diagnosis, prevention and
 treatment of cancer.
 PS Claim 1; Page 60; 219pp; English.

CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive

CC immunotherapy
 XX SQ Sequence 10 BP; 1 A; 4 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred.No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCAGGAGA 736
 |||||
 Db 8 CCAGGAGA 1

RESULT 841
 AAZ82836
 ID AAZ82836 standard; DNA; 10 BP.
 XX AC AAZ82836;
 XX DT 07-APR-2000 (first entry)
 XX DE Metastatic breast tumour cell upregulated transcript tag #2070.
 XX DE Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 XX OS Homo sapiens.
 XX PN WO9965928-A2.
 XX PD 23-DEC-1999.
 XX PF 18-JUN-1999; 99WO-US013647.
 XX PR 19-JUN-1998; 98US-0089853P.
 XX PR 19-JUN-1998; 98US-0089997P.
 XX PR 19-JUN-1998; 98US-0090039P.
 XX PR 19-JUN-1998; 98US-0090040P.
 XX PR 19-JUN-1998; 98US-0090041P.
 XX PA (GENZ) GENZYME CORP.
 XX PA (ROBE/) ROBERTS B L.
 XX PA (SHAN/) SHANKARA S.
 XX PI Roberts BL, Shankara S;
 XX WPI; 2000-106079/09.
 XX Isolated polynucleotides differentially expressed between metastatic and
 non-metastatic breast cancer cells, useful for diagnosis, prevention and
 treatment of cancer.
 PS Claim 1; Page 115; 219pp; English.

CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive

CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 2 A; 3 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 727 TGCCAGGA 734
 |||||
 Db 1 TGCCAGGA 8

RESULT 842
 AAZ82679/c
 ID AAZ82679 standard; DNA; 10 BP.

XX AC AAZ82679;

XX DT 07-APR-2000 (first entry)

XX DE Metastatic breast tumour cell upregulated transcript tag #1913.

XX KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 XX KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 XX KW antimetastatic; vaccine; diagnosis; ss.

XX OS Homo sapiens.

XX PN WO9965928-A2.

XX PD 23-DEC-1999.

XX PF 18-JUN-1999; 99WO-US013647.

XX PR 19-JUN-1998; 98US-0089853P.

XX PR 19-JUN-1998; 98US-0089997P.

XX PR 19-JUN-1998; 98US-0090039P.

XX PR 19-JUN-1998; 98US-0090040P.

XX PR 19-JUN-1998; 98US-0090041P.

XX PA (GENZ) GENZYME CORP.

XX PA (ROBE/) ROBERTS B L.

XX PA (SHAN/) SHANKARA S.

XX PI Roberts BL, Shankara S;

XX DR WPI; 2000-106079/09.

XX PT Isolated polynucleotides differentially expressed between metastatic and

XX PT non-metastatic breast cancer cells, useful for diagnosis, prevention and

XX PT treatment of cancer.

XX PS Claim 1; Page 110; 219pp; English.

XX CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 XX CC that are preferentially transcribed in the metastatic breast tumour
 XX CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 XX CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 XX CC preferentially transcribed in the primary or non-metastatic breast tumour
 XX CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 XX CC transcripts can be used for diagnosis, prognosis, monitoring and
 XX CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 XX CC by standard immunoassays or hybridisation/amplification reactions.
 XX CC Compounds that modulate expression of the transcripts are potentially
 XX CC useful for treatment of (metastatic) breast cancer, while promoters from
 XX CC the transcripts are used to direct expression, in selected cell types, of
 XX CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 XX CC particularly an antigen-encoding sequence for use in gene or cell-based
 XX CC vaccines. Polypeptides encoded by the transcripts are also useful in
 XX CC vaccines; for diagnosing breast cancer and for raising specific

CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX

SQ Sequence 10 BP; 0 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 728 GCCAGGAG 735
 |||||
 Db 10 GCCAGGAG 3

RESULT 843
 AAZ81170/c
 ID AAZ81170 standard; DNA; 10 BP.

XX AC AAZ81170;

XX DT 07-APR-2000 (first entry)

XX DE Metastatic breast tumour cell upregulated transcript tag #404.

XX KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 XX KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 XX KW antimetastatic; vaccine; diagnosis; ss.

XX OS Homo sapiens.

XX PN WO9965928-A2.

XX PD 23-DEC-1999.

XX PF 18-JUN-1999; 99WO-US013647.

XX PR 19-JUN-1998; 98US-0089853P.

XX PR 19-JUN-1998; 98US-0089997P.

XX PR 19-JUN-1998; 98US-0090039P.

XX PR 19-JUN-1998; 98US-0090040P.

XX PR 19-JUN-1998; 98US-0090041P.

XX PA (GENZ) GENZYME CORP.

XX PA (ROBE/) ROBERTS B L.

XX PA (SHAN/) SHANKARA S.

XX PI Roberts BL, Shankara S;

XX DR WPI; 2000-106079/09.

XX PT Isolated polynucleotides differentially expressed between metastatic and
 XX PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 XX PT treatment of cancer.

XX PS Claim 1; Page 69; 219pp; English.

XX CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 XX CC that are preferentially transcribed in the metastatic breast tumour
 XX CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 XX CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 XX CC preferentially transcribed in the primary or non-metastatic breast tumour
 XX CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 XX CC transcripts can be used for diagnosis, prognosis, monitoring and
 XX CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 XX CC by standard immunoassays or hybridisation/amplification reactions.
 XX CC Compounds that modulate expression of the transcripts are potentially
 XX CC useful for treatment of (metastatic) breast cancer, while promoters from
 XX CC the transcripts are used to direct expression, in selected cell types, of
 XX CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 XX CC particularly an antigen-encoding sequence for use in gene or cell-based
 XX CC vaccines. Polypeptides encoded by the transcripts are also useful in
 XX CC vaccines; for diagnosing breast cancer and for raising specific

CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 1 A; 2 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 739 CAGAACAC 746
 |||||
 Db 8 CAGAACAC 1
 RESULT 844
 AAZ86201
 ID AAZ86201 standard; DNA; 10 BP.
 XX AC
 XX AAZ86201;
 DT 07-APR-2000 (first entry)
 XX
 DE Metastatic breast tumour cell downregulated transcript tag #5435.
 XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9965928-A2.
 XX
 XX 23-DEC-1999.
 XX
 XX 18-JUN-1999; 99WO-US013647.
 XX
 XX 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089997P.
 PR 19-JUN-1998; 98US-0090039P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 XX
 XX (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 XX
 PI Roberts BL, Shankara S;
 XX
 XX WPI; 2000-106079/09.
 DR
 XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX
 XX Claim 1; Page 202; 219pp; English.
 PS
 CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of

CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 3 A; 2 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 728 GCCAGGAG 735
 |||||
 Db 3 GCCAGGAG 10
 RESULT 845
 AAZ81797
 ID AAZ81797 standard; DNA; 10 BP.
 XX AC
 XX AAZ81797;
 DT 07-APR-2000 (first entry)
 XX
 DE Metastatic breast tumour cell upregulated transcript tag #1031.
 XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9965928-A2.
 XX
 XX 23-DEC-1999.
 XX
 XX 18-JUN-1999; 99WO-US013647.
 XX
 XX 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089997P.
 PR 19-JUN-1998; 98US-0090039P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 XX
 XX (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 XX
 PI Roberts BL, Shankara S;
 XX
 XX WPI; 2000-106079/09.
 DR
 XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX
 XX Claim 1; Page 86; 219pp; English.
 PS
 CC AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially

CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 3 A; 3 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 728 GCCAGGAG 735
 Db 2 GCCAGGAG 9
 |||||

RESULT 846
 AAZ83594
 ID AAZ83594 standard; DNA; 10 BP.
 AC AAZ83594;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #2828.

XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.

XX Homo sapiens.

XX WO9965928-A2.

XX 23-DEC-1999.

XX 18-JUN-1999; 99WO-US013647.

XX 19-JUN-1998; 98US-0089853P.

XX 19-JUN-1998; 98US-0089997P.

XX 19-JUN-1998; 98US-0090039P.

XX 19-JUN-1998; 98US-0090040P.

XX (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.

PA (SHAN/) SHANKARA S.

XX Roberts BL, Shankara S;

XX WPI; 2000-106079/09.

XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.

XX Claim 1; Page 134; 219pp; English.

XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is

CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC vaccines; for diagnosing breast cancer and for raising specific
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX

SQ Sequence 10 BP; 3 A; 4 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;

Best Local Similarity 100.0%; Pred. No. 6e+02;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 GAACACCG 748
 Db 1 GAACACCG 8
 |||||

RESULT 847
 AAZ82358/C
 ID AAZ82358 standard; DNA; 10 BP.
 XX
 AC AAZ82358;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #1592.

XX Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.

XX Homo sapiens.

XX WO9965928-A2.

XX 23-DEC-1999.

XX 18-JUN-1999; 99WO-US013647.

XX 19-JUN-1998; 98US-0089853P.

XX 19-JUN-1998; 98US-0089997P.

XX 19-JUN-1998; 98US-0090039P.

XX 19-JUN-1998; 98US-0090040P.

XX (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.

PA (SHAN/) SHANKARA S.

XX Roberts BL, Shankara S;

XX WPI; 2000-106079/09.

XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.

XX Claim 1; Page 101; 219pp; English.

XX AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942
 CC to AAZ86677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These

transcripts can be used for diagnosis, prognosis, monitoring and treatment of breast cancer, particularly where metastatic. Diagnosis is by standard immunoassays or hybridisation/amplification reactions. Compounds that modulate expression of the transcripts are potentially useful for treatment of (metastatic) breast cancer, while promoters from the transcripts are used to direct expression, in selected cell types, of e.g. therapeutic genes (also ribozymes or antisense sequences), particularly an antigen-encoding sequence for use in gene or cell-based vaccines. Polypeptides encoded by the transcripts are also useful in vaccines; for diagnosing breast cancer and for raising specific antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic agents. Host cells that produce the polypeptides can be used to expand and isolate populations of educated, antigen-specific immune effector cells, e.g. cytotoxic T lymphocytes, and these used for adoptive immunotherapy

Sequence 10 BP; 0 A; 2 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 736 AACAGAA 743

DB 9 AACAGAA 2

RESULT 848

AAZ83845
ID AAZ83845 standard; DNA; 10 BP.

AC AAZ83845;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #3079.

Human; metastatic breast tumour tissue; breast cancer; tag; primer;
non-metastatic breast tumour tissue; gene therapy; anticancer;
antimetastatic; vaccine; diagnosis; ss.

OS Homo sapiens.

PN WO9965928-A2.

PD 23-DEC-1999.

PF 18-JUN-1999; 99WO-US013647.

PR 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089997P.

PR 19-JUN-1998; 98US-0090039P.

PR 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.

(GENZ) GENZYME CORP.

(ROBE/) ROBERTS B L.

(SHAN/) SHANKARA S.

Roberts BL, Shankara S;

WPI; 2000-106079/09.

Isolated polynucleotides differentially expressed between metastatic and non-metastatic breast cancer cells, useful for diagnosis, prevention and treatment of cancer.

Claim 1; Page 141; 219pp; English.

AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts that are preferentially transcribed in the metastatic breast tumour tissue (i.e. are upregulated in metastatic breast tumour cells). AAZ83942 to AAZ86677 represent tags corresponding to distinct transcripts that are

preferentially transcribed in the primary or non-metastatic breast tumour tissue (i.e. are downregulated in metastatic breast tumour cells). These transcripts can be used for diagnosis, prognosis, monitoring and treatment of breast cancer, particularly where metastatic. Diagnosis is by standard immunoassays or hybridisation/amplification reactions. Compounds that modulate expression of the transcripts are potentially useful for treatment of (metastatic) breast cancer, while promoters from the transcripts are used to direct expression, in selected cell types, of e.g. therapeutic genes (also ribozymes or antisense sequences), particularly an antigen-encoding sequence for use in gene or cell-based vaccines. Polypeptides encoded by the transcripts are also useful in vaccines; for diagnosing breast cancer and for raising specific antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic agents. Host cells that produce the polypeptides can be used to expand and isolate populations of educated, antigen-specific immune effector cells, e.g. cytotoxic T lymphocytes, and these used for adoptive immunotherapy

Sequence 10 BP; 3 A; 4 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;

Best Local Similarity 100.0%; Pred. No. 6e+02;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCAGGAGA 736

DB 3 CCAGGAGA 10

RESULT 849

AAZ81230/C
ID AAZ81230 standard; DNA; 10 BP.

AC AAZ81230;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #464.

Human; metastatic breast tumour tissue; breast cancer; tag; primer;

non-metastatic breast tumour tissue; gene therapy; anticancer;

antimetastatic; vaccine; diagnosis; ss.

OS Homo sapiens.

PN WO9965928-A2.

PD 23-DEC-1999.

PF 18-JUN-1999; 99WO-US013647.

PR 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089997P.

PR 19-JUN-1998; 98US-0090039P.

PR 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.

(GENZ) GENZYME CORP.

(ROBE/) ROBERTS B L.

(SHAN/) SHANKARA S.

Roberts BL, Shankara S;

WPI; 2000-106079/09.

Isolated polynucleotides differentially expressed between metastatic and non-metastatic breast cancer cells, useful for diagnosis, prevention and treatment of cancer.

Claim 1; Page 70; 219pp; English.

AAZ80767 to AAZ83941 represent tags corresponding to distinct transcripts that are preferentially transcribed in the metastatic breast tumour

CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
 CC to AA286677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 1 A; 3 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 735 GAAACAGA 742
 Db 8 GAAACAGA 1
 RESULT 850
 AA285663/c
 ID AA285663 standard; DNA; 10 BP.
 XX AC AA285663;
 XX DT 07-APR-2000 (first entry)
 XX DE Metastatic breast tumour cell downregulated transcript tag #4897.
 XX DE Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 XX OS Homo sapiens.
 XX PN W09965928-A2.
 XX PD 23-DEC-1999.
 XX PF 18-JUN-1999; 99WO-US013647.
 XX PR 19-JUN-1998; 98US-0089853P.
 XX PR 19-JUN-1998; 98US-0089997P.
 XX PR 19-JUN-1998; 98US-0090039P.
 XX PR 19-JUN-1998; 98US-0090040P.
 XX PR 19-JUN-1998; 98US-0090041P.
 XX PA (GENZ) GENZYME CORP.
 XX PA (ROBE/) ROBERTS B.L.
 XX PA (SHAN/) SHANKARA S.
 XX PI Roberts BL, Shankara S;
 XX WPI; 2000-106079/09.
 XX Isolated polynucleotides differentially expressed between metastatic and
 PT non-metastatic breast cancer cells, useful for diagnosis, prevention and
 PT treatment of cancer.
 XX
 PS Claim 1; Page 189; 219pp; English.

CC AA280767 to AA283941 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the metastatic breast tumour
 CC tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942
 CC to AA286677 represent tags corresponding to distinct transcripts that are
 CC preferentially transcribed in the primary or non-metastatic breast tumour
 CC tissue (i.e. are downregulated in metastatic breast tumour cells). These
 CC transcripts can be used for diagnosis, prognosis, monitoring and
 CC treatment of breast cancer, particularly where metastatic. Diagnosis is
 CC by standard immunoassays or hybridisation/amplification reactions.
 CC Compounds that modulate expression of the transcripts are potentially
 CC useful for treatment of (metastatic) breast cancer, while promoters from
 CC the transcripts are used to direct expression, in selected cell types, of
 CC e.g. therapeutic genes (also ribozymes or antisense sequences),
 CC particularly an antigen-encoding sequence for use in gene or cell-based
 CC vaccines. Polypeptides encoded by the transcripts are also useful in
 CC antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic
 CC agents. Host cells that produce the polypeptides can be used to expand
 CC and isolate populations of educated, antigen-specific immune effector
 CC cells, e.g. cytotoxic T lymphocytes, and these used for adoptive
 CC immunotherapy
 XX
 SQ Sequence 10 BP; 0 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 Db 10 AGGAGAAA 3
 RESULT 851
 AAH63186
 ID AAH63186 standard; cDNA; 10 BP.
 XX AC AAH63186;
 XX DT 20-SEP-2001 (first entry)
 XX DE Human colon epithelium specific transcriptome sequence SEQ ID NO: 26.
 XX Human; transcriptome; gene expression pattern; cancer; drug screening;
 KW cancer diagnosis; cell specific gene expression; ss.
 XX OS Homo sapiens.
 XX PN W0200138577-A2.
 XX PD 31-MAY-2001.
 XX PF 21-NOV-2000; 2000WO-US031922.
 XX PR 24-NOV-1999; 99US-00448480.
 XX PA (UYJO) UNIV JOHNS HOPKINS.
 XX PI Velculescu VE, Vogelstein B, Kinzler KW;
 XX WPI; 2001-367706/38.
 XX New isolated polynucleotides, useful for identifying specific cell type,
 PT such as cancer cell, comprises transcriptomes expressed in particular
 PT cell types.
 XX
 PS Claim 11; Page 39; 94pp; English.
 XX The present invention describes a method of identifying the type of cell
 CC in a sample, involving determining which of the sequences AAH63186-
 CC AAH64724 is expressed by the cell. The transcriptomes described in the
 CC invention are cell-type specific, cancer specific or ubiquitously
 CC expressed in humans. They can also be used to screen for drugs, reduce

PR 24-NOV-1999; 99US-00448480.
XX (UYJO) UNIV JOHNS HOPKINS.
XX Velculescu VE, Vogelstein B, Kinzler KW;
XX WPI; 2001-367706/38.
XX
XX New isolated polynucleotides, useful for identifying specific cell type,
XX such as cancer cell, comprises transcriptomes expressed in particular
XX cell types.
XX
XX Claim 13; Page 69; 94pp; English.
XX
XX The present invention describes a method of identifying the type of cell
XX in a sample, involving determining which of the sequences AAH63161-
XX AH64724 is expressed by the cell. The transcriptomes described in the
XX invention are cell-type specific, cancer specific or ubiquitously
XX expressed in humans. They can also be used to screen for drugs, reduce
XX cancer specific gene expression, standardise expression and restore the
XX function of a diseased cell or tissue. The present sequence is one of the
XX transcriptomes described in the exemplification of the invention
XX
XX Sequence 10 BP; 0 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 728 GCCAGGAG 735
DB 10 GCCAGGAG 3
RESULT 855
AAH63237
ID AAH63237 standard; cDNA; 10 BP.
XX
XX AAH63237;
AC
XX 20-SEP-2001 (first entry)
DT
XX Human colon epithelium specific transcriptome sequence SEQ ID NO: 77.
DE
XX Human; transcriptome; gene expression pattern; cancer; drug screening;
XX cancer diagnosis; cell specific gene expression; ss.
OS Homo sapiens.
XX
XX WO200138577-A2.
PN
XX 31-MAY-2001.
PD
XX 21-NOV-2000; 2000WO-US031922.
XX
XX 24-NOV-1999; 99US-00448480.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX Velculescu VE, Vogelstein B, Kinzler KW;
XX
XX WPI; 2001-367706/38.
XX
XX New isolated polynucleotides, useful for identifying specific cell type,
XX such as cancer cell, comprises transcriptomes expressed in particular
XX cell types.
XX
XX Claim 1; Page 40; 94pp; English.
XX
XX The present invention describes a method of identifying the type of cell
XX in a sample, involving determining which of the sequences AAH63161-
XX AH64724 is expressed by the cell. The transcriptomes described in the
XX invention are cell-type specific, cancer specific or ubiquitously

CC expressed in humans. They can also be used to screen for drugs, reduce
CC cancer specific gene expression, standardise expression and restore the
CC function of a diseased cell or tissue. The present sequence is one of the
CC transcriptomes described in the exemplification of the invention
XX
XX Sequence 10 BP; 7 A; 1 C; 2 G; 0 T; 0 U; 0 Other;
SQ
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 736 AAACAGAA 743
DB 3 AAACAGAA 10
RESULT 856
AAAF37890
ID AAFA37890 standard; DNA; 10 BP.
XX
XX AAFA37890;
AC
XX 23-MAR-2001 (first entry)
DT
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:4629.
DE
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX nor previously assigned open reading frame; nonannotated ORF; SAGE;
XX serial analysis of gene expression; antifungal; tag; identification;
XX linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.
OS
XX WO200077214-A2.
PN
XX 21-DEC-2000.
PD
XX 14-JUN-2000; 2000WO-US016223.
XX
XX 16-JUN-1999; 99US-00335032.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX Velculescu V, Vogelstein B, Kinzler K;
XX
XX WPI; 2001-061874/07.
DR
XX Yeast gene coding sequences comprising NORF genes with serial analysis of
XX gene expression (SAGE) tags, useful for studying, monitoring and
XX affecting phases of the cell cycle.
XX
XX Example; Page 165; 419pp; English.
XX
XX The present invention describes an isolated DNA molecule comprising a
XX coding sequence of a yeast gene selected from a group of 745 NORF (not
XX previously assigned open reading frame; or nonannotated ORF) genes
XX comprising a SAGE (serial analysis of gene expression) tag. Also
XX described are: (1) a method (M1) of using NORF genes to affect the cell
XX cycle comprising administering a NORF gene whose expression varies by at
XX least 10% between any two phases of the cell cycle selected from log
XX phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX antifungal drugs comprising: (a) contacting a test substance with a yeast
XX cell; and (b) monitoring expression of a NORF gene whose expression
XX varies in M1, where a test substance which modifies the expression of
XX the yeast gene is a candidate antifungal drug; (3) a method (M3) for
XX identifying human genes which are involved in cell cycle progression
XX comprising contacting human DNA with a probe which comprises at least 10
XX contiguous nucleotides of a NORF gene whose expression varies as in M1;
XX and (4) a method (M4) for identifying a candidate drug as a member of a
XX class of drugs having a characteristic effect on gene expression in a
XX yeast cell comprising contacting a yeast cell with a candidate drug and
XX monitoring expression in the yeast cell of at least 1 NORF gene whose
XX expression is affected by the class of drugs. The NORF genes may be used

CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX Sequence 10 BP; 4 A; 3 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 740 AGAACACC 747
 |||||
 Db 3 AGAACACC 10

RESULT 857
 AAF35950
 ID AAF35950 standard; DNA; 10 BP.
 XX
 AC AAF35950;
 XX
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2689.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.

XX WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu V, Vogelstein B, Kinzler K;
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 PS Example; Page 96; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a

CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX Sequence 10 BP; 4 A; 1 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 CAGGAGAA 737
 |||||
 Db 2 CAGGAGAA 9

RESULT 858
 AAF41069/C
 ID AAF41069 standard; DNA; 10 BP.
 XX
 AC AAF41069;
 XX
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7808.

XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds..
 XX
 OS Saccharomyces cerevisiae.

XX WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu V, Vogelstein B, Kinzler K;
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.

XX Example; Page 278; 419pp; English.
 XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10

CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 0 A; 3 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AACACAGAA 743
 Db 10 AACACAGAA 3
 RESULT 859
 AAF38498
 ID AAF38498 standard; DNA; 10 BP.
 XX
 AC AAF38498;
 XX
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5237.
 XX
 KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Veiculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 PS Example; Page 187; 419pp; English.
 XX
 CC The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of

CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 6 A; 2 C; 2 G; 0 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AACACAGAA 743
 Db 1 AACACAGAA 8
 RESULT 860
 AAF36885
 ID AAF36885 standard; DNA; 10 BP.
 XX
 AC AAF36885;
 XX
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3624.
 XX
 KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Veiculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 PS Example; Page 129; 419pp; English.
 XX
 CC The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate

CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 7 A; 1 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 736 AAACAGAA 743
 |||||
 Db 2 AAACAGAA 9

RESULT 861
 AAF33978
 ID AAF33978 standard; DNA; 10 BP.
 XX AAF33978;
 AC AAF33978;
 XX
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:717.
 XX
 KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 XX

PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 PS Claim 1; Page 400; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell

CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX
 SQ Sequence 10 BP; 4 A; 1 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 CAGGAGAA 737
 |||||
 Db 2 CAGGAGAA 9

RESULT 862
 AAF35089/C
 ID AAF35089 standard; DNA; 10 BP.
 XX AAF35089;
 AC AAF35089;
 XX
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:1828.
 XX
 KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 XX

PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 PS Example; Page 65; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell

PD 07-MAR-2002.
 XX 28-AUG-2001; 2001WO-US026899.
 XX 28-AUG-2000; 2000US-0228496P.
 XX (GENA-) GENAISSANCE PHARM INC.
 PI Anastasio AE, Finkel K, Koshy B, Kumar AM, Lee HH;
 XX WPI; 2002-339655/37.
 XX New genetic variants having polymorphisms in the small inducible cytokine
 PT A1 (SCYA2) gene, useful for studying the function of SCYA2, and for
 PT treating disorders affected by expression or function of the SCYA2
 PT isogene.
 XX Claim 19; Page 13; 58pp; English.
 XX The invention relates to single nucleotide polymorphisms in the gene
 CC encoding human small inducible cytokine A2 (SCYA2) polypeptide. A method
 CC for haplotyping the SCYA2 gene in an individual comprises identifying the
 CC nucleotide at one or more polymorphic sites and determining whether one
 CC of the copies of the gene is defined by one of the SCYA2 haplotypes given
 CC in the specification or whether both copies are defined by a haplotype
 CC pair. This method is useful in genotyping, whereby all possible haplotype
 CC pairs can be assigned to specific genotypes. An association between a
 CC trait and a haplotype or haplotype pair of the SCYA2 gene can be
 CC identified by comparing the frequency of the haplotype or haplotype pair
 CC in a population exhibiting the trait with the frequency of the haplotype
 CC or haplotype pair in a reference population, where a higher haplotype
 CC frequency in the trait population indicates the trait is associated with
 CC the haplotype or haplotype pair. SCYA2 and its corresponding DNA are used
 CC for studying the expression and function of SCYA2, and in screening for
 CC candidate drugs to treat diseases related to SCYA2 activity, such as
 CC atherosclerosis. Sequences ABK68593-ABK68704 represent allele-specific
 CC oligonucleotide PCR primers used for detecting SCYA2 gene polymorphisms
 XX
 SQ Sequence 10 BP; 5 A; 1 C; 4 G; 0 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 730 CAGGAGAA 737
 DB 1 CAGGAGAA 8
 RESULT 865
 ID ABL42788 standard; cDNA; 10 BP.
 XX
 AC ABL42788;
 XX
 DT 12-APR-2002 (first entry)
 XX
 DE Human maturation/activation dendritic cell expression gene tag #162.
 XX
 KW Human; maturation/activation dendritic cell expression gene; tag;
 KW maturation; activation; dendritic cell; ss.
 XX
 OS Homo sapiens.
 XX
 FN JP2001327293-A.
 XX
 PD 27-NOV-2001.
 XX
 PF 22-MAY-2000; 2000JP-00150562.
 XX
 PR 22-MAY-2000; 2000JP-00150562.
 XX
 PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

XX WPI; 2002-127070/17.
 XX Human maturation/activation dendritic cell expression gene group.
 PT Claim 10; Page 13; 41pp; Japanese.
 XX
 CC The present invention describes a human maturation/activation dendritic
 CC cell (DC) expression gene group consisting of 100 genes which show the
 CC highest expression among the genes expressed in human maturation/
 CC activation DC. Also described are: (1) a protein expressed by the above
 CC human maturation/activation DC expression gene; (2) an antibody against
 CC the protein; and (3) an antagonist against the expression of each gene
 CC belonging to the above gene group. The gene group is useful for the
 CC treatment and the diagnosis of various human diseases related to human
 CC DC. ABL42627 to ABL42926 represent specifically claimed human
 CC maturation/activation DC expression gene tags from the present invention
 XX
 SQ Sequence 10 BP; 2 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 728 GCCAGGAG 735
 DB 1 GCCAGGAG 8
 RESULT 866
 ID AAL48074/C standard; DNA; 10 BP.
 XX
 AC AAL48074;
 XX
 DT 27-SEP-2002 (first entry)
 XX
 DE Human CSF3 gene allele specific primer extension oligo SEQ ID NO: 52.
 XX
 KW Human; colony stimulating factor 3 (granulocyte); CSF3; SNP; isogene;
 KW chromosome 17q11-12; single nucleotide polymorphism; immunostimulant;
 KW neutropenia; promyelocytic leukaemia; haematological disorder;
 KW gene therapy; PCR; primer extension oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200194364-A2.
 XX
 PD 13-DEC-2001.
 XX
 PF 11-JUN-2001; 2001WO-US018813.
 XX
 PR 09-JUN-2000; 2000US-0210380P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Duda A, Kazemi A, Messer C, Sausker EA;
 XX
 XX WPI; 2002-566435/60.
 XX
 PT New variants of colony stimulating factor 3 (CSF3) isogenes, useful for
 PT improving efficiency and reliability in the development of drugs for
 PT treating diseases associated with CSF3 activity e.g. neutropenia.
 XX
 XX Claim 19; Page 13; 68pp; English.
 XX
 CC The present invention provides the protein, gene and cDNA sequences of
 CC human colony stimulating factor 3 (granulocyte) CSF3. Also described are
 CC single nucleotide polymorphisms (SNPs) identified within these sequences.
 CC The sequences can be used in the treatment of neutropenia, promyelocytic
 CC leukaemia and haematological disorders. The present sequence is an allele
 CC specific primer extension oligonucleotide used to isolate the coding
 CC sequences of the invention

```
XX SQ Sequence 10 BP; 1 A; 4 C; 1 G; 4 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 730 CAGGAGAA 737
|||||
Db 10 CAGGAGAA 3

RESULT 867
ABV99817
ID ABV99817 standard; DNA; 10 BP.
XX
AC ABV99817;
XX
DT 24-FEB-2003 (first entry)
XX
DE Human PFKFB2 PCR primer #19.
XX
KW Human; 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2; PFKFB2;
KW cytosolic; antidiabetic; Gene therapy; cancer; diabetes; ss; PCR;
KW primer; polymorphism.
XX
OS Homo sapiens.
XX
PN WO200194363-A2.
XX
FD 13-DEC-2001.
XX
XX 07-JUN-2001; 2001WO-US018458.
XX
XX 07-JUN-2000; 2000US-0209935P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Duda A, Kazemi A, Koshy B;
XX
XX WPI; 2002-566434/60.
XX
PT New 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) gene
PT variants, for improving efficiency and reliability in the development of
PT drugs for treating diseases associated with PFKFB2 activity e.g. cancer.
XX
PS Claim 17; Page 14; 95pp; English.
XX
CC The invention relates to a novel human 6-phosphofructo-2-kinase/ fructose
CC -2,6-bisphosphatase 2 (PFKFB2) isogene. The PFKFB2 of the invention has
CC cytosolic and antidiabetic activity. The polynucleotides may have a use
CC in gene therapy. The identified candidate agents targeting PFKFB2, are
CC useful for treating cancer and diabetes. The methods of the invention are
CC useful for improving the efficiency and reliability of several steps in
CC the discovery and development of drugs for treating diseases associated
CC with PFKFB2 activity. The present sequence represents a PCR primer used
CC in the invention to detect PFKFB2 gene polymorphisms by primer extension
XX
SQ Sequence 10 BP; 5 A; 2 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 738 ACAGAACA 745
|||||
Db 1 ACAGAACA 8

RESULT 868
ABV78493
ID ABV78493 standard; cDNA; 10 BP.
XX
```

```
AC ABV78493;
XX
DT 29-NOV-2002 (first entry)
XX
DE Human COP9 SAGE tag, SEQ ID NO:204.
XX
KW SAGE tag; serial analysis of gene expression; human; Th1 cell;
KW activated T cell; T lymphocyte; immune response; expression pattern;
KW preferential expression; immune disorder; ss.
XX
XX Homo sapiens.
XX
PN JP2002186482-A.
XX
PD 02-JUL-2002.
XX
PF 19-DEC-2000; 2000JP-00385816.
XX
PR 19-DEC-2000; 2000JP-00385816.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI; 2002-594261/64.
XX
PT Human activated Th1 and Th2 cell expression gene group, useful for the
PT diagnosis and treatment of Th1 and Th2-related diseases.
XX
PS Claim 19; Page 11; 60pp; Japanese.
XX
CC The invention relates to SAGE (serial analysis of gene expression) tags
CC representing groups of genes which are expressed in activated human Th1
CC and/or Th2 cells. The SAGE tags of this invention consist of a sequence
CC of 10 nucleotides located downstream of the 5'-CARG-3' sequence motif
CC lying nearest to the polyA region of cDNAs derived from a variety of
CC genes. These tags serve to uniquely identify each transcript and can thus
CC be used to analyse the pattern of gene expression in particular cell
CC types. The invention also relates to proteins encoded by the genes
CC expressed in Th1 and/or Th2 cells, antibodies against these proteins, and
CC inhibitors of the expression of groups of genes that are expressed in
CC either or both the two cell types. Groups of genes expressed in Th1
CC and/or Th2 cell types may be used for the diagnosis and treatment of Th1
CC and Th2-related disorders. Sequences ABV78390-ABV78560 are SAGE tags
CC representing 171 genes which are more highly expressed in Th1 cells
CC compared with Th2 cells
XX
SQ Sequence 10 BP; 4 A; 2 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCAGGAGA 736
|||||
Db 3 CCAGGAGA 10

RESULT 869
ABK23469/C
ID ABK23469 standard; DNA; 10 BP.
XX
AC ABK23469;
XX
DT 09-APR-2002 (first entry)
XX
DE Transcript tag DNA sequence #59 induced or suppressed by N-myc.
XX
KW Myc-dependent downstream gene; neoplastic; cancer; growth; invasion;
KW spread; myc target; myc tag; SAGE; serial analysis of gene expression;
KW myc oncogene; N-myc; human neuroblastoma; cytostatic; ds.
XX
XX Homo sapiens.
XX
PN WO200185941-A2.
```

XX PD 15-NOV-2001.
 XX PF 11-MAY-2001; 2001WO-NL000361.
 XX PR 11-MAY-2000; 2000EP-00201698.
 XX PR 29-JUN-2000; 2000EP-00202284.
 XX PA (UYAM-) UNIV AMSTERDAM ACAD ZIEKENHUIS BIJ VAN.
 XX PI Versteeg R, Caron HN;
 XX WPI; 2002-066603/09.
 XX A new nucleic acid library of myc-dependent downstream genes capable of
 PT supporting a neoplastic characteristic of cancer is useful to find new
 PT therapies and diagnoses for cancer.
 XX PS Disclosure; Page 50; 69pp; English.
 XX CC The present invention relates to a nucleic acid library comprising myc-
 CC dependent downstream genes or their functional fragments essentially
 CC capable of supporting a neoplastic character of cancer such as growth,
 CC invasion or spread. These myc target or tag sequences are identified by
 CC SAGE (serial analysis of gene expression). The library is useful to find
 CC new diagnoses and treatments for cancer. The invention is also useful to
 CC enhance production of recombinant proteins in a production system with
 CC high expression of endogenous or transfected myc oncogenes. ABK23412-
 CC ABK23828 represent transcript tag DNA sequences that are activated or
 CC repressed by N-myc in human neuroblastoma
 XX Sequence 10 BP; 0 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 728 GCCAGGAG 735
 DB 10 GCCAGGAG 3
 RESULT 870
 ID ABK96609 standard; DNA; 10 BP.
 XX AC ABK96609;
 XX DT 24-SEP-2002 (first entry)
 XX DE Human interleukin 6 primer extension primer 3' terminus #4.
 XX Human; ss; primer; interleukin-6; IL6; myeloma; arthritis; CAD;
 KW Kaposi sarcoma; coronary artery disease; inflammatory cytokine;
 KW hypercalcaemia; bone disease; inflammatory disease; HIV; PCR;
 KW human immunodeficiency virus infection; stunted growth; isogene;
 KW systemic onset juvenile chronic arthritis; haplotype; genotype;
 KW chromosome 7p21-p15; gene therapy; primer extension; SNP;
 KW single nucleotide polymorphism.
 XX OS Homo sapiens.
 XX PN WO200238586-A2.
 XX PD 16-MAY-2002.
 XX PF 09-NOV-2001; 2001WO-US047077.
 XX PR 09-NOV-2000; 2000US-0247578P.
 XX PR 21-AUG-2001; 2001US-0313963P.
 XX PA (GENA-) GENAISANCE PHARM INC.
 XX

PI Bentivegna SC, Bieglecki KM, Chew A, Denton RR, Lachowicz M;
 PI Nandabalan K, Parks KE, Sausker EA;
 XX WPI; 2002-519290/55.
 XX Genetic variants of interleukin-6 isogenes for improving efficiency and
 PT reliability in drug development for treating myeloma, coronary artery
 PT disease, arthritis and Kaposi sarcoma.
 XX Claim 17; Page 16; 86pp; English.
 XX CC The invention relates to a polynucleotide comprising a first nucleotide
 CC sequence (NS1) comprising a IL6 (interleukin-6, an inflammatory cytokine)
 CC isogene selected from isogenes 1-11 and 13-18 given in the specification,
 CC where each isogene comprises the regions of NS1 and is further defined by
 CC the corresponding sequence of polymorphisms whose locations and
 CC identities are defined in the specification (PS2-PS6, PS8 and PS10-PS17),
 CC or a second nucleotide sequence (NS2) complementary to NS1.
 CC Alternatively, the sequence comprises a coding sequence for an IL6
 CC isogene. Also included are methods of haplotyping/ genotyping (and
 CC predicting the haplotype/genotype) of the IL6 gene of an individual,
 CC identifying an association between a trait and at least one haplotype or
 CC haplotype pair of the IL6 gene, an isolated oligonucleotide for detecting
 CC a polymorphism in the IL6 gene, a recombinant non-human organism (III)
 CC transformed or transfected with the IL6 polynucleotide, an isolated
 CC fragment of the IL6 isogene comprising at least 10 and containing one of
 CC the identified single- nucleotide polymorphisms (SNP), an isolated
 CC polypeptide (or fragment) comprising an amino acid sequence which is a
 CC polymorphic variant of IL6, an isolated monoclonal antibody specific for
 CC IL6, a computer system for storing and analysing polymorphism data for
 CC the IL6 gene, and a genome anthology for the IL6 gene. The IL6
 CC polymorphic variant is useful in screening for drugs targeting IL6 that
 CC are useful for treating myeloma, coronary artery disease (CAD),
 CC arthritis, Kaposi sarcoma (associated with human immunodeficiency virus
 CC infection, HIV), hypercalcaemia, bone disease, inflammatory disease,
 CC stunted growth and systemic onset juvenile chronic arthritis. The methods
 CC are useful for improving the efficiency and reliability in the discovery
 CC and development of drugs and in the validation of IL6 as a drug target.
 CC The antibody is useful in diagnostic, prognostic and therapeutic methods.
 CC The IL6 isogene is useful in studying the expression and function of IL6,
 CC and in expressing IL6 protein for use in screening for candidate drugs.
 CC The gene for IL6 is located on chromosome 7p21-p15. The present sequence
 CC is the 3' terminus of an allele specific primer used to detect an IL6
 CC polymorphism using the method of primer extension
 XX Sequence 10 BP; 0 A; 3 C; 4 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCAGGAGA 736
 DB 8 CCAGGAGA 1
 RESULT 871
 ID ABK96611/c
 XX ID ABK96611 standard; DNA; 10 BP.
 XX AC ABK96611;
 XX DT 24-SEP-2002 (first entry)
 XX DE Human interleukin 6 primer extension primer 3' terminus #6.
 XX Human; ss; primer; interleukin-6; IL6; myeloma; arthritis; CAD;
 KW Kaposi sarcoma; coronary artery disease; inflammatory cytokine;
 KW hypercalcaemia; bone disease; inflammatory disease; HIV; PCR;
 KW human immunodeficiency virus infection; stunted growth; isogene;
 KW systemic onset juvenile chronic arthritis; haplotype; genotype;
 KW chromosome 7p21-p15; gene therapy; primer extension; SNP;
 KW single nucleotide polymorphism.

XX OS Homo sapiens.
XX AC WO200238586-A2.
XX DT 16-MAY-2002.
XX DE 09-NOV-2001; 2001WO-US047077.
XX KW 09-NOV-2000; 2000US-0247578P.
XX KW 21-AUG-2001; 2001US-0313963P.
XX PR (GENA-) GENAISSANCE PHARM INC.
XX PA Bentivegna SC, Bieglicki KM, Chew A, Denton RR, Lachowicz M;
XX PI Nandabalan K, Parks KE, Sausker EA;
XX PT WPI; 2002-519290/55.
XX PS Genetic variants of interleukin-6 isogenes for improving efficiency and
XX PT reliability in drug development for treating myeloma, coronary artery
XX PT disease, arthritis and Kaposi sarcoma.
XX FS Claim 17; Page 16; 86pp; English.
XX CC The invention relates to a polynucleotide comprising a first nucleotide
XX CC sequence (NS1) comprising a IL6 (interleukin-6, an inflammatory cytokine)
XX CC isogene selected from isogenes 1-11 and 13-18 given in the specification,
XX CC where each isogene comprises the regions of NS1 and is further defined by
XX CC the corresponding sequence of polymorphisms whose locations and
XX CC identities are defined in the specification (PS2-PS6, PS8 and PS10-PS17),
XX CC or a second nucleotide sequence (NS2) complementary to NS1.
XX CC Alternatively, the sequence comprises a coding sequence for an IL6
XX CC isogene. Also included are methods of haplotyping/ genotyping (and
XX CC predicting the haplotype/genotype) of the IL6 gene of an individual,
XX CC identifying an association between a trait and at least one haplotype or
XX CC haplotype pair of the IL6 gene, an isolated oligonucleotide for detecting
XX CC a polymorphism in the IL6 gene, a recombinant non-human organism (III)
XX CC transformed or transfected with the IL6 polynucleotide, an isolated
XX CC fragment of the IL6 isogene comprising at least 10 and containing one of
XX CC the identified single- nucleotide polymorphisms (SNP), an isolated
XX CC polypeptide (or fragment) comprising an amino acid sequence which is a
XX CC polymorphic variant of IL6, an isolated monoclonal antibody specific for
XX CC IL6, a computer system for storing and analysing polymorphism data for
XX CC the IL6 gene, and a genome anthology for the IL6 gene. The IL6
XX CC polymorphic variant is useful in screening for drugs targeting IL6 that
XX CC are useful for treating myeloma, coronary artery disease (CAD),
XX CC arthritis, Kaposi sarcoma (associated with human immunodeficiency virus
XX CC infection, HIV), hypercalcaemia, bone disease, inflammatory disease,
XX CC stunted growth and systemic onset juvenile chronic arthritis. The methods
XX CC are useful for improving the efficiency and reliability in the discovery
XX CC and development of drugs and in the validation of IL6 as a drug target.
XX CC The antibody is useful in diagnostic, prognostic and therapeutic methods.
XX CC The IL6 isogene is useful in studying the expression and function of IL6,
XX CC and in expressing IL6 protein for use in screening for candidate drugs.
XX CC The gene for IL6 is located on chromosome 7p21-p15. The present sequence
XX CC is the 3' terminus of an allele specific primer used to detect an IL6
XX CC polymorphism using the method of primer extension
XX SQ Sequence 10 BP; 0 A; 4 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 730 CAGGAGAA 737
DB 10 CAGGAGAA 3
RESULT 872
AAS19962
ID AAS19962 standard; DNA; 10 BP.

XX AAS19962;
XX 26-MAR-2002 (first entry)
XX DE Primer-extension oligonucleotide #14 to detect human DNAL4 polymorphisms.
XX KW Human; single nucleotide polymorphism; SNP; DNAL4; chromosome 22q13.1;
XX KW dynein axonemal light polypeptide chain 4; haplotyping; genotyping;
XX KW neuroprotective; neurological disorder; primer; ss.
XX OS Homo sapiens.
XX XX WO200179235-A2.
XX XX 25-OCT-2001.
XX XX 16-APR-2001; 2001WO-US012304.
XX PR 17-APR-2000; 2000US-0197460P.
XX XX (GENA-) GENAISSANCE PHARM INC.
XX PI Bentivegna SC, Chew A, Choi JY, Koshy B;
XX WPI; 2002-075065/10.
XX CC Genotyping human dynein, axonemal light polypeptide chain 4 gene of
XX CC individual, useful for determining haplotype of individual, comprises
XX CC determining identity of nucleotide pair at specific polymorphic sites for
XX CC two copies of gene.
XX CC Claim 18; Page 14; 79pp; English.
XX CC The present invention relates to novel single nucleotide polymorphisms
XX CC (SNPs) in the human dynein, axonemal light polypeptide chain 4 (DNAL4)
XX CC gene located on chromosome 22q13.1, and methods for haplotyping and/or
XX CC genotyping the DNAL4 gene. The methods of the invention make use of
XX CC allele-specific oligonucleotides (ASOs) as probes and primers and/or
XX CC primer-extension oligonucleotides for detecting the DNAL4 gene
XX CC polymorphisms. The polynucleotides and screened compounds are useful for
XX CC the treatment of diseases associated with DNAL4 activity, such as
XX CC neurological disorders. AAS19949-AAS19976 represent primer-extension
XX CC oligonucleotides for detecting human DNAL4 gene polymorphisms
XX SQ Sequence 10 BP; 4 A; 3 C; 3 G; 0 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCAGGAGA 736
DB 3 CCAGGAGA 10
RESULT 873
AAL43004/C
ID AAL43004 standard; DNA; 10 BP.
XX AC AAL43004;
XX XX 08-AUG-2002 (first entry)
XX DE Human cerberus 1 (CER1) gene primer-extension oligonucleotide 9.
XX KW Human; PCR; ss; allele-specific; SNP; single nucleotide polymorphism;
XX KW cerberus 1 homologue; cysteine knot superfamily; CER1; drug screening;
XX KW developmental disorder; polymorphic site; CER1 haplotyping; primer.
XX OS Homo sapiens.
XX XX WO200232929-A2.
XX PN

XX PD 25-APR-2002.
 XX PF 19-OCT-2001; 2001WO-US046100.
 XX PR 19-OCT-2000; 2000US-0241634P.
 XX PA (GENA-) GENAISSANCE PHARM INC.
 XX PI Kazemi A, Shah N;
 XX WPI; 2002-435527/46.
 XX Novel genetic variants of Cerberus 1 (Xenopus laevis) Homolog (Cysteine Knot Superfamily) (CER1) isogenes, useful for improving efficiency and reliability in drug development for treating developmental disorders.
 XX Claim 16; Page 14; 75pp; English.
 XX The invention relates to the identification of 13 novel polymorphic sites in the human cerberus 1 (Xenopus laevis) homologue (cysteine knot superfamily) (CER1) gene. The invention also comprises the amino acid and coding sequence of CER1. The CER1 protein is useful for screening drugs that target CER1 - for the treatment of developmental disorders. The CER1 coding sequence is useful in studying the expression of CER1 isogenes, for screening and testing of drugs targeted against CER1 protein, and in testing the efficacy of therapeutic agents for treating developmental disorders. The 13 novel polymorphic sites identified in the invention are useful for haplotyping the CER1 gene of an individual. The present DNA sequence represents a human CER1 gene primer-extension oligonucleotide
 XX Sequence 10 BP; 1 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
 XX Query Match 36.4%; Score 8; DB 1; Length 10;
 XX Best Local Similarity 100.0%; Pred. No. 6e+02;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 739 CAGAACAC 746
 DB 10 CAGAACAC 3
 RESULT 874
 ABL45804/c
 ID ABL45804 standard; DNA; 10 BP.
 AC ABL45804;
 DT 03-MAY-2002 (first entry)
 DE Human MMP13 gene allele specific primer extension oligo SEQ ID NO: 92.
 XX Human; matrix metalloproteinase 13 (collagenase 3); MMP13; cancer;
 XX arthritis; haplotype; single nucleotide polymorphism; SNP; enzyme;
 XX cyrostatic; antiarthritic; gene therapy; chromosome 11q22.3; PCR primer;
 XX ss.
 XX Homo sapiens.
 XX WO200206294-A2.
 XX 24-JAN-2002.
 XX 13-JUL-2001; 2001WO-US022238.
 XX 13-JUL-2000; 2000US-0217950P.
 XX 17-AUG-2000; 2000WO-US022693.
 XX (GENA-) GENAISSANCE PHARM INC.
 XX Finkel K, Kliem SE, Messer C, Tanguay DA;
 XX WPI; 2002-171797/22.

XX Novel genetic variants of matrix metalloproteinase 13 (collagenase 3) gene useful in studying expression and function of the protein, and for screening drugs to treat diseases e.g. cancer and arthritis.
 XX Claim 18; Page 15; 110pp; English.
 XX The present invention provides the cDNA, protein and gene fragments of the human matrix metalloproteinase 13 (collagenase 3) (MMP13). Also provided are single nucleotide polymorphisms (SNPs) identified within the sequences. The sequences can be used to haplotype an individual and in the treatment of cancer and arthritis, including metastatic cancers. The present sequence is a primer extension oligonucleotide for the MMP13 CC gene, which is found on chromosome 11q22.3
 XX Sequence 10 BP; 2 A; 1 C; 1 G; 6 T; 0 U; 0 Other;
 XX Query Match 36.4%; Score 8; DB 1; Length 10;
 XX Best Local Similarity 100.0%; Pred. No. 6e+02;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AAACAGAA 743
 DB 10 AAACAGAA 3
 RESULT 875
 ABN81268/c
 ID ABN81268 standard; DNA; 10 BP.
 XX AC ABN81268;
 XX 16-AUG-2002 (first entry)
 XX Oligonucleotide primer #19 for detecting CYP1B1 gene polymorphisms.
 XX Cytochrome P450; dioxin-inducible; glaucoma 3; CYP1B1; cytostatic;
 XX ophthalmological; gene therapy; polymorphism; breast cancer; PCR;
 XX primary congenital glaucoma; primer extension; primer; ss.
 XX Homo sapiens.
 XX WO200230951-A2.
 XX 18-APR-2002.
 XX 15-OCT-2001; 2001WO-US042726.
 XX 13-OCT-2000; 2000US-0240211P.
 XX (GENA-) GENAISSANCE PHARM INC.
 XX Han J, Kliem SE, Sanchis A;
 XX WPI; 2002-426265/45.
 XX New genetic variants of cytochrome P450, subfamily I dioxin-inducible, polypeptide 1, glaucoma 3, primary infantile gene, CYP1B1 for treatment and expressing CYP1B1 protein for use in identifying drugs to breast cancer.
 XX Claim 17; Page 16; 96pp; English.
 XX The present invention relates to a novel isolated polynucleotide comprising a nucleotide sequence which is a polymorphic variant of a reference sequence for cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile), (CYP1B1) gene or its fragment, or a polymorphic variant of a reference sequence for a CYP1B1 cDNA or its fragment. The polypeptide of the invention has cytostatic and ophthalmological activity. The polynucleotide may have a use in gene therapy, and antisense gene therapy. The polymorphism and haplotype data of the invention are useful for validating whether CYP1B1 is a suitable target for drugs to treat breast cancer and primary congenital glaucoma,

CC screening for such drugs and reducing bias in clinical trials of such
CC drugs. The sequence represents an oligonucleotide primer, used in the
CC invention to detect polymorphisms in the CYP1B1 gene by primer extension
XX
SQ Sequence 10 BP; 0 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 731 AGGAGAA 738
|||||||
Db 10 AGGAGAA 3

RESULT 876

ID ACC78771/c
XX ACC78771 standard; DNA; 10 BP.

AC ACC78771;

DT 02-SEP-2003 (first entry)

DE Normal estrogen responsive cells derived SAGE tag.

XX ERE; reporter construct; estrogen response element; cytostatic; rat;
KW gene therapy; breast cancer; SAGE; ds.

XX Homo sapiens.

XX WO2003042364-A2.

XX 22-MAY-2003.

XX 08-NOV-2002; 2002WO-US035901.

XX 09-NOV-2001; 2001US-0338136P.

XX (DAND) DANA FARBER CANCER INST INC.

XX Polyak K, Pankaj S;

XX WPI; 2003-449570/42.

PT New reporter construct for identifying and isolating estrogen-responsive
PT cells comprises an estrogen response segment, a promoter segment and a
PT nucleotide sequence that encodes a reporter polypeptide.

XX Example 4; Page 32; 51pp; English.

XX The invention relates to a reporter construct comprising: (a) an estrogen
CC response segment having 5 or more estrogen response elements (ERE); (b) a
CC promoter segment having at least one promoter nucleic acid sequence; and
CC (c) a nucleotide sequence that encodes a reporter polypeptide, where the
CC nucleotide sequence is operably linked to the promoter segment and the
CC estrogen response segment. The reporter construct and vector are useful
CC in identifying and isolating estrogen-responsive cells. The methods are
CC useful in inhibiting the proliferation or survival of estrogen-responsive
CC breast cancer cells or in enhancing the proliferation or survival of
CC estrogen-receptor non-expressing, estrogen-non-responsive cells.
CC Sequences ACC78740-75 represent SAGE tags for transcripts specifically or
CC most abundantly expressed in normal estrogen responsive cells

XX Sequence 10 BP; 1 A; 4 C; 2 G; 3 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 729 CCAGGAGA 736
|||||||
Db 8 CCAGGAGA 1

XX 729 CCAGGAGA 736

XX 8 CCAGGAGA 1

RESULT 877

AA58112
ID AAD58112 standard; DNA; 10 BP.

AC AAD58112;

DT 20-NOV-2003 (first entry)

DE Leader DNA #2 used in the synthesis of siRNA of increased potency.

XX Small interfering RNA; siRNA; RNA interference application; anti-viral;
KW transplant rejection; autosomal dominant genetic disease; anti-tumour;
XX inherited disorder; Huntington's chorea; therapy; ds.

XX Unidentified.

XX WO2003064621-A2.

XX 07-AUG-2003.

XX 31-JAN-2003; 2003WO-US003023.

XX 01-FEB-2002; 2002US-0353332P.

XX (AMBI-) AMBION INC.

XX Brown D, Ford LP, Jarvis R, Pallotta V, Pasloske B;

XX WPI; 2003-689529/65.

PT Making small interfering RNA useful for treating Huntington's chorea by
PT incorporating nucleotides into siRNA such that the siRNA has a sequence
PT substantially identical to at least a portion of selected target gene.

XX Claim 38; Fig 3; 85pp; English.

XX The invention relates to a method for making small interfering RNA
CC (siRNA) of increased potency. The method involves obtaining nucleotides
CC and incorporating the nucleotides into siRNA so that RNA duplex of 15-30
CC contiguous nucleotides is formed, where the siRNA has a sequence
CC substantially identical to at least a portion of a selected target gene.
CC The method is also useful for attenuating the expression of a target gene
CC in a cell. The siRNA is useful in RNA interference applications which
CC include a wide range of research, industrial and medical processes,
CC materials and applications. Medical applications include anti-viral and
CC anti-tumour compositions and therapies; and compositions and therapies
CC for inherited disorders. siRNA is also useful in therapies for treating
CC autosomal dominant genetic disease such as Huntington's chorea and
CC management of transplant rejection. The present sequence is a leader DNA
CC used in the synthesis of siRNA of increased potency

XX Sequence 10 BP; 4 A; 2 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 732 GGAGAAAC 739

|||||||
Db 2 GGAGAAAC 9

RESULT 878

ADD71433/c
ID ADD71433 standard; DNA; 10 BP.

AC ADD71433;

DT 15-JAN-2004 (first entry)

DE Stimulus-responsive DNA organization oligonucleotide #3.

KW ss; stimulus-responsive DNA organization; supercoil; rotation;
 KW external stimulus; medical micromachines; artificial muscle.
 OS Synthetic.
 XX WO2003072772-A1.
 XX
 XX PD 04-SEP-2003.
 XX
 XX PF 28-AUG-2002; 2002WO-JP008656.
 XX
 XX PR 27-FEB-2002; 2002JP-00051927.
 XX
 XX PA (NTSC-) JAPAN SCI & TECHNOLOGY CORP.
 XX
 XX FI Yui N, Ootani T;
 XX
 XX DR WPI; 2003-679952/64.
 XX
 XX PT Stimulus-responsive DNA organization of highly compatible functional
 PT material undergoing reversible formation/dissociation of supercoil or
 PT rotation in response to external stimulus, useful as e.g. artificial
 PT muscles.
 XX
 XX PS Example 3; SEQ ID NO 4; 29pp; Japanese.
 XX
 XX CC The invention relates to a stimulus-responsive DNA organization
 CC undergoing formation/dissociation of a supercoil or rotation in response
 CC to an external stimulus and comprises a number of plasmid DNAs ligated in
 CC it. The DNA organization is applicable in various materials and body
 CC parts or medical micromachines e.g. artificial muscles. This sequence
 CC represents an oligonucleotide used in the method of the invention.
 XX
 XX SQ Sequence 10 BP; 0 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 6e-02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 DB 9 AGGAGAAA 2
 RESULT 879
 AAF82244
 ID AAF82244 standard; DNA; 11 BP.
 XX
 XX AC AAF82244;
 XX
 XX DT 14-JUN-2001 (first entry)
 XX
 XX DE DNA sequence that forms complex with alphaPNA CTCCT(b2).
 KW AlphaPNA; alpha-helical peptide nucleic acid; alphaPNA.DNA complex;
 KW solid-phase peptide synthesis; molecular switching; diagnosis; therapy;
 KW backbone 2; b2; ss.
 XX
 XX OS Synthetic.
 XX
 XX FH Key Location/Qualifiers
 FT Misc_binding 4
 FT /tag= a
 FT /bound moiety= "Alpha-helical peptide nucleic acid
 FT (alphaPNA) shown in AAB74017"
 FT /note= "this nucleotide hybridises to the thymine at
 FT position 19 of AB74017 to form an alphaPNA.DNA complex"
 FT 5
 FT Misc_binding
 FT /tag= b
 FT /bound moiety= "Alpha-helical peptide nucleic acid
 FT (alphaPNA) shown in AAB74017"
 FT /note= "this nucleotide hybridises to the thymine at
 FT position 15 of AB74017 to form an alphaPNA.DNA complex"
 FT 15

FT Misc_binding 6
 FT /tag= c
 FT /bound moiety= "Alpha-helical peptide nucleic acid
 FT (alphaPNA) shown in AAB74017"
 FT /note= "this nucleotide hybridises to the thymine at
 FT position 11 of AB74017 to form an alphaPNA.DNA complex"
 FT 7
 FT Misc_binding
 FT /tag= d
 FT /bound moiety= "Alpha-helical peptide nucleic acid
 FT (alphaPNA) shown in AAB74017"
 FT /note= "this nucleotide hybridises to the thymine at
 FT position 7 of AB74017 to form an alphaPNA.DNA complex"
 FT 8
 FT Misc_binding
 FT /tag= e
 FT /bound moiety= "Alpha-helical peptide nucleic acid
 FT (alphaPNA) shown in AAB74017"
 FT /note= "this nucleotide hybridises to the thymine at
 FT position 3 of AB74017 to form an alphaPNA.DNA complex"
 FT 9
 XX WO200114398-A1.
 XX
 XX PD 01-MAR-2001.
 XX
 XX PF 11-AUG-2000; 2000WO-US021845.
 XX
 XX PR 25-AUG-1999; 99US-0150637P.
 XX
 XX PA (GARN/) GARNER P P.
 XX
 XX PI Garner PP;
 XX
 XX DR WPI; 2001-265835/27.
 XX
 XX PT New peptide-based nucleic acid surrogate (PNAs) for use in therapeutic,
 PT diagnostic and molecular switching applications e.g. alpha-PNA chips.
 XX
 XX PS Example; Page 12; 32pp; English.
 XX
 XX CC The present sequence is a DNA sequence which hybridises to an alpha-
 CC helical peptide nucleic acid (alphaPNA). The invention relates to novel
 CC peptide-based nucleic acid surrogates comprising a secondary structure
 CC and a subunit with the sequence (AAB-aa)n, where: AA = hydroxyl-amino
 CC acid; B = nucleobase; aa = amino acid; n and m = greater than or equal to
 CC 1. Resin-bound PNAs are formed by solid-phase peptide synthesis and the
 CC resin is then cleaved from the PNAs. The PNAs are useful in therapeutic,
 CC diagnostic and molecular switching applications. The present sequence
 CC binds to nucleotides attached to the alphaPNA to form an alphaPNA.DNA
 CC complex
 XX
 XX SQ Sequence 11 BP; 8 A; 0 C; 3 G; 0 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e-02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 DB 4 AGGAGAAA 11
 RESULT 880
 ABA01034/c
 ID ABA01034 standard; DNA; 11 BP.
 XX
 XX AC ABA01034;
 XX
 XX DT 23-JAN-2002 (first entry)
 XX
 XX DE Mutational DNA exon 17a.
 XX
 XX KW Mutation detection; ion pair chromatography; exon; mutant; ds.
 XX
 XX OS Unidentified.

XX US2001034029-A1.
XX 25-OCT-2001.
XX 09-APR-2001; 2001US-00828211.
XX 19-APR-2000; 2000JP-00118597.
XX (SHMA) SHIMADZU CORP.
XX Fujiwake H;
XX WPI; 2001-656558/75.
XX
XX Detecting mutations in the base sequences of nucleic acids comprises
XX using ion pair chromatography and reversed phase separation columns.
XX Disclosure; Fig 3; 10pp; English.
XX
XX The invention relates to a method for detecting mutations in the base
XX sequences of nucleic acids. The method comprises using ion pair
XX chromatography involving a reversed phase column as a separation column,
XX and setting the separation column at a temperature that causes
XX differences in stability between hetero- and homoduplexes. The present
XX sequence is an exon from a mutated DNA sequence that can be analysed by
XX the method of the invention
XX
XX Sequence 11 BP; 1 A; 3 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 735 GAAACAGA 742
DB 8 GAAACAGA 1
RESULT 881
AAS05724
ID AAS05724 standard; DNA; 11 BP.
XX AAS05724;
XX 07-SEP-2001 (first entry)
XX Polypyrimidine-rich capture RP-TFO sequence.
XX reverse phase triplex forming oligonucleotide; RP-TFO;
XX protected nucleic acid sequence; PNAS; single nucleotide polymorphism;
XX SNP; short tandem repeat; cancer; CSF1PO; ss.
XX Synthetic.
XX WO200132929-A1.
XX 10-MAY-2001.
XX 03-NOV-2000; 2000WO-US030534.
XX 03-NOV-1999; 99US-0163356P.
XX 03-NOV-1999; 99US-0163416P.
XX 21-DEC-1999; 99US-0171348P.
XX 07-JUL-2000; 2000US-0216579P.
XX (CYGE-) CYGENE INC.
XX (OSTE/) OSTE C C.
XX Oste CC, Ramberg ER;
XX WPI; 2001-343488/36.
XX

PT Analyzing target nucleic acid sequences, useful for population genetics,
PT drug development and diagnosing cancer, comprises hybridizing triple
PT forming oligonucleotide and probe to target sequence.
XX
XX Example 4; Page 69; 141pp; English.
XX
XX The sequence is the polypyrimidine rich region of the capture reverse
XX phase triplex forming oligonucleotide, RP-TFO, used to analyse the CSF1PO
XX locus using the method of the invention. The invention relates to
XX analysing target nucleic acid sequences comprising restricting isolated
XX DNA, hybridising at least one triplex forming oligonucleotide (TFO),
XX adding a 3' to 5' exonuclease to form a protected nucleic acid sequence
XX (PNAS) tail structure, hybridising the captured structure with a single
XX nucleotide polymorphisms (SNP) identification probe and determining the
XX SNP score. The methods can be used for analysing target nucleic acid
XX sequences, especially genomic DNA sequences, to determine if they contain
XX SNPs or short tandem repeats (STRs). The methods can be used to detect
XX SNPs for use in population genetics, drug development, forensics, cancer,
XX genetic disease research, genomic analysis, diagnostics and therapeutics
XX in humans, plants and animals
XX
XX Sequence 11 BP; 6 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 731 AGGAGAAA 738
DB 4 AGGAGAAA 11
RESULT 892
AAS05726/C
ID AAS05726 standard; DNA; 11 BP.
XX AAS05726;
XX 07-SEP-2001 (first entry)
XX Polypyrimidine-rich RP-TFO sequence.
XX reverse phase triplex forming oligonucleotide; RP-TFO;
XX protected nucleic acid sequence; PNAS; single nucleotide polymorphism;
XX SNP; short tandem repeat; cancer; CSF1PO; ss.
XX Synthetic.
XX WO200132929-A1.
XX 10-MAY-2001.
XX 03-NOV-2000; 2000WO-US030534.
XX 03-NOV-1999; 99US-0163356P.
XX 03-NOV-1999; 99US-0163416P.
XX 21-DEC-1999; 99US-0171348P.
XX 07-JUL-2000; 2000US-0216579P.
XX (CYGE-) CYGENE INC.
XX (OSTE/) OSTE C C.
XX Oste CC, Ramberg ER;
XX WPI; 2001-343488/36.
XX
XX Analyzing target nucleic acid sequences, useful for population genetics,
XX drug development and diagnosing cancer, comprises hybridizing triple
XX forming oligonucleotide and probe to target sequence.
XX
XX Example 4; Page 70; 141pp; English.
XX
XX The sequence is the polypyrimidine rich region of a reverse phase triplex

CC forming oligonucleotide, RP-TPO, used to analyse the CSF1PO locus using
 CC the method of the invention. The invention relates to analysing target
 CC nucleic acid sequences comprising restriction isolated DNA, hybridising
 CC at least one triplex forming oligonucleotide (TPO), adding a 3' to 5'
 CC exonuclease to form a protected nucleic acid sequence (PNAS) tail
 CC structure, hybridising the captured structure with a single nucleotide
 CC polymorphisms (SNP) identification probe and determining the SNP score.
 CC The methods can be used for analysing target nucleic acid sequences,
 CC especially genomic DNA sequences, to determine if they contain SNPs or
 CC short tandem repeats (STRs). The methods can be used to detect SNPs for
 CC use in population genetics, drug development, forensics, cancer, genetic
 CC disease research, genomic analysis, diagnostics and therapeutics in
 CC humans, plants and animals
 XX
 SQ Sequence 11 BP; 0 A; 5 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 AGGAGAAA 738
 Db 8 AGGAGAAA 1
 |||||

RESULT 883

AAI64929
 ID AAI64929 standard; DNA; 11 BP.

XX AC AAI64929;
 XX DT 04-DEC-2001 (first entry)
 XX DE Human Cream1 protein coding sequence exon 1/intron 1 junction.
 XX KW Human; Cream1; repeat; transcriptional control factor; Rb;
 XX KW retinoblastoma protein; intron-exon junction; ds.
 XX OS Homo sapiens.

XX PN CN1303961-A.
 XX PD 18-JUL-2001.

XX PF 07-JAN-2000; 2000CN-00111426.
 XX PR 07-JAN-2000; 2000CN-00111426.

XX PA (SHAN-) SHANGHAI INST CYTOBIOLOGY CHINESE ACAD.
 XX PI Zhu X, Yan X, Qian M;

XX DR WPI; 2001-566148/64.
 XX PT New retinoblastoma protein binding protein, its preparation and
 XX application.

XX PS Disclosure; Fig 3B; 35pp; Chinese.
 XX CC The present invention relates to the coding sequence of human Cream1,
 CC which is a protein containing a repetitive 86 amino acid motif. The
 CC protein is a transcriptional control factor, and is a conjugate of
 CC retinoblastoma protein (Rb). The present sequence is the an intron-exon
 CC junction in the coding sequence of the invention

XX SQ Sequence 11 BP; 5 A; 0 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 AGGAGAAA 738
 |||||

Db 4 AGGAGAAA 11

RESULT 884

ABQ87632
 ID ABQ87632 standard; cDNA; 11 BP.

XX AC ABQ87632;
 XX DT 10-SEP-2002 (first entry)

XX DE Human skin stress/ageing related EST SEQ ID NO 1387.
 XX KW Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.

XX PN WO200253773-A2.
 XX PD 11-JUL-2002.

XX PF 20-DEC-2001; 2001WO-EP015178.
 XX PR 03-JAN-2001; 2001DE-01000121.
 XX PA (HENK) HENKEL KGAA.

XX PI Petersohn D, Conradt M, Hofmann K;
 XX DR WPI; 2002-528865/56.

XX PT Identifying genes involved in skin stress and aging, useful e.g. in
 XX screening for cosmetic or therapeutic agents, based on differential gene
 XX expression.
 XX PS Claim 8; Page 96; 325pp; German.

XX CC The invention relates to identifying (M1) genes in vitro that, in humans
 CC or animals, are important for skin ageing and/or skin stress by serial
 CC analysis of gene expression between mixtures of transcribed and
 CC optionally translated, genetically encoded factors (A) obtained from
 CC young and aged skin, to identify that genes that show strong differential
 CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 CC useful for: identifying markers of skin ageing and/or stress; determining
 CC skin ageing and/or stress; and identifying or determining the effects of
 CC pharmaceutical or cosmetic agents for control of skin ageing. The present
 CC sequence is one of a group of human skin ageing/stress related expressed
 CC sequence tags (ABQ86246-ABQ87680) of the invention

XX SQ Sequence 11 BP; 5 A; 3 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 733 GAGAAACA 740
 Db 1 GAGAAACA 8
 |||||

RESULT 885

ABQ86959
 ID ABQ86959 standard; cDNA; 11 BP.

XX AC ABQ86959;
 XX DT 10-SEP-2002 (first entry)

XX DE Human skin stress/ageing related EST SEQ ID NO 714.
 XX KW Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.

XX WO200253773-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015178.
 XX 03-JAN-2001; 2001DE-01000121.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-528865/56.
 XX Identifying genes involved in skin stress and aging, useful e.g. in
 XX screening for cosmetic or therapeutic agents, based on differential gene
 XX expression.
 XX Claim 8; Page 66; 325pp; German.
 XX The invention relates to identifying (M1) genes in vitro that, in humans
 XX or animals, are important for skin ageing and/or skin stress by serial
 XX analysis of gene expression between mixtures of transcribed and
 XX optionally translated, genetically encoded factors (A) obtained from
 XX young and aged skin, to identify that genes that show strong differential
 XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 XX useful for: identifying markers of skin ageing and/or stress; determining
 XX skin ageing and/or stress; and identifying or determining the effects of
 XX pharmaceutical or cosmetic agents for control of skin ageing. The present
 XX sequence is one of a group of human skin ageing/stress related expressed
 XX sequence tags (ABQ86246-ABQ87680) of the invention
 XX Query Match 36.4%; Score 8; DB 1; Length 11;
 XX Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 728 GCCAGGAG 735
 XX 1 GCCAGGAG 8
 XX
 XX RESULT 886
 XX ABQ86697/C
 XX ID ABQ86697 standard; cDNA; 11 BP.
 XX AC ABQ86697;
 XX 10-SEP-2002 (first entry)
 XX Human skin stress/ageing related EST SEQ ID NO 452.
 XX Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 XX WO200253773-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015178.
 XX 03-JAN-2001; 2001DE-01000121.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-528865/56.
 XX Identifying genes involved in skin stress and aging, useful e.g. in

PT screening for cosmetic or therapeutic agents, based on differential gene
 PT expression.
 XX Claim 8; Page 55; 325pp; German.
 XX The invention relates to identifying (M1) genes in vitro that, in humans
 XX or animals, are important for skin ageing and/or skin stress by serial
 XX analysis of gene expression between mixtures of transcribed and
 XX optionally translated, genetically encoded factors (A) obtained from
 XX young and aged skin, to identify that genes that show strong differential
 XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 XX useful for: identifying markers of skin ageing and/or stress; determining
 XX skin ageing and/or stress; and identifying or determining the effects of
 XX pharmaceutical or cosmetic agents for control of skin ageing. The present
 XX sequence is one of a group of human skin ageing/stress related expressed
 XX sequence tags (ABQ86246-ABQ87680) of the invention
 XX Query Match 36.4%; Score 8; DB 1; Length 11;
 XX Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 736 AAACAGAA 743
 XX 11 AAACAGAA 4
 XX
 XX RESULT 887
 XX ABV66378
 XX ID ABV66978 standard; cDNA; 11 BP.
 XX AC ABV66978;
 XX 21-OCT-2002 (first entry)
 XX Human skin EST 4764.
 XX Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhoeic;
 XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 XX homeostasis and identifying cosmetic or pharmaceutical agents against
 XX e.g. skin cancer.
 XX Disclosure; Page 156; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 XX in the skin of humans or animals by subjecting a mixture of genetically
 XX encoded factors from skin, to serial analysis of gene expression (SAGE)
 XX so as to identify skin-expressed genes and quantify their expression. (M1)
 XX is useful for identifying genes involved in skin homeostasis; to
 XX determine skin homeostasis and to test agent (A) that maintains or
 XX promotes skin homeostasis or that can be used for treating skin
 XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;

CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 4 A; 4 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 739 CAGAACAC 746
 |||||
 3 CAGAACAC 10
 Db
 RESULT 888
 ABV70231/c
 ID ABV70231 standard; cDNA; 11 BP.
 XX
 AC ABV70231;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 8017.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-590638/63.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-590638/63.
 XX
 In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Claim 24; Page 255; 1345pp; German.
 XX
 The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 1 A; 4 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCAGGAGA 736
 |||||
 8 CCAGGAGA 1
 Db
 RESULT 890
 ABV67502/c
 ID ABV67502 standard; cDNA; 11 BP.
 XX
 AC ABV67502;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 5288.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;

RESULT 889
 ABV71675/c
 ID ABV71675 standard; cDNA; 11 BP.
 XX
 AC ABV71675;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 9461.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-590638/63.
 XX
 In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Claim 24; Page 305; 1345pp; German.
 XX
 The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 1 A; 6 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 728 GCCAGGAG 735
 |||||
 8 GCCAGGAG 1
 Db
 RESULT 890
 ABV67502/c
 ID ABV67502 standard; cDNA; 11 BP.
 XX
 AC ABV67502;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 5288.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;

KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 OS Homo sapiens.
 XX
 XX
 FN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 171; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 1 A; 2 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 739 CAGAACAC 746
 DB 8 CAGAACAC 1
 RESULT 891
 ABV67881/C
 ID ABV67881 standard; cDNA; 11 BP.
 XX
 AC ABV67881;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 5667.
 XX
 KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX

PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 182; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 SQ Sequence 11 BP; 1 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AAACAGAA 743
 DB 9 AAACAGAA 2
 RESULT 892
 ABV71609
 ID ABV71609 standard; cDNA; 11 BP.
 XX
 AC ABV71609;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 9395.
 XX
 KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 XX WPI; 2002-590638/63.
 XX
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Claim 24; Page 303; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed

CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention

XX SQ Sequence 11 BP; 7 A; 1 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 736 AACACAGAA 743
 Db 3 AACACAGAA 10
 |||||

RESULT 993

ABV64703
 ID ABV64703 standard; cDNA; 11 BP.

XX AC ABV64703;

XX DT 21-OCT-2002 (first entry)

XX DE Human skin EST 2489.

XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

XX OS Homo sapiens.

XX PN WO200253774-A2.

XX PD 11-JUL-2002.

XX PF 20-DEC-2001; 2001WO-EP015179.

XX PR 03-JAN-2001; 2001DE-01000127.

XX PA (HENK) HENKEL KGAA.

XX PI Petersohn D, Conradt M, Hofmann K;

XX DR WPI; 2002-590638/63.

XX In vitro identification of skin-expressed genes, useful for determining
 XX homeostasis and identifying cosmetic or pharmaceutical agents against
 XX e.g. skin cancer.

XX FS Disclosure; Page 94; 1345pp; German.

XX The invention relates to in vitro identification (M1) of genes expressed
 XX in the skin of humans or animals by subjecting a mixture of genetically
 XX encoded factors from skin, to serial analysis of gene expression (SAGE).
 XX so as to identify skin-expressed genes and quantify their expression.
 XX (M1) is useful for identifying genes involved in skin homeostasis; to
 XX determine skin homeostasis and to test agent (A) that maintains or
 XX promotes skin homeostasis or that can be used for treating skin
 XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 XX skin. The present sequence is that of a human expressed sequence tag
 XX (EST) of the invention

XX SQ Sequence 11 BP; 3 A; 5 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 741 GAACACCG 748

Db 1 GAACACCG 8
 |||||

RESULT 894

ABV65140/c
 ID ABV65140 standard; cDNA; 11 BP.

XX AC ABV65140;

XX DT 21-OCT-2002 (first entry)

XX DE Human skin EST 2926.

XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

XX OS Homo sapiens.

XX PN WO200253774-A2.

XX PD 11-JUL-2002.

XX PF 20-DEC-2001; 2001WO-EP015179.

XX PR 03-JAN-2001; 2001DE-01000127.

XX PA (HENK) HENKEL KGAA.

XX PI Petersohn D, Conradt M, Hofmann K;

XX DR WPI; 2002-590638/63.

XX In vitro identification of skin-expressed genes, useful for determining
 XX homeostasis and identifying cosmetic or pharmaceutical agents against
 XX e.g. skin cancer.

XX FS Disclosure; Page 106; 1345pp; German.

XX The invention relates to in vitro identification (M1) of genes expressed
 XX in the skin of humans or animals by subjecting a mixture of genetically
 XX encoded factors from skin, to serial analysis of gene expression (SAGE).
 XX so as to identify skin-expressed genes and quantify their expression.
 XX (M1) is useful for identifying genes involved in skin homeostasis; to
 XX determine skin homeostasis and to test agent (A) that maintains or
 XX promotes skin homeostasis or that can be used for treating skin
 XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 XX skin. The present sequence is that of a human expressed sequence tag
 XX (EST) of the invention

XX SQ Sequence 11 BP; 1 A; 2 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 738 ACAGAACCA 745

Db 11 ACAGAACCA 4
 |||||

RESULT 895

ABV62451/c
 ID ABV62451 standard; cDNA; 11 BP.

XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 41; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention.
XX
SQ Sequence 11 BP; 1 A; 4 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCAGGAGA 736
DB 8 CCAGGAGA 1
|||||||
RESULT 898
ABV65528/C
ID ABV65528 standard; cDNA; 11 BP.
XX
AC ABV65528;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 3314.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
FN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 117; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE).
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or

CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention.
XX
SQ Sequence 11 BP; 3 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 737 AACAGAAC 744
DB 8 AACAGAAC 1
|||||||
RESULT 899
ABV68871/C
ID ABV68871 standard; cDNA; 11 BP.
XX
AC ABV68871;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 6657.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
FN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 210; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention.
XX
SQ Sequence 11 BP; 1 A; 3 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```

Qy 735 GAAACAGA 742
Db 8 GAAACAGA 1

RESULT 900
ABV69872/C
ID ABV69872 standard; cDNA; 11 BP.
XX AC ABV69872;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 7658.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PR 03-JAN-2001; 2001DE-01000127.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX PS WPI; 2002-590638/63.
XX PT In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX PS Disclosure; Page 136; 1345pp; German.
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX SQ Sequence 11 BP; 1 A; 4 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 732 GGAGGAAC 739
Db 10 GGAGGAAC 3

RESULT 902
ABV64188
ID ABV64188 standard; cDNA; 11 BP.
XX AC ABV64188;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 1974.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.

Qy 728 GCCAGGAG 735
Db 11 GCCAGGAG 4

RESULT 901
ABV66245/C
ID ABV66245 standard; cDNA; 11 BP.
XX AC ABV66245;
XX DT 21-OCT-2002 (first entry)
XX PF 20-DEC-2001; 2001WO-EP015179.

```

XX PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX DR WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX PS Disclosure; Page 79; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 7 A; 1 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AAACAGAA 743
 Db 3 AAACAGAA 10
 |||||
 |||||
 RESULT 903
 ABV69727
 ID ABV69727 standard; cDNA; 11 BP.
 XX AC
 XX ABV69727;
 XX 21-OCT-2002 (first entry)
 XX Human skin EST 7513.
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX WO200253774-A2;
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.

PS Claim 24; Page 237; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 5 A; 3 C; 3 G; 0 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 730 CAGGAGAA 737
 Db 4 CAGGAGAA 11
 |||||
 |||||
 RESULT 904
 ABV66934
 ID ABV66934 standard; cDNA; 11 BP.
 XX AC
 XX ABV66934;
 XX 21-OCT-2002 (first entry)
 XX Human skin EST 4720.
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX Disclosure; Page 155; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag

```

CC (EST) of the invention
SQ Sequence 11 BP; 4 A; 2 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 CAGGAGAA 737
   |||||
Db 1 CAGGAGAA 8

RESULT 905
ABV71928
ID ABV71928 standard; cDNA; 11 BP.
XX
AC ABV71928;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 9714.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
PS WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Claim 24; Page 314; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 3 A; 3 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 728 GCCAGGAG 735
   |||||
Db 1 GCCAGGAG 8

RESULT 906
ABV62306
ID ABV62306 standard; cDNA; 11 BP.
XX
AC ABV62306;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 92.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK ) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
PS WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 28; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 5 A; 3 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 CAGGAGAA 737
   |||||
Db 4 CAGGAGAA 11

RESULT 907
ABV67368
ID ABV67368 standard; cDNA; 11 BP.
XX
AC ABV67368;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 5154.
XX
KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

```


CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 CC
 SQ Sequence 11 BP; 0 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 728 GCCAGGAG 735
 DB 10 GCCAGGAG 3
 RESULT 910
 ABV71634/c
 ID ABV71634 standard; cDNA; 11 BP.
 XX
 AC ABV71634;
 XX
 DT 21-OCT-2002 (first entry)
 XX Human skin EST 9420.
 DE
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrheic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 FN
 XX 11-JUL-2002.
 PD
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX 03-JAN-2001; 2001DE-01000127.
 PR
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Conradt M, Hofmann K;
 PI
 XX WPI; 2002-590638/63.
 DR
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Claim 24; Page 304; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 CC
 SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AACACGAA 743
 DB 11 AACACGAA 4
 RESULT 912
 ABV64254/c
 ID ABV64254 standard; cDNA; 11 BP.
 XX
 AC ABV64254;
 XX
 DT 21-OCT-2002 (first entry)
 XX Human skin EST 1999.
 DE
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrheic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 FN
 XX 11-JUL-2002.
 PD
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX 03-JAN-2001; 2001DE-01000127.
 PR
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Conradt M, Hofmann K;
 PI
 XX WPI; 2002-590638/63.
 DR
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Claim 24; Page 304; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 CC
 SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AACACGAA 743
 DB 11 AACACGAA 4
 RESULT 911
 ABV64213/c
 ID ABV64213 standard; cDNA; 11 BP.
 XX
 AC ABV64213;
 XX
 DT 21-OCT-2002 (first entry)
 XX Human skin EST 1999.
 DE
 XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrheic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 OS
 XX WO200253774-A2.
 FN
 XX 11-JUL-2002.
 PD
 XX 20-DEC-2001; 2001WO-EP015179.
 PF
 XX 03-JAN-2001; 2001DE-01000127.
 PR
 XX (HENK) HENKEL KGAA.
 PA
 XX Petersohn D, Conradt M, Hofmann K;
 PI
 XX WPI; 2002-590638/63.
 DR
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 80; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 CC
 SQ Sequence 11 BP; 1 A; 1 C; 2 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 36.4%; Score 8; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6.2e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 736 AACACGAA 743
 DB 11 AACACGAA 4
 RESULT 912
 ABV64254/c
 ID ABV64254 standard; cDNA; 11 BP.
 XX
 AC ABV64254;
 XX

```

XX 21-OCT-2002 (first entry)
XX Human skin EST 2040.
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253774-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015179.
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK ) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX Disclosure; Page 81; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE).
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX Sequence 11 BP; 1 A; 6 C; 2 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 36.4%; Score 8; DB 1; Length 11;
XX Best Local Similarity 100.0%; Pred. No. 6.2e+02;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 728 GCCAGGAG 735
XX Db 8 GCCAGGAG 1
XX
XX RESULT 913
XX ABV65655
XX ID ABV65655 standard; cDNA; 11 BP.
XX AC ABV65655;
XX 21-OCT-2002 (first entry)
XX Human skin EST 3441.
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253774-A2.
XX
XX Query Match 36.4%; Score 8; DB 1; Length 11;
XX Best Local Similarity 100.0%; Pred. No. 6.2e+02;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 728 GCCAGGAG 735
XX Db 8 GCCAGGAG 1
XX
XX RESULT 913
XX ABV65655
XX ID ABV65655 standard; cDNA; 11 BP.
XX AC ABV65655;
XX 21-OCT-2002 (first entry)
XX Human skin EST 3441.
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX Homo sapiens.
XX WO200253774-A2.
XX
XX Query Match 36.4%; Score 8; DB 1; Length 11;
XX Best Local Similarity 100.0%; Pred. No. 6.2e+02;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 728 GCCAGGAG 735
XX Db 8 GCCAGGAG 1
XX
XX RESULT 914
XX ABL91967/c
XX ID ABL91967 standard; cDNA; 11 BP.
XX AC ABL91967;
XX 30-MAY-2002 (first entry)
XX Human Pan-Endothelial Marker SEQ ID NO 65.
XX Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
XX normal endothelial marker; pan-endothelial marker; immunostimulant;
XX antiangiogenic; tumour; neoangiogenesis; vascularised tumour;
XX polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
XX psoriasis; ss.
XX Homo sapiens.
XX WO200210217-A2.
XX 07-FEB-2002.
XX 01-AUG-2001; 2001WO-US024031.
XX 02-AUG-2000; 2000US-0222599P.
XX 11-AUG-2000; 2000US-0224360P.
XX 11-APR-2001; 2001US-0282850P.
XX (UYJO ) UNIV JOHNS HOPKINS.
XX St Croix B, Kinzler KW, Vogelstein B;

```

```

PD 11-JUL-2002.
XX 20-DEC-2001; 2001WO-EP015179.
XX 03-JAN-2001; 2001DE-01000127.
XX (HENK ) HENKEL KGAA.
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX Disclosure; Page 120; 1345pp; German.
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE).
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX Sequence 11 BP; 3 A; 2 C; 5 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 36.4%; Score 8; DB 1; Length 11;
XX Best Local Similarity 100.0%; Pred. No. 6.2e+02;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 728 GCCAGGAG 735
XX Db 3 GCCAGGAG 10
XX
XX RESULT 914
XX ABL91967/c
XX ID ABL91967 standard; cDNA; 11 BP.
XX AC ABL91967;
XX 30-MAY-2002 (first entry)
XX Human Pan-Endothelial Marker SEQ ID NO 65.
XX Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
XX normal endothelial marker; pan-endothelial marker; immunostimulant;
XX antiangiogenic; tumour; neoangiogenesis; vascularised tumour;
XX polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
XX psoriasis; ss.
XX Homo sapiens.
XX WO200210217-A2.
XX 07-FEB-2002.
XX 01-AUG-2001; 2001WO-US024031.
XX 02-AUG-2000; 2000US-0222599P.
XX 11-AUG-2000; 2000US-0224360P.
XX 11-APR-2001; 2001US-0282850P.
XX (UYJO ) UNIV JOHNS HOPKINS.
XX St Croix B, Kinzler KW, Vogelstein B;

```

XX WPI; 2002-291856/33.
XX An isolated molecule comprising an antibody variable region which
PT specifically binds to an extracellular domain of a tumor endothelial
PT marker (TEM) protein, useful for inhibiting tumor growth.
XX
XX Example 4; Page 326; 331pp; English.
XX
XX The invention relates to an isolated molecule comprising an antibody
CC variable region which specifically binds to an extracellular domain of a
CC tumor endothelial marker (TEM) protein selected from ABB90732, ABB90740,
CC ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
CC proteins have cytostatic, immunostimulant and antiangiogenic activity.
CC They are useful for inhibiting tumour growth, neoangiogenesis in subjects
CC bearing a vascularised tumour, polycystic kidney disease, diabetic
CC retinopathy, rheumatoid arthritis and psoriasis. Human, mouse and rat TEM
CC genes and the encoded proteins (ABL92075-ABL92141 and ABB90721-ABB90789)
CC are disclosed, as are marker oligonucleotide sequences: tumour
CC endothelial markers (TEM) ABL91996-ABL92041 and ABL92143-ABL92191; normal
CC endothelial markers (NEM) ABL92042-ABL92074; and pan-endothelial markers
CC (PEM) ABL91903-ABL91995. The present sequence is that of an
CC oligonucleotide marker useful to the invention
XX
SQ Sequence 11 BP; 1 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 728 GCCAGGAG 735
Db 11 GCCAGGAG 4

RESULT 915
ABQ81877
ID ABQ81877 standard; DNA; 11 BP.
XX
XX AC ABQ81877;
XX
XX 19-NOV-2002 (first entry)
XX
XX Kaposi's Sarcoma SAGE library Tag No.7 SEQ ID NO:27.
DE
XX Human; Kaposi's sarcoma; tumour; angiogenesis; tag; ss.
XX
XX Homo sapiens.
OS
XX EPI225233-A2.
PN
XX 24-JUL-2002.
PD
XX 23-JAN-2002; 2002EP-00075264.
PF
XX 23-JAN-2001; 2001EP-00200228.
PR
XX 28-SEP-2001; 2001EP-00203703.
PR
XX 28-SEP-2001; 2001US-0325722P.
PR
XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
PA
XX Van Der Kuyl AC, Cornelissen M;
PI
XX WPI; 2002-668396/72.
DR
XX
XX Determining presence of a tumor cell or angiogenesis, and the
PT effectiveness of treatment, by detecting the presence of marker genes is
PT useful to detect and monitor treatment of Kaposi's Sarcoma.
XX
XX Claim 12; Page 8; 38pp; English.
PS
XX The present invention describes a method for determining if an individual
CC has a tumour cell or site of angiogenesis, or if a treatment is effective

CC in changing angiogenesis or changing a status of a set of target cells,
CC comprising determining if a sample of the subject has an expression
CC product of at least one marker gene. Also described is a compound capable
CC of altering the expression or activity of Keratin 14, TIE 1, Salivoadhesin
CC or Siglec in a cell. Peripheral blood mononuclear cell (PBMC)-expressed
CC Keratin 14, TIE 1, Salivoadhesin or Siglec, and kits containing them from
CC the present invention can be used in a diagnostic method, particularly as
CC an indicator of angiogenesis or to determine presence of a tumour cell.
CC The method of the invention is suitable to determine within a few days if
CC a certain treatment against Kaposi's Sarcoma is successful. ABQ81851 to
CC ABQ82006 represent nucleotide sequence used in the exemplification of the
CC present invention
XX
SQ Sequence 11 BP; 5 A; 3 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6.2e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 CAGGAGAA 737
Db 4 CAGGAGAA 11

RESULT 916
ABX71892/c
ID ABX71892 standard; DNA; 11 BP.
XX
XX AC ABX71892;
XX
XX 12-MAR-2003 (first entry)
XX
XX DNA tag used to identify human gene encoding PEM 65.
DE
XX Human; endothelial cell; EC; tumour endothelial cell; TEM; NEM;
XX tumour endothelial marker; normal endothelial marker; PEM;
XX pan-endothelial marker; polycystic kidney disease; psoriasis;
XX diabetic retinopathy; rheumatoid arthritis; tumour angiogenesis;
XX neoangiogenesis; immune response; cytostatic; antidiabetic;
XX ophthalmological; antirheumatic; antiarthritic; antipsoriatic; ds.
XX
XX Homo sapiens.
OS
XX WO200283874-A2.
PN
XX 24-OCT-2002.
PD
XX 10-APR-2002; 2002WO-US008253.
PF
XX 11-APR-2001; 2001US-0282850P.
PR
XX 06-FEB-2002; 2002US-0354262P.
PR
XX (UYJO) UNIV JOHNS HOPKINS.
PA
XX Carson-Walter E, St Croix B, Kinzler KW, Vogelstein B;
PI
XX WPI; 2003-093016/08.
DR
XX New purified human transmembrane protein, designated as tumor endothelial
PT marker (TEM) 3, useful for detecting, diagnosing or treating tumors,
PT polycystic kidney disease, diabetic retinopathy, rheumatoid arthritis or
PT psoriasis.
XX
XX Disclosure; Page 97; 374pp; English.
PS
XX The present invention relates to a novel method for the isolation of
CC endothelial cells (ECs), and the identification of genes expressed in
CC normal and tumour ECs. Tumour endothelial marker (TEM), normal
CC endothelial marker (NEM), and pan-endothelial marker (PEM) genes are
CC identified in human ECs. The human EC marker proteins and the
CC polynucleotide sequences encoding them are useful for detecting,
CC diagnosing or treating tumours as well as polycystic kidney disease,
CC diabetic retinopathy, rheumatoid arthritis, and psoriasis. They are also

XX
XX
Lawrence J. O'Connor

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738
 Db 8 AGGAGAAA 1
 RESULT 922
 ABI45370
 ID ABI45370 standard; DNA; 12 BP.
 XX
 AC ABI45370;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 345343 for detecting SNP TSC0043986.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 345343; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 Db 2 AGGAGAAA 9
 RESULT 923
 ABI68872
 ID ABI68872 standard; DNA; 12 BP.
 XX
 AC ABI68872;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 368845 for detecting SNP TSC0057263.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 368845; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;

XX Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 Db 3 AGGAGAAA 10
 RESULT 924
 ABI55796
 ID ABI55796 standard; DNA; 12 BP.
 XX

```

AC AB155796;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 355769 for detecting SNP TSC0049804.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 355769; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Claim 1; SEQ ID NO 355769; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 36.4%; Score 8; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred.No. 6.4e+02;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 731 AGGAGAAA 738
XX |||||
XX 5 AGGAGAAA 12
XX
XX RESULT 925
XX AB173752
XX ID AB173752 standard; DNA; 12 BP.
XX
XX AC AB173752;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 373725 for detecting SNP TSC0060290.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

```

```

XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 373725; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 36.4%; Score 8; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred.No. 6.4e+02;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 731 AGGAGAAA 738
XX |||||
XX 1 AGGAGAAA 8
XX
XX RESULT 926
XX AB179664
XX ID AB179664 standard; DNA; 12 BP.
XX
XX AC AB179664;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 379637 for detecting SNP TSC0063401.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 379637; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738

Db 3 AGGAGAAA 10

RESULT 927

ABI05358/c

ID ABI05358 standard; DNA; 12 BP.

AC ABI05358;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 305331 for detecting SNP TSC0021391.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 305331; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738

Db 10 AGGAGAAA 3

RESULT 928

ABH85801

ID ABH85801 standard; DNA; 12 BP.

AC ABH85801;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 285794 for detecting SNP TSC0012441.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 285794; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 319470; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 0 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 731 AGGAGAAA 738
Db |||||
4 AGGAGAAA 11
RESULT 932
ABH76828
ID ABH76828 standard; DNA; 12 BP.
XX
XX AC ABH76828;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 276821 for detecting SNP TSC0004297.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 276821; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 731 AGGAGAAA 738
Db |||||
3 AGGAGAAA 10
RESULT 933
ABI64170
ID ABI64170 standard; DNA; 12 BP.
XX
XX AC ABI64170;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 364143 for detecting SNP TSC0054292.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 364143; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPITG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 338123; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 0 Other;
 : Query Match 36.4%; Score 8; DB 1; Length 12;
 : Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 : Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 Db 11 AGGAGAAA 4
 RESULT 937
 ABI56943
 ID ABI56943 standard; DNA; 12 BP.
 XX AC ABI56943;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 356916 for detecting SNP TSC0050373.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPITG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI

XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 356916; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;
 : Query Match 36.4%; Score 8; DB 1; Length 12;
 : Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 : Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 Db 4 AGGAGAAA 11
 RESULT 938
 ABI05035
 ID ABI05035 standard; DNA; 12 BP.
 XX AC ABI05035;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 305008 for detecting SNP TSC0021207.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPITG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 305008; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;
 : Query Match 36.4%; Score 8; DB 1; Length 12;
 : Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 : Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGGAGAAA 738
 Db 4 AGGAGAAA 11
 RESULT 938
 ABI05035
 ID ABI05035 standard; DNA; 12 BP.
 XX AC ABI05035;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 305008 for detecting SNP TSC0021207.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPITG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 305008; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 4 A; 2 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 732 GGAGAAAC 739
 Db 5 GGAGAAAC 12
 RESULT 939
 ABH93562
 ID ABH93562 standard; DNA; 12 BP.
 AC ABH93562;
 XX
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 293555 for detecting SNP TSC0015668.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 293555; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGAGAGAA 738
 Db 5 AGAGAGAA 12
 RESULT 940
 ABH80366/C
 ID ABH80366 standard; DNA; 12 BP.
 XX
 XX ABH80366;
 AC
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 280359 for detecting SNP TSC0008516.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 280359; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 731 AGAGAGAA 738
 Db 10 AGAGAGAA 3
 RESULT 941
 ABI34495/C
 ID ABI34495 standard; DNA; 12 BP.
 XX
 XX ABI34495;
 AC
 XX

```

DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 334468 for detecting SNP TSC0038169.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 334468; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 7 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 731 AGGAGAAA 738
Db 9 AGGAGAAA 2
XX
RESULT 942
ABI05034
ID ABI05034 standard; DNA; 12 BP.
XX
AC ABI05034;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 305007 for detecting SNP TSC0021207.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.

```

```

XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
PR (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 305007; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
XX
Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 732 GGAGAAAC 739
Db 5 GGAGAAAC 12
XX
RESULT 943
ABI71127/C
ID ABI71127 standard; DNA; 12 BP.
XX
AC ABI71127;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 371100 for detecting SNP TSC0058576.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine

```

PT methylation status.
XX
PS Claim 1; SEQ ID NO 371100; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738
DB 12 AGGAGAAA 5
|||||

RESULT 944
ABH95691/c
ID ABH95691 standard; DNA; 12 BP.
AC ABH95691;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 295684 for detecting SNP TSC0016686.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
XX Claim 1; SEQ ID NO 295684; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738
DB 12 AGGAGAAA 5
|||||

RESULT 944
ABH95691/c
ID ABH95691 standard; DNA; 12 BP.
AC ABH95691;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 295684 for detecting SNP TSC0016686.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
XX Claim 1; SEQ ID NO 295684; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738
DB 12 AGGAGAAA 5
|||||

RESULT 945
ABI63697/c
ID ABI63697 standard; DNA; 12 BP.
XX
XX ABI63697;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 363670 for detecting SNP TSC0053994.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
XX Claim 1; SEQ ID NO 363670; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738
DB 8 AGGAGAAA 1
|||||

PA (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 349805; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC range of diseases including immune system, gastrointestinal, respiratory,
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC central nervous system, cardiovascular and metabolic disorders. The
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 731 AGGAGAAA 738
Db 5 AGGAGAAA 12
|||||
RESULT 949
ABH96106
ID ABH96106 standard; DNA; 12 BP.
XX
AC ABH96106;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 296099 for detecting SNP TSC0016900.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177394-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 296099; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 1 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 732 GGAGAAAC 739
Db 4 GGAGAAAC 11
|||||
RESULT 950
ABI01362
ID ABI01362 standard; DNA; 12 BP.
XX
AC ABI01362;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 301335 for detecting SNP TSC0019456.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 301335; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738
 |||||
 Db 2 AGGAGAAA 9

RESULT 951

ABH80835/C
 ID ABH80835 standard; DNA; 12 BP.

XX AC ABH80835;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 280828 for detecting SNP TSC0009139.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 280828; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 0 A; 5 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 AGGAGAAA 738
 |||||
 Db 9 AGGAGAAA 2

RESULT 952

AAD52664
 ID AAD52664 standard; DNA; 12 BP.

XX AAD52664;
 XX DT 14-MAY-2003 (first entry)
 XX DE Human ALT2 gene intron11/exon12 junction DNA.
 XX KW Human; alanine transaminase; ALT2; diagnosis; injury; ds.
 XX OS Homo sapiens.

XX FH Key Location/Qualifiers
 XX FT intron 1..6
 FT /tag= a
 FT /number= 11
 FT /partial
 FT exon 11..12
 FT /tag= b
 FT /number= 12
 FT /partial

XX WO200292768-A2.

XX 21-NOV-2002.

XX PF 14-MAY-2002; 2002WO-US015103.

XX PR 14-MAY-2001; 2001US-0290829P.

XX PA (UYMA-) UNIV MARYLAND BALTIMORE.

XX PI Gong D, Shuldiner A, Yang R;

XX WPI; 2003-129280/12.

XX New human alanine transaminase polypeptide (ALT2) and gene, useful for
 PT detecting injury, damage or disease involving a tissue that contains the
 PT ALT2 in an animal, or in diagnosing conditions associated with altered
 PT levels of ALT2.

XX Disclosure; Page 15; 57pp; English.

XX The invention relates to human alanine transaminase polypeptide (ALT2)
 CC and gene. The invention is useful for diagnosing or detecting injury,
 CC damage or disease involving a tissue that contains the ALT2 polypeptide
 CC in an animal, in diagnosing conditions associated with altered levels of
 CC ALT2 and/or ALT1 in bodily fluids. The present sequence is human ALT2
 CC gene intron/exon junction DNA

XX Sequence 12 BP; 3 A; 3 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 727 TGCCAGGA 734
 |||||
 Db 1 TGCCAGGA 8

RESULT 953

AAD52660

ID AAD52660 standard; DNA; 12 BP.

XX AC AAD52660;

XX DT 14-MAY-2003 (first entry)

XX DE Human ALT2 gene intron9/exon10 junction DNA.

XX KW Human; alanine transaminase; ALT2; diagnosis; injury; ds.

XX OS Homo sapiens.

```

XX FH Key Location/Qualifiers
XX FT intron 1..6
XX FT /*tag= a
XX FT /number= 9
XX FT /partial
XX FT 11..12
XX FT /*tag= b
XX FT /number= 10
XX FT /partial
XX PN WO200292768-A2.
XX PD 21-NOV-2002.
XX PP 14-MAY-2002; 2002WO-US015103.
XX PR 14-MAY-2001; 2001US-0290829P.
XX PA (UTMA-) UNIV MARYLAND BALTIMORE.
XX PI Gong D, Shuldiner A, Yang R;
XX DR WPI; 2003-129280/12.
XX PT New human alanine transaminase polypeptide (ALT2) and gene, useful for
XX FT detecting injury, damage or disease involving a tissue that contains the
XX FT ALT2 in an animal, or in diagnosing conditions associated with altered
XX FT levels of ALT2.
XX PS Disclosure; Page 15; 57pp; English.
XX CC The invention relates to human alanine transaminase polypeptide (ALT2)
XX CC and gene. The invention is useful for diagnosing or detecting injury,
XX CC damage or disease involving a tissue that contains the ALT2 polypeptide
XX CC in an animal, in diagnosing conditions associated with altered levels of
XX CC ALT2 and/or ALT1 in bodily fluids. The present sequence is human ALT2
XX CC gene intron/exon junction DNA
XX SQ Sequence 12 BP; 5 A; 2 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 CAGGAGAA 737
DB 4 CAGGAGAA 11

RESULT 954
ACD40404/C
ID ACD40404 standard; cDNA; 12 BP.
XX AC ACD40404;
XX DT 04-SEP-2003 (first entry)
XX DE Human APL1 cDNA fragment #22.
XX KW Human; ss; aryl-hydrocarbon receptor interacting protein-like 1; APL1;
XX KW Leber congenital amaurosis 4; LCA4; chromosome 17p13; retinopathy;
XX KW retinal disease; Leber congenital amaurosis; dominant cone-rod dystrophy;
XX KW juvenile retinitis pigmentosa; ophthalmological.
XX OS Homo sapiens.
XX PN US2003022165-A1.
XX PD 30-JAN-2003.
XX PF 17-JAN-2001; 2001US-00765061.
XX

PR 17-JAN-2001; 2001US-00765061.
XX (SOHO/) SOHOCKI M M.
XX PA (DAIG/) DAIGER S P.
XX PI Schocki MM, Daiger SP;
XX DR WPI; 2003-416993/39.
XX PT New aryl-hydrocarbon receptor interacting protein-like 1 (AIP1L1)
XX FT polynucleotides and proteins, useful for diagnosing or treating retinal
XX FT diseases associated with AIP1L1 mutations, e.g. Leber congenital
XX FT amaurosis.
XX PS Claim 4; Page 37; 65pp; English.
XX CC The invention relates to a composition comprising an aryl-hydrocarbon
XX CC receptor interacting protein-like 1 (AIP1L1) sequence within the Leber
XX CC congenital amaurosis 4 (LCA4) region of chromosome 17p13, which is a wild
XX CC type or a mutant AIP1L1 sequence. The aryl-hydrocarbon receptor
XX CC interacting protein-like 1 (AIP1L1) polynucleotides and polypeptides are
XX CC useful for diagnosing or treating retinal diseases associated with AIP1L1
XX CC mutations, for example, Leber congenital amaurosis, juvenile retinitis
XX CC pigmentosa, dominant cone-rod dystrophy or other inherited or acquired
XX CC retinopathies. The AIP1L1 polynucleotides and polypeptides are also useful
XX CC for determining if a cell or sample has an AIP1L1 mutation or if an animal
XX CC has a retinal disease or has a propensity to pass a retinal disease to
XX CC offspring. The methods are useful for screening of compounds that
XX CC specifically bind to the mutated polypeptides, which can be used to treat
XX CC resistant diseases that are associated with the mutations. Sequences
XX CC ACD40383-ACD40433 represent human AIP1L1 cDNA fragments of the invention
XX SQ Sequence 12 BP; 1 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 36.4%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 732 GGAGAAAC 739
DB 9 GGAGAAAC 2

RESULT 955
AAZ18763/C
ID AAZ18763 standard; DNA; 11 BP.
XX AC AAZ18763;
XX DT 22-OCT-1999 (first entry)
XX DE Murine C57BL/6 SAGE tag 3587962.
XX KW Wound healing; non-MRL healer mouse; quantitative trait locus; QTL;
XX KW healing response; microsatellite marker; treatment; central nerve;
XX KW peripheral nerve; nerve injury; SAGE tag; murine; ss.
XX OS Mus sp.
XX PN WO9941364-A2.
XX PD 19-AUG-1999.
XX PF 12-FEB-1999; 99WO-US002962.
XX PR 13-FEB-1998; 98US-0074737P.
XX PR 26-AUG-1998; 98US-0097937P.
XX PR 28-SEP-1998; 98US-0102051P.
XX PA (WIST-) WISTAR INST.
XX PI Heber-katz E;
XX

```

WPI; 1999-229400/19.

New antisense oligonucleotides used in treatment of, e.g. pulmonary vasoconstriction.

Disclosure; Page 46; 120pp; English.

The specification describes antisense oligonucleotides (AA53869-X55271) directed against at least 2 mRNAs selected from target genes, coding and non-coding regions of RNAs corresponding to target genes, gene initiation codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-end and the juxta-section between coding and non-coding regions and all segments of RNAs encoding proteins associated with one or more diseases, conditions or mixtures. The antisense oligonucleotides may be derived from sequences AA5372-74. These multiple target oligonucleotides (specifically AA53180-271) can be used for the antisense treatment of diseases and conditions. Typical diseases and conditions are those associated with impaired respiration and inflammation, including lung diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis, acute asthma, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as well as all types of cancers which may metastasize or have metastasized to the lungs, including breast and prostate cancer

Sequence 11 BP; 0 A; 4 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

731 AGCAGAAACAG 741
||| ||||| |||
11 AGCAGAAACAG 1

RESULT 957
AX14702

ID AX14702 standard; DNA; 11 BP.

AX14702;
AX14702;
24-MAR-1999 (first entry)

Triple helix forming nucleotides 21-31 of superoxide dismutase gene.

Triple-helix forming region; Triplex formation; DNA detection;
identification; Bacteria; oncogene; virus; ds.

Homo sapiens.
US5861244-A.
19-JAN-1999.

22-DEC-1993; 93US-00173489.
29-OCT-1992; 92US-00968436.
(PROF-) PROFILE DIAGNOSTIC SCI INC.
Hepburn AG, Wang C;
WPI; 1999-130384/11.

Assay of genetic sequences based on triplex formation from double stranded analyte - and hybrid of anchor and reporter sequences, with reporter released if triplex formation occurs, used e.g. to identify bacteria.

PS Disclosure; Col 17-18; 168pp; English.

XX The present sequence represents a potential triple-helix forming region.

CC It can be used to demonstrate the assay of the invention. The assay

CC comprises adding a sample containing double-stranded DNA test sequences,

CC e.g. containing the present sequence, to an aqueous medium containing at

CC least one complex of anchor DNA, attached to a solid support, and

CC reporter DNA, where either a part of the anchor DNA or reporter DNA is

CC designed to form a triple-strand structure with part of the test

CC sequence. Triplex formation results in displacement of the reporter DNA

CC which is detected as an indication of the presence of the DNA test

CC sequence. The method is used to detect DNA sequences, particularly for

CC identification of bacteria (by detecting genes for ribosomal RNA) in

CC clinical samples, but also detection of oncogenes and Hepatitis B virus

XX

SQ Sequence 11 BP; 6 A; 0 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 6.6e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAACAG 741

DB 1 AGGAGAGAAAG 11

RESULT 958

AAA34048/c

ID AAA34048 standard; DNA; 11 BP.

AC AAA34048;

XX

DT 28-JUL-2000 (first entry)

XX

DE Human adenosine receptor related polynucleotide SEQ ID NO:1737.

XX

KW Human; adenosine receptor; low adenosine antisense oligonucleotide;

KW phosphorothioate; impaired respiration; inflammation; allergy;

KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;

KW antiallergic; antiasthmatic; cytotatic; analgesic; impaired airway;

KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;

KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;

KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;

KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX

OS Homo sapiens.

XX

FN WO200009525-A2.

XX

PD 24-FEB-2000.

XX

PF 03-AUG-1999; 99WO-US017712.

XX

PR 03-AUG-1998; 98US-0095212P.

XX

PA (UYEC-) UNIV EAST CAROLINA.

XX

PI Nyce JW;

XX

XX WPI; 2000-205971/18.

XX

XX New antisense oligonucleotides useful for treating e.g. pulmonary

PT vasoconstriction, inflammation, allergies, asthma, hypertension, or

PT bronchitis, emphysema, respiratory distress syndrome, ischemia or

PT cancers.

XX

PS Disclosure; Page 481; 1343pp; English.

XX

XX The present invention describes a new composition comprising an antisense

CC oligonucleotide (ON) with low adenosine (up to 15%), which targets

CC nucleic acids involved in bronchoconstriction, allergies, and/or

CC inflammation. The ON can have antiinflammatory, antiallergic,

CC antiasthmatic, cytotatic and analgesic activities. The compositions are

CC

CC useful for the treatment of diseases associated with inflammation,

CC impaired airways, including lung disease and diseases whose secondary

CC effects afflict the lungs of a subject. They can be used for treating

CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,

CC impaired respiration, respiratory distress syndrome, pain, cystic

CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive

CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,

CC carcinomas, and cancers which may metastasise to the lungs, including

CC breast and prostate cancer. The reduction of the adenosine content of the

CC ONs reduces side effects. The A-containing ONs break down with the

CC release of deoxyadenosine which activates adenosine receptors causing the

CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the

CC nucleotide sequences given in the sequence listing from the present

CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185

CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ

CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to

CC AAA33992) are specifically claimed ONs from the present invention. N.B.

CC Sequences given in the disclosure of the present invention do not match

CC up with their corresponding SEQ ID NO: sequences given in the sequence

CC listing

XX

SQ Sequence 11 BP; 0 A; 4 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;

Best Local Similarity 81.8%; Pred. No. 6.6e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAACAG 741

DB 11 AGGAGAGAAAG 1

RESULT 959

AAF20170/c

ID AAF20170 standard; DNA; 11 BP.

AC AAF20170;

XX

DT 14-MAR-2001 (first entry)

XX

DE Human eosinophil derived neurotoxin polynucleotide fragment #1737.

XX

KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;

KW human; airway disorder; bronchoconstriction; lung inflammation;

KW surfactant depletion; respiratory bronchodilator; antiinflammatory;

KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytotatic;

KW respiratory obstruction; pulmonary obstruction; impeded respiration;

KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;

KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;

KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;

KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;

KW cancer; ss.

XX

OS Homo sapiens.

XX

PN WO200062736-A2.

XX

PD 26-OCT-2000.

XX

PF 24-MAR-2000; 2000WO-US008020.

XX

PR 06-APR-1999; 99US-0127958P.

XX

PA (UYEC-) UNIV EAST CAROLINA.

XX

PA (NYCE/) NYCE J W.

XX

PI Nyce JW;

XX

XX WPI; 2000-679539/56.

XX

XX Low adenosine (A) content antisense oligonucleotides which do not trigger

PT adenosine receptors during metabolism, useful e.g. for treating cancers

PT and respiratory obstructions.

XX PS Claim 14; Page 142; 1592pp; English.

XX CC The present invention describes low adenosine (A) content antisense oligonucleotides and compositions (I) comprising them. In the antisense oligonucleotides the A is replaced by a 'Universal' or alternative base. (I) can have respiratory, bronchodilator, antiinflammatory, analgesic, immunosuppressive, antilasthmatic, hypotensive and cytostatic activities. The antisense oligonucleotides and (I) can be used to down-regulate the expression and or activity of target polypeptides associated with lung/respiratory disorders and malignancies, such as stimulating and activating peptide factors and transmitters, transcription factors, immunoglobulins and antibodies, antibody receptors, cytokines and chemokines, endogenously produced specific and non-specific enzymes, binding proteins, adhesion molecules and their receptors, cytokine and chemokine receptors, adenosine receptors, bradykinin receptors, central nervous system (CNS) and peripheral nervous and non-nervous system receptors, CNS and peripheral nervous and non-nervous system peptide transmitters, defensins, growth factors, vasoactive peptides and receptors, binding proteins and malignancy associated proteins. The antisense oligonucleotides may be used in this way to treat disorders including respiratory obstruction (especially pulmonary obstruction and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or sulfactant hypoproduction which are associated with a disease or condition selected from pulmonary vasoconstriction, inflammation, allergies, asthma, impaired respiration, respiratory distress syndrome (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), pulmonary transplantation rejection, pulmonary infections, bronchitis, and/or cancer. AAF18434 to AAF21543 represent human polynucleotide fragments and antisense oligonucleotides used in the exemplification of the present invention

XX SQ Sequence 11 BP; 0 A; 4 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 731 AGGAGAAACAG 741
 |||||
 Db 11 AGCAGAAAG 1

RESULT 960
 AAI70541/c
 ID AAI70541 standard; DNA; 11 BP.
 XX AC AAI70541;
 XX DT 21-JAN-2002 (first entry)
 XX DE Rice alpha-amylase gene promoter probe fragment.
 XX KW Alpha-amylase; promoter; rice; transgenic plant; angiosperm; monocot;
 XX KW cereal; brewing; ds.
 XX OS Oryza sativa.
 XX FN US6288302-B1.
 XX PD 11-SEP-2001.
 XX PF 04-MAY-1998; 98US-00072917.
 XX PR 04-NOV-1992; 92US-00973324.
 XX PR 22-NOV-1994; 94US-00343380.
 XX PR 01-AUG-1995; 95US-00509962.
 XX PR 08-OCT-1997; 97US-00947201.
 XX PA (NASC-) NAT SCI COUNCIL ROC.
 XX PI Yu S, Liu L, Chan M;

XX DR WPI; 2001-647191/74.

XX PT Producing a transgenic monocot plant comprising a transgene under control of an alpha amylase promoter and signal peptide sequences, provides transgenic plants particularly cereals for the brewing industry.

XX PS Example 1; Col 20; 44pp; English.

XX CC The present sequence is that of a fragment of HS01, a DNA probe located at the 5' end of the promoter region of a rice alpha-amylase gene, OSamy-b. It covers nucleotides -108 to -119 of the gene and has a sequence similar to that of the animal core enhancer. Rice aleurone was found to contain proteins that interacted with this HS01 DNA fragment. The invention relates to the use of an alpha-amylase gene promoter and signal sequence (see AAI70536-39) in the production of recombinant proteins in transgenic plants and transgenic plant seeds. A transgenic monocot is obtained by transforming an immature embryo with DNA comprising a plant alpha-amylase promoter that is induced under a sugar-depleted or sugar-free condition, a signal peptide sequence, and an exogenous sequence encoding a gene product, regenerating the transformed plant; and growing the transgenic plant, which expresses the gene product under sugar-depleted or sugar-free conditions. The transgenic plants and their CC products are useful in brewing and to produce glucose from starch

XX SQ Sequence 11 BP; 0 A; 2 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAARACAGAC 744
 |||||
 Db 11 AGAARACGAC 1

RESULT 961
 ABQ87289/c
 ID ABQ87289 standard; cDNA; 11 BP.
 XX AC ABQ87289;
 XX DT 10-SEP-2002 (first entry)
 XX DE Human skin stress/ageing related EST SEQ ID NO 1044.
 XX KW Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX FN WO200253773-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015178.
 XX PR 03-JAN-2001; 2001DE-01000121.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-528865/56.
 XX PT Identifying genes involved in skin stress and aging, useful e.g. in screening for cosmetic or therapeutic agents, based on differential gene expression.
 XX PS Claim 8; Page 80; 325pp; German.
 XX CC The invention relates to identifying (M1) genes in vitro that, in humans or animals, are important for skin ageing and/or skin stress by serial analysis of gene expression between mixtures of transcribed and

CC optionally translated, genetically encoded factors (A) obtained from
 CC young and aged skin, to identify that genes that show strong differential
 CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 CC useful for: identifying markers of skin ageing and/or stress; determining
 CC skin ageing and/or stress; and identifying or determining the effects of
 CC pharmaceutical or cosmetic agents for control of skin ageing. The present
 CC sequence is one of a group of human skin ageing/stress related expressed
 CC sequence tags (ABQ86246-ABQ87680) of the invention
 CC
 SQ Sequence 11 BP; 1 A; 5 C; 1 G; 4 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 732 GGAGAAACAGA 742
 DB 11 GGGATACAGA 1
 RESULT 962
 ABQ86542/c
 ID ABQ86542 standard; cDNA; 11 BP.
 XX
 AC ABQ86542;
 XX
 DT 10-SEP-2002 (first entry)
 DE Human skin stress/ageing related EST SEQ ID NO 297.
 XX Human; skin ageing; skin stress; EST; expressed sequence tag; ss.
 XX Homo sapiens.
 XX WO200253773-A2.
 XX 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015178.
 PR 03-JAN-2001; 2001DE-01000121.
 XX (HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-528865/56.
 XX Identifying genes involved in skin stress and aging, useful e.g. in
 XX screening for cosmetic or therapeutic agents, based on differential gene
 XX expression.
 XX Claim 8; Page 49; 325pp; German.
 XX The invention relates to identifying (M1) genes in vitro that, in humans
 XX or animals, are important for skin ageing and/or skin stress by serial
 XX analysis of gene expression between mixtures of transcribed and
 XX optionally translated, genetically encoded factors (A) obtained from
 XX young and aged skin, to identify that genes that show strong differential
 XX expression. (A) comprises protein or mRNAs or their fragments. (M1) is
 XX useful for: identifying markers of skin ageing and/or stress; determining
 XX skin ageing and/or stress; and identifying or determining the effects of
 XX pharmaceutical or cosmetic agents for control of skin ageing. The present
 XX sequence is one of a group of human skin ageing/stress related expressed
 XX sequence tags (ABQ86246-ABQ87680) of the invention
 XX
 SQ Sequence 11 BP; 2 A; 3 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 727 TGCCAGGAGAA 737

Db 11 TGCCAGGAGTA 1
 RESULT 963
 ABV63070
 ID ABV63070 standard; cDNA; 11 BP.
 XX
 AC ABV63070;
 XX
 DT 21-OCT-2002 (first entry)
 DE Human skin EST 856.
 XX
 KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrheic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX WO200253774-A2.
 XX 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX (HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 XX homeostasis and identifying cosmetic or pharmaceutical agents against
 XX e.g. skin cancer.
 XX Disclosure; Page 49; 1345pp; German.
 XX The invention relates to in vitro identification (M1) of genes expressed
 XX in the skin of humans or animals by subjecting a mixture of genetically
 XX encoded factors from skin, to serial analysis of gene expression (SAGE)
 XX so as to identify skin-expressed genes and quantify their expression.
 XX (M1) is useful for identifying genes involved in skin homeostasis; to
 XX determine skin homeostasis and to test agent (A) that maintains or
 XX promotes skin homeostasis or that can be used for treating skin
 XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 XX skin. The present sequence is that of a human expressed sequence tag
 XX (EST) of the invention
 XX
 SQ Sequence 11 BP; 7 A; 1 C; 3 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 735 GAAACAGGAGAA 745
 DB 1 GAAACAGGAGAA 11
 RESULT 964
 ABV64588/c
 ID ABV64588 standard; cDNA; 11 BP.
 XX
 AC ABV64588;
 XX
 DT 21-OCT-2002 (first entry)
 DE Human skin EST 2374.

ABV68950/c
 ID ABV68950 standard; cDNA; 11 BP.
 XX AC ABV68950;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 6736.
 XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX PN WO200253774-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX DR WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX PS Disclosure; Page 212; 1345pp; German.
 XX CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE).
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 0 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 737 AACAGACACC 747
 DB 11 AACAAACAGC 1
 RESULT 970
 ABV65783
 ID ABV65783 standard; cDNA; 11 BP.
 XX AC ABV65783;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 3569.
 XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

OS Homo sapiens.
 XX WO200253774-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX DR WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX PS Disclosure; Page 124; 1345pp; German.
 XX CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE).
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 7 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 736 AACAGACACC 746
 DB 1 AACAAATACAC 11
 RESULT 971
 ABV69415/c
 ID ABV69415 standard; cDNA; 11 BP.
 XX AC ABV69415;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 7201.
 XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX PN WO200253774-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 728 GCCAGGAGAAA 738
 |||||
 Db 1 GCCAGGTGAA 11

RESULT 974
 ABV63121/c
 ID ABV63121 standard; cDNA; 11 BP.
 XX
 AC ABV63121;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 907.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 WPI; 2002-590638/63.
 XX
 WO200253774-A2.
 XX
 11-JUL-2002.
 XX
 20-DEC-2001; 2001WO-EP015179.
 XX
 03-JAN-2001; 2001DE-01000127.
 XX
 (HENK) HENKEL KGAA.
 XX
 Petersohn D, Conradt M, Hofmann K;
 XX
 WPI; 2002-590638/63.
 XX
 In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 Disclosure; Page 50; 1345pp; German.
 XX
 The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 Sequence 11 BP; 0 A; 2 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 733 GAGCAACAGAA 743
 |||||
 Db 11 GAGCAACAAA 1

RESULT 975
 ABV64498
 ID ABV64498 standard; cDNA; 11 BP.
 XX
 AC ABV64498;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 8328.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 8328.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX

DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 2284.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 WPI; 2002-590638/63.
 XX
 In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 Disclosure; Page 88; 1345pp; German.
 XX
 The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX
 Sequence 11 BP; 5 A; 4 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAACACAGAAC 744
 |||||
 Db 1 AGCACACAGAAC 11

RESULT 976
 ABV70542/c
 ID ABV70542 standard; cDNA; 11 BP.
 XX
 AC ABV70542;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 8328.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX


```

XX PF 20-DEC-2001; 2001WO-EP015179.
XX PR 03-JAN-2001; 2001DE-01000127.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-590638/63.
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX SQ Sequence 11 BP; 0 A; 2 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 11;
XX Best Local Similarity 81.8%; Pred. No. 6.6e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 733 GAGAAACAGAA 743
XX Db 11 GAGCAACAAA 1
XX
XX RESULT 977
XX ABV63621 standard; cDNA; 11 BP.
XX AC ABV63621;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 1407.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX FN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PR 03-JAN-2001; 2001DE-01000127.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against

```

```

PT e.g. skin cancer.
XX Disclosure; Page 64; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX SQ Sequence 11 BP; 6 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 11;
XX Best Local Similarity 81.8%; Pred. No. 6.6e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 733 GAGAAACAGAA 743
XX Db 1 GAGAGAGAGAA 11
XX
XX RESULT 978
XX ABV67609/c
XX ID ABV67609 standard; cDNA; 11 BP.
XX AC ABV67609;
XX DT 21-OCT-2002 (first entry)
XX DE Human skin EST 5395.
XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX FN WO200253774-A2.
XX PD 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PR 03-JAN-2001; 2001DE-01000127.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-590638/63.
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX Disclosure; Page 174; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;

```

CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 0 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 735 GAAACAGAAC 745
Db 11 GAAACAGAAC 1
RESULT 979
ABV68198/c
ID ABV68198 standard; cDNA; 11 BP.
XX
AC ABV68198;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 5984.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
PS WPI; 2002-590638/63.
XX
DR In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 191; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 0 A; 2 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 734 AGAAACAGAAC 744
Db 11 AGAAACAGAAC 1
RESULT 980
ABV72009/c
ID ABV72009 standard; cDNA; 11 BP.
XX
AC ABV72009;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 9795.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
PS WPI; 2002-590638/63.
XX
DR In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Claim 24; Page 317; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 2 A; 4 C; 1 G; 4 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 732 GGAGAAACAGAC 742
Db 11 GGAGAAACAGAC 1
RESULT 981
ABV66736
ID ABV66736 standard; cDNA; 11 BP.
XX
AC ABV66736;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 4522.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;

KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
FN WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Disclosure; Page 149; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
XX Sequence 11 BP; 7 A; 1 C; 3 G; 0 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 728 GCCAGGAGGAAA 738
DB 1 GCACGAGAAAA 11
XX
RESULT 982
ABV69413/C
ID ABV69413 standard; cDNA; 11 BP.
XX
XX AC ABV69413;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 7199.
XX
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX

PA (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Disclosure; Page 226; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
XX Sequence 11 BP; 0 A; 3 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 735 GAACAGAGACA 745
DB 11 GAACAGAGACA 1
XX
RESULT 983
ABV70065
ID ABV70065 standard; cDNA; 11 BP.
XX
XX AC ABV70065;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 7851.
XX
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Claim 24; Page 250; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX

CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 CC
 XX Sequence 11 BP; 5 A; 5 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 738 ACAGAACACCG 748
 |||||
 Db 1 ACAGAACACCG 11

RESULT 984
 ABV71919
 ID ABV71919 standard; cDNA; 11 BP.
 XX
 AC ABV71919;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 9705.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-590638/63.
 XX
 PT In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Claim 24; Page 314; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 CC
 XX Sequence 11 BP; 5 A; 4 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAAC 744
 |||||
 Db 1 AGAACAGAAC 11

RESULT 985
 ABV62644
 ID ABV62644 standard; cDNA; 11 BP.
 XX
 AC ABV62644;
 XX
 DT 21-OCT-2002 (first entry)
 XX
 DE Human skin EST 430.
 XX
 KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200253774-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 20-DEC-2001; 2001WO-EP015179.
 XX
 PR 03-JAN-2001; 2001DE-01000127.
 XX
 PA (HENK) HENKEL KGAA.
 XX
 PI Petersohn D, Conradt M, Hofmann K;
 XX
 DR WPI; 2002-590638/63.
 XX
 PT In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX
 PS Disclosure; Page 37; 1345pp; German.
 XX
 CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 CC
 XX Sequence 11 BP; 5 A; 5 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 738 ACAGAACACCG 748
 |||||
 Db 1 ACAGAACACCG 11

RESULT 986
 ABV66108/c
 ID ABV66108 standard; cDNA; 11 BP.

XX AC ABV66108;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 3894.
 XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX PN WO200253774-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX PS Disclosure; Page 133; 1345pp; German.
 XX CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 1 A; 2 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 11;
 XX Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 734 AGAATCAGCAC 744
 XX ||||| |||||
 XX 11 AGAATCAGCAC 1
 XX
 XX RESULT 987
 XX ABV66524
 XX ID ABV66524 standard; cDNA; 11 BP.
 XX AC ABV66524;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 4310.
 XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.

PN WO200253774-A2.
 XX 11-JUL-2002.
 XX 20-DEC-2001; 2001WO-EP015179.
 XX 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.
 XX In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX PS Disclosure; Page 144; 1345pp; German.
 XX CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 7 A; 1 C; 3 G; 0 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 11;
 XX Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 735 GAAACAGACAA 745
 XX ||||| |||||
 XX 1 GAACGAGAAA 11
 XX
 XX RESULT 988
 XX ABV69076/c
 XX ID ABV69076 standard; cDNA; 11 BP.
 XX AC ABV69076;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 6862.
 XX KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX PN WO200253774-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX (HENK) HENKEL KGAA.
 XX Petersohn D, Conradt M, Hofmann K;
 XX WPI; 2002-590638/63.

XX In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 216; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 0 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAACAG 741
Db 11 AGGAGACCAG 1
|||||

RESULT 989
ABV68102
ID ABV68102 standard; cDNA; 11 BP.
XX
AC ABV68102;
XX
DT 21-OCT-2002 (first entry)
DE Human skin EST 5888.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 188; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or

CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 5 A; 3 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 730 CAGCAGAACCA 740
Db 1 CAGCAGAACCA 11
|||||

RESULT 990
ABV68680
ID ABV68680 standard; cDNA; 11 BP.
XX
AC ABV68680;
XX
DT 21-OCT-2002 (first entry)
DE Human skin EST 6466.
XX
KW Human; skin; dermatological; vulnary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
XX WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 205; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 7 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX DR WPI; 2002-590638/63.
 XX PT In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX PS Disclosure; Page 113; 1345pp; German.
 XX CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 0 A; 3 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 734 AGAACAGAAC 744
 DB 11 AGAACAGAGC 1
 RESULT 994
 ABV70491
 ID ABV70491 standard; cDNA; 11 BP.
 XX AC ABV70491;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 8277.
 XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX PN WO200253774-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX DR WPI; 2002-590638/63.
 XX PT In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.

XX PS Claim 24; Page 265; 1345pp; German.
 XX CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag
 CC (EST) of the invention
 XX SQ Sequence 11 BP; 7 A; 1 C; 3 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 735 GAAACAGAGAAC 745
 DB 1 GAAACAGAGAAC 11
 RESULT 995
 ABV71042
 ID ABV71042 standard; cDNA; 11 BP.
 XX AC ABV71042;
 XX DT 21-OCT-2002 (first entry)
 XX DE Human skin EST 8828.
 XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhaic;
 KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
 KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
 XX OS Homo sapiens.
 XX PN WO200253774-A2.
 XX PD 11-JUL-2002.
 XX PF 20-DEC-2001; 2001WO-EP015179.
 XX PR 03-JAN-2001; 2001DE-01000127.
 XX PA (HENK) HENKEL KGAA.
 XX PI Petersohn D, Conradt M, Hofmann K;
 XX DR WPI; 2002-590638/63.
 XX PT In vitro identification of skin-expressed genes, useful for determining
 PT homeostasis and identifying cosmetic or pharmaceutical agents against
 PT e.g. skin cancer.
 XX PS Claim 24; Page 283; 1345pp; German.
 XX CC The invention relates to in vitro identification (M1) of genes expressed
 CC in the skin of humans or animals by subjecting a mixture of genetically
 CC encoded factors from skin, to serial analysis of gene expression (SAGE)
 CC so as to identify skin-expressed genes and quantify their expression.
 CC (M1) is useful for identifying genes involved in skin homeostasis; to
 CC determine skin homeostasis and to test agent (A) that maintains or
 CC promotes skin homeostasis or that can be used for treating skin
 CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
 CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
 CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
 CC skin. The present sequence is that of a human expressed sequence tag

CC (EST) of the invention
XX Sequence 11 BP; 6 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
SQ

Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAACACAGAA 743
DB 1 GAGACAGAGAA 11

RESULT 996
ABL91951
ID ABL91951 standard; cDNA; 11 BP.
XX
XX ABL91951;
XX
DT 30-MAY-2002 (first entry)
XX
DE Human Pan-Endothelial Marker SEQ ID NO 49.
XX
XX Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
KW normal endothelial marker; pan-endothelial marker; immunostimulant;
KW angiogenic; tumour; neovascularisation; vascularised tumour;
KW polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
KW psoriasis; ss.
XX
XX Homo sapiens.
XX
XX WO200210217-A2.
XX
PD 07-FEB-2002.
XX
XX
XX 01-AUG-2001; 2001WO-US024031.
XX
XX 02-AUG-2000; 2000US-0222599P.
PR 11-AUG-2000; 2000US-0224360P.
PR 11-APR-2001; 2001US-0282850P.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX St Croix B, Kinzler KW, Vogelstein B;
PI
DR WPI; 2002-291856/33.
XX
XX An isolated molecule comprising an antibody variable region which
PT specifically binds to an extracellular domain of a tumor endothelial
PT marker (TEM) protein, useful for inhibiting tumor growth.
XX
XX Example 4; Page 325; 331pp; English.

The invention relates to an isolated molecule comprising an antibody
CC variable region which specifically binds to an extracellular domain of a
CC tumour endothelial marker (TEM) protein selected from ABB90732, ABB90740,
CC ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
CC proteins have cytostatic, immunostimulant and angiogenic activity.
CC They are useful for inhibiting tumour growth, neovascularisation in subjects
CC bearing a vascularised tumour, polycystic kidney disease, diabetic
CC retinopathy, rheumatoid arthritis and psoriasis. Human, mouse and rat TEM
CC genes and the encoded proteins (ABL92075-ABL92141 and ABB90721-ABB90789)
CC are disclosed, as are marker oligonucleotide sequences: tumour
CC endothelial markers (TEM) ABL91996-ABL92041 and ABL92143-ABL92191; normal
CC endothelial markers (NEM) ABL92042-ABL92074; and pan-endothelial markers
CC (PEM) ABL91993-ABL91995. The present sequence is that of an
CC oligonucleotide marker useful to the invention
XX
SQ Sequence 11 BP; 2 A; 3 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 727 TGCCAGGAGAA 737
DB 1 TGCCAGGTGCA 11

RESULT 997
ABZ95864/c
ID ABZ95864 standard; DNA; 11 BP.
XX
XX ABZ95864;
AC
XX
DT 17-OCT-2003 (first entry)
XX
DE Human eosinophil derived neurotoxin antisense fragment no.1724.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW anti-inflammatory steroid; ubiunone; anti-inflammatory; anti-allergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX WO200285308-A2.
PN
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX 24-APR-2001; 2001US-0286137P.
PR
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
DR
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiunone.
XX
XX Disclosure; SEQ ID NO 11106; 872pp; English.

The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC anti-inflammatory steroid and ubiunone. A composition of the invention
CC has anti-inflammatory, anti-allergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC anti-inflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 11 BP; 0 A; 4 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 6.6e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 999
ACA61506

PT A modified promoter, an expression cassette, an expression vector, a
 PT recombinant microbe, preparation of a protein.

XX Example 5; Page 8; 15pp; Japanese.

XX The invention describes a promoter which can function in a Bacillus genus
 CC microbe in which the ratio of adenine to cytosine in the sequence near
 CC the 3'-end of said promoter is 0.5 to 2 and the activity of the promoter
 CC is higher than that of a natural promoter. The promoter is useful in the
 CC preparation of a protein. This sequence represents a modified promoter
 CC associated DNA

XX Sequence 11 BP; 4 A; 2 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 6.6e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 731 AGGAGAACAG 741
 Db 1 AGGAGTACCAG 11

RESULT 1001

AA30191
 ID AA30191 standard; DNA; 12 BP.

AC AA30191;

XX 25-MAR-2003 (revised)
 DT 25-MAY-1992 (first entry)

DE Sequence of probe/primer which corresp. to bps 579-590 porcine
 DE preprorelaxin cDNA.

XX Relaxin; hormone; ds.

XX Sus scrofa domestica.

XX EP86649-A.

XX 24-AUG-1983.

XX 11-FEB-1983; 83EP-00300714.

XX 12-FEB-1982; 82AU-00002695.

XX 11-FEB-1983; 83AU-00011834.

XX (FLOR-) FLOREY INST EXP PHY.

XX (FLOR-) FLOREY HOWARD INST.

XX Hudson PJ, Haley JD, Niall HD, Shine J;

XX WPI; 1983-748587/35.

XX Genes and DNA transfer vectors for prorelaxin expression - useful in
 PT prodn. of porcine relaxin for veterinary and human use.

XX Claim 12; Page 5; 50pp; English.

XX The inventors claim synthetic porcine preprorelaxin and prorelaxin and
 CC synthetic A, B and C peptide chains of prolaxin, and a gene for
 CC expression of porcine preprorelaxin or prorelaxin, and their sub- units
 CC (see AA30186). They also claim a double-stranded DNA fragment for the
 CC expression of the signal peptide chain of porcine preprorelaxin
 CC comprising a coding strand and a complementary strand corresp. to a
 CC defined mRNA sequence (see AA30187-N30194) which corresp. to the most
 CC homologous regions between the pig and rat cDNA sequences. A probe
 CC (AA30195) is also claimed. (Updated on 25-MAR-2003 to correct PF field.)
 CC (Updated on 25-MAR-2003 to correct PA field.)

XX Sequence 12 BP; 6 A; 1 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 735 GAAACAGAACCA 745
 Db 2 GAAGCAGAGAGA 12

RESULT 1002

AAQ88668/c
 ID AAQ88668 standard; DNA; 12 BP.

XX AAQ88668;

XX 03-JAN-1996 (first entry)

XX Human mitochondrial D-loop region DNA probe 12-15.

XX Tiling strategy; immobilised nucleic acid probe array; mitochondrial DNA;
 KW D-loop region; biological chip; hybridisation fingerprint;
 KW interrogation position; ss.

XX Synthetic.

XX Key Location/Qualifiers
 FH modified_base 12
 FT /*tag= a
 FT /note="3'-end of probe is covalently attached to chip
 FT surface"

XX WO9511995-A1.

XX 04-MAY-1995.

XX 26-OCT-1994; 94WO-US012305.

XX 26-OCT-1993; 93US-00143312.

XX 02-AUG-1994; 94US-00284064.

XX (AFFY-) AFFYMAX TECHNOLOGIES NV.

XX Chee M, Cronin WT, Fodor SP, Gingeras TR, Huang XC, Hubbell EA;
 PI Lipshutz RJ, Lobban PE, Miyada CG, Morris MS, Shah N, Sheldon EL;

XX WPI; 1995-178887/23.

XX New arrays of oligonucleotide probes - used for comparing known
 PT sequences with variants for detection of mutation(s) and sequencing.

XX Disclosure; Page 108; 223pp; English.

XX A DNA chip was prepared for analysing sequences contained in a 1.3kb
 CC fragment of human mitochondrial DNA from the D-loop region, the most
 CC polymorphic region of human mitochondrial DNA. The chip comprised a set
 CC of 268 overlapping oligonucleotide probes (see AAQ88421-088684) of
 CC varying length (9-14 nucleotides) with varying overlaps arranged in a 1cm
 CC x 1cm array. Each position in the sequence was represented by at least
 CC one probe (usually 2 or more). DNA was amplified from six human donors
 CC and then transcribed to give the 1.3kb RNA transcripts which were
 CC fragmented and hybridised to the chip. For each individual, a unique
 CC hybridisation fingerprint was produced on the chip; all differences could
 CC be correlated with differences in the cloned genomic DNA sequence

XX Sequence 12 BP; 1 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 732 GGAGAACAGCA 742
 Db 12 GGGAGAGCAGA 2

```

RESULT 1003
AAT11908
ID AAT11908 standard; DNA; 12 BP.
XX
XX
AC AAT11908;
XX
XX
DT 13-JUL-1996 (first entry)
XX
XX
DE Antisense DNA to inhibit isoprenyl protein transferase expression.
XX
XX isoprenyl protein transferase; farnesyl; geranyl geranyl; prenylation;
KW inhibition; abnormal; uncontrolled; cell proliferation; cancer;
KW cardiovascular disease; treatment; ss.
XX
XX Synthetic.
OS
XX GB2290791-A.
FN
XX
PD 10-JAN-1996.
XX
XX 29-JUN-1995; 95GB-00013246.
XX
XX 29-JUN-1994; 94GB-00013035.
XX
XX (SCRC ) SCRAS SOC CONSEILS RECH APPL SCI.
PA
XX Colote S, Pirotzky E;
PI
XX WPI; 1996-042231/05.
DR
XX Anti-sense oligo-nucleotide(s) hybridising to isoprenyl protein
PT transferase genes - or their transcripts, for treating abnormal or
PT uncontrolled cell proliferation e.g. cancer.
XX
XX Claim 2; Page 12; 27pp; English.
PS
XX
XX AAT11906-41 are antisense oligonucleotides that are selectively
CC hybridisable with a gene or the transcription products for sub-units of
CC isoprenyl protein transferases, pref. farnesyl protein transferase or a
CC geranyl geranyl protein transferase. Oligonucleotides contg. these
CC antisense sequences or their derivs. are useful in human or veterinary
CC medicine for treatment of abnormal and/or uncontrolled cell
CC proliferation, e.g. in cases of cardiovascular disease, cancer, viral
CC infections or dermatology. Inhibiting prenylation prevents proteins from
CC binding to active sites on cell membranes, so prevents transduction of
CC extracellular cell signals and thus cell proliferation
XX
XX Sequence 12 BP; 5 A; 1 C; 5 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
DB 2 AGGAGTAGCAG 12

RESULT 1004
AAV05933
ID AAV05933 standard; DNA; 12 BP.
XX
XX
AC AAV05933;
XX
XX
DT 05-JUN-1998 (first entry)
XX
XX Translation rate controlling sequence AN.EKEK.
DE
XX Translation rate; heterologous protein; hydrophobicity; human; 115ORF;
KW transmembrane domain; insertion; vaccine; ds.
XX
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9735972-A1.
PN
XX 02-OCT-1997.
PD
XX
XX 25-MAR-1997; 97WO-FR000523.
PF
XX
XX 26-MAR-1996; 96FR-00003731.
PR
XX (COMS ) COMMISSARIAT ENERGIE ATOMIQUE.
PA
XX Kepes F;
PI
XX WPI; 1997-489636/45.
DR
XX
XX Nucleic acid encoding protein with hydrophobic or trans-membrane domain -
PT includes downstream of this domain a region that slows down translation,
PT improves product and assembly yield and correct incorporation into the
PT membrane, e.g. for use in vaccines.
XX
XX Disclosure; Fig 5; 73pp; French.
PS
XX This oligonucleotide comprises a sequence that is used to control the
CC rate of translation of a protein in a heterologous organism. The sequence
CC is based on regions of amino acid hydrophobicity in the amino acid
CC sequence of the human 115ORF protein and is adapted for controlling the
CC rate of protein translation in Aspergillus nidulans. The rate control
CC sequences are found downstream of regions encoding transmembrane domains
CC (TMD) and at a distance of 50-85 codons from these regions. The control
CC region increases production and assembly yield of the heterologous
CC protein and improves correct insertion into the membrane. The translation
CC delay imposed by the sequence favours formation of the protein with its
CC native 3-dimensional structure. The control sequence can be used to
CC generate construct for the expression of heterologous proteins especially
CC for use in vaccines
XX
XX Sequence 12 BP; 10 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
SQ
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGAACCA 745
DB 1 GAAACAGAAAA 11

RESULT 1005
AAT63016/C
ID AAT63016 standard; DNA; 12 BP.
XX
XX
AC AAT63016;
XX
XX
DT 02-FEB-1998 (first entry)
XX
XX TNF-alpha mRNA series 1 (5' untranslated cap region) oligonucleotide 3.
DE
XX Tumour necrosis factor alpha; TNF-alpha; therapeutic agent;
KW chimeric oligonucleotide library; antisense binding site;
KW antisense compound; drug target validation; 5' untranslated cap region;
XX ss.
XX
XX Synthetic.
OS
XX WO9710332-A2.
PN
XX
XX 20-MAR-1997.
PD
XX
XX 13-SEP-1996; 96WO-GB002275.
PF
XX
XX 14-SEP-1995; 95GB-00018864.
PR

```

```

XX (BRAX-) BRAX GENOMICS LTD.
XX Schmidt G;
XX WPI; 1997-202228/18.
XX Chimeric oligo:nucleotide library - for use in identifying anti-sense
XX binding sites in target messenger RNA.
XX Example 2; Page 27; 44pp; English.
XX Oligonucleotides of series 1.AAT63014-21, have specific anti-mRNA
XX sequences to the 5' untranslated cap region of tumour necrosis factor
XX (TNF)-alpha mRNA. These oligonucleotides are an example of a new chimeric
XX oligonucleotide library, used to identify an antisense binding site in a
XX target mRNA (in this case TNF-alpha). The library comprises a set of
XX distinct chimeric oligonucleotides capable of hybridising to mRNA to form
XX a duplex, the nucleotide sequences of which each have a common length of
XX 7-20 bases. All of the nucleotides of the common length which are present
XX as subsequences in the target mRNA are present in the library. Each
XX nucleotide sequence comprises a recognition region recognisable by a
XX duplex-cutting RNase, and a flanking region of chemically modified
XX nucleotides which binds to the mRNA sufficiently tightly to stabilise the
XX duplex for the RNase. Each oligonucleotide is protected against
XX exonuclease attack. The libraries can be used to identify optimal
XX effective antisense compounds against specific mRNA targets. The
XX antisense compounds are useful as potential therapeutic agents, and as
XX tools for drug target validation
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 734 AGAAACAGAC 744
XX |||||
XX 12 AGGAAGAGAC 2
XX
XX RESULT 1006
XX AAV55018
XX ID AAV55018 standard; DNA; 12 BP.
XX AC
XX AC AAV55018;
XX DT
XX DT 11-NOV-1998 (first entry)
XX DE
XX DE CCR-5 gene targeting sequence TF01.
XX KW CCR-5 gene; CCR-5; chemokine receptor; triple-stranded complex; therapy;
XX KW co-receptor prevention; human immunodeficiency virus resistance; HIV;
XX KW macrophage entry inhibition; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX modified_base 1
XX FT /*tag= a
XX FT /note= "Clamb-NH-(CH2)6-O-PG nucleotide, where Clamb is
XX FT chlorambucil"
XX FT modified_base 12
XX FT /*tag= b
XX FT /note= "Gp-O-(CH2)6-OH modified nucleotide"
XX FT
XX FN WO9834945-A1.
XX XX
XX XX 13-AUG-1998.
XX XX
XX PF 06-FEB-1998; 98WO-US002314.
XX XX
XX PR 06-FEB-1997; 97US-0037464P.

```

```

PR 05-FEB-1998; 98US-00019387.
XX (EPOCH-) EPOCH PHARM INC.
XX Meyer RB, Kuttyavin IV;
XX WPI; 1998-447163/38.
XX Oligo:nucleotide(s) that form triplex(es) with part of chemokine receptor
XX CCR-5 gene - are modified with crosslinking agents to alter gene so that
XX cells are rendered resistant to human immunodeficiency virus.
XX Claim 7; Page 23; 33pp; English.
XX This sequence represents an oligonucleotide of the invention, that forms
XX a triple-stranded complex with part of the gene for CCR-5. CCR-5 is a
XX chemokine receptor, also known as CKR-5. The oligonucleotide, when
XX modified by attachment of alkylating (cross-linking) agents, modify the
XX CCR-5 gene, preventing its product from acting as a co-receptor for human
XX immunodeficiency virus (HIV), and rendering cells resistant to this
XX virus. They can be used to prevent entry of HIV into macrophages or
XX therapeutically to prevent viral spread in infected subjects. The
XX oligonucleotides can be introduced into cells by any method of nucleic
XX acid delivery, e.g. transfection, co-precipitation, liposome-mediated
XX transfer etc. The sequences have a longer lasting effect than antisense
XX sequences directed to mRNA, and may produce heritable modifications in
XX the gene
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 732 GGAGAACACAGA 742
XX |||||
XX 1 GGAGAGAGAAGA 11
XX
XX RESULT 1007
XX AAV16650
XX ID AAV16650 standard; DNA; 12 BP.
XX AC
XX AC AAV16650;
XX DT
XX DT 12-JUN-1998 (first entry)
XX DE
XX DE Probe H30 used to identify HLA-DR sequences.
XX KW DR region; major histocompatibility complex; HLA-DR; HLA-typing;
XX KW HLA-DR beta consensus sequence; allelic polymorphism;
XX KW HLA-DR beta-allelic polymorphism; probe; bone marrow; transplant; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX XX
XX XX US5702885-A.
XX XX
XX XX 30-DEC-1997.
XX XX
XX XX 08-APR-1993; 93US-00057957.
XX XX
XX XX 27-JUN-1990; 90US-00544218.
XX XX
XX XX (BLOO-) BLOOD CENT RES FOUND INC.
XX XX
XX XX Gorski JA, Baxter-Lowe LA;
XX XX
XX XX WPI; 1998-076408/07.
XX XX
XX XX Oligo:nucleotide probes and primers and methods for HLA typing -
XX XX particularly for tissue typing for bone marrow transplants.

```

PS Disclosure; Col 29; 20pp; English.

XX Probes AAV1647-64 are used to identify differences in the DR region of

CC human major histocompatibility complex (HLA-DR). The specification

CC describes a method for HLA-typing, which includes an oligonucleotide

CC probe which undergoes sequence-specific hybridisation with an HLA-DR beta

CC consensus sequence at positions 61-64. The probe contains a labelling

CC substance other than a nucleotide sequence, which facilitates detection

CC of the probe. The HLA sequence of a subject is PCR amplified, and a probe

CC that recognises an allelic polymorphism at a selected HLA locus is

CC contacted with the amplified product. This first probe recognises a HLA-

CC DR beta-allelic polymorphism. A second (different) probe is brought into

CC contact with a second sample of the amplified DNA in a separate reaction,

CC and hybridisation detected. The probes and primers are used for HLA

XX typing, e.g. for tissue, especially bone marrow, transplants

SQ Sequence 12 BP; 4 A; 3 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 730 CAGGAGAAACA 740

DB 1 CTGGAGAGACA 11

RESULT 1008

AAAX08771

ID AAX08771 standard; DNA; 12 BP.

XX AC AAX08771;

XX DT 27-SEP-1999 (first entry)

XX DE Antioxidant responsive element sequence.

XX KW Antioxidant responsive element; ARE; low density lipoprotein; LDL;

XX KW high density lipoprotein; HDL; apolipoprotein; apo AI; atherosclerosis;

XX KW heart disease; transcription; ss.

XX OS Synthetic.

XX PN CA2238662-A.

XX PD 23-NOV-1998.

XX PF 22-MAY-1998; 98CA-02238662.

XX PR 23-MAY-1997; 97US-00862431.

XX PA (TOOH) UNIV QUEENS KINGSTON.

XX PI Tam S;

XX DR WPI; 1999-229918/20.

XX PT New Antioxidant Response Element (ARE), useful for identifying drugs and

XX PT transcription factors for increasing transcription of mRNA, useful for

XX PT treatment of atherosclerosis.

PS Disclosure; Page 16; 115pp; English.

XX DNA constructs comprising antioxidant responsive elements (AREs) are

CC useful for screening for compounds and transcription factors that bind to

CC the ARE and increase transcription levels of a mRNA regulated by an ARE.

CC AREs may also be useful as a reagent for purification of a compound

CC (preferably a transcription factor) with which it interacts. High Density

CC lipoprotein (HD) has antioxidative activity and protects against oxidized

CC low-density lipoprotein (LDL) which has a role in the etiology of

CC atherosclerosis. Apolipoprotein (apo) AI is a major component of HDL, and

CC is believed to promote the process of reverse cholesterol transport. The

CC transcription of apo AI is effected by cis- and trans-acting factors (i.e

CC an ARE). UV cross-linking studies using an apoAI-ARE probe isolated two

CC polypeptides of 100 and 115 kDa. These compounds are useful for treatment

CC of a human or animal with atherosclerosis. ARE's can also be used in DNA

CC constructs when operably linked to heterologous protein coding sequences

CC to effect the transcription of those heterologous sequences

XX Sequence 12 BP; 5 A; 2 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 734 AGAACAACAGAC 744

DB 1 AGGAACAGAGC 11

RESULT 1009

AAAX14842

ID AAX14842 standard; DNA; 12 BP.

XX AC AAX14842;

XX DT 24-MAR-1999 (first entry)

XX DE Triple helix forming nucleotides 1628-1639 of 23S rRNA gene.

XX KW Triple-helix forming region; Triplex formation; DNA detection;

XX KW identification; bacteria; oncogene; virus; ds.

XX OS Halococcus morrhuae.

XX PN US5861244-A.

XX PD 19-JAN-1999.

XX PF 22-DEC-1993; 93US-00173489.

XX PR 29-OCT-1992; 92US-00968436.

XX PA (PROF-) PROFILE DIAGNOSTIC SCI INC.

XX PI Hepburn AG, Wang C;

XX DR WPI; 1999-130384/11.

XX PT Assay of genetic sequences based on triplex formation from double

XX PT stranded analyte - and hybrid of anchor and reporter sequences, with

XX PT reporter released if triplex formation occurs, used e.g. to identify

XX PT bacteria.

PS Disclosure; Col 21-22; 168pp; English.

XX The present sequence represents a potential triple-helix forming region.

CC It can be used to demonstrate the assay of the invention. The assay

CC comprises adding a sample containing double-stranded DNA test sequences,

CC e.g. containing the present sequence, to an aqueous medium containing at

CC least one complex of anchor DNA, attached to a solid support, and

CC reporter DNA, where either a part of the anchor DNA or reporter DNA is

CC designed to form a triple-strand structure with part of the test

CC sequence. Triplex formation results in displacement of the reporter DNA

CC which is detected as an indication of the presence of the DNA test

CC sequence. The method is used to detect DNA sequences, particularly for

CC identification of bacteria (by detecting genes for ribosomal RNA) in

CC clinical samples, but also detection of oncogenes and Hepatitis B virus

XX Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 733 GAGAAACAGAA 743

```

Db      ||||| |||||
        1 GAGATAGAGAA 11

RESULT 1010
AAAX14964
ID AAX14964 standard; DNA; 12 BP.
XX AC AAX14964;
XX AC AAX14964;
XX DT 24-MAR-1999 (first entry)
XX DE Triple helix forming nucleotides1066-1077 of the p53 gene.
XX KW Triple-helix forming region; Triplex formation; DNA detection;
XX KW identification; bacteria; oncogene; virus; ds.
XX OS Homo sapiens.
XX PN US5861244-A.
XX PD 19-JAN-1999.
XX PF 22-DEC-1993; 93US-00173489.
XX PR 29-OCT-1992; 92US-00968436.
XX PA (PROP-) PROFILE DIAGNOSTIC SCI INC.
XX PI Hepburn AG, Wang C;
XX DR WPI; 1999-130384/11.
XX PT Assay of genetic sequences based on triplex formation from double
XX PT stranded analyte - and hybrid of anchor and reporter sequences, with
XX PT reporter released if triplex formation occurs, used e.g. to identify
XX PT bacteria.
XX PS Disclosure; Col 25-26; 168pp; English.
XX CC The present sequence represents a potential triple-helix forming region.
XX CC It can be used to demonstrate the assay of the invention. The assay
XX CC comprises adding a sample containing double-stranded DNA test sequences,
XX CC e.g. containing the present sequence, to an aqueous medium containing at
XX CC least one complex of anchor DNA, attached to a solid support, and
XX CC reporter DNA, where either a part of the anchor DNA or reporter DNA is
XX CC designed to form a triple-strand structure with part of the test
XX CC sequence. Triplex formation results in displacement of the reporter DNA
XX CC which is detected as an indication of the presence of the DNA test
XX CC sequence. The method is used to detect DNA sequences, particularly for
XX CC identification of bacteria (by detecting genes for ribosomal RNA) in
XX CC clinical samples, but also detection of oncogenes and Hepatitis B virus
XX CC
XX SQ Sequence 12 BP; 7 A; 0 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
DB 2 GAGGAGAGAGAA 12

RESULT 1011
AAAX14828
ID AAX14828 standard; DNA; 12 BP.
XX AC AAX14828;
XX DT 24-MAR-1999 (first entry)
XX DE Triple helix forming nucleotides 212-223 of 23S rRNA gene.

```

```

XX KW Triple-helix forming region; Triplex formation; DNA detection;
XX KW identification; bacteria; oncogene; virus; ds.
XX OS Escherichia coli.
XX PN US5861244-A.
XX PD 19-JAN-1999.
XX PF 22-DEC-1993; 93US-00173489.
XX PR 29-OCT-1992; 92US-00968436.
XX PA (PROP-) PROFILE DIAGNOSTIC SCI INC.
XX PI Hepburn AG, Wang C;
XX DR WPI; 1999-130384/11.
XX PT Assay of genetic sequences based on triplex formation from double
XX PT stranded analyte - and hybrid of anchor and reporter sequences, with
XX PT reporter released if triplex formation occurs, used e.g. to identify
XX PT bacteria.
XX PS Disclosure; Col 21-22; 168pp; English.
XX CC The present sequence represents a potential triple-helix forming region.
XX CC It can be used to demonstrate the assay of the invention. The assay
XX CC comprises adding a sample containing double-stranded DNA test sequences,
XX CC e.g. containing the present sequence, to an aqueous medium containing at
XX CC least one complex of anchor DNA, attached to a solid support, and
XX CC reporter DNA, where either a part of the anchor DNA or reporter DNA is
XX CC designed to form a triple-strand structure with part of the test
XX CC sequence. Triplex formation results in displacement of the reporter DNA
XX CC which is detected as an indication of the presence of the DNA test
XX CC sequence. The method is used to detect DNA sequences, particularly for
XX CC identification of bacteria (by detecting genes for ribosomal RNA) in
XX CC clinical samples, but also detection of oncogenes and Hepatitis B virus
XX CC
XX SQ Sequence 12 BP; 8 A; 0 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
DB 1 GAGGAGAGAGAA 11

RESULT 1012
AAAX22069
ID AAX22069 standard; DNA; 12 BP.
XX AC AAX22069;
XX DT 20-MAR-2003 (revised)
XX DT 20-MAY-1999 (first entry)
XX DE Probe analyte #1.
XX KW Probe; nucleic acid determination; sequence determination;
XX KW triple stranded binding complex; ss.
XX OS Synthetic.
XX PN EP897991-A2.
XX PD 24-FEB-1999.
XX PF 19-AUG-1998; 98EP-00115582.

```

```

PR 22-AUG-1997; 97EP-00114512.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA (HOFF ) ROCHE DIAGNOSTICS GMBH.
XX
XX Naesby M;
PI
XX
XX WPI; 1999-134650/12.
XX
XX Determining nucleic acids by formation of a triple stranded binding
XX complex - using two separate probe molecules which bind to the nucleic
XX acid via Watson-Crick and Hoogsteen base pairing.
XX
XX Example 1; Page 14; 28pp; English.
XX
XX This sequence represents a probe analyte used to test the method of the
XX invention. The method is for the determination of a nucleic acid A, and
XX comprises formation of a triple stranded binding complex (I) between A
XX and two different nucleic acid binding molecules B and C, the formation
XX of (I) detected by inclusion of B or C. (I) is more thermostable than a
XX complex between A and two Bs or two identical Cs. The nucleic acid
XX binding molecules B and C are useful as probes for specifically
XX determining a nucleic acid, useful in diagnostics. Short Hoogsteen
XX binding oligomer B is stabilised by a longer Watson-Crick molecule C,
XX preventing the need for a long homopurine tract in A, allowing the high
XX discriminatory power of short Hoogsteen binding probes without loss of
XX specificity. (Updated on 20-MAR-2003 to correct PA field.)
XX
XX Sequence 12 BP; 5 A; 3 C; 2 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 729 CCAGGAGAAC 739
XX Db 2 CCAGAGATAC 12
XX
XX RESULT 1013
XX AAA93383
XX ID AAA93383 standard; DNA; 12 BP.
XX AC AAA93383;
XX
XX DT 10-JAN-2001 (first entry)
XX
XX DE DNA encoding caspase-6 substrate recognition sequence, SEQ ID NO:65.
XX
XX KW Bioreceptor protein; fusion protein; recognition site;
XX KW cellular targeting sequence; cellular localisation; fluorescent protein;
XX KW protease activity detection; toxin detection; cellular stress detection;
XX KW drug discovery; cell based screening; protease recognition site;
XX KW cleavage site; ds.
XX
XX OS Unidentified.
XX
XX PN WO2000050872-A2.
XX
XX PD 31-AUG-2000.
XX
XX PF 25-FEB-2000; 2000WO-US004794.
XX
XX PR 26-FEB-1999; 99US-0122152P.
XX PR 08-MAR-1999; 99US-0123399P.
XX PR 12-JUL-1999; 99US-00352171.
XX
XX (CELL-) CELLOMICS INC.
XX
XX FI Giuliano KA, Kapur R;
XX
XX DR WPI; 2000-594086/56.
XX P-PSDB; AAB22892.
XX
XX Automated cell-based characterization of toxin by contacting cells
XX containing luminescent reporter molecules with test substance and
XX analyzing optically.
XX
XX Example 11; Fig 29B; 336pp; English.
XX
XX The invention relates to systems, methods and reagents for cell-based
XX screening or detection of compounds which affect particular biological
XX functions. The methods of the invention utilise fluorescent bioreceptor
XX molecules which, when acted on by a compound of interest, cause an
XX alteration in the cellular distribution of at least the fluorescent
XX moiety. In one embodiment, the biosensors comprise heat shock proteins
XX (HSPs) fused to a fluorescent protein (e.g., jellyfish green fluorescent
XX protein (GFP), or derivatives thereof). Such biosensors are located in
XX the cytoplasm, but on stress activation translocate to the nucleus. In
XX another embodiment bioreceptor proteins can be used to detect protease
XX activity. Such protease bioreceptor fusion proteins comprise one or more
XX fluorescent proteins; a recognition signal which is cleaved by the
XX protease; and at least one cellular localisation signal. The latter two
XX components may be components of a single protein which is acted upon by
XX the protease, or may be from heterologous sources. Due to the
XX localisation signal, the bioreceptor protein is localised to a particular
XX region of the cell. Once acted on by the protease of interest, the
XX fluorescent protein is cleaved from the localisation sequence, and is
XX free to migrate to other locations within the cell. The presence of a
XX second localisation signal attached to the fluorescent protein enables
XX the fluorescent protein to be directed to a different cellular
XX compartment after cleavage of the protease recognition sequence. The
XX change in distribution of the fluorescent protein can be detected using
XX imaging methods with a high degree of spatial resolution. The methods and
XX biosensors of the invention can be used to investigate a wide range of
XX cellular activities and to screen compounds which modulate these
XX activities. Biosensors containing a recognition site for caspase, for
XX example, may be used for the screening of compounds which modulate
XX apoptosis, while biosensors containing other protease recognition sites
XX may be used for the detection of proteolytic toxins (such as anthrax
XX lethal factor). The method provides improved target validation and
XX candidate compound optimisation by combining many cell screening formats
XX with fluorescence-based molecular reagents and computer-based feature
XX extraction, data analysis and automation, resulting in increased quantity
XX and speed of data collection and faster evaluation of drug candidates.
XX Sequences AAA93377-A93411 and AAA93440 represent protease recognition
XX sites (AAB22886-B22920, AAB22935) which may be used as components of
XX biosensor fusion proteins of the invention
XX
XX Sequence 12 BP; 6 A; 1 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 732 GGAGAAACAGA 742
XX Db 1 GTAGAAATAGA 11
XX
XX RESULT 1014
XX AAA06712
XX ID AAA06712 standard; DNA; 12 BP.
XX
XX AC AAA06712;
XX
XX DT 05-JUN-2000 (first entry)
XX
XX DE VEGF derived short antisense oligonucleotide SEQ ID NO:21.
XX
XX KW Human; vascular endothelial growth factor; VEGF; phosphorothioate;
XX KW antisense oligonucleotide; inhibition; cytostatic; angiogenic;
XX KW gene therapy; abnormal vascular permeability; cell proliferation;
XX KW cell permeation; angiogenesis; neovascularisation; tumour cell growth;
XX KW metastasis; ss.
XX

```


OS Homo sapiens.
OS Synthetic.
XX EP979869-A1.
XX 16-FEB-2000.
XX 07-AUG-1998; 98EP-00114853.
XX 07-AUG-1998; 98EP-00114853.
XX (HMRI) HOECHST MARION ROUSSEL DEUT GMBH.
XX Uihmann E, Peyman A, Bitonti AJ, Woessner RD;
XX WPI; 2000-258586/23.
XX Novel oligonucleotides corresponding to a part of a vascular endothelial
PT growth factor, useful for treating e.g. tumor cell growth and/or
PT metastasis.
XX
XX Example 1; Page 16; 73pp; English.
XX The present invention describes oligonucleotides (I) of 10-15 residues
CC corresponding to a part of a vascular endothelial growth factor (VEGF)
CC comprising 1 of 6 sequences given in AAA06692 to AAA06697. AAA06698 to
CC AAA06783 represent VEGF antisense oligonucleotides used in the
CC exemplification of the present invention. The antisense oligonucleotides
CC can contain phosphorothioate linkages. Oligonucleotides from the present
CC invention have cytostatic and angiogenic activities, and can be used in
CC gene therapy. The oligonucleotides are useful for inhibiting the
CC expression of VEGF, e.g. for the treatment of diseases associated with
CC abnormal vascular permeability, cell proliferation, cell permeation,
CC angiogenesis, neovascularisation, tumour cell growth and/or metastasis.
CC AAA06784 represents a human VEGF nucleotide sequence from which the
CC oligonucleotides are derived
XX
XX Sequence 12 BP; 6 A; 2 C; 4 G; 0 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 728 GCCAGGAGAAA 738
DB 1 GACAGCAGAAA 11
RESULT 1015
AAA27583
ID AAA27583 standard; DNA; 12 BP.
XX
XX AAA27583;
XX 29-AUG-2000 (first entry)
XX
XX DNA encoding caspase-6 substrate recognition sequence.
XX
XX Protease; biosensor; caspase-6; substrate recognition sequence;
KW cell screening; assay; analysis; drug discovery; ss.
XX
XX Unidentified.
OS
XX WO200026408-A2.
XX
XX 11-MAY-2000.
XX
XX 29-OCT-1999; 99WO-US025431.
XX
XX 30-OCT-1998; 98US-0106308P.
XX 26-MAY-1999; 99US-0136078P.
XX
XX (CELL-) CELLOMICS INC.
PA

XX
PI
XX
DR WPI; 2000-365644/31.
DR P-PSDB; AAY79594.
XX
XX Recombinant nucleic acid encoding a protease biosensor useful for
PT fluorescence based cell and molecular biochemical assays for drug
PT discovery comprising three operably linked nucleic acid sequences.
XX
XX Claim 6; Fig 29B; 218pp; English.
XX
XX The present sequence is that of DNA encoding the substrate recognition
CC sequence (see AAY79594) of caspase-6. The DNA is used in a claimed
CC recombinant nucleic acid encoding a protease biosensor. The nucleic acid
CC (see AAY27583-43) comprises: (1) a sequence (see AAA27588-76) encoding at
CC least 1 detectable signal polypeptide; (2) a sequence (see AAA27577-611)
CC that encodes at least 1 protease recognition site, such as the present
CC sequence; and (3) a sequence (see AAA27611-26) that encodes at least 1
CC reactant target sequence. An expression vector, a genetically engineered
CC host cell and a recombinant protease biosensor are also claimed. A
CC claimed method for identifying compounds that modify protease activity in
CC a cell involves contacting a host cell that possesses the recombinant
CC protease biosensor with a test compound, and determining the protease
CC biosensor distribution in the host cell, where changes in the
CC distribution of the protease biosensor are correlated with modification
CC of protease activity by the test compound. Claimed kits for identifying
CC compounds that modify protease activity in a host cell include the
CC recombinant nucleic acid, or the recombinant protease biosensor, or the
CC vector, or the host cell. The protease biosensor is useful in high
CC content screens to detect in vivo activation of enzymatic activity, and
CC to identify specific activity based on cleavage of a known recognition
CC motif
XX
XX Sequence 12 BP; 6 A; 1 C; 3 G; 2 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 732 CGAGAAACAGA 742
DB 1 GTAGAAATAGA 11
RESULT 1016
AAA88229/c
ID AAA88229 standard; DNA; 12 BP.
XX
XX AAA88229;
XX
XX 15-DEC-2000 (first entry)
XX
XX pp32 upstream consensus sequence for an active steroid receptor #1.
XX
XX Human; pp32; chromosome 15q22.3-q23; cancer; phosphoprotein; APRIL;
KW acidic protein rich in leucine; chromosome 15q25; tumour suppressor;
KW malignant; cytostatic; gene therapy; ss.
XX
XX Homo sapiens.
OS
XX WO200045852-A1.
XX
XX 10-AUG-2000.
XX
XX 03-FEB-2000; 2000WO-US002856.
XX
XX 03-FEB-1999; 99US-0118667P.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX Pasternack GR, Bai J;
PI
XX

DR WPI; 2000-514896/46.
 XX Treatment of cancer comprising restoration of pp32 function in malignant
 PT cells.
 XX
 PS Example 3; Page 41; 90pp; English.
 XX
 CC The present invention describes a method (M1) for treating malignant
 CC cells comprising restoration of pp32 function. Also described are: (1) a
 CC method (M2) of screening to determine whether a compound is an inducer of
 CC pp32 expression comprising measuring pp32 expression by cells cultured in
 CC the presence and absence of the compound; and (2) a method (M3) of
 CC screening to determine whether a compound is an inducer of pp32 function
 CC comprising measuring protein phosphatase activity in cells cultured in
 CC the presence and absence of the compound. The methods are useful for
 CC treating cancer and for identifying agents which may be used to treat
 CC cancer. Human pp32 is a phosphoprotein which has been mapped to
 CC chromosome 15q22.3-q23. The present sequence represents a consensus
 CC sequence for an active steroid receptor found in the upstream sequence of
 CC pp32, which is used in an example from the present invention
 XX
 SQ Sequence 12 BP; 0 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 735 GAACACGACAA 745
 DB 12 GAACACGACAAA 2
 RESULT 1017
 AAH20822
 ID AAH20822 standard; DNA; 12 BP.
 AC AAH20822;
 XX
 DT 13-AUG-2001 (first entry)
 XX
 DE Complex PCR amplification type 2 primer #3.
 XX
 KW PCR primer; amplification; microarray; genotyping; mutational analysis;
 KW cytosine methylation pattern; ss.
 OS Unidentified.
 XX
 PN WO200136669-A2.
 XX
 PD 25-MAY-2001.
 XX
 PF 12-NOV-2000; 2000WO-DE003973.
 XX
 PR 12-NOV-1999; 99DE-01056203.
 PR 12-OCT-2000; 2000DE-01051714.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Berlin K;
 XX
 DR WPI; 2001-343834/36.
 XX
 PS Controlling performance of complex polymerase chain reaction
 PT amplification, useful e.g. for genotyping, using a set of many specific
 PT primers and non-specific counter-strand primers.
 XX
 PS Example 2; Page 18; 26pp; German.
 XX
 CC This invention describes a novel controllable performance method of
 CC complex polymerase chain reaction (PCR) amplifications. Firstly, PCR is
 CC carried out with at least 50 different primers (P1) of one type, PCR is
 CC complementary to one strand of sample DNA, and with a primer (or library
 CC of primers) of a second type (P2) complementary to the other strand of

CC the DNA, with P2 carrying a marker (M1). Amplicons are hybridized either
 CC to an array of oligonucleotides (ON) that hybridize to the primer used
 CC for the first step, or to its complement, or to an array of ON
 CC complementary to the primers used in PCR, and then the lengths of
 CC amplicons bound to the array are determined using a second marker (M2),
 CC different from M1, that is correlated with the length of the relevant DNA
 CC fragments. Signals from M1 and M2 are quantified at relevant positions in
 CC the ON array. The method is used in whole genomic applications, e.g. determining
 CC genotyping, mutational analysis or related applications. The method makes possible
 CC the cytosine methylation pattern of DNA. The method makes possible
 CC determination of the number and length of many different amplicons,
 CC something that is almost impossible when using two non-specific primers,
 CC as in the conventional method. AAH20756-AAH20823 represent the PCR
 CC primers used to illustrate the method of the invention
 XX
 SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGACAC 746
 DB 2 AAACAGACAC 12
 RESULT 1018
 AAF61471/c
 ID AAF61471 standard; RNA; 12 BP.
 XX
 AC AAF61471;
 XX
 DT 18-JUN-2001 (first entry)
 XX
 DE Wildtype Influenza virus C promoter-UP 3' RNA conserved region.
 XX
 KW Major histocompatibility complex restricted antigen; antitumor vaccine;
 KW MHC-restricted antigen; T cell-restricted antigen;
 KW antigen identification; promoter; ss.
 XX
 OS Influenza virus.
 XX
 PN DE19962508-A1.
 XX
 PD 29-MAR-2001.
 XX
 PF 23-DEC-1999; 99DE-01062508.
 XX
 PR 21-SEP-1999; 99DE-01045171.
 PR 26-OCT-1999; 99DE-01051543.
 XX
 XX (GSFU-) GSF FORSCHUNGSZENTRUM UMMELT & GESUNDHEIT.
 PA (ARTE-) ARTEMIS PHARM GMBH.
 XX
 PI Mautner J, Bornkamm GW, Nimmerjahn F, Hobom G;
 XX
 DR WPI; 2001-246290/26.
 XX
 PT Identifying major histocompatibility complex-restricted antigens, useful
 PT potentially in antitumor vaccines, by forming DNA bank in virus and
 PT testing for T cell stimulation.
 XX
 PS Disclosure; Col 5; 10pp; German.
 XX
 CC This invention describes a novel method for identifying major
 CC histocompatibility complex (MHC)-restricted antigens. A gene or cDNA bank
 CC is constructed from the cells or organism under test, then incorporated
 CC into a retroviral genome or, as additional RNA, into a modified influenza
 CC virus that has increased transcription, replication and/or expression
 CC rate, relative to the wild type, so as to produce viral particles (VP).
 CC VP are used to infect immortalized autologous cells that express MHC
 CC Class I and/or II molecules on the surface, so that proteins encoded by
 CC the gene bank inserts are expressed and their cleavage products exposed

CC on the cell surface. These cells are co-cultured with T cells which are
CC stimulated if the autologous cells express a T cell-restricted antigen.
CC Clones that express antigens are isolated and the antigens sequenced. The
CC products of the invention can be used for identifying antigens for
CC possible use in antitumor vaccines, but may also identify autoantigens or
CC microbial antigens. The method does not require knowledge of the
CC restricted MHC molecule, allows unlimited proliferation of target cells
CC and can identify, simultaneously, both Class I and II antigens. The
CC lymphoblastic cell lines used as target cells ensure efficient gene
CC transfer, with high level expression of the inserted gene, providing high
CC sensitivity and simple detection
XX
SQ Sequence 12 BP; 0 A; 5 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 731 AGGAGAAACAG 741
DB 12 AGCAGAGCAG 2
|||||

RESULT 1019
AB117626/c
ID AB117626 standard; DNA; 12 BP.
XX
AC AB117626;
XX
DT 22-FEB-2002 (first entry)
XX

Oligonucleotide primer SEQ ID NO 317599 for detecting SNP TSC0028132.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
PS Claim 1; SEQ ID NO 317599; 29pp + Sequence Listing; German.
XX

This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 731 AGGAGAAACAG 741
DB 12 AGCAGAGCAG 2
|||||

RESULT 1021
ABH69899/c
ID ABH69899 standard; DNA; 12 BP.
XX
AC ABH94714;
XX
DT 22-FEB-2002 (first entry)
XX

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 732 GGAGAAACAGA 742
DB 11 GGAGTAATAGA 1
|||||

RESULT 1020
ABH94714/c
ID ABH94714 standard; DNA; 12 BP.
XX
AC ABH94714;
XX
DT 22-FEB-2002 (first entry)
XX

Oligonucleotide primer SEQ ID NO 294707 for detecting SNP TSC0016233.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
PS Claim 1; SEQ ID NO 294707; 29pp + Sequence Listing; German.
XX

This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 1 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 735 GAAACAGAACCA 745
DB 11 GAAACAAAAA 1
|||||

RESULT 1021
ABH69899/c
ID ABH69899 standard; DNA; 12 BP.
XX
AC ABH94714;
XX
DT 22-FEB-2002 (first entry)
XX

Oligonucleotide primer SEQ ID NO 294707 for detecting SNP TSC0016233.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
PS Claim 1; SEQ ID NO 294707; 29pp + Sequence Listing; German.
XX

XX AC ABH69899;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 269876 for detecting SNP TSC0001913.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 269876; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAAAC 745
 DB 12 AACAAAAAAC 2
 RESULT 1022
 ABH95393
 ID ABH95393 standard; DNA; 12 BP.
 XX
 AC ABH95393;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 295386 for detecting SNP TSC0016574.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX

PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 295386; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAAAC 747
 DB 2 AAAATAACACC 12
 RESULT 1023
 AB122321
 ID AB122321 standard; DNA; 12 BP.
 XX
 AC AB122321;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 322294 for detecting SNP TSC0030783.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 322294; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
Db 2 AATCAAAACAC 12
|||||
RESULT 1024
ABH97378/c
ID ABH97378 standard; DNA; 12 BP.
XX
XX ABH97378;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 297371 for detecting SNP TSC0017549.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 297371; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
Db 11 AAACACCACAC 1
|||||
RESULT 1025
ABH98878/c
ID ABH98878 standard; DNA; 12 BP.
XX
XX ABH98878;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 298871 for detecting SNP TSC0018320.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 298871; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
 Db 12 AACAAACAC 2
 RESULT 1026
 ABH00237
 ID ABI00237 standard; DNA; 12 BP.
 AC ABI00237;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 300210 for detecting SNP TSC0018905.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 300210; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAACACAC 744
 Db 1 ATAAACACAC 11
 RESULT 1027
 ABH75522
 ID ABH75522 standard; DNA; 12 BP.
 AC ABH75522;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide primer SEQ ID NO 275513 for detecting SNP TSC0003914.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 275513; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 Db 1 AACAAACAC 11
 RESULT 1028
 ABH03349
 ID ABH03349 standard; DNA; 12 BP.
 AC ABH03349;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 303322 for detecting SNP TSC0020434.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.

```

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 303322; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 10 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 733 GAGAAACAGAA 743
XX Db 1 GAAAAACAAA 11
XX
XX RESULT 1030
XX ABI29614/c
XX ID ABI29614 standard; DNA; 12 BP.
XX AC ABI29614;
XX XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 329587 for detecting SNP TSC0035020.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 329587; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 734 AGAAACAGAAC 744
XX Db 2 AAAAAACAAAC 12
XX
XX RESULT 1029
XX ABH79106
XX ID ABH79106 standard; DNA; 12 BP.
XX AC ABH79106;
XX XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 279099 for detecting SNP TSC0006896.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

```

```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAGACGAC 744
DB 11 AAAAAACATAC 1

RESULT 1031
ABI30078/C
ID ABI30078 standard; DNA; 12 BP.
XX
AC ABI30078;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 330051 for detecting SNP TSC0035297.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 330051; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 738 ACAGAACACCG 748
DB 12 AAAAAACACCG 2

RESULT 1032
ABI07757
ID ABI07757 standard; DNA; 12 BP.
XX
AC ABI07757;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 307730 for detecting SNP TSC0022657.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 307730; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
DB 2 AAACACATAC 12

RESULT 1033
ABI07919
ID ABI07919 standard; DNA; 12 BP.
XX
AC ABI07919;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 307892 for detecting SNP TSC0022757.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
```


CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACAC 746
 DB 12 AAATACACAC 2
 |||||
 |||||

RESULT 1036
 ABI46539/c
 ID ABI46539 standard; DNA; 12 BP.
 XX
 AC ABI46539;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 346512 for detecting SNP TSC0044618.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 346512; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAAACAGA 742
 DB 11 GGTGAAGAAGA 1
 |||||
 |||||

RESULT 1037
 ABI68995/c
 ID ABI68995 standard; DNA; 12 BP.
 XX
 AC ABI68995;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 368968 for detecting SNP TSC0057362.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 368968; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACAC 746
 DB 11 AAATACACAC 1
 |||||
 |||||

RESULT 1038
 ABI69973
 ID ABI69973 standard; DNA; 12 BP.
 XX
 AC ABI69973;

XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 369946 for detecting SNP TSC0057901.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PF Claim 1; SEQ ID NO 369946; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 733 GAGAACACAGAA 743
XX Db 2 GAGAAATAGTA 12
XX
XX RESULT 1039
XX ABI56400
XX ID ABI56400 standard; DNA; 12 BP.
XX AC ABI56400;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 369946 for detecting SNP TSC0050079.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PF Claim 1; SEQ ID NO 356373; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 8 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 735 GAAACAGACA 745
XX Db 2 GAAACAGATA 12
XX
XX RESULT 1040
XX ABI57976
XX ID ABI57976 standard; DNA; 12 BP.
XX AC ABI57976;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 357949 for detecting SNP TSC0050891.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
 TT methylation status.

XX Claim 1; SEQ ID NO 357949; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746

Db 1 ACACAAACAC 11

RESULT 1041

ABI61268/C

ID ABI61268 standard; DNA; 12 BP.

XX AC ABI61268;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 361241 for detecting SNP TSC0052515.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 361241; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746

Db 12 AACACAAAC 2

RESULT 1042

ABI76796

ID ABI76796 standard; DNA; 12 BP.

XX AC ABI76796;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 376769 for detecting SNP TSC0010247.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 376769; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746

|||||

XX PA (EPIG-) EPIGENOMICS AG.
 XX PT Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 293675; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACC 747
 Db 11 AACAAACACC 1
 RESULT 1046
 ABH94122/c
 ID ABH94122 standard; DNA; 12 BP.
 XX AC ABH94122;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 294115 for detecting SNP TSC0015962.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 294115; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACC 747
 Db 11 AACAAACACC 1
 RESULT 1047
 ABH70233
 ID ABH70233 standard; DNA; 12 BP.
 XX AC ABH70233;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 270210 for detecting SNP TSC0002047.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 270210; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ

SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGACAC 747
D 2 ATCAACAC 12
RESULT 1048
ABH70846
ID ABH70846 standard; DNA; 12 BP.
XX AC ABH70846;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 270823 for detecting SNP TSC0002290.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN W0200177384-A2.
XX PD 18-OCT-2001.
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 270823 for detecting SNP TSC0002290.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN W0200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 270823; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACAGACAC 746
D 2 AACACACAC 12
RESULT 1049
ABH71165

ID ABH71165 standard; DNA; 12 BP.
XX AC ABH71165;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 271142 for detecting SNP TSC0002409.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN W0200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 271142; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 4 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACAGACAC 746
D 1 AAACACACAC 11
RESULT 1050
ABH96584
ID ABH96584 standard; DNA; 12 BP.
XX AC ABH96584;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 296577 for detecting SNP TSC0017153.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

```

XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 296577; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 736 AACAGAACAC 746
Db 2 AACACAAAC 12
|||||
RESULT 1051
ABI23586/C
ID ABI23586 standard; DNA; 12 BP.
XX AC ABI23586;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 323559 for detecting SNP TSC0031445.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 324499; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 736 AACAGAACAC 746
Db 2 AACACAAAC 12
|||||
RESULT 1052
ABI24526/C
ID ABI24526 standard; DNA; 12 BP.
XX AC ABI24526;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 324499 for detecting SNP TSC0032058.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 324499; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 737 AACAGAACAC 747
Db 11 AAAAAAACAC 1
|||||
RESULT 1052
ABI24526/C
ID ABI24526 standard; DNA; 12 BP.
XX AC ABI24526;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 324499 for detecting SNP TSC0032058.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 324499; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

```


CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 1 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
 DB 11 GAAAAACAAAA 1

RESULT 1053
 ABI02156/C
 ID ABI02156 standard; DNA; 12 BP.
 XX AC
 XX AB102156;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 302129 for detecting SNP TSC0019815.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 302129; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
 DB 11 AAACCTAACAC 1

RESULT 1054
 ABI02367/C
 ID ABI02367 standard; DNA; 12 BP.
 XX AC
 XX AB102367;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 302340 for detecting SNP TSC0019947.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 302340; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGACAC 745
 DB 12 GAAAAAGAAAA 2

RESULT 1055
 ABI35801
 ID ABI35801 standard; DNA; 12 BP.
 XX AC
 XX AB135801;
 XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 335774 for detecting SNP TSC0039007.
 XX XX
 XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX XX
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX XX
 XX 07-APR-2000; 2000DE-01019173.
 XX XX
 XX (EPIG-) EPIGENOMICS AG.
 XX XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX XX
 XX WPI; 2001-657177/75.
 XX XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX XX
 XX Claim 1; SEQ ID NO 335774; 29pp + Sequence Listing; German.
 XX XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX Sequence 12 BP; 8 A; 3 C; 1 G; 0 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 738 ACAGAACCCG 748
 XX DB 1 ACAAAACCCG 11
 XX
 XX RESULT 1056
 XX ABI12030
 XX ID ABI12030 standard; DNA; 12 BP.
 XX AC
 XX AB112030;
 XX XX
 XX 22-FEB-2002 (first entry)
 XX XX
 XX Oligonucleotide primer SEQ ID NO 312003 for detecting SNP TSC0024799.
 XX DE
 XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX XX
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX

PF 06-APR-2001; 2001WO-IB000713.
 XX XX
 XX 07-APR-2000; 2000DE-01019173.
 XX XX
 XX (EPIG-) EPIGENOMICS AG.
 XX XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX XX
 XX WPI; 2001-657177/75.
 XX XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX XX
 XX Claim 1; SEQ ID NO 312003; 29pp + Sequence Listing; German.
 XX XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX Sequence 12 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 734 AGAACACGAC 744
 XX DB 1 ATAAACACGAC 11
 XX
 XX RESULT 1057
 XX ABI45744/C
 XX ID ABI45744 standard; DNA; 12 BP.
 XX AC
 XX AB145744;
 XX XX
 XX 22-FEB-2002 (first entry)
 XX XX
 XX Oligonucleotide primer SEQ ID NO 345717 for detecting SNP TSC0044157.
 XX DE
 XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX XX
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX XX
 XX 07-APR-2000; 2000DE-01019173.
 XX XX
 XX (EPIG-) EPIGENOMICS AG.
 XX XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX XX
 XX WPI; 2001-657177/75.
 XX XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX XX

XX Claim 1; SEQ ID NO 34517; 29pp + Sequence Listing; German.
PS
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 1 G; 9 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 735 GAAACAGAAC 745
Db 12 GAAATAAAC 2
RESULT 1058
ABI56179
ID ABI56179 standard; DNA; 12 BP.
AC ABI56179;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 356152 for detecting SNP TSC0049982.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 356152; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 734 AGAAACAGAAC 744
Db 1 ATAAACAAAC 11
RESULT 1059
ABI71623/c
ID ABI71623 standard; DNA; 12 BP.
AC ABI71623;
XX
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 371596 for detecting SNP TSC0058880.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 371596; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGAACAC 747
Db 11 AACCTAACAC 1

RESULT 1060
 AB160839
 ID AB160839 standard; DNA; 12 BP.
 XX
 AC AB160839;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 360812 for detecting SNP TSC0052304.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 360812; 29pp + Sequence Listing; German.
 XX
 This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -AB099989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAACAGAAC 744
 Db 2 ATAAACATAAC 12
 RESULT 1061
 AB118875/C
 ID AB118875 standard; DNA; 12 BP.
 XX
 AC AB118875;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 318848 for detecting SNP TSC0028921.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 318848; 29pp + Sequence Listing; German.
 XX
 This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -AB099989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACCC 747
 Db 12 AATCGAACACC 2
 RESULT 1062
 ABH69811
 ID ABH69811 standard; DNA; 12 BP.
 XX
 AC ABH69811;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 269788 for detecting SNP TSC0001884.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.


```

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
DB 2 AACACACCCC 12
|||||
RESULT 1065
ABH75639/c
ID ABH98926 standard; DNA; 12 BP.
XX
AC ABH98926;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 298919 for detecting SNP TSC0018346.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 298919; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
DB 12 AACACACACC 2
|||||
RESULT 1066
ABH75639/c
ID ABH75639 standard; DNA; 12 BP.
XX
AC ABH75639;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275702 for detecting SNP TSC0003971.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 275630; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAARACAGAAC 744
DB 11 ATAAACAAAC 1
|||||
RESULT 1067
ABH75709
ID ABH75709 standard; DNA; 12 BP.
XX
AC ABH75709;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275702 for detecting SNP TSC0003971.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.

```

XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 275702; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
CC
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACAGAACAC 746
DB 2 AACAAATCAC 12
|||||
RESULT 1068
ABH77101/C
ID ABH77101 standard; DNA; 12 BP.
XX
XX ABH77101;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 277094 for detecting SNP TSC0004382.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 275702; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACAGAACAC 746
DB 2 AACAAATCAC 12
|||||
RESULT 1068
ABH77101/C
ID ABH77101 standard; DNA; 12 BP.
XX
XX ABH77101;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 277094 for detecting SNP TSC0004382.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 275702; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACAGAACAC 746
DB 11 AAAAAAACAC 1
|||||
RESULT 1069
ABH77342
ID ABH77342 standard; DNA; 12 BP.
XX
XX ABH77342;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 277335 for detecting SNP TSC0004442.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 277335; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 277094; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
CC
CC Query Match 35.5%; Score 7.8; DB 1; Length 12;
CC Best Local Similarity 81.8%; Pred. No. 6.8e+02;
CC Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACAGAACAC 746
DB 11 AAAAAAACAC 1
|||||
RESULT 1069
ABH77342
ID ABH77342 standard; DNA; 12 BP.
XX
XX ABH77342;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 277335 for detecting SNP TSC0004442.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 277335; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
 DB 1 AACTAAACACC 11
 ||| |||||

RESULT 1070
 ABH78437
 ID ABH78437 standard; DNA; 12 BP.
 XX AC ABH78437;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 278430 for detecting SNP TSC0006002.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 278430; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743

DB 2 GATAAACACAA 12
 ||| ||||| ||
 RESULT 1071
 AB129767/C
 ID AB129767 standard; DNA; 12 BP.
 XX AC AB129767;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 329740 for detecting SNP TSC0035122.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 329740; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGAACAA 745
 DB 12 GAAACAGAAAA 2
 ||| |||||

RESULT 1072
 AB131517
 ID AB131517 standard; DNA; 12 BP.
 XX AC AB131517;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 331490 for detecting SNP TSC0036272.


```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 331490; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACAGAACAC 746
Db 2 ATACACAAACAC 12
RESULT 1073
ABH81430/C
ID ABH81430 standard; DNA; 12 BP.
XX
XX ABH81430;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 281423 for detecting SNP TSC0009740.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
```

```
PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 281423; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACAGAACAC 746
Db 11 ATACACAAACAC 1
RESULT 1074
ABH84641/C
ID ABH84641 standard; DNA; 12 BP.
XX
XX ABH84641;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 284634 for detecting SNP TSC0011911.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 284634; 29pp + Sequence Listing; German.
PS
```

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACACAGAACAC 746
Db 12 AACCAAAACAC 2

RESULT 1075
ABI10189/C
ID ABI10189 standard; DNA; 12 BP.
AC ABI10189;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 310162 for detecting SNP TSC0023842.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 310162; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 735 GAAACAGAACAC 745
Db 11 GAAAAACACAC 1

RESULT 1076
ABI11030
ID ABI11030 standard; DNA; 12 BP.
XX AC ABI11030;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 311003 for detecting SNP TSC0024262.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 311003; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACACAGAACAC 747
Db 2 AATATAACAC 12

RESULT 1077

XX DR WPI; 2001-657177/75.
 XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 339630; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX CC Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 735 GAAACAGAACCA 745
 DB 12 GTAACAGAACCA 2
 |||||
 RESULT 1080
 ABH91152
 ID ABH91152 standard; DNA; 12 BP.
 AC ABH91152;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 291145 for detecting SNP TSC0014659.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 291145; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX CC Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX CC Sequence 12 BP; 5 A; 0 C; 6 G; 1 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 731 AGGAGAGAGAG 741
 DB 2 AGGAGAGAGAG 12
 |||||
 RESULT 1081
 ABI41426/C
 ID ABI41426 standard; DNA; 12 BP.
 AC ABI41426;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 341399 for detecting SNP TSC0042021.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 341399; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX CC Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 Db 12 ATACATAACAC 2

RESULT 1082
 ABH16969/C
 ID ABH16969 standard; DNA; 12 BP.
 AC ABH16969;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 316942 for detecting SNP TSC0027702.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 316942; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 Db 12 AAACATAAACAC 2

RESULT 1083
 ABH67263/C
 ID ABH67263 standard; DNA; 12 BP.
 XX
 XX
 AC ABH67263;
 XX

DT 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 267240 for detecting SNP TSC0000063.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 267240; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 Db 11 AAACATAAACAC 1

RESULT 1084
 ABH42846
 ID ABH42846 standard; DNA; 12 BP.
 XX
 XX ABH42846;
 XX
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 342819 for detecting SNP TSC0005871.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.

```

XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX PR
XX PA
XX (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR
XX WIPI; 2001-657177/75.
XX PT
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PT
XX Claim 1; SEQ ID NO 342819; 29pp + Sequence Listing; German.
XX PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 733 GAGAAACAGAA 743
XX DB ||||| |||||
XX 1 GAGATAAGAA 11
XX
XX RESULT 1085
XX ABI67458/c
XX ID ABI67458 standard; DNA; 12 BP.
XX AC ABI67458;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX Oligonucleotide primer SEQ ID NO 367431 for detecting SNP TSC00066564.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX XX
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WIPI; 2001-657177/75.
XX PT
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PT
XX

```

methylation status.

Claim 1; SEQ ID NO 367431; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF99989, ABF00010-ABH99989, ABH00010-ABH99989 and ABH00010-ABH82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

736 AACACGACAC 746
|||||
11 AACAAAATC 1

RESULT 1086
ABI68462/C
ID ABI68462 standard; DNA; 12 BP.
XX AC
XX ABI68462;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE
XX Oligonucleotide primer SEQ ID NO 368435 for detecting SNP TSC0057027.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX PN
XX 18-OCT-2001.
XX PD
XX PF 06-APR-2001; 2001WO-IB000713.
XX PP 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PT
XX Claim 1; SEQ ID NO 368435; 29pp + Sequence Listing; German.
XX PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010-
XX ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACGAAACACC 747
|||||
Db 12 AACACAAACCC 2

RESULT 1087

ABI68928/C
ID ABI68928 standard; DNA; 12 BP.
XX AC
XX ABI68928;
XX AC
XX AC
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 368901 for detecting SNP TSC0057306.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 368901; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 3 A; 2 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
|||||
Db 12 GAGAAATATAA 2

RESULT 1088

ABI57057
ID ABI57057 standard; DNA; 12 BP.

XX AC
XX ABI57057;
XX AC
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 357030 for detecting SNP TSC0050441.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 357030; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
|||||
Db 2 AGGTGAAAAAG 12

RESULT 1089

ABI72322/C
ID ABI72322 standard; DNA; 12 BP.

XX AC
XX ABI72322;
XX AC
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 372295 for detecting SNP TSC0059297.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 372295; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 1 A; 2 C; 0 G; 9 T; 0 U; 0 Other;
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 733 GAGAAACAGAA 743
 DB 12 GAGAAAAAAA 2
 RESULT 1090
 AB162385/C
 ID AB162385 standard; DNA; 12 BP.
 XX AC AB162385;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 362358 for detecting SNP TSC0053184.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 362358; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 0 A; 4 C; 1 G; 7 T; 0 U; 0 Other;
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAGACAGAA 744
 DB 12 AGAAGACAGAA 2
 RESULT 1091
 AB163323/C
 ID AB163323 standard; DNA; 12 BP.
 XX AC AB163323;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 363296 for detecting SNP TSC0053756.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 363296; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
DB 12 AACAAATACACC 2
|||||

RESULT 1092

ABI77334
ID ABI77334 standard; DNA; 12 BP.

XX AC
AC ABI77334;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 377307 for detecting SNP TSC0062255.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DB-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 377307; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACACC 746
DB 2 AACAACTACAC 12
|||||

RESULT 1093

ABI17457/c
ID ABI17457 standard; DNA; 12 BP.

XX AC
AC ABI17457;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 317430 for detecting SNP TSC0028004.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 317430; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
DB 11 AATAAAACACC 1
|||||

RESULT 1094

ABH94174/c
ID ABH94174 standard; DNA; 12 BP.

XX AC ABH94174;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 294167 for detecting SNP TSC0015981.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 294167; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT02073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 0 A; 4 C; 0 G; 8 T; 0 U; 0 Other;
 XX
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT02073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 0 A; 4 C; 0 G; 8 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX Qy 733 GAGAAACAGAA 743
 XX Db 11 GAGAGAAAGAA 1
 XX
 XX RESULT 1095
 XX ID ABH96946 standard; DNA; 12 BP.
 XX AC ABH96946;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 296939 for detecting SNP TSC0017352.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

PN WO200177384-A2.
 XX 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 296939; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT02073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX Qy 736 AAACAGAACAC 746
 XX Db 2 AAACAGAACAC 12
 XX
 XX RESULT 1096
 XX ID ABH99367 standard; DNA; 12 BP.
 XX AC ABH99367;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 299360 for detecting SNP TSC0018537.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 299360; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACGACAC 746
DB 11 AACACAAAAC 1
|||||
RESULT 1097
ABI25367/C
ID ABI25367 standard; DNA; 12 BP.
XX
AC ABI25367;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 325340 for detecting SNP TSC0032513.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 325340; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 ACAACAGAAC 744
DB 11 ACAACAAAAC 1
|||||
RESULT 1098
ABI26855/C
ID ABI26855 standard; DNA; 12 BP.
XX
AC ABI26855;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 326828 for detecting SNP TSC0033289.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 326828; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAACAGACAC 745
 DB 12 GAACATCAC 2

RESULT 1099
 ABI01762/c
 ID ABI01762 standard; DNA; 12 BP.
 AC ABI01762;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 301735 for detecting SNP TSC0019628.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 301735; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAC 744
 DB 11 ATAAACAAAC 1

RESULT 1100
 ABI03834
 ID ABI03834 standard; DNA; 12 BP.
 AC ABI03834;
 XX
 DT 22-FEB-2002 (first entry)
 XX

QY 736 AAACGACAC 746
 DB 2 AACATAAC 12

RESULT 1101
 ABI05890
 ID ABI05890 standard; DNA; 12 BP.
 XX
 AC ABI05890;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 305863 for detecting SNP TSC0021676.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX

QY 736 AAACGACAC 746
 DB 2 AACATAAC 12

RESULT 1101
 ABI05890
 ID ABI05890 standard; DNA; 12 BP.
 XX
 AC ABI05890;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 305863 for detecting SNP TSC0021676.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 305863; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 736 AAACAGAACAC 746
Db 2 AAACAAACTC 12
|||||
RESULT 1102
ABI05981/C
ID ABI05981 standard; DNA; 12 BP.
XX
XX AC ABI05981;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 305954 for detecting SNP TSC0021718.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 305954; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 736 AAACAGAACAC 746
Db 12 AAAATATACAC 2
|||||
RESULT 1103
ABH81103/C
ID ABH81103 standard; DNA; 12 BP.
XX
XX AC ABH81103;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 281096 for detecting SNP TSC0009436.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 281096; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

```

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAGACAGACAC 746
DB 11 AATACATAAAC 1

RESULT 1104
ABH81845/c
ID ABH81845 standard; DNA; 12 BP.
XX
AC ABH81845;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 281838 for detecting SNP TSC0010104.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 281838; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAAC 744
DB 12 AAAAAACACAC 2

RESULT 1105
ABH81845/c
ID ABH81845 standard; DNA; 12 BP.
XX
AC ABH81845;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 332558 for detecting SNP TSC0036990.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 332558; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB09989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAAC 744
DB 1 AAAAAACACAC 11

RESULT 1106
ABH83841
ID ABH83841 standard; DNA; 12 BP.
XX
AC ABH83841;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 283834 for detecting SNP TSC0011529.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX FT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 283934; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAAGACAC 746
 DB 1 AACAAGACAC 11
 RESULT 1107
 ABH83992/C
 ID ABH83992 standard; DNA; 12 BP.
 XX AC ABH83992;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 283985 for detecting SNP TSC0011609.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX FT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 283985; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 ACAAACAGAAC 744
 DB 12 ACAAACAGAAC 2
 RESULT 1108
 ABI09859
 ID ABI09859 standard; DNA; 12 BP.
 XX AC ABI09859;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 309832 for detecting SNP TSC0023694.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX FT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 309832; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligomers are used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACC 747
 DB 2 AACAAAAACC 12
 RESULT 1109
 ABH85351/c
 ID ABH85351 standard; DNA; 12 BP.
 XX
 AC ABH85351;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285344 for detecting SNP TSC0012249.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 285344; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACC 747
 DB 2 AACAAAAACC 12
 RESULT 1110
 ABH85351/c
 ID ABH85351 standard; DNA; 12 BP.
 XX
 AC ABH85351;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 285344 for detecting SNP TSC0012249.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 285344; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACC 747
 DB 2 AACAAAAACC 12
 RESULT 1111
 ABH89723/c
 ID ABH89723 standard; DNA; 12 BP.
 XX
 AC ABH89723;
 XX

Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAACAGAAC 744
 DB 11 ACAAAACATAAC 1
 RESULT 1110
 ABI35476/c
 ID ABI35476 standard; DNA; 12 BP.
 XX
 AC ABI35476;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 335449 for detecting SNP TSC0038833.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 335449; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 733 GAGAAACAGAA 743
 DB 11 GAGAAATAGTA 1
 RESULT 1111
 ABH89723/c
 ID ABH89723 standard; DNA; 12 BP.
 XX
 AC ABH89723;
 XX

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 346679; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. NO. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743

Db 12 GCGAATAGAA 2

RESULT 1114

ABI49128/C
ID ABI49128 standard; DNA; 12 BP.

XX AC ABI49128;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 349101 for detecting SNP TSC0045912.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 349101; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. NO. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACAC 747

Db 11 AACAAATACC 1

RESULT 1115

ABI49581/C
ID ABI49581 standard; DNA; 12 BP.

XX AC ABI49581;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 349554 for detecting SNP TSC0046211.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 349554; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. NO. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACAC 746

Db 11 AACAAATACC 1

Db 11 ATACACACAC 1

RESULT 1116
ABI52144/C
ID ABI52144 standard; DNA; 12 BP.
XX
AC ABI52144;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 352117 for detecting SNP TSC0047677.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 367669; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Claim 1; SEQ ID NO 352117; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 737 AACGACACAC 747
XX 12 ACCAAACACAC 2
XX
RESULT 1117
ABI67696
ID ABI67696 standard; DNA; 12 BP.
XX
AC ABI67696;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367669 for detecting SNP TSC0056475.
XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 367669; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 732 GCAGAAACAGA 742
XX 1 GCAGAAATAGA 11
XX
RESULT 1118
ABI55064
ID ABI55064 standard; DNA; 12 BP.
XX
XX ABI55064;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 355037 for detecting SNP TSC0000340.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 35037; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGAACAC 746
 DB 1 AAACAATCAC 11
 RESULT 1119
 ABI60846/C
 ID ABI60846 standard; DNA; 12 BP.
 XX
 XX ABI60846;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 360819 for detecting SNP TSC0052306.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 360819; 29pp + Sequence Listing; German.
 PS
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 733 GAGAAACAGAA 743
 DB 12 GAGAAAGAGTA 2
 RESULT 1120
 ABH67704
 ID ABH67704 standard; DNA; 12 BP.
 XX
 XX ABH67704;
 AC
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 267681 for detecting SNP TSC0000442.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 267681; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX

SQ Sequence 12 BP; 10 A; 2 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAC 744
 Db 2 AAAAAACAC 12
 |||||
 |||||

RESULT 1121
 ABH68620
 ID ABH68620 standard; DNA; 12 BP.
 AC
 XX
 AC ABH68620;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 XX
 DE Oligonucleotide primer SEQ ID NO 317872 for detecting SNP TSC0028313.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 317872 for detecting SNP TSC0028313.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 06-APR-2001; 2001WO-IB000713.
 XX
 DE 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 317872; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 PS Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AATCATATAC 11
 Db 1 AATCATATAC 11
 |||||
 |||||

RESULT 1122
 ABH68620

ID ABH68620 standard; DNA; 12 BP.
 XX
 AC ABH68620;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 XX
 DE Oligonucleotide primer SEQ ID NO 268597 for detecting SNP TSC0001243.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DT 06-APR-2001; 2001WO-IB000713.
 XX
 DE 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 268597; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 PS Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAC 744
 Db 2 AAAAAACAC 12
 |||||
 |||||

RESULT 1123
 ABH68620
 ID ABH68620 standard; DNA; 12 BP.
 AC
 XX
 AC ABH68620;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 XX
 DE Oligonucleotide primer SEQ ID NO 319079 for detecting SNP TSC0029059.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 319079; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 1 C; 1 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 735 GAAACACAGCA 745
XX Db 12 GAAACAAAATA 2
XX
XX RESULT 1124
XX AB119218
XX ID AB119218 standard; DNA; 12 BP.
XX AC AB119218;
XX XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 319191 for detecting SNP TSC0029111.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX

DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 319191; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 0 C; 6 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 731 AGGAGAACAG 741
XX Db 1 AGGAGAGTAG 11
XX
XX RESULT 1125
XX ABH95505
XX ID ABH95505 standard; DNA; 12 BP.
XX AC ABH95505;
XX XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 295498 for detecting SNP TSC0016614.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 295498; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAGACAGAAC 744
 Db 1 ACAACATATC 11
 RESULT 1126
 ABH73050
 ID ABH73050 standard; DNA; 12 BP.
 AC ABH73050;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 273035 for detecting SNP TSC0003023.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 273035; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGACACC 747
 Db 2 AACACACACC 12
 RESULT 1128
 ABH98296
 ID ABH98296 standard; DNA; 12 BP.
 AC ABH98296;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 298289 for detecting SNP TSC0018011.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 298289; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGACACC 747
 Db 2 AACACACACC 12
 RESULT 1128
 ABH98427/c
 ID ABH98427 standard; DNA; 12 BP.
 AC ABH98427;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 298289 for detecting SNP TSC0018011.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 298289; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGACACC 747
 Db 2 AACACACACC 12
 RESULT 1128
 ABH98427/c
 ID ABH98427 standard; DNA; 12 BP.
 AC ABH98427;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 298289 for detecting SNP TSC0018011.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 298289; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGACACC 747
 Db 2 AACACACACC 12
 RESULT 1128
 ABH98296
 ID ABH98296 standard; DNA; 12 BP.
 AC ABH98296;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 298289 for detecting SNP TSC0018011.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 298289; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX PS Claim 1; SEQ ID NO 276531; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AAGACAGAACAC 746
Db 1 AAGACCAACAC 11
RESULT 1131
ABH77615/C
XX ID ABH77615 standard; DNA; 12 BP.
XX AC ABH77615;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 277608 for detecting SNP TSC0004523.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 277608; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 733 GAGAAACAGAA 743
Db 11 GAGGAGAGAA 1
RESULT 1132
ABI03493/C
XX ID ABI03493 standard; DNA; 12 BP.
XX AC ABI03493;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 303466 for detecting SNP TSC0020490.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 303466; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 1 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 735 GAAACAGAAACA 745
Db 12 GAAACATAATA 2

XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 305113; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 731 AGGAGAAACAG 741
XX ||||| |||||
XX 11 AGGATAAGAG 1
XX
XX RESULT 1136
XX ABH81597
XX ID ABH81597 standard; DNA; 12 BP.
XX AC ABH81597;
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 281590 for detecting SNP TSC0009913.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 281590; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 4 C; 1 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 738 ACAGAACACCG 748
XX ||||| |||||
XX 1 AAACACACCG 11
XX
XX RESULT 1137
XX ABI31926
XX ID ABI31926 standard; DNA; 12 BP.
XX AC ABI31926;
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 331899 for detecting SNP TSC0036566.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 331899; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AAACAGAACAC 746

Db 2 AAACCTTAACAC 12

RESULT 1138

ABH82802/C

ID ABH82802 standard; DNA; 12 BP.

XX XX

AC ABH82802;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 282795 for detecting SNP TSC0011001.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 282795; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AAACAGAACAC 746

Db 12 AAACCAACAC 2

RESULT 1139

AB133250/C

ID AB133250 standard; DNA; 12 BP.

XX XX

AC AB133250;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 333223 for detecting SNP TSC0037427.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 333223; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AAACAGAACAC 746

Db 12 AAACATAATAC 2

RESULT 1140

AB109315/C

ID AB109315 standard; DNA; 12 BP.

XX AC

XX AB109315;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 309288 for detecting SNP TSC0023461.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

XX PN

XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 309288; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABJ00010-ABJ82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAGAACAC 746
 DB 11 AACACCAACAC 1
 RESULT 1141
 ABH84745/C
 ID ABH84745 standard; DNA; 12 BP.
 XX AC ABH84745;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 284738 for detecting SNP TSC0011971.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 284738; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABJ00010-ABJ82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAGAACAC 747
 DB 12 AATTAACAC 2
 RESULT 1142
 ABH13398/C
 ID ABH13398 standard; DNA; 12 BP.
 XX AC ABH13398;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 313371 for detecting SNP TSC0025704.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 313371; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 746
 DB 12 AACATACAC 2
 RESULT 1143
 ABH89743/C
 ID ABH89743 standard; DNA; 12 BP.
 XX
 AC ABH89743;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 288736 for detecting SNP TSC0013650.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 288736; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 746

DB 12 AACATACAC 2
 RESULT 1144
 ABH89349
 ID ABH89349 standard; DNA; 12 BP.
 XX
 AC ABH89349;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 289342 for detecting SNP TSC0013898.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 289342; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 733 GAGAACACAGAA 743
 DB 1 GAAAGAGAGAA 11
 RESULT 1145
 ABI15497/c
 ID ABI15497 standard; DNA; 12 BP.
 XX
 AC ABI15497;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 315470 for detecting SNP TSC0026928.

```

XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 315470; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 0 A; 2 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 735 GAACACGACCA 745
XX Db 12 GAACCGACCA 2
XX
XX RESULT 1146
XX ABI48367/C
XX ID ABI48367 standard; DNA; 12 BP.
XX
XX AC ABI48367;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 348340 for detecting SNP TSC0008611.
XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX

```

```

PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 348340; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AAACAGACAC 746
XX Db 12 AAACATAATAC 2
XX
XX RESULT 1147
XX ABI50627/C
XX ID ABI50627 standard; DNA; 12 BP.
XX
XX AC ABI50627;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 350600 for detecting SNP TSC0046773.
XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 350600; 29pp + Sequence Listing; German.
XX

```

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACGAGACACC 747
Db 11 AACCAATCACC 1
|||||

RESULT 1148
ABI68733/C
ID ABI68739 standard; DNA; 12 BP.
XX AC ABI68739;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 368712 for detecting SNP TSC0057176.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 368712; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 CGAGAAACAGA 742
Db 12 CGAGAAATGGA 2
|||||

RESULT 1149
ABI58123/C
ID ABI58123 standard; DNA; 12 BP.
XX AC ABI58123;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 358096 for detecting SNP TSC0050951.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 358096; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGAACCA 745
Db 12 GAAACAGAAA 2
|||||

RESULT 1150


```

ABI72256
ID ABI72256 standard; DNA; 12 BP.
XX
AC ABI72256;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 372229 for detecting SNP TSC0000966.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 374009; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 736 AAACAGAACAC 746
DB 2 AAATTAACAC 12
XX
XX RESULT 1151
XX ABI74036/c
XX ID ABI74036 standard; DNA; 12 BP.
XX
XX AC ABI74036;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 374009 for detecting SNP TSC00060448.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 372229; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 736 AAACAGAACAC 746
DB 2 AAATTAACAC 12
XX
XX RESULT 1151
XX ABI74036/c
XX ID ABI74036 standard; DNA; 12 BP.
XX
XX AC ABI74036;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 374009 for detecting SNP TSC00060448.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;

```

XX DR WPI; 2001-657177/75.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 PT acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 PT and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX PS Claim 1; SEQ ID NO 268837; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX PS Sequence 12 BP; 7 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
 XX CC Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 732 GGAGAAACAGA 742
 DB 2 GGAAACAGA 12
 |||||
 |||||
 RESULT 1153
 ABH94151
 ID ABH94151 standard; DNA; 12 BP.
 XX AC ABH94151;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 294144 for detecting SNP TSC0015973.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A. Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 294144; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX PS Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 XX CC Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 DB 1 AACATAACAC 11
 |||||
 |||||
 RESULT 1154
 ABH94621/C
 ID ABH94621 standard; DNA; 12 BP.
 XX AC ABH94621;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 294614 for detecting SNP TSC0016206.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A. Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 294614; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX PS Sequence 12 BP; 0 A; 2 C; 2 G; 8 T; 0 U; 0 Other;
 XX CC Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 7 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 733 GAGAAACAGAA 743
 |||||
 Db 1 GAGAGAGAGAA 11

RESULT 1160
 ABH73248/C
 ID ABH73248 standard; DNA; 12 BP.
 XX AC ABH73248;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 273233 for detecting SNP TSC0003098.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 273233; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 734 AGAAACAGAAC 744
 |||||
 Db 11 AAAAACAACAAAC 1

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAAACAGAAC 744
 |||||
 Db 11 AAAAACAACAAAC 1

RESULT 1161
 ABH73280/C
 ID ABH73280 standard; DNA; 12 BP.
 XX AC ABH73280;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 273265 for detecting SNP TSC0003118.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 273265; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AAACAGACAC 746
 |||||
 Db 11 AAACAAATCAC 1

RESULT 1162
 AB123336
 ID AB123336 standard; DNA; 12 BP.

XX AC AB123336;
 XX DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 323309 for detecting SNP TSC0031323.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 273398; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 732 GGAGAAACAGA 742
 DB 1 GGAGAAACAGA 11
 RESULT 1163
 ABH73413/C
 ID ABH73413 standard; DNA; 12 BP.
 AC ABH73413;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 273398 for detecting SNP TSC0003169.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 273398; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 736 AAACAGAACAC 746
 DB 12 AAACAGAACAC 2
 RESULT 1164
 ABH98987
 ID ABH98987 standard; DNA; 12 BP.
 AC ABH98987;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 298980 for detecting SNP TSC0018381.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT Claim 1; SEQ ID NO 298980; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746
 Db 1 AACACAAATC 11
 ||||| |||||

RESULT 1165
 ABH74242/C
 ID ABH74242 standard; DNA; 12 BP.
 AC ABH74242;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 274227 for detecting SNP TSC0003485.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 274227; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACACAGAACAC 747
 Db 11 AACAAATCACC 1
 ||||| |||||

RESULT 1167
 ABI25571/C
 ID ABI25571 standard; DNA; 12 BP.

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGAACAC 745
 Db 12 GAAACTAACA 2
 ||||| |||||

RESULT 1166
 ABH74441/C
 ID ABH74441 standard; DNA; 12 BP.
 AC ABH74441;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 274426 for detecting SNP TSC0003542.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 274426; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACACAGAACAC 747
 Db 11 AACAAATCACC 1
 ||||| |||||

RESULT 1167
 ABI25571/C
 ID ABI25571 standard; DNA; 12 BP.

```
XX AC ABI25571;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 325544 for detecting SNP TSC0032598.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 325544; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AAACGAGACAC 746
Db 12 AAACAAACCC 2
RESULT 1168
ABH75743
ID ABH75743 standard; DNA; 12 BP.
XX AC ABH75743;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 275736 for detecting SNP TSC0033981.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
```

```
PN WO200177384-A2.
XX 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 275736; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AAACGAGACAC 746
Db 2 AAACAAACCC 12
RESULT 1169
ABI01324/c
ID ABI01324 standard; DNA; 12 BP.
XX AC ABI01324;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 301297 for detecting SNP TSC0019438.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
```


XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 301297; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 736 AACACAGAAC 746
XX 11 AACATATAAAC 1
XX
XX RESULT 1170
XX ABI02443
XX ID ABI02443 standard; DNA; 12 BP.
XX AC ABI02443;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 302416 for detecting SNP TSC0019990.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 302416; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 734 AGAAACAGAAC 744
XX 1 AAAACACACAC 11
XX
XX RESULT 1171
XX ABI03120
XX ID ABI03120 standard; DNA; 12 BP.
XX AC ABI03120;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 303093 for detecting SNP TSC0020318.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 303093; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 3 C; 1 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746
 |||||
 Db 1 AACACGTAAACAC 11

RESULT 1172
 ABI29661/c
 ID ABI29661 standard; DNA; 12 BP.
 XX
 AC ABI29661;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 329634 for detecting SNP TSC0035052.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 329634; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
 XX
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746
 |||||
 Db 12 AACACAAATAC 2

RESULT 1173
 ABI06318
 ID ABI06318 standard; DNA; 12 BP.
 XX
 AC ABI06318;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide primer SEQ ID NO 306291 for detecting SNP TSC0021928.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 306291; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
 XX
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACACAGAACAC 747
 |||||
 Db 1 AACAAAAAACAC 11

RESULT 1174
 ABI07219
 ID ABI07219 standard; DNA; 12 BP.
 XX
 AC ABI07219;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 307192 for detecting SNP TSC0022381.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 307192; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 734 AGAACAGAAC 744
XX | | | | |
XX 2 ATAAACAAAC 12
XX
XX RESULT 1175
XX ABH82668
XX ID ABH82668 standard; DNA; 12 BP.
XX AC ABH82668;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 282661 for detecting SNP TSC0010937.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 282661; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 735 AAACAGAACAC 746
XX | | | | |
XX 2 AAACATATAC 12
XX
XX Db
XX
XX RESULT 1176
XX ABI09948/c
XX ID ABI09948 standard; DNA; 12 BP.
XX AC ABI09948;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 309921 for detecting SNP TSC0023735.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 309921; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at

```

CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
Db 12 AACACAAACACC 2
    ||||| |||||
    ||||| |||||

RESULT 1178
ABH86977
ID ABH86977 standard; DNA; 12 BP.
XX
AC ABH86977;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 337350 for detecting SNP TSC0039831.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB0000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PWPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 337350; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 0 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
Db 1 GAGAAACAGAA 11
    ||||| |||||
    ||||| |||||

RESULT 1179
ABH13567/c
ID ABH13567 standard; DNA; 12 BP.
XX
AC ABH13567;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 313540 for detecting SNP TSC0035831.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
KW

```


CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
 Db 11 AAGAGAAATAG 1
 |||||
 |||||

RESULT 1182
 ABI15116/C
 ID ABI15116 standard; DNA; 12 BP.
 AC ABI15116;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 315089 for detecting SNP TSC0026713.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 315089; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 0 A; 1 C; 1 G; 10 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGAACCA 745
 Db 12 GAAAAAACA 2
 |||||
 |||||

RESULT 1183
 ABI48138
 ID ABI48138 standard; DNA; 12 BP.
 AC ABI48138;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 348111 for detecting SNP TSC0045447.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 348111; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 Db 1 AAACCAACAC 11
 |||||
 |||||

RESULT 1184
 ABI50150
 ID ABI50150 standard; DNA; 12 BP.
 XX
 AC ABI50150;

```
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 350123 for detecting SNP TSC0046517.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX FN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 350123; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 9 A; 2 C; 1 G; 0 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 735 GAAACAGACACA 745
XX Db ||||| |||
XX 2 GAAACAAAAA 12
XX RESULT 1185
XX ABI51368/C
XX ID ABI51368 standard; DNA; 12 BP.
XX AC ABI51368;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 351341 for detecting SNP TSC0047238.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX FN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 351341; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 735 GAAACAGACACA 745
XX Db ||||| |||
XX 2 GAAACAAAAA 12
XX RESULT 1186
XX ABI54086
XX ID ABI54086 standard; DNA; 12 BP.
XX AC ABI54086;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 354059 for detecting SNP TSC0048875.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX FN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
```

```
PD 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 351341; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 733 GAGAAACAGACA 743
XX Db ||||| |||
XX 12 GAAATAGAA 2
XX RESULT 1186
XX ABI54086
XX ID ABI54086 standard; DNA; 12 BP.
XX AC ABI54086;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 354059 for detecting SNP TSC0048875.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX FN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 354059; 29pp + Sequence Listing; German.

XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACACAGACAC 746

Db 2 AACACACAC 12

RESULT 1187

ABI68359

ID ABI68359 standard; DNA; 12 BP.

AC ABI68359;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 368332 for detecting SNP TSC0056931.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 368332; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACACAGACAC 746

Db 2 AACACACAC 12

RESULT 1188

ABI58539

ID ABI58539 standard; DNA; 12 BP.

AC ABI58539;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 358512 for detecting SNP TSC0051167.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 358512; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AACACAGACAC 744

Db 2 AAAAAACAAAC 12

RESULT 1189
ABI72502
ID ABI72502 standard; DNA; 12 BP.

XX
AC ABI72502;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 372475 for detecting SNP TSC0059414.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 372475; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACAGAACACC 747
Db 1 ACCATAACACC 11
||| |||||
||| |||||

RESULT 1190
ABI58927/C
ID ABI58927 standard; DNA; 12 BP.
XX
AC ABI58927;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 358900 for detecting SNP TSC0051372.
XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 358900; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 733 GAGAAACAGAA 743
Db 12 GAAAAAAGAA 2
||| |||||
||| |||||

RESULT 1191
ABI75454
ID ABI75454 standard; DNA; 12 BP.
XX
AC ABI75454;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 375427 for detecting SNP TSC0061244.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.

XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 375427; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 733 GAGAAACAGAA 743
DB 2 GAGAAATATAA 12
|||||
RESULT 1192
ABI75528/c
ID ABI75528 standard; DNA; 12 BP.
XX AC ABI75528;
XX XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 375501 for detecting SNP TSC0061294.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX XX
XX 18-OCT-2001.
XX XX
XX 06-APR-2001; 2001WO-IB000713.
XX XX
XX 07-APR-2000; 2000DE-01019173.
XX XX
XX (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 375501; 29pp + Sequence Listing; German.
XX PS
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 736 AAACAGAACAC 746
DB 12 AAACAGAACAC 2
|||||
RESULT 1193
ABI62507/c
ID ABI62507 standard; DNA; 12 BP.
XX AC ABI62507;
XX XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 362480 for detecting SNP TSC0053255.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX XX
XX 18-OCT-2001.
XX XX
XX 06-APR-2001; 2001WO-IB000713.
XX XX
XX 07-APR-2000; 2000DE-01019173.
XX XX
XX (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 362480; 29pp + Sequence Listing; German.
XX PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX

ID	ABI55867 standard; DNA; 12 BP.	
XX	AC	
XX	ABI55867;	
XX	22-FEB-2002 (first entry)	
DT		
XX	Oligonucleotide primer SEQ ID NO 365840 for detecting SNP TSC0055386.	
DE		
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
KW		
OS	Homo sapiens.	
XX		
XX	WO200177384-A2.	
PN		
XX	18-OCT-2001.	
PD		
XX	06-APR-2001; 2001WO-IB000713.	
PF		
XX	07-APR-2000; 2000DE-01019173.	
XX		
PR	(EPIG-) EPIGENOMICS AG.	
XX		
PA	Olek A, Piepenbrock C, Berlin K;	
PI	WPI; 2001-657177/75.	
XX		
DR	Set of oligonucleotides, useful for diagnosis and cell typing, is	
XX	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
PT		
XX		
PS	Claim 1; SEQ ID NO 365840; 29pp + Sequence Listing; German.	
XX		
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP).	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010	
CC	-ABC99989, ABT00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
XX	ftp.wipo.int/pub/published_pct_sequences	
XX		
SQ	Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;	
	Query Match 35.5%; Score 7.8; DB 1; Length 12;	
	Best Local Similarity 81.8%; Pred. No. 6.8e+02;	
	Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0	
QY	736 AAACAGACAC 746	
DB	12 AAATAAACAC 2	
RESULT 1196		
ABI66074		
ID	ABI66074 standard; DNA; 12 BP.	
DT		
XX	22-FEB-2002 (first entry)	
XX		
AC	ABI66074;	
XX		
DE	Oligonucleotide primer SEQ ID NO 366047 for detecting SNP TSC0055502.	
XX		
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX		
OS	Homo sapiens.	

XX FN WO200177384-A2.
 XX XX 18-OCT-2001.
 XX PD
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 366047; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 8 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACACGAC 744
 Db 1 ATAAACAAAC 11
 RESULT 1197
 ABH93366/C
 ID ABH93366 standard; DNA; 12 BP.
 XX AC ABH93366;
 XX XX 22-FEB-2002 (first entry)
 XX DT
 XX DE Oligonucleotide primer SEQ ID NO 293359 for detecting SNP TSC0015581.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 293359; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 8 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 293359; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
 Db 12 AAACAAACATC 2
 RESULT 1198
 ABH68684
 ID ABH68684 standard; DNA; 12 BP.
 XX AC ABH68684;
 XX XX 22-FEB-2002 (first entry)
 XX DT
 XX DE Oligonucleotide primer SEQ ID NO 268661 for detecting SNP TSC0001286.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 268661; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACAGAACACC 747
Db 1 AACACACAC 11
|||||
1 AACACACAC 11

RESULT 1199
ABI21464
ID ABI21464 standard; DNA; 12 BP.
XX
AC ABI21464;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 321437 for detecting SNP TSC0030239.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 321437; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACAGAACACC 747
Db 1 AACACACAC 11
|||||
1 AACACACAC 11

RESULT 1201
ABI23106
ID ABI23106 standard; DNA; 12 BP.
XX
AC ABI23106;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 321437 for detecting SNP TSC0030239.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 321437; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACAGAACACC 747
Db 1 AACACACAC 11
|||||
1 AACACACAC 11

RESULT 1200
ABI22137/c
ID ABI22137 standard; DNA; 12 BP.
XX
AC ABI22137;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 322110 for detecting SNP TSC0030668.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 322110; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACACACAC 745
Db 12 AACACACAC 2
|||||
12 AACACACAC 2

RESULT 1201
ABI23106
ID ABI23106 standard; DNA; 12 BP.
XX
AC ABI23106;
XX
DT 22-FEB-2002 (first entry)
XX


```
XX PS Claim 1; SEQ ID NO 275205; 29pp + Sequence Listing; German.
XX CC
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 734 AGAAACAGAAC 744
XX Db 12 AAAAAACAAAC 2
XX
XX RESULT 1204
XX ABH81321
XX ID ABH81321 standard; DNA; 12 BP.
XX AC ABH81321;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 281314 for detecting SNP TSC0009649.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 281314; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 734 AGAAACAGAAC 744
XX Db 12 AAAAAACAAAC 2
XX
XX RESULT 1204
XX ABH81321
XX ID ABH81321 standard; DNA; 12 BP.
XX AC ABH81321;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 281314 for detecting SNP TSC0009649.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 281314; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AAACAGAACAC 746
XX Db 1 ATACATAACAC 11
XX
XX RESULT 1205
XX ABI06387
XX ID ABI06387 standard; DNA; 12 BP.
XX AC ABI06387;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 306360 for detecting SNP TSC0031973.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 306360; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AAACAGAACAC 746
XX Db 1 ATACATAACAC 11
XX
```

```
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 734 AGAAACAGAAC 744
XX Db 1 AATAACAAAC 11
XX
XX RESULT 1205
XX ABI06387
XX ID ABI06387 standard; DNA; 12 BP.
XX AC ABI06387;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 306360 for detecting SNP TSC0031973.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 306360; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AAACAGAACAC 746
XX Db 1 ATACATAACAC 11
XX
```

```

RESULT 1206
ABI06563
ID ABI06563 standard; DNA; 12 BP.
XX
AC ABI06563;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306536 for detecting SNP TSC0022068.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 306536; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 2 C; 1 G; 0 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
Db 2 GAAAAACAAAA 12

RESULT 1207
ABI08091/c
ID ABI08091 standard; DNA; 12 BP.
XX
AC ABI08091;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 308064 for detecting SNP TSC0022861.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

```

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 308064; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAAC 744
Db 11 AAAAAACATAAC 1

RESULT 1208
ABI33927
ID ABI33927 standard; DNA; 12 BP.
XX
AC ABI33927;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 333900 for detecting SNP TSC0037824.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.

```



```

XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 333900; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e-02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 737 AACAGAACACC 747
XX Db 1 AACAAACCCC 11
XX
XX RESULT 1209
XX ABI37823/c
XX ID ABI37823 standard; DNA; 12 BP.
XX
XX AC ABI37823;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 337796 for detecting SNP TSC0040079.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e-02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 737 AACAGAACACC 747
XX Db 1 AACAAACCCC 11
XX
XX RESULT 1209
XX ABI37823/c
XX ID ABI37823 standard; DNA; 12 BP.
XX
XX AC ABI37823;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 337796 for detecting SNP TSC0040079.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e-02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 737 AACAGAACACC 747
XX Db 1 AACAAACCCC 11
XX
XX RESULT 1209
XX ABI37823/c
XX ID ABI37823 standard; DNA; 12 BP.
XX
XX AC ABI37823;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 337838 for detecting SNP TSC0040099.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 337796; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```

```

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e-02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 737 AACAGAACACC 747
XX Db 12 AACAAACATC 2
XX
XX RESULT 1210
XX ABI37865/c
XX ID ABI37865 standard; DNA; 12 BP.
XX
XX AC ABI37865;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 337838 for detecting SNP TSC0040099.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 337838; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX

```

```
Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
Db 12 AATAAACACC 2

RESULT 1211
ABI13546/C
ID ABI13546 standard; DNA; 12 BP.
XX
AC ABI13546;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 313519 for detecting SNP TSC0025813.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 313519; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
Db 11 AATAAACACC 1

RESULT 1212
ABI40033
ID ABI40033 standard; DNA; 12 BP.
XX
```

```
AC
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 340006 for detecting SNP TSC0041301.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 340006; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
Db 1 AACCCAACACC 11

RESULT 1213
ABI41019
ID ABI41019 standard; DNA; 12 BP.
XX
AC ABI41019;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 340992 for detecting SNP TSC0041786.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
```

XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 340992; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 733 GAGAAACAGAA 743
 DB 1 GAGAAAGTA 11
 RESULT 1214
 ABI42044/C
 ID ABI42044 standard; DNA; 12 BP.
 XX AC ABI42044;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 342017 for detecting SNP TSC0042333.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 342017; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGACAC 746
 DB 11 AAACAACACAC 1
 RESULT 1215
 AB43358
 ID ABI43358 standard; DNA; 12 BP.
 XX AC ABI43358;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 343331 for detecting SNP TSC0043003.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 343331; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACAC 747
 Db 2 AACAGAACAC 12
 RESULT 1216
 ABI48485
 ID ABI48485 standard; DNA; 12 BP.
 AC ABI48485;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 348458 for detecting SNP TSC0045601.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 348458; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 746
 Db 2 AACAGAACAC 12
 RESULT 1216
 ABI56761
 ID ABI56761 standard; DNA; 12 BP.
 AC ABI56761;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 356734 for detecting SNP TSC0050284.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 348458; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 746

Db 1 AAACACTACAC 11
 RESULT 1217
 ABI48743
 ID ABI48743 standard; DNA; 12 BP.
 AC ABI48743;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 348716 for detecting SNP TSC0045718.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 348716; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 746
 Db 1 AAATATAACAC 11
 RESULT 1218
 ABI56761
 ID ABI56761 standard; DNA; 12 BP.
 AC ABI56761;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 356734 for detecting SNP TSC0050284.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 348716; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 746
 Db 1 AAATATAACAC 11
 RESULT 1218
 ABI56761
 ID ABI56761 standard; DNA; 12 BP.
 AC ABI56761;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 356734 for detecting SNP TSC0050284.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 348716; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACAC 746

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 356734; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABIC0010-ABIC2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 0 Other;
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABIC0010-ABIC2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 0 Other;
 XX
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 733 GAGAAACAGAA 743
 Db 1 GAGAAAGTGA 11
 RESULT 1219
 ABI71030/c
 ID ABI71030 standard; DNA; 12 BP.
 XX ABI71030;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 371003 for detecting SNP TSC0058514.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 371003; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ASC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABIC0010-ABIC2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
 XX
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 736 AAACAGACAC 746
 Db 11 AAAATAACAC 1
 RESULT 1220
 ABI59260
 ID ABI59260 standard; DNA; 12 BP.
 XX ABI59260;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 359233 for detecting SNP TSC0051522.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 359233; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACGAAACAC 746
Db 2 AACACTATAC 12
|||||

RESULT 1221
ABI62103/c
ID ABI62103 standard; DNA; 12 BP.
AC ABI62103;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 362076 for detecting SNP TSC0053012.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
PN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
PR (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 362076; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACGAAACAC 746
Db 11 AAACCAACAC 1
|||||

RESULT 1222
ABI65270/c
ID ABI65270 standard; DNA; 12 BP.
XX AC ABI65270;
XX 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 365243 for detecting SNP TSC0054993.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
PN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
PR (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 365243; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACGAAACAC 746
Db 12 AAACCAACAC 2
|||||

RESULT 1223

XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 272831; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
SQ

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACAGAACACC 747
Db 1 AACCAACACC 11
|||||
1 AACCAACACC 11

RESULT 1226
ABI22970/C
ID ABI22970 standard; DNA; 12 BP.
XX
AC ABI22970;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 322943 for detecting SNP TSC0031137.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PS WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 322943; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
SQ

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAAACAGAAC 744
Db 12 ATAACATAC 2
|||||
12 ATAACATAC 2

RESULT 1227
ABH73930
ID ABH73930 standard; DNA; 12 BP.
XX
AC ABH73930;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 273915 for detecting SNP TSC0003360.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PS WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 273915; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 6 A; 4 C; 1 G; 1 T; 0 U; 0 Other;
SQ

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;


```

XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 326412; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 736 AAACAGACAC 746
DB 11 AAACATAAAC 1
RESULT 1231
ABH76862/c
ID ABH76862 standard; DNA; 12 BP.
XX AC ABH76862;
XX DI 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 276855 for detecting SNP TSC0004311.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```

```

PT methylation status.
XX Claim 1; SEQ ID NO 276955; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 733 GAGAAACAGAA 743
DB 12 GAGAAATAGGA 2
RESULT 1232
AB128082
ID AB128082 standard; DNA; 12 BP.
XX AC AB128082;
XX DI 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 328055 for detecting SNP TSC0034053.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 328055; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

```

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746
|||||
2 AAACAAAATAC 12

RESULT 1233

ABH83179
ID ABH83179 standard; DNA; 12 BP.

XX AC
XX ABH83179;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 283172 for detecting SNP TSC0011183.

XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX FN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 283172; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746
|||||
2 AAAAATAACAC 12

RESULT 1234

ABH83179
ID ABH83179 standard; DNA; 12 BP.

XX AC
XX ABH83179;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 333587 for detecting SNP TSC0037618.

XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 333587; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746
|||||
2 AAACAAAATAC 12

RESULT 1235

ABH84624/C
ID ABH84624 standard; DNA; 12 BP.

XX AC
XX ABH84624;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 284617 for detecting SNP TSC0011904.

XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 284617; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 12 BP; 0 A; 0 C; 2 G; 10 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGAACAC 746
 DB ||||| |||||
 12 AAACAAAAAC 2
 RESULT 1236
 ID ABI35866 standard; DNA; 12 BP.
 XX ABI35866;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 335839 for detecting SNP TSC0039050.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 335839; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGAACAC 746
 DB ||||| |||||
 11 AAACACAATAC 1
 RESULT 1237
 ID ABH87594/c
 XX ABH87594 standard; DNA; 12 BP.
 XX ABH87594;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 287587 for detecting SNP TSC0013164.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 287587; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
Db 11 AGTAGAAAG 1

RESULT 1238
ABI38254/C
ID ABI38254 standard; DNA; 12 BP.
XX AC ABI38254;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 338227 for detecting SNP TSC0040355.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX Claim 1; SEQ ID NO 338227; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACAC 746
Db 12 AACTAATACAC 2

RESULT 1239
ABH89924
ID ABH89924 standard; DNA; 12 BP.
XX AC ABH89924;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 289917 for detecting SNP TSC0014148.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX Claim 1; SEQ ID NO 289917; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACAC 747
Db 2 AACAAACAC 12

RESULT 1240
ABH15677
ID ABH15677 standard; DNA; 12 BP.

XX AC AB115677;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 315650 for detecting SNP TSC0027020.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WI WIPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 315650; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACAGACAC 746
 Db 2 AAAAAACACAC 12
 RESULT 1241
 AB116497/c
 ID AB116497 standard; DNA; 12 BP.
 XX AC AB116497;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 316470 for detecting SNP TSC0027461.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WI WIPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 316470; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACACAGACAC 747
 Db 11 AAAAAACAC 1
 RESULT 1242
 AB148081
 ID AB148081 standard; DNA; 12 BP.
 XX AC AB148081;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 348054 for detecting SNP TSC0045416.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WI WIPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 348054; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACACACACC 747
Db 1 AACACACACC 11
RESULT 1243
AB150311
ID AB150311 standard; DNA; 12 BP.
XX
AC AB150311;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 350284 for detecting SNP TSC0045584.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
FN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 350284; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 9 A; 2 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACACACC 746
Db 1 AAAAAAACAC 11
RESULT 1244
AB151092
ID AB151092 standard; DNA; 12 BP.
XX
AC AB151092;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 351065 for detecting SNP TSC0047050.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
FN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 351065; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
 Db 2 AAAAATACAC 12

RESULT 1245
 ABI53202
 ID ABI53202 standard; DNA; 12 BP.
 XX AC ABI53202;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 353175 for detecting SNP TSC0008584.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 353175; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
 Db 2 AAACTCACAC 12

RESULT 1246
 ABI57058/c
 ID ABI57058 standard; DNA; 12 BP.
 XX AC ABI57058;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 372908 for detecting SNP TSC0059724.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.

DE Oligonucleotide primer SEQ ID NO 357031 for detecting SNP TSC0050442.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPiG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 357031; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
 Db 12 AGGTGAAAAG 2

RESULT 1247
 ABI72935/c
 ID ABI72935 standard; DNA; 12 BP.
 XX AC ABI72935;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 372908 for detecting SNP TSC0059724.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 372908; 29pp + Sequence Listing; German.
XX XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 736 AAACAGACAC 746
Db 12 AATCATAACAC 2
|||||
RESULT 1248
ABH92402/C
ID ABH92402 standard; DNA; 12 BP.
XX AC ABH92402;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 292395 for detecting SNP TSC0015197.
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX

PS Claim 1; SEQ ID NO 292395; 29pp + Sequence Listing; German.
XX XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 0 A; 1 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 735 GAAACAGACAC 745
Db 12 GAAACAGACAC 2
|||||
RESULT 1249
ABI17866/C
ID ABI17866 standard; DNA; 12 BP.
XX AC ABI17866;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 317839 for detecting SNP TSC0028286.
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 317839; 29pp + Sequence Listing; German.
XX XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at

```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACAC 746
Db 12 AAAAAAACAC 2

RESULT 1250
ABH68546/c
ID ABH68546 standard; DNA; 12 BP.
XX
AC ABH68546;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 268523 for detecting SNP TSC0001198.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 268523; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 4 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAAACAGA 742
Db 11 GGATAAAAGA 1

RESULT 1251
ABH70569
ID ABH70569 standard; DNA; 12 BP.
XX
AC ABH70569;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 270546 for detecting SNP TSC0002178.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 270546; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACAC 747
Db 1 AACAAAAACTCC 11

RESULT 1252
ABH71401
ID ABH71401 standard; DNA; 12 BP.
XX
AC ABH71401;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 271378 for detecting SNP TSC0002486.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```


CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 DB 12 AAAATAACAC 2
 |||||
 |||||

RESULT 1255
 ABH97698/C
 ID ABH97698 standard; DNA; 12 BP.
 XX
 AC ABH97698;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 297691 for detecting SNP TSC0017702.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 297691; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 DB 12 AAAATAACAC 2
 |||||
 |||||

RESULT 1255
 ABH97698/C
 ID ABH97698 standard; DNA; 12 BP.
 XX
 AC ABH97698;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 297691 for detecting SNP TSC0017702.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 297691; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 DB 12 AAAATAACAC 2
 |||||
 |||||

RESULT 1255
 ABH74520/C
 ID ABH74520 standard; DNA; 12 BP.
 XX
 AC ABH74520;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 322780 for detecting SNP TSC0031055.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 322780; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 8 A; 3 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGAACAC 745
 DB 1 GACACAAACAC 11
 |||||
 |||||

RESULT 1257
 ABH74520/C
 ID ABH74520 standard; DNA; 12 BP.
 XX
 AC ABH74520;
 XX

```

XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 274505 for detecting SNP TSC0003574.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 274505; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 2 G; 10 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 734 AGAACAGAAC 744
XX Db 11 AAAAAACAAAC 1
XX RESULT 1258
XX ID ABH75109/c
XX ABH75109 standard; DNA; 12 BP.
XX AC ABH75109;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 275096 for detecting SNP TSC0003783.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 274505; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 2 G; 10 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 734 AGAACAGAAC 744
XX Db 11 AAAAAACAAAC 1
XX RESULT 1258
XX ID ABH75109/c
XX ABH75109 standard; DNA; 12 BP.
XX AC ABH75109;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 275096 for detecting SNP TSC0003783.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 275096; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 736 AAACAGAACAC 746
XX Db 11 AAACCAACAC 1
XX RESULT 1259
XX ID ABH101097
XX ABH101097 standard; DNA; 12 BP.
XX AC ABH101097;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 301070 for detecting SNP TSC0019335.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 301070; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746

Db 2 ACACATACAC 12

RESULT 1260

ABIO1648

ID ABI01648 standard; DNA; 12 BP.

AC ABI01648;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 301621 for detecting SNP TSC0019577.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 301621; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAC 744

Db 1 AAAAACAATAC 11

RESULT 1261

ABIO2112/C

ID ABI02112 standard; DNA; 12 BP.

XX ABI02112;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 302085 for detecting SNP TSC0019787.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 302085; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746

```

Db      11 AAAAAAACAC 1
RESULT 1262
ABI28665/c
ID      ABI28665 standard; DNA; 12 BP.
XX
XX      AC
XX      ABI28665;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 328638 for detecting SNP TSC0034432.
DE
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 328638; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
XX
XX      Query Match      35.5%; Score 7.8; DB 1; Length 12;
XX      Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX      Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX      QY      736 AAAAAAACAC 746
XX      Db      11 AAAAAAACAC 1
XX
XX      RESULT 1263
XX      ABI30226
XX      ID      ABI30226 standard; DNA; 12 BP.
XX
XX      AC
XX      ABI30226;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 330199 for detecting SNP TSC0035382.
DE
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 328638; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX      Query Match      35.5%; Score 7.8; DB 1; Length 12;
XX      Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX      Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX      QY      737 AACAGAACAC 747
XX      Db      2 AACAAAAACCC 12
XX
XX      RESULT 1264
XX      ABI06388
XX      ID      ABI06388 standard; DNA; 12 BP.
XX
XX      AC
XX      ABI06388;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide primer SEQ ID NO 306361 for detecting SNP TSC0001973.
DE
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
OS
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX

```

XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 306361; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 6 A; 3 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 5.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 736 AACACGACAC 746
 Db 1 ATACATAAC 11
 RESULT 1265
 ABI07748/C
 ID ABI07748 standard; DNA; 12 BP.
 AC ABI07748;
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 307721 for detecting SNP TSC0022653.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 307721; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 737 AACACGACAC 747
 Db 12 AACCAACAC 2
 RESULT 1266
 ABI08342
 ID ABI08342 standard; DNA; 12 BP.
 XX
 XX ABI08342;
 AC
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 308315 for detecting SNP TSC0022949.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 308315; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AAGACAGACAC 746
DB 11 AACTCAACAC 1
RESULT 1272
ABI49237/c
ID ABI49237 standard; DNA; 12 BP.
XX
XX
AC ABI49237;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 349210 for detecting SNP TSC0045997.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGNOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 349210; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 4 C; 0 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAAACAGA 742
DB 12 GGAGAAAGAA 2
RESULT 1273
ABI50288/c
ID ABI50288 standard; DNA; 12 BP.
XX
XX
AC ABI50288;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 350261 for detecting SNP TSC0046575.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGNOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 350261; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 735 GAAACAGACAC 745
DB 11 GAAACATATAA 1
RESULT 1274
ABI52148
ID ABI52148 standard; DNA; 12 BP.
XX
XX
AC ABI52148;
XX
DT 22-FEB-2002 (first entry)
XX

XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 321163; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACGACAC 746
 DB 11 AACACAAAC 1
 RESULT 1282
 ABH96220/c
 ID ABH96220 standard; DNA; 12 BP.
 AC ABH96220;
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 296213 for detecting SNP TSC0016960.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 296213; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACAC 747
 DB 12 AAAATAACAC 2
 RESULT 1283
 ABH72581/c
 ID ABH72581 standard; DNA; 12 BP.
 AC ABH72581;
 XX
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 272566 for detecting SNP TSC0002861.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 272566; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

•


```

XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 298617; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 737 AACAGAACACC 747
DB 1 AACAAATACC 11
|||||
RESULT 1287
ABI24220
ID ABI24220 standard; DNA; 12 BP.
XX AC ABI24220;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 324193 for detecting SNP TSC0031856.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 324263; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 736 AACAGAACACC 746
DB 1 AACACAAAC 11
|||||
RESULT 1288
ABI24290/c
ID ABI24290 standard; DNA; 12 BP.
XX AC ABI24290;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 324263 for detecting SNP TSC0031917.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 324263; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

```

```
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAGACAGAAC 744
Db 12 ACAAGACAGAAC 2

RESULT 1289
ABI25115
ID ABI25115 standard; DNA; 12 BP.
XX
AC ABI25115;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 325088 for detecting SNP TSC0032385.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 325088; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGACACC 747
```

```
Db 1 ACCAAACACAC 11

RESULT 1290
ABI01758/c
ID ABI01758 standard; DNA; 12 BP.
XX
AC ABI01758;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 301731 for detecting SNP TSC0019628.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 301731; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match      35.5%; Score 7.8; DB 1; Length 12;
  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGACACC 746
Db 12 AACACCAACAC 2

RESULT 1291
ABH77031/c
ID ABH77031 standard; DNA; 12 BP.
XX
AC ABH77031;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 277024 for detecting SNP TSC0004361.
```

```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
OS Homo sapiens.  
XX WO200177384-A2.  
XX 18-OCT-2001.  
XX 06-APR-2001; 2001WO-IB000713.  
XX 07-APR-2000; 2000DE-01019173.  
XX (EPIG-) EPIGENOMICS AG.  
XX Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX Claim 1; SEQ ID NO 277024; 29pp + Sequence Listing; German.  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published_pct_sequences  
XX  
XX Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;  
Query Match 35.5%; Score 7.8; DB 1; Length 12;  
Best Local Similarity 81.8%; Pred. No. 6.8e+02;  
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
OY 737 AACAGAACACC 747  
Db 12 AACAAACACC 2  
RESULT 1292  
ABH77113  
ID ABH77113 standard; DNA; 12 BP.  
XX AC ABH77113;  
XX 22-FEB-2002 (first entry)  
XX Oligonucleotide primer SEQ ID NO 277106 for detecting SNP TSC0004385.  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
OS Homo sapiens.  
XX WO200177384-A2.  
XX 18-OCT-2001.  
XX 06-APR-2001; 2001WO-IB000713.  
XX
```

```
PR 07-APR-2000; 2000DE-01019173.  
XX (EPIG-) EPIGENOMICS AG.  
XX Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX Claim 1; SEQ ID NO 277106; 29pp + Sequence Listing; German.  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published_pct_sequences  
XX  
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;  
Query Match 35.5%; Score 7.8; DB 1; Length 12;  
Best Local Similarity 81.8%; Pred. No. 6.8e+02;  
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
OY 736 AACAGAACACC 746  
Db 1 AACAAACACC 11  
RESULT 1293  
ABH77616/C  
ID ABH77616 standard; DNA; 12 BP.  
XX AC ABH77616;  
XX 22-FEB-2002 (first entry)  
XX Oligonucleotide primer SEQ ID NO 277609 for detecting SNP TSC0004523.  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
OS Homo sapiens.  
XX WO200177384-A2.  
XX 18-OCT-2001.  
XX 06-APR-2001; 2001WO-IB000713.  
XX 07-APR-2000; 2000DE-01019173.  
XX (EPIG-) EPIGENOMICS AG.  
XX Olek A, Piepenbrock C, Berlin K;  
XX WPI; 2001-657177/75.  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX Claim 1; SEQ ID NO 277609; 29pp + Sequence Listing; German.
```

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 5 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
 Db 11 GAGGAAGAGAA 1
 ||| ||| |||

RESULT 1294
 ABH78361/c
 ID ABH78361 standard; DNA; 12 BP.
 AC ABH78361;
 DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 278354 for detecting SNP TSC0005920.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 278354; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACAC 747
 Db 11 AACATACAC 1
 ||| ||| |||

RESULT 1295
 ABI05124/c
 ID ABI05124 standard; DNA; 12 BP.
 AC ABI05124;
 DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 305097 for detecting SNP TSC0021282.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 305097; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACAC 746
 Db 11 AACATACAC 1
 ||| ||| |||

RESULT 1296

```

ABI131761
ID ABI131761 standard; DNA; 12 BP.
XX
AC ABI131761;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 331734 for detecting SNP TSC0036439.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 309299; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 8 A; 3 C; 1 G; 0 T; 0 U; 0 Other;
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 734 AGAAACGAGAC 744
DB 2 AAAAACCGAAC 12
XX
RESULT 1297
ABI09326
ID ABI09326 standard; DNA; 12 BP.
XX
AC ABI09326;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 309299 for detecting SNP TSC0023469.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;

```

XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 334486; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 0 A; 2 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAACAGAAC 744
 Db 12 AAAAAAGAAC 2
 RESULT 1299
 ABH84458
 ID ABH84458 standard; DNA; 12 BP.
 AC ABH84458;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 284451 for detecting SNP TSC0011838.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 284451; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGAACAC 746
 Db 1 AAACAAACCC 11
 RESULT 1300
 ABI37162
 ID ABI37162 standard; DNA; 12 BP.
 AC ABI37162;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 337135 for detecting SNP TSC0039693.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 337135; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 737 AACAGAACAC 747
 ||||| |||||
 Db 2 AACAAACATC 12

RESULT 1301
 ABH88327
 ID ABH88327 standard; DNA; 12 BP.
 XX AC
 AC ABH88327;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 288320 for detecting SNP TSC0013464.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 FN WO200177384-A2.
 XX
 AC
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 288320 for detecting SNP TSC0013464.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 FN WO200177384-A2.
 XX
 AC
 XX
 DT 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 FA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 288320; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACAGAACAC 746
 ||||| |||||
 Db 2 AACCTAACAC 12

RESULT 1302
 ABI14362/c
 ID ABI14362 standard; DNA; 12 BP.
 XX
 AC ABI14362;
 XX

DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 314335 for detecting SNP TSC0026287.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 FN WO200177384-A2.
 XX
 AC
 XX
 DT 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 FA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 314335; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACAGAACAC 746
 ||||| |||||
 Db 12 AACATTACAC 2

RESULT 1303
 ABI14363/c
 ID ABI14363 standard; DNA; 12 BP.
 XX
 AC ABI14363;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 314336 for detecting SNP TSC0026287.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 FN WO200177384-A2.
 XX
 AC
 XX
 DT 18-OCT-2001.
 XX

XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 314336; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 2 A; 1 C; 3 G; 6 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACGACGACAC 746
DB 12 AACATTACAC 2
RESULT 1304
ABH90392/C
ID ABH90392 standard; DNA; 12 BP.
XX AC ABH90392;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 290385 for detecting SNP TSC0014330.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 316943; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGAACAC 747
DB 12 AACATACAC 2
RESULT 1305
ABI16970/C
ID ABI16970 standard; DNA; 12 BP.
XX AC ABI16970;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 316943 for detecting SNP TSC0027702.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 316943; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
DB 12 AAACATAAAC 2

RESULT 1306
ABI44222
ID ABI44222 standard; DNA; 12 BP.
XX AC ABI44222;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 344195 for detecting SNP TSC0043437.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 344195; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
DB 1 AAACATAAAC 11

RESULT 1307
ABI47912
ID ABI47912 standard; DNA; 12 BP.
XX AC ABI47912;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 347885 for detecting SNP TSC0045323.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 347885; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGACAC 745
DB 1 GAAATAGACAC 11

RESULT 1308
ABI48414
ID ABI48414 standard; DNA; 12 BP.

XX AC ABI48414;
XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 348387 for detecting SNP TSC0045573.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 348387; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGACAC 746
 Db 2 AAACATAAAC 12
 |||||
 |||||
 RESULT 1309
 ABI50966/c
 ID ABI50966 standard; DNA; 12 BP.
 AC ABI50966;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 350939 for detecting SNP TSC0046996.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 354264; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 350939; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 735 GAAACAGACCA 745
 Db 12 GCAACATAAAC 2
 |||||
 |||||
 RESULT 1310
 ABI54291
 ID ABI54291 standard; DNA; 12 BP.
 AC ABI54291;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 354264 for detecting SNP TSC0049006.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 354264; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 12 BP; 5 A; 5 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 738 ACAGAACACCG 748
 Db 1 ACAAACTCCG 11

RESULT 1311
 ABI55063
 ID ABI55063 standard; DNA; 12 BP.
 XX
 AC ABI55063;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 355036 for detecting SNP TSC0000340.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 WO200177384-A2.
 FN
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 355036; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 Db 1 AAACAAATCAC 11

RESULT 1312
 ABI71186/c
 ID ABI71186 standard; DNA; 12 BP.
 XX
 AC ABI71186;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 371159 for detecting SNP TSC0058621.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 WO200177384-A2.
 FN
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 371159; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 12 BP; 2 A; 3 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAACACGA 742
 Db 11 GGAGAAAAATA 11

RESULT 1313
 ABI71208/c
 ID ABI71208 standard; DNA; 12 BP.

```

XX AC AB171208;
XX XX
DT 22-FEB-2002 (first entry)
XX XX
DE Oligonucleotide primer SEQ ID NO 371181 for detecting SNP TSC0058636.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX XX
XX WO200177384-A2.
XX XX
PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIG-) EPIGENOMICS AG.
XX XX
PI Olek A, Piepenbrock C, Berlin K;
XX XX
DR WPI; 2001-657177/75.
XX XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX XX
PS Claim 1; SEQ ID NO 371181; 29pp + Sequence Listing; German.
XX XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 735 GAACAGACAA 745
DB 12 GAACACATACA 2
|||||
RESULT 1314
ABI58196
ID ABI58196 standard; DNA; 12 BP.
XX AC
XX ABI58196;
XX XX
DT 22-FEB-2002 (first entry)
XX XX
DE Oligonucleotide primer SEQ ID NO 358169 for detecting SNP TSC0050979.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.

```

```

PN WO200177384-A2.
XX XX
PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIG-) EPIGENOMICS AG.
XX XX
PI Olek A, Piepenbrock C, Berlin K;
XX XX
DR WPI; 2001-657177/75.
XX XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX XX
PS Claim 1; SEQ ID NO 358169; 29pp + Sequence Listing; German.
XX XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 736 AAACAGACAA 746
DB 2 AAACACATACA 12
|||||
RESULT 1315
ABI58935/c
ID ABI58935 standard; DNA; 12 BP.
XX AC
XX ABI58935;
XX XX
DT 22-FEB-2002 (first entry)
XX XX
DE Oligonucleotide primer SEQ ID NO 358908 for detecting SNP TSC0051375.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX XX
XX WO200177384-A2.
XX XX
PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIG-) EPIGENOMICS AG.
XX XX
PI Olek A, Piepenbrock C, Berlin K;
XX XX
DR WPI; 2001-657177/75.

```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 358908; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
SQ

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAGACAGAAC 744
Db 11 AAAAAGACAGAAC 1
|||||

RESULT 1316
ABI79820/C
ID ABI79820 standard; DNA; 12 BP.
XX
XX AC ABI79820;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 379793 for detecting SNP TSC0063470.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 379793; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
SQ

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGACAGACC 747
Db 11 AAACGACAGACC 1
|||||

RESULT 1317
ABH69142
ID ABH69142 standard; DNA; 12 BP.
XX
XX AC ABH69142;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 269119 for detecting SNP TSC0001616.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 269119; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
SQ

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX 07-APR-2000; 2000DE-01019173.
PR (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 271141; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 736 AACAGACAC 746
DB 1 AACAGACAC 11
XX
RESULT 1321
ABH98267
ID ABH98267 standard; DNA; 12 BP.
XX
AC ABH98267;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 298260 for detecting SNP TSC0017996.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 298260; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 737 AACAGACAC 747
DB 1 AACATATACC 11
XX
RESULT 1322
ABH75051/C
ID ABH75051 standard; DNA; 12 BP.
XX
AC ABH75051;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275038 for detecting SNP TSC0003769.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 275038; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAACACAA 743

DB 12 GACAAACATAA 2

RESULT 1323

ABI25979

ID ABI25979 standard; DNA; 12 BP.

XX AC ABI25979;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 325952 for detecting SNP TSC0032822.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PI WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 325952; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747

DB 1 AAAAAACACC 11

RESULT 1324

ABI01553
ID ABI01553 standard; DNA; 12 BP.

XX AC ABI01553;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 301526 for detecting SNP TSC0019537.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PI WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 301526; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 5 A; 7 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747

DB 1 AACAGAACACC 11

RESULT 1325

ABH76553/c

ID ABH76553 standard; DNA; 12 BP.

XX AC ABH76553;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 276546 for detecting SNP TSC0004220.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.


```

XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 276546; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGAACACC 747
DB 12 AACAAAAACCC 2
|||||
RESULT 1326
ABH76703/C
ID ABH76703 standard; DNA; 12 BP.
XX AC ABH76703;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 276596 for detecting SNP TSC0004265.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 276596; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGAACACC 747
DB 12 AACAAAAACCC 2
|||||
RESULT 1326
ABH76703/C
ID ABH76703 standard; DNA; 12 BP.
XX AC ABH76703;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 276596 for detecting SNP TSC0004265.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 276596; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGAACACC 747
DB 12 AACAAAAACCC 2
|||||
RESULT 1327
ABI07551/C
ID ABI07551 standard; DNA; 12 BP.
XX AC ABI07551;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 307524 for detecting SNP TSC0022540.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 307524; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGAACACC 747
DB 12 AACAAAAACCC 2
|||||

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 738 ACAGAACACCG 748
 DB 12 ACATAAACCG 2
 RESULT 1328
 ABH84047/C
 ID ABH84047 standard; DNA; 12 BP.
 XX
 AC ABH84047;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 284040 for detecting SNP TSC0011633.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 284040; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 0 A; 1 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAACACAGA 742
 DB 11 GGCGAATAGA 1
 RESULT 1330
 ABI09325
 ID ABI09325 standard; DNA; 12 BP.
 XX
 AC ABI09325;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAACACAGA 743
 DB 12 GACAAACAAA 2

RESULT 1329
 ABI09185/C
 ID ABI09185 standard; DNA; 12 BP.
 XX
 AC ABI09185;

XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 309158 for detecting SNP TSC0023389.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 309158; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAACACAGA 742
 DB 11 GGCGAATAGA 1

RESULT 1330
 ABI09325
 ID ABI09325 standard; DNA; 12 BP.
 XX
 AC ABI09325;

```
XX 22-FEB-2002 (first entry)
XX DT
XX DE Oligonucleotide primer SEQ ID NO 309298 for detecting SNP TSC0023469.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 309298; 29pp + Sequence Listing; German.
XX SQ
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 731 AGGAGAGACAG 741
XX DB 1 AGGAGAGAGAG 11
XX RESULT 1331
XX ABI35772/c
XX ID ABI35772 standard; DNA; 12 BP.
XX AC ABI35772;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 335745 for detecting SNP TSC0038992.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 309298; 29pp + Sequence Listing; German.
XX SQ
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 731 AGGAGAGACAG 741
XX DB 1 AGGAGAGAGAG 11
XX RESULT 1331
XX ABI35772/c
XX ID ABI35772 standard; DNA; 12 BP.
XX AC ABI35772;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 335745 for detecting SNP TSC0024345.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
```

```
PD 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 335745; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 736 AAACAGAACAC 746
XX DB 11 AAATACACAC 1
XX RESULT 1332
XX ABI11212/c
XX ID ABI11212 standard; DNA; 12 BP.
XX AC ABI11212;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide primer SEQ ID NO 311185 for detecting SNP TSC0024345.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 311185; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746

Db 11 AACACAGAACAC 1

RESULT 1333

ID ABI11567/c

ID ABI11567 standard; DNA; 12 BP.

AC ABI11567;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 311540 for detecting SNP TSC0024547.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 311540; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746

Db 11 AACACAGAACAC 1

RESULT 1334

ID ABI13745/c

ID ABI13745 standard; DNA; 12 BP.

AC ABI13745;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 313718 for detecting SNP TSC0025933.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 313718; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGAACAC 746

Db 11 AACACAGAACAC 1

Db 12 AACACACACC 2

RESULT 1335

ABH8930/c

ID ABH8930 standard; DNA; 12 BP.

XX AC ABH8930;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 288923 for detecting SNP TSC0013731.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIC-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 314630; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGACAC 746

Db 11 AACACACAC 1

RESULT 1336

ABI14657/c

ID ABI14657 standard; DNA; 12 BP.

XX AC ABI14657;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 314630 for detecting SNP TSC0026470.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

Db 12 AACACACACC 2

RESULT 1335

ABH8930/c

ID ABH8930 standard; DNA; 12 BP.

XX AC ABH8930;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 288923 for detecting SNP TSC0013731.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIC-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 288923; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGACAC 746

Db 11 AACACACAC 1

RESULT 1336

ABI14657/c

ID ABI14657 standard; DNA; 12 BP.

XX AC ABI14657;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 314630 for detecting SNP TSC0026470.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIT-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 316474; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 Db 12 AACAAACCCC 2
 RESULT 1338
 ABI47270/C
 ID ABI47270 standard; DNA; 12 BP.
 AC ABI47270;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 347243 for detecting SNP TSC0044976.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIT-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 347243; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;
 XX
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACACC 746
 Db 11 AACACAAAC 1
 RESULT 1339
 ABI47997/C
 ID ABI47997 standard; DNA; 12 BP.
 XX ABI47997;
 AC 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 347970 for detecting SNP TSC0045385.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIT-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 347970; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

ID	ABI72567 standard; DNA; 12 BP.
XX	ABI72567;
XX	22-FEB-2002 (first entry)
XX	Oligonucleotide primer SEQ ID NO 372540 for detecting SNP TSC0059450.
DE	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
KW	Homo sapiens.
OS	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	(EPIG-) EPIGENOMICS AG.
PA	Olek A, Piepenbrock C, Berlin K;
XX	WFI; 2001-657177/75.
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PT	Claim 1; SEQ ID NO 372540; 29pp + Sequence Listing; German.
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-BEF99989, ABH00010-AKH99989 and ABI00010-ABI92073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;
XX	Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX	Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX	Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	733 GAGAAACAGAA 743
DB	11 GACAAACAAA 1
DE	RESULT 1342
XX	ABI74526
ID	ABI74526 standard; DNA; 12 BP.
XX	ABI74526;
XX	22-FEB-2002 (first entry)
XX	Oligonucleotide primer SEQ ID NO 374499 for detecting SNP TSC0060741.
DE	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	Homo sapiens.
OS	

XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 374499; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACACC 747
 Db 2 AACAAATACC 12
 RESULT 1343
 ABH68976/C
 ID ABH68976 standard; DNA; 12 BP.
 XX ABH68976;
 AC ABH68976;
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 268953 for detecting SNP TSC0001515.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 294352; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACACC 747
 Db 2 AACAAATACC 12
 RESULT 1343
 ABH68976/C
 ID ABH68976 standard; DNA; 12 BP.
 XX ABH68976;
 AC ABH68976;
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 294352 for detecting SNP TSC0016077.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 294352; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 731 AGGAGAAACAG 741
 Db 12 AGGAAAAAAG 2
 RESULT 1344
 ABH94359/C
 ID ABH94359 standard; DNA; 12 BP.
 XX ABH94359;
 AC ABH94359;
 XX 22-FEB-2002 (first entry)
 DT
 DE Oligonucleotide primer SEQ ID NO 294352 for detecting SNP TSC0016077.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 294352; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AACAAGACAC 746
Db 11 AAAAAACACAC 1

RESULT 1345
ABH69746/c
ID ABH69746 standard; DNA; 12 BP.
XX
AC ABH69746;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 269723 for detecting SNP TSC0001860.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 269723; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 AGAACAGAAC 744
Db 11 AAAAAACACAC 1

RESULT 1346
ABH70048/c
ID ABH70048 standard; DNA; 12 BP.
XX
AC ABH70048;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 270025 for detecting SNP TSC0001962.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 270025; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 12 BP; 0 A; 1 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 733 GAGAAACAGAA 743
Db 12 GAAAAACAAA 2

RESULT 1347
ABH95193
ID ABH95193 standard; DNA; 12 BP.
XX
AC ABH95193;
XX
DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 295186 for detecting SNP TSC0016477.
 XX DE
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX XX (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX XX
 XX PS Claim 1; SEQ ID NO 295186; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 DB 1 AACAAAAACCC 11
 RESULT 1348
 ABH97185/c
 ID ABH97185 standard; DNA; 12 BP.
 XX AC ABH97185;
 XX XX
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 297178 for detecting SNP TSC0017472.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX

PF 06-APR-2001; 2001WO-IB000713.
 XX XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX XX (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX XX
 XX PS Claim 1; SEQ ID NO 297178; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX XX
 XX SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGAACACC 746
 DB 12 AACACAAATAC 2
 RESULT 1349
 ABH97831/c
 ID ABH97831 standard; DNA; 12 BP.
 XX AC ABH97831;
 XX XX
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 297824 for detecting SNP TSC0017788.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX XX (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX XX

XX PS Claim 1; SEQ ID NO 297824; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAACAGAACAC 745
Db 12 GAACAGAACAC 2
|||||

RESULT 1350
ABH72992
ID ABH72992 standard; DNA; 12 BP.

XX AC ABH72992;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 272977 for detecting SNP TSC0003000.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX CS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX PS Claim 1; SEQ ID NO 272977; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAACAGAACAC 745
Db 12 GAACAGAACAC 2
|||||

RESULT 1351
ABH73017/c
ID ABH73017 standard; DNA; 12 BP.

XX AC ABH73017;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 273002 for detecting SNP TSC0003008.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX CS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX PS Claim 1; SEQ ID NO 273002; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
Db 12 AAACAGAACAC 2
|||||

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
Db 1 AAACAGAACAC 11
|||||

RESULT 1351
ABH73017/c
ID ABH73017 standard; DNA; 12 BP.

XX AC ABH73017;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 273002 for detecting SNP TSC0003008.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX CS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX PS Claim 1; SEQ ID NO 273002; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
Db 12 AAACAGAACAC 2
|||||

```

KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  Homo sapiens.
XX  WO200177384-A2.
XX  ABH98307;
XX  22-FEB-2002 (first entry)
XX  Oligonucleotide primer SEQ ID NO 298300 for detecting SNP TSC0018015.
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  Homo sapiens.
XX  WO200177384-A2.
XX  18-OCT-2001.
XX  06-APR-2001; 2001WO-IB000713.
XX  07-APR-2000; 2000DE-01019173.
XX  (EPIG-) EPIGENOMICS AG.
XX  Olek A, Piepenbrock C, Berlin K;
XX  WPI; 2001-657177/75.
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX  Claim 1; SEQ ID NO 298300; 29pp + Sequence Listing; German.
XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  central nervous system, cardiovascular and metabolic disorders. The
XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX  represent the oligomers described in the invention. NOTE: The sequence
XX  data for this patent did not form part of the printed specification, but
XX  was obtained in electronic format from WIPO at
XX  ftp.wipo.int/pub/published_pct_sequences
XX  Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX  Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  QY 736 AAACAGACAC 746
XX  Db 11 AAACAGACAC 1
XX  RESULT 1353
XX  ABH73368
XX  ID ABH73368 standard; DNA; 12 BP.
XX  AC ABH73368;
XX  22-FEB-2002 (first entry)
XX  Oligonucleotide primer SEQ ID NO 273353 for detecting SNP TSC0003149.
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  Homo sapiens.
XX  WO200177384-A2.
XX  18-OCT-2001.
XX  06-APR-2001; 2001WO-IB000713.
XX  07-APR-2000; 2000DE-01019173.
XX  (EPIG-) EPIGENOMICS AG.

```

```

KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  Homo sapiens.
XX  WO200177384-A2.
XX  18-OCT-2001.
XX  06-APR-2001; 2001WO-IB000713.
XX  07-APR-2000; 2000DE-01019173.
XX  (EPIG-) EPIGENOMICS AG.
XX  Olek A, Piepenbrock C, Berlin K;
XX  WPI; 2001-657177/75.
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX  Claim 1; SEQ ID NO 273353; 29pp + Sequence Listing; German.
XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  central nervous system, cardiovascular and metabolic disorders. The
XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX  represent the oligomers described in the invention. NOTE: The sequence
XX  data for this patent did not form part of the printed specification, but
XX  was obtained in electronic format from WIPO at
XX  ftp.wipo.int/pub/published_pct_sequences
XX  Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
XX  Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX  Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX  Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  QY 734 AGAACAGACAC 744
XX  Db 1 AAACAGACAC 11
XX  RESULT 1354
XX  ABH73404
XX  ID ABH73404 standard; DNA; 12 BP.
XX  AC ABH73404;
XX  22-FEB-2002 (first entry)
XX  Oligonucleotide primer SEQ ID NO 273389 for detecting SNP TSC0003164.
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX  Homo sapiens.
XX  WO200177384-A2.
XX  18-OCT-2001.
XX  06-APR-2001; 2001WO-IB000713.
XX  07-APR-2000; 2000DE-01019173.
XX  (EPIG-) EPIGENOMICS AG.

```

XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 273389; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC range of diseases including immune system, cardiovascular and metabolic disorders. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 DB 1 AAAATACACC 11
 RESULT 1355
 ABI24633/c
 ID ABI24633 standard; DNA; 12 BP.
 XX
 AC ABI24633;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 324606 for detecting SNP TSC0032133.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 324606; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 DB 12 AAAAATACACC 2
 RESULT 1356
 ABH74718/c
 ID ABH74718 standard; DNA; 12 BP.
 XX
 AC ABH74718;
 XX
 XX 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 274703 for detecting SNP TSC0003649.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 274703; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

```

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAAACAGAA 742
DB 12 GGAGATAAAGA 2

RESULT 1357
ABI01737/c
ID ABI01737 standard; DNA; 12 BP.
XX
AC ABI01737;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 301710 for detecting SNP TSC0019617.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB0000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 301710; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 1 A; 1 C; 1 G; 9 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
DB 12 GAAAAACAAA 2

RESULT 1358
ABI03290/c
ID ABI03290 standard; DNA; 12 BP.
XX
AC ABI03290;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 278680 for detecting SNP TSC0006264.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX

```

```

AC ABI03290;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 303263 for detecting SNP TSC0020412.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB0000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 303263; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 12 BP; 0 A; 1 C; 2 G; 9 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
DB 12 GAAAAACAAA 2

RESULT 1359
ABH78687/c
ID ABH78687 standard; DNA; 12 BP.
XX
AC ABH78687;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 278680 for detecting SNP TSC0006264.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX

```

18-OCT-2001.
06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.
Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
Claim 1; SEQ ID NO 279697; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 738 ACGAACACCG 748
DB 12 ACAAAACAACG 2
|||||
|||||

RESULT 1361
ABH81788
ID ABH81788 standard; DNA; 12 BP.
XX
AC ABH81788;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 281781 for detecting SNP TSC0010062.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WC200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PT Claim 1; SEQ ID NO 281781; 29pp + Sequence Listing; German.
XX
PS This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

18-OCT-2001.
06-APR-2001; 2001WO-IB000713.
07-APR-2000; 2000DE-01019173.
(EPIG-) EPIGENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2001-657177/75.
Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
Claim 1; SEQ ID NO 279697; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACGACAC 746
DB 11 AAATATAAC 1
|||||
|||||

RESULT 1360
ABH79704/C
ID ABH79704 standard; DNA; 12 BP.
XX
AC ABH79704;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 279697 for detecting SNP TSC0007711.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
PT Claim 1; SEQ ID NO 279697; 29pp + Sequence Listing; German.
XX
PS This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 1 G; 0 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 738 ACAGAACACCG 748
DB 1 ACAAAACAACG 11

RESULT 1362
ABI09227/c
ID ABI09227 standard; DNA; 12 BP.
XX
AC ABI09227;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 309200 for detecting SNP TSC0023411.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 309200; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
DB 1 AAACAGAACAC 11

RESULT 1364
ABH87869/c
ID ABH87869 standard; DNA; 12 BP.
XX
AC ABH87869;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 287862 for detecting SNP TSC0013282.

```

```

Db 11 AAACAAATCAC 1
||||| |
RESULT 1363
ABI34525
ID ABI34525 standard; DNA; 12 BP.
XX
AC ABI34525;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 334498 for detecting SNP TSC0038193.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 334498; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 10 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
DB 1 AAACAGAACAC 11

RESULT 1364
ABH87869/c
ID ABH87869 standard; DNA; 12 BP.
XX
AC ABH87869;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 287862 for detecting SNP TSC0013282.

```



```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 313091; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 737 AACAGACACACC 747
DB 12 AACACACACACC 2
|||||
RESULT 1365
ABI13118
ID ABI13118 standard; DNA; 12 BP.
AC ABI13118;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 313091 for detecting SNP TSC0025474.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PS Claim 1; SEQ ID NO 313091; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 737 AACAGACACACC 747
DB 12 AACACACACACC 2
|||||
RESULT 1366
ABI53296
ID ABI53296 standard; DNA; 12 BP.
AC ABI53296;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 353269 for detecting SNP TSC0048413.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 353269; 29pp + Sequence Listing; German.
```

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 3 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
||| |||||
Db 1 AAACAGACAC 11

RESULT 1367
ABI53718/c
ID ABI53718 standard; DNA; 12 BP.
XX AC ABI53718;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 353691 for detecting SNP TSC0048657.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX Claim 1; SEQ ID NO 353691; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
||| |||||
Db 11 AAACAGACAC 11

RESULT 1368
ABI54744/c
ID ABI54744 standard; DNA; 12 BP.
XX AC ABI54744;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 354717 for detecting SNP TSC0049243.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX Claim 1; SEQ ID NO 354717; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 4 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAACAGAA 743
||| |||||
Db 11 GAGAACAGAA 11

RESULT 1369

```
AB154938/c
ID AB154938 standard; DNA; 12 BP.
XX
AC AB154938;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 354911 for detecting SNP TSC0049361.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
PS Claim 1; SEQ ID NO 354911; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e-02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 736 AAACAGACAC 746
DB 11 AAACAAATAC 1
XX
RESULT 1370
AB162175/c
ID AB162175 standard; DNA; 12 BP.
XX
AC AB162175;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362148 for detecting SNP TSC0053037.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
PS Claim 1; SEQ ID NO 362148; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e-02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 736 AAACAGACAC 746
DB 11 AAACAAATAC 1
XX
RESULT 1370
AB162175/c
ID AB162175 standard; DNA; 12 BP.
XX
AC AB162175;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 362148 for detecting SNP TSC0053624.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
```

XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 363052; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAACACAC 746

Db 11 ACACATACAC 1

RESULT 1372

ABI64640/c
 ID ABI64640 standard; DNA; 12 BP.

XX ABI64640;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 364613 for detecting SNP TSC0054614.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

PN 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 364613; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743

Db 11 GAGATAAGAA 1

RESULT 1373

ABI65561/c
 ID ABI65561 standard; DNA; 12 BP.

XX ABI65561;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 365534 for detecting SNP TSC0055189.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

PN 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 365534; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;

```

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
   |||||
Db 12 GTGAAAAGAA 2

RESULT 1374
ABH80463
ID ABH80463 standard; DNA; 12 BP.
XX AC ABH80463;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 380436 for detecting SNP TSC0063822.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 380436; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACAGAACAC 746
   |||||
Db 1 ATACAAACAC 11

RESULT 1375
ABH96901/C
ID ABH96901 standard; DNA; 12 BP.
XX AC ABH96901;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 297286 for detecting SNP TSC0017504.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 297286 for detecting SNP TSC0017504.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX

```


CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 736 AACACAGAAC 746
 |||||
 Db 2 AACACAGAAC 12

RESULT 1379

ABH75398/c
 ID ABH75398 standard; DNA; 12 BP.

XX AC ABH75398;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 275389 for detecting SNP TSC0003880.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPITG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 275389; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 736 AACACAGAAC 746
 |||||
 Db 11 AACACAAACCC 1

RESULT 1380

AB100578

XX ID AB100578 standard; DNA; 12 BP.

XX AC AB100578;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 300551 for detecting SNP TSC0019086.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPITG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 300551; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 7 A; 1 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 734 AGAACAGAAC 744

Db 1 AGAATATATAC 11

RESULT 1381

ABH75866/c

ID ABH75866 standard; DNA; 12 BP.

XX AC ABH75866;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 275859 for detecting SNP TSC0004023.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 275859; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 0 A; 0 C; 2 G; 10 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACGACAC 746
 Db ||| |||||
 11 AAAAAAACAC 1
 RESULT 1382
 ABI26252/C
 ID ABI26252 standard; DNA; 12 BP.
 XX
 XX ABI26252;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 326225 for detecting SNP TSC0032964.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 326225; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 0 A; 0 C; 2 G; 10 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACGACAC 746
 Db ||| |||||
 11 AAAAAAACAC 1
 RESULT 1382
 ABI26252/C
 ID ABI26252 standard; DNA; 12 BP.
 XX
 XX ABI26252;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 326225 for detecting SNP TSC0032964.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 326225; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 326225; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACGACAC 746
 Db ||| |||||
 11 AAAAAAACAC 1
 RESULT 1383
 ABI30147
 ID ABI30147 standard; DNA; 12 BP.
 XX
 XX ABI30147;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 330120 for detecting SNP TSC0035350.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 330120; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAAC 744
 Db 2 ATAAACAAAC 12

RESULT 1384
 ABI30627
 ID ABI30627 standard; DNA; 12 BP.
 XX AC ABI30627;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 330600 for detecting SNP TSC0035613.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX PS Claim 1; SEQ ID NO 330600; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAAC 744
 Db 2 ATAAACAAAC 12

RESULT 1386
 ABI10974/C
 ID ABI10974 standard; DNA; 12 BP.

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AATACAGACAC 746
 Db 1 AATACAGACAC 11

RESULT 1385
 ABH85253/C
 ID ABH85253 standard; DNA; 12 BP.
 XX AC ABH85253;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 285246 for detecting SNP TSC0012209.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX PS Claim 1; SEQ ID NO 285246; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 0 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAAC 744
 Db 11 AATACAGACAC 1

RESULT 1386
 ABI10974/C
 ID ABI10974 standard; DNA; 12 BP.

```

XX AC
XX AB110974;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 310947 for detecting SNP TSC0024237.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 310947; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Claim 1; SEQ ID NO 310947; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 0 A; 1 C; 5 G; 6 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 738 ACAGAACACCC 748
XX Db 12 ACAGAACACCC 2
XX RESULT 1387
XX ABI36636
XX ID ABI36636 standard; DNA; 12 BP.
XX AC
XX AB136636;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 336609 for detecting SNP TSC0039445.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

```

```

PN WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 336609; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 12 BP; 7 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 733 GAGAACAGAA 743
XX Db 2 GAGAACAGAA 12
XX RESULT 1388
XX ABH87873/C
XX ID ABH87873 standard; DNA; 12 BP.
XX AC
XX ABH87873;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 287866 for detecting SNP TSC0013284.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 287866; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 1 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACGAAAC 746
Db 11 ATACGAAAC 1
RESULT 1389
ABI13569/c
ID ABI13569 standard; DNA; 12 BP.
XX
XX ABI13569;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 313542 for detecting SNP TSC0025831.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPTG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 313542; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 0 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACACGAAAC 746
Db 12 AAACGAAAC 2
RESULT 1390
ABI39751/c
ID ABI39751 standard; DNA; 12 BP.
XX
XX ABI39751;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 339724 for detecting SNP TSC0041152.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 339724; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;


```
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 353696; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AACAGACAC 746
XX ||||| |||
XX 1 AACACAAACCC 11
XX
XX RESULT 1394
XX ABI56602
XX ID ABI56602 standard; DNA; 12 BP.
XX AC ABI56602;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 356575 for detecting SNP TSC0050201.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
```

```
PS Claim 1; SEQ ID NO 356575; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AACAGACAC 746
XX ||||| |||
XX 2 AACAAAACTC 12
XX
XX RESULT 1395
XX ABI59888
XX ID ABI59888 standard; DNA; 12 BP.
XX AC ABI59888;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 359861 for detecting SNP TSC0051810.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 359861; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
```

```

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACGACAC 746
Db 1 AAAAAACAC 11

RESULT 1396
ABI60584
ID ABI60584 standard; DNA; 12 BP.
XX
AC ABI60584;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 360557 for detecting SNP TSC0052132.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 360557; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACGACAC 746
Db 2 AAAAACTC 12

RESULT 1397
ABI64795
ID ABI64795 standard; DNA; 12 BP.
XX
AC ABI64795;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 364768 for detecting SNP TSC0054707.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 364768; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACGACAC 746
Db 2 AACATAATAC 12

RESULT 1398
ABI18056
ID ABI18056 standard; DNA; 12 BP.
XX
AC ABI18056;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 318029 for detecting SNP TSC0028403.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB0000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 318617; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABK00010-ABK2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 0 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGACACC 747
 DB 11 AACAAACCCC 1
 RESULT 1400
 ABH70069
 ID ABH70069 standard; DNA; 12 BP.
 XX AC ABH70069;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 270046 for detecting SNP TSC0001972.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB0000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 270046; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABK00010-ABK2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 0 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGACACC 746
 DB 2 AAACAATACAC 12
 RESULT 1399
 ABI18644/c
 ID ABI18644 standard; DNA; 12 BP.
 XX AC ABI18644;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 318617 for detecting SNP TSC0028770.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB0000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 OS WPI; 2001-657177/75.
 PN Set of oligonucleotides, useful for diagnosis and cell typing, is
 PD designed to detect single-nucleotide polymorphisms and cytosine
 PD methylation status.
 PF Claim 1; SEQ ID NO 318029; 29pp + Sequence Listing; German.
 PR This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABK00010-ABK2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACAGACACC 746
 DB 2 AAACAATACAC 12
 RESULT 1399
 ABI18644/c
 ID ABI18644 standard; DNA; 12 BP.
 XX AC ABI18644;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide primer SEQ ID NO 318617 for detecting SNP TSC0028770.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB0000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 ID Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
 Db 2 AAACAAAAAC 12

RESULT 1401
 ABH98381/c
 ID ABH98381 standard; DNA; 12 BP.
 XX
 AC ABH98381;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 298374 for detecting SNP TSC0018056.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 298374; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 1 A; 1 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGACA 745
 Db 12 GAAACACAATA 2

RESULT 1402
 ABH74220/c
 ID ABH74220 standard; DNA; 12 BP.
 XX
 AC ABH74220;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide primer SEQ ID NO 274205 for detecting SNP TSC0003476.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 274205; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 12 BP; 0 A; 0 C; 2 G; 10 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e-02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746
 Db 12 AAACAAAAAC 2

RESULT 1403
 ABH75097/c
 ID ABH75097 standard; DNA; 12 BP.
 XX
 AC ABH75097;

Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 302548; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGACAC 746

Db 1 AAAAATAACAC 11

RESULT 1406

ABI03651/C

ID ABI03651 standard; DNA; 12 BP.

AC ABI03651;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 303624 for detecting SNP TSC0020559.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 303624; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 0 A; 1 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGACCA 745

Db 11 GAAACACACCA 1

RESULT 1407

ABI29134/C

ID ABI29134 standard; DNA; 12 BP.

AC ABI29134;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 329107 for detecting SNP TSC0034763.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 329107; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 12 BP; 1 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGACCA 745

Db 11 GAAACACACCA 1

Db 12 GAACATAACA 2

RESULT 1408

AB107001/c

ID AB107001 standard; DNA; 12 BP.

XX AC

XX AB107001;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 306974 for detecting SNP TSC0022276.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 306974; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 0 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746

Db 11 AACCCAAACAC 1

RESULT 1409

ABH84507

ID ABH84507 standard; DNA; 12 BP.

XX AC

XX ABH84507;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 284500 for detecting SNP TSC0011861.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 284500; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746

Db 1 ACACAAACAC 11

RESULT 1410

AB136588

ID AB136588 standard; DNA; 12 BP.

XX AC

XX AB136588;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 336561 for detecting SNP TSC0039423.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 336561; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 12 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AAACAGAACAC 746
 Db 2 AAACAAACCAC 12
 |||||
 |||||
 RESULT 1411
 ABH87138/C
 ID ABH87138 standard; DNA; 12 BP.
 AC
 AC ABH87138;
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 287131 for detecting SNP TSC0012962.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 287131; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 12 BP; 0 A; 1 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 730 CAGGAGAACAC 740
 Db 12 CACGAAAAACA 2
 |||||
 |||||
 RESULT 1412
 ABI39339
 ID ABI39339 standard; DNA; 12 BP.
 XX
 AC ABI39339;
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 339312 for detecting SNP TSC0040939.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 339312; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 291829; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 DB 1 AAAAAAACACC 11
 RESULT 1416
 ABI42523
 ID ABI42523 standard; DNA; 12 BP.
 XX AC ABI42523;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 342496 for detecting SNP TSC0042568.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 342496; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACAGAACACC 747
 DB 1 AAAAAAACACC 11
 RESULT 1416
 ABI42523
 ID ABI42523 standard; DNA; 12 BP.
 XX AC ABI42523;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 342496 for detecting SNP TSC0042568.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 346513; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAACAGAAC 744
 DB 2 ATAAACCGAAC 12
 RESULT 1417
 ABI46540/C
 ID ABI46540 standard; DNA; 12 BP.
 XX AC ABI46540;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 346513 for detecting SNP TSC0044618.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 346513; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 342496; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAACAGAAC 744
 DB 2 ATAAACCGAAC 12
 RESULT 1417
 ABI46540/C
 ID ABI46540 standard; DNA; 12 BP.
 XX AC ABI46540;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 346513 for detecting SNP TSC0044618.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 346513; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 1 A; 4 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAACAGCA 742
DB 11 GGTGAAAAAGA 1

RESULT 1418
ABI70452/c
ID ABI70452 standard; DNA; 12 BP.
XX
XX AC ABI70452;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 370425 for detecting SNP TSC0058171.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 370425; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
DB 11 AAAACACACACC 1

RESULT 1419
ABI77819
ID ABI77819 standard; DNA; 12 BP.
XX
XX AC ABI77819;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 377792 for detecting SNP TSC0062498.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 377792; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAACACAGCA 743
DB 2 GAGAAATAGCA 12

RESULT 1420
ABI64706
ID ABI64706 standard; DNA; 12 BP.
XX
XX AC ABI64706;
XX
DT 22-FEB-2002 (first entry)

```

XX DE Oligonucleotide primer SEQ ID NO 364679 for detecting SNP TSC0054651.
XX KW SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB0000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 364679; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;
XX CC
XX CC Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX CC Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX CC Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX CC
XX QY 733 GAGAAACAGAA 743
XX DB ||||| |||||
XX DB 1 GAGAAACAGAA 11
XX
XX RESULT 1421
XX ABI65216
XX ID ABI65216 standard; DNA; 12 BP.
XX AC ABI65216;
XX AC
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 365189 for detecting SNP TSC0054956.
XX XX
XX KW SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX

```

```

PF 06-APR-2001; 2001WO-IB0000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 365189; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 6 A; 4 C; 2 G; 0 T; 0 U; 0 Other;
XX CC
XX CC Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX CC Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX CC Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX CC
XX QY 734 AGAAACAGAAC 744
XX DB ||||| |||||
XX DB 1 ACAACCCGAAAC 11
XX
XX RESULT 1422
XX ABI80460/c
XX ID ABI80460 standard; DNA; 12 BP.
XX AC ABI80460;
XX AC
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 380433 for detecting SNP TSC0063821.
XX XX
XX KW SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB0000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```


XX Claim 1; SEQ ID NO 380433; 29pp + Sequence Listing; German.
PS This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGACACACC 747
Db 12 AACAAATCACC 2
|||||

RESULT 1423
ABI67260/c
ID ABI67260 standard; DNA; 12 BP.
XX
AC ABI67260;
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 367233 for detecting SNP TSC0056237.
DE
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB0000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 367233; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
Db 12 AACAGAAAAG 2
|||||

RESULT 1424
ABH68427/c
ID ABH68427 standard; DNA; 12 BP.
XX
AC ABH68427;
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 268404 for detecting SNP TSC0001102.
DE
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB0000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 268404; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 4 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGAAACA 745
Db 12 GAAAGAGAAATA 2
|||||

```

RESULT 1425
ABI20393
ID ABI20393 standard; DNA; 12 BP.
XX
AC ABI20393;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 320366 for detecting SNP TSC0029676.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WI WI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 320366; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 735 GAAACAGAACAC 745
Db ||||| |||||
2 GAAACTCAACA 12
RESULT 1426
ABH73762
ID ABH73762 standard; DNA; 12 BP.
XX
AC ABH73762;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 273747 for detecting SNP TSC0003291.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

```

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WI WI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 273747; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 736 AAACAGAACAC 746
Db ||||| |||||
2 AAACACATCAC 12
RESULT 1427
ABH75483
ID ABH75483 standard; DNA; 12 BP.
XX
AC ABH75483;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 275474 for detecting SNP TSC0003903.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.

```

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 275474; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 734 ACAACACAGAAC 744
DB 2 ACAACACAAAC 12
RESULT 1428
ABI28569
ID ABI28569 standard; DNA; 12 BP.
XX AC ABI28569;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 328542 for detecting SNP TSC0034392.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 328542; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 735 GAAACACAGAAC 745
DB 2 GAAACACAAAC 12
RESULT 1429
ABH79548/C
ID ABH79548 standard; DNA; 12 BP.
XX AC ABH79548;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 279541 for detecting SNP TSC0007466.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 279541; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 0 A; 0 C; 2 G; 10 T; 0 U; 0 Other;
SQ

XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIC-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 305623; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 733 GAGAACAGAA 743
DB 12 GAGAAATAAAA 2
RESULT 1433
ABI06182/c
ID ABI06182 standard; DNA; 12 BP.
XX
XX ABI06182;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 306155 for detecting SNP TSC0021828.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 305623; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 733 GAGAACAGAA 743
DB 12 GAGAAATAAAA 2
RESULT 1433
ABI06182/c
ID ABI06182 standard; DNA; 12 BP.
XX
XX ABI06182;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 306155 for detecting SNP TSC0021828.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PD designed to detect single-nucleotide polymorphisms and cytosine
PD methylation status.
XX
XX Claim 1; SEQ ID NO 306155; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AATCAGACAC 746
DB 11 AATCATAATAC 1
RESULT 1434
ABI32093/c
ID ABI32093 standard; DNA; 12 BP.
XX
XX ABI32093;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 332066 for detecting SNP TSC0036682.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
FN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 332066; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

```

CC -ABC99989, ABFC0010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAACAGACA 742
Db 12 GGAGTAGAGA 2

RESULT 1435
ABH84551/c
ID ABH84551 standard; DNA; 12 BP.
XX
AC ABH84551;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 284544 for detecting SNP TSC0011875.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 284544; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGACA 745

```

```

Db 12 GAAACATTACA 2

RESULT 1436
ABI13475
ID ABI13475 standard; DNA; 12 BP.
XX
AC ABI13475;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 313448 for detecting SNP TSC0025771.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 313448; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match      35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAAC 744
Db 2 ACAACAAAC 12

RESULT 1437
ABH90450
ID ABH90450 standard; DNA; 12 BP.
XX
AC ABH90450;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 290443 for detecting SNP TSC0014352.

```

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 315635; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABH0010-ABH9989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACAGACAC 746
Db 2 AACCTTACAC 12
RESULT 1439
ABI49818
ID ABI49818 standard; DNA; 12 BP.
XX
AC ABI49818;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 349791 for detecting SNP TSC0046328.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 349791; 29pp + Sequence Listing; German.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 290443; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABH0010-ABH9989
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGACAC 747
Db 2 AACACACTCC 12
RESULT 1438
ABI15662
ID ABI15662 standard; DNA; 12 BP.
XX
AC ABI15662;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 315635 for detecting SNP TSC0027012.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
 Db 1 AGTAAAGAG 11
 |||||

RESULT 1440
 ABI52057/c
 ID ABI52057 standard; DNA; 12 BP.
 XX AC ABI52057;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 352030 for detecting SNP TSC0047642.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 FN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB0000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 352030; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAACAGAAC 744
 Db 12 AAAACATAAC 2
 |||||

RESULT 1441
 ABI52706
 ID ABI52706 standard; DNA; 12 BP.
 XX AC ABI52706;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide primer SEQ ID NO 352679 for detecting SNP TSC0048031.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 FN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB0000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 352679; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
 Db 1 AACAAACATCC 11
 |||||

RESULT 1442

OS ABI53175/c
 ID ABI53175 standard; DNA; 12 BP.
 XX AC ABI53175;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 353148 for detecting SNP TSC0048333.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX PI WPI; 2001-657177/75.
 XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 376788; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 736 AACACAGAAC 746
 DB 11 AAAAAAATAC 1
 RESULT 1444
 ABI78370/c
 ID ABI78370 standard; DNA; 12 BP.
 XX AC ABI78370;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 378343 for detecting SNP TSC0062733.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;

ABI53175/c
 ID ABI53175 standard; DNA; 12 BP.
 XX AC ABI53175;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 353148 for detecting SNP TSC0048333.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX PI WPI; 2001-657177/75.
 XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX PT designed to detect single-nucleotide polymorphisms and cytosine
 XX PT methylation status.
 XX PS Claim 1; SEQ ID NO 353148; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
 XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX CC range of diseases including immune system, gastrointestinal, respiratory,
 XX CC central nervous system, cardiovascular and metabolic disorders. The
 XX CC oligomers are also used for detecting cell type differentiation. ABC00010
 XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX CC represent the oligomers described in the invention. NOTE: The sequence
 XX CC data for this patent did not form part of the printed specification, but
 XX CC was obtained in electronic format from WIPO at
 XX CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 12 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AACACAGAAC 744
 DB 11 AAAAAAATAC 1
 RESULT 1443
 ABI76815/c
 ID ABI76815 standard; DNA; 12 BP.
 XX AC ABI76815;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 376788 for detecting SNP TSC0061985.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

[illegible]

Journal of Management Studies, 19(1), 67-80
© Blackwell Publishers Ltd. 1996

XX
PF 06-APR-2001; 2001WO-IB0000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 232984; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 10 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2;

QY 736 AAACAGACAC 746
DB 2 AACCAAAAC 12
RESULT 1450
ABH94505/c
ID ABH94505 standard; DNA; 12 BP.
XX
XX AC ABH94505;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 294498 for detecting SNP TSC0016150.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX Central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PT methylation status.
XX
PS Claim 1; SEQ ID NO 294498; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2;

QY 736 AAACAGACAC 746
DB 11 AACCAAAAC 1

RESULT 1451
ABH95694/c
ID ABH95694 standard; DNA; 12 BP.

XX
XX AC ABH95694;
XX
XX 22-FEB-2002 (first entry)
XX

XX Oligonucleotide primer SEQ ID NO 295687 for detecting SNP TSC0016687.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX Central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.

XX
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 295687; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 6 C; 0 G; 5 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAACAGAC 742
DB 12 GGAGAGGTAGA 2
RESULT 1452
ABH71751
ID ABH71751 standard; DNA; 12 BP.

XX AC ABH71751;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 271728 for detecting SNP TSC0002600.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS WO200177384-A2.
FN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 271728; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AACACAGACAC 746
DB 2 AACAAATCAC 12

RESULT 1453
ABH72328
ID ABH72328 standard; DNA; 12 BP.

XX AC ABH72328;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 272307 for detecting SNP TSC0002774.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
XX WO200177384-A2.
FN 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 272307; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
DB 1 AACATAAACACC 11

RESULT 1454
AB123966
ID AB123966 standard; DNA; 12 BP.

XX AC AB123966;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 323939 for detecting SNP TSC0031675.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 323939; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACGAGAACCC 747
 DB 1 AACGAGAACCC 11
 RESULT 1455
 ABH74796
 ID ABH74796 standard; DNA; 12 BP.
 XX
 AC ABH74796;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 274781 for detecting SNP TSC0003674.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 274781; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 737 AACGAGAACCC 747
 DB 1 AACGAGAACCC 11
 RESULT 1455
 ABH74796
 ID ABH74796 standard; DNA; 12 BP.
 XX
 AC ABH74796;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 274781 for detecting SNP TSC0003674.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 274781; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 274781; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 734 AGAAGACGAC 744
 DB 2 AAAAAACATAAC 12
 RESULT 1456
 ABH76081/c
 ID ABH76081 standard; DNA; 12 BP.
 XX
 AC ABH76081;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 276074 for detecting SNP TSC0004082.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 276074; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

```
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the invention. NOTE: The sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAAGACAGAC 744
DB 11 ACAAGACAC 1

RESULT 1457
ABI26715
ID ABI26715 standard; DNA; 12 BP.
XX
AC ABI26715;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 326688 for detecting SNP TSC0033234.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 326688; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the invention. NOTE: The sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 2 G; 0 T; 0 U; 0 Other;
```

```
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
DB 1 GCGAAACAAA 11

RESULT 1458
ABI02659
ID ABI02659 standard; DNA; 12 BP.
XX
AC ABI02659;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 302632 for detecting SNP TSC0020091.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 302632; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the invention. NOTE: The sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
DB 1 AGGAGAGAAAG 11

RESULT 1459
ABI03308
ID ABI03308 standard; DNA; 12 BP.
```

```

XX AC AB103308;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 303281 for detecting SNP TSC0020420.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX XX
XX PS Claim 1; SEQ ID NO 303281; 29pp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 12 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 737 AACAGAACACC 747
XX Db 1 AATAAACACC 11
XX
XX RESULT 1460
XX ABI28965/c
XX ID ABI28965 standard; DNA; 12 BP.
XX XX
XX AC ABI28965;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 328938 for detecting SNP TSC0034660.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX

```

```

PN WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 328938; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 736 AACAGAACACC 746
XX Db 12 AACACCCACC 2
XX
XX RESULT 1461
XX ABH79806
XX ID ABH79806 standard; DNA; 12 BP.
XX AC ABH79806;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 279799 for detecting SNP TSC0007838.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX

```


XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 279799; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AAACAGAACAC 746
Db 2 AAAAAAACAC 12
|||||

RESULT 1462
ABH80068
ID ABH80068 standard; DNA; 12 BP.
XX
AC ABH80068;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 280061 for detecting SNP TSC0008110.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 280061; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 10 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 AAACAGAACAC 746
Db 2 AAAAAAACAC 12
|||||

RESULT 1463
ABI05818
ID ABI05818 standard; DNA; 12 BP.
XX
AC ABI05818;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 305791 for detecting SNP TSC0021632.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 305791; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 3 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 Db 1 AAACATAACAC 11

RESULT 1466
 ABI06252/c
 ID ABI06252 standard; DNA; 12 BP.
 XX AC ABI06252;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 306225 for detecting SNP TSC0021890.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 306225; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 2 A; 2 C; 1 G; 7 T; 0 U; 0 Other;
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 AGAACAGAACAC 744
 Db 11 AGAATAGTAC 1

RESULT 1465
 ABI09548
 ID ABI09548 standard; DNA; 12 BP.
 XX AC ABI09548;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 288301 for detecting SNP TSC0013451.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.

DE Oligonucleotide primer SEQ ID NO 309521 for detecting SNP TSC0023558.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 309521; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 6 A; 3 C; 1 G; 2 T; 0 U; 0 Other;
 XX Query Match 35.5%; Score 7.8; DB 1; Length 12;
 XX Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 XX Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
 Db 1 AAACATAACGC 11

RESULT 1466
 ABH88308
 ID ABH88308 standard; DNA; 12 BP.
 XX AC ABH88308;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide primer SEQ ID NO 288301 for detecting SNP TSC0013451.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 288301; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 8 A; 3 C; 1 G; 0 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AAACGAAAC 12
DB 2 AAACGAAAC 12
RESULT 1467
ABH8677
ID ABH8677 standard; DNA; 12 BP.
XX
XX ABH8677;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 288670 for detecting SNP TSC0013623.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 288670; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AAACGAAAC 746
DB 1 AAACGAAAC 11
RESULT 1468
ABI41860
ID ABI41860 standard; DNA; 12 BP.
XX
XX ABI41860;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 341833 for detecting SNP TSC0042250.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 341833; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACAGAACAC 746
Db 2 AAACAAACCC 12

RESULT 1469
ABI45273/c
ID ABI45273 standard; DNA; 12 BP.
XX
AC ABI45273;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 345246 for detecting SNP TSC0000735.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 345246; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 2 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743
Db 12 GAGAAACAAAA 2

RESULT 1470
ABI46462/c
ID ABI46462 standard; DNA; 12 BP.
XX
AC ABI46462;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 346435 for detecting SNP TSC0044583.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 346435; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 737 AACAGAACACC 747
Db 12 AACATAACCAAC 2

RESULT 1471
ABI47815
ID ABI47815 standard; DNA; 12 BP.
XX
AC ABI47815;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 347788 for detecting SNP TSC0045257.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
XX	07-APR-2000; 2000DE-01019173.
XX	(EPIG-) EPIGENOMICS AG.
XX	Olek A, Piepenbrock C, Berlin K;
PFI	WPI; 2001-657177/75.
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PPT	designed to detect single-nucleotide polymorphisms and cytosine
PPT	methylation status.
XX	Claim 1; SEQ ID NO 347788; 29pp + Sequence Listing; German.
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. AEC00010
CC	-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	Sequence 12 BP; 8 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
SEQ	
	Query Match 35.5%; Score 7.8; DB 1; Length 12;
	Best Local Similarity 81.8%; Pred. No. 6.8e+02;
	Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
DY	733 GAGAAACAGAA 743
Ddb	2 GATAAACA AAA 12
	RESULT 1472
ABIA9456	ID
AB	AB:49456 standard; DNA; 12 BP.
ACC	AB:49456;
XX	22-FEB-2002 (first entry)
DDT	Oligonucleotide primer SEQ ID NO 349429 for detecting SNP TSC0046139.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
DE	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
KW	Homo sapiens.
XX	WO200177384-A2.
XX	18-OCT-2001.
XX	06-APR-2001; 2001WO-IB000713.
PFP	07-APR-2000; 2000DE-01019173.
XX	(EPIG-) EPIGENOMICS AG.
XX	
XX	
XX	

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX Sequence 12 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 AAACGACAC 745

DB 11 AAACAAACCC 1

RESULT 1474

ABI68631/c
 ID ABI68631 standard; DNA; 12 BP.

XX AC ABI68631;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 368604 for detecting SNP TSC0057109.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 368604; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX Sequence 12 BP; 1 A; 2 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 GAGAAACAGAA 743

DB 11 GAAAAATAGAA 1

RESULT 1475

ABI57978
 ID ABI57978 standard; DNA; 12 BP.

XX AC ABI57978;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 357951 for detecting SNP TSC0050892.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 357951; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX Sequence 12 BP; 7 A; 4 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GAAACAGACAA 745

DB 2 GACACAAACA 12

RESULT 1476

AAF92714
 ID AAF92714 standard; DNA; 12 BP.

XX AC AAF92714;

XX 16-MAY-2001 (first entry)
DT Mutiple allele detection probe #4.
DE Human; leukocyte antigen; HLA; typing; sequence specific probe; SSOPH;
KW ss.
KW Homo sapiens.
OS
XX US6194147-B1.
PN 27-FEB-2001.
XX 30-DEC-1997; 97US-00000805.
PF 27-JUN-1990; 90US-00544218.
PR 08-APR-1993; 93US-00057957.
XX (BLOO-) BLOOD CENT RES FOUND INC.
PA Baxter-Lowe LA, Gorski JA;
PI WPI; 2001-217923/22.
DR Human leukocyte antigen typing by amplifying a sample followed by
PT sequence specific oligonucleotide hybridization with labeled
PT oligonucleotide probes that hybridize with a series of known control DNA
PT sequences.
XX Example; Col 22-23; 16pp; English.
PS The present invention relates to human leukocyte antigen (HLA) typing.
CC The method involves detecting polymorphic residues by sequence specific
CC oligonucleotide probe hybridization (SSOPH) with labeled oligonucleotide
CC probes
XX Sequence 12 BP; 4 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 730 CAGGAGAACACA 740
DB 1 CTGGAGAGACA 11
RESULT 1477
AAL37779/c
ID AAL37779 standard; RNA; 12 BP.
XX AAL37779;
DT 05-AUG-2002 (first entry)
XX 3' conserved RNA region of wild-type influenza C virus.
DE Cytostatic; antiviral; tumour associated antigen; TAA; dendritic cell;
KW virus-associated antigen; VAA; recombinant influenza virus; vaccine;
KW viral infection; immune; wild-type; influenza C virus; ss.
XX Influenza virus.
OS
XX EP1201760-A1.
PN 02-MAY-2002.
PD 30-OCT-2000; 2000EP-00123687.
PF 30-OCT-2000; 2000EP-00123687.
PR 30-OCT-2000; 2000EP-00123687.
XX (ARTE-) ARTEMIS PHARM GMBH.
PA

XX Schuler G, Hobom G, Steinkasserer A, Strobel I, Grassmann R;
PI WPI; 2002-418777/45.
DR
XX Expressing tumor or viral associated antigens by dendritic cells, used
PT for treating tumors or viral infections, comprises using recombinant
PT influenza virus containing nucleic acid encoding the antigens.
XX Disclosure; Page 5; 33pp; English.
PS The invention relates to a method for the expression of tumour associated
XX antigens (TAA) or virus-associated antigens (VAA) by dendritic cells
CC comprising: preparing a recombinant influenza virus containing a
CC nucleotide sequence coding for the TAA or VAA; and infecting dendritic
CC cells with the recombinant virus. The method is used for expressing TAA
CC or VAA in dendritic cells. The cells are used for preparing a medicament
CC for treating tumours or viral infections. A vaccine can be created by
CC using dendritic cells presenting tumour antigens to induce an immune
CC response. This polynucleotide sequence represents a 3' conserved RNA
CC region of the wild-type influenza C virus of the invention
XX Sequence 12 BP; 0 A; 5 C; 2 G; 0 T; 5 U; 0 Other;
SQ Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 731 AGGAGAAACAG 741
DB 12 AGCAGAGACAG 2
RESULT 1478
AAL37802/c
ID AAL37802 standard; RNA; 12 BP.
XX AAL37802;
AC
XX 05-AUG-2002 (first entry)
DT Modified 3' RNA region of Influenza A virus #2.
DE Cytostatic; antiviral; tumour associated antigen; TAA; dendritic cell;
KW virus-associated antigen; VAA; recombinant influenza virus; vaccine;
KW viral infection; immune; Influenza A virus; ss.
XX Unidentified.
OS
XX EP1201760-A1.
PN 02-MAY-2002.
PD 30-OCT-2000; 2000EP-00123687.
PF 30-OCT-2000; 2000EP-00123687.
PR 30-OCT-2000; 2000EP-00123687.
XX (ARTE-) ARTEMIS PHARM GMBH.
PA Schuler G, Hobom G, Steinkasserer A, Strobel I, Grassmann R;
PI WPI; 2002-418777/45.
DR Expressing tumor or viral associated antigens by dendritic cells, used
PT for treating tumors or viral infections, comprises using recombinant
PT influenza virus containing nucleic acid encoding the antigens.
XX Claim 7; Page 19; 33pp; English.
PS The invention relates to a method for the expression of tumour associated
XX antigens (TAA) or virus-associated antigens (VAA) by dendritic cells
CC comprising: preparing a recombinant influenza virus containing a
CC nucleotide sequence coding for the TAA or VAA; and infecting dendritic
CC

CC cells with the recombinant virus. The method is used for expressing TAA
 CC or VAA in dendritic cells. The cells are used for preparing a medicament
 CC for treating tumours or viral infections. A vaccine can be created by
 CC using dendritic cells presenting tumour antigens to induce an immune
 CC response. This polynucleotide sequence represents a modified 3' RNA
 CC region of the Influenza A virus of the invention
 XX
 SQ Sequence 12 BP; 1 A; 3 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
 ||| |||||
 DB 12 ACTAAACAG 2

RESULT 1479
 ABS71501
 ID ABS71501 standard; DNA; 12 BP.

AC ABS71501;

DT 27-NOV-2002 (first entry)

DE DNA encoding protease biosensor recognition site #7.

KW Detection; classification; identification; toxin detection; protease;
 KW ADP-ribosylating toxin; cytotoxic phospholipase; exfoliative toxin;
 KW toxic threat agent; ds.

OS Synthetic.

PN US6416959-B1.

PD 09-JUL-2002.

PF 25-FEB-2000; 2000US-00513783.

PR 27-FEB-1997; 97US-00810983.

PR 27-FEB-1998; 98US-00031271.

PR 26-FEB-1999; 99US-0122152P.

PR 08-MAR-1999; 99US-0123399P.

PR 12-JUL-1999; 99US-00352171.

PR 31-AUG-1999; 99US-0151797P.

PR 17-SEP-1999; 99US-00398965.

PR 29-OCT-1999; 99US-00430656.

PR 01-DEC-1999; 99US-0168408P.

XX (GIUL/) GIULIANO K.

PA (KAPU/) KAPUR R.

PI Giuliano K, Kapur R;

XX WPI; 2002-634730/68.

DR P-PSDB; ABG94454.

XX Automated cell-based toxin detection, classification, and/or
 PT identification by treating cells involves use of three classes of
 PT luminescent reporter molecules such as detectors, classifiers or
 PT identifiers.

PS Example 10; Fig 29B; 214pp; English.

CC The invention describes methods of automated detection, classification
 CC and identification comprising treating cells containing luminescent
 CC reporter molecules (I) in array of locations with a test substance, where
 CC (I) are detectors, classifiers or identifiers, imaging cells in each
 CC location to obtain luminescent signals and converting optical information
 CC into digital data to interpret presence of toxins in the test substance.
 CC The method are useful for detection of toxins chosen from proteases, ADP-
 CC ribosylating toxins, cytotoxic phospholipases, and exfoliative toxins.

CC Three classes of cell-based luminescent reporter molecules such as
 CC detectors, classifiers and identifiers are described and serve as
 CC reporters of toxic threat agents. The first two levels of
 CC characterization ensure a rapid readout of toxin class without
 CC sacrificing the ability to detect many new mutant toxins or dissect
 CC several complex mixtures of known toxins. This sequence encodes a
 CC protease biosensor recognition site used in the cell-based screening
 XX system

SQ Sequence 12 BP; 6 A; 1 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
 Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 GGAGAAACAGA 742
 ||| |||||
 DB 1 GTAGAAATAGA 11

RESULT 1480
 ABQ75462/C
 ID ABQ75462 standard; RNA; 12 BP.

XX AC ABQ75462;

XX DT 07-NOV-2002 (first entry)

XX Modified influenza virus A 3' conserved region SEQ ID NO:4.

XX Influenza virus; transcription; replication; RNA polymerase; vaccine;
 XX gene therapy; cytostatic; anti-HIV; hepatotropic; antiinflammatory;
 XX immunomodulator; virucide; infectious disease; ss.

OS Influenza virus.

OS Synthetic.

PN WO200264757-A2.

XX 22-AUG-2002.

XX 07-FEB-2002; 2002WO-EP001257.

XX 09-FEB-2001; 2001EP-00103060.

XX (ARTE-) ARTEMIS PHARM GMBH.

XX Hobom G, Menke A;

XX WPI; 2002-657594/70.

XX New human influenza virus comprising an RNA-sequence encoding a modified
 PT RNA-polymerase, useful for preparing agents for therapeutic and
 PT prophylactic vaccination, or treating a growing tumor or a chronic
 PT infectious disease.

XX Claim 10; Page 50; 172pp; English.

XX The present invention describes a human influenza virus (I) comprising an
 CC RNA-sequence encoding a modified RNA-polymerase that differs from the
 CC wild-type RNA-polymerase of the human influenza virus in that at least 1
 CC of the amino acid residues distinguishing the wild-type RNA-polymerase of
 CC the human influenza virus from FpV Bratislava RNA-polymerase has been
 CC replaced with the corresponding amino acid residue(s) as present in FpV
 CC Bratislava RNA-polymerase. (I) has virucide, cytostatic, anti-HIV,
 CC hepatotropic, antiinflammatory and immunomodulator activities and can be
 CC used in gene therapy and vaccines. The influenza virus is useful for
 CC preparing agents for: (a) gene transfer into cells, preferably into
 CC mammalian cells, particularly into human cells, by viral infection; (b)
 CC gene transfer into antigen-presenting cells, and the use of the obtained
 CC product for ex vivo immunotherapy; in vivo somatic gene therapy; in vivo
 CC vaccination, including therapeutic and prophylactic vaccination; (c)
 CC eliciting an immune response, including the induction of a T-cell

CC response; (d) treating a growing tumour or a chronic infectious disease;
CC (e) immunotherapy, preferably for autologous immunotherapy; (f) transfer
CC and expression of foreign genes into cells infected by such viruses; or
CC (g) transfer and expression of RNA molecules into cells infected by such
CC viruses, preferably the RNA molecules to be expressed are antisense
CC sequences or double-strand sequences relative to the target cellular mRNA
CC silencing, and/or the agent is suitable for sequence-specific gene
CC silencing, preferably by antisense RNA or RNA interference mechanisms
CC such as ribozyme cleavages of target RNAs. The recombinant viruses can be
CC made for use in vaccines against HIV, hepatitis B or C virus, herpes
CC viruses or papilloma viruses. The present sequence represents a modified
CC 3' conserved region of an influenza virus, given in the exemplification
CC of the present invention
XX
SQ Sequence 12 BP; 1 A; 3 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
DB 12 AGTAAACAG 2

RESULT 1481
ABQ75461/C
ID ABQ75461 standard; RNA; 12 BP.
XX
AC ABQ75461;
XX
DT 07-NOV-2002 (first entry)
XX
DE Influenza virus C 3' conserved region SEQ ID NO:3.
XX
KW Influenza virus; transcription; replication; RNA polymerase; vaccine;
KW gene therapy; cytosolic; anti-HIV; hepatotropic; antiinflammatory;
KW immunomodulator; virucide; infectious disease; ss.
XX
OS Influenza virus.
XX
FN WO200264757-A2.
XX
PD 22-AUG-2002.
XX
PF 07-FEB-2002; 2002WO-EP001257.
XX
PR 09-FEB-2001; 2001EP-00103060.
XX
PA (ARTE-) ARTEMIS PHARM GMBH.
XX
PI Hobom G, Menke A;
XX
DR WPI; 2002-657594/70.
XX
PT New human influenza virus comprising an RNA-sequence encoding a modified
PT RNA-polymerase, useful for preparing agents for therapeutic and
PT prophylactic vaccination, or treating a growing tumor or a chronic
PT infectious disease.
PS Disclosure; Page 15; 172pp; English.
XX
CC The present invention describes a human influenza virus (I) comprising an
CC RNA-sequence encoding a modified RNA-polymerase that differs from the
CC wild-type RNA-polymerase of the human influenza virus in that at least 1
CC of the amino acid residues distinguishing the wild-type RNA-polymerase of
CC the human influenza virus from FV Brattslava RNA-polymerase has been
CC replaced with the corresponding amino acid residue(s) as present in FV
CC Brattslava RNA-polymerase. (II) has virucide, cytosolic, anti-HIV,
CC hepatotropic, antiinflammatory and immunomodulator activities and can be
CC used in gene therapy and vaccines. The influenza virus is useful for
CC preparing agents for: (a) gene transfer into cells, preferably into
CC mammalian cells, particularly into human cells, by viral infection; (b)

CC Gene transfer into antigen-presenting cells, and the use of the obtained
CC product for ex vivo immunotherapy; in vivo somatic gene therapy; in vivo
CC vaccination, including therapeutic and prophylactic vaccination; (c)
CC eliciting an immune response, including the induction of a T-cell
CC response; (d) treating a growing tumour or a chronic infectious disease;
CC (e) immunotherapy, preferably for autologous immunotherapy; (f) transfer
CC and expression of foreign genes into cells infected by such viruses; or
CC (g) transfer and expression of RNA molecules into cells infected by such
CC viruses, preferably the RNA molecules to be expressed are antisense
CC sequences or double-strand sequences relative to the target cellular mRNA
CC molecules, and/or the agent is suitable for sequence-specific gene
CC silencing, preferably by antisense RNA or RNA interference mechanisms
CC such as ribozyme cleavages of target RNAs. The recombinant viruses can be
CC made for use in vaccines against HIV, hepatitis B or C virus, herpes
CC viruses or papilloma viruses. The present sequence represents a 3'
CC conserved region of a wild type influenza virus, given in the
CC exemplification of the present invention
XX
SQ Sequence 12 BP; 0 A; 5 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 AGGAGAAACAG 741
DB 12 AGCAGAGCAG 2

RESULT 1482
ABK99290
ID ABK99290 standard; RNA; 12 BP.
XX
AC ABK99290;
XX
DT 21-OCT-2002 (first entry)
XX
DE Hepatitis C virus (HCV) NS5B replicase RNA synthesis template #20.
XX
KW Hepatitis C virus; HCV; NS5B replicase; ss; RNA polymerase.
XX
OS Synthetic.
XX
FN US2002064771-A1.
XX
PD 30-MAY-2002.
XX
PF 06-APR-2001; 2001US-00828034.
XX
PR 07-APR-2000; 2000US-0195852P.
XX
PA (ZHON/) ZHONG W.
PA (HONG/) HONG Z.
PA (FERR/) FERRARI E.
XX
PI Zhong W, Hong Z, Ferrari E;
XX
DR WPI; 2002-582330/62.
XX
PT Novel replicase complex comprising hepatitis C virus NS5B replicase, a 3'
PT nucleotide-long template to which a 2 nucleotide-long primer is annealed,
PT and template and primer which do not form a stable duplex in the absence
PT of HCV NS5B.
XX
PS Example; Page 6; 17pp; English.
XX
CC The invention relates to a replicase complex comprising a hepatitis C
CC virus (HCV) NS5B replicase protein, a linear nucleic acid template and a
CC complementary nucleic acid primer which is annealed to the 3' terminus of
CC the template, where the template is at least three nucleotides and the
CC primer is two or three nucleotides, and the template and primer do not
CC form a stable duplex in solution in the absence of the HCV NS5B protein.
CC The complex is useful for detecting HCV replicase activity and permits

Query Match	35.5%;	Score 7.8;	DB 1;	Length 12;
Best Local Similarity	81.8%;	Pred. No. 5.8e+02;		
Matches	9;	Conservative	0;	Mismatches 2;
				Indels 0;
				Gaps 0;

RESULT 1484
AAD39657
ID AAD39657 standard; DNA; 12 BP.

ID	AAD39657	standard; DNA; 12 BP.
XX		
AC	AAD39657	

DT	22-OCT-2002 (first entry)
XX	Luc (luciferase)-1547/10-2 construct DNA.

XX	Recombinant vector; insertion cassette; small nuclear RNA; snRNA;
KW	transgenic animal; ds.
KW	
XX	

US
XX
XX
PN
XX

UNIDENTIFIED.

US2002058287 - A1.

FD
XX
XX
PF
XX
16-FBI-2002.
12-MAR-2001; 2001US-0080481.

PK
 XX
 XX
 PA
 YY
 YY
 (WHED) WHITEHEAD INST BIOMEDICAL RES.
 10-MAR-2000; 2000JUS-0188304P.

PI Graai DD, Lander ES;
XX WPI; 2002-499510/53.
DR
YY

PT New recombinant vector containing sequence for small nuclear RNA, useful
PT e.g. for identifying variant snRNA that suppresses expression of
PT transcription products.
yy

PS Example; Fig 3; 18pp; English.
XX
CC The invention relates to a recombinant vector which comprises DNA,
CC relating to a secretory cascade contained between at least two
CC

CC insertion sites, that encodes a small nuclear (sn) RNA. The invention is
CC used to identify snRNA modifications that inhibit expression of
CC transcription products (and the identified snRNA are used to suppress
CC transcription products).

CC create transgenic animals. The present sequence is Luc (luciferase) -
CC 1547/10+2 construct DNA. (Updated on 07-AUG-2003 to correct OS field.)
XX

Query Match	35.5%;	Score	7.8;	DB	1;	Length	12;
Best Local Similarity	81.8%;	Pred.	No.	6.8e+02;			

QY 734 AGAACAGAC 744

```
RESULT 1485
ABQ77279
ID ABQ77279 standard; DNA; 12 BP.
XX
AC ABQ77279;
XX
DT 25-APR-2003 (first entry)
XX
DE Sequencing oligonucleotide #1.
XX
KW Parallel analysis; gene expression; tumorigenesis; detection; ss.
XX
OS Synthetic.
XX
PN WO200288381-A2.
XX
PD 07-NOV-2002.
XX
PF 26-APR-2002; 2002WO-EP004657.
XX
PR 27-APR-2001; 2001DE-01020798.
XX
PA (GENO-) GENOVOKX GMBH.
XX
PI Tcherkassov D;
XX
DR WPI; 2003-183838/18.
XX
PT Parallel analysis of gene expression, useful e.g. for identifying genes
PT involved in tumorigenesis, by cyclical extension of randomly arranged
PT primers using modified nucleotides.
XX
PS Example 4; Page 54; 107pp; German.
XX
CC This invention describes a novel method for parallel analysis of gene
CC expression which comprises binding complexes, formed between a single-
CC stranded gene product and an individual primer, or many different
CC primers, to a surface in a random arrangement. Cyclical extension of the
CC complementary strand of the gene product is then performed using one or
CC more polymerases by treating the bound complexes with a solution
CC containing a polymerase and 1-4 modified nucleotides (NTX), labeled with
CC fluorescent dyes. NTX are base-modified so that if one NTX is
CC incorporated by polymerase then a second can not be incorporated into the
CC same strand. The method is used for quantitative analysis of the
CC expression of many genes, e.g. for identifying genes involved in
CC tumorigenesis. The gene products can be bound to any position on the
CC surface, eliminating the need for synthesis of different oligonucleotides
CC at specific positions. Analysis is performed on a standardised surface,
CC expression of unknown genes can be determined, since many molecules are
CC analysed, even weakly expressed genes can be detected, only small amounts
CC of starting material are required (mRNA from a single cell) and all steps
CC are suitable for automation. Only short sequences (10-50 nucleotides)
CC need to be determined for identification of genes, if their sequences are
CC available in databases. This sequence represents an oligonucleotide used
CC to illustrate the method of the invention
XX
SQ Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 737 AACAGAACACC 747
Db 1 ACCAAACACC 11
RESULT 1486
ABQ77340
ID ABQ77340 standard; DNA; 12 BP.
XX
AC ABQ77340;
XX
08-MAY-2003 (first entry)
Parallel sequencing associated oligonucleotide SEQ ID 3.
Parallel sequencing; cyclical extension; ds.
Synthetic.
WO200288382-A2.
07-NOV-2002.
26-APR-2002; 2002WO-EP004659.
27-APR-2001; 2001DE-01020797.
(GENO-) GENOVOKX GMBH.
Tcherkassov D;
WPI; 2003-183839/18.
Parallel sequencing of nucleic acid fragments, useful e.g. for analysis
of single-nucleotide polymorphisms, by cyclical extension of primers with
modified nucleotides.
Example 4; Page 59; 121pp; German.
This invention describes a novel method for parallel sequencing of
nucleic acid fragments which comprises: (i) binding fragments of about 50
-100 nucleotides that represent overlapping parts of a complete sequence,
as a complex with an individual primer, or many different primers, to a
reaction surface, in a random arrangement. (ii) Cyclical extension of the
complementary strand of the nucleic acid fragment is then performed using
one or more polymerases by treating the bound complexes with a solution
containing polymerases and 1-4 modified nucleotides, labeled with
fluorescent dyes and if two or more modified nucleotides are used, then
fluorescent signals from each can be measured separately. (iii) the
modified nucleotides are base-modified such that if one nucleotide is
incorporated by a polymerase then a second can not be incorporated into
the same strand, fluorescent dye can be cleaved and the modification into
the nucleotides is a cleavable sterically bulky ligand. (iv) The surface
is incubated so that each complementary strand is extended by one
nucleotide, then washed to remove unincorporated modified nucleotides and
the incorporated nucleotides are detected from a fluorescent signal at
the surface, simultaneously for all signals, (v) fluorescent dye and the
bulky ligand are removed from complementary strand, the surface washed
and the cycle repeated. (vi) The relative positions, on the surface, of
the bound fragment and the sequence of the nucleic acid fragments in them
are determined by correlation of the signals detected in many cycles at
each position. The method is used to sequence nucleic acids, especially
to detect all single-nucleotide polymorphisms in a sequence, also more
generally for mutational analysis and for detection of alternatively
spliced products. The method provides a cheaper, quicker and more
efficient analysis of sequences, many sequences can be determined in
parallel, including long (several Mb) or short (containing SNPs or
mutations) sequences, and all steps can be automated. Since individual
molecules can be detected, there is little risk of errors as a result of
desynchronisation, and it is immaterial if synthesis of a molecule at a
neighbouring site is progressing or not. The molecules do not have to be
fixed to the carrier in a defined pattern, since the signal is recorded
from individual molecules rather than from a spatially defined
population. This sequence represents an oligonucleotide used to
illustrate the method of the invention
XX
SQ Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 737 AACAGAACACC 747
Db 1 ACCAAACACC 11
```


DE NSKF target DNA sequence.
XX parallel sequencing; fluorescence; detection; mutational analysis; NSKF;
KW ds.
XX
XX Unidentified.
XX WO2003020968-A2.
XX 13-MAR-2003.
XX 28-AUG-2002; 2002WO-EP009614.
XX 29-AUG-2001; 2001DE-01042256.
XX (GENO-) GENOV0XX GMBH.
XX Tcherkassov D;
XX WPI; 2003-290205/28.
XX Parallel sequencing of nucleic acid fragments, useful e.g. for detecting
XX mutations, comprises sequential single-base extension of immobilized
XX fragment-primer complex.
XX
XX Example 2; Page 56; 114pp; German.
XX
XX This invention described a novel method for parallel sequencing analysis
XX of nucleic acids in which single-stranded fragments, of 50-1000 bases,
XX are generated, representing overlapping fragments of a complete sequence.
XX The fragments are then attached, as a complex with one or primers, in
XX random fashion to a reaction surface. The complementary strand of the
XX single stranded fragment is constructed using one or more DNA polymerases
XX in a cycle involving incubating the bound complex with at least one
XX polymerase and 1-4 modified nucleotides, labelled with a fluorescent dye,
XX different for each modified nucleotide, so that they can be distinguished.
XX Individual incorporated modified nucleotides can be detected from the
XX characteristic fluorescence, with simultaneous detection of the relative
XX positions of the complex on the surface and optionally repeating the
XX entire cycle. Detection is by broad-field epifluorescence, laser-
XX scanning fluorescence or total internal reflection fluorescence
XX microscopy. The relative positions of individual complexes and their
XX sequences are determined through specific correlation of the signal
XX detected in successive cycles. Each fragment includes a primer binding
XX site (PBS), one in each strand for double-stranded sequences, and this
XX site is the same for all fragments. The method is used (i) to identify
XX mutations, particularly all single-nucleotide polymorphisms in a gene and
XX (ii) for analysis of gene expression. Compared with known methods, this
XX process is less expensive, quicker and more efficient, especially it
XX allows many fragments to be sequenced simultaneously, from very large
XX (Mb) segments to short fragments for mutational analysis, in the same
XX process. Since single nucleic acid molecules can be detected, the risk of
XX errors through failure of synchronization in a population is avoided,
XX molecules do not have to be fixed at specific positions, and multiple
XX copies of the nucleic acid do not need to be made (eliminating cloning
XX and PCR). Even weakly expressed, or unknown, genes can be sequenced and
XX only a tiny amount of starting material (e.g. mRNA from a single cell) is
XX needed. This sequence represents a fragment of NSKF used as a target
XX sequence to illustrate the method of the invention.
XX
XX Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 737 AACAGAACACC 747
Db 1 ACCAAACACC 11
RESULT 1490
ADC22510/C

ID ADC22510 standard; DNA; 12 BP.
XX
AC ADC22510;
XX
DT 18-DEC-2003 (first entry)
XX
DE Protein binding domain nucleotide sequence SEQ ID NO:359.
XX
DE recombinant fusion protein; fusion protein; binding; detection;
KW localisation domain; binding domain;
KW subcellular compartment localisation; gene; ds.
XX
OS Homo sapiens.
XX
XX WO2003012068-A2.
XX
XX 13-FEB-2003.
XX
XX 01-AUG-2002; 2002WO-US024572.
XX
XX 01-AUG-2001; 2001US-0309395P.
XX
XX 13-DEC-2001; 2001US-0341589P.
XX
XX (CELL-) CELLOMICS INC.
XX
XX Bright G, Premkumar DR, Chen Y;
XX
XX WPI; 2003-248174/24.
XX
XX P-PSDB; ADC22511.
XX
XX New recombinant fusion protein comprising detection and first
XX localization domains and a binding domain for the molecule of interest,
XX useful for detecting binding of a molecule of interest.
XX
XX Disclosure; SEQ ID NO 359; 101pp; English.
XX
XX The present invention describes a recombinant fusion protein (I) for
XX detecting binding of a molecule of interest. (I) comprises: (a) a
XX detection domain; (b) a first localisation domain; and (c) a binding
XX domain for the molecule of interest. The detection domain, the first
XX localisation domain and the binding domain for the molecule of interest
XX constituting the recombinant fusion protein for detecting binding of a
XX molecule of interest are operably linked. The binding domain for the
XX molecule of interest is separated from the first localisation domain by 0
XX -20 amino acid residues. The first localisation domain and the binding
XX domain for the molecule of interest both do not occur in a single non-
XX recombinant protein with the same spacing as in the recombinant fusion
XX protein for detecting binding of a molecule of interest. Also described:
XX (1) a recombinant nucleic acid encoding the recombinant fusion protein;
XX (2) a recombinant expression vector comprising the nucleic acid control;
XX sequences operably linked to the recombinant nucleic acid molecule; (3) a
XX genetically engineered host cell transfected with the recombinant
XX expression vector; (4) a kit for detecting binding of the molecule of
XX interest; and (5) a method for identifying compounds that alter the
XX binding of the molecule of interest. The recombinant fusion protein is
XX useful for detecting binding of a molecule of interest. The recombinant
XX fusion protein eliminates the need to construct two or more chimeric
XX proteins and enables the monitoring of biochemical events in live, intact
XX or fixed cells. The present sequence is used in the exemplification of
XX the present invention.
XX
XX Sequence 12 BP; 0 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 35.5%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 6.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 736 AACAGAACACC 746
Db 12 AGACAGACGC 2
RESULT 1491

ADCL8377
 ID ADCL8377 standard; DNA; 12 BP.
 AC ADCL8377;
 DT 18-DEC-2003 (first entry)
 XX
 DE Protease recognition site for caspase-6 DNA #1.
 KW ds; cell based toxin; luminescent reporter molecule; biosensor;
 KW microchip; drug discovery; MAP4; epitope; affinity tag;
 KW protease recognition site; caspase; target domain.
 XX
 OS Unidentified.
 XX
 PN US2003096322-A1.
 XX
 PD 22-MAY-2003.
 XX
 PF 19-MAR-2002; 2002US-00100957.
 XX
 PR 27-FEB-1997; 97US-00810983.
 PR 27-FEB-1998; 98US-00031271.
 PR 26-FEB-1999; 99US-0121522P.
 PR 08-MAR-1999; 99US-0123399P.
 PR 12-JUL-1999; 99US-00352171.
 PR 31-AUG-1999; 99US-0151797P.
 PR 17-SEP-1999; 99US-00398965.
 PR 29-OCT-1999; 99US-00430656.
 PR 01-DEC-1999; 99US-0168408P.
 PR 25-FEB-2000; 2000US-00513783.
 XX
 PA (CELL-) CELLOMICS INC.
 XX
 PI Giuliano K, Kapur R;
 XX
 DR WPI: 2003-786988/74.
 DR P-PSDB; ADCL8378.
 XX
 PT Cell based toxin characterization method for e.g. in drug discovery
 PT paradigm, involves treating cells possessing luminescent reporter
 PT molecules with fluorescence based molecular reagents to detect presence
 PT of toxins.
 XX
 PS Example 10; SEQ ID NO 65; 98pp; English.

XX The invention relates to characterising cell based toxins, where the cell
 CC possessing luminescent reporter molecules (biosensors) are provided on a
 CC microchip, and are treated with fluorescence based molecular reagents.
 CC The cells are photographed with fluorescence optics, and the optical
 CC information is converted into digital data. The presence of the toxin in
 CC a reagent, is detected using the digital data, based on changes in the
 CC localisation, distribution structure of identifier, detector and
 CC classifier in each cell. Also included are a computer readable storage
 CC medium storing a cell based toxin characterisation program, and a kit for
 CC cell based toxin detection. The method is used for characterising or
 CC detecting a biological cell based toxin that affect particular biological
 CC functions and for preparing molecular biochemical arrays for new drug
 CC discovery paradigm. It is also used in automated DNA sequencing, PCR
 CC application, positional cloning, hybridisation arrays and bioinformatics
 CC using cell based scanning and screening system. The method improves the
 CC target validation and candidate optimisation by combining many cell
 CC screening formats with fluorescence based molecular reagents, thereby
 CC resulting in increased quantity and speed of data collection, shortened
 CC cycle times and faster evaluation of promising drug candidates. The
 CC method also provides increased throughput while decreasing the volumes of
 CC reagent and test compounds required in each assay. The biosensor
 CC comprises a signal component (fluorescent protein (fused e.g. MAP4,
 CC tethering it to microtubules) or detectable signal (epitope or affinity
 CC tag)), a protease recognition site (e.g. for a caspase protein) and a
 CC target domain (localising the biosensor to a particular cellular
 CC compartment). The present sequence encodes a protease recognition site
 CC for a biosensor of the invention.

XX
 SQ Sequence 12 BP; 6 A; 1 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 35.5%; Score 7.8; DB 1; Length 12;
 : Best Local Similarity 81.8%; Pred. No. 6.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 732 GGAGAAACAGA 742
 Db 1 GTAGAAATAGA 11
 Search completed: October 18, 2004, 14:07:21
 Job time : 8 secs

96

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 18, 2004, 14:39:47 ; Search time 0.001 Seconds
(without alignments)
38.836 Million cell updates/sec

Title: US-09-695-451-1
Perfect score: 73
Sequence: 1 cccgtgctattttcttgggt.....atgtagctaccacgggtg 73

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 26 seqs, 266 residues

Total number of hits satisfying chosen parameters: 52

Minimum DB seq length: 8
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 27 summaries

Database : rst1-899.seq*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	12.4	17.0	19	1	ACCESSION:AZ386064
2	9.8	13.4	13	1	ACCESSION:BQ589768
3	8.8	12.1	13	1	ACCESSION:BQ582420
4	8.4	11.5	12	1	ACCESSION:B07312
5	7.8	10.7	12	1	ACCESSION:BQ587766
6	7.8	10.7	12	1	ACCESSION:CG677120
7	7.6	10.4	9	1	ACCESSION:AL394889
8	7.4	10.1	10	1	ACCESSION:CF311011
9	7.4	10.1	10	1	ACCESSION:CK298980
10	7.4	10.1	11	1	ACCESSION:BQ585171
11	7.4	10.1	11	1	ACCESSION:CF299850
12	7.4	10.1	11	1	ACCESSION:CF304450
13	7.4	10.1	11	1	ACCESSION:CF309889
14	7.4	10.1	11	1	ACCESSION:CF343159
15	7.4	10.1	12	1	ACCESSION:B07312
16	6.4	8.8	8	1	CF277997
17	6.4	8.8	8	1	ACCESSION:CF301888
18	6.4	8.8	8	1	ACCESSION:CF302851
19	6.4	8.8	8	1	CF312818
20	6.4	8.8	9	1	ACCESSION:CA794325
21	6.4	8.8	9	1	ACCESSION:CA851674
22	6.4	8.8	9	1	ACCESSION:CF312817
23	6.4	8.8	9	1	CF318771
24	6.4	8.8	9	1	ACCESSION:CF330649
25	6.4	8.2	8	1	CA794554
26	6.4	8.2	8	1	ACCESSION:CF313731
27	5.4	7.4	8	1	ACCESSION:CA851350

ALIGNMENTS

AZ386064

LOCUS 1M0145C04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0145C04 F, genomic survey sequence.

ACCESSION AZ386064

VERSION AZ386064.1

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

REFERENCE

AUTHORS

1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Iellam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

TITLE

JOURNAL

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0145 row: C column: 04

Seq primer: CGTTGTAACACGACGGCCAGT

Class: plasmid ends

High quality sequence stop: 19.

FEATURES

source

1..19

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0145C04"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/notes="Vector: FWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of pWB42 (G14732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and

purified. The sheared, adapted mouse DNA was annealed to

adapted vector DNA, and transformed into

chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

Query Match 17.0%; Score 12.4; DB 1; Length 19;

Best Local Similarity 92.9%; Pred. No. 1.3;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 918 TCCTTGGCCTTTTAT 931

|||||

Db 4 TCCTTGGCCTTTTGT 17

RESULT 2

BQ589768

RESULT 1

LOCUS BQ589768 13 bp mRNA linear EST 06-DEC-2002
 DEFINITION E012680-024-020-D03-SP6 MP1Z-ADIS-024-storage root Beta vulgaris
 ACCESSION BQ589768
 VERSION BQ589768.1 GI:26119351
 KEYWORDS EST.
 SOURCE Beta vulgaris
 ORGANISM Beta vulgaris
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
 REFERENCE 1 (bases 1 to 13)
 AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
 TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
 JOURNAL Plant J. 32 (5), 845-857 (2002)
 MEDLINE 22362189
 PUBMED 12472698
 COMMENT Contact: Weisshaar B
 ADIS DNA core facility at MPIZ
 Max-Planck-Institute for Plant Breeding Research
 Carl-von-Linne Weg 10, 50829 Koeln, Germany
 Fax: 00492215062851
 Email: weisshaar@piz-koeln.mpg.de
 Insert Length: 13 Std Error: 0.00
 Plate: 20 row: D column: 03
 Seq primer: SP6; CATACGATTAGTGACACTATAG.
 Location/Qualifiers
 1. 13
 /organism="Beta vulgaris"
 /mol_type="mRNA"
 /cultivar="KWS2320 (double haploid, monogerm breeding line)"
 /db_xref="GABI:190356"
 /db_xref="taxon:161934"
 /clone="024-020-D03"
 /tissue_type="storage root"
 /lab_host="EMDH10B"
 /clone_lib="MP1Z-ADIS-024-storage root"
 /note="Vector: pCMVSPORT6; Site 1: Sali; Site 2: NotI; cDNA library from sugar beet, library provided by KWS Kleinvanzlebener Saat-zucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites Sali-NotI, primer sites and orientation:
 SP6-Sali-CCACGGCTCGG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"
 Query Match 13.4%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 932 CCCTCCTCTTCAT 944
 |||||
 Db 1 CCCTCCTCTTCAT 13

RESULT 3
 BQ582420/c
 LOCUS BQ582420 13 bp mRNA linear EST 06-DEC-2002
 DEFINITION E012207-024-001-J02-SP6 MP1Z-ADIS-024-inflorescence Beta vulgaris
 ACCESSION BQ582420
 VERSION BQ582420.1 GI:26111997
 KEYWORDS EST.
 SOURCE Beta vulgaris
 ORGANISM Beta vulgaris
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

Caryophyllales; Amaranthaceae; Beta.
 REFERENCE 1 (bases 1 to 13)
 AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
 TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
 JOURNAL Plant J. 32 (5), 845-857 (2002)
 MEDLINE 22362189
 PUBMED 12472698
 COMMENT Contact: Weisshaar B
 ADIS DNA core facility at MPIZ
 Max-Planck-Institute for Plant Breeding Research
 Carl-von-Linne Weg 10, 50829 Koeln, Germany
 Fax: 00492215062851
 Email: weisshaar@piz-koeln.mpg.de
 Insert Length: 13 Std Error: 0.00
 Plate: 1 row: J column: 02
 Seq primer: SP6; CATACGATTAGTGACACTATAG.
 Location/Qualifiers
 1. 13
 /organism="Beta vulgaris"
 /mol_type="mRNA"
 /cultivar="KWS2320 (double haploid, monogerm breeding line)"
 /db_xref="GABI:181155"
 /db_xref="taxon:161934"
 /clone="024-001-J02"
 /tissue_type="inflorescence"
 /lab_host="EMDH10B"
 /clone_lib="MP1Z-ADIS-024-inflorescence"
 /note="Vector: pCMVSPORT6; Site 1: Sali; Site 2: NotI; cDNA library from sugar beet, library provided by KWS Kleinvanzlebener Saat-zucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites Sali-NotI, primer sites and orientation:
 SP6-Sali-CCACGGCTCGG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"
 Query Match 12.1%; Score 8.8; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 3.4;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 910 TTCTTTGGTCTT 921
 |||||
 Db 13 TTCTTTGGTCTT 2

RESULT 4
 BQ7312
 LOCUS BQ7312 12 bp DNA linear GSS 26-MAR-1997
 DEFINITION G36073 MVAT4 sheared genomic library Trypanosoma brucei rhodesiense genomic clone G360, genomic survey sequence.
 ACCESSION BQ7312
 VERSION BQ7312.1 GI:1667053
 KEYWORDS GSS.
 SOURCE Trypanosoma brucei rhodesiense
 ORGANISM Trypanosoma brucei rhodesiense
 Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
 REFERENCE 1 (bases 1 to 12)
 AUTHORS El-Sayed,N.M.A. and Donelson,J.E.
 TITLE A survey of the Trypanosoma brucei rhodesiense genome using shotgun sequencing
 JOURNAL Mol. Biochem. Parasitol. 84 (2), 167-178 (1997)
 MEDLINE 97237559
 PUBMED 9084037
 COMMENT Other GSSs: G360T7
 Contact: El-Sayed NMA
 John Donelson's Laboratory

Howard Hughes Medical Institute
300 EMBR, Dept. of Biochemistry, University of Iowa, Iowa City, IA
52242
Tel: 319 335 6918
Fax: 319 335 6764
Email: nelsayed@vaxa.weeg.uiowa.edu
Insert Length: 700 Std Error: 200.00
Seq primer: T3 primer
Class: shotgun.

FEATURES

source

Location/Qualifiers

1..12
/organism="Trypanosoma brucei rhodesiense"
/mol_type="genomic DNA"
/sub_species="rhodesiense"
/db_xref="taxon:31286"
/clone="G360"
/dev_stage="Bloodstream form"
/clone_lib="MVAT4 sheared genomic library"
/note="Vector: PCR-Script Amp SK(+)
Srf I; Genomic DNA was isolated from a cloned population
of bloodstream trypanosomes reexpressing the MVAT4
metacyclic variant surface glycoprotein (VSG). For the
shotgun library construction, the DNA was mechanically
sheared to give a tight size distribution, then
blunt-ended with T4 DNA polymerase. Following
dephosphorylation with Shrimp Alkaline Phosphatase, DNA
fragments were cloned into the PCR-Script vector
(Stratagene)."

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.4;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 955 TATCGCTACC 964

Db 1 TATCGATACC 10

RESULT 5

BQ587766

LOCUS

DEFINITION E012340-024-010-M01-SP6 MP12-ADIS-024-leaf Beta vulgaris cDNA clone

024-010-M01 5-PRIME, mRNA sequence.

ACCESSION BQ587766

VERSION BQ587766.1

KEYWORDS EST.

SOURCE Beta vulgaris

ORGANISM Beta vulgaris

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

Caryophyllales; Amaranthaceae; Beta.

REFERENCE 1 (bases 1 to 12)

AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,

Drungowski,M., Stahl,D., Wruock,W., Menze,A., O'Brien,J., Lehrach,H.

and Radelof,U.

Construction of a 'unigene' cDNA clone set by oligonucleotide

fingerprinting allows access to 25 000 potential sugar beet genes

Plant J. 32 (5), 845-857 (2002)

JOURNAL MEDLINE 22362189

PUBMED 12472698

COMMENT Contact: Weisshaar B

ADIS DNA core facility at MPIZ

Max-Planck-Institute for Plant Breeding Research

Carl-von-Linne Weg 10, 50829 Koeln, Germany

Fax: 00492215062851

Email: weissshaar@piz-koeln.mpg.de

Insert Length: 12 Std Error: 0.00

Plate: 10 row: M column: 01

Seq primer: SP6; CATACGATTAGTGACACTATAG.

Location/Qualifiers

1..12

/organism="Beta vulgaris"

/mol_type="mRNA"

/cultivar="KWS2320 (double haploid, monogerm breeding
line)"
/db_xref="GABI:185095"
/db_xref="taxon:161934"
/clone="024-010-M01"
/tissue_type="leaf"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-leaf"
/notes="Vector: pCMVSPORT6; Site 1: Sali; Site 2: NotI;
cDNA library from sugar beet, library provided by KWS
Kleinwanzlebener Saatgut AG Einbeck, Germany, contact:
b.schulz@kws.de; cloning sites Sali-NotI, primer sites and
orientation:
SP6-Sali-CCACGCGTCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
Sequencing granted in the context of the GABI-Best
Project, local PI: Dr. Katharina Schneider, coordinator:
Prof. Christian Jung; Sequence submission managed by
RZPD/GABI-Primary database:http://gabi.rzpd.de"

Query Match 10.7%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 4.6;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 931 TCCTCTCTCTT 941

Db 2 TCCTCTCTCTT 12

RESULT 6

CG677120

LOCUS

DEFINITION tmf0875 tmf Aegilops tauschii genomic clone tmf17C15, genomic

survey sequence.

ACCESSION CG677120

VERSION CG677120.1

KEYWORDS GSS

SOURCE Aegilops tauschii

ORGANISM Aegilops tauschii

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Pooideae; Triticeae; Aegilops.

REFERENCE 1 (bases 1 to 12)

AUTHORS Li,W., Zhang,P., Fellers,J., Friebe,B. and Gill,B.S.

Sequence composition, organization and evolution of a basic

Triticeae genome of the grass family

Unpublished (2003)

JOURNAL

COMMENT Contact: Li, W

Dr. Bikram S. Gill's Lab

Wheat Genetics Resource Center, Kansas State University

4024 Throckmorton, Manhattan, KS 66506-5502, USA

Tel: 785-532-1108

Fax: 785-532-5692

Email: wli@ksu.edu

Seq primer: T7

Class: sheared ends.

Location/Qualifiers

1..12

/organism="Aegilops tauschii"

/mol_type="genomic DNA"

/strain="AL 8/78"

/db_xref="taxon:37682"

/clone="tmf17C15"

/tissue_type="leaves"

/dev_stage="shoot"

/lab_host="E. coli strain DH5alpha"

/clone_lib="tmf"

/notes="Vector: PCR 4Blunt-TOP; 0.8-1.2 kb methylation

filtered genomic DNA library"

Query Match 10.7%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 4.6;

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Qy 950 TAATGATATCGC 960
Db 1 TAACGAATCGC 11

RESULT 7
LOCUS CNS06ESN/c 9 bp DNA linear GSS 17-JUN-2001
DEFINITION T3 end of clone AR0AA018H04 of library AR0AA from strain CBS 732 of
Zygosaccharomyces rouxii, genomic survey sequence.
ACCESSION AL394689
VERSION AL394689.1 GI:12145788
KEYWORDS GSS.
SOURCE Zygosaccharomyces rouxii
ORGANISM Zygosaccharomyces rouxii
REFERENCE 1 (bases 1 to 9)
AUTHORS Souciet,J.L., Aigle,M., Artiguenave,F., Blandin,G.,
Bolotin-Fukuhara,M., Bon,E., Brattier,P., Casaregola,S.,
de-Montigny,J., Dujon,B., Durrens,P., Lepingle,A., Liorente,B.,
Malpertuy,A., Neuvéglise,C., Ozier-Kalogeropoulos,O., Potier,S.,
Saurin,W., Tekala,F., Toffano-Nioche,C., Wesolowski-Louvel,M.,
Winkler,P. and Weissensbach,J.
TITLE Genomic exploration of the hemiascomycetous yeasts: 1. A set of
yeast species for molecular evolution studies
JOURNAL FEBS Lett. 487 (1), 3-12 (2000)
MEDLINE 20584711
PUBMED 11152876
REFERENCE 2 (bases 1 to 9)
AUTHORS de Montigny,J., Straub,M., Potier,S., Tekala,F., Dujon,B.,
Winkler,P., Artiguenave,F. and Souciet,J.
TITLE Genomic exploration of the hemiascomycetous yeasts: 8.
Zygosaccharomyces rouxii
JOURNAL FEBS Lett. 487 (1), 52-55 (2000)
MEDLINE 20584718
PUBMED 11152883
REFERENCE 3 (bases 1 to 9)
AUTHORS Genoscope.
TITLE Direct Submission
JOURNAL Submitted (06-SEP-2000) Genoscope - Centre National de Séquençage,
2 rue Gaston Crémieux, CP 5706, 91057 EVRY cedex, FRANCE. (E-mail :
seqref@genoscope.cns.fr - Web : www.genoscope.cns.fr)
COMMENT This GSS is part of a random genomic sequencing program of thirteen
yeast species: Saccharomyces bayanus var. uvarum, Saccharomyces
exiguus, Saccharomyces servazzii, Zygosaccharomyces rouxii,
Saccharomyces kluyveri, Kluyveromyces thermotolerans, Kluyveromyces
lactis var. lactis, Kluyveromyces marxianus var. marxianus, Pichia
angusta, Debaryomyces hansenii var. hansenii, Pichia sorbitophila,
Candida tropicalis and Yarrowia lipolytica. Genomic inserts of 3 to
5 kb were prepared and both extremities were sequenced. See
keywords for description of this sequence and for the sequence of
the other extremity of this insert.

FEATURES
source
Location/Qualifiers
1..9
/organism="Zygosaccharomyces rouxii"
/mol_type="genomic DNA"
/strain="CBS 732"
/db_xref="taxon:4956"
/clone="AR0AA018H04"
/clone_lib="AR0AA"
/note="end : T3"

Query Match 10.4%; Score 7.6; DB 1; Length 9;
Best Local Similarity 87.5%; Pred. No. 35;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 904 GTCAATTTT 911
Db 9 GTCAATTTT 2

RESULT 8

```

```

CF311011 10 bp mRNA linear EST 15-AUG-2003
LOCUS ABF--06-B02.b1 ABF3-overexpressing transgenic rice plasmid cDNA
DEFINITION Library (ABF) Oryza sativa cDNA clone ABF--06-B02, mRNA sequence.
ACCESSION CF311011
VERSION CF311011.1 GI:33682772
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
REFERENCE 1 (bases 1 to 10)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nam,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nam B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnam@ggbio.com, bhnam@bio.myongji.ac.kr.

FEATURES
source
Location/Qualifiers
1..10
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="ABF--06-B02"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="ABF3-overexpressing transgenic rice plasmid
cDNA library (ABF)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; Leaf was dried
for 2hrs. Oligo-capped mRNA was reverse transcribed and
then used for PCR. mRNA was prepared from ABA-responsive
element binding transcription factor 3 overexpression
line."

Query Match 10.1%; Score 7.4; DB 1; Length 10;
Best Local Similarity 88.9%; Pred. No. 3 6;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTC 942
Db 2 CTCCTCTTC 10

RESULT 9
CK298980 10 bp mRNA linear EST 15-DEC-2003
LOCUS EST761694 Nicotiana benthamiana mixed tissue cDNA library,
DEFINITION normalized, full-length Nicotiana benthamiana cDNA clone NBMDJ48 3',
end, mRNA sequence.
ACCESSION CK298980
VERSION CK298980.1 GI:39886896
KEYWORDS EST.
SOURCE Nicotiana benthamiana
ORGANISM Nicotiana benthamiana
REFERENCE 1 (bases 1 to 10)
AUTHORS Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
asterids; lamids; Solanales; Solanaceae; Nicotiana.
Buell,C.R., Hart,A., Zismann,V., Karamycheva,S.A., Day,B.,
Staskawicz,B., Jin,H. and Baker,B.
TITLE Generation of EST sequences from Nicotiana benthamiana
JOURNAL Unpublished (2003)
COMMENT Other ESTs: EST761693
Contact: Robin Buell
The Institute for Genomic Research

```

9712 Medical Center Dr, Rockville, MD 20850, USA
 Email: potato-array@tigr.org
 Clones can be requested from TIGR via potato@tigr.org
 Seq primer: GFA ATA CGA CTC ACT ATA GGG C.

FEATURES source

Location/Qualifiers
 1. .110
 /organism="Nicotiana benthamiana"
 /mol_type="mRNA"
 /db_xref="taxon:4100"
 /clone="NBMDJ48"
 /tissue_type="abiotic and biotic stress-treated leaves, callus tissue and root tissue"
 /lab_host="DH10B-Tona"
 /clone_lib="Nicotiana benthamiana mixed tissue cDNA library, normalized, full-length"
 /note="Vector: pCMVSPORT6.1; Site 1: EcoRI; Site 2: NotI; supplier: RNA was isolated from Nicotiana benthamiana tissues that include callus, roots from liquid culture grown plants, heat-stressed leaves (38 C, 3 hr and 6 hr), cold-stressed leaves (5 C 3 hr, 6hr), and pathogen challenged leaves (Pseudomonas syringae pv tomato 12 hr; Xanthomonas campestris pv campestris 12 hr, 18hr; Pseudomonas syringae pv phaseolicola 18hr, and Xanthomonas campestris pv vesicatoria 18hr). RNA was isolated from these tissues and pooled in approximately equal molar amounts."

Query Match 10.1%; Score 7.4; DB 1; Length 10;
 Best Local Similarity 88.9%; Pred. No. 3.6;
 Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 907 ATTTTCTTT 915
 |||||
 Db 1 ATTTTCTTT 9

RESULT 10

BQ585171/c
 LOCUS BQ585171 11 bp mRNA linear EST 06-DEC-2002
 DEFINITION S04222-024-001-J02-SP6 MP12-ADIS-024-inflorescence Beta vulgaris cDNA clone 024-001-J02 5-PRIME, mRNA sequence.

ACCESSION

VERSION BQ585171
 KEYWORDS EST.

SOURCE

Beta vulgaris
 Beta vulgaris
 ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.

REFERENCE

1 (bases 1 to 11)
 AUTHORS Herwig, R., Schulz, B., Weishaar, B., Hennig, S., Steinfath, M., Drungowski, M., Stahl, D., Wruck, W., Menze, A., O'Brien, J., Leirach, H. and Radelof, U.

TITLE

Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes

JOURNAL

Plant J. 32 (5), 845-857 (2002)

MEDLINE

22362189

PUBMED

12472698

COMMENT

Contact: Weishaar B
 ADIS DNA core facility at MP12
 Max-Planck-Institute for Plant Breeding Research
 Carl-von-Linne Weg 10, 50829 Koeln, Germany
 Fax: 00492215062851
 Email: weissshaar@mpi-z-koeln.mpg.de
 Insert Length: 11 Std Error: 0.00
 Plate: 1 row, J column: 02

Seq primer: SP6; CATACGATTAGTGACACTATAG.

FEATURES source

Location/Qualifiers
 1. .11
 /organism="Beta vulgaris"
 /mol_type="mRNA"
 /cultivar="KWS2320 (double haploid, monogerm breeding line)"

/db_xref="GABI:181534"
 /db_xref="taxon:161934"
 /clone="024-001-J02"
 /tissue_type="inflorescence"
 /lab_host="EMDH10B"
 /clone_lib="MP12-ADIS-024-inflorescence"
 /note="Vector: pCMVSPORT6; Site 1: SalI; Site 2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatgut AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
 SP6-SalI-CCACGCTCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Best project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 10.1%; Score 7.4; DB 1; Length 11;
 Best Local Similarity 88.9%; Pred. No. 4.6;
 Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 913 TTTCGTCTT 921
 |||||
 Db 10 TTTCGTCTT 2

RESULT 11

CF299850/c
 LOCUS CF299850 11 bp mRNA linear EST 15-AUG-2003
 DEFINITION 7LEAF-04-A13-g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza sativa cDNA clone 7LEAF-04-A13, mRNA sequence.

ACCESSION

VERSION CF299850
 KEYWORDS EST.

SOURCE

Oryza sativa
 Oryza sativa
 ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE

1 (bases 1 to 11)
 AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

TITLE

Large-scale Sequencing Analysis of Rice ESTs

COMMENT

Unpublished (2003)
 Contact: Nahm, B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
 Yongin, Gyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES source

Location/Qualifiers
 1. .11
 /organism="Oryza sativa"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:4530"
 /clone="7LEAF-04-A13"
 /tissue_type="leaf"
 /dev_stage="7 days after germination"
 /lab_host="E.coli DH10B"
 /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
 /note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 10.1%; Score 7.4; DB 1; Length 11;
 Best Local Similarity 88.9%; Pred. No. 4.6;
 Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 907 ATTTTCTTT 915
 |||||
 Db 9 ATTTTCTTT 1

RESULT 12

CF304450/c

LOCUS 11 bp mRNA linear EST 15-AUG-2003
 DEFINITION ABP1--05-A03_g1 ABP3-overexpressing transgenic rice lambda phage
 CDNA library (ABP1) Oryza sativa cDNA clone ABP1--05-A03, mRNA
 sequence.

ACCESSION CF304450

VERSION CF304450.1 GI:33676211

KEYWORDS EST.

SOURCE Oryza sativa

ORGANISM Oryza sativa

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE 1 (bases 1 to 11)

AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

UNPUBLISHED (2003)

CONTACT: Nahm B.H.

GENOMICS AND GENETICS INSTITUTE, GREENGENE BIOTECH INC.; DIVISION
 OF BIOSCIENCE AND BIOINFORMATICS, MYONGJI UNIVERSITY

Yongin, Kyeonggi, Korea

Tel: 82 31 320 6193

Fax: 82 31 321 6355

Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1. .11

/organism="Oryza sativa"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:4530"

/clone="ABP1--05-A03"

/tissue_type="leaf"

/dev_stage="14 days after germination"

/lab_host="E.coli SOLR"

/clone_lib="ABP3-overexpressing transgenic rice lambda

phage CDNA library (ABP1)"

/note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:

XhoI; Leaf was dried for 2hrs. cDNA was inserted into

lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end

with XhoI site. mRNA was prepared from ABA-responsive

element binding transcription factor 3 overexpression

line."

Query Match 10.1%; Score 7.4; DB 1; Length 11;

Best Local Similarity 88.9%; Pred. No. 4.6;

Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 930 ATCCCTCCT 938

Db 11 ATCCCTCGT 3

RESULT 13

CF309889

LOCUS 11 bp mRNA linear EST 15-AUG-2003
 DEFINITION ABP--04-E09_g1 ABP3-overexpressing transgenic rice plasmid cDNA
 library (ABP) Oryza sativa cDNA clone ABP--04-E09, mRNA sequence.

ACCESSION CF309889

VERSION CF309889.1 GI:33681650

KEYWORDS EST.

SOURCE Oryza sativa

ORGANISM Oryza sativa

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE 1 (bases 1 to 11)

AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

JOURNAL

COMMENT

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University

Yongin, Kyeonggi, Korea

Tel: 82 31 320 6193

Fax: 82 31 321 6355

Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1. .11

/organism="Oryza sativa"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:4530"

/clone="ABP--04-E09"

/tissue_type="leaf"

/dev_stage="14 days after germination"

/lab_host="E.coli DH10B"

/clone_lib="ABP3-overexpressing transgenic rice plasmid

CDNA library (ABP)"

/note="Vector: PCR4-TOPO; Site_1: EcoRI; Leaf was dried

for 2hrs. Oligo-capped mRNA was reverse transcribed and

then used for PCR. mRNA was prepared from ABA-responsive

element binding transcription factor 3 overexpression

line."

Query Match 10.1%; Score 7.4; DB 1; Length 11;

Best Local Similarity 88.9%; Pred. No. 4.6;

Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 923 GCCTTTTAT 931

Db 2 GCCTTTT 10

RESULT 14

CF543159

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

PUBMED

COMMENT

CF543159 11 bp mRNA linear EST 22-SEP-2003

S014578-024-030-006-SP6 MP12-ADIS-024-leaf Beta vulgaris cDNA clone

024-030-006 5-PRIME, mRNA sequence.

CF543159 GI:34891599

EST.

Beta vulgaris

Beta vulgaris

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

Caryophyllales; Amaranthaceae; Beta.

1 (bases 1 to 11)

Herwig, R., Schulz, B., Weisshaar, B., Hennig, S., Steinfath, M.,

Drungowski, M., Stahl, D., Wruck, W., Menze, A., O'Brien, J., Lehrach, H.

and Radelof, J.

Construction of a 'unigene' cDNA clone set by oligonucleotide

fingerprinting allows access to 25 000 potential sugar beet genes

Plant J 32 (5), 845-857 (2002)

22362189

12472698

Contact: Weisshaar B

ADIS DNA core facility at MP12

Max-Planck-Institute for Plant Breeding Research

Carl-von-Linne Weg 10, 50829 Koeln, Germany

Fax: 00492215062851

Email: weisshaar@piz-koeln.mpg.de

Insert length: 11 Std Error: 0.00

Plate: 30 row: 0 column: 06

Seq primer: SP6.

Location/Qualifiers

1. .11

/organism="Beta vulgaris"

/mol_type="mRNA"

/cultivar="KWS320 (double haploid, monogerm breeding

line)"

/db_xref="GABI:936619"

```

/db_xref="taxon:161934"
/clone="024-030-006"
/tissue_type="leaf"
/lab_host="EMDH10B"
/clone_lib="MP1Z-ADIS-024-leaf"
/note="Vector: pCMVSPORT6; Site 1: SalI; Site 2: NotI;
cDNA library from sugar beet, library provided by KWS
Kleinwanzlebener Saatzzucht AG Binbeck, Germany, contact:
b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
orientation:
SP6-Sali-CCACCGTCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
Sequencing granted in the context of the GABI-Beet
Project, local PI: Dr. Katharina Schneider, coordinator:
Prof. Christian Jung; Sequence submission managed by
RZPD/GABI-Primary database:http://gabi.rzpd.de"

Query Match      10.1%; Score 7.4; DB 1; Length 11;
Best Local Similarity 88.9%; Pred. No. 4.6;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 906 CATTTCCTT 914
Db 3 CACTTCCTT 11

RESULT 15
LOCUS      B07312/c
DEFINITION G360T3 MVAT4 sheared genomic library Trypanosoma brucei rhodesiense
ACCESSION  G360T3
VERSION     1
KEYWORDS   GSS.
SOURCE     Trypanosoma brucei rhodesiense
ORGANISM   Trypanosoma brucei rhodesiense
            Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae;
            Trypanosoma.
REFERENCE  1 (bases 1 to 12)
AUTHORS   El-Sayed,N.M.A. and Donelson,J.E.
TITLES    A survey of the Trypanosoma brucei rhodesiense genome using shotgun
            sequencing
JOURNAL   Mol. Biochem. Parasitol. 84 (2), 167-178 (1997)
MEDLINE   97237559
PUBMED    9084037
COMMENT   Other GSSs: G360T7
            Contact: El-Sayed NWA
            John Donelson's Laboratory
            Howard Hughes Medical Institute
            300 EXRB, Dept. of Biochemistry, University of Iowa, Iowa City, IA
            52242
            Tel: 319 335 6918
            Fax: 319 335 6764
            Email: nelsayed@vaxa.weeg.uiowa.edu
            Insert Length: 700 Std Error: 200.00
            Seq primer: T3 primer
            Class: shotgun.
FEATURES   location/Qualifiers
            1..12
            /organism="Trypanosoma brucei rhodesiense"
            /mol_type="genomic DNA"
            /sub_species="rhodesiense"
            /db_xref="taxon:31286"
            /clone="G360"
            /dev_stage="Bloodstream form"
            /clone_lib="MVAT4 sheared genomic library"
            /note="Vector: pCR-Script Amp SK(+)(Stratagene); Site 1:
            Srf I; Genomic DNA was isolated from a cloned population
            of bloodstream trypanosomes reexpressing the MVAT4
            metacyclic variant surface glycoprotein (VSG). For the
            shotgun library construction, the DNA was mechanically
            sheared to give a tight size distribution, then
            blunt-ended with T4 DNA polymerase. Following
            dephosphorylation with Shrimp Alkaline Phosphatase, DNA
            fragments were cloned into the pCR-Script vector
            (Stratagene)."
```

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.

1 (bases 1 to 8)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University

Yongin, Gyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1..8
Location/Qualifiers
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF-06-017"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 8.8%; Score 6.4; DB 1; Length 8;
Best Local Similarity 87.5%; Pred. No. 39;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915

Db 8 TTTTCTTT 1

RESULT 18

CF302851/c

LOCUS 8 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF-08-M07.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
sativa cDNA clone 7LEAF-08-M07, mRNA sequence.

ACCESSION CF302851

VERSION CF302851.1 GI:33674612

KEYWORDS EST.

SOURCE Oryza sativa

ORGANISM

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.

1 (bases 1 to 8)

Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University

Yongin, Gyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1..8
Location/Qualifiers
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF-08-M07"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"

/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match 8.8%; Score 6.4; DB 1; Length 8;

Best Local Similarity 87.5%; Pred. No. 39;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915

Db 8 TTTTCTTT 1

RESULT 19

CF312818/c

LOCUS 8 bp mRNA linear EST 15-AUG-2003

DEFINITION ABF-08-L15.g1 ABF3-overexpressing transgenic rice plasmid cDNA
library (ABF) Oryza sativa cDNA clone ABF-08-L15, mRNA sequence.

ACCESSION CF312818

VERSION CF312818.1 GI:33684579

KEYWORDS EST.

SOURCE Oryza sativa

ORGANISM

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.

1 (bases 1 to 8)

Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University

Yongin, Gyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1..8
Location/Qualifiers
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="ABF-08-L15"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="ABF3-overexpressing transgenic rice plasmid
cDNA library (ABF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; Leaf was dried
for 2hrs. Oligo-capped mRNA was reverse transcribed and
then used for PCR. mRNA was prepared from ABA-responsive
element binding transcription factor 3 overexpression
line."

Query Match 8.8%; Score 6.4; DB 1; Length 8;

Best Local Similarity 87.5%; Pred. No. 39;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915

Db 8 TTTTCTTT 1

RESULT 20

CA794225/c

LOCUS 9 bp mRNA linear EST 05-DEC-2002

DEFINITION Cac BL 1208 Cac BL (Bean and Leaf from Amelonardo type Cacao)

THEOBROMA CACAO cDNA clone Cac BL_1208 5', mRNA sequence.

ACCESSION CA794225

VERSION CA794225.1 GI:26051301

RESULT 23

CF318771
LOCUS
DEFINITION HD--09-A13.g1 OshDACL-overexpressing transgenic rice plasmid cDNA library (HD) Oryza sativa cDNA clone HD--09-A13, mRNA sequence.

ACCESSION CF318771
VERSION
KEYWORDS

SOURCE CF318771.1 GI:33690532

ORGANISM Oryza sativa

REFERENCE Oryza sativa

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaeae; Oryza.

1 (bases 1 to 9)

Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division

of Bioscience and Bioinformatics, Myongji University

Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1..9

/organism="Oryza sativa"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:4530"

/clone="HD--09-A13"

/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"

/lab_host="E. coli DH10B"

/clone_lib="OSHDACL-overexpressing transgenic rice plasmid

cDNA library (HD)"

/note="Vector: pCRA-TOPO; Site 1: EcoRI; Callus was

treated with ABA(20um) for 1hr. Oligo-capped mRNA was

reverse transcribed and then used for PCR. mRNA was

derived from rice Histone Deacetylase overexpression

line."

Query Match 8.8%; Score 6.4; DB 1; Length 9;

Best Local Similarity 87.5%; Pred. No. 35;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915

|||||

1 TTTTTTT 8

RESULT 24

CF330649
LOCUS
DEFINITION NACL--06-H06.b1 Rice callus plasmid cDNA library (NACL) Oryza sativa cDNA clone NACL--06-H06, mRNA sequence.

ACCESSION CF330649

VERSION

KEYWORDS

SOURCE CF330649.1 GI:33809535

ORGANISM Oryza sativa

REFERENCE Oryza sativa

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Ehrhartoideae; Oryzaeae; Oryza.

1 (bases 1 to 9)

Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division

of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1..9

/organism="Oryza sativa"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:4530"

/clone="NACL--06-H06"

/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 30 days"

/lab_host="E. coli DH10B"

/clone_lib="Rice callus plasmid cDNA library (NACL)"

/note="Vector: PCR-TOPO; Site 1: EcoRI; mRNA was capped

with oligoribonucleotides and then used as templates for

RT-PCR."

Query Match 8.8%; Score 6.4; DB 1; Length 9;

Best Local Similarity 87.5%; Pred. No. 35;

Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915

|||||

1 TTTTTTT 8

RESULT 25

CA794554/c

LOCUS

DEFINITION

CA794554

VERSION

KEYWORDS

SOURCE

ORGANISM

CA794554.1 GI:26051630

EST

Theobroma cacao (cacao)

Theobroma cacao

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Malvales; Malvaceae; Byttnerioideae;

Theobroma.

1 (bases 1 to 8)

Jones, P.G., Allaway, D., Gilmour, D.M., Harris, C., Rankin, D.,

Retzel, E.R. and Jones, C.A.

Gene discovery and microarray analysis of cacao (Theobroma cacao

L.) varieties

JOURNAL

MEDLINE

PUBMED

COMMENT

12447539

Contact: Jones, Paul

Masterfoods

3d Dundee Road, Slough, Berkshire, UK, SL1 4LG

Tel: +44 1664 416644

Email: Paul.Jones@effem.com

Seq primer: T3

Location/Qualifiers

1..8

/organism="Theobroma cacao"

/mol_type="mRNA"

/strain="Amelonado type"

/db_xref="taxon:3641"

/clone="Cac BL 1496"

/tissue_type="Mature leaf and mature bean"

/cell_type="Whole organ"

/dev_stage="maturity"

/lab_host="XL-1 Blue MRF"

/clone_lib="Cac BL (Bean and Leaf from Amelonado type

Cacao)"

/note="Vector: pBK-CMV; Bean and leaf tissue from an

Amelonado type Cacao tree."

Query Match 8.2%; Score 6; DB 1; Length 8;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 924 CTTT 929
 |||||
 DB 7 CTTT 2

RESULT 26
 CF313731
 LOCUS HD-01-P12.g1 OSHDAC1-overexpressing transgenic rice plasmid cDNA
 DEFINITION library (HD) Oryza sativa cDNA clone HD-01-P12, mRNA sequence.
 ACCESSION CF313731
 VERSION CF313731.1 GI:33685492
 KEYWORDS EST.
 SOURCE Oryza sativa
 ORGANISM Oryza sativa
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.
 REFERENCE 1 (bases 1 to 8)
 AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
 Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, S.H.
 TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)
 COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongsin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
 source
 1..8
 Location/Qualifiers
 /organism="Oryza sativa"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:4530"
 /clone="HD-01-P12"
 /tissue_type="callus"
 /dev_stage="proliferated callus on 2N6 media for 2 weeks"
 /lab_host="E. coli DH10B"
 /clone_lib="OSHDAC1-overexpressing transgenic rice plasmid
 cDNA library (HD)"
 /note="Vector: pCR4-TOPO; Site 1: EcoRI; Callus was
 treated with ABA(20um) for 1hr. Oligo-capped mRNA was
 reverse transcribed and then used for PCR. mRNA was
 derived from rice Histone Deacetylase overexpression
 line."

Query Match 8.2%; Score 6; DB 1; Length 8;
 Best Local Similarity 100.0%; Pred. No. 39;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 TGGTTT 950
 |||||
 DB 2 TGGTTT 7

RESULT 27
 CA851350/c
 LOCUS CA851350 8 bp mRNA linear EST 01-AUG-2003
 DEFINITION D12G08_N20.14.ab1 cDNA Peking library 2, 4 day SCN3 Glycine max
 cDNA clone D12G08 5', mRNA sequence.
 ACCESSION CA851350
 VERSION CA851350.1 GI:33388143
 KEYWORDS EST.
 SOURCE Glycine max (soybean)
 ORGANISM Glycine max
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
 Glycine.
 REFERENCE 1 (bases 1 to 8)
 AUTHORS Alkharouf, N.W., Khan, R. and Matthews, B.F.
 TITLE Analysis of expressed sequence tags from roots of resistant soybean
 JOURNAL infected by the soybean cyst nematode
 COMMENT Unpublished (2002)
 CONTACT: Alkharouf, N.W.
 Soybean Genomics and Improvement Laboratory (SGIL)
 US Department of Agriculture (USDA), ARS, PSI
 Bldg. 006, Rm 118, 10300 Baltimore Ave., Beltsville, MD 20705-2350,
 USA
 Tel: 301 504 5750
 Fax: 301 504 5728
 Email: alkharouf@ba.ars.usda.gov.

FEATURES
 source
 1..8
 Location/Qualifiers
 /organism="Glycine max"
 /mol_type="mRNA"
 /cultivar="Peking"
 /db_xref="taxon:3847"
 /clone="D12G08"
 /tissue_type="Roots"
 /dev_stage="Seedlings"
 /clone_lib="cDNA Peking library 2, 4 day SCN3"
 /note="Vector: pBluescript SK-; cDNA clones from mRNA
 extracted from Peking roots 2 and 4 days past invasion."

Query Match 7.4%; Score 5.4; DB 1; Length 8;
 Best Local Similarity 75.0%; Pred. No. 39;
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 911 TCTTTGGT 918
 |||||
 DB 8 TTTTGGGT 1

Search completed: October 18, 2004, 14:39:48
 Job time : 1 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 18, 2004, 14:27:49 ; Search time 1 Seconds
(without alignments)

1.155 Million cell updates/sec

Title: US-09-695-451-1

Perfect score: 73

Sequence: 1 cccgtgcatttttttgggt.....atgtatgcctaccaacgggtg 73

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 616 seqs, 7913 residues

Total number of hits satisfying chosen parameters: 1232

Minimum DB seq length: 8

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 616 summaries

Database : rni1-899.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	18	24.7	18	1	US-09-106-038A-54
2	18	24.7	18	1	US-09-106-038A-55
3	18	24.7	18	1	US-09-106-038A-56
4	18	24.7	18	1	US-09-106-038A-57
5	18	24.7	18	1	US-09-106-038A-58
6	18	24.7	18	1	US-09-106-038A-59
7	15.4	21.1	17	1	US-08-584-040-7257
8	15.4	21.1	17	1	US-09-371-772B-3066
9	15	20.5	23	1	US-09-068-319-5
10	14.6	20.0	21	1	US-08-757-653-180
11	14.6	20.0	21	1	US-08-823-516-83
12	14.6	20.0	21	1	US-08-758-038-119
13	14.6	20.0	21	1	US-08-758-314-119
14	14.6	20.0	21	1	US-09-306-420C-12
15	14.6	20.0	21	1	US-09-306-420C-16
16	14.6	20.0	21	1	US-09-684-938-119
17	14.6	20.0	21	1	US-09-308-825A-119
18	14.4	19.7	20	1	US-08-904-901-134
19	14.4	19.7	20	1	US-09-249-730-134
20	14.4	19.7	20	1	US-09-249-730-134
21	13.6	18.6	20	1	US-09-249-730-134
22	13.6	18.6	20	1	US-09-377-309-87
23	13.6	18.6	20	1	US-09-446-754-11
24	13.6	18.6	20	1	US-09-446-754-17
25	13.6	18.6	20	1	US-09-198-452A-4603
26	13.4	18.4	20	1	US-09-792-251-23
27	13.2	18.1	20	1	US-09-706-197-77
28	13.2	18.1	20	1	US-09-531-000-29
29	13.2	18.1	20	1	US-08-607-384A-24
30	12.8	17.5	18	1	US-09-198-452A-2716
31	12.8	17.5	18	1	US-08-239-431A-8
32	12.8	17.5	18	1	US-09-205-144-36
33	12.8	17.5	18	1	US-09-267-423-8
					US-09-422-978-10295
					Sequence 10295, A

1	US-08-261-822A-32	18	17.0	12.4	C 34	Sequence 32, Appl
1	US-08-506-296B-12	18	17.0	12.4	C 35	Sequence 12, Appl
1	PCT-US95-0774A-32	18	17.0	12.4	C 36	Sequence 32, Appl
1	US-09-422-978-7250	19	17.0	12.4	C 37	Sequence 7250, Ap
1	US-08-373-124A-65	38	12.2	16.7	C 38	Sequence 65, Appl
1	US-08-435-628-65	39	12.2	16.7	C 39	Sequence 65, Appl
1	US-09-371-772B-5632	40	12.2	16.7	C 40	Sequence 5632, Ap
1	US-08-384-324-2	41	12.2	16.7	C 41	Sequence 2, Appl
1	US-09-527-0300-108	42	12.2	16.7	C 42	Sequence 108, Appl
1	US-09-920-760-89	43	12.2	16.7	C 43	Sequence 89, Appl
1	US-09-422-978-5922	44	12.2	16.7	C 44	Sequence 5922, Ap
1	US-09-422-978-7176	45	12.2	16.7	C 45	Sequence 7176, Ap
1	PCT-US96-01473-2	46	12.2	16.7	C 46	Sequence 2, Appl
1	5219727-64	47	12.2	16.7	C 47	Patent No. 5219727
1	US-08-584-040-8450	48	12	16.4	C 48	Sequence 8450, Ap
1	US-09-371-772B-4106	49	12	16.4	C 49	Sequence 4106, Ap
1	US-09-371-772B-5670	50	12	16.4	C 50	Sequence 5670, Ap
1	US-08-584-040-1499	51	12	16.4	C 51	Sequence 1499, Ap
1	US-08-584-040-1500	52	12	16.4	C 52	Sequence 1500, Ap
1	US-09-371-772B-44	53	12	16.4	C 53	Sequence 1501, Ap
1	US-09-371-772B-45	54	12	16.4	C 54	Sequence 44, Appl
1	US-09-371-772B-46	55	12	16.4	C 55	Sequence 45, Appl
1	US-09-371-772B-47	56	12	16.4	C 56	Sequence 46, Appl
1	US-09-371-772B-4244	57	12	16.4	C 57	Sequence 4244, Ap
1	US-09-166-203-21	58	12	16.4	C 58	Sequence 21, Appl
1	US-09-377-309-21	59	12	16.4	C 59	Sequence 21, Appl
1	US-09-479-005A-303	60	11.8	16.2	C 60	Sequence 303, App
1	PCT-US91-03680-98	61	11.8	16.2	C 61	Sequence 98, Appl
1	US-09-068-195-8	62	11.8	16.2	C 62	Sequence 8, Appl
1	US-08-584-040-1874	63	11.8	16.2	C 63	Sequence 1874, Ap
1	US-09-371-772B-419	64	11.8	16.2	C 64	Sequence 419, App
1	US-09-529-812A-4	65	11.8	16.2	C 65	Sequence 4, Appl
1	US-09-280-409-72	66	11.8	16.2	C 66	Sequence 72, Appl
1	US-09-061-769A-21	67	11.8	16.2	C 67	Sequence 21, Appl
1	US-09-167-109-154	68	11.8	16.2	C 68	Sequence 154, App
1	US-09-422-978-6620	69	11.8	16.2	C 69	Sequence 6620, Ap
1	US-08-311-760A-77	70	11.4	15.6	C 70	Sequence 77, Appl
1	US-08-311-760A-78	71	11.4	15.6	C 71	Sequence 78, Appl
1	US-08-774-310-77	72	11.4	15.6	C 72	Sequence 77, Appl
1	US-08-774-310-78	73	11.4	15.6	C 73	Sequence 78, Appl
1	US-08-929-856-57	74	11.4	15.6	C 74	Sequence 57, Appl
1	PCT-US91-03680-96	75	11.4	15.6	C 75	Sequence 96, Appl
1	US-09-270-543-186	76	11.2	15.3	C 76	Sequence 186, Appl
1	US-09-479-005A-176	77	11.2	15.3	C 77	Sequence 176, App
1	US-08-299-849B-48	78	11.2	15.3	C 78	Sequence 48, Appl
1	US-08-373-124A-366	79	11.2	15.3	C 79	Sequence 366, App
1	US-08-373-124A-1012	80	11.2	15.3	C 80	Sequence 1012, Ap
1	US-08-435-628-366	81	11.2	15.3	C 81	Sequence 366, App
1	US-08-435-628-1012	82	11.2	15.3	C 82	Sequence 1012, Ap
1	US-08-967-727-28	83	11.2	15.3	C 83	Sequence 28, Appl
1	US-08-606-505B-47	84	11.2	15.3	C 84	Sequence 47, Appl
1	US-08-037-230D-28	85	11.2	15.3	C 85	Sequence 28, Appl
1	US-08-584-040-1574	86	11.2	15.3	C 86	Sequence 1574, Ap
1	US-08-584-040-2874	87	11.2	15.3	C 87	Sequence 2874, Ap
1	US-09-583-850-28	88	11.2	15.3	C 88	Sequence 28, Appl
1	US-09-579-197-28	89	11.2	15.3	C 89	Sequence 28, Appl
1	US-09-404-026-28	90	11.2	15.3	C 90	Sequence 28, Appl
1	US-09-371-772B-119	91	11.2	15.3	C 91	Sequence 119, App
1	US-09-371-772B-1398	92	11.2	15.3	C 92	Sequence 1398, Ap
1	US-09-371-772B-5149	93	11.2	15.3	C 93	Sequence 5149, Ap
1	US-09-827-998-621	94	11.2	15.3	C 94	Sequence 621, App
1	US-09-827-998-622	95	11.2	15.3	C 95	Sequence 622, App
1	US-09-866-108A-7083	96	11.2	15.3	C 96	Sequence 7083, Ap
1	US-09-866-108A-7084	97	11.2	15.3	C 97	Sequence 7084, Ap
1	US-08-256-568B-34	98	11	15.1	C 98	Sequence 34, Appl
1	US-09-038-369B-34	99	11	15.1	C 99	Sequence 34, Appl
1	US-09-378-900A-34	100	11	15.1	C 100	Sequence 34, Appl
1	US-09-899-044-34	101	11	15.1	C 101	Sequence 34, Appl
1	US-07-906-930E-8	102	10.8	14.8	C 102	Sequence 8, Appl
1	US-08-334-847-45	103	10.8	14.8	C 103	Sequence 45, Appl
1	US-08-334-847-46	104	10.8	14.8	C 104	Sequence 46, Appl
1	US-08-317-432A-2	105	10.8	14.8	C 105	Sequence 2, Appl
1		106	10.8	14.8	C 106	Sequence 2, Appl

c 107	10.8	14.8	15	1	US-08-894-922A-1	Sequence 1, Appli	c 180	9.8	13.4	15	1	US-08-441-887A-16	Sequence 16, Appli
c 108	10.8	14.8	15	1	US-08-585-684B-271	Sequence 271, App	c 181	9.8	13.4	15	1	US-08-441-887A-17	Sequence 17, Appli
c 109	10.8	14.8	15	1	US-08-959-853-7	Sequence 7, Appli	c 182	9.8	13.4	15	1	US-08-173-489C-142	Sequence 142, App
c 110	10.8	14.8	15	1	US-09-038-073-271	Sequence 271, App	c 183	9.8	13.4	15	1	US-08-585-684B-1748	Sequence 1748, App
c 111	10.8	14.8	15	1	US-10-032-307-68	Sequence 68, Appli	c 184	9.8	13.4	15	1	US-08-585-684B-1811	Sequence 1811, App
c 112	10.4	14.2	12	1	US-08-173-489C-85	Sequence 85, Appli	c 185	9.8	13.4	15	1	US-08-544-381B-114	Sequence 114, App
c 113	10.4	14.2	12	1	US-09-473-947A-286	Sequence 286, App	c 186	9.8	13.4	15	1	US-09-071-845-121	Sequence 121, App
c 114	10.4	14.2	14	1	US-08-487-799-87	Sequence 87, Appli	c 187	9.8	13.4	15	1	US-09-071-845-288	Sequence 288, App
c 115	10.4	14.2	15	1	US-08-105-483-345	Sequence 435, App	c 188	9.8	13.4	15	1	US-09-071-845-289	Sequence 289, App
c 116	10.4	14.2	15	1	US-08-319-492B-438	Sequence 438, App	c 189	9.8	13.4	15	1	US-09-038-073-1748	Sequence 1748, App
c 117	10.4	14.2	15	1	US-08-319-492B-439	Sequence 439, App	c 190	9.8	13.4	15	1	US-09-038-073-1811	Sequence 1811, App
c 118	10.4	14.2	15	1	US-08-502-185-19	Sequence 19, Appli	c 191	9.8	13.4	15	1	US-09-081-646-3	Sequence 3, Appli
c 119	10.4	14.2	15	1	US-08-398-945-19	Sequence 19, Appli	c 192	9.8	13.4	15	1	US-08-584-040-8493	Sequence 4, Appli
c 120	10.4	14.2	15	1	US-08-501-779-19	Sequence 19, Appli	c 193	9.8	13.4	15	1	US-09-346-551-4	Sequence 4, Appli
c 121	10.4	14.2	15	1	US-08-501-779-19	Sequence 19, Appli	c 194	9.8	13.4	15	1	US-08-461-210-5	Sequence 5, Appli
c 122	10.4	14.2	15	1	US-08-378-860-19	Sequence 19, Appli	c 195	9.8	13.4	15	1	US-10-001-344-4	Sequence 4, Appli
c 123	10.4	14.2	15	1	US-08-709-209-245	Sequence 245, App	c 196	9.8	13.4	15	1	US-09-371-772B-4147	Sequence 4147, App
c 124	10.4	14.2	15	1	US-08-458-101-245	Sequence 245, App	c 197	9.8	13.4	15	1	PCT-US92-06821A-129	Sequence 129, App
c 125	10.4	14.2	15	1	US-08-501-626-19	Sequence 19, Appli	c 198	9.8	13.4	15	1	PCT-US92-06821A-131	Sequence 131, App
c 126	10.4	14.2	15	1	US-08-501-356-19	Sequence 19, Appli	c 199	9.4	12.9	11	1	US-08-259-148A-39	Sequence 39, Appli
c 127	10.4	14.2	15	1	US-08-584-040-8458	Sequence 8458, App	c 200	9.4	12.9	11	1	US-08-173-489C-307	Sequence 307, App
c 128	10.4	14.2	15	1	US-09-371-772B-4114	Sequence 4114, App	c 201	9.4	12.9	11	1	US-07-876-941A-35	Sequence 55, Appli
c 129	10.4	14.2	16	1	US-08-173-489C-167	Sequence 167, App	c 202	9.4	12.9	11	1	US-09-593-323-2	Sequence 2, Appli
c 130	10.4	14.2	16	1	US-08-928-465-9	Sequence 9, Appli	c 203	9.4	12.9	11	1	US-09-593-323-3	Sequence 3, Appli
c 131	10.4	14.2	16	1	US-08-666-341A-101	Sequence 101, App	c 204	9.4	12.9	11	1	US-09-594-108-2	Sequence 2, Appli
c 132	10.4	14.2	16	1	US-09-813-781-57	Sequence 57, Appli	c 205	9.4	12.9	11	1	US-09-594-108-3	Sequence 3, Appli
c 133	10.4	14.2	16	1	5312912-9	Patent No. 5312912	c 206	9.4	12.9	11	1	US-09-344-300-2	Sequence 2, Appli
c 134	10.2	14.0	15	1	US-08-334-847-47	Sequence 47, Appli	c 207	9.4	12.9	11	1	US-09-344-300-3	Sequence 3, Appli
c 135	10.2	14.0	15	1	US-08-334-847-53	Sequence 53, Appli	c 208	9.4	12.9	11	1	US-09-249-155A-59	Sequence 59, Appli
c 136	10.2	14.0	15	1	US-08-311-486C-36	Sequence 36, Appli	c 209	9.4	12.9	11	1	US-09-249-155A-279	Sequence 279, App
c 137	10.2	14.0	15	1	US-08-173-489C-45	Sequence 45, Appli	c 210	9.4	12.9	12	1	US-08-173-489C-9	Sequence 9, Appli
c 138	10.2	14.0	15	1	US-08-585-684B-272	Sequence 272, App	c 211	9.4	12.9	13	1	US-08-173-489C-216	Sequence 216, App
c 139	10.2	14.0	15	1	US-09-038-073-272	Sequence 272, App	c 212	9.4	12.9	13	1	US-08-874-601-88	Sequence 88, Appli
c 140	10.2	14.0	15	1	US-09-478-770A-13	Sequence 13, Appli	c 213	9.4	12.9	14	1	US-08-173-489C-98	Sequence 9, Appli
c 141	10.2	14.0	15	1	US-09-478-770A-15	Sequence 15, Appli	c 214	9.4	12.9	14	1	US-08-439-819-9	Sequence 9, Appli
c 142	10.2	14.0	15	1	US-09-031-952-8	Sequence 8, Appli	c 215	9.4	12.9	14	1	US-08-838-545-50	Sequence 50, Appli
c 143	10.2	14.0	15	1	US-09-475-947A-254	Sequence 254, App	c 216	9.4	12.9	14	1	US-08-765-340-147	Sequence 147, App
c 144	10.2	14.0	15	1	US-08-192-946-31	Sequence 31, Appli	c 217	9.4	12.9	14	1	US-09-349-532-50	Sequence 50, Appli
c 145	10	13.7	12	1	US-08-363-233B-13	Sequence 13, Appli	c 218	9.4	12.9	14	1	US-08-173-489C-78	Sequence 78, Appli
c 146	10	13.7	14	1	US-08-173-489C-185	Sequence 185, App	c 219	9.2	12.6	14	1	US-08-173-489C-97	Sequence 97, Appli
c 147	10	13.7	14	1	US-08-173-489C-197	Sequence 197, App	c 220	9.2	12.6	14	1	US-08-173-489C-318	Sequence 318, App
c 148	10	13.7	15	1	US-08-585-684B-2257	Sequence 2257, App	c 221	9.2	12.6	14	1	US-09-458-481B-2	Sequence 2, Appli
c 149	10	13.7	15	1	US-08-585-684B-2258	Sequence 2258, App	c 222	9.2	12.6	14	1	US-08-535-249-118	Sequence 118, App
c 150	10	13.7	15	1	US-09-038-073-2257	Sequence 2257, App	c 223	9.2	12.6	14	1	US-09-531-000-14	Sequence 14, Appli
c 151	10	13.7	15	1	US-09-038-073-2258	Sequence 2258, App	c 224	9.2	12.6	14	1	US-09-531-000-48	Sequence 48, Appli
c 152	9.8	13.4	13	1	US-08-441-887A-268	Sequence 268, App	c 225	9	12.3	10	1	US-08-388-353-182	Sequence 182, App
c 153	9.8	13.4	13	1	US-08-173-489C-56	Sequence 56, Appli	c 226	9	12.3	10	1	US-08-388-353-183	Sequence 183, App
c 154	9.8	13.4	13	1	US-08-544-381B-29	Sequence 29, Appli	c 227	9	12.3	10	1	US-08-488-551B-182	Sequence 182, App
c 155	9.8	13.4	13	1	US-08-778-794A-57	Sequence 57, Appli	c 228	9	12.3	10	1	US-08-488-551B-183	Sequence 183, App
c 156	9.8	13.4	14	1	US-08-242-664-15	Sequence 15, Appli	c 229	9	12.3	10	1	US-09-445-388A-5	Sequence 5, Appli
c 157	9.8	13.4	14	1	US-08-484-138-15	Sequence 15, Appli	c 230	9	12.3	10	1	US-09-508-753B-60	Sequence 60, Appli
c 158	9.8	13.4	14	1	US-08-535-249-29	Sequence 29, Appli	c 231	9	12.3	10	1	US-09-508-753B-80	Sequence 80, Appli
c 159	9.8	13.4	14	1	US-09-874-601-111	Sequence 111, App	c 232	9	12.3	10	1	US-07-854-596B-6	Sequence 6, Appli
c 160	9.8	13.4	14	1	PCT-US95-06379-15	Sequence 15, Appli	c 233	9	12.3	11	1	US-08-373-124A-46	Sequence 46, Appli
c 161	9.8	13.4	14	1	US-07-744-282C-123	Sequence 123, App	c 234	9	12.3	11	1	US-08-373-124A-46	Sequence 46, Appli
c 162	9.8	13.4	15	1	US-07-744-282C-125	Sequence 125, App	c 235	9	12.3	11	1	US-08-435-628-46	Sequence 46, Appli
c 163	9.8	13.4	15	1	US-08-319-492B-64	Sequence 64, Appli	c 236	9	12.3	11	1	US-08-450-905B-33	Sequence 33, Appli
c 164	9.8	13.4	15	1	US-08-319-492B-73	Sequence 73, Appli	c 237	9	12.3	11	1	US-08-173-489C-134	Sequence 134, App
c 165	9.8	13.4	15	1	US-08-319-492B-169	Sequence 169, App	c 238	9	12.3	11	1	US-08-173-489C-196	Sequence 196, App
c 166	9.8	13.4	15	1	US-08-319-492B-170	Sequence 170, App	c 239	9	12.3	11	1	US-07-982-759P-33	Sequence 33, Appli
c 167	9.8	13.4	15	1	US-08-319-492B-436	Sequence 436, App	c 240	9	12.3	11	1	US-09-249-155A-222	Sequence 222, App
c 168	9.8	13.4	15	1	US-08-319-492B-437	Sequence 437, App	c 241	9	12.3	11	1	US-09-529-812A-6	Sequence 6, Appli
c 169	9.8	13.4	15	1	US-08-363-240A-227	Sequence 227, App	c 242	9	12.3	12	1	US-08-874-825-88	Sequence 88, Appli
c 170	9.8	13.4	15	1	US-08-363-240A-228	Sequence 228, App	c 243	9	12.3	12	1	US-08-663-824-88	Sequence 88, Appli
c 171	9.8	13.4	15	1	US-08-294-424-48	Sequence 48, Appli	c 244	9	12.3	12	1	US-09-231-303-88	Sequence 88, Appli
c 172	9.8	13.4	15	1	US-08-311-486C-74	Sequence 74, Appli	c 245	9	12.3	13	1	US-08-280-441-7	Sequence 7, Appli
c 173	9.8	13.4	15	1	US-08-311-486C-75	Sequence 75, Appli	c 246	9	12.3	13	1	US-08-410-116B-24	Sequence 24, Appli
c 174	9.8	13.4	15	1	US-08-480-736-4	Sequence 4, Appli	c 247	9	12.3	13	1	US-08-667-689A-24	Sequence 24, Appli
c 175	9.8	13.4	15	1	US-08-292-620A-121	Sequence 121, App	c 248	9	12.3	13	1	US-08-712-011-24	Sequence 24, Appli
c 176	9.8	13.4	15	1	US-08-292-620A-288	Sequence 288, App	c 249	9	12.3	13	1	US-08-478-238A-24	Sequence 24, Appli
c 177	9.8	13.4	15	1	US-08-292-620A-289	Sequence 289, App	c 250	9	12.3	13	1	US-07-958-133-2	Sequence 87, Appli
c 178	9.8	13.4	15	1	US-08-441-887A-8	Sequence 8, Appli	c 251	8.9	12.1	12	1	US-07-958-133-2	Sequence 2, Appli
c 179	9.8	13.4	15	1			c 252	8.9	12.1	12	1		

C 253	8.8	12.1	12	1	US-08-413-913-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 16, Appli
C 254	8.8	12.1	12	1	US-08-441-887A-30	Sequence 30, Appli	Sequence 30, Appli	Sequence 64, Appli
C 255	8.8	12.1	12	1	US-08-441-887A-197	Sequence 197, App	Sequence 197, App	Sequence 99, Appl
C 256	8.8	12.1	12	1	US-08-173-489C-165	Sequence 165, App	Sequence 165, App	Sequence 121, App
C 257	8.8	12.1	12	1	US-08-173-489C-187	Sequence 187, App	Sequence 187, App	Sequence 57, Appli
C 258	8.8	12.1	12	1	US-08-173-489C-227	Sequence 227, App	Sequence 227, App	Sequence 2, Appli
C 259	8.8	12.1	12	1	US-08-173-489C-237	Sequence 237, App	Sequence 237, App	Sequence 16, Appli
C 260	8.8	12.1	12	1	US-08-173-489C-249	Sequence 249, App	Sequence 249, App	Sequence 2, Appli
C 261	8.8	12.1	12	1	US-08-173-489C-259	Sequence 259, App	Sequence 259, App	Sequence 16, Appli
C 262	8.8	12.1	12	1	US-08-173-489C-263	Sequence 263, App	Sequence 263, App	Sequence 44, Appli
C 263	8.8	12.1	12	1	US-08-927-165A-17	Sequence 17, Appli	Sequence 17, Appli	Sequence 15, Appli
C 264	8.8	12.1	12	1	US-08-477-831C-26	Sequence 26, Appli	Sequence 26, Appli	Sequence 2, Appli
C 265	8.8	12.1	13	1	US-07-715-183C-9	Sequence 9, Appli	Sequence 9, Appli	Sequence 16, Appli
C 266	8.8	12.1	13	1	US-08-651-835A-9	Sequence 9, Appli	Sequence 9, Appli	Sequence 2, Appli
C 267	8.8	12.1	13	1	US-08-173-489C-334	Sequence 334, App	Sequence 334, App	Sequence 16, Appli
C 268	8.8	12.1	13	1	US-08-761-243C-18	Sequence 18, Appli	Sequence 18, Appli	Sequence 4, Appli
C 269	8.8	12.1	13	1	US-08-607-798-4	Sequence 2, Appli	Sequence 2, Appli	Sequence 1, Appli
C 270	8.8	12.1	13	1	US-08-930-778A-4	Sequence 4, Appli	Sequence 4, Appli	Patent No. 542251
C 271	8.8	12.1	13	1	US-09-502-778A-4	Sequence 4, Appli	Sequence 4, Appli	Sequence 44, Appli
C 272	8.8	12.1	13	1	US-09-353-921-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 50, Appli
C 273	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 5, Appli
C 274	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 315, App
C 275	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 4, Appli
C 276	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 1, Appli
C 277	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Patent No. 542251
C 278	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 44, Appli
C 279	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 20, Appli
C 280	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 5, Appli
C 281	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 315, App
C 282	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 4, Appli
C 283	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 15, Appli
C 284	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 27, Appli
C 285	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 15, Appli
C 286	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 22, Appli
C 287	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 89, Appli
C 288	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 89, Appli
C 289	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 39, Appli
C 290	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 55, Appli
C 291	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 39, Appli
C 292	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 7, Appli
C 293	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 20, Appli
C 294	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 22, Appli
C 295	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 26, Appli
C 296	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 262, App
C 297	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 285, App
C 298	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 309, App
C 299	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 4, Appli
C 300	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 13, Appli
C 301	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 13, Appli
C 302	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 62, Appli
C 303	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 9, Appli
C 304	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 13, Appli
C 305	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 537, App
C 306	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 538, App
C 307	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 85, App
C 308	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 18, Appli
C 309	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 4, Appli
C 310	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 43, Appli
C 311	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 39, Appli
C 312	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 49, Appli
C 313	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 51, Appli
C 314	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 49, Appli
C 315	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 51, Appli
C 316	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 49, Appli
C 317	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 51, Appli
C 318	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 56, Appli
C 319	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 58, Appli
C 320	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 49, Appli
C 321	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 51, Appli
C 322	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 8, Appli
C 323	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 24, Appli
C 324	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 4, Appli
C 325	8.8	12.1	13	1	US-09-360-344-2	Sequence 2, Appli	Sequence 2, Appli	Sequence 43, Appli

C 399	8	11.0	10	1	US-08-388-353-181	Sequence 181, App	C 472	8	11.0	12	1	US-08-173-489C-83	Sequence 83, Appl
C 400	8	11.0	10	1	US-08-388-353-227	Sequence 227, App	C 473	8	11.0	12	1	US-08-467-346-12	Sequence 12, Appl
C 401	8	11.0	10	1	US-08-388-353-228	Sequence 228, App	C 474	8	11.0	12	1	US-08-467-346-13	Sequence 13, Appl
C 402	8	11.0	10	1	US-08-388-353-231	Sequence 231, App	475	8	11.0	12	1	US-08-467-346-30	Sequence 30, Appl
C 403	8	11.0	10	1	US-08-388-353-232	Sequence 232, App	C 476	8	11.0	12	1	US-08-232-081B-33	Sequence 33, Appl
C 404	8	11.0	10	1	US-08-388-353-233	Sequence 233, App	C 477	8	11.0	12	1	US-08-663-823B-65	Sequence 65, Appl
C 405	8	11.0	10	1	US-08-388-353-274	Sequence 274, App	C 478	8	11.0	12	1	US-08-507-032-13	Sequence 13, Appl
C 406	8	11.0	10	1	US-08-388-353-308	Sequence 308, App	479	8	11.0	12	1	US-08-779-825-10	Sequence 10, Appl
C 407	8	11.0	10	1	US-08-388-353-309	Sequence 309, App	480	8	11.0	12	1	US-08-874-825-86	Sequence 86, Appl
C 408	8	11.0	10	1	US-08-488-551B-181	Sequence 181, App	481	8	11.0	12	1	US-08-874-825-87	Sequence 87, Appl
C 409	8	11.0	10	1	US-08-488-551B-227	Sequence 227, App	482	8	11.0	12	1	US-08-874-825-112	Sequence 112, App
C 410	8	11.0	10	1	US-08-488-551B-228	Sequence 228, App	483	8	11.0	12	1	US-08-938-835A-10	Sequence 10, Appl
C 411	8	11.0	10	1	US-08-488-551B-231	Sequence 231, App	C 484	8	11.0	12	1	US-08-910-632-8	Sequence 8, Appl
C 412	8	11.0	10	1	US-08-488-551B-232	Sequence 232, App	C 485	8	11.0	12	1	US-08-910-632-11	Sequence 11, Appl
C 413	8	11.0	10	1	US-08-488-551B-273	Sequence 273, App	C 486	8	11.0	12	1	US-08-910-632-36	Sequence 36, Appl
C 414	8	11.0	10	1	US-08-488-551B-274	Sequence 274, App	487	8	11.0	12	1	US-08-663-824-86	Sequence 86, Appl
C 415	8	11.0	10	1	US-08-488-551B-308	Sequence 308, App	488	8	11.0	12	1	US-08-663-824-87	Sequence 87, Appl
C 416	8	11.0	10	1	US-08-488-551B-309	Sequence 309, App	489	8	11.0	12	1	US-08-663-824-112	Sequence 112, App
C 417	8	11.0	10	1	US-08-905-691-14	Sequence 14, Appl	C 490	8	11.0	12	1	US-08-805-631A-8	Sequence 8, Appl
C 418	8	11.0	10	1	US-08-522-384-74	Sequence 74, Appl	C 491	8	11.0	12	1	US-08-805-631A-11	Sequence 11, Appl
C 419	8	11.0	10	1	US-08-522-384-102	Sequence 102, App	C 492	8	11.0	12	1	US-08-805-631A-36	Sequence 36, Appl
C 420	8	11.0	10	1	US-08-588-661F-20	Sequence 20, Appl	C 493	8	11.0	12	1	US-08-805-631A-45	Sequence 45, Appl
C 421	8	11.0	10	1	US-08-588-661F-22	Sequence 22, Appl	C 494	8	11.0	12	1	US-09-594-108-45	Sequence 45, Appl
C 422	8	11.0	10	1	US-08-150-156A-2	Sequence 2, Appl	C 495	8	11.0	12	1	US-09-281-418-185	Sequence 185, App
C 423	8	11.0	10	1	US-08-150-156A-5	Sequence 5, Appl	C 496	8	11.0	12	1	US-09-344-300-45	Sequence 45, Appl
C 424	8	11.0	10	1	US-08-150-156A-14	Sequence 14, Appl	497	8	11.0	12	1	US-09-354-231B-59	Sequence 59, Appl
C 425	8	11.0	10	1	US-08-150-156A-16	Sequence 16, Appl	C 498	8	11.0	12	1	US-09-569-344-8	Sequence 8, Appl
C 426	8	11.0	10	1	US-08-108-591B-8	Sequence 8, Appl	C 499	8	11.0	12	1	US-09-569-344-11	Sequence 11, Appl
C 427	8	11.0	10	1	US-08-108-591B-9	Sequence 9, Appl	C 500	8	11.0	12	1	US-09-569-344-36	Sequence 36, Appl
C 428	8	11.0	10	1	US-08-108-591B-10	Sequence 10, Appl	501	8	11.0	12	1	US-09-231-303-86	Sequence 86, Appl
C 429	8	11.0	10	1	US-08-108-591B-12	Sequence 12, Appl	502	8	11.0	12	1	US-09-231-303-87	Sequence 87, Appl
C 430	8	11.0	10	1	US-08-108-591B-14	Sequence 14, Appl	503	8	11.0	12	1	US-09-231-303-112	Sequence 112, App
C 431	8	11.0	10	1	US-08-686-114B-56	Sequence 56, Appl	504	8	11.0	12	1	US-09-475-947A-19	Sequence 19, Appl
C 432	8	11.0	10	1	US-08-686-114B-58	Sequence 58, Appl	505	8	11.0	12	1	PCr-US91-03680-93	Sequence 93, Appl
C 433	8	11.0	10	1	US-09-154-750A-18	Sequence 18, Appl	506	8	11.0	12	1	PCr-US95-03602-2	Sequence 2, Appl
C 434	8	11.0	10	1	US-09-508-753B-20	Sequence 20, Appl	507	8	11.0	12	1	PCr-US95-03602-3	Sequence 3, Appl
C 435	8	11.0	10	1	US-09-508-753B-27	Sequence 27, Appl	C 508	8	11.0	12	1	PCr-US95-03602-2	Sequence 2, Appl
C 436	8	11.0	10	1	US-09-508-753B-50	Sequence 50, Appl	509	7.8	10.7	11	1	US-08-242-409-2	Sequence 2, Appl
C 437	8	11.0	10	1	US-09-508-753B-113	Sequence 113, App	C 510	7.8	10.7	11	1	US-08-049-283A-2	Sequence 2, Appl
C 438	8	11.0	10	1	US-09-508-753B-440	Sequence 440, App	C 511	7.8	10.7	11	1	US-08-435-350-109	Sequence 109, App
C 439	8	11.0	10	1	US-09-524-346-5	Sequence 5, Appl	C 512	7.8	10.7	11	1	US-08-196-103A-13	Sequence 13, Appl
C 440	8	11.0	10	1	US-09-337-304-56	Sequence 56, Appl	C 513	7.8	10.7	11	1	US-08-314-309A-34	Sequence 34, Appl
C 441	8	11.0	10	1	US-09-337-304-58	Sequence 58, Appl	514	7.8	10.7	11	1	US-08-357-396-13	Sequence 13, Appl
C 442	8	11.0	11	1	US-08-246-373-6	Sequence 6, Appl	515	7.8	10.7	11	1	US-08-386-141-13	Sequence 13, Appl
C 443	8	11.0	11	1	US-08-173-489C-73	Sequence 73, Appl	516	7.8	10.7	11	1	US-08-173-489C-60	Sequence 60, Appl
C 444	8	11.0	11	1	US-08-173-489C-74	Sequence 74, Appl	517	7.8	10.7	11	1	US-08-173-489C-138	Sequence 138, App
C 445	8	11.0	11	1	US-08-910-632-27	Sequence 27, Appl	C 518	7.8	10.7	11	1	US-08-173-489C-150	Sequence 150, App
C 446	8	11.0	11	1	US-08-803-631A-27	Sequence 27, Appl	C 519	7.8	10.7	11	1	US-08-173-489C-251	Sequence 221, App
C 447	8	11.0	11	1	US-09-569-344-27	Sequence 27, Appl	C 520	7.8	10.7	11	1	US-08-173-489C-266	Sequence 226, App
C 448	8	11.0	11	1	US-09-475-947A-230	Sequence 230, App	C 521	7.8	10.7	11	1	US-08-173-489C-265	Sequence 265, App
C 449	8	11.0	11	1	US-09-249-155A-18	Sequence 18, Appl	C 522	7.8	10.7	11	1	US-08-173-489C-295	Sequence 295, App
C 450	8	11.0	11	1	US-09-249-155A-31	Sequence 31, Appl	523	7.8	10.7	11	1	US-08-282-383-2	Sequence 2, Appl
C 451	8	11.0	11	1	US-09-249-155A-191	Sequence 191, App	524	7.8	10.7	11	1	US-08-227-180B-18	Sequence 18, Appl
C 452	8	11.0	11	1	US-09-249-155A-251	Sequence 251, App	525	7.8	10.7	11	1	US-08-991-830A-6	Sequence 6, Appl
C 453	8	11.0	12	1	US-07-754-918A-4	Sequence 4, Appl	526	7.8	10.7	11	1	US-08-991-830A-7	Sequence 7, Appl
C 454	8	11.0	12	1	US-08-115-497-11	Sequence 11, Appl	527	7.8	10.7	11	1	US-09-105-515-3	Sequence 3, Appl
C 455	8	11.0	12	1	US-08-363-475-27	Sequence 27, Appl	C 528	7.8	10.7	11	1	US-08-679-494A-67	Sequence 67, Appl
C 456	8	11.0	12	1	US-08-280-441-8	Sequence 8, Appl	529	7.8	10.7	11	1	US-09-487-130-9	Sequence 9, Appl
C 457	8	11.0	12	1	US-08-214-603-11	Sequence 11, Appl	530	7.8	10.7	11	1	US-09-487-130-11	Sequence 11, Appl
C 458	8	11.0	12	1	US-08-410-116B-26	Sequence 26, Appl	C 531	7.8	10.7	11	1	US-09-157-257-39	Sequence 39, Appl
C 459	8	11.0	12	1	US-08-408-656-1	Sequence 1, Appl	532	7.8	10.7	11	1	US-09-748-044-3	Sequence 3, Appl
C 460	8	11.0	12	1	US-08-408-656-2	Sequence 2, Appl	C 533	7.8	10.7	11	1	US-09-475-947A-167	Sequence 167, App
C 461	8	11.0	12	1	US-08-408-656-3	Sequence 3, Appl	534	7.8	10.7	11	1	US-09-475-947A-231	Sequence 231, App
C 462	8	11.0	12	1	US-08-413-813-12	Sequence 12, Appl	535	7.8	10.7	11	1	US-09-373-129A-14	Sequence 14, Appl
C 463	8	11.0	12	1	US-08-413-813-13	Sequence 13, Appl	536	7.8	10.7	11	1	US-09-395-017B-48	Sequence 48, Appl
C 464	8	11.0	12	1	US-08-413-813-30	Sequence 30, Appl	C 537	7.8	10.7	11	1	US-09-529-812A-5	Sequence 5, Appl
C 465	8	11.0	12	1	US-08-667-689A-26	Sequence 26, Appl	538	7.8	10.7	11	1	PCr-US95-05835-2	Sequence 2, Appl
C 466	8	11.0	12	1	US-08-662-335A-16	Sequence 16, Appl	539	7.8	10.7	11	1	PCr-US95-09475-2	Sequence 2, Appl
C 467	8	11.0	12	1	US-08-466-670-11	Sequence 11, Appl	C 540	7.8	10.7	12	1	US-07-990-297-4	Sequence 4, Appl
C 468	8	11.0	12	1	US-08-686-631-7	Sequence 7, Appl	541	7.8	10.7	12	1	US-08-242-409-1	Sequence 1, Appl
C 469	8	11.0	12	1	US-08-712-011-26	Sequence 26, Appl	C 542	7.8	10.7	12	1	US-08-235-503B-22	Sequence 22, Appl
C 470	8	11.0	12	1	US-08-770-565-4	Sequence 4, Appl	C 543	7.8	10.7	12	1	US-08-242-664-13	Sequence 13, Appl
C 471	8	11.0	12	1	US-08-478-239A-26	Sequence 26, Appl	544	7.8	10.7	12	1	US-08-110-158-13	Sequence 13, Appl

```

ALIGNMENTS
-----
RESULT 1
US-09-106-038A-54/c
; Sequence 54, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Co.
; TITLE OF INVENTION: ANTISENSE MODULATION
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RYS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 54:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-106-038A-54

Query Match          24.7%; Score 18; D
Best Local Similarity 100.0%; Prad. No. 5
Matches 18; Conservative 0; Mismatche

QY      906 CATTTCCTTTGGTCTTTC 923
Db      18 CATTTCCTTTGGTCTTTC 1

RESULT 2
US-09-106-038A-55/c
; Sequence 55, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Co.
; TITLE OF INVENTION: ANTISENSE MODULATION
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible

```

```

; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 55:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-106-038A-55

```

```

Query Match 24.7%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 911 TCTTGGCTCTTGGCCCTT 928
DB 18 TCTTGGCTCTTGGCCCTT 1

```

```

RESULT 3
US-09-106-038A-56/c
; Sequence 56, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-106-038A-56

```

```

Query Match 24.7%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 921 TTGCTTTTATCCCTCT 938
DB 18 TTGCTTTTATCCCTCT 1

```

```

RESULT 4
US-09-106-038A-57/c
; Sequence 57, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-106-038A-57

```

```

Query Match 24.7%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 929 TATCCCTCTCTTCATTG 946
DB 18 TATCCCTCTCTTCATTG 1

```

```

RESULT 5
US-09-106-038A-58/c
; Sequence 58, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible

```


OPERATING SYSTEM: Windows NT
SOFTWARE: Microsoft Word 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/106,038A
FILING DATE: June 26, 1998
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Laurel Spear Bernstein
REGISTRATION NUMBER: 37,280
REFERENCE/DOCKET NUMBER: RTS-0004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (760) 931-9200
TELEFAX: (760) 603-3820
INFORMATION FOR SEQ ID NO: 58:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-106-038A-58

Query Match 24.7%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTCATTGGTTAA 952
Db 18 TCCTCTTCATTGGTTAA 1

RESULT 6
US-09-106-038A-59/c
Sequence 59, Application US/09106038A
Patent No. 6007995
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker and Lex M. Cowsert
TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
TITLE OF INVENTION: EXPRESSION
NUMBER OF SEQUENCES: 91
CORRESPONDENCE ADDRESS:
ADDRESSEE: Isis Pharmaceuticals, Inc.
STREET: 2322 Paraday Avenue
CITY: Carlsbad
STATE: CA
COUNTRY: U.S.A.
ZIP: 92008

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: Windows NT
SOFTWARE: Microsoft Word 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/106,038A
FILING DATE: June 26, 1998
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Laurel Spear Bernstein
REGISTRATION NUMBER: 37,280
REFERENCE/DOCKET NUMBER: RTS-0004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (760) 931-9200
TELEFAX: (760) 603-3820
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-106-038A-59

Query Match 24.7%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 952 ATGTATCGCTACCAACGG 969
Db 18 ATGTATCGCTACCAACGG 1
RESULT 7
US-08-584-040-7257/c
Sequence 7257, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7257:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7257

Query Match 21.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 921 TTGCTTTTATCCCTCC 937
Db 17 TTGCTTTTATCCCTCC 1

RESULT 8
US-09-371-772B-3066/c
Sequence 3066, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggan, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3066
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3066

Query Match      21.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 921 TTGCCTTTTATCCCTCC 937
DB 17 TTGCCTGTTATCCCTCC 1

RESULT 9
US-09-068-319-5
; Sequence 5, Application US/09068319A
; Patent No. 6277560
; GENERAL INFORMATION:
; APPLICANT: Jean-Marie Andrieu
; APPLICANT: Wei Lu
; TITLE OF INVENTION: MICROORGANISM QUANTITATION DETECTION
; TITLE OF INVENTION: METHOD AND KIT
; FILE REFERENCE: 31736 PCT USA 072995
; CURRENT APPLICATION NUMBER: US/09/068,319A
; EARLIER FILING DATE: 1998-05-04
; EARLIER APPLICATION NUMBER: PCT/FR96/01736
; EARLIER FILING DATE: 1996-11-05
; EARLIER APPLICATION NUMBER: 95/13093
; EARLIER FILING DATE: 1995-11-06
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Human Immunodeficiency Virus
US-09-068-319-5

Query Match      20.5%; Score 15; DB 1; Length 23;
Best Local Similarity 78.3%; Pred. No. 29;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 910 TTCTTTGGTCTTTGCTTTATC 932
DB 1 TCCTTTGGTCTTTGCTTTATGTC 23

RESULT 10
US-08-757-653-180
; Sequence 180, Application US/08757653
; Patent No. 5843669
; GENERAL INFORMATION:
; APPLICANT: Kaiser, Michael W.
; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Lyamichev, Natasha
; TITLE OF INVENTION: Cleavage Of Nucleic Acid Using
; TITLE OF INVENTION: Thermostable FEN-1 Endonucleases

; APPLICANT: Hall, Jeff G.
; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Mast, Andrea L.
; APPLICANT: Brow, Mary Ann D.
; TITLE OF INVENTION: Detection Of Nucleic Acids By Multiple
; TITLE OF INVENTION: Sequential Invasive Cleavages
; NUMBER OF SEQUENCES: 163
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/823,516
; FILING DATE: 24-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US97/01072

```

```

; NUMBER OF SEQUENCES: 190
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,653
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: FORS-02565
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 180:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-08-757-653-180

Query Match      20.0%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 917 GTCTTTGCCCTTTTATCCCTCC 937
DB 1 GCCTATGCCCTTTTATTCCTCC 21

RESULT 11
US-08-823-516-83
; Sequence 83, Application US/08823516
; Patent No. 5994069
; GENERAL INFORMATION:
; APPLICANT: Hall, Jeff G.
; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Mast, Andrea L.
; APPLICANT: Brow, Mary Ann D.
; TITLE OF INVENTION: Detection Of Nucleic Acids By Multiple
; TITLE OF INVENTION: Sequential Invasive Cleavages
; NUMBER OF SEQUENCES: 163
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/823,516
; FILING DATE: 24-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US97/01072

```

```

; FILING DATE: 21-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/759,038
; FILING DATE: 02-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/758,314
; FILING DATE: 02-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/756,386
; FILING DATE: 29-NOV-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/682,853
; FILING DATE: 12-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/599,491
; FILING DATE: 24-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: FORS-02736
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
;
; INFORMATION FOR SEQ ID NO: 83:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-08-823-516-83

Query Match 20.0%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 917 GCTTTGCTTTTATCCCTCC 937
Db 1 GCCTATGCCCTTTATCTCTCC 21

RESULT 12
US-08-759-038-119
; Sequence 119, Application US/08759038
; Patent No. 6090543
; GENERAL INFORMATION:
; APPLICANT: Prudent, James R.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Brow, Mary Ann D.
; APPLICANT: Dahlberg, James E.
; TITLE OF INVENTION: Cleavage Of Nucleic Acids
; NUMBER OF SEQUENCES: 134
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/759,038
; FILING DATE: 02-DEC-1996
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/599,491
; FILING DATE: 12-JUL-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: FORS-02575
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/682,853
; FILING DATE: 12-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/599,491
; FILING DATE: 24-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: FORS-02574
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 119:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-08-759-038-119

Query Match 20.0%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 917 GCTTTGCTTTTATCCCTCC 937
Db 1 GCCTATGCCCTTTATCTCTCC 21

RESULT 13
US-08-758-314-119
; Sequence 119, Application US/08758314
; Patent No. 6090606
; GENERAL INFORMATION:
; APPLICANT: Kaiser, Michael W.
; APPLICANT: Lyamichev, Victor I.
; APPLICANT: Lyamichev, Natasha
; TITLE OF INVENTION: Improved Cleavage Agents
; NUMBER OF SEQUENCES: 134
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,314
; FILING DATE: 02-DEC-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/
; FILING DATE: 29-NOV-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/682,853
; FILING DATE: 12-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/599,491
; FILING DATE: 24-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: FORS-02575
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410

```

```
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 119:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 21 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: other nucleic acid
;   DESCRIPTION: /desc = "DNA"
US-08-758-314-119

Query Match      20.0%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 917 GTCCTTGGCTTTATCCCTCC 937
Db 1 GCCTATGCCCTTATTCCTCC 21

RESULT 14
US-09-306-420C-12
; Sequence 12, Application US/09306420C
; Patent No. 655311
; GENERAL INFORMATION:
; APPLICANT: LOCARNINI, STEPHEN A
; APPLICANT: BARTHOLOMEUSZ, ANGELINE I
; APPLICANT: AYE, THEIN T
; APPLICANT: DEMAN, ROBERT A
; TITLE OF INVENTION: VIRAL VARIANTS AND METHODS FOR DETECTING SAME
; FILE REFERENCE: 2551-28
; CURRENT APPLICATION NUMBER: US/09/306,420C
; PRIOR FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/AU97/00520
; PRIOR FILING DATE: 1997-08-15
; PRIOR APPLICATION NUMBER: P03519
; PRIOR FILING DATE: 1996-11-08
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Hepatitis B virus
US-09-306-420C-12

Query Match      20.0%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 908 TTTTCTTTGGCTTTATCCCTTT 928
Db 1 TTTTCTTTGGCTTTATTCGGTAT 21

RESULT 15
US-09-306-420C-16/c
; Sequence 16, Application US/09306420C
; Patent No. 655311
; GENERAL INFORMATION:
; APPLICANT: LOCARNINI, STEPHEN A
; APPLICANT: BARTHOLOMEUSZ, ANGELINE I
; APPLICANT: AYE, THEIN T
; APPLICANT: DEMAN, ROBERT A
; TITLE OF INVENTION: VIRAL VARIANTS AND METHODS FOR DETECTING SAME
; FILE REFERENCE: 2551-28
; CURRENT APPLICATION NUMBER: US/09/306,420C
; PRIOR FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/AU97/00520
; PRIOR FILING DATE: 1997-08-15
; PRIOR APPLICATION NUMBER: P03519
; PRIOR FILING DATE: 1996-11-08
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.0

; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 119:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Hepatitis B virus
US-09-306-420C-16

Query Match      20.0%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 908 TTTTCTTTGGCTTTATCCCTTT 928
Db 21 TTTTCTTTGGCTTTATTCGGTAT 1

RESULT 16
US-09-684-938-119
; Sequence 119, Application US/09684938
; Patent No. 655357
; GENERAL INFORMATION:
; APPLICANT: KAISER, Michael W.
; APPLICANT: LYAMICHEV, Victor I.
; APPLICANT: LYAMICHEV, Natasha
; TITLE OF INVENTION: Improved Cleavage Agents
; FILE REFERENCE: FORS-03755
; CURRENT APPLICATION NUMBER: US/09/684,938
; CURRENT FILING DATE: 2000-10-06
; PRIOR APPLICATION NUMBER: 09/308,825
; PRIOR FILING DATE: 1999-05-25
; PRIOR APPLICATION NUMBER: 08/757,653
; PRIOR FILING DATE: 1996-11-29
; PRIOR APPLICATION NUMBER: 08/758,314
; PRIOR FILING DATE: 1996-12-02
; PRIOR APPLICATION NUMBER: PCT/US97/21783
; PRIOR FILING DATE: 1997-11-29
; NUMBER OF SEQ ID NOS: 188
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 119
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-684-938-119

Query Match      20.0%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 917 GTCCTTGGCTTTATCCCTCC 937
Db 1 GCCTATGCCCTTATTCCTCC 21

RESULT 17
US-09-308-825A-119
; Sequence 119, Application US/09308825A
; Patent No. 6562611
; GENERAL INFORMATION:
; APPLICANT: KAISER, Michael W.
; APPLICANT: LYAMICHEV, Victor I.
; APPLICANT: LYAMICHEV, Natasha
; TITLE OF INVENTION: Improved Cleavage Agents
; FILE REFERENCE: FORS-03755
; CURRENT APPLICATION NUMBER: US/09/308,825A
; CURRENT FILING DATE: 1999-10-08
; PRIOR APPLICATION NUMBER: 08/757,653
; PRIOR FILING DATE: 1996-11-29
; PRIOR APPLICATION NUMBER: 08/758,314
; PRIOR FILING DATE: 1996-12-02
; PRIOR APPLICATION NUMBER: PCT/US97/21783
; PRIOR FILING DATE: 1997-11-29
; NUMBER OF SEQ ID NOS: 188
```

THE UNIVERSITY OF CHICAGO

OTHER INFORMATION: primer for PCR
US-09-792-251-23

Query Match 18.6%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 905 TCATTTCTTTGCTCTTGC 924
||||| ||| |||||
Db 20 TCATTTCTTTGCCCTTGC 1

RESULT 26
US-09-706-197-77
; Sequence 77, Application US/09706197
; Patent No. 6475797
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: David Spector
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF SR-CVP EXPRESSION
; FILE REFERENCE: RTS-0145
; CURRENT APPLICATION NUMBER: US/09/706,197
; CURRENT FILING DATE: 2000-11-03
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-706-197-77

Query Match 18.4%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 900 CCTGTCATTTCTT 914
||||| |||||
Db 2 CATGTCATTTCTT 16

RESULT 27
US-09-531-000-29
; Sequence 29, Application US/09531000
; Patent No. 6461810
; GENERAL INFORMATION:
; APPLICANT: JOHNSON, Marion D.
; APPLICANT: FRESCO, Jacques R.
; TITLE OF INVENTION: TRIPLEX IN-SITU HYBRIDIZATION
; FILE REFERENCE: 2448-103
; CURRENT APPLICATION NUMBER: US/09/531,000
; CURRENT FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: PCT/US98/23765
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: 60/064,997
; PRIOR FILING DATE: 1997-11-10
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target
; OTHER INFORMATION: sequences
US-09-531-000-29

Query Match 18.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 48;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 927 TTTATCCCTCTCTTCAT 944

Db 1 TTCTCCTTTCTCTTCAT 18

RESULT 28
US-08-607-384A-24/c
; Sequence 24, Application US/08607384A
; Patent No. 5849488
; GENERAL INFORMATION:
; APPLICANT: ALATOSSAVA, JOUKO TAPANI
; APPLICANT: FORSMAN, P IVI TUULIKKI
; APPLICANT: TILSALA-TIMISJ RVI, ANU KYLLIKKI
; TITLE OF INVENTION: DNA SEQUENCE-BASED DIAGNOSIS OF MASTITIS
; TITLE OF INVENTION: FROM A MILK SAMPLE
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/607,384A
; FILING DATE: 27-FEB-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: BYRNE, THOMAS E.
; REGISTRATION NUMBER: 32,205
; REFERENCE/DOCKET NUMBER: 227-75
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ORIGINAL SOURCE:
; ORGANISM: Staphylococcus epidermidis
; STRAIN: ATCC 12228
US-08-607-384A-24

Query Match 18.1%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 51;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 929 TATCCCTCTCTTCATG 946
||||| |||||
Db 19 TATCCCTCTCTTCGTAG 2

RESULT 29
US-09-198-452A-2716/c
; Sequence 2716, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849

FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
CURRENT FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 10295
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..19
OTHER INFORMATION: downstream amplification primer 99-10966 for SEQ 2430, in complement
US-09-422-978-10295

Query Match 17.5%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 61;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 909 TTCTTTGCTCTTGC 924
DB 18 TTCTTTGCTATGCC 3

RESULT 34
US-08-261-822A-32/c
Sequence 32, Application US/08261822A
Patent No. 5650533
GENERAL INFORMATION:
APPLICANT: Ecker, Joseph R. et al.
TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
TITLE OF INVENTION: and Pathogens
NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5650533ris
STREET: One Liberty Place, 46th floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/261,822A
FILING DATE: 17-JUN-1994
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Beardell, Lori Y.
REGISTRATION NUMBER: 34,293
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
US-08-261-822A-32

Query Match 17.0%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 68;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTCCTCTTCATG 946
DB 17 CCTCCTCTTCATG 4

RESULT 35
US-08-506-296B-12
Sequence 12, Application US/08506296B
Patent No. 6313265
GENERAL INFORMATION:
APPLICANT: Phillips, Greg
APPLICANT: Cunningham, Bruce A.
APPLICANT: Crossin, Kathryn L.
TITLE OF INVENTION: NEURITE OUTGROWTH-PROMOTING POLYPEPTIDES
TITLE OF INVENTION: CONTAINING FIBRONECTIN TYPE III REPEATS AND METHODS OF USE
NUMBER OF SEQUENCES: 77
CORRESPONDENCE ADDRESS:
ADDRESSEE: The Scripps Research Institute
STREET: 10550 No. 6313265th Torrey Pines Road, TPC-8
CITY: La Jolla
STATE: California
COUNTRY: U.S.
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/506,296B
FILING DATE: 24-JUL-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Fitting, Thomas
REGISTRATION NUMBER: 34,163
REFERENCE/DOCKET NUMBER: TSRI 488.0
TELEPHONE: (619) 554-2937
TELEFAX: (619) 554-6312
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-506-296B-12

Query Match 17.0%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 68;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTCCTCTTCATG 946
DB 1 CCTCCTCTTCATG 14

RESULT 36
PCT-US95-07744A-32/c
Sequence 32, Application PC/TUS9507744A
GENERAL INFORMATION:
APPLICANT: Trustees of The University of Pennsylvania
TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
TITLE OF INVENTION: and Pathogens
NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & Norris
STREET: One Liberty Place, 46th floor
CITY: Philadelphia

schultz1-899.rni

Mon Oct 18 14:40:17 2004

STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/07744A
FILING DATE: 15-JUNE-1995
CLASSIFICATION:
PRIORITY APPLICATION DATA:
PRIORITY APPLICATION NUMBER: 08/261,822
FILING DATE: June 17, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Beardell, Lori Y.
REGISTRATION NUMBER: 34,293
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
PCT-US95-07744A-32

Query Match 17.0%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 68;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTCTCTTTCATTG 946
DB 17 CCTCTCTTTCATTG 4

RESULT 37
US-09-422-978-7250/c
Sequence 7250, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CP1
CURRENT APPLICATION NUMBER: US/09/422,978
CURRENT FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 7250
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..19
OTHER INFORMATION: upstream amplification primer 99-3217 for SEQ 3316,
US-09-422-978-7250

Query Match 17.0%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 72;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 917 GTCTTTGCCCTTTTA 930
DB 19 GTCTTTGCCCTTTTA 6

RESULT 38
US-08-373-124A-65
Sequence 65, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storageable
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-65

Query Match 16.7%; Score 12.2; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 70;
Matches 7; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 910 TTCTTTGGTCTTTGCCCT 926
DB 1 UGCUAUGGUCUAGCCU 17

RESULT 39
US-08-435-628-65
Sequence 65, Application US/08435628

```
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; CANCER USING RIBOZYMES
; FILE REFERENCE: MEHBOO.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5632

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-65

Query Match 16.7%; Score 12.2; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 70;
Matches 7; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 910 TTCTTGGCTTTGGCT 926
| : : : : : : : : : :
Db 1 UGCUAUGGUCUUGCCU 17

RESULT 40
US-09-371-772B-5632
; Sequence 5632, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
```

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; sulting from Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHBOO.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5632

Query Match 16.7%; Score 12.2; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 70;
Matches 5; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 907 ATTTCTTTGGCTTTG 923
| : : : : : : : : : :
Db 1 AUAUUCUCUCUCUUG 17

RESULT 41
US-08-384-324-2
; Sequence 2, Application US/08384324
; Patent No. 5844110
; GENERAL INFORMATION:
; APPLICANT: Gold, Barry I.
; TITLE OF INVENTION: Synthetic Triple Helix-Forming Compounds
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dann, Dorfman, Herrell and Skillman
; STREET: 1601 Market Street, Suite 720
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/384,324
; FILING DATE: 31-JAN-1995
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Reed, Janet E.
; REGISTRATION NUMBER: 36,252
; REFERENCE/DOCKET NUMBER: 63076
; TELEPHONE: (215) 563-4100
; TELEFAX: (215) 563-4044
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: not relevant
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ANTI-SENSE: YES
; US-08-384-324-2

Query Match 16.7%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 908 TTTTCTTTGGCTTTC 924
|||||
Db 1 TTTTCTTTTCTTTC 17

RESULT 42

US-09-527-030G-108
; Sequence 108, Application US/09527030G
; Patent No. 6482588
; GENERAL INFORMATION:
; APPLICANT: VAN DOORN, Leen-Jan et al.
; TITLE OF INVENTION: Detection and Identification of Human Papillomavirus by PCR and
; FILE OF INVENTION: Specific reverse hybridization.
; FILE REFERENCE: 3501-0101P
; CURRENT APPLICATION NUMBER: US/09/527,030G
; CURRENT FILING DATE: 2000-03-16
; NUMBER OF SEQ ID NOS: 497
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 108
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Type specific probe derived from the Human Papillomavirus (HPV)
US-09-527-030G-108

Query Match 16.7%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 945 TCGTTTAATGATCGCT 961
|||||
Db 1 TCGTTTAATGAATGTT 17

RESULT 43

US-09-920-760-89/c
; Sequence 89, Application US/09920760
; Patent No. 6492173
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYCLIN D2 EXPRESSION
; FILE REFERENCE: RTS-0275
; CURRENT APPLICATION NUMBER: US/09/920,760
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 89
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-920-760-89

Query Match 16.7%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 914 TTGGTCTTTCCTTTTA 930
|||||
Db 18 TTGTTCTTTGCTTTTA 2

RESULT 44

US-09-422-978-5922/c
; Sequence 5922, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI

; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5922
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-7792 for SEQ 1988,
US-09-422-978-5922

Query Match 16.7%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 927 TTTATCCCTCCTTCCA 943
|||||
Db 17 TTTATCCCTCCTTCCA 1

RESULT 45

US-09-422-978-7176/c
; Sequence 7176, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7176
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-2636 for SEQ 3242,
US-09-422-978-7176

Query Match 16.7%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 929 TATCCCTCCTTTCATT 945
|||||
Db 17 TGTCCCTCCTGCTCATT 1

RESULT 46

PCT-US96-01473-2
; Sequence 2, Application PC/TUS9601473
; GENERAL INFORMATION:
; APPLICANT: University of Nebraska, Board of Regents
; APPLICANT: Gold, Barry I.
; TITLE OF INVENTION: Synthetic Triple Helix-Forming Compounds

NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dan, Dorfman, Herrrell and Skillman
STREET: 1601 Market Street Suite 720
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103-2307
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/01473
FILING DATE: 29-JAN-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/384,324
FILING DATE: 01-FEB-1995
ATTORNEY/AGENT INFORMATION:
NAME: Reed, Janet E.
REGISTRATION NUMBER: 36,252
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 563-4100
TELEFAX: (215) 563-4044
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: not relevant
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: YES
ANTI-SENSE: YES
PCT-US96-01473-2

Query Match 16.7%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 908 TTTTCTTTGGCTTTGC 924
|||||
DB 1 TTTTCTTTTCTTTTC 17

RESULT 47
5219727-64
PATENT NO. 5219727
APPLICANT: WANG, ALICE M.; DOYLE, MICHAEL V.; MARK, DAVID F.
TITLE OF INVENTION: QUANTIFICATION OF NUCLEIC ACIDS USING THE
POLYMERASE CHAIN REACTION
NUMBER OF SEQUENCES: 64
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/413,623
FILING DATE: 28-SEP-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 396,986
FILING DATE: 21-AUG-1989
SEQ ID NO: 64:
LENGTH: 18
5219727-64

Query Match 16.7%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 913 TTTGCTCTTTGCTTTT 929
|||||
DB 1 TTTGCTCTTTGCTTTAT 17

RESULT 48

US-08-584-040-8450
SEQUENCE 8450, Application US/08584040
PATENT NO. 8346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 8450:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-8450

Query Match 16.4%; Score 12; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 66;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGCTCTTGGCT 926
|||||
DB 2 UGGCUUUGCCU 13

RESULT 49

US-09-371-772B-4106
SEQUENCE 4106, Application US/09371772B
PATENT NO. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
LATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
FILE REFERENCE: MEH800,876-J (237/199)

```
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4106
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4106

Query Match          16.4%; Score 12; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 66;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCGCT 926
Db 2 UGGUCUUUGCCU 13

RESULT 50
US-09-371-772B-5670
; Sequence 5670, Application US/09371772B
; Patent No. 6566137
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/1398)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5670
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5670

Query Match          16.4%; Score 12; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 71;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCGCT 926
Db 3 UGGUCUUUGCCU 14

RESULT 51
US-08-584-040-1499
; Sequence 1499, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
```

```
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1499:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1499

Query Match          16.4%; Score 12; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 76;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCGCT 926
Db 5 UGGUCUUUGCCU 16

RESULT 52
US-08-584-040-1500
; Sequence 1500, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
```

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1500:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1500

Query Match 16.4%; Score 12; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 76;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCCT 926
DB 3 UGGUCUUUGCCU 14

RESULT 53
US-08-584-040-1501
Sequence 1501, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1501:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1501

Query Match 16.4%; Score 12; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 76;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCCT 926
DB 2 UGGUCUUUGCCU 13

RESULT 54
US-09-371-772B-44
Sequence 44, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MEHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patentin version 3.0
SEQ ID NO 44
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-44

Query Match 16.4%; Score 12; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 76;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCCT 926
DB 5 UGGUCUUUGCCU 16

RESULT 55
US-09-371-772B-45
Sequence 45, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MEHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 45
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-45

Query Match 16.4%; Score 12; DB 1; Length 17;
 Best Local Similarity 50.0%; Pred. No. 76;
 Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCCT 926
 :||:||||:
 Db 3 UGGUCUUUGCCU 14

RESULT 56
 US-09-371-772B-46
 ; Sequence 46, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; FILE REFERENCE: MBH800, 876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 46
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-46

Query Match 16.4%; Score 12; DB 1; Length 17;
 Best Local Similarity 50.0%; Pred. No. 76;
 Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCCT 926
 :||:||||:
 Db 2 UGGUCUUUGCCU 13

RESULT 57
 US-09-371-772B-4244
 ; Sequence 4244, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; FILE REFERENCE: MBH800, 876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4244
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-4244

Query Match 16.4%; Score 12; DB 1; Length 17;
 Best Local Similarity 50.0%; Pred. No. 76;
 Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCCT 926
 :||:||||:
 Db 4 UGGUCUUUGCCU 15

RESULT 58
 US-09-166-203-21/c
 ; Sequence 21, Application US/09166203A
 ; Patent No. 5968826
 ; GENERAL INFORMATION:
 ; APPLICANT: Bennett, C. Frank
 ; APPLICANT: Condon, Tom P.
 ; APPLICANT: Cowsett, Lex M.
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN 4 EXPRESSION
 ; FILE REFERENCE: ISPH-0323
 ; CURRENT APPLICATION NUMBER: US/09/166,203A
 ; CURRENT FILING DATE: 1998-10-05
 ; NUMBER OF SEQ ID NOS: 60
 ; SEQ ID NO 21
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: antisense sequence
 US-09-166-203-21

Query Match 16.4%; Score 12; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 81;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 901 CTGGTCATTTC 912
 |||||
 Db 12 CTGGTCATTTC 1

RESULT 59
 US-09-377-309-21/c
 ; Sequence 21, Application US/09377309B
 ; Patent No. 6258790
 ; GENERAL INFORMATION:
 ; APPLICANT: Bennett, C. Frank
 ; APPLICANT: Condon, Tom P.
 ; APPLICANT: Cowsett, Lex M.
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN 4 EXPRESSION
 ; FILE REFERENCE: ISPH-0390
 ; CURRENT APPLICATION NUMBER: US/09/377,309B
 ; CURRENT FILING DATE: 1999-08-19
 ; EARLIER APPLICATION NUMBER: 09/166,203
 ; EARLIER FILING DATE: 1998-10-05
 ; NUMBER OF SEQ ID NOS: 99
 ; SEQ ID NO 21
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: antisense sequence
 US-09-377-309-21

Query Match 16.4%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 901 CTGGTCATTTC 912
Db 12 CTGGTCATTTC 1

RESULT 60
US-09-479-005A-303
; Sequence 303, Application US/09479005A
; Patent No. 6856731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 303
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-303

Query Match 16.2%; Score 11.8; DB 1; Length 16;
Best Local Similarity 40.0%; Pred. No. 78;
Matches 6; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 937 CTCCTTCATTGGTTTA 951
Db 2 CACUCCAUUGUUUUA 16

RESULT 61
PCT-US91-03680-98
; Sequence 98, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40

TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-327-7250
TELEFAX: 415-327-2951
TELEX: 706141
INFORMATION FOR SEQ ID NO: 98:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: modified_base
LOCATION: 3
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION:
FEATURE:
NAME/KEY: modified_base
LOCATION: 8..9
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION:
FEATURE:
NAME/KEY: modified_base
LOCATION: 14
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION:
FEATURE:
NAME/KEY: modified_base
LOCATION: 16
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION:
OTHER INFORMATION: /note= "T-T, linking group o-xyloso (nucleotides
that have xylose sugar linked via the o-xyloso
OTHER INFORMATION: ring")
PCT-US91-03680-98

Query Match 16.2%; Score 11.8; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 78;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 918 TCTTGCCTTTATC 932
Db 2 TMTTTMTTTTTC 16

RESULT 62
US-09-068-195-8
; Sequence 8, Application US/09068195B
; Patent No. 6140078
; GENERAL INFORMATION:
; APPLICANT: Sanders, Jan W.
; APPLICANT: Ledebor, Adrianus M.
; APPLICANT: Venema, Gerard
; APPLICANT: Kok, Jan
; TITLE OF INVENTION: Salt-Inducible Promoter Derivable from a Lactic Acid
; TITLE OF INVENTION: Bacterium, and its Use in a Lactic Acid Bacterium for
; FILE REFERENCE: Sanders-60113/025227
; CURRENT APPLICATION NUMBER: US/09/068,195B
; CURRENT FILING DATE: 1998-07-29
; EARLIER APPLICATION NUMBER: PCT/EP97/04755
; EARLIER FILING DATE: 1997-08-20
; EARLIER APPLICATION NUMBER: EP 97200744/7
; EARLIER FILING DATE: 1997-03-13
; EARLIER APPLICATION NUMBER: EP 96202444/4
; EARLIER FILING DATE: 1996-09-05
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer NS3-10
; FEATURE:

```
; NAME/KEY: primer bind
; LOCATION: (1)..(17)
US-09-068-195-8

Query Match          16.2%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 83;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 936 CCTTTCATGTTT 950
Db 1 CCGCTTCATGTTT 15

RESULT 63
US-08-584-040-1874
; Sequence 1874, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1874:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1874

Query Match          16.2%; Score 11.8; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 83;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 924 CTTTTCCTCCT 938
Db 3 CCUAUUAACCCUCCU 17

NAME/KEY: primer bind
LOCATION: (1)..(17)
US-09-068-195-8

Query Match          16.2%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 83;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 936 CCTTTCATGTTT 950
Db 1 CCGCTTCATGTTT 15

RESULT 64
US-09-371-772B-419
; Sequence 419, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re:
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH001876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 419
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-419

Query Match          16.2%; Score 11.8; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 83;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 924 CTTTTCCTCCT 938
Db 3 CCUAUUAACCCUCCU 17

NAME/KEY: primer bind
LOCATION: (1)..(17)
US-09-068-195-8

Query Match          16.2%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 83;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 936 CCTTTCATGTTT 950
Db 1 CCGCTTCATGTTT 15

RESULT 65
US-09-529-812A-4/c
; Sequence 4, Application US/09529812A
; Patent No. 6682930
; GENERAL INFORMATION:
; APPLICANT: LU, CHANGE
; TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN
; TITLE OF INVENTION: ANTI-HBV
; FILE REFERENCE: 017227/0160
; CURRENT APPLICATION NUMBER: US/09/529,812A
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/CN98/00248
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: CN 97106667.1
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Triplex
; OTHER INFORMATION: forming oligonucleotide
; OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
US-09-529-812A-4

Query Match          16.2%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 83;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 931 TCCCTCCTCCTCATT 945
Db 15 TCCCTCCTCCTCCTT 11
```

[illegible]

```
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/311,760A
/ FILING DATE: September 23, 1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/155
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 77:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-311-760A-77
/
/ Query Match 15.6%; Score 11.4; DB 1; Length 15;
/ Best Local Similarity 46.2%; Pred. No. 86;
/ Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Oy 933 CCTCTCTTCATT 945
Db 2 CAUCCUCUUAU 14

RESULT 71
US-08-311-760A-78
/ Sequence 78, Application US/08311760A
/ Patent No. 5599706
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramnarack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ TITLE OF INVENTION:
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/774,310
/ FILING DATE: December 23, 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/311,760
/ FILING DATE: September 23, 1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 223/229
/ TELECOMMUNICATION INFORMATION:

Oy 935 TCCTCTTCATTGG 947
Db 2 UCCUCUUAUUG 14

RESULT 72
US-08-774-310-77
/ Sequence 77, Application US/08774310
/ Patent No. 5877022
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Daniel T.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Newton, Roger S.
/ APPLICANT: Ramnarack, Randy
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
/ TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
/ TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
/ TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
/ TITLE OF INVENTION:
/ NUMBER OF SEQUENCES: 392
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/774,310
/ FILING DATE: December 23, 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/311,760
/ FILING DATE: September 23, 1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 223/229
/ TELECOMMUNICATION INFORMATION:
```

```

; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 77:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-310-77

Query Match 15.6%; Score 11.4; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 86;
Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 933 CTCCTCTCTTCATT 945
Db 2 CAUCCUUAUUG 14

RESULT 73
US-08-774-310-78
; Sequence 78, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 78:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-310-78

Query Match 15.6%; Score 11.4; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 86;
Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 933 TCCTCTCTTCATTGG 947
Db 2 UCCUCUUAUUG 14

Matches 6; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 935 TCCTCTCTTCATTGG 947
Db 2 UCCUCUUAUUG 14

RESULT 74
US-08-929-856-57/c
; Sequence 57, Application US/08929856
; Patent No. 6136568
; GENERAL INFORMATION:
; APPLICANT: Hiatt, Andrew
; APPLICANT: Rose, Floyd
; TITLE OF INVENTION: DE NOVO POLYNUCLEOTIDE SYNTHESIS USING
; TITLE OF INVENTION: ROLLING TEMPLATES
; NUMBER OF SEQUENCES: 190
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LERNER, DAVID, LITTENBERG, KRUMHOLZ &
; ADDRESSEE: MENTILIK
; STREET: 600 South, Avenue West
; CITY: Westfield
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07090
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/929,856
; FILING DATE: 15-SEP-1997
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Foley, Shawn P.
; REGISTRATION NUMBER: 33,071
; REFERENCE/DOCKET NUMBER: ROSE 3.0-057
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908-654-5000
; TELEFAX: 908-654-7866
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-929-856-57

Query Match 15.6%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 86;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCTCTCTCTTCA 943
Db 15 TGCCTCTCTTCA 3

RESULT 75
PCT-US91-03680-96
; Sequence 96, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
```

STATE: California
COUNTRY: USA
ZIP: 94025
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/03680
FILING DATE: 19910524
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Murashige, Kate H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 4610-0011.40
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-327-7250
TELEFAX: 415-327-2951
TELEX: 706141
INFORMATION FOR SEQ ID NO: 96:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: modified_base
LOCATION: 3
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 8
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION:
FEATURE:
NAME/KEY: modified_base
LOCATION: 9
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 14
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 16
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 16
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
OTHER INFORMATION: that have xylose sugar linked via the o-xyloene
OTHER INFORMATION: ring"
PCT-US91-03680-96

Query Match 15.6%; Score 11.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 92;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 918 TCTTTCCTTTATC 932
Db 2 TCTTTCCTTTATC 16

RESULT 76

US-09-270-542-186
Sequence 186, Application US/09270542
Patent No. 6322976
GENERAL INFORMATION:
APPLICANT: Altman, Timothy
APPLICANT: Scott, James
APPLICANT: Stanton, Lawrence
TITLE OF INVENTION: Compositions and Methods of Disease Diagnosis and

TITLE OF INVENTION: Therapy
FILE REFERENCE: 4198/78179
CURRENT APPLICATION NUMBER: US/09/270,542
CURRENT FILING DATE: 1999-03-17
EARLIER APPLICATION NUMBER: 09/221,222
EARLIER FILING DATE: 1999-12-23
NUMBER OF SEQ ID NOS: 207
SOFTWARE: Patent in Ver. 2.0
SEQ ID NO 186
LENGTH: 16
TYPE: DNA
ORGANISM: Rattus norvegicus
US-09-270-542-186

Query Match 15.3%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 936 CCTCTTCATTGGTTTA 951
Db 1 CCTATCTTTGGCTTA 16

RESULT 77

US-09-479-005A-176/c
Sequence 176, Application US/09479005A
Patent No. 6656731
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
FILE REFERENCE: MBH00-884-C
CURRENT APPLICATION NUMBER: US/09/479,005A
CURRENT FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 09/444,209
PRIOR FILING DATE: 1999-11-19
PRIOR APPLICATION NUMBER: US 09/159,274
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: US 60/059,473
NUMBER OF SEQ ID NOS: 1208
SOFTWARE: Patent in version 3.0
SEQ ID NO 176
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-479-005A-176

Query Match 15.3%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 937 CTCTTCATTGGTTAA 952
Db 16 CACTTCATTGGTTAA 1

RESULT 78

US-08-299-849B-48/c
Sequence 48, Application US/08299849B
Patent No. 5612201
GENERAL INFORMATION:
APPLICANT: De Plaen, Etienne; Boon-Falleur, Thierry;
APPLICANT: Leth, Bernard; Szikora, Jean-Pierre; De Smet, Charles;
APPLICANT: Chomez, Patrick
TITLE OF INVENTION: Isolated Nucleic Acid Molecules Useful In
Determination of Expression of A Tumor Antigen Precursor
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Felfe & Lynch
STREET: 805 Third Avenue
CITY: New York City
STATE: New York
ZIP: 10022

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
COMPUTER: IBM
OPERATING SYSTEM: PC-DOS
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/299,849B
FILING DATE: 1-SEPTEMBER-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/037,230
FILING DATE: 26-MARCH-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/04354
FILING DATE: 22-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/807,043
FILING DATE: 12-DECEMBER-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/764,364
FILING DATE: 23-SEPTEMBER-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/728,838
FILING DATE: 9-JULY-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/705,702
FILING DATE: 23-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Hanson, No. 5612201man D.
REGISTRATION NUMBER: 30,946
REFERENCE/DOCKET NUMBER: LUD 5355
TELEPHONE: (212) 688-9200
TELEFAX: (212) 838-3884
INFORMATION FOR SEQ ID NO: 48:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-299-849B-48

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.le+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 927 TTTATCCCTCTCTTC 942
||| |||||
Db 16 TTGGCCCTCTCTTC 1

RESULT 79
US-08-373-124A-366/c
Sequence 366, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
COMPUTER: IBM
OPERATING SYSTEM: PC-DOS
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/299,849B
FILING DATE: 1-SEPTEMBER-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/037,230
FILING DATE: 26-MARCH-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/04354
FILING DATE: 22-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/807,043
FILING DATE: 12-DECEMBER-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/764,364
FILING DATE: 23-SEPTEMBER-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/728,838
FILING DATE: 9-JULY-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/705,702
FILING DATE: 23-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Hanson, No. 5612201man D.
REGISTRATION NUMBER: 30,946
REFERENCE/DOCKET NUMBER: LUD 5355
TELEPHONE: (212) 688-9200
TELEFAX: (212) 838-3884
INFORMATION FOR SEQ ID NO: 48:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-299-849B-48

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 366:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-366

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.le+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 948 TTTAATGTCGCTAC 963
||| |||||
Db 16 TTACATGTAACGCTAC 1

RESULT 80
US-08-373-124A-1012
Sequence 1012, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1012:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1012

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 1.1e+02;
Matches 6; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 913 TTGTGCTTTGCTTT 928
Db 1 UAUGGCUUAGCCUGU 16

RESULT 81
US-08-435-628-366/c
; Sequence 366, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035

; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 366:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-366

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 948 TTTAATGTCGCTAC 963
Db 16 TTACATGTAACGCTAC 1

RESULT 82
US-08-435-628-1012
; Sequence 1012, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
```



```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1012:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1012

Query Match          15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 1.1e+02;
Matches 6; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 913 TTGTGCTTTGCTTT 928
Db 1 UAUGGCUUAGCCUGU 16

RESULT 83
US-08-967-727-28/c
; Sequence 28, Application US/08967727
; Patent No. 6025474
; GENERAL INFORMATION:
; APPLICANT: Gaugier, B atrice; Van den Eynde, Beno t;
; APPLICANT: van der Bruggen, Pierre; Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For
; TITLE OF INVENTION: Tumor Rejection Antigen Precursor Mage-3 And Uses Thereof
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/967,727
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/037,230
; FILING DATE: 26-MARCH-1993
; APPLICATION NUMBER: PCT/US92/04354
; FILING DATE: 22-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/807,043
; FILING DATE: 12-DECEMBER-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/764,365
; FILING DATE: 23-SEPTEMBER-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/728,838
; FILING DATE: 9-JULY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/705,702
; FILING DATE: 23-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6025474man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5353
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-967-727-28

Query Match          15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 927 TTTATCCCTCCTCTTC 942
Db 16 TTGGCCCTCCTCTTC 1

RESULT 84
US-08-606-505B-47
; Sequence 47, Application US/08606505B
; Patent No. 6114601
; GENERAL INFORMATION:
; APPLICANT: KIKUCHI, Yasuhiro
; APPLICANT: KIYOKAWA, Shigeto
; APPLICANT: SHIMADA, Yukihisa
; APPLICANT: OHBAYASHI, Masaya
; APPLICANT: SHIMADA, Ritsuko
; APPLICANT: OKINAKA, Yasushi
; TITLE OF INVENTION: NOVEL PLANT GENES
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FITZPATRICK, CELLA, HARPER & SCINTO
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10112-3601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.50 inch, 720 Kb storage.
; COMPUTER: IBM PS/IV
; OPERATING SYSTEM: MS-DOS Ver3.30
; SOFTWARE: PATENT AID Ver1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/606,505B
; FILING DATE: 23-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP44963/92
; FILING DATE: 02-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-218-2100
; TELEFAX: 212-218-2200
; INFORMATION FOR SEQ ID NO: 47:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; DESCRIPTION: Synthetic DNA
US-08-606-505B-47

Query Match          15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 900 CCTGGTCATTTCTTCG 916
Db 1 CCNGGCGCATTTCTTCG 17

RESULT 85
US-09-616-990-47
; Sequence 47, Application US/09616990
```

```

; Patent No. 6232109
; GENERAL INFORMATION:
; APPLICANT: KIKUCHI, Yasuhiro
; KIKUCHI, Yasuhiro
; SHIMADA, Yukihisa
; OHYASHI, Masaya
; SHIMADA, Ritsuko
; OKINAKA, Yasushi
; TITLE OF INVENTION: NOVEL PLANT GENES
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESS: FITZPATRICK, CELLA, HARPER & SCINTO
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10112-3801
; MEDIUM TYPE: Diskette - 3.50 inch, 720 kb storage.
; COMPUTER: IBM PS/V
; OPERATING SYSTEM: MS-DOS Ver3.30
; SOFTWARE: PATENT AID Ver1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/616,990
; FILING DATE: 14-Jul-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP44963/92
; FILING DATE: 02-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Petty, Lawrence S.
; REGISTRATION NUMBER: 31865
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-218-2100
; TELEFAX: 212-218-2200
; INFORMATION FOR SEQ ID NO: 47:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; DESCRIPTION: Synthetic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 47
US-09-616-990-47

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 900 CCTGGTCATTCTTTG 916
Db 1 CCNGGGCATATCTTCG 17

RESULT 86
US-037-230D-28/c
; Sequence 28, Application US/08037230D
; Patent No. 6235525
; GENERAL INFORMATION:
; APPLICANT: Gaugler, B atrice; Van den Eynde, Beno t;
; APPLICANT: van der Bruggen, Pierre; Boon-Palleur, Thierry
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For
; TITLE OF INVENTION: Tumor Rejection Antigen Precursor Mage-3 And Uses Thereof
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM

```

```

; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/037,230D
; FILING DATE: 26-MARCH-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/04354
; FILING DATE: 22-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/807,043
; FILING DATE: 12-DECEMBER-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/764,364
; FILING DATE: 23-SEPTEMBER-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/728,838
; FILING DATE: 9-JULY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/705,702
; FILING DATE: 23-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6235525man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5353
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-037-230D-28

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 927 TTTATCCCTCTCTTC 942
Db 16 TTGGCCCTCTCTTC 1

RESULT 87
US-08-584-040-1574/c
; Sequence 1574, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

```

```
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1574:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-1574

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 909 TTTCTTTGGTCTTGC 924
Db 17 TTTCTTTGGTCTTGC 2

RESULT 88
US-08-584-040-2874
; Sequence 2874, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Strinchcomb, Jan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064

; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2874:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2874

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 25.0%; Pred. No. 1.1e+02;
Matches 4; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

Qy 907 ATTTCTTTGGTCTTT 922
Db 2 AUAUUCUCUCUCUUU 17

RESULT 89
US-09-583-850-28/c
; Sequence 28, Application US/09583850
; Patent No. 6498021
; GENERAL INFORMATION:
; APPLICANT: Gaugler, Batrice; Van den Eynde, BenoEt;
; APPLICANT: van der Bruggen, Pierre; Boon-falleur, Thierry
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For
; TITLE OF INVENTION: Tumor Rejection Antigen Precursor Mage-3 And Uses Thereof
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felfe & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/583,850
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/583,613
; FILING DATE:
; APPLICATION NUMBER: PCT/US92/04354
; FILING DATE: 22-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/807,043
; FILING DATE: 12-DECEMBER-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/764,365
; FILING DATE: 23-SEPTEMBER-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/728,838
; FILING DATE: 9-JULY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/705,702
; FILING DATE: 23-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6498021man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5353
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
```

```
;
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-583-850-28

Query Match          15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 927 TTTATCCCTCCTCTTC 942
DB 16 TTGGCCCTCCTCTTC 1

RESULT 90
US-09-579-197-28/c
; Sequence 28, Application US/09579197
; Patent No. 6552180
; GENERAL INFORMATION:
; APPLICANT: Gaugler, Beatrice; Van den Eynde, Benoît;
; van der Bruggen, Pierre; Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding
; For Tumor Rejection Antigen Precursor Mage-3 And Uses Thereof
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felle & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; ZIP: 10022
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/579,197
; FILING DATE: 26-MAY-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/037,230
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/807,043
; FILING DATE: 12-DECEMBER-1991
; APPLICATION NUMBER: 07/764,364
; FILING DATE: 23-SEPTEMBER-1991
; APPLICATION NUMBER: 07/728,838
; FILING DATE: 9-JULY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6552180man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5353
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-579-197-28

Query Match          15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 927 TTTATCCCTCCTCTTC 942
DB 16 TTGGCCCTCCTCTTC 1

RESULT 91
US-09-404-026-28/c
; Sequence 28, Application US/09404026
; Patent No. 6565857
; GENERAL INFORMATION:
; APPLICANT: Gaugler, Beatrice; Van den Eynde, Benoît;
; van der Bruggen, Pierre; Boon-Falleur, Thierry
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For
; Tumor Rejection Antigen Precursor Mage-3 And Uses Thereof
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Felle & Lynch
; STREET: 805 Third Avenue
; CITY: New York City
; STATE: New York
; ZIP: 10022
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/404,026
; FILING DATE: 23-SEPT-1999
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/037,230
; FILING DATE: 26-MARCH-1993
; APPLICATION NUMBER: PCT/US92/04354
; FILING DATE: 22-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/807,043
; FILING DATE: 12-DECEMBER-1991
; APPLICATION NUMBER: 07/764,364
; FILING DATE: 23-SEPTEMBER-1991
; APPLICATION NUMBER: 07/728,838
; FILING DATE: 9-JULY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/705,702
; FILING DATE: 23-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6565857man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5353
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 688-9200
; TELEFAX: (212) 838-3884
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-404-026-28

Query Match          15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 927 TTTATCCCTCCTCTTC 942
DB 16 TTGGCCCTCCTCTTC 1

RESULT 92
US-09-371-772B-119/c
; Sequence 119, Application US/09371772B
; Patent No. 6566127
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 119
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-119

Query Match      15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 909 TTCTCTTGGTCTTTC 924
DB 17 TTCTCTTGACGTTC 2

RESULT 93
US-09-371-772B-1398
; Sequence 1398, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1398
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1398

Query Match      15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 25.0%; Pred. No. 1.1e+02;
Matches 4; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 907 ATTTCCTTGGTCTTT 922
DB 2 AUAUUCUCGUCUCUU 17

RESULT 94
US-09-371-772B-5149/c
; Sequence 5149, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5149
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5149
```

```
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5149
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5149

Query Match      15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 914 TTGCTCTTTCCTTT 929
DB 17 TTGCTTTTGCCTTTT 2

RESULT 95
US-09-827-998-621/c
; Sequence 621, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHWRP-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 621
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-621

Query Match      15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 922 TGCCTTTTATCCCTCC 937
DB 17 TGCCTTCTATGCCCTCC 2

RESULT 96
US-09-827-998-622/c
; Sequence 622, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHWRP-8
```

; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686700
; SEQ ID NO 622
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-622

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 922 TCCCTTTTATCCCTCC 937
DB 16 TGGCTTCTATGCTCC 1

RESULT 97
US-09-866-108A-7083/c
; Sequence 7083, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7083
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7083

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 922 TCCCTTTTATCCCTCC 937
DB 16 TGGCTTCTATGCTCC 1

QY 934 CTCCTCTTCATGGTT 949
DB 17 CTCCTCTCTCTGGCT 2

RESULT 98
US-09-866-108A-7084/c
; Sequence 7084, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7084
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7084

Query Match 15.3%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 934 CTCCTCTTCATGGTT 949
DB 16 CTCCTCTCTCTGGCT 1

RESULT 99
US-08-256-568B-34
; Sequence 34, Application US/08256568B
; Patent No. 5845704
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN

```

; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/256,568B
; FILING DATE: 18-JUL-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-256-568B-34

Query Match 15.1%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 900 CCTGGTCATT 910
Db 3 CCTGGTCATT 13

US-08-256-568B-34

RESULT 100
US-09-038-369B-34
; Sequence 34, Application US/09038369B
; Patent No. 6171784
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,900A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:

```

APPLICATION NUMBER: EP/93/402,129.6
FILING DATE: 31-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP/92/403,222.0
FILING DATE: 27-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: CHARLES A. MUSERLIAN
REGISTRATION NUMBER: 19,683
REFERENCE/DOCKET NUMBER: 410.004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 661-8000
TELEFAX: (212) 661-8002
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-378-900A-34

Query Match 15.1%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 900 CCTGGTCATT 910
|||||
Db 3 CCTGGTCATT 13

RESULT 102
US-09-899-044-34
Sequence 34, Application US/09899044
Patent No. 6548244
GENERAL INFORMATION:
APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
ISOLATES
NUMBER OF SEQUENCES: 97
CORRESPONDENCE ADDRESS:
ADDRESSEE: BIERMAN & MUSERLIAN
STREET: 600 THIRD AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10016
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/899,044
FILING DATE: 06-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/378,900
FILING DATE: <Unknown>
APPLICATION NUMBER: PCT/EP93/03325
FILING DATE: 26-NOV-1993
APPLICATION NUMBER: EP/93/402,129.6
FILING DATE: 31-AUG-1993
APPLICATION NUMBER: EP/92/403,222.0
FILING DATE: 27-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: CHARLES A. MUSERLIAN
REGISTRATION NUMBER: 19,683
REFERENCE/DOCKET NUMBER: 410.004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 661-8000

TELEFAX: (212) 661-8002
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-899-044-34

Query Match 15.1%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 900 CCTGGTCATT 910
|||||
Db 3 CCTGGTCATT 13

RESULT 103
US-07-906-930E-8/c
Sequence 8, Application US/07906930E
Patent No. 5534631
GENERAL INFORMATION:
APPLICANT: Gaynor, Richard B.
APPLICANT: Nitula, Ajay
APPLICANT: Li, Ching
TITLE OF INVENTION: DNA ENCODING THE INTERLEUKIN BINDING
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P. O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/906,930E
FILING DATE: 30-JUN-1992
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Sertich, Gary J.
REGISTRATION NUMBER: 34,430
REFERENCE/DOCKET NUMBER: UTSD:262/SER
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512-418-3000
TELEFAX: 512-474-7577
TELEX: NOT APPLICABLE
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-07-906-930E-8

Query Match 14.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCATTG 947
|||||


```

Db      14 CTCTCCTTCATG 1

RESULT 104
US-08-334-847-45/c
; Sequence 45, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 45:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-334-847-45

Query Match      14.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      944 TTGGTTTAATGTAT 957
Db      14 TTAGTTAAATGTAT 1

RESULT 106
US-08-317-432A-2/c
; Sequence 2, Application US/08317432A
; Patent No. 5710028
; GENERAL INFORMATION:
; APPLICANT: Nurit Eyal and Nir Navot
; TITLE OF INVENTION: A method of quick screening and
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Mark M. Friedman c/o Robert Sheinbein
; STREET: 2940 Birchtree lane
; CITY: Silver Spring
; STATE: Maryland
; COUNTRY: United States of America
; ZIP: 20906
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 1.44 megabyte, 3.5" microdisk
; COMPUTER: Twinhead+ Slimnote-890TX
; OPERATING SYSTEM: MS DOS version 6.2,
; OPERATING SYSTEM: Windows version 3.11
; SOFTWARE: Word for Windows version 2.0
; SOFTWARE: converted to ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/317,432A
; FILING DATE: 4-Oct-94
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

```

```
/ APPLICATION NUMBER: 08/919,872
/ FILING DATE: 27-Jul-92
/ APPLICATION NUMBER: 08/084,505
/ FILING DATE: 1-Jul-93
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Friedmam, Mark M.
/ REGISTRATION NUMBER: 33,883
/ REFERENCE/DOCKET NUMBER: 128/7
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 972-3-562553
/ TELEFAX: 972-3-562554
/ TELEX:
/ INFORMATION FOR SEQ ID NO: 2:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-317-432A-2

Query Match 14.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 911 TCTTTGGTCTTGC 924
Db 14 TCTTTGGTCTTCC 1

RESULT 107
US-08-894-922A-1/c
/ Sequence 1, Application US/08894922A
/ Patent No. 5863765
/ GENERAL INFORMATION:
/ APPLICANT: BERRY, Mark John
/ APPLICANT: DAVIS, Paul James
/ APPLICANT: VAN DER LOGT, Cornelius P.E.
/ APPLICANT: WHITELAM, Garry Clark
/ TITLE OF INVENTION: PRODUCTION IN YEASTS OF STABLE ANTIBODY
/ NUMBER OF SEQUENCES: 14
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Pillsbury Madison & Sutro, L.L.P.
/ STREET: 1100 New York Avenue, N.W.
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: United States
/ ZIP: 20005-3918
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: MS Word
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/894,922A
/ FILING DATE: 03-SEP-1997
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9504344.4
/ FILING DATE: 03-MAR-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/GB96/00468
/ FILING DATE: 01-MAR-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kokulis, Paul K.
/ REGISTRATION NUMBER: 16,773
/ REFERENCE/DOCKET NUMBER: 60113/241261
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202)-861-3503
/ TELEFAX: (202)-822-0944
/ INFORMATION FOR SEQ ID NO: 1:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid

FRAGME

/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ US-08-894-922A-1

Query Match 14.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 CCTTTATCCTCC 937
Db 15 CCTTTATCCTC 2

RESULT 108
US-08-585-684B-271
/ Sequence 271, Application US/08585684B
/ Patent No. 5877021
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Daniel T.
/ APPLICANT: Jarvis, Thale
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: METHOD AND REAGENT FOR THE
/ TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
/ TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
/ NUMBER OF SEQUENCES: 2751
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/585,684B
/ FILING DATE: January 16, 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/000,951
/ FILING DATE: July 7, 1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 271:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-585-684B-271

Query Match 14.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 42.9%; Pred. No. 1.1e+02;
Matches 6; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 943 ATTGGTTTAATGA 956
Db 1 AUUUGCUAUGUA 14

RESULT 109
US-08-959-853-7/c
```



```
;
; RELEVANT RESIDUES IN SEQ ID NO: 85 :FROM 1 TO 12
US-08-173-489C-85

Query Match 14.2%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred.No.1e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCATT 945
Db 12 CTCCTCTTCATT 1

RESULT 113
US-09-475-947A-286/c
; Sequence 286, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 286
; LENGTH: 12
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-286

Query Match 14.2%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred.No.1e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCCTCTCTCTTC 942
Db 12 TCCCTCTCTCTTC 1

RESULT 114
US-08-487-799-87
; Sequence 87, Application US/08487799C
; Patent No. 6010908
; GENERAL INFORMATION:
; APPLICANT: Gruenert, Dieter C.
; APPLICANT: Kunzelmann, Karl
; TITLE OF INVENTION: GENE THERAPY BY SMALL FRAGMENTS HOMOLOGOUS REPLACEMENT
; FILE REFERENCE: 480.18-1 (HV)
; CURRENT APPLICATION NUMBER: US/08/487,799C
; CURRENT FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 07/933,471
; EARLIER FILING DATE: 1992-08-21
; EARLIER APPLICATION NUMBER: 08/409,544
; EARLIER FILING DATE: 1995-03-24
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 87
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: PCR product
US-08-487-799-87

Query Match 14.2%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred.No.1.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 911 TCTTTGGTCTTT 922
Db 3 TCTTTGGTCTTT 14
```

```
;
; RELEVANT RESIDUES IN SEQ ID NO: 85 :FROM 1 TO 12
US-08-173-489C-85

Query Match 14.2%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred.No.1e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCATT 945
Db 12 CTCCTCTTCATT 1

RESULT 113
US-09-475-947A-286/c
; Sequence 286, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 286
; LENGTH: 12
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-286

Query Match 14.2%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred.No.1e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCCTCTCTCTTC 942
Db 12 TCCCTCTCTCTTC 1

RESULT 114
US-08-487-799-87
; Sequence 87, Application US/08487799C
; Patent No. 6010908
; GENERAL INFORMATION:
; APPLICANT: Gruenert, Dieter C.
; APPLICANT: Kunzelmann, Karl
; TITLE OF INVENTION: GENE THERAPY BY SMALL FRAGMENTS HOMOLOGOUS REPLACEMENT
; FILE REFERENCE: 480.18-1 (HV)
; CURRENT APPLICATION NUMBER: US/08/487,799C
; CURRENT FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 07/933,471
; EARLIER FILING DATE: 1992-08-21
; EARLIER APPLICATION NUMBER: 08/409,544
; EARLIER FILING DATE: 1995-03-24
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 87
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: PCR product
US-08-487-799-87

Query Match 14.2%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred.No.1.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 911 TCTTTGGTCTTT 922
Db 3 TCTTTGGTCTTT 14
```

```
Best Local Similarity 85.7%; Pred.No.1.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 940 TTCATTGGTTTAAAT 953
Db 2 TTCATTGGTTGTAAT 15

RESULT 112
US-08-173-489C-85/c
; Sequence 85, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; DESCRIPTION: retinoblastoma gene (Accession #
; DESCRIPTION: M33647, J02994) nucleotides 2236 to 2247
; HYPOTHETICAL: No
; ANTI-SENSE: No
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: chromosome 13
; MAP POSITION: 13q14.2
; PUBLICATION INFORMATION:
; AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,
; AUTHORS: Wang X F, Bogenmann, E, Li, F P, Weinberg,
; AUTHORS: R A.
; TITLE: Deletions of a DNA sequence
; TITLE: in retinoblastomas and mesenchymal tumors:
; TITLE: Organization of the sequence and its encoded
; TITLE: protein
; JOURNAL: Proceedings of the National Academy of
; JOURNAL: Sciences, USA
; VOLUME: 84
; PAGES: 9059-9063
; DATE: 1987
```

RESULT 115
US-08-105-483-245
; Sequence 245, Application US/08105483
; Patent No. 5494807
; GENERAL INFORMATION:
; APPLICANT: Paolotti, Enzo
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
; NUMBER OF SEQUENCES: 462
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis, Morris & Safford
; ADDRESSEE: c/o William S. Frommer
; STREET: 530 Fifth Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 12-AUG-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/847,951
; FILING DATE: 08-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2400
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 245:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-105-483-245

Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 1.3e-02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 945 TGGTTTAATGTA 956
Db 4 TGGTTTAATGCA 15

RESULT 116
US-08-319-492B-438
; Sequence 438, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/319,492B
FILING DATE: October 7, 1994
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/276
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 438:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-319-492B-438

Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 41.7%; Pred. No. 1.3e+02;
Matches 5; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 935 TCCTCTTCATG 946
Db 2 UCCUCUUGUG 13

RESULT 117
US-08-319-492B-439
; Sequence 439, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B

```
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 439:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-319-492B-439
Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 41.7%; Pred. No. 1.3e+02;
Matches 5; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 935 TCCTCTTCATTG 946
Db 1 UCCUCUUCGUUG 12

RESULT 118
US-08-502-185-19
; Sequence 19, Application US/08502185
; Patent No. 5639736
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; TITLE OF INVENTION: Human VEGF-Specific
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/502,185
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HY2-031CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-398-945-19
Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCATT 945
Db 3 CTCCTCTTCCTT 14

RESULT 120
US-08-501-779-19
; Sequence 19, Application US/08501779
; Patent No. 5661135
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; TITLE OF INVENTION: Human VEGF-Specific
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/502,185
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HY2-031CPDV1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
```

```
; ANTI-SENSE: YES
; US-08-502-185-19
Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCATT 945
Db 3 CTCCTCTTCCTT 14

RESULT 119
US-08-398-945-19
; Sequence 19, Application US/08398945
; Patent No. 5639872
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; TITLE OF INVENTION: Human VEGF-Specific
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/398,945
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HY2-031CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-398-945-19
Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCATT 945
Db 3 CTCCTCTTCCTT 14

RESULT 120
US-08-501-779-19
; Sequence 19, Application US/08501779
; Patent No. 5661135
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; TITLE OF INVENTION: Human VEGF-Specific
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/398,945
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HY2-031CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-398-945-19
Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCATT 945
Db 3 CTCCTCTTCCTT 14

RESULT 120
US-08-501-779-19
; Sequence 19, Application US/08501779
; Patent No. 5661135
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; TITLE OF INVENTION: Human VEGF-Specific
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/398,945
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HY2-031CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
```


Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCATT 945
 |||||
 Db 3 CTCCTCTTCCTT 14

RESULT 123

US-08-709-209-245
 ; Sequence 245, Application US/08709209
 ; Patent No. 5762938
 ; GENERAL INFORMATION:
 ; APPLICANT: Paoletti, Enzo
 ; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
 ; TITLE OF INVENTION: STRAIN
 ; NUMBER OF SEQUENCES: 462
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Curtis, Morris & Safford
 ; STREET: 530 Fifth Avenue
 ; CITY: New York
 ; STATE: NY
 ; COUNTRY: USA
 ; ZIP: 10036
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent in Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/709,209
 ; FILING DATE: 21-AUG-1996
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/105,483
 ; FILING DATE: 12-AUG-1993
 ; APPLICATION NUMBER: US 07/847,951
 ; FILING DATE: 06-MAR-1992
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Frommer, William S.
 ; REGISTRATION NUMBER: 25,506
 ; REFERENCE/DOCKET NUMBER: 454310-2400
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212) 840-3333
 ; TELEFAX: (212) 840-0712
 ; INFORMATION FOR SEQ ID NO: 245:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 15 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-709-209-245

Query Match 14.2%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 945 TGGTTTAATGTA 956
 |||||
 Db 4 TGGTTTAATGCA 15

RESULT 124

US-08-458-101-245
 ; Sequence 245, Application US/08458101
 ; Patent No. 5766599
 ; GENERAL INFORMATION:
 ; APPLICANT: Paoletti, Enzo
 ; APPLICANT: Perkus, Marion E.
 ; APPLICANT: Taylor, Jill
 ; APPLICANT: Tartaglia, James
 ; APPLICANT: No. 5766599ton, Elizabeth K.
 ; APPLICANT: Riviere, Michel

APPLICANT: de Taisne, Charles
 APPLICANT: Limbach, Keith J.
 APPLICANT: Johnson, Gerard P.
 APPLICANT: Fincus, Steven E.
 APPLICANT: Cox, William I.
 APPLICANT: Audonnet, Jean-Christophe Francis
 APPLICANT: Gettig, Russell Robert
 TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE
 TITLE OF INVENTION: STRAIN
 NUMBER OF SEQUENCES: 467
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Curtis, Morris & Safford
 ADDRESSEE: c/o William S. Frommer
 STREET: 530 Fifth Avenue
 CITY: New York
 STATE: NY
 COUNTRY: USA
 ZIP: 10036
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/458,101
 FILING DATE: 01-JUN-1995
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: Frommer, William S.
 REGISTRATION NUMBER: 25,506
 REFERENCE/DOCKET NUMBER: 454310-2740
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 840-3333
 TELEFAX: (212) 840-0712
 INFORMATION FOR SEQ ID NO: 245:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-458-101-245

Query Match 14.2%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 945 TGGTTTAATGTA 956
 |||||
 Db 4 TGGTTTAATGCA 15

RESULT 125

US-08-501-626-19
 ; Sequence 19, Application US/08501626
 ; Patent No. 5801156
 ; GENERAL INFORMATION:
 ; APPLICANT: Robinson, Gregory S.
 ; APPLICANT: Smith, Lois E.H.
 ; TITLE OF INVENTION: Inhibition of
 ; TITLE OF INVENTION: Neovascularization Using
 ; TITLE OF INVENTION: VEGF-Specific
 ; TITLE OF INVENTION: Oligonucleotides
 ; NUMBER OF SEQUENCES: 53
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lappin & Kusmer
 ; STREET: 200 State Street
 ; CITY: Boston
 ; STATE: Massachusetts
 ; COUNTRY: USA
 ; ZIP: 02109
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible


```

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/501,626
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Keirner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HYZ-031DV4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-501-626-19

Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 934 CTCCTCTTCATT 945
DB 3 CTCCTCTTCATT 14

RESULT 126
US-08-501-356-19
; Sequence 19, Application US/08501356
; Patent No. 5814620
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; APPLICANT: Smith, Lois E.H.
; TITLE OF INVENTION: Inhibition of
; TITLE OF INVENTION: Neovascularization Using
; TITLE OF INVENTION: VEGF-Specific
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusner
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/501,356
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Keirner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HYZ-031DV3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/501,626
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Keirner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HYZ-031DV4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-501-356-19

Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 934 CTCCTCTTCATT 945
DB 3 CTCCTCTTCATT 14

RESULT 127
US-08-584-040-8458
; Sequence 8458, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8458:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-8458

Query Match 14.2%; Score 10.4; DB 1; Length 15;
Best Local Similarity 41.7%; Pred. No. 1.3e+02;
Matches 5; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 922 TGCCTTTATCC 933
DB 3 TGCCTTTATCC 14
```

Mon Oct 18 14:40:17 2004

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: not relevant
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA Oligonucleotide"
; HYPOTHETICAL: NO
US-08-928-465-9

Query Match      14.2%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 948 TTTAATGATGCG 959
Db 13 TTTAATGATGCG 2

RESULT 131
US-08-666-341A-101/c
; Sequence 101, Application US/08666341A
; Patent No. 6365345
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Antisense nucleic Acids for the
; TITLE OF INVENTION: prevention and treatment of disorders in which expression
; TITLE OF INVENTION: Of c-erbB plays a role
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESS: 106
; ADDRESSEE: Jacobson, Price, Holman and Stern, PLLC
; STREET: 400 Seventh street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disc
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/666,341A
; FILING DATE: 15-AUG-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93120710.4
; INFORMATION FOR SEQ ID NO: 101:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
US-08-666-341A-101

Query Match      14.2%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 917 GTCTTTGCCCTTT 928
Db 13 GTCTTTGCCCTTT 2

RESULT 132
US-08-813-781-57/c
; Sequence 57, Application US/09813781
; Patent No. 6405989
; GENERAL INFORMATION:
; APPLICANT: WEIDANZ, JON A.
; APPLICANT: CARD, KIMBERLYN F.
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: FUSION PROTEINS COMPRISING BACTERIOPHAGE COAT PROTEIN
```

```
; TITLE OF INVENTION: AND A SINGLE-CHAIN T-CELL RECEPTOR
; FILE REFERENCE: 46745 (1758)
; CURRENT APPLICATION NUMBER: US/09/813,781
; CURRENT FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 57
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: oligonucleotide
US-09-813-781-57

Query Match      14.2%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 917 GTCTTTGCCCTTT 928
Db 13 GTCTTTGCCCTTT 2

RESULT 133
5312912-9/c
; Patent No. 5312912
; APPLICANT: HADWIGER, LEE A.; CHIANG, CHIN C.; HOROVITZ,
; DANIEL A.
; TITLE OF INVENTION: PROCEDURES AND REGULATORY DNA SEQUENCES
; FOR GENETICALLY ENGINEERING DISEASE RESISTANCE AND OTHER
; INDUCIBLE TRAITS IN PLANTS
; NUMBER OF SEQUENCES: 9
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/393,301
; FILING DATE: 13-JUN-1989
; SEQ ID NO: 9
; LENGTH: 16
5312912-9

Query Match      14.2%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 940 TTCATTGGTTTA 951
Db 13 TTCATTGGTTTA 2

RESULT 134
US-08-334-847-47/c
; Sequence 47, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```

UW

US-08-311-486C-36

Query Match 14.0%; Score 10.2; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 1.4e+02;
Matches 7; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 923 GCCTTTATCCCTCC 937
|||: : : : :
Db 1 GCCUCUCCUCC 15

RESULT 137

US-08-173-489C-45
; Sequence 45, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:

; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage

; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Handelman, Joseph H.

; REGISTRATION NUMBER: 26,179

; REFERENCE/DOCKET NUMBER: U9518-6

; TELEPHONE: (attorney) (212) 708-1880

; TELEFAX: (attorney) (212) 246-8959

; INFORMATION FOR SEQ ID NO: 45:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: Nucleic Acid

; STRANDEDNESS: double stranded

; TOPOLOGY: linear

; MOLECULE TYPE: Genomic DNA

; DESCRIPTION: gystrophin gene (Accession # M18533,

; DESCRIPTION: M17154, M18026) nucleotides 13280 to 13294

; HYPOTHETICAL: NO

; ANTI-SENSE: NO

; ORIGINAL SOURCE:

; ORGANISM: Homo sapiens

; POSITION IN GENOME:

; CHROMOSOME/SEGMENT: X-chromosome

; MAP POSITION: Xp21.3-p21.1

; PUBLICATION INFORMATION:

; AUTHORS: Koenig, M., Hoffman, E P, Bertelson, C J,

; AUTHORS: Monaco, A P, Feener, C, Kunkel, L M.

; TITLE: Complete cloning of the

; TITLE: Duchenne muscular dystrophy (DMD) cDNA and

; TITLE: preliminary genomic organization of the DMD

; TITLE: gene in normal and affected individuals

; JOURNAL: Cell

; VOLUME: 50

; PAGES: 509-517

DATE: 1987

AUTHORS: Hoffman, E P, Monaco, A P, Feener, C C,

AUTHORS: Kunkel, L M.

TITLE: Conservation of the Duchenne

TITLE: muscular dystrophy gene in mice and humans

JOURNAL: Science

VOLUME: 238

PAGES: 347-350

DATE: 1987

AUTHORS: Koenig, M, Monaco, A P, Kunkel, L M.

TITLE: The complete sequence of

TITLE: dystrophin predicts a rod-shaped cytoskeletal

TITLE: protein

JOURNAL: Cell

VOLUME: 53

PAGES: 219-228

DATE: 1988

RELEVANT RESIDUES IN SEQ ID NO: 45 :FROM 1 TO 15

US-08-173-489C-45

Query Match

Best Local Similarity 80.0%; Score 10.2; DB 1; Length 15;

Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 908 TTTTCTTTGGCTTT 922

|||||

Db 1 TTTTCTTTCCITT 15

RESULT 138

US-08-585-684B-272

; Sequence 272, Application US/08585684B

; Patent No. 5877021

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

; NUMBER OF SEQUENCES: 2751

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Suite 4700

; STATE: Los Angeles

; COUNTRY: California

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FastSeq Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/585,684B

; FILING DATE: January 16, 1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/000,951

; FILING DATE: July 7, 1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 218/078

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 272:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-272

Query Match 14.0%; Score 10.2; DB 1; Length 15;
Best Local Similarity 40.0%; Pred. No. 1.4e+02;
Matches 6; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 944 TTGGTTTAATGATC 958
Db 1 UUUGCUAUAAGUAC 15

RESULT 139

US-09-038-073-272
; Sequence 272, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: PastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073

FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 272:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-272

Query Match 14.0%; Score 10.2; DB 1; Length 15;
Best Local Similarity 40.0%; Pred. No. 1.4e+02;
Matches 6; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 944 TTGGTTTAATGATC 958
Db 1 UUUGCUAUAAGUAC 15

RESULT 140

US-09-479-770A-13
; Sequence 13, Application US/09479770A

; Patent No. 6391555
; GENERAL INFORMATION:
; APPLICANT: Johnson, Eric S.
; TITLE OF INVENTION: Assay for the Detection of Avian Leukosis/Sarcoma
; Viruses (ALSV) in DNA from Human and Animal Biological Spec;
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GARVEY, SMITH, NEHRBASS & DOODY, L.L.C.
; STREET: Three Lakeway Center, Suite 3290 3838 No. 6391555th Causeway
; CITY: Metairie
; STATE: LA
; COUNTRY: USA
; ZIP: 70002-1767

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: Dell Dimension XPS D300
OPERATING SYSTEM: Windows 98
SOFTWARE: Microsoft Word 2000
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/479,770A
FILING DATE: 07-OCT-2000
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/115,087
FILING DATE: 07-JAN-1999
ATTORNEY/AGENT INFORMATION:
NAME: Nehrbass, Seth M.
REGISTRATION NUMBER: 31,281
REFERENCE/DOCKET NUMBER: A98146US (88126.1)

TELECOMMUNICATION INFORMATION:
TELEPHONE: (504) 835-2000
TELEFAX: (504) 835-2070
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-479-770A-13

Query Match 14.0%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 930 ATCCCTCCTCTTCAT 944
Db 1 AGCCTCCGCTTCAT 15

RESULT 141

US-09-479-770A-15
; Sequence 15, Application US/09479770A
; Patent No. 6391555
; GENERAL INFORMATION:
; APPLICANT: Johnson, Eric S.
; TITLE OF INVENTION: Assay for the Detection of Avian Leukosis/Sarcoma
; Viruses (ALSV) in DNA from Human and Animal Biological Spec;

NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: GARVEY, SMITH, NEHRBASS & DOODY, L.L.C.
STREET: Three Lakeway Center, Suite 3290 3838 No. 6391555th Causeway
CITY: Metairie
STATE: LA
COUNTRY: USA
ZIP: 70002-1767

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: Dell Dimension XPS D300
OPERATING SYSTEM: Windows 98
SOFTWARE: Microsoft Word 2000

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/479,770A
; FILING DATE: 07-Oct-2000
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/115,087
; FILING DATE: 07-JAN-1999
; ATTORNEY/AGENT INFORMATION:
; NAME: Nehrbass, Seth M.
; REGISTRATION NUMBER: 31,281
; REFERENCE/DOCKET NUMBER: A98146US (88126.1)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (504) 835-2000
; TELEFAX: (504) 835-2070
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-479-770A-15

Query Match 14.0%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 930 ATCCCTCTCTTCAT 944
Db 1 AGCCATCCGCTTCAT 15

RESULT 142
US-09-031-952-8/c
; Sequence 8, Application US/09031952A
; Patent No. 6395476
; GENERAL INFORMATION:
; APPLICANT: Thomas, Howard C.
; APPLICANT: Summerfield, John A.
; TITLE OF INVENTION: METHODS OF PREDICTING THE OUTCOME OF INFECTION
; FILE REFERENCE: Thomas
; CURRENT APPLICATION NUMBER: US/09/031,952A
; CURRENT FILING DATE: 1998-01-27
; EARLIER APPLICATION NUMBER: 9515393.8
; EARLIER FILING DATE: 1995-07-27
; EARLIER APPLICATION NUMBER: 9521025.8
; EARLIER FILING DATE: 1995-10-13
; EARLIER APPLICATION NUMBER: 9514414.2
; EARLIER FILING DATE: 1996-07-09
; EARLIER APPLICATION NUMBER: PCT/GB96/01819
; EARLIER FILING DATE: 1996-07-25
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: unknown
US-09-031-952-8

Query Match 14.0%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 934 CTCCTCTTCATGGT 948
Db 15 CTTTCTCTCTTCAT 1

RESULT 143
US-09-475-947A-254/c

; Sequence 254, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 254
; LENGTH: 15
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-254

Query Match 14.0%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 928 TTATCCCTCTCTTC 942
Db 15 TTCTCTCTCTCTCTC 1

RESULT 144
US-08-192-946-31
; Sequence 31, Application US/08192946
; Patent No. 6258585
; GENERAL INFORMATION:
; APPLICANT: KENNETH G. DRAPER
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING INFLUENZA VIRUS
; TITLE OF INVENTION: REPLICATION
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/192,946
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,713
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 197/294
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-192-946-31

Query Match 13.7%; Score 10; DB 1; Length 10;
```

Best Local Similarity 40.0%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 4; Conservative 6; Mismatches 0;

Qy 902 TGGTCATTTT 911
Db 1 UGGUCAUUU 10

RESULT 145

US-08-363-233B-13/c
; Sequence 13, Application US/08363233B
; Patent No. 5714383
; GENERAL INFORMATION:
; APPLICANT: Thompson, James D.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATING CHRONIC
; MYELOGENOUS LEUKEMIA
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363.233B
; FILING DATE: December 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below: 2
; APPLICATION NUMBER: 07/882,822
; FILING DATE: May 14, 1992
; APPLICATION NUMBER: 08/193,922
; FILING DATE: February 7, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/165
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 958-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-233B-13

Query Match 13.7%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 903 GGTCAATTTT 912
Db 10 GGTCAATTTT 1

RESULT 146

US-08-173-489C-185
; Sequence 185, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.

; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173.489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/969,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 185:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: hepatitis B virus adw2 isolate,
; DESCRIPTION: nucleotides 1810 to 1823
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Hepatitis B virus
; INDIVIDUAL ISOLATE: adw2
; PUBLICATION INFORMATION:
; AUTHORS: Valenzuela, P., Quiroga, M., Zaldivar, J.,
; AUTHORS: Gray, P., Ruter, W.J.,
; TITLE: The nucleotide sequence of
; TITLE: the Hepatitis B viral genome and the
; TITLE: identification of the major viral genes
; JOURNAL: In "Animal Virus Genetics", Fields, B N,
; JOURNAL: Jaenisch, R., Fox C F eds
; VOLUME:
; PAGES: 57-70
; DATE: 1980
; RELEVANT RESIDUES IN SEQ ID NO: 185 :FROM 1 TO 14
; US-08-173-489C-185

Query Match 13.7%; Score 10; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTCAT 944
Db 2 TCCTCTTCAT 11

RESULT 147

US-08-173-489C-197
; Sequence 197, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.

APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT

OPERATING SYSTEM: MS-DOS version 6.2

SOFTWARE: Wordperfect Version 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/173,489C

FILING DATE: 22 DEC 1993

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/968,436

FILING DATE: 29 OCT 1992

ATTORNEY/AGENT INFORMATION:

NAME: Handelman, Joseph H.

REGISTRATION NUMBER: 26,179

REFERENCE/DOCKET NUMBER: U9518-6

TELECOMMUNICATION INFORMATION:

TELEPHONE: (attorney) (212) 708-1880

TELEFAX: (attorney) (212) 246-8959

INFORMATION FOR SEQ ID NO: 197:

SEQUENCE CHARACTERISTICS:

LENGTH: 14 base pairs

TYPE: nucleic acid

STRANDEDNESS: double stranded

TOPOLOGY: linear

MOLECULE TYPE: genomic DNA

DESCRIPTION: hepatitis B virus adr isolate,

DESCRIPTION: nucleotides 274 to 287

HYPOTHETICAL: no

ANTI-SENSE: no

ORIGINAL SOURCE:

ORGANISM: Hepatitis B virus

INDIVIDUAL ISOLATE: adr

PUBLICATION INFORMATION:

AUTHORS: Fujiyama, A, Miyahara, A, No. 5861244aki, C,

AUTHORS: Toneyama, T., Ohromo, N, Matsubara, K.

TITLE: Cloning and structural

TITLE: analysis of Hepatitis B virus DNAs subtype adr

JOURNAL: Nucleic Acids Research

VOLUME: 11

PAGES: 4601-4610

DATE: 1983

RELEVANT RESIDUES IN SEQ ID NO: 197 :FROM 1 TO 14

US-08-173-489C-197

Query Match 13.7%; Score 10; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTCAT 944

Db 2 TCCTCTTCAT 11

RESULT 148

US-08-585-684B-2257

Sequence 2257, Application US/08585684B

Patent No. 5877021

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: Jarvis, Thale

APPLICANT: McSwiggen, James

TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: California

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/585,684B

FILING DATE: January 16, 1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/000,951

FILING DATE: July 7, 1995

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 218/078

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 499-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 2257:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-585-684B-2257

Query Match 13.7%; Score 10; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 917 GTCTTTCCT 926

Db 4 GUCUUUGCU 13

RESULT 149

US-08-585-684B-2258

Sequence 2258, Application US/08585684B

Patent No. 5877021

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.

APPLICANT: Jarvis, Thale

APPLICANT: McSwiggen, James

TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

NUMBER OF SEQUENCES: 2751

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: California

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

```
;/ OPERATING SYSTEM: IBM P.C. DOS 5.0
;/ SOFTWARE: FastSEQ Version 1.5
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/585,684B
;/ FILING DATE: January 16, 1996
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 60/000,951
;/ FILING DATE: July 7, 1995
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Warburg, Richard
;/ REGISTRATION NUMBER: 32,327
;/ REFERENCE/DOCKET NUMBER: 218/078
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (213) 489-1600
;/ TELEFAX: (213) 955-0440
;/ TELEX: 67-3510
;/ INFORMATION FOR SEQ ID NO: 2258:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ US-08-585-684B-2258
```

```
Query Match 13.7%; Score 10; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 5; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 917 GTCCTTGCCCT 926
DB 4 GUCUUGCCU 13
```

```
RESULT 150
US-09-038-073-2257
; Sequence 2257, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
```

```
;/ INFORMATION FOR SEQ ID NO: 2257:
```

```
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ US-09-038-073-2257
```

```
Query Match 13.7%; Score 10; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 5; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 917 GTCCTTGCCCT 926
DB 4 GUCUUGCCU 13
```

```
RESULT 151
US-09-038-073-2258
; Sequence 2258, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2258:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-2258
```

```
Query Match 13.7%; Score 10; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 5; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 917 GTCCTTGCCCT 926
DB 4 GUCUUGCCU 13
```

```

RESULT 152
US-08-441-887A-268/c
; Sequence 268, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipschutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/082,937
; FILING DATE: 25-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joseph O.
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004160US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-326-2400
; TELEFAX: 650-326-2422
; INFORMATION FOR SEQ ID NO: 268:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (probe)
US-08-441-887A-268

Query Match 13.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 910 TCTTTGGTCTTT 922
Db 13 TTCTCTGTCTTT 1

RESULT 153
US-08-173-489C-56
; Sequence 56, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.

```

```

; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 bases
; TYPE: Nucleic Acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from HER-2
; DESCRIPTION: sequence region in Seq ID No. 586124455
; HYPOTHETICAL: Yes
; ANTI-SENSE: NO
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 56 :FROM 1 TO 13
US-08-173-489C-56

Query Match 13.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 924 CCTTTTATCCCTC 936
Db 1 CCTTTTCCCTTC 13

RESULT 154
US-08-544-381B-29
; Sequence 29, Application US/08544381B
; Patent No. 6027680
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipschutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP

```

STREET: Two Embarcadero Center, 8th Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/544,381B
FILING DATE: 10-OCT-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/12305
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-004130US
TELEPHONE: 415-576-0200
TELEFAX: 415-576-0300
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-544-381B-29

Query Match 13.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 915 TGGTCTTTGCCCT 927
Db 1 TGGTCTTTGCCCT 13

RESULT 155
US-08-778-794A-87
Sequence 87, Application US/08778794A
Patent No. 6309823
GENERAL INFORMATION:
APPLICANT: Cronin, Maureen T.
APPLICANT: Miyada, Charles Garrett
APPLICANT: Hubbell, Earl A.
APPLICANT: Chee, Mark
APPLICANT: Fodor, Stephen P.A.
APPLICANT: Huang, Xiaohua C.
APPLICANT: Lipshutz, Robert J.
APPLICANT: Lobban, Peter E.
APPLICANT: Morris, Macdonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes
NUMBER OF SEQUENCES: 156
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco

STATE: CA
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/778,794A
FILING DATE: 03-JAN-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
APPLICATION NUMBER: WO PCT/US94/12305
FILING DATE: 26-OCT-1994
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995
APPLICATION NUMBER: US 08/544,381
FILING DATE: 10-OCT-1995
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-015700US
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0200
TELEX:
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-778-794A-87

Query Match 13.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 915 TGGTCTTTGCCCT 927
Db 1 TGGTCTTTGCCCT 13

RESULT 156
US-08-242-664-15/c
Sequence 15, Application US/08242664
Patent No. 5571937
GENERAL INFORMATION:
APPLICANT: Watanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Weil, Roger
TITLE OF INVENTION: Complementary DNA and Toxins
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/242,664

;; FILING DATE: May 12, 1994
;; CLASSIFICATION: 514
;; ATTORNEY/AGENT INFORMATION:
;; NAME: White, John P.
;; REGISTRATION NUMBER: 28,678
;; REFERENCE/DOCKET NUMBER: 44683
;; TELEPHONE: 212-977-9550
;; TELEFAX: 212-664-0525
;; INFORMATION FOR SEQ ID NO: 15:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 14 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-242-664-15

Query Match 13.4%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTTTGCCTTTTAT 931
Db 13 CTTTGCCTTTT 1

RESULT 157
US-08-484-138-15/c
; Sequence 15, Application US/08484138
; Patent No. 5652350
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Weil, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESS: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44MB
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484.138
FILING DATE: June 7, 1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-Z/JPW/MJG
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-484-138-15

Query Match 13.4%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTTTGCCTTTTAT 931
Db 13 CTTTGCCTTTT 1

RESULT 158
US-08-535-249-29
; Sequence 29, Application US/08535249
; Patent No. 6455689
; GENERAL INFORMATION:
; APPLICANT: Schlingensiepen, Georg-Ferdinand
; APPLICANT: Brysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; immunosuppressive effect of transforming-growth-factor beta (a)
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; COUNTRY: U.S.A.
; ZIP: 20004

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/535,249
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93 107 089.0
FILING DATE: 30-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93 107 849.7
FILING DATE: 13-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELEPHONE: (202) 638-6666
TELEFAX: (202) 393-5350
TELEX: RCA 248993 IDEA UR
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-08-535-249-29

Query Match 13.4%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 928 TTATCCCTCTCT 940
Db 2 TTATCCCTCTGT 14

RESULT 159
US-09-874-601-110/c
; Sequence 110, Application US/09874601
; Patent No. 6632057
; GENERAL INFORMATION:
; APPLICANT: LEWIN, ALFRED S.
; APPLICANT: SHAW, LYNN C.

2/4/04 14:40:17

APPLICANT: GRANT, MARIA B.
TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
FILE REFERENCE: 4300.014100
CURRENT APPLICATION NUMBER: US/09/874,601
CURRENT FILING DATE: 2001-05-01
PRIOR APPLICATION NUMBER: 09/063,667
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/046,147
PRIOR FILING DATE: 1997-05-09
PRIOR APPLICATION NUMBER: 60/044,492
PRIOR FILING DATE: 1997-04-21
NUMBER OF SEQ ID NOS: 182
SOFTWARE: PatentIn version 3.0
SEQ ID NO 110
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION: ()
OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-110

Query Match 13.4%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 922 TGCCTTTTATCCC 934
|||||
DB 14 TGCCTTTTATCCC 2

RESULT 160
US-09-874-601-111/c
Sequence 111, Application US/09874601
Patent No. 6632057
GENERAL INFORMATION:
APPLICANT: LEWIN, ALFRED S.
APPLICANT: SHAW, LYNN C.
APPLICANT: GRANT, MARIA B.
TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
FILE REFERENCE: 4300.014100
CURRENT APPLICATION NUMBER: US/09/874,601
CURRENT FILING DATE: 2001-05-01
PRIOR APPLICATION NUMBER: 09/063,667
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/046,147
PRIOR FILING DATE: 1997-05-09
PRIOR APPLICATION NUMBER: 60/044,492
PRIOR FILING DATE: 1997-04-21
NUMBER OF SEQ ID NOS: 182
SOFTWARE: PatentIn version 3.0
SEQ ID NO 111
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION: ()
OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-111

Query Match 13.4%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 922 TGCCTTTTATCCC 934
|||||
DB 14 TGCCTTTTATCCC 2

RESULT 161
PCT-US95-06379-15/c
Sequence 15, Application PC/TUS9506379
GENERAL INFORMATION:
APPLICANT: Watanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Weil, Roger
TITLE OF INVENTION: Complementary DNA and Toxins
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.24
CURRENT APPLICATION DATA: PCT/US95/06379
APPLICATION NUMBER: PCT/US95/06379
FILING DATE: May 13, 1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-PCT
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0526
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US95-06379-15

Query Match 13.4%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTTTGCTTTTAT 931
|||||
DB 13 CTTTGCTTTTAT 1

RESULT 162
US-07-744-282C-123
Sequence 123, Application US/07744282C
Patent No. 5521300
GENERAL INFORMATION:
APPLICANT: Shah, Jyotsna S.
APPLICANT: Nicupski, Raymond M.
APPLICANT: Liu, Jing
TITLE OF INVENTION: Oligonucleotides Complementary to
TITLE OF INVENTION: Mycobacterial Nucleic Acids
NUMBER OF SEQUENCES: 127
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kevin M. Farrell, P.C.
STREET: P.O. Box 999
CITY: York Harbor
STATE: ME
COUNTRY: USA
ZIP: 03911
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/744,282C
; FILING DATE: August 13, 1991
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin M. Farrell
; REGISTRATION NUMBER: 35,505
; REFERENCE/DOCKET NUMBER: GTR90-05
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (207) 363-0558
; TELEFAX: (207) 363-0528
; INFORMATION FOR SEQ ID NO: 123:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-744-282C-123

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 920 TTGCGCTTTTATCCC 934
Db 1 TTAGCMTTTCACCCC 15

RESULT 163
US-07-744-282C-125
; Sequence 125, Application US/07744282C
; Patent No. 5521300
; GENERAL INFORMATION:
; APPLICANT: Shah, Jyotsna S.
; APPLICANT: Nietupski, Raymond M.
; APPLICANT: Liu, Jing
; TITLE OF INVENTION: Oligonucleotides Complementary to
; TITLE OF INVENTION: Mycobacterial Nucleic Acids
; NUMBER OF SEQUENCES: 127
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kevin M. Farrell, P.C.
; STREET: P.O. Box 999
; CITY: York Harbor
; STATE: ME
; COUNTRY: USA
; ZIP: 03911
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/744,282C
; FILING DATE: August 13, 1991
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin M. Farrell
; REGISTRATION NUMBER: 35,505
; REFERENCE/DOCKET NUMBER: GTR90-05
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (207) 363-0558
; TELEFAX: (207) 363-0528
; INFORMATION FOR SEQ ID NO: 125:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-744-282C-125

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Matches 11; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

```

```

Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 920 TTGCGCTTTTATCCC 934
Db 1 TTGCGMTTTCACCCC 15

RESULT 164
US-08-319-492B-64/c
; Sequence 64, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-319-492B-64

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 943 ATTGTTTATGT 955
Db 15 ATTGTTTACTCT 3

RESULT 165
US-08-319-492B-73
; Sequence 73, Application US/08319492B

```

```

; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-319-492B-73

```

```

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 1.7e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 944 TTGGTTTAATGTA 956
Db 1 UUGUGUNAUGAA 13

```

```

RESULT 166
US-08-319-492B-169
; Sequence 169, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:

```

```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 169:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-319-492B-169

```

```

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 30.8%; Pred. No. 1.7e+02;
Matches 4; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 943 ATTGGTTTAATGT 955
Db 2 AUUUAUUAUGU 14

```

```

RESULT 167
US-08-319-492B-170
; Sequence 170, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

```



```

: FILING DATE: December 7, 1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 209/276
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 436:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-319-492B-436

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 61.5%; Pred. No. 1.7e+02;
Matches 8; Conservative 3; Mismatches 2; Indels

Qy 931 TCCCTCCTCTTCA 943
   :|||:|||:
Db 3 UCCUCUCCCUCA 15

RESULT 169
US-08-319-492B-437
: Sequence 437, Application US/08319492B
: Patent No. 5616488
: GENERAL INFORMATION:
: APPLICANT: Sullivan, Sean M.
: APPLICANT: Draper, Kenneth G.
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
: TITLE OF INVENTION: OF IL-5
: NUMBER OF SEQUENCES: 751
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: STREET: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/319,492B
: FILING DATE: October 7, 1994
: PRIOR APPLICATION DATA: including application
: PRIOR APPLICATION DATA: described below:
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/008,895
: FILING DATE: January 19, 1993
: APPLICATION NUMBER: 07/985,849
: FILING DATE: December 7, 1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 209/276
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 437:
: SEQUENCE CHARACTERISTICS:

```

; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-319-492B-437

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 61.5%; Pred. No. 1.7e+02;
Matches 8; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 931 TCCTCTCTTCA 943
DB 3 UCCUCCCUCA 15

RESULT 170
US-08-363-240A-227
; Sequence 227, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 227:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-227

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 38.5%; Pred. No. 1.7e+02;
Matches 5; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 915 TGGTCTTGCCTT 927
DB 2 UGGACUUUGCUU 14

RESULT 171
US-08-363-240A-228
; Sequence 228, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 228:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-228

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 38.5%; Pred. No. 1.7e+02;
Matches 5; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 915 TGGTCTTGCCTT 927
DB 1 UGGACUUUGCUU 13

RESULT 172
US-08-294-424-48/c
; Sequence 48, Application US/08294424
; Patent No. 5800984
; GENERAL INFORMATION:
; APPLICANT: Vary, Calvin
; TITLE OF INVENTION: NUCLEIC ACID SEQUENCE DETECTION BY
; TITLE OF INVENTION: TRIPLE HELIX FORMATION
; NUMBER OF SEQUENCES: 49
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston

```
/ STATE: Massachusetts
/ COUNTRY: U.S.A.
/ ZIP: 02110-2804
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
/ OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
/ SOFTWARE: WordPerfect (Version 5.0)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/294,424
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/000,922
/ FILING DATE: 16 JAN 1993
/ APPLICATION NUMBER: US/07/629,601B
/ FILING DATE: 17-DEC-1990
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Freeman, John W.
/ REGISTRATION NUMBER: 29,066
/ REFERENCE/DOCKET NUMBER: 00088-037001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (617) 542-5070
/ TELEFAX: (617) 542-8906
/ TELEX: 200154
/ INFORMATION FOR SEQ ID NO: 48 :
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-294-424-48

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 CTTTTCCTCCCTC 936
Db 13 CTTTTCCTCCCTC 1

RESULT 173
US-08-311-486C-74
; Sequence 74, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849

STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
SOFTWARE: WordPerfect (Version 5.0)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/294,424
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/000,922
FILING DATE: 16 JAN 1993
APPLICATION NUMBER: US/07/629,601B
FILING DATE: 17-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Freeman, John W.
REGISTRATION NUMBER: 29,066
REFERENCE/DOCKET NUMBER: 00088-037001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 48 :
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-294-424-48

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 CTTTTCCTCCCTC 936
Db 13 CTTTTCCTCCCTC 1

RESULT 173
US-08-311-486C-74
; Sequence 74, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849

FILING DATE: September 23, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-74

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 53.8%; Pred. No. 1.7e+02;
Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 935 TCCTTCCTCATGG 947
Db 2 UCCUCUCAAAGG 14

RESULT 174
US-08-311-486C-75
; Sequence 75, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
```

```
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 499-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 75:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-75

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 53.8%; Pred. No. 1.7e+02;
Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 935 TCCTTCATGG 947
Db 1 UCCUCUACAGG 13

RESULT 175
US-08-480-736-4/c
; Sequence 4, Application US/08480736
; Patent No. 5830477
; GENERAL INFORMATION:
; APPLICANT: LATHE, Richard
; APPLICANT: KIENY, Marie-Paule
; APPLICANT: DRILLIEN, Robert
; APPLICANT: LECOQ, Jean-Pierre
; TITLE OF INVENTION: VACCINE AGAINST RABIES AND PROCESS FOR
; PREPARATION THEREOF
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/480,736
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/231,457
; FILING DATE: 21-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/038,052
; FILING DATE: 29-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/759,138
; FILING DATE: 11-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/378,801
; FILING DATE: 11-JUL-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 06/829,144
; FILING DATE: 24-DEC-1985
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 84/06499
; FILING DATE: 25-APR-1984
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: WO PCT/FR85/00096
; FILING DATE: 24-APR-1985
; ATTORNEY/AGENT INFORMATION:
; NAME: Rea, Teresa Stanek
; REGISTRATION NUMBER: 30,427
; REFERENCE/DOCKET NUMBER: 017753-061
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "oligonucleotide"
; US-08-480-736-4

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 941 TCATTGGTTTAAAT 953
Db 13 TCCTTGGTATAAT 1

RESULT 176
US-08-292-620A-121/c
; Sequence 121, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-288

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 959 GCTACCAACGGTG 971
Db 15 GCTAACCAAGGTG 3
|||||
|||||

RESULT 178
US-08-292-620A-289/c
; Sequence 289, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (1-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 289:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-289

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-288

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 959 GCTACCAACGGTG 971
Db 15 GCTAACCAAGGTG 3
|||||
|||||

RESULT 178
US-08-292-620A-289/c
; Sequence 289, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (1-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 289:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-289

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e-02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 959 GCTACCAACGGTG 971
||||| ||| |||
Db 14 GCTAACAAAGGTG 2

RESULT 179
US-08-441-887A-8/C
; Sequence 8, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/441,887A
FILING DATE: 16-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/082,937
FILING DATE: 25-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joseph O.
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-004160US
TELEPHONE: 650-326-2400
TELEFAX: 650-326-2422
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (probe)
US-08-441-887A-8

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 938 TCTTCATTGGTTT 950
||||| ||| |||
Db 14 TCATCATTGGTGT 2

RESULT 180

US-08-441-887A-16/C
; Sequence 16, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/441,887A
FILING DATE: 16-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/082,937
FILING DATE: 25-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joseph O.
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-004160US
TELEPHONE: 650-326-2400
TELEFAX: 650-326-2422
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (probe)
US-08-441-887A-16

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 911 TCTTTGGTCTTTGC 924
||||| ||| |||
Db 14 TCTTTGGTCTTTCC 1

RESULT 181
US-08-441-887A-17/C
; Sequence 17, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.

APPLICANT: Hubbell, Earl A.
APPLICANT: Lipshutz, Robert J.
APPLICANT: Lobban, Peter E.
APPLICANT: Morris, Macdonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
TITLE OF INVENTION: Biological Chips
NUMBER OF SEQUENCES: 360
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/441,887A
FILING DATE: 16-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/082,937
FILING DATE: 25-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joseph O.
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-00416005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-326-2400
TELEFAX: 650-326-2422
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (probe)
US-08-441-887A-17

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 911 TCTTTGGTCTTTGC 924
| | | | | | | | | | | | | | |
Db 15 TCTTTGNTGTTTCC 2

RESULT 182
US-08-173-489C-142
Sequence 142, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 142:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from Hepatitis B
DESCRIPTION: isolate adr sequence region in Seg ID No. 5861244141
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 142 :FROM 1 TO 15
US-08-173-489C-142

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 CCTTTTATCCCTC 936
| | | | | | | | | | | | | | |
Db 3 CCTTTCTCCCTC 15

RESULT 183
US-08-585-684B-1748/c
Sequence 1748, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1748:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1748

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 938 TCTTCTAGGTTT 950
|||||
DB 14 TCTTCTAGGTTT 2

RESULT 184
US-08-585-684B-1811
Sequence 1811, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1811:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-585-684B-1811

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 1.7e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCTCTTCATTG 946
|:|:|:|:|:|
DB 3 CUGCUCAUG 15

RESULT 185
US-08-544-381B-114/c
Sequence 114, Application US/08544381B
Patent No. 6027880
GENERAL INFORMATION:
APPLICANT: Cronin, Maureen T.
APPLICANT: Miyada, Charles Garrett
APPLICANT: Hubbell, Earl A.
APPLICANT: Chee, Mark
APPLICANT: Fodor, Stephen P.A.
APPLICANT: Huang, Xiaohua C.
APPLICANT: Lipshutz, Robert J.
APPLICANT: Lobban, Peter E.
APPLICANT: Morris, Macdonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
Detecting Cystic Fibrosis
NUMBER OF SEQUENCES: 250
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/544,381B
FILING DATE: 10-OCT-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/12305
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-004130US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-576-0200
TELEFAX: 415-576-0300
INFORMATION FOR SEQ ID NO: 114:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-544-381B-114

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 938 TCTTCATTCGTTT 950
DB 14 TCATCATTCGTTG 2

RESULT 186
US-09-071-845-121/c
; Sequence 121, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-121

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 901 CTGGTCATTTTCT 913
DB 13 CTGGGATTTTCT 1

RESULT 187
US-09-071-845-288/c
; Sequence 288, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 288:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-288

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 959 GCTACCAACGGTG 971
DB 15 GCTACCAAGGTG 3

RESULT 188
US-09-071-845-289/c
; Sequence 289, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 289:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-289

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 959 GCTACCAACGGTG 971
Db 14 GCTACCAAGGTG 2

RESULT 189
US-09-038-073-1748/c
Sequence 1748, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1748:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1748

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 938 TCTTCATTGGTTT 950
Db 14 TCTTCATTGGTTT 2

RESULT 190
US-09-038-073-1811
Sequence 1811, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073

```

; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1811:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-1811

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 1.7e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 934 CTCCTTCATG 946
Db 3 CUGCUCAUG 15

RESULT 191
US-09-081-646-3
; Sequence 3, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107-74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-3

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 922 TGCCTTTATCCC 934
Db 3 TGCCTGTAATCCC 15

RESULT 192
US-08-584-040-8493
; Sequence 8493, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Sincicomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TREATMENT OF DISEASES OR

; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1811:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-1811

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 1.7e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 934 CTCCTTCATG 946
Db 3 CUGCUCAUG 15

RESULT 191
US-09-081-646-3
; Sequence 3, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107-74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-3

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 922 TGCCTTTATCCC 934
Db 3 TGCCTGTAATCCC 15

RESULT 192
US-08-584-040-8493
; Sequence 8493, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Sincicomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TREATMENT OF DISEASES OR

; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; OF VASCULAR ENDOTHELIAL
; GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8493:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8493

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 1.7e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 916 GGTCTTTGCCTTT 928
Db 3 GGUCUAUGCAU 15

RESULT 193
US-09-346-551-4
; Sequence 4, Application US/09346551B
; Patent No. 6361945
; GENERAL INFORMATION:
; APPLICANT: BECKER, Michael M.
; APPLICANT: SCHROTH, Gary P.
; TITLE OF INVENTION: MOLECULAR TORCHES
; FILE REFERENCE: GP098-02.UT
; CURRENT APPLICATION NUMBER: US/09/346,551B
; CURRENT FILING DATE: 1999-07-01
; EARLIER APPLICATION NUMBER: US 60/091,616
; EARLIER FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; nucleotide base recognition sequence substantially
; complementary to SEQ ID No. 6361945. 1 and 3
```

US-09-346-551-4

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 908 TTTTCTTGCTCT 920
||||| |||||
Db 2 TTTTCTTGCTCT 14

RESULT 194

US-08-461-210-5/c
Sequence 5, Application US/08461210
Patent No. 6395475
GENERAL INFORMATION:
APPLICANT: Leggett, Carol G.
TITLE OF INVENTION: Semiautomated Method for Fingerprinting
TITLE OF INVENTION: Bacterial DNA
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
ADDRESSEE: Russell
STREET: 200 East Broward Boulevard
CITY: Fort Lauderdale
STATE: Florida
COUNTRY: USA
ZIP: 33301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/461,210
FILING DATE:
CLASSIFICATION: 436
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,596
FILING DATE: 18-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Manso, Peter J.
REGISTRATION NUMBER: 32,264
REFERENCE/DOCKET NUMBER: FL20979-20
TELEPHONE: 305/527/2498
TELEFAX: 305/764/4996
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 904 GTCAATTTCTTTG 916
||||| |||||
Db 13 GTCAATTTCTTTG 1

RESULT 195

US-10-001-344-4
Sequence 4, Application US/10001344
Patent No. 6534274
GENERAL INFORMATION:
APPLICANT: BECKER, Michael M.
APPLICANT: SCHROTH, Gary P.
TITLE OF INVENTION: MOLECULAR TORCHES

FILE REFERENCE: GP098-02.UT
CURRENT APPLICATION NUMBER: US/10/001,344
CURRENT FILING DATE: 2001-10-31
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/346,551
PRIOR FILING DATE: EARLIER FILING DATE: 1999-07-01
NUMBER OF SEQ ID NOS: 9
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 4
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
OTHER INFORMATION: nucleotide base recognition sequence substantially
OTHER INFORMATION: complementary to SEQ ID NO. 6534274. 1 and 3
US-10-001-344-4

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.8%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 908 TTTTCTTGCTCT 920
||||| |||||
Db 2 TTTTCTTGCTCT 14

RESULT 196

US-09-371-772B-4147
Sequence 4147, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc..
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEH000,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4147
LENGTH: 15
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-4147

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 1.7e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 916 GGCTTTTGCTTT 928
||||| |||||
Db 3 GGCTTTTGCTTT 15

RESULT 197

PCT-US92-06821A-129
Sequence 129, Application PC/TUS9206821A
GENERAL INFORMATION:
APPLICANT: Shan, Jyotsna S.
APPLICANT: Nietupski, Raymond M.
APPLICANT: Liu, Jing
TITLE OF INVENTION: Oligonucleotides Complementary to
TITLE OF INVENTION: Mycobacterial Nucleic Acids
NUMBER OF SEQUENCES: 133
CORRESPONDENCE ADDRESS:

ADDRESSEE: Amoco Corporation
STREET: 200 East Randolph Drive, P.O. Box 87703
CITY: Chicago
STATE: Illinois
COUNTRY: U.S.A.
ZIP: 60680
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06821A
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/744,282
FILING DATE: 13-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Galloway, Norval B.
REGISTRATION NUMBER: 33,595
REFERENCE/DOCKET NUMBER: CN 5851
TELEPHONE: 312-856-7180
TELEFAX: 312-856-4972
INFORMATION FOR SEQ ID NO: 129:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
PCT-US92-06821A-129

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 920 TTGGCTTTTATCCC 934
|||:|||||
Db 1 TTAGCMTTTCACCC 15

RESULT 198
PCT-US92-06821A-131
Sequence 131, Application PC/TUS9206821A
GENERAL INFORMATION:
APPLICANT: Shah, Jyotsna S.
APPLICANT: Nietupski, Raymond M.
APPLICANT: Liu, Jing
TITLE OF INVENTION: Oligonucleotides Complementary to
TITLE OF INVENTION: Mycobacterial Nucleic Acids
NUMBER OF SEQUENCES: 133
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amoco Corporation
STREET: 200 East Randolph Drive, P.O. Box 87703
CITY: Chicago
STATE: Illinois
COUNTRY: U.S.A.
ZIP: 60680
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/06821A
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/744,282
FILING DATE: 13-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Galloway, Norval B.
REGISTRATION NUMBER: 33,595
REFERENCE/DOCKET NUMBER: CN 5851
TELECOMMUNICATION INFORMATION:

TELEPHONE: 312-856-7180
TELEFAX: 312-856-4972
INFORMATION FOR SEQ ID NO: 131:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
PCT-US92-06821A-131

Query Match 13.4%; Score 9.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.7e+02;
Matches 11; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 920 TTGGCTTTTATCCC 934
|||:|||||
Db 1 TTAGCMTTTCACCC 15

RESULT 199
US-08-259-148A-39
Sequence 39, Application US/08259148A
Patent No. 5741490
GENERAL INFORMATION:
APPLICANT: Reyes, Gregory R.
APPLICANT: Bradley, Daniel W.
APPLICANT: Twu, Jr-Shin
APPLICANT: Purdy, Michael A.
APPLICANT: Tam, Albert W.
APPLICANT: Krawczynski, Krzysztof Z.
APPLICANT: Yarbough, Patrice D.
TITLE OF INVENTION: Hepatitis E Virus Vaccine and Method
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/259,148A
FILING DATE: 13-JUN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 822,335
FILING DATE: 17-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 505,888
FILING DATE: 05-APR-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 420,921
FILING DATE: 13-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 367,486
FILING DATE: 16-JUN-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 336,672
FILING DATE: 11-APR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 208,997
FILING DATE: 17-JUN-1988
ATTORNEY/AGENT INFORMATION:
NAME: Sholtz, Charles K.
REGISTRATION NUMBER: 38,615
REFERENCE/DOCKET NUMBER: 4600-0093.20
TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: DNA sequence, Fig. 7
US-08-259-148A-39

Query Match 12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 915 TGGTCTTTGCC 925
||| |||||
Db 1 TGGACTTTGCC 11

RESULT 200
US-08-173-489C-307
Sequence 307, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-9959
INFORMATION FOR SEQ ID NO: 307:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 16s rRNA gene from *Corynebacterium*
DESCRIPTION: renale (Accession # M29553) nucleotides 997 to
DESCRIPTION: 1007
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:

ORGANISM: *Corynebacterium renale*
PUBLICATION INFORMATION:
AUTHORS: Stahl, D A, Urbance, J W.
TITLE: The division between fast-
TITLE: and slow-growing species corresponds to natural
TITLE: relationships among the mycobacteria
JOURNAL: Journal of Bacteriology
VOLUME: 167
PAGES: 570-574
DATE: 1986
RELEVANT RESIDUES IN SEQ ID NO: 307 :FROM 1 TO 11
US-08-173-489C-307

Query Match 12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 918 TCTTTGCCCTTT 928
||| |||||
Db 1 TCTTTGCCCTTT 11

RESULT 201
US-07-876-941A-55
Sequence 55, Application US/07876941A
Patent No. 5885768
GENERAL INFORMATION:
APPLICANT: Reyes, Gregory R.
APPLICANT: Bradley, Daniel W.
APPLICANT: Tam, Albert W.
APPLICANT: Mitchell, Carl
TITLE OF INVENTION: Hepatitis E Virus Peptide Antigen and
TITLE OF INVENTION: Antibodies
NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pehlinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/876,941A
FILING DATE: 01-MAY-1992
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 822,335
FILING DATE: 17-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 505,888
FILING DATE: 05-APRIL-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 420,921
FILING DATE: 13-OCTOBER-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 367,486
FILING DATE: 16-JUNE-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 336,672
FILING DATE: 11-APRIL-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 208,997
FILING DATE: 17-JUNE-1988
ATTORNEY/AGENT INFORMATION:
NAME: Sholtz, Charles K.
REGISTRATION NUMBER: 38,615
REFERENCE/DOCKET NUMBER: 4600-0093.33
TELECOMMUNICATION INFORMATION:

```
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 55:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: DNA sequence, Fig. 7
; US-07-876-941A-55

Query Match          12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 915 TGGTCTTGGCC 925
Db 1 TGGACTTGGCC 11

RESULT 202
US-09-593-323-2/c
; Sequence 2, Application US/09593323
; Patent No. 6265213
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/593,323
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-593-323-2

Query Match          12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 11 CCTTTATACC 1

RESULT 203
US-09-593-323-3/c
; Sequence 3, Application US/09593323
; Patent No. 6265213
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/593,323
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-593-323-3

Query Match          12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 11 CCTTTATACC 1

RESULT 205
US-09-594-108-3/c
; Sequence 3, Application US/09594108
; Patent No. 6284468
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/594,108
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-594-108-3

Query Match          12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 11 CCTTTATACC 1

RESULT 204
US-09-594-108-2/c
; Sequence 2, Application US/09594108
; Patent No. 6284468
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/594,108
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-594-108-2

Query Match          12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 11 CCTTTATACC 1

RESULT 206
US-09-594-108-3/c
; Sequence 3, Application US/09594108
; Patent No. 6284468
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/594,108
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-594-108-3
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-594-108-3

Query Match 12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 11 CCTTTATACC 1

RESULT 206
US-09-344-300-2/c
; Sequence 2, Application US/09344300B
; Patent No. 6297013
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; APPLICANT: Severini, Alberto
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/344,300B
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-344-300-2

Query Match 12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 11 CCTTTATACC 1

RESULT 207
US-09-344-300-3/c
; Sequence 3, Application US/09344300B
; Patent No. 6297013
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; APPLICANT: Severini, Alberto
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/344,300B
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-344-300-3

Query Match 12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 11 CCTTTATACC 1

RESULT 208
US-09-249-155A-59
; Sequence 59, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; TITLE OF INVENTION: Healing
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249,155A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 59
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-59

Query Match 12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 1 CCTTTATACC 11

RESULT 209
US-09-249-155A-279
; Sequence 279, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; TITLE OF INVENTION: Healing
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249,155A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 279
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-279

Query Match 12.9%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 1.4e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 924 CCTTTATCCC 934
Db 1 CCTTTATACC 11

RESULT 210
US-08-173-489C-9/c
Sequence 9, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
DESCRIPTION: c-myc gene (Accession # X00364,
DESCRIPTION: K01908, V00501) nucleotides 6650 to 6661
HYPOTHETICAL: NO
ANTI-SENSE: No
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
PUBLICATION INFORMATION:
AUTHORS: Gazin, C, Dupont, S, de Dinechin, D,
AUTHORS: Hampe, A, Masson, J M, Martin, P, Stehelin,
AUTHORS: D, Galibert, F.
TITLE: Nucleotide sequence of the
TITLE: human c-myc locus: provocative open reading
TITLE: frame within the first exon.
JOURNAL: EMBO Journal
VOLUME: 3
PAGES: 383-387
DATE: 1984
AUTHORS: Colby, W W, Chen, E Y, Smith, D H,
AUTHORS: Levinson, A D.
TITLE: Identification and nucleotide
TITLE: sequence of a human locus homologous to the v-
TITLE: myc oncogene of avian myelocytomatosis virus
TITLE: MC29
JOURNAL: Nature
VOLUME: 301
PAGES: 722-725
DATE: 1983
AUTHORS: Saito, H, Hayday, A C, Wiman, K G,
AUTHORS: Hayward, W S, Tonegawa, S.
TITLE: Activation of the c-myc gene

by translocation: a model for translational
TITLE: control
JOURNAL: Proceedings of the National Academy of
JOURNAL: Sciences, USA
VOLUME: 80
PAGES: 7476-7480
DATE: 1983
AUTHORS: Gazin, C, Rigolet, M, Briand, J P, Van
AUTHORS: Regemortel, M H V, Galibert, F.
TITLE: Immunohistochemical detection of
TITLE: proteins related to the human c-myc exon 1
JOURNAL: EMBO Journal
VOLUME: 5
PAGES: 2241-2250
DATE: 1986
RELEVANT RESIDUES IN SEQ ID NO: 9 :FROM 1 TO 12
US-08-173-489C-9
Query Match 12.9% Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 1.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 931 TCCTCTCTCTT 941
Db 12 TTCCTCTCTT 2
RESULT 211
US-08-173-489C-216
Sequence 216, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 216:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from E. coli 23s
DESCRIPTION: region in Seq ID No. 5861244215
HYPOTHETICAL: yes

```
; ANTI-SENSE: no
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 216 :FROM 1 TO 12
; US-08-173-489C-216

Query Match 12.9%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 1.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 905 TCATTTCCTTT 915
Db 2 TCCTTTCCTTT 12

RESULT 212
US-09-874-601-88
; Sequence 88, Application US/09874601
; Patent No. 6632057
; GENERAL INFORMATION:
; APPLICANT: LEWIN, ALFRED S.
; APPLICANT: SHAW, LYNN C.
; APPLICANT: GRANT, MARIA B.
; TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
; FILE REFERENCE: 4300.014100
; CURRENT APPLICATION NUMBER: US/09/874,601
; CURRENT FILING DATE: 2001-05-01
; PRIOR FILING DATE: 1998-04-21
; PRIOR FILING DATE: 1997-05-09
; PRIOR FILING DATE: 1997-05-09
; PRIOR APPLICATION NUMBER: 60/046,147
; PRIOR APPLICATION NUMBER: 60/044,492
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 88
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1..1)
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
; US-09-874-601-88

Query Match 12.9%; Score 9.4; DB 1; Length 13;
Best Local Similarity 36.4%; Pred. No. 1.7e+02;
Matches 4; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 914 TTGGTCCTTGC 924
Db 2 UUGGUCUUGC 12

RESULT 213
US-08-173-489C-98
; Sequence 98, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage

; ANTI-SENSE: no
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 216 :FROM 1 TO 12
; US-08-173-489C-216

COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 98:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from superoxide
DESCRIPTION: dismutase sequence region in Seq ID No. 586124497
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 98 :FROM 1 TO 14
US-08-173-489C-98

Query Match 12.9%; Score 9.4; DB 1; Length 14;
Best Local Similarity 30.3%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 TCCTCTCTCTT 941
Db 2 TCCTCTCTTT 12

RESULT 214
US-08-439-819-9
; Sequence 9, Application US/08439819
; Patent No. 5925517
; GENERAL INFORMATION:
; APPLICANT: Tyagi, Sanjay
; APPLICANT: Kramer, Fred R.
; APPLICANT: Lizardi, Paul M.
; TITLE OF INVENTION: DETECTABLY LABELED DUAL CONFORMATION
; TITLE OF INVENTION: OLIGONUCLEOTIDE PROBES, ASSAYS AND KITS
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 45 Rockefeller Pl., Suite 2800
; CITY: New York
; STATE: N.Y.
; COUNTRY: USA
; ZIP: 10111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/439,819
; FILING DATE: 12-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/152,006
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: William J. Hone
```

REGISTRATION NUMBER: 26,739
REFERENCE/DOCKET NUMBER: 07763/027001
TELEPHONE: 212-765-5070
TELEFAX: 212-258-2291
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-439-819-9

Query Match 12.9%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 942 CATGGTTTAA 952
||| |||||
Db 1 CATAGGTTAA 11

RESULT 215
US-08-838-545-50/c
Sequence 50, Application US/08838545
Patent No. 6046307
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Piatyzek, Mieczyslaw A.
APPLICANT: Corey, David R.
APPLICANT: No. 6046307ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-001610US
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 50:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "peptide nucleic acid (PNA),
DESCRIPTION: where (deoxy(ribose-phosphate linkages are replaced by
DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
DESCRIPTION: glycine amino N through a methylenecarbonyl linker"

US-08-838-545-50

Query Match 12.9%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTTGGTCT 920
||| |||||
Db 12 TTTTGGTCT 2

RESULT 216
US-08-765-340-147
Sequence 147, Application US/08765340
Patent No. 6150092
GENERAL INFORMATION:
APPLICANT: UCHIDA, K.,
APPLICANT: UCHIDA, T.,
APPLICANT: TANAKA, Y.,
APPLICANT: MATSUDA, Y.,
APPLICANT: KONDO, S.,
TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
TITLE OF INVENTION: COMPOUND
NUMBER OF SEQUENCES: 185
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version
SOFTWARE: #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/765,340
FILING DATE: 23-DEC-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 145146/94
FILING DATE: 27-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 311130/94
FILING DATE: 21-NOV-1994
ATTORNEY/AGENT INFORMATION:
NAME: SERUNIAN, LESLIE
REGISTRATION NUMBER: 35,353
REFERENCE/DOCKET NUMBER: 1452-4005
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
INFORMATION FOR SEQ ID NO: 147:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"

US-08-765-340-147

Query Match 12.9%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 CCTGTGTCATT 909
||| |||||
Db 3 CCTGTGTCATT 13

RESULT 217

```

US-09-349-532-50/c
; Sequence 50, Application US/09349532
; Patent No. 6294650
; GENERAL INFORMATION:
; APPLICANT: Shay, Jerry W.
; APPLICANT: Wright, Woodring E.
; APPLICANT: Piatyszek, Mieczyslaw A.
; APPLICANT: Corey, David R.
; APPLICANT: No. 6294650ton, James C.
; TITLE OF INVENTION: Modulation of Mammalian Telomerase by
; TITLE OF INVENTION: Peptide Nucleic Acids
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/349,532
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/838,545
; FILING DATE: 09-APR-1997
; APPLICATION NUMBER: US 08/630,019
; FILING DATE: 09-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Storella, John R.
; REGISTRATION NUMBER: 32,944
; REFERENCE/DOCKET NUMBER: 015389-001610US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "peptide nucleic acid (PNA),
; DESCRIPTION: where (deoxy)(ribose-phosphate linkages are replaced by
; DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
; DESCRIPTION: glycine amino N through a methylenecarbonyl linker"
US-09-349-532-50

Query Match 12.9%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTTGGTCT 920
Db 12 TTTTGGTCT 2

RESULT 218
US-08-173-489C-78
; Sequence 78, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:

```

; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: prealbumin gene exons 1 and 2
; DESCRIPTION: (accession # M15515) nucleotides 250 to 263
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: chromosome 18
; MAP POSITION: 18q11.2-12.1
; PUBLICATION INFORMATION:
; AUTHORS: Maeda, S, Mita, S, Araki, S, Shimada,
; AUTHORS: K.
; TITLE: Structure and expression of
; TITLE: the mutant prealbumin gene associated with
; TITLE: familial amyloidotic polyneuropathy
; JOURNAL: Molecular Biological Medicine
; VOLUME: 3
; PAGES: 329-338
; DATE: 1986
; RELEVANT RESIDUES IN SEQ ID NO: 97 :FROM 1 TO 14
US-08-173-489C-97

Query Match 12.6%; Score 9.2; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 926 TTTTATCCTCTCTC 939
Db 14 TTTTTCCTCCCTC 1

RESULT 220
US-08-173-489C-318
; Sequence 318, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSES: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 318:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 bases
; TYPE: nucleic acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from H.
; DESCRIPTION: influenzae 16s region in Seq ID No. 5861244317
; HYPOTHETICAL: yes
; ANTI-SENSE: no
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 318 :FROM 1 TO 14
US-08-173-489C-318

Query Match 12.6%; Score 9.2; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 931 TCCTCTCTCTTCAT 944
Db 1 TCCTCTCTCTCTT 14

RESULT 221
US-09-458-481B-2
; Sequence 2, Application US/09458481B
; Patent No. 6310048
; GENERAL INFORMATION:
; APPLICANT: KUMAR, Vijaya B.
; TITLE OF INVENTION: ANTISENSE MODULATION OF AMYLOID BETA PROTEIN EXPRESSION
; FILE REFERENCE: 16153-9250
; CURRENT APPLICATION NUMBER: US/09/458,481B
; CURRENT FILING DATE: 1999-12-09
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; FEATURE: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
US-09-458-481B-2

Query Match 12.6%; Score 9.2; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 930 ATCCCTCTCTTCA 943
Db 1 AAGCCACATCTTCA 14

RESULT 222
US-08-535-249-118
; Sequence 118, Application US/08535249
; Patent No. 6455689
; GENERAL INFORMATION:
; APPLICANT: Schlengersiepen, Georg-Ferdinand

```

; APPLICANT: Brysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; TITLE OF INVENTION: immuno-suppressive effect of transforming-growth-factor beta
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,249
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 089.0
; FILING DATE: 30-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 849.7
; FILING DATE: 13-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 118:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
; US-08-535-249-118

Query Match 12.6%; Score 9.2; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 945 TGGTTTAATGATC 958
Db 1 TGGGTTGCGTATC 14

RESULT 223
US-09-531-000-14/c
; Sequence 14, Application US/09531000
; Patent No. 6461810
; GENERAL INFORMATION:
; APPLICANT: JOHNSON, Marion D.
; APPLICANT: FRESCO, Jacques R.
; TITLE OF INVENTION: TRIPLEX IN-SITU HYBRIDIZATION
; FILE REFERENCE: 2448-103
; CURRENT APPLICATION NUMBER: US/09/531,000
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: PCT/US98/23765
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: 60/064,997
; PRIOR FILING DATE: 1997-11-10
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 14

Query Match 12.6%; Score 9.2; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 945 TGGTTTAATGATC 958
Db 1 TGGGTTGCGTATC 14

RESULT 223
US-09-531-000-14/c
; Sequence 14, Application US/09531000
; Patent No. 6461810
; GENERAL INFORMATION:
; APPLICANT: JOHNSON, Marion D.
; APPLICANT: FRESCO, Jacques R.
; TITLE OF INVENTION: TRIPLEX IN-SITU HYBRIDIZATION
; FILE REFERENCE: 2448-103
; CURRENT APPLICATION NUMBER: US/09/531,000
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: PCT/US98/23765
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: 60/064,997
; PRIOR FILING DATE: 1997-11-10
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 14
```

```

; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target
; OTHER INFORMATION: sequences
; US-09-531-000-14

Query Match 12.6%; Score 9.2; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 921 TTGCTTTTATCC 934
Db 14 TTTCCTTTTCTACC 1

RESULT 224
US-09-531-000-48/c
; Sequence 48, Application US/09531000
; Patent No. 6461810
; GENERAL INFORMATION:
; APPLICANT: JOHNSON, Marion D.
; APPLICANT: FRESCO, Jacques R.
; TITLE OF INVENTION: TRIPLEX IN-SITU HYBRIDIZATION
; FILE REFERENCE: 2448-103
; CURRENT APPLICATION NUMBER: US/09/531,000
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: PCT/US98/23765
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: 60/064,997
; PRIOR FILING DATE: 1997-11-10
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 48
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target
; OTHER INFORMATION: sequences
; US-09-531-000-48

Query Match 12.6%; Score 9.2; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 920 TTGCTTTTATCC 933
Db 14 TTTCCTTTTCTACC 1

RESULT 225
US-08-388-353-182/c
; Sequence 182, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Leamont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM: floppy disk
; MEDIUM TYPE: Floppy disk
```

```

;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 182:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-182

Query Match 12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CCTCCTCTT 941
Db 10 CCTCCTCTT 2

RESULT 226
US-08-388-353-183/c
; Sequence 183, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 183:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid

```

```

;
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-183

Query Match 12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CCTCCTCTT 941
Db 9 CCTCCTCTT 1

RESULT 227
US-08-488-551B-182/c
; Sequence 182, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 182:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-488-551B-182

Query Match 12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CCTCCTCTT 941
Db 10 CCTCCTCTT 2

```

RESULT 228
US-08-488-551B-183/c
; Sequence 183, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/389,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGILIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 183:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-183

Query Match 12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CCTCTCTT 941
Db 9 CCTCTCTT 1

RESULT 229
US-09-445-388A-5/c
; Sequence 5, Application US/09445388A
; Patent No. 6534259
; GENERAL INFORMATION:
; APPLICANT: Wakefield, Andrew J.
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITION FOR REGRESSIVE BEHAVIORAL DISORDER
; FILE REFERENCE: ABLE-0012
; CURRENT APPLICATION NUMBER: US/09/445,388A
; CURRENT FILING DATE: 2000-03-23
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: PCT/GB98/01637

; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Majority consequences sequence.
US-09-445-388A-5

Query Match 12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 CTTTCATTGG 947
Db 10 CTTTCATTGG 2

RESULT 230
US-09-508-753B-60
; Sequence 60, Application US/09508753B
; Patent No. 6544736
; GENERAL INFORMATION:
; APPLICANT: Akira SHIMAMOTO
; APPLICANT: Yasuhiro FURUICHI
; APPLICANT: Yuko SHIBATA
; APPLICANT: Hiroko FUNAKI
; APPLICANT: Eiji OHARA
; APPLICANT: Masanori WATAHAKI
; TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
; FILE REFERENCE: 00162/HG
; CURRENT APPLICATION NUMBER: US/09/508,753B
; CURRENT FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: JP 9/270324
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 60
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-60

Query Match 12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 917 GTCCTTTGCC 925
Db 2 GTCCTTTGCC 10

RESULT 231
US-09-508-753B-80/c
; Sequence 80, Application US/09508753B
; Patent No. 6544736
; GENERAL INFORMATION:
; APPLICANT: Akira SHIMAMOTO
; APPLICANT: Yasuhiro FURUICHI
; APPLICANT: Yuko SHIBATA
; APPLICANT: Hiroko FUNAKI
; APPLICANT: Eiji OHARA
; APPLICANT: Masanori WATAHAKI
; TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
; FILE REFERENCE: 00162/HG
; CURRENT APPLICATION NUMBER: US/09/508,753B
; CURRENT FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: JP 9/270324
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 80


```

; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-80

Query Match      12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 911 TCCTTGGTC 919
      |||||
Db 9 TCCTTGGTC 1

RESULT 232
US-09-508-753B-143
; Sequence 143, Application US/09508753B
; Patent No. 6544736
; GENERAL INFORMATION:
; APPLICANT: Akira SHIMAMOTO
; APPLICANT: Yasuhiro FURUICHI
; APPLICANT: Yuko SHIBATA
; APPLICANT: Hiroko FUNAKI
; APPLICANT: Eiji OHARA
; APPLICANT: Masanori WATAHUKI
; TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
; FILE REFERENCE: 00162/HG
; CURRENT APPLICATION NUMBER: US/09/508,753B
; CURRENT FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: JP 9/270324
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 143
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-143

Query Match      12.3%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 911 TCCTTGGTC 919
      |||||
Db 2 TCCTTGGTC 10

RESULT 233
US-07-854-596B-6
; Sequence 6, Application US/07854596B
; Patent No. 5434073
; GENERAL INFORMATION:
; APPLICANT: Dawson, Keith M
; APPLICANT: Hunter, Michael G
; APPLICANT: Czaplowski, Lloyd G
; TITLE OF INVENTION: Proteins and nucleic acids
; NUMBER OF SEQUENCES: 73
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dr. John J. McDonnell
; STREET: Ten South Wacker Drive, Suite 3000
; CITY: Chicago
; STATE: IL
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/854,596B
; FILING DATE: 03-JUN-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McDonnell, John J
; REGISTRATION NUMBER: 26,949
; REFERENCE/DOCKET NUMBER: 92,337
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-715-1000
; TELEFAX: 312-715-1234
; TELEX: 910-221-5317
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..11
; OTHER INFORMATION: /note="bottom strand of adapter to
; OTHER INFORMATION: fuse c-terminal end of the a-factor pro-peptide to
; OTHER INFORMATION: synthetic hirudin gene"
US-07-854-596B-6

Query Match      12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 925 CTTTATCC 933
      |||||
Db 2 CTTTATCC 10

RESULT 234
US-08-373-124A-46/c
; Sequence 46, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992

```

APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 46:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-46

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 906 CATTTCCTT 914
|||||
Db 9 CATTTCCTT 1

RESULT 235
US-08-435-628-46/c
Sequence 46, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
FILING DATE: 05-MAY-1995
APPLICATION NUMBER: US/08/435,628
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/997,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 46:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-46

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 906 CATTTCCTT 914
|||||
Db 9 CATTTCCTT 1

RESULT 236
US-08-450-905B-33
Sequence 33, Application US/08450905B
Patent No. 5856301
GENERAL INFORMATION:
APPLICANT: Stem Cell Inhibiting Proteins
TITLE OF INVENTION: Stem Cell Inhibiting Proteins
NUMBER OF SEQUENCES: 178
CORRESPONDENCE ADDRESS:
ADDRESSEE: HALE and DORR
STREET: 60 State Street
CITY: Boston
STATE: MA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/450,905B
FILING DATE: 26-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,759
FILING DATE: 08-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9127319.3
FILING DATE: 23-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9221587.0
FILING DATE: 14-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: BAKER, HOLLIE L.
REGISTRATION NUMBER: 31,321
REFERENCE/DOCKET NUMBER: 102,378,120DV-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-526-6110
TELEFAX: 617-526-5000
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: misc.feature
LOCATION: 1..11
OTHER INFORMATION: /product= "BOTTOM STRAND OF
OTHER INFORMATION: OLIGONUCLEOTIDE ADAPTOR"
US-08-450-905B-33

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 925 CTTTATCC 933
|||||
Db 2 CTTTATCC 10

RESULT 237
US-08-173-489C-134
Sequence 134, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IEM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173/489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 134:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from Hepatitis B
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 134 :FROM 1 TO 11
US-08-173-489C-134

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 932 CCCTCCTCT 940
|||||
Db 3 CCCTCCTCT 11

RESULT 238
US-08-173-489C-160
Sequence 160, Application US/08173489C
Patent No. 5861244

GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IEM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173/489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 160:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from Hepatitis B
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 160 :FROM 1 TO 11
US-08-173-489C-160

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 932 CCCTCCTCT 940
|||||
Db 3 CCCTCCTCT 11

RESULT 239
US-08-173-489C-196
Sequence 196, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173.489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 196:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from Hepatitis B
DESCRIPTION: isolate adw2 sequence region in Seq ID No. 5861244195
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 196 :FROM 1 TO 11
US-08-173-489C-196

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 932 CCTCTCTCT 940
Db 3 CCTCTCTCT 11

RESULT 240
US-07-982-759F-33
Sequence 33, Application US/07982759F
Patent No. 6057123
GENERAL INFORMATION:
APPLICANT: CRAIG, Stewart
APPLICANT: GEORGE, Michael
APPLICANT: EDWARDS, Richard Mark
APPLICANT: CZAPLEWSKI, Lloyd George
APPLICANT: GILBERT, Richard
TITLE OF INVENTION: Stem Cell Inhibiting Proteins
NUMBER OF SEQUENCES: 178
CORRESPONDENCE ADDRESS:
ADDRESSEE: HALE and DORR LLP
STREET: 60 State Street
CITY: Boston
STATE: MA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/982,759F
FILING DATE: 08-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9127319.3
FILING DATE: 23-DEC-1991
PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9221587.0
FILING DATE: 14-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: BAKER, HOLLIE L.
REGISTRATION NUMBER: 31,321
REFERENCE/DOCKET NUMBER: 102378.120
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-526-6000
TELEFAX: 617-526-5000
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..11
OTHER INFORMATION: /product= "BOTTOM STRAND OF
OTHER INFORMATION: OLIGONUCLEOTIDE ADAPTOR"
US-07-982-759F-33

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 925 CTTTATCC 933
Db 2 CTTTATCC 10

RESULT 241
US-09-249-155A-222
Sequence 222, Application US/09249155A
Patent No. 6538173
GENERAL INFORMATION:
APPLICANT: Heber-Katz, Ellen
TITLE OF INVENTION: Compositions and Methods for Wound
Healing
FILE REFERENCE: 00486.78503
CURRENT APPLICATION NUMBER: US/09/249,155A
CURRENT FILING DATE: 1999-02-12
PRIOR APPLICATION NUMBER: US 60/074,737
PRIOR FILING DATE: 1998-02-13
PRIOR APPLICATION NUMBER: US 60/097,937
PRIOR FILING DATE: 1998-08-26
PRIOR APPLICATION NUMBER: US 60/102,051
PRIOR FILING DATE: 1998-09-28
NUMBER OF SEQ ID NOS: 346
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 222
LENGTH: 11
TYPE: DNA
ORGANISM: Mus musculus
US-09-249-155A-222

Query Match 12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 910 TTCTTTGGT 918
Db 1 TTCTTTGGT 9

RESULT 242
US-09-529-812A-6/c
Sequence 6, Application US/09529812A
Patent No. 6882930
GENERAL INFORMATION:
APPLICANT: LU, CHANGDE
TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN

```
/ TITLE OF INVENTION: ANTI-HBV
/ FILE REFERENCE: 017227/0160
/ CURRENT APPLICATION NUMBER: US/09/529,812A
/ CURRENT FILING DATE: 2000-07-24
/ PRIOR APPLICATION NUMBER: PCT/CN98/00248
/ PRIOR FILING DATE: 1998-10-19
/ PRIOR APPLICATION NUMBER: CN 97106667.1
/ PRIOR FILING DATE: 1997-10-21
/ NUMBER OF SEQ ID NOS: 18
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 6
/ LENGTH: 11
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Triplex
/ OTHER INFORMATION: forming oligonucleotide
/ OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
US-09-529-812A-5

Query Match      12.3%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      932 CCTCTCTCT 940
Db      9 CCTCTCTCT 1

RESULT 243
US-08-874-825-88
/ Sequence 88, Application US/08874825
/ Patent No. 6057101
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ APPLICANT: Yang, Meijia
/ APPLICANT: Knight, James
/ APPLICANT: Kalbfleisch, Theodore
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF
/ TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS
/ NUMBER OF SEQUENCES: 122
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Pennie & Edmonds
/ STREET: 1155 Avenue of the Americas
/ CITY: New York
/ STATE: NY
/ COUNTRY: USA
/ ZIP: 10036/2711
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FastSeq Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/874,825
/ FILING DATE: 13-JUN-1997
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/663,824
/ FILING DATE: 14-JUN-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Mistrock, S. Leslie
/ REGISTRATION NUMBER: 18,872
/ REFERENCE/DOCKET NUMBER: 7934-045
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212-790-9090
/ TELEFAX: 212-869-8864
/ TELEX: 66141 PENNIE
/ INFORMATION FOR SEQ ID NO: 88:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
```

```
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-874-825-88

Query Match      12.3%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      936 CCTCTTCAT 944
Db      3 CCTCTTCAT 11

RESULT 244
US-08-824-88
/ Sequence 88, Application US/08663824
/ Patent No. 6083693
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
/ TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS
/ FILE REFERENCE: 7934-006
/ CURRENT APPLICATION NUMBER: US/08/663,824
/ CURRENT FILING DATE: 1996-06-14
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 88
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: linker
US-08-663-824-88

Query Match      12.3%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      936 CCTCTTCAT 944
Db      3 CCTCTTCAT 11

RESULT 245
US-09-231-303-88
/ Sequence 88, Application US/09231303
/ Patent No. 6395478
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
/ TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS AND
/ TITLE OF INVENTION: IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
/ FILE REFERENCE: 7934-087
/ CURRENT APPLICATION NUMBER: US/09/231,303
/ CURRENT FILING DATE: 1999-01-12
/ EARLIER APPLICATION NUMBER: 08/663,824
/ EARLIER FILING DATE: 1996-06-14
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 88
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-231-303-88

Query Match      12.3%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
```



```
/ NAME: Stephen C. Macevitz
/ REGISTRATION NUMBER: 30,285
/ REFERENCE/DOCKET NUMBER: 801-06
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (510) 670-9365
/ TELEFAX: (510) 670-9302
/ INFORMATION FOR SEQ ID NO: 24:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 13 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-667-689A-24

Query Match 12.3%; Score 9; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTCA 943
Db 5 TCCTCTTCA 13

RESULT 249
US-08-712-011-24
; Sequence 24, Application US/08712011
; Patent No. 5831065
; GENERAL INFORMATION:
; APPLICANT: Sydney Brenner
; TITLE OF INVENTION: Kits for DNA Sequencing by Stepwise Ligation and Cleavage
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevitz, Spectragen, Inc.
; STREET: 3832 Bay Center Place
; CITY: Hayward
; STATE: California
; COUNTRY: USA
; ZIP: 94545
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/712,011
; FILING DATE: 11-SEP-96
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,116
; FILING DATE: 24-MAR-95
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222,300
; FILING DATE: 04-APR-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/280,441
; FILING DATE: 25-JUL-94
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevitz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: 801-06
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 670-9365
; TELEFAX: (510) 670-9302
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-712-011-24

Query Match 12.3%; Score 9; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTCA 943
Db 5 TCCTCTTCA 13

RESULT 250
US-08-478-239A-24
; Sequence 24, Application US/08478239A
; Patent No. 5856093
; GENERAL INFORMATION:
; APPLICANT: Sydney Brenner
; TITLE OF INVENTION: Method of Determining Zygosity
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevitz, Spectragen, Inc.
; STREET: 3832 Bay Center Place
; CITY: Hayward
; STATE: California
; COUNTRY: USA
; ZIP: 94545
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/478,239A
; FILING DATE: 07-JUN-95
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,116
; FILING DATE: 24-MAR-95
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222,300
; FILING DATE: 04-APR-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/280,441
; FILING DATE: 25-JUL-94
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevitz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: slc3c1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 670-9365
; TELEFAX: (510) 670-9302
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-478-239A-24

Query Match 12.3%; Score 9; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTCA 943
Db 5 TCCTCTTCA 13

RESULT 251
US-09-516-667-87/c
; Sequence 87, Application US/09516667
; Patent No. 6610533
; GENERAL INFORMATION:
; APPLICANT: Inouye, Masayori
; APPLICANT: Wang, Nan
; APPLICANT: Yamataka, Kunitoshi
; TITLE OF INVENTION: COLD-SHOCK REGULATORY ELEMENTS, CONSTRUCTS THEREOF, AND
```

; TITLE OF INVENTION: METHODS OF USE
; FILE REFERENCE: 1053-00
; CURRENT APPLICATION NUMBER: US/09/516,667
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 87
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-516-667-87

Query Match 12.3%; Score 9; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTGGTCTT 921
DB 13 TTGGTCTT 5

RESULT 252
US-07-958-133-2/c
; Sequence 2, Application US/07958133
; Patent No. 5403709
; GENERAL INFORMATION:
; APPLICANT: Agrawal, Sudhir
; APPLICANT: Tang, Jin-Yan
; TITLE OF INVENTION: Method of Sequencing Synthetic
; TITLE OF INVENTION: Oligonucleotides Containing No. 5403709-Phosphodiester
; TITLE OF INVENTION: Internucleotide Linkages
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Allegretti & Witcoff, Ltd.
; STREET: 75 State Street, Suite 2300
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/958,133
FILING DATE: 19921006
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Keown, Wayne A
REGISTRATION NUMBER: 33,923
REFERENCE/DOCKET NUMBER: 92,620
TELEPHONE: 617/345-9100
TELEFAX: 617/345-9111
TELEX: No. 5403709e
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 933 CCTCCTCTTCAT 944
DB 12 CCTTCTCTCCAT 1

RESULT 253
US-08-412-913-2/c
; Sequence 2, Application US/08412913
; Patent No. 5652103
; GENERAL INFORMATION:
; APPLICANT: Agrawal, Sudhir
; APPLICANT: Tang, Jin-Yan
; TITLE OF INVENTION: Method of Sequencing Synthetic
; TITLE OF INVENTION: Oligonucleotides Containing No. 5652103-Phosphodiester
; TITLE OF INVENTION: Internucleotide Linkages
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Allegretti, Ltd.
; STREET: 10 South Wacker Drive, Suite 3000
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1 for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/412,913
FILING DATE: March 29, 1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Greenfield, Michael S.
REGISTRATION NUMBER: 37,142
REFERENCE/DOCKET NUMBER: 92,620-R
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 715-1000
TELEFAX: (312) 715-1234
TELEX: No. 5652103e
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 933 CCTCCTCTTCAT 944
DB 12 CCTTCTCTCCAT 1

RESULT 254
US-08-441-887A-30/c
; Sequence 30, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipschutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.


```
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/082,937
; FILING DATE: 25-JUN-1993
; NAME: Liebeschuetz, Joseph O.
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004160US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-326-2400
; TELEFAX: 650-326-2422
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (probe)
; US-08-441-887A-30

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 915 TGGTCTTTGCCT 926
Db 12 TGGTCTAGCCT 1

RESULT 255
US-08-441-887A-197/c
; Sequence 197, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipschutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
```

```
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/082,937
; FILING DATE: 25-JUN-1993
; NAME: Liebeschuetz, Joseph O.
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004160US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-326-2400
; TELEFAX: 650-326-2422
; INFORMATION FOR SEQ ID NO: 197:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (probe)
; US-08-441-887A-197

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 930 ATCCCTCCTCTT 941
Db 12 ATCCCTCTCTGT 1

RESULT 256
US-08-173-489C-165/c
; Sequence 165, Application US/08173489C
; Patent No. 5862244
; GENERAL INFORMATION:
; APPLICANT: Wang, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
```

ATTORNEY/AGENT INFORMATION:
 NAME: Handelman, Joseph H.
 REGISTRATION NUMBER: 26,179
 REFERENCE/DOCKET NUMBER: U9518-6
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (attorney) (212) 708-1880
 TELEFAX: (attorney) (212) 246-8959
 INFORMATION FOR SEQ ID NO: 165:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double stranded
 TOPOLOGY: linear
 MOLECULE TYPE: genomic DNA
 DESCRIPTION: hepatitis B virus ayw isolate,
 DESCRIPTION: nucleotides 2750 to 2761
 HYPOTHETICAL: no
 ANTI-SENSE: no
 ORIGINAL SOURCE:
 ORGANISM: Hepatitis B virus
 INDIVIDUAL ISOLATE: ayw
 PUBLICATION INFORMATION:
 AUTHORS: Galibert, F, Mandart, E, Pitoussi, F,
 AUTHORS: Tiollais, P, Charnay, P.
 TITLE: Nucleotide sequence of the
 TITLE: Hepatitis B virus genome (subtype ayw) cloned
 TITLE: in E coli
 JOURNAL: Nature
 VOLUME: 281
 PAGES: 646-650
 DATE: 1979
 RELEVANT RESIDUES IN SEQ ID NO: 165 :FROM 1 TO 12
 US-08-173-489C-165

Query Match 12.1%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 933 CCTCCTCTTCAT 944
 |||||
 Db 12 CCTCATCTTCTT 1

RESULT 257
 US-08-173-489C-187
 Sequence 187, Application US/08173489C
 Patent No. 5861244
 GENERAL INFORMATION:
 APPLICANT: WANG, C. -G.
 APPLICANT: HEPBURN, A. G.
 TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
 TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
 NUMBER OF SEQUENCES: 365
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
 STREET: 510 EAST 73RD STREET,
 CITY: NEW YORK
 STATE: NEW YORK
 COUNTRY: USA
 ZIP: 10021.
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44Mb storage
 COMPUTER: IBM PC/XT/AT
 OPERATING SYSTEM: MS-DOS version 6.2
 SOFTWARE: Wordperfect Version 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/173,489C
 FILING DATE: 22 DEC 1993
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/968,436
 FILING DATE: 29 OCT 1992
 ATTORNEY/AGENT INFORMATION:

NAME: Handelman, Joseph H.
 REGISTRATION NUMBER: 26,179
 REFERENCE/DOCKET NUMBER: U9518-6
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (attorney) (212) 708-1880
 TELEFAX: (attorney) (212) 246-8959
 INFORMATION FOR SEQ ID NO: 187:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double stranded
 TOPOLOGY: linear
 MOLECULE TYPE: genomic DNA
 DESCRIPTION: hepatitis B virus adw2 isolate,
 DESCRIPTION: nucleotides 1833 to 1844
 HYPOTHETICAL: no
 ANTI-SENSE: no
 ORIGINAL SOURCE:
 ORGANISM: Hepatitis B virus
 INDIVIDUAL ISOLATE: adw2
 PUBLICATION INFORMATION:
 AUTHORS: Valenzuela, P, Quiroga, M, Zaldivar, J,
 AUTHORS: Gray, P, Ruter, W J.
 TITLE: The nucleotide sequence of
 TITLE: the Hepatitis B viral genome and the
 TITLE: identification of the major viral genes
 JOURNAL: In "Animal Virus Genetics", Fields, B N,
 JOURNAL: Jaenisch, R, Fox C F eds
 VOLUME:
 PAGES: 57-70
 DATE: 1980
 RELEVANT RESIDUES IN SEQ ID NO: 187 :FROM 1 TO 12
 US-08-173-489C-187

Query Match 12.1%; Score 8.8; DB 1; Length 12;
 Best Local Similarity 83.3%; Pred. No. 2e+02;
 Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 933 CCTCCTCTTCAT 944
 |||||
 Db 1 CCTCATCTTCTT 12

RESULT 258
 US-08-173-489C-227/C
 Sequence 227, Application US/08173489C
 Patent No. 5861244
 GENERAL INFORMATION:
 APPLICANT: WANG, C. -G.
 APPLICANT: HEPBURN, A. G.
 TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
 TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
 NUMBER OF SEQUENCES: 365
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
 STREET: 510 EAST 73RD STREET,
 CITY: NEW YORK
 STATE: NEW YORK
 COUNTRY: USA
 ZIP: 10021.
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44Mb storage
 COMPUTER: IBM PC/XT/AT
 OPERATING SYSTEM: MS-DOS version 6.2
 SOFTWARE: Wordperfect Version 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/173,489C
 FILING DATE: 22 DEC 1993
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/968,436
 FILING DATE: 29 OCT 1992
 ATTORNEY/AGENT INFORMATION:

NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 227:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 23s rRNA gene from Halococcus morrhuae
DESCRIPTION: (Accession # X05481) nucleotides 880 to 891
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Halococcus morrhuae
PUBLICATION INFORMATION:
AUTHORS: Jeffers, H, Kjems, J, Ostergaard, L,
AUTHORS: Larsen, N, Garrett, R A.
TITLE: Evolutionary Relationship
TITLE: Amongst Archaeobacteria: A Comparative Study of
TITLE: 23 S Ribosomal RNAs of a Sulphur-dependent
TITLE: Extreme Thermophile, an Extreme Halophile and a
TITLE: Thermophilic Methanogen
JOURNAL: Journal of Molecular Biology
VOLUME: 195
PAGES: 43-61
DATE: 1987
RELEVANT RESIDUES IN SEQ ID NO: 227 :FROM 1 TO 12
US-08-173-489C-227

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02; Indels 2; Gaps 0;
Matches 10; Conservative 0; Mismatches 2; Indels 2; Gaps 0;

Qy 924 CCTTTATCCCT 935
||| |
Db 12 CCTTCACCCCT 1

RESULT 259
US-08-173-489C-237/c
Sequence 237, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESS: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:

NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 237:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 23s rRNA gene from Leptospira
DESCRIPTION: interrogans (Accession # X14249) nucleotides
DESCRIPTION: 842 to 853
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Leptospira interrogans serovar canicola
STRAIN: moulton
PUBLICATION INFORMATION:
AUTHORS: Fukunga, M, Horie, I, Mifuchi, I.
TITLE: Nucleotide sequence of a 23s
TITLE: ribosomal RNA gene for Leptospira interrogans
TITLE: serovar canicola strain moulton
JOURNAL: Nucleic Acids Research
VOLUME: 17
PAGES: 2123-2123
DATE: 1989
RELEVANT RESIDUES IN SEQ ID NO: 237 :FROM 1 TO 12
US-08-173-489C-237

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02; Indels 2; Gaps 0;
Matches 10; Conservative 0; Mismatches 2; Indels 2; Gaps 0;

Qy 924 CCTTTATCCCT 935
||| |
Db 12 CCTTCACCCCT 1

RESULT 260
US-08-173-489C-249/c
Sequence 249, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESS: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.

REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 249:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 23s rRNA gene from Micrococcus luteus
DESCRIPTION: (Accession # X06484) nucleotides 859 to 870
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Micrococcus luteus
STRAIN: dsm 20030
PUBLICATION INFORMATION:
AUTHORS: Regensburger, A, Ludwig, W, Frank, R,
AUTHORS: Bloeker, H, Schleifer, K H.
TITLE: Complete nucleotide sequence
TITLE: of a 23S ribosomal RNA gene from Micrococcus
TITLE: luteus
JOURNAL: Nucleic Acids Research
VOLUME: 16
PAGES: 2344-2344
DATE: 1988
RELEVANT RESIDUES IN SEQ ID NO: 249 :FROM 1 TO 12
US-08-173-489C-249

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 924 CCTTTATCCCT 935
Db 12 CCTTCACCCCT 1

RESULT 261
US-08-173-489C-259/c
Sequence 259, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179

REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 259:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 23s rRNA gene from Frankia sp
DESCRIPTION: (Accession # M55343) nucleotides 3314 to 3325
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Frankia sp.
PUBLICATION INFORMATION:
AUTHORS: No. 5861244mand, P.
TITLE: unpublished
JOURNAL:
VOLUME:
PAGES:
DATE: 1991
RELEVANT RESIDUES IN SEQ ID NO: 259 :FROM 1 TO 12
US-08-173-489C-259

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 924 CCTTTATCCCT 935
Db 12 CCTTCACCCCT 1

RESULT 262
US-08-173-489C-263/c
Sequence 263, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 263:

SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 23s rRNA gene from Rhodobacter
DESCRIPTION: capsulatus (Accession # X06485) nucleotides 842
DESCRIPTION: to 853
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Rhodobacter capsulatus
STRAIN: dsm 938
PUBLICATION INFORMATION:
AUTHORS: Regensburger, A, Ludwig, W, Frank, R,
AUTHORS: Bloecker, H, Schleifer, K H.
TITLE: Complete nucleotide sequence
TITLE: of a 23s ribosomal RNA gene from Rhodobacter
TITLE: capsulatus
JOURNAL: Nucleic Acids Research
VOLUME: 16
PAGES: 2343-2343
DATE: 1988
RELEVANT RESIDUES IN SEQ ID NO: 263 :FROM 1 TO 12
US-08-173-489C-263

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02; Mismatches 0; Indels 2; Gaps 0;
Matches 10; Conservative 0;

Qy 924 CTTTTCACCCCT 935
Db 12 CTTTTCACCCCT 1

RESULT 263
US-08-927-165A-17/c
Sequence 17, Application US/08927165A
Patent No. 6410226
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Holloman, William K.
APPLICANT: Rice, Michael C.
APPLICANT: Smith, Sheryl T.
APPLICANT: Shu, Zhigang
TITLE OF INVENTION: Mammalian and Human Rec2
NUMBER OF SEQUENCES: 39
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kimeragen, Inc.
STREET: 300 Pleasant Run
CITY: Newtown
STATE: PA
COUNTRY: USA
ZIP: 18940
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/927,165A
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Hansburg, Daniel
REGISTRATION NUMBER: 36156
REFERENCE/DOCKET NUMBER: 7991-010-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-504-4444

TELEFAX: 215-504-4545
TELEX:
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-927-165A-17
Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02; Mismatches 0; Indels 2; Gaps 0;
Matches 10; Conservative 0;

Qy 926 TTTTATCCCTCC 937
Db 12 TTTAATGCCTCC 1

RESULT 264
US-08-477-831C-26
Sequence 26, Application US/08477831C
Patent No. 6429291
GENERAL INFORMATION:
APPLICANT: TURLEY, EVA A.
APPLICANT: SHUEN, ZHANG
APPLICANT: ENTWISTLE, JOYCELYN
TITLE OF INVENTION: HVALUROMAN RECEPTOR PROTEIN
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: FISH & NEAVE
STREET: 1251 AVENUE OF THE AMERICAS
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 10020-1104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Rel. #1.0, ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,831C
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: PIERRI, MARGARET A.
REGISTRATION NUMBER: 30,709
REFERENCE/DOCKET NUMBER: SIM-10
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-596-9000
TELEFAX: 212-596-9090
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE:
DESCRIPTION: /desc = intron sequence
US-08-477-831C-26

Query Match 12.1%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2e+02; Mismatches 0; Indels 2; Gaps 0;
Matches 10; Conservative 0;

Qy 917 GTCTTTCCTTT 928
Db 1 GTATTTCCTTT 12

RESULT 265
US-07-715-183C-9

; Sequence 9, Application US/07715183C
; Patent No. 5304473
; GENERAL INFORMATION:
; APPLICANT: Belagaje, Rama M
; APPLICANT: Dimarchi, Richard D
; APPLICANT: Heath, William F
; APPLICANT: Long, Harlan B
; TITLE OF INVENTION: A-C-B PROINSULIN, METHOD OF
; TITLE OF INVENTION: MANUFACTURING AND USING SAME, AND INTERMEDIATES IN
; TITLE OF INVENTION: INSULIN PRODUCTION
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: Indiana
; COUNTRY: USA
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/715,183C
; FILING DATE: 19910611
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Conrad, William A
; REGISTRATION NUMBER: 32,089
; REFERENCE/DOCKET NUMBER: X-7866
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 317-276-6013
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
; US-07-715-183C-9

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTTGCGCTTTTA 930
||| ||||| |||
Db 1 CTTGCGCTTCTA 12

RESULT 266
US-08-651-835A-9
; Sequence 9, Application US/08651835A
; Patent No. 5707866
; GENERAL INFORMATION:
; APPLICANT: BRAKIER-GINGRAS, Lea
; APPLICANT: MELANCON, Pierre
; APPLICANT: COTE, Marc
; APPLICANT: PAYANT, Catherine
; TITLE OF INVENTION: USE OF DNA OLIGOMERS FOR INHIBITION OF
; TITLE OF INVENTION: HIV BY DECREASING RIBOSOMAL FRAMESHIFTING
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KLAUBER & JACKSON
; STREET: Continental Plaza, 411 Hackensack Avenue
; CITY: Hackensack
; STATE: N.J.
; COUNTRY: U.S.A.
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/651,835A
; FILING DATE: 21-MAY-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/409,852
; FILING DATE: 23-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/220,604
; FILING DATE: 30-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: JACKSON, David A.
; REGISTRATION NUMBER: 26,742
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (201) 487-5800
; TELEFAX: (201) 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-651-835A-9

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 904 GTCAATTCCTTT 915
||| ||||| |||
Db 2 GTCAATTCCTTT 13

RESULT 267
US-08-173-489C-334
; Sequence 334, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:

TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 334:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from N.
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 334 :FROM 1 TO 13
US-08-173-489C-334

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 931 TCCCTCTCTTC 942
Db 1 TCCCTCTCTTC 12

RESULT 268
US-08-761-243C-18/c
Sequence 18, Application US/08761243C
Patent No. 5879879
GENERAL INFORMATION:
APPLICANT: Kamal D. Mehta
TITLE OF INVENTION: No. 5879879el Cis-Acting Element In The Human LDL Receptor Pro
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSES: Benjamin Aaron Adler, Ph.D., J.D.
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77071
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh
SOFTWARE: Microsoft Word for Macintosh
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/761,243C
FILING DATE: December 6, 1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Benjamin Aaron Adler, Ph.D., J.D.
REGISTRATION NUMBER: 35,423
REFERENCE/DOCKET NUMBER: D5956
TELEPHONE: 713-777-2321
TELEFAX: 713-777-6908
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 bp
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
MOLECULE TYPE:
DESCRIPTION: other nucleic acid
HYPOTHETICAL: No
ANTI-SENSE: No
ORIGINAL SOURCE:
US-08-761-243C-18

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 923 GCCTTTTATCCC 934
Db 12 GCCTTTTATCCC 1

RESULT 269
US-08-607-078-2/c
Sequence 2, Application US/08607078
Patent No. 6090947
GENERAL INFORMATION:
APPLICANT: California Institute of Technology
TITLE OF INVENTION: Method for the Synthesis of Pyrrole
TITLE OF INVENTION: and Imidazole Carboxamides on a
TITLE OF INVENTION: Solid Support
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSES: Swanson & Bratschun, L.L.C. 200
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MG
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/607,078
FILING DATE: February 26, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Rosemary P. Kellogg
REGISTRATION NUMBER: 39,726
REFERENCE/DOCKET NUMBER: CIT 2347
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-607-078-2

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 918 TCTTTGCTTTT 929
Db 13 TTTTGTCTTTT 2

RESULT 270
US-08-930-798-4
Sequence 4, Application US/08930798
Patent No. 6150095
GENERAL INFORMATION:
APPLICANT: SOUTHERN, EDWIN
TITLE OF INVENTION: A METHOD FOR ANALYSING A POLYNUCLEOTIDE CONTAINING A
TITLE OF INVENTION: VARIABLE SEQUENCE AND A SET OR ARRAY OF
TITLE OF INVENTION: OLIGONUCLEOTIDES THEREFOR (AS AMENDED)
FILE REFERENCE: 97-1173*/wmc/263
CURRENT APPLICATION NUMBER: US/08/930,798
CURRENT FILING DATE: 1997-10-06
NUMBER OF SEQ ID NOS: 12
SOFTWARE: Patentin Ver. 2.0

; SEQ ID NO 4
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism:synthetic - other
; OTHER INFORMATION: dna
US-08-930-798-4

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 925 CTTTATCCCTC 936
Db 1 CTTATTCCTC 12

RESULT 271
US-09-502-778A-4
; Sequence 4, Application US/09502778A
; Patent No. 6307039
; GENERAL INFORMATION:
; APPLICANT: SOUTHERN, EDWIN
; TITLE OF INVENTION: A METHOD FOR ANALYSING A POLYNUCLEOTIDE CONTAINING A
; TITLE OF INVENTION: VARIABLE SEQUENCE AND A SET OR ARRAY OF
; TITLE OF INVENTION: OLIGONUCLEOTIDES THEREFOR (AS AMENDED)
; FILE REFERENCE: 97-1173*/wmc/263
; CURRENT APPLICATION NUMBER: US/09/502,778A
; CURRENT FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism:synthetic - other
; OTHER INFORMATION: dna
US-09-502-778A-4

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 925 CTTTATCCCTC 936
Db 1 CTTATTCCTC 12

RESULT 272
US-09-359-921-2/c
; Sequence 2, Application US/09359921
; Patent No. 6545162
; GENERAL INFORMATION:
; APPLICANT: DERVAN, PETER B.
; APPLICANT: BAIRD, ELDON E.
; TITLE OF INVENTION: METHOD FOR THE SYNTHESIS OF PYRROLE AND IMIDAZOLE
; TITLE OF INVENTION: CARBOXAMIDES ON A SOLID SUPPORT
; FILE REFERENCE: 025098-1602
; CURRENT APPLICATION NUMBER: US/09/359,921
; CURRENT FILING DATE: 1999-07-22
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-09-359-921-2

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 918 TCTTGGCTTTT 929
Db 13 TTTTGTCTTTT 2

RESULT 273
US-09-360-344-2/c
; Sequence 2, Application US/09360344
; Patent No. 6683189
; GENERAL INFORMATION:
; APPLICANT: DERVAN, PETER B.
; APPLICANT: BAIRD, ELDON E.
; TITLE OF INVENTION: METHOD FOR THE SYNTHESIS OF PYRROLE AND IMIDAZOLE
; TITLE OF INVENTION: CARBOXAMIDES ON A SOLID SUPPORT
; FILE REFERENCE: 025098-1604
; CURRENT APPLICATION NUMBER: US/09/360,344
; CURRENT FILING DATE: 1999-07-22
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-09-360-344-2

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 918 TCTTGGCTTTT 929
Db 13 TTTTGTCTTTT 2

RESULT 274
PCT-US93-02957-3
; Sequence 3, Application PC/TUS9302957
; GENERAL INFORMATION:
; APPLICANT: Alexander T. Young
; TITLE OF INVENTION: GENE THERAPY USING TARGETED
; TITLE OF INVENTION: VIRAL VECTORS
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3 5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.00)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/02957
; FILING DATE: 19930331
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/862,795
; FILING DATE: April 3, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul T. Clark
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 05140/002002
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US93-02957-3

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 908 TTTTCTTTGGTC 919
Db 2 TTTTCTTTATC 13

RESULT 275

5455029-9
; Patent No. 5455029
; APPLICANT: HARTMAN, JACOB R.; OPPENHEIM, AMOS B.; GORECKI,
; MARIAN; AVIV, HAIM; OREN, RACHEL
; TITLE OF INVENTION: THERAPEUTIC COMPOSITIONS COMPRISING
; A MIXTURE OF HUMAN CUZIN SUPEROXIDE DISMUTASE ANALOGS
; NUMBER OF SEQUENCES: 30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/933,500
; FILING DATE: 21-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 449,125
; FILING DATE: 08-DEC-1989
; APPLICATION NUMBER: 202,238
; FILING DATE: 03JUN-1988
; APPLICATION NUMBER: 897,056
; FILING DATE: 14-AUG-1985
; APPLICATION NUMBER: 767,143
; FILING DATE: 19-AUG-1985
; APPLICATION NUMBER: 644,245
; FILING DATE: 27-AUG-1984
; SEQ ID NO: 9:
; LENGTH: 13
5455029-9

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 955 TATGCTACCAA 966
Db 1 TATGCTACTAA 12

RESULT 276

5514646-34
; Patent No. 5514646
; APPLICANT: CHANCE, RONALD E.; DIMARCHI, RICHARD D.; FRANK,
; BRUCE H.; SHIELDS, JAMES B.
; TITLE OF INVENTION: INSULIN ANALOGS MODIFIED AT POSITION
; 29 OF THE B CHAIN
; NUMBER OF SEQUENCES: 52
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/57,201
; FILING DATE: 05-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 686,632
; FILING DATE: 17-APR-1991
; APPLICATION NUMBER: 388,201
; FILING DATE: 04-AUG-1989
; APPLICATION NUMBER: 308,352
; FILING DATE: 09-FEB-1989

; SEQ ID NO: 34:
; LENGTH: 13
5514646-34

Query Match 12.1%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 919 CTTTGCTTTTA 930
Db 1 CTGTGCTTCTA 12

RESULT 277

US-09-163-485-25/c
; Sequence 25, Application US/09163485
; Patent No. 6277571
; GENERAL INFORMATION:
; APPLICANT: FILLMORE, HELEN
; APPLICANT: BROADBUSH, WILLIAM
; APPLICANT: GILLIES, GEORGE
; TITLE OF INVENTION: SEQUENTIAL CONSENSUS REGION-DIRECTED AMPLIFICATION OF
; FILE REFERENCE: VCU1P4B
; CURRENT APPLICATION NUMBER: US/09/163,485
; CURRENT FILING DATE: 1998-08-30
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 25
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide, consensus sequence from human
; OTHER INFORMATION: matrix metalloproteinases
; FEATURE:
; NAME/KEY: MOD RES
; LOCATION: (9)
; OTHER INFORMATION: A, T, C, G, other or unknown
US-09-163-485-25

Query Match 11.8%; Score 8.6; DB 1; Length 12;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 8; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 930 ATCCCTCTCTT 941
Db 12 ATCTTCTCTCT 1

RESULT 278

US-07-651-710A-5/c
; Sequence 5, Application US/07651710A
; Patent No. 5362864
; GENERAL INFORMATION:
; APPLICANT: Chua, Nam-Hai
; TITLE OF INVENTION: Trans-Activating Factor-1
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/651,710A

SEQUENCE CHARACTERISTICS:
LENGTH: 10
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-060-952C-11

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 91 TCATTGGTTT 950
Db 1 TCATTGGTGT 10

RESULT 280
US-08-173-489C-68
Sequence 68, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44MB storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 5.1
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelsman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 68:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 bases
TYPE: Nucleic Acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from esterase D
HYPOTHETICAL: Yes
ANTI-SENSE: NO
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 68 :FROM 1 TO 10
US-08-173-489C-68

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 958 CGCTACCAAC 967
Db 10 CGCCACCAAC 1

RESULT 279
US-08-060-952C-11
Sequence 11, Application US/08060952C
Patent No. 5695932
GENERAL INFORMATION:
APPLICANT: Michael D. West
APPLICANT: Jerry W. Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth Blackburn
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
TITLE OF INVENTION: RELATED TO TELOMERE LENGTH AND/OR
TITLE OF INVENTION: TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/060,952C
FILING DATE: May 13, 1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/882,438
FILING DATE: May 13, 1992
APPLICATION NUMBER: 08/038,766
FILING DATE: March 24, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 202/045
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 11:

Qy 905 TCATTTTCTT 914
Db 11

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 1 TCCTTTCTTT 10

RESULT 281
US-08-173-489C-71/c
; Sequence 71, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; DESCRIPTION: esterase D gene (Accession # M13450)
; DESCRIPTION: nucleotides 710 to 719
; HYPOTHETICAL: No
; ANTI-SENSE: No
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: chromosome 13
; MAP POSITION: 13q14.1-q14.2
; PUBLICATION INFORMATION:
; AUTHORS: Lee, E Y H P, Lee, W H.
; TITLE: Molecular cloning of the
; TITLE: human esterase D gene, a genetic marker of
; TITLE: retinoblastoma
; JOURNAL: Proceedings of the National Academy of
; JOURNAL: Sciences, USA
; VOLUME: 83
; PAGES: 6337-6341
; DATE: 1986
; RELEVANT RESIDUES IN SEQ ID NO: 71 :FROM 1 TO 10
US-08-173-489C-71

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 918 TCCTTGCCCT 927

Db 10 TCCTTCCCTT 1

RESULT 282
US-08-892-770-13
; Sequence 13, Application US/08892770
; Patent No. 5962670
; GENERAL INFORMATION:
; APPLICANT: Walling, Linda L.
; APPLICANT: Pautot, Veronique
; APPLICANT: Gu, Yong-Qiang
; APPLICANT: Chao, Wun Shaw
; TITLE OF INVENTION: Improved Promoters for Enhancing Plant
; TITLE OF INVENTION: Productivity
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/892,770
; FILING DATE: 15-JUL-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Quine, Jonathan A.
; REGISTRATION NUMBER: F-41,261
; REFERENCE/DOCKET NUMBER: 023070-072100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-892-770-13

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 905 TCATTTCTTT 914

Db 1 TCATTTCTTT 10

RESULT 283
US-08-388-353-49/c
; Sequence 49, Application US/08388353
; Patent No. 6010695
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City

STATE: New York
COUNTRY: United States
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-49

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02; 1; Indels 0;
Matches 9; Conservative 0; Mismatches 1; Gaps 0;

QY 918 TCTTTCCTT 927
|||||
DB 10 TCTTTCCTT 1

RESULT 284
US-08-388-353-135/c
Sequence 135, Application US/08388353
Patent No. 6010895
GENERAL INFORMATION:
APPLICANT: Deacon, Nicholas J.
APPLICANT: Learmont, Jennifer C.
APPLICANT: McPhee, Dale A.
APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366

TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 135:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-135

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02; 1; Indels 0;
Matches 9; Conservative 0; Mismatches 1; Gaps 0;

QY 954 GTATCGCTAC 963
|||||
DB 10 GTATCGCTAC 1

RESULT 285
US-08-388-353-136/c
Sequence 136, Application US/08388353
Patent No. 6010895
GENERAL INFORMATION:
APPLICANT: Deacon, Nicholas J.
APPLICANT: Learmont, Jennifer C.
APPLICANT: McPhee, Dale A.
APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 136:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-136

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02; 1; Indels 0;
Matches 9; Conservative 0; Mismatches 1; Gaps 0;

QY 953 TGATCGCTA 962
|||||
DB 10 TGATCGCTA 1

```
RESULT 286
US-08-388-353-184/c
; Sequence 184, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-184

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCTCTCTCT 940
Db 10 TTCTCTCTCT 1

RESULT 287
US-08-388-353-191/c
; Sequence 191, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-184

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCTCTCTCT 940
Db 10 TTCTCTCTCT 1

RESULT 288
US-08-388-353-192/c
; Sequence 192, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 192:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-191

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 933 CCTCTCTCTT 942
Db 10 CCACCTCTTC 1
```

```
/ LENGTH: 10 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-08-388-353-192

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 932 CCTCTCTCTT 941
Db 10 CCCACCTCTT 1

RESULT 289
US-08-388-353-229/c
/ Sequence 229, Application US/08388353
/ Patent No. 6010895
/ GENERAL INFORMATION:
/ APPLICANT: Deacon, Nicholas J.
/ APPLICANT: Learmont, Jennifer C.
/ APPLICANT: McPhee, Dale A.
/ APPLICANT: Crowe, Suzanne
/ APPLICANT: Cooper, David
/ TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
/ NUMBER OF SEQUENCES: 800
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: United States
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/388,353
/ FILING DATE: 14-FEB-1995
/ CLASSIFICATION: 424
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 9606
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ TELEX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 800
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 10 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-08-388-353-230

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 911 TCCTTGCTCT 920
Db 10 TCATTGCTCT 1

RESULT 291
US-08-388-353-275/c
/ Sequence 275, Application US/08388353
/ Patent No. 6010895
/ GENERAL INFORMATION:
/ APPLICANT: Deacon, Nicholas J.
/ APPLICANT: Learmont, Jennifer C.
/ APPLICANT: McPhee, Dale A.
/ APPLICANT: Crowe, Suzanne
/ APPLICANT: Cooper, David
/ TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
/ NUMBER OF SEQUENCES: 800
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: United States
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/388,353
/ FILING DATE: 14-FEB-1995
/ CLASSIFICATION: 424
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 9606
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ TELEX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 229
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 10 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-08-388-353-229

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 912 CTTTGCTCTT 921
Db 10 CATTGCTCTT 1

RESULT 290
US-08-388-353-230/c
/ Sequence 230, Application US/08388353
```

```

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 275:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-275

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 906 TTTTCTTT 915
Db 10 CTTTCTTT 1

RESULT 292
US-08-388-353-310/c
; Sequence 310, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 310:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 310:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-49

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 918 TTTTGCCTT 927
Db 10 TCTTCCCTT 1

RESULT 293
US-08-488-551B-49/c
; Sequence 49, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-49

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 918 TCTTGCCTT 927
Db 10 TCTTCCCTT 1
```

RESULT 294
US-08-488-551B-135/c
; Sequence 135, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 96062
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 135:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-135
Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 954 GTATCGCTAC 963
Db 10 GTATCGCTAC 1
RESULT 295
US-08-488-551B-136/c
; Sequence 136, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA

CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 136:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-136
Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 953 TGTATCGCTA 962
Db 10 TGTATCGCTA 1
RESULT 296
US-08-488-551B-184/c
; Sequence 184, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 184:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-184

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 TCCCTCTCTCT 940
Db 10 TTCTCTCTCT 1

RESULT 297
US-08-488-551B-191/c
Sequence 191, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z

TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 191:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-191

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CTCCTCTCTTC 942
Db 10 CCACCTCTTC 1

RESULT 298
US-08-488-551B-192/c
Sequence 192, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 192:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-192

Query Match 11.5%; Score 8.4; DB 1; Length 10;

Best Local Similarity 90.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 1;

Qy 932 CCTCTCTT 941
Db 10 CCCACTCTT 1

RESULT 299

US-08-488-551B-229/c
; Sequence 229, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGILIO
; REFERENCE/DOCKET NUMBER: 9606Z

TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 229:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-229

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 1;

Qy 912 CTTTGCTT 921
Db 10 CATTGCTT 1

RESULT 300

US-08-488-551B-230/c
; Sequence 230, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:

APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGILIO
; REFERENCE/DOCKET NUMBER: 9606Z

TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 230:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-230

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 1;

Qy 911 TCTTGTCT 920
Db 10 TCATTGTCT 1

RESULT 301

US-08-488-551B-275/c
; Sequence 275, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:

APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:

;/ MEDIUM TYPE: Floppy disk
;/ COMPUTER: IBM PC compatible
;/ OPERATING SYSTEM: PC-DOS/MS-DOS
;/ SOFTWARE: Patent In Release #1.0, Version #1.25
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/488,551B
;/ FILING DATE: 07-JUN-1995
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: PM3864 (AU)
;/ FILING DATE: 14-FEB-1994
;/ APPLICATION NUMBER: PM4002 (AU)
;/ FILING DATE: 21-FEB-1994
;/ APPLICATION NUMBER: PM0284 (AU)
;/ FILING DATE: 23-DEC-1994
;/ APPLICATION NUMBER: US 08/388,353
;/ FILING DATE: 14-FEB-1995
;/ APPLICATION NUMBER: PM3021/95
;/ FILING DATE: 17-MAY-1995
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: FRANK S. DIGIGLIO
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (516) 742-4343
;/ TELEFAX: (516) 742-4366
;/ INFORMATION FOR SEQ ID NO: 275:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 10 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: DNA
;/ US-08-488-551B-275

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 906 CATTTCCTTT 915
Db 10 CCTTTCCTTT 1

RESULT 302
US-08-488-551B-310/c
; Sequence 310, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)

;/ FILING DATE: 23-DEC-1994
;/ APPLICATION NUMBER: US 08/388,353
;/ FILING DATE: 14-FEB-1995
;/ APPLICATION NUMBER: PM3021/95
;/ FILING DATE: 17-MAY-1995
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: FRANK S. DIGIGLIO
;/ REFERENCE/DOCKET NUMBER: 9606Z
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (516) 742-4343
;/ TELEFAX: (516) 742-4366
;/ INFORMATION FOR SEQ ID NO: 310:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 10 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: DNA
;/ US-08-488-551B-310

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 908 TTTTCTTTGG 917
Db 10 TCTTCTTTGG 1

RESULT 303
US-09-008-303-3/c
; Sequence 3, Application US/09008303
; Patent No. 6033889
; GENERAL INFORMATION:
; APPLICANT: HAN, YE SUN
; APPLICANT: YU, GYU YU
; APPLICANT: KIM, SUNG HOU
; APPLICANT: LIM, JAE HWAN
; APPLICANT: RYU, JAE RYEON
; APPLICANT: CHOI, IN GEOL
; TITLE OF INVENTION: GENE SEQUENCE OF AQUIFEX PYROPHILUS
; TITLE OF INVENTION: SUPEROXIDE DISMUTASE AND PROTEIN EXPRESSED IN ESCHERICHIA
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, FOURTH FLOOR
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/008,303
; FILING DATE: 16-JAN-1998
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 97-1140
; FILING DATE: 16-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 2901-0109-0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:

```
/ LENGTH: 10 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-09-008-303-3

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTCCTCTTC 942
Db 10 CCTCCTTTTC 1

RESULT 304
US-08-522-384-11
/ Sequence 11, Application US/08522384
/ Patent No. 6110667
/ GENERAL INFORMATION:
/ APPLICANT: LOPEZ-NIETO, CARLOS E
/ APPLICANT: NIGAM, SANJAY KUMAR
/ TITLE OF INVENTION: PROCESSES, APPARATUS AND COMPOSITIONS FOR
/ TITLE OF INVENTION: CHARACTERIZING NUCLEOTIDE SEQUENCES
/ FILE REFERENCE: 2458-4029
/ CURRENT APPLICATION NUMBER: US/08/522,384
/ CURRENT FILING DATE: 1996-11-15
/ NUMBER OF SEQ ID NOS: 122
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 11
/ LENGTH: 10
/ TYPE: DNA
/ ORGANISM: Unknown Organism
/ FEATURE:
/ OTHER INFORMATION: Description of Unknown Organism: Primer
US-08-522-384-11

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTCCTCTTC 942
Db 1 CATCCTCTTC 10

RESULT 305
US-08-675-816-10
/ Sequence 10, Application US/08675816
/ Patent No. 6171864
/ GENERAL INFORMATION:
/ APPLICANT: Coughlan, Sean J.
/ APPLICANT: Winfrey, Jr., Ron J.
/ TITLE OF INVENTION: CALRETICULIN AND CALNEXIN GENES AND PROMOTER REGIONS AND USES
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Seed and Berry
/ STREET: 701 Fifth Ave. Suite 6300
/ CITY: Seattle
/ STATE: Washington
/ COUNTRY: U.S.A.
/ ZIP: 98104-7092
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/675,816
/ FILING DATE: 05-JUL-1996
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: No. 6171864tenburg, Carol
/ REGISTRATION NUMBER: 39,317
/ REFERENCE/DOCKET NUMBER: 750027.401
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (206)-622-4900
/ TELEFAX: (206)-682-6031
/ INFORMATION FOR SEQ ID NO: 15:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 10 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-675-816-15

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 905 TCATTTTCTT 914
Db 1 TCATCTTCTT 10

RESULT 306
US-08-675-816-15
/ Sequence 15, Application US/08675816
/ Patent No. 6171864
/ GENERAL INFORMATION:
/ APPLICANT: Coughlan, Sean J.
/ APPLICANT: Winfrey, Jr., Ron J.
/ TITLE OF INVENTION: CALRETICULIN AND CALNEXIN GENES AND PROMOTER REGIONS AND USES
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Seed and Berry
/ STREET: 701 Fifth Ave. Suite 6300
/ CITY: Seattle
/ STATE: Washington
/ COUNTRY: U.S.A.
/ ZIP: 98104-7092
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/675,816
/ FILING DATE: 05-JUL-1996
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: No. 6171864tenburg, Carol
/ REGISTRATION NUMBER: 39,317
/ REFERENCE/DOCKET NUMBER: 750027.401
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (206)-622-4900
/ TELEFAX: (206)-682-6031
/ INFORMATION FOR SEQ ID NO: 15:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 10 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-675-816-15

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 905 TCATTTTCTT 914
Db 1 TCATCTTCTT 10

RESULT 307
```

US-08-894-324A-4
; Sequence 4, Application US/08894324A
; Patent No. 6204437
; GENERAL INFORMATION:
; APPLICANT: Grierson, Donald
; APPLICANT: Blume, Beatrice
; APPLICANT: Hamilton, Andrew
; APPLICANT: Holdsworth, Michael
; APPLICANT: Barry, Cornelius
; TITLE OF INVENTION: DNA Constructs and Plants Incorporating
; TITLE OF INVENTION: Them
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Zeneca Inc.
; STREET: 1800 Concord Pike
; CITY: Wilmington
; STATE: DE
; COUNTRY: USA
; ZIP: 19850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/894,324A
; FILING DATE: 14-AUG-1997
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB96/00564
; FILING DATE: 11-MAR-1996
; APPLICATION NUMBER: GB 95056081.1
; FILING DATE: 17-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Hohenschutz, Liza D.
; REGISTRATION NUMBER: 33712
; REFERENCE/DOCKET NUMBER: SEE 45003/UST
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (302) 886-1699
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ORIGINAL SOURCE:
; ORGANISM: TCA MOTIF
US-08-894-324A-4
Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 905 TCATTCTTCTT 914
Db 1 TCATTCTTCTT 10
RESULT 308
US-08-464-011B-11
; Sequence 11, Application US/08464011B
; Patent No. 6368789
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Jerry W. Shay
; Woodring E. Wright
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
; RELATED TO TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 61
; CORRESPONDENCE ADDRESS:

ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/464,011B
FILING DATE: 05-Jun-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/882,438
FILING DATE: May 13, 1992
APPLICATION NUMBER: 08/038,766
FILING DATE: March 24, 1993
APPLICATION NUMBER: 08/060,952
FILING DATE: May 13, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 202/045
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 10
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-08-464-011B-11
Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 941 TCATTGGTTT 950
Db 1 TCATTGGTTT 10
RESULT 309
US-09-154-750A-4
; Sequence 4, Application US/09154750A
; Patent No. 6432640
; GENERAL INFORMATION:
; APPLICANT: Vogelstein, Bert
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Polyak, Kornelia
; TITLE OF INVENTION: P53-Induced Apoptosis
; FILE REFERENCE: 1107.75357
; CURRENT APPLICATION NUMBER: US/09/154,750A
; CURRENT FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/059,153
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/079817
; PRIOR FILING DATE: 1998-03-30
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-154-750A-4

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 932 CCTCTCTCT 941
Db 1 CCCGCTCTT 10

RESULT 310
US-09-394-457C-7
; Sequence 7, Application US/09394457C
; Patent No. 6440705
; GENERAL INFORMATION:
; APPLICANT: Variagenics, Inc.
; TITLE OF INVENTION: A Method for Analyzing Polynucleotides
; FILE REFERENCE: 246/020
; CURRENT APPLICATION NUMBER: US/09/394,457C
; CURRENT FILING DATE: 1999-09-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hypothetical sequence to demonstrate application.
US-09-394-457C-7

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 929 TATCCCTCTCT 938
Db 1 TATCCCTCTCT 10

RESULT 311
US-09-261-115-61/c
; Sequence 61, Application US/09261115
; Patent No. 6458584
; GENERAL INFORMATION:
; APPLICANT: MIRZABEKOV, ANDREI
; APPLICANT: GUSCHIN, DMITRY Y.
; APPLICANT: SHIK, VALENTINE
; APPLICANT: DROBYSHEV, ALEKSEI
; APPLICANT: FOTIN, ALEXANDER
; APPLICANT: YERSHOV, GENNADIY
; APPLICANT: LYSOV, YU
; TITLE OF INVENTION: CUSTOMIZED OLIGONUCLEOTIDE MICROCHIPS THAT CONVERT
; TITLE OF INVENTION: MULTIPLE GENETIC INFORMATION TO SIMPLE PATTERNS, ARE
; FILE REFERENCE: 21416/90184
; CURRENT APPLICATION NUMBER: US/09/261,115
; CURRENT FILING DATE: 1999-03-03
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 61
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Customized
US-09-261-115-61

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 915 TGGTCTTTGC 924

Db 10 TGGTCTTTGC 1

RESULT 312
US-09-709-596A-7
; Sequence 7, Application US/09709596A
; Patent No. 6458945
; GENERAL INFORMATION:
; APPLICANT: Variagenics, Inc.
; TITLE OF INVENTION: A Method for Analyzing Polynucleotides
; FILE REFERENCE: 258/239
; CURRENT APPLICATION NUMBER: US/09/709,596A
; CURRENT FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hypothetical sequence to demonstrate application.
US-09-709-596A-7

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 929 TATCCCTCTCT 938
Db 1 TATCCCTCTCT 10

RESULT 313
US-09-914-259-129
; Sequence 129, Application US/09914259
; Patent No. 6495336
; GENERAL INFORMATION:
; APPLICANT: Makowski, Lee
; APPLICANT: Hyman, Paul
; APPLICANT: Williams, Mark
; TITLE OF INVENTION: STAGED ASSEMBLY OF NANOSTRUCTURES
; FILE REFERENCE: 8471-010-999
; CURRENT APPLICATION NUMBER: US/09/914,259
; CURRENT FILING DATE: 2000-11-21
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 129
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Theoretical sequence designed to show proper and improper joining
US-09-914-259-129

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 905 TCATTTCTT 914
Db 1 TCATTTCTT 10

RESULT 314
US-09-655-104A-7
; Sequence 7, Application US/09655104A
; Patent No. 6500650
; GENERAL INFORMATION:
; APPLICANT: Variagenics, Inc.
; TITLE OF INVENTION: A Method for Identifying Polymorphisms
; FILE REFERENCE: 257/078

```
; CURRENT APPLICATION NUMBER: US/09/655,104A
; CURRENT FILING DATE: 2000-09-05
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hypothetical sequence to demonstrate application.
US-09-655-104A-7

Query Match      11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 929 TATCCCTCCT 938
Db 1 TATTCCTCCT 10

RESULT 317
US-10-104-818-7
; Sequence 7, Application US/10104818
; Patent No. 6582923
; GENERAL INFORMATION:
; APPLICANT: Varigenics, Inc.
; TITLE OF INVENTION: A Method for Analyzing Polynucleotides
; FILE REFERENCE: 265/034
; CURRENT APPLICATION NUMBER: US/10/104,818
; CURRENT FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 09/394,774
; PRIOR FILING DATE: 1999-09-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hypothetical sequence to demonstrate application.
US-10-104-818-7

Query Match      11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 929 TATCCCTCCT 938
Db 1 TATTCCTCCT 10

RESULT 318
US-09-989-789-1659/c
; Sequence 1659, Application US/09989789
; Patent No. 6588746
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4885
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1659
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
US-09-989-789-1659

Query Match      11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTCCTCTTC 942
Db 10 CATCCTCTTC 1

RESULT 319
```

```
; CURRENT APPLICATION NUMBER: US/09/655,104A
; CURRENT FILING DATE: 2000-09-05
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hypothetical sequence to demonstrate application.
US-09-655-104A-7

Query Match      11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 929 TATCCCTCCT 938
Db 1 TATTCCTCCT 10

RESULT 315
US-09-867-915-22/c
; Sequence 22, Application US/09867915
; Patent No. 6521747
; GENERAL INFORMATION:
; APPLICANT: Genassance Pharmaceuticals, Inc.
; APPLICANT: Anastasio, Allison E.
; APPLICANT: Finkel, Kevin
; APPLICANT: Koshiy, Beena
; APPLICANT: Lee, Helen H.
; TITLE OF INVENTION: HAPLOTYPES OF THE AGTR1 GENE
; FILE REFERENCE: AGTR1-1138test
; CURRENT APPLICATION NUMBER: US/09/867,915
; CURRENT FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: 60/228,542
; PRIOR FILING DATE: 2000-08-28
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-867-915-22

Query Match      11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 902 TGGTCATTTT 911
Db 10 TGCTCATTTT 1

RESULT 316
US-09-394-467-7
; Sequence 7, Application US/09394467
; Patent No. 6566059
; GENERAL INFORMATION:
; APPLICANT: Varigenics, Inc.
; TITLE OF INVENTION: A Method for Analyzing Polynucleotides
; FILE REFERENCE: 245/287
; CURRENT APPLICATION NUMBER: US/09/394,467
; CURRENT FILING DATE: 1999-09-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Used to demonstrate how indicated aspect of invention works.
US-09-394-467-7
```

US-09-989-789-1663/c
; Sequence 1663, Application US/09989789
; Patent No. 6588746
; GENERAL INFORMATION:
; APPLICANT: LIU, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.20 / S11-US2
; CURRENT APPLICATION NUMBER: US/09/989,789
; CURRENT FILING DATE: 2002-03-25
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1663
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
; OTHER INFORMATION: DNA
US-09-989-789-1663

Query Match 11.5%; Score 8.4; DB 1; Length 10;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 933 CTTCTCTTTC 942
Db 10 CATCTCTTTC 1

RESULT 320
US-08-344-695-24/c
; Sequence 24, Application US/08344695
; Patent No. 5614398
; GENERAL INFORMATION:
; APPLICANT: O'BROCHTA, DAVID
; APPLICANT: WARREN, WILLIAM
; APPLICANT: ATKINSON, PETER
; TITLE OF INVENTION: A GENE TRANSFER SYSTEM FOR INSECTS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,695
; FILING DATE: 18-NOV-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kelber, Steven B.
; REGISTRATION NUMBER: 30,073
; REFERENCE/DOCKET NUMBER: 2747-058-27
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 413-3000
; TELEFAX: (703) 413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: other nucleic acid
US-08-344-695-24

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 926 TTTTATCCCT 935
Db 11 TTTCATCCCT 2

RESULT 321
US-08-344-695-25
; Sequence 25, Application US/08344695
; Patent No. 5614398
; GENERAL INFORMATION:
; APPLICANT: O'BROCHTA, DAVID
; APPLICANT: WARREN, WILLIAM
; APPLICANT: ATKINSON, PETER
; TITLE OF INVENTION: A GENE TRANSFER SYSTEM FOR INSECTS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,695
; FILING DATE: 18-NOV-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kelber, Steven B.
; REGISTRATION NUMBER: 30,073
; REFERENCE/DOCKET NUMBER: 2747-058-27
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 413-3000
; TELEFAX: (703) 413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: other nucleic acid
US-08-344-695-25

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 926 TTTTATCCCT 935
Db 1 TTTCATCCCT 10

RESULT 322
US-08-344-695-26/c
; Sequence 26, Application US/08344695
; Patent No. 5614398
; GENERAL INFORMATION:
; APPLICANT: O'BROCHTA, DAVID
; APPLICANT: WARREN, WILLIAM
; APPLICANT: ATKINSON, PETER
; TITLE OF INVENTION: A GENE TRANSFER SYSTEM FOR INSECTS
; NUMBER OF SEQUENCES: 50

;; CORRESPONDENCE ADDRESS:
;; ADDRESSES: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
;; ADDRESSES: P.C.
;; STREET: 1755 S. Jefferson Davis Highway, Suite 400
;; CITY: Arlington
;; STATE: Virginia
;; COUNTRY: U.S.A.
;; ZIP: 22202
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/344,695
;; FILING DATE: 18-NOV-1994
;; CLASSIFICATION: 536
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Kelber, Steven B.
;; REGISTRATION NUMBER: 30,073
;; REFERENCE/DOCKET NUMBER: 2747-058-27
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (703) 413-3000
;; TELEFAX: (703) 413-2220
;; TELEX: 248855 OPAT UR
;; INFORMATION FOR SEQ ID NO: 26:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 11 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: unknown
;; TOPOLOGY: unknown
;; MOLECULE TYPE: other nucleic acid
US-08-344-695-26

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 926 TTTTATCCCT 935
Db 11 TTTTATCCCT 2

RESULT 323
US-08-344-695-27
; Sequence 27, Application US/08344695
; Patent No. 5614398
; GENERAL INFORMATION:
; APPLICANT: O'BROCHTA, DAVID
; APPLICANT: WARREN, WILLIAM
; APPLICANT: ATKINSON, PETER
; TITLE OF INVENTION: A GENE TRANSFER SYSTEM FOR INSECTS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSES: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSES: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,695
; FILING DATE: 18-NOV-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kelber, Steven B.
; REGISTRATION NUMBER: 30,073

;; REFERENCE/DOCKET NUMBER: 2747-058-27
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (703) 413-3000
;; TELEFAX: (703) 413-2220
;; TELEX: 248855 OPAT UR
;; INFORMATION FOR SEQ ID NO: 27:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 11 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: unknown
;; TOPOLOGY: unknown
;; MOLECULE TYPE: other nucleic acid
US-08-344-695-27

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 926 TTTTATCCCT 935
Db 1 TTTTATCCCT 10

RESULT 324
US-08-344-695-29
; Sequence 29, Application US/08344695
; Patent No. 5614398
; GENERAL INFORMATION:
; APPLICANT: O'BROCHTA, DAVID
; APPLICANT: WARREN, WILLIAM
; APPLICANT: ATKINSON, PETER
; TITLE OF INVENTION: A GENE TRANSFER SYSTEM FOR INSECTS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSES: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSES: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,695
; FILING DATE: 18-NOV-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kelber, Steven B.
; REGISTRATION NUMBER: 30,073
; REFERENCE/DOCKET NUMBER: 2747-058-27
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 413-3000
; TELEFAX: (703) 413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: other nucleic acid
US-08-344-695-29

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 926 TTTTATCCCT 935
Db 11 TTTTATCCCT 10


```

; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 bases
; TYPE: Nucleic Acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from gamma-
; DESCRIPTION: crystallin sequence region in Seq ID No. 586124463
; HYPOTHETICAL: Yes
; ANTI-SENSE: No
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 64 :FROM 1 TO 11
US-08-173-489C-64

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 920 TTTGGCTTTT 929
Db 2 TTTGGCTTTT 11

RESULT 328
US-08-173-489C-99
; Sequence 99, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: prealbumin gene exons 1 and 2
; DESCRIPTION: (accession # M15515) nucleotides 1344 to 1354
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens

```

```

; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: chromosome 18
; MAP POSITION: 18q11.2-12.1
; PUBLICATION INFORMATION:
; AUTHORS: Maeda, S, Mita, S, Araki, S, Shimada,
; AUTHORS: K.
; TITLE: Structure and expression of
; TITLE: the mutant prealbumin gene associated with
; TITLE: familial amyloidotic polyneuropathy
; JOURNAL: Molecular Biological Medicine
; VOLUME: 3
; PAGES: 329-338
; DATE: 1986
; RELEVANT RESIDUES IN SEQ ID NO: 99 :FROM 1 TO 11
US-08-173-489C-99

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 926 TTTTATCCCT 935
Db 1 TTTTATCCCT 10

RESULT 329
US-08-173-489C-121
; Sequence 121, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: alpha-2-globin gene (accession #
; DESCRIPTION: V00516) nucleotides 139 to 149
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:

```

```

; ORGANISM: Homo sapiens
; PUBLICATION INFORMATION:
; AUTHORS: O'Kin, S H, Goff, S C, Hechtman, R L.
; TITLE: Mutation in an intervening
; TITLE: sequence splice junction in man
; JOURNAL: Proceedings of the National Academy of
; JOURNAL: Sciences, USA
; VOLUME: 78
; PAGES: 5041-5045
; DATE: 1981
; RELEVANT RESIDUES IN SEQ ID NO: 121 :FROM 1 TO 11
US-08-173-489C-121

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 TCCCTCCTCT 940
Db 2 TCCCTCCTCT 11

RESULT 330
US-08-590-571-57/c
; Sequence 57, Application US/08590571
; Patent No. 5861246
; GENERAL INFORMATION:
; APPLICANT: Sherman Weissman and Girish N. Nallur
; TITLE OF INVENTION: MULTIPLE SELECTION PROCESS
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Yahwak & Associates
; STREET: 25 Skytop Drive
; CITY: Trumbull
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06611
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Microsoft Word 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/590,571
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: George M. Yahwak
; REGISTRATION NUMBER: 26,824
; REFERENCE/DOCKET NUMBER: Yale
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203)268-1951
; TELEFAX: (203)268-1951
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-590-571-57

```

```

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 925 CTTTATCCC 934
Db 10 CGTTATCCC 1

```

```

RESULT 331
US-08-460-890A-2

```

```

; Sequence 2, Application US/08460890A
; Patent No. 5994109
; GENERAL INFORMATION:
; APPLICANT: Woo, Savio L.C.
; APPLICANT: Smith, Louis C.
; APPLICANT: Cristiano, Richard J.
; APPLICANT: Gottchalk, Stephen
; TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
; TITLE OF INVENTION: METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,890A
; FILING DATE: June 5, 1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/167,841
; FILING DATE: December 14, 1993
; APPLICATION NUMBER: 07/855,389
; FILING DATE: March 20, 1992
; APPLICATION NUMBER: PCT/US93/02725
; FILING DATE: March 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/066
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; FEATURE:
; OTHER INFORMATION: "C" stands for 5-methylcytosine
US-08-460-890A-2

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 TCCCTCCTCT 940
Db 2 TCCCTCCTCT 11

RESULT 332
US-08-460-890A-16
; Sequence 16, Application US/08460890A
; Patent No. 5994109
; GENERAL INFORMATION:
; APPLICANT: Woo, Savio L.C.
; APPLICANT: Smith, Louis C.
; APPLICANT: Cristiano, Richard J.
; APPLICANT: Gottchalk, Stephen
; TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND

```

```

; TITLE OF INVENTION: METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: December 14, 1993
; FILING DATE: June 5, 1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/855,389
; FILING DATE: March 20, 1992
; APPLICATION NUMBER: PCT/US93/02725
; FILING DATE: March 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/066
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: Other nucleic acid
; FEATURE:
; OTHER INFORMATION: "C" stands for 5-methylcytosine
; US-08-167-641C-2

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2,2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCCTCCTCT 940
Db 2 TTCTCCTCT 11

RESULT 333
US-08-167-641C-16
; Sequence 16, Application US/08167641C
; Patent No. 6033884
; GENERAL INFORMATION:
; APPLICANT: Woo, Savio L.C.
; APPLICANT: Smith, Louis C.
; APPLICANT: Cristiano, Richard J.
; APPLICANT: Gottchalk, Stephen
; TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
; METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/167,641C
; FILING DATE: December 14, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/855,389
; FILING DATE: March 20, 1992
; APPLICATION NUMBER: PCT/US93/02725
; FILING DATE: March 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: Other nucleic acid
; FEATURE:
; OTHER INFORMATION: "C" stands for 5-methylcytosine
; US-08-167-641C-2

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2,2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCCTCCTCT 940
Db 2 TTCTCCTCT 11

RESULT 334
US-08-167-641C-16
; Sequence 16, Application US/08167641C
; Patent No. 6033884
; GENERAL INFORMATION:
; APPLICANT: Woo, Savio L.C.
; APPLICANT: Smith, Louis C.
; APPLICANT: Cristiano, Richard J.
; APPLICANT: Gottchalk, Stephen
; TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
; METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/167,641C
; FILING DATE: December 14, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/855,389
; FILING DATE: March 20, 1992
; APPLICATION NUMBER: PCT/US93/02725
; FILING DATE: March 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/066
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: Other nucleic acid
; FEATURE:
; OTHER INFORMATION: "C" stands for 5-methylcytosine
; US-08-167-641C-2

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2,2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCCTCCTCT 940
Db 2 TTCTCCTCT 11

RESULT 333
US-08-167-641C-2
; Sequence 2, Application US/08167641C
; Patent No. 6033884
; GENERAL INFORMATION:
; APPLICANT: Woo, Savio L.C.
; APPLICANT: Smith, Louis C.
; APPLICANT: Cristiano, Richard J.
; APPLICANT: Gottchalk, Stephen
; TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
; METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
```

```
;
; FILING DATE: December 14, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/855,389
; FILING DATE: March 20, 1992
; APPLICATION NUMBER: PCT/US93/02725
; FILING DATE: March 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; FEATURE:
; OTHER INFORMATION: "C" stands for 5-methylcytosine
;
; US-08-167-641C-16
;
; Query Match 11.5%; Score 8.4; DB 1; Length 11;
; Best Local Similarity 90.0%; Pred. No. 2.2e+02;
; Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 931 TCCTCTCTCT 940
; DB 2 TTCTCTCTCT 11
;
; RESULT 335
; US-08-906-691-44/c
; Sequence 44, Application US/08906691
; Patent No. 6066452
; GENERAL INFORMATION:
; APPLICANT: Weissman, Sherman M.
; APPLICANT: Nallur, Girish N.
; APPLICANT: Kulkarni, Prakash
; TITLE OF INVENTION: MULTIPLEX SELECTION TECHNIQUE FOR
; IDENTIFYING PROTEIN-BINDING SITES FOR DNA-BINDING PROTEINS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 981094
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/906,691
; FILING DATE: 31-JUL-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6066452tenburg Ph.D., Carol
; REGISTRATION NUMBER: 39,317
; REFERENCE/DOCKET NUMBER: 390036.403C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 822-4900
; TELEFAX: (206) 882-6031
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
;
; FILING DATE: December 14, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/855,389
; FILING DATE: March 20, 1992
; APPLICATION NUMBER: PCT/US93/02725
; FILING DATE: March 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; FEATURE:
; OTHER INFORMATION: "C" stands for 5-methylcytosine
;
; US-08-167-641C-16
;
; Query Match 11.5%; Score 8.4; DB 1; Length 11;
; Best Local Similarity 90.0%; Pred. No. 2.2e+02;
; Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 931 TCCTCTCTCT 940
; DB 2 TTCTCTCTCT 11
;
; RESULT 335
; US-08-906-691-44/c
; Sequence 44, Application US/08906691
; Patent No. 6066452
; GENERAL INFORMATION:
; APPLICANT: Weissman, Sherman M.
; APPLICANT: Nallur, Girish N.
; APPLICANT: Kulkarni, Prakash
; TITLE OF INVENTION: MULTIPLEX SELECTION TECHNIQUE FOR
; IDENTIFYING PROTEIN-BINDING SITES FOR DNA-BINDING PROTEINS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 981094
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/906,691
; FILING DATE: 31-JUL-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6066452tenburg Ph.D., Carol
; REGISTRATION NUMBER: 39,317
; REFERENCE/DOCKET NUMBER: 390036.403C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 822-4900
; TELEFAX: (206) 882-6031
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
;
; FILING DATE: December 14, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/855,389
; FILING DATE: March 20, 1992
; APPLICATION NUMBER: PCT/US93/02725
; FILING DATE: March 19, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-906-691-44
;
; Query Match 11.5%; Score 8.4; DB 1; Length 11;
; Best Local Similarity 90.0%; Pred. No. 2.2e+02;
; Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 925 CTTTATCCC 934
; DB 10 CGTTATCCC 1
;
; RESULT 336
; US-08-793-331-15/c
; Sequence 15, Application US/08793331
; Patent No. 6071877
; GENERAL INFORMATION:
; APPLICANT: DELECLUSE, ARMELLE
; APPLICANT: THIERY, ISABELLE
; TITLE OF INVENTION: NEW POLYPEPTIDES HAVING A TOXIC ACTIVITY AGAINST
; TITLE OF INVENTION: INSECTS OF THE DIPTERA FAMILY
; FILE REFERENCE: 0660-0116-0 PCT
; CURRENT APPLICATION NUMBER: US/08/793,331
; CURRENT FILING DATE: 1997-05-13
; EARLIER APPLICATION NUMBER: PCT/FR95/01116
; EARLIER FILING DATE: 1995-08-24
; EARLIER APPLICATION NUMBER: FR 94/10299
; EARLIER FILING DATE: 1994-08-25
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO: 15
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:RIBOSOME
; OTHER INFORMATION: BINDING SITE (FIGURE 5)
; US-08-793-331-15
;
; Query Match 11.5%; Score 8.4; DB 1; Length 11;
; Best Local Similarity 90.0%; Pred. No. 2.2e+02;
; Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 932 CCCTCTCTCT 941
; DB 11 CCCTCTCTCT 2
;
; RESULT 337
; US-08-460-971A-2
; Sequence 2, Application US/08460971A
; Patent No. 6150168
; GENERAL INFORMATION:
; APPLICANT: Woo, Savio, L.C.
; APPLICANT: Smith, Louis C.
; APPLICANT: Cristiano, Richard J.
; APPLICANT: Gottchalk, Stephen
; TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
; METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
```

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,971A
FILING DATE: June 5, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/167,641
FILING DATE: December 14, 1993
APPLICATION NUMBER: 07/855,389
FILING DATE: March 20, 1992
APPLICATION NUMBER: PCT/US93/02725
FILING DATE: March 19, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/063
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
FEATURE:
OTHER INFORMATION: "C" stands for 5-methylcytosine
US-08-460-971A-2

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCCTCCTCT 940
Db 2 TTCTCCTCT 11

RESULT 338
US-08-460-971A-16
Sequence 16, Application US/08460971A
Patent No. 6150168
GENERAL INFORMATION:
APPLICANT: Woo, Savio L.C.
APPLICANT: Smith, Louis C.
APPLICANT: Cristiano, Richard J.
APPLICANT: Gottchalk, Stephen
TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
METHODS OF USE
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,971A
FILING DATE: June 5, 1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/167,641
FILING DATE: December 14, 1993
APPLICATION NUMBER: 07/855,389
FILING DATE: March 20, 1992
APPLICATION NUMBER: PCT/US93/02725
FILING DATE: March 19, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/063
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
FEATURE:
OTHER INFORMATION: "C" stands for 5-methylcytosine
US-08-460-971A-16

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 931 TCCCTCCTCT 940
Db 2 TTCTCCTCT 11

RESULT 339
US-08-462-040-2
Sequence 2, Application US/08462040
Patent No. 6177554
GENERAL INFORMATION:
APPLICANT: Woo, Savio L.C.
APPLICANT: Smith, Louis C.
APPLICANT: Cristiano, Richard J.
APPLICANT: Gottchalk, Stephen
TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
METHODS OF USE
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,040
FILING DATE: June 5, 1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/167,641
FILING DATE: December 14, 1993
APPLICATION NUMBER: 07/855,389
FILING DATE: March 20, 1992
APPLICATION NUMBER: PCT/US93/02725
FILING DATE: March 19, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
FEATURE:
OTHER INFORMATION: "C" stands for 5-methylcytosine
US-08-462-040-2

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 TCCTCTCTCT 940
DB 2 TTCTCTCTCT 11

RESULT 340
US-08-462-040-16
Sequence 16, Application US/08462040
Patent No. 6177554
GENERAL INFORMATION:
APPLICANT: Woo, Savio L. C.
APPLICANT: Smith, Louis C.
APPLICANT: Cristiano, Richard J.
APPLICANT: Gottchalk, Stephen
TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND
TITLE OF INVENTION: METHODS OF USE
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/462,040
FILING DATE: June 5, 1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/167,641
FILING DATE: December 14, 1993
APPLICATION NUMBER: 07/855,389
FILING DATE: March 20, 1992
APPLICATION NUMBER: PCT/US93/02725
FILING DATE: March 19, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:

LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
FEATURE:
OTHER INFORMATION: "C" stands for 5-methylcytosine
US-08-462-040-16

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 TCCTCTCTCT 940
DB 2 TTCTCTCTCT 11

RESULT 341
US-08-722-015A-4/c
Sequence 4, Application US/08722015A
Patent No. 6379881
GENERAL INFORMATION:
APPLICANT: Fouchier, Ronaldus A. M.
APPLICANT: Schuitemaker, Johanna
TITLE OF INVENTION: NUCLEIC ACIDS AND METHODS FOR THE DISCRIMINATION BETWEEN SYNCYTII
TITLE OF INVENTION: INDUCING AND NON SYNCYTII INDUCING VARIANTS OF THE HUMAN IMMUNO
FILE REFERENCE: 9250.25
CURRENT APPLICATION NUMBER: US/08/722,015A
CURRENT FILING DATE: 1996-11-19
NUMBER OF SEQ ID NOS: 258
SOFTWARE: Patent in version 3.1
SEQ ID NO: 4
LENGTH: 11
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide.
US-08-722-015A-4

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 905 TCATTTTCTT 914
DB 11 TCTTTTCTT 2

RESULT 342
US-09-358-664-1
Sequence 1, Application US/09358664
Patent No. 6495320
GENERAL INFORMATION:
APPLICANT: LOCKHART, DAVID J.
APPLICANT: LAI, CHAO-QIANG
APPLICANT: GUNDERSON, KEVIN
TITLE OF INVENTION: EVEN LENGTH PROPORTIONAL AMPLIFICATION OF NUCLEIC ACIDS
FILE REFERENCE: 23879.0004
CURRENT APPLICATION NUMBER: US/09/358,664
CURRENT FILING DATE: 1999-07-21
NUMBER OF SEQ ID NOS: 1
SOFTWARE: Patent in Ver. 2.1
SEQ ID NO: 1
LENGTH: 11
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Homopyrimidine
OTHER INFORMATION: Oligonucleotide
US-09-358-664-1

Query Match 11.5%; Score 8.4; DB 1; Length 11;

Best Local Similarity 90.0%; Pred. No. 2.2e+02; Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 TCCTCTCTCT 940
Db 2 TCCTCTCTCT 11

RESULT 343
5422251-1/c
; Patent NO. 5422251
; APPLICANT: FRESCO, JACQUES R.
; TITLE OF INVENTION: TRIPLE-STRANDED NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 4
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/187,890
; FILING DATE: 28-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 841,218
; FILING DATE: 27-FEB-1992
; APPLICATION NUMBER: 622,330
; FILING DATE: 27-NOV-1990
; APPLICATION NUMBER: 366,244
; FILING DATE: 09-JUN-1989
; APPLICATION NUMBER: 935,047
; FILING DATE: 26-NOV-1986
; SEQ ID NO:1:
; LENGTH: 11
5422251-1

Query Match 11.5%; Score 8.4; DB 1; Length 11;
Best Local Similarity 90.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTCTCTCTC 942
Db 10 CCTCTCTCTC 1

RESULT 344
US-07-668-517-44
; Sequence 44, Application US/07668517
; Patent No. 5262309
; GENERAL INFORMATION:
; APPLICANT: SATOSHI NAKAMURA et al.
; TITLE OF INVENTION: No. 5262309el Physiologically Active
; TITLE OF INVENTION: Polypeptide, Recombinant Plasmid, Recombinant Microorganism
; TITLE OF INVENTION: Cell, Pharmaceutical Composition and Method of Recovering
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wenderoth, Lind & Ponack
; STREET: 805 Fifteenth Street, N.W., #700
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 500 Kb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: DisplayWrite
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/668,517
; FILING DATE: 19910322
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Matthew Jacob
; REGISTRATION NUMBER: 25,154
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-371-8850
TELEFAX: 202-371-8856
TELEX:
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: circular
; FEATURE:
; NAME/KEY:
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION:
US-07-668-517-44

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 905 TCATTTCTT 914
Db 2 TTATTTCTT 11

RESULT 345
US-08-031-147A-20/c
; Sequence 20, Application US/08031147A
; Patent No. 5514577
; GENERAL INFORMATION:
; APPLICANT: Draper et al.
; TITLE OF INVENTION: Oligonucleotide Therapies for
; TITLE OF INVENTION: Modulating the Effects of Herpesviruses
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5514577ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/031,147A
; FILING DATE: March 12, 1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 485,297
; FILING DATE: February 26, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 852,132
; FILING DATE: April 28, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 954,185
; FILING DATE: September 29, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0469
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

ANTI-SENSE: yes
US-08-031-147A-20

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 CCTGGTGCAT 908
DB 11 CCCCCTGCAT 2

RESULT 346

US-08-211-820-5
Sequence 5, Application US/08211820
Patent No. 553859
GENERAL INFORMATION:
APPLICANT: Prockop, Darwin J.
APPLICANT: Ala-Kokko, Leena
APPLICANT: Fertala, Andrzej
APPLICANT: Sieron, Aleksander
APPLICANT: Kivirikko, Kari I.
APPLICANT: Geddis, Amy
TITLE OF INVENTION: Synthesis of Human Procollagens
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5593859ris
STREET: One Liberty place, 46th floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/211,820
FILING DATE: 11-AUG-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/09061
FILING DATE: 22-OCT-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/780,899
FILING DATE: 23-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: Deluga, Mark
REGISTRATION NUMBER: 33,229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..12
US-08-211-820-5

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 CCTGGTGCAT 908
DB 3 CCCCCTGCAT 12

RESULT 347

US-08-173-489C-315/c
Sequence 315, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS: PROFILE DIAGNOSTIC SCIENCES, INC.,
ADDRESSEE: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 315:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 16s rRNA gene from Haemophilus
DESCRIPTION: influenzae (Accession # M35019, M59433)
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Haemophilus influenzae
PUBLICATION INFORMATION:
AUTHORS: Dewhirst, F E, Paster, B J, La Fontaine,
AUTHORS: S, Rood, J I.
TITLE: Transfer of Kingella
TITLE: indologenes (Shell and Lapage 1976) to the
TITLE: genus Suttoneella gen nov as Suttoneella
TITLE: indologenes comb nov transfer of Bacteroides
TITLE: nodosus (Beveridge 1941) to the genus
TITLE: Dichelobacter gen nov as Dichelobacter nodosus
TITLE: comb nov.
JOURNAL: unpublished
VOLUME:
PAGES:
DATE: 1991
RELEVANT RESIDUES IN SEQ ID NO: 315 :FROM 1 TO 12
US-08-173-489C-315

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 936 CCTCTTCATT 945

```
Db      11 CTTCTTCATT 2

RESULT 348
US-08-403-888A-4/c
; Sequence 4, Application US/08403888A
; Patent No. 5952490
; GENERAL INFORMATION:
; APPLICANT: Hanecak et al.
; TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
; TITLE OF INVENTION: Sequence
; NUMBER OF SEQUENCES: 146
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/403,888A
; FILING DATE: 12-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/954,185
; FILING DATE: 29-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul K. Legaard
; REGISTRATION NUMBER: 38,534
; REFERENCE/DOCKET NUMBER: ISIS-1229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-403-888A-4

Query Match      11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches      9; Conservative      0; Mismatches      1; Indels      0; Gaps      0;

Qy      899 CCTCGTGCAT 908
Db      11 CCCCGGTGAT 2

RESULT 349
US-08-676-782-15
; Sequence 15, Application US/08676782
; Patent No. 5976792
; GENERAL INFORMATION:
; APPLICANT: CHEUNG, Ambrose
; APPLICANT: FISCHETTI, Vincent A.
; TITLE OF INVENTION: REGULATION OF EXOPROTEIN IN
; TITLE OF INVENTION: STAPHYLOCOCCUS AUREUS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404

Query Match      11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches      9; Conservative      0; Mismatches      1; Indels      0; Gaps      0;

Qy      905 TCATTTTCCT 914
Db      2 TCATCTTCCT 11

RESULT 350
US-08-442-809A-27
; Sequence 27, Application US/08442809A
; Patent No. 5978873
; GENERAL INFORMATION:
; APPLICANT: Bohinski, Robert J.,
; APPLICANT: Whitsett, Jeffrey A.
; TITLE OF INVENTION: Nucleic Acid Sequences
; TITLE OF INVENTION: Controlling Lung Cell -
; TITLE OF INVENTION: Specific Gene Expression
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/442,809A
; FILING DATE: 17-MAY-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,356
; FILING DATE: 18-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 271010-360
; TELECOMMUNICATION INFORMATION:
```

TELEPHONE: 201-994-1700
TELEFAX: 201-994-1744
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-08-442-803A-27

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 917 GTCCTTGCCT 926
||| |||||
Db 3 GGTGTTGCCT 12

RESULT 351
US-08-474-700B-22
Sequence 22, Application US/08474700B
Patent No. 6001990
GENERAL INFORMATION:
APPLICANT: Wands, Jack
APPLICANT: Wakita, Takaji
APPLICANT: Moradpour, Darius
TITLE OF INVENTION: ANTISENSE INHIBITION OF HEPATITIS C
TITLE OF INVENTION: ANTISENSE INHIBITION OF HEPATITIS C
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 502 or 55SX
OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,700B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/240,382
FILING DATE: 10 May 1994
ATTORNEY/AGENT INFORMATION:
NAME: Fraser, Janis K.
REGISTRATION NUMBER: 34,819
REFERENCE/DOCKET NUMBER: 00786/279001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-474-700B-22

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 913 TTGTGCTCTT 922
|||||
Db 1 TTGTGCTTTT 10

RESULT 352
US-08-874-825-89
Sequence 89, Application US/08874825
Patent No. 6057101
GENERAL INFORMATION:
APPLICANT: Nandabalan, Krishnan
APPLICANT: Rothberg, Jonathan
APPLICANT: Yang, Meijia
APPLICANT: Knight, James
APPLICANT: Kalbfleisch, Theodore
TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF
TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS
TITLE OF INVENTION: AND IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
NUMBER OF SEQUENCES: 122
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036/2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/874,825
FILING DATE: 13-JUN-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/663,824
FILING DATE: 14-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Misrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-045
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9030
TELEFAX: 212-869-8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 89:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-874-825-89

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 935 TCCTCTTCAT 944
|||||
Db 2 TACTCTTCAT 11

RESULT 353
US-08-663-824-89
Sequence 89, Application US/08663824
Patent No. 6083693
GENERAL INFORMATION:
APPLICANT: Nandabalan, Krishnan
APPLICANT: Rothberg, Jonathan
TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS
FILE REFERENCE: 7934-006
CURRENT APPLICATION NUMBER: US/08/663,824
CURRENT FILING DATE: 1996-06-14
NUMBER OF SEQ ID NOS: 118

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 89
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-08-663-824-89

Query Match      11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 935 TCCTCTTCAT 944
Db 2 TACTCTTCAT 11

RESULT 354
US-09-393-783A-39/c
; Sequence 39, Application US/09393783A
; Patent No. 6355428
; GENERAL INFORMATION:
; APPLICANT: Schroth, Gary P. Wayne
; APPLICANT: Bruice, Thomas Wayne
; APPLICANT: Suh, Young J.
; TITLE OF INVENTION: Nucleic Acid Ligand Interaction Assays
; FILE REFERENCE: 4600-0128.30
; CURRENT APPLICATION NUMBER: US/09/393,783A
; CURRENT FILING DATE: 1999-10-09
; PRIOR APPLICATION NUMBER: US 09/151,890
; PRIOR FILING DATE: 1998-09-11
; NUMBER OF SEQ ID NOS: 80
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc.binding
; LOCATION: (1)...(12)
; OTHER INFORMATION: synthesized test oligonucleotide for binding
; OTHER INFORMATION: studies
US-09-393-783A-39

Query Match      11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 908 TTTCTTTGG 917
Db 10 TTTTITTTGG 1

RESULT 355
US-09-231-303-89
; Sequence 89, Application US/09231303
; Patent No. 6395478
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
; TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS AND
; TITLE OF INVENTION: IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
; FILE REFERENCE: 7934-087
; CURRENT APPLICATION NUMBER: US/09/231,303
; CURRENT FILING DATE: 1999-01-12
; EARLIER APPLICATION NUMBER: 08/663,824
; EARLIER FILING DATE: 1996-06-14
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 89
; LENGTH: 12
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-231-303-89

Query Match      11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 935 TCCTCTTCAT 944
Db 2 TACTCTTCAT 11

RESULT 356
US-09-513-783A-55
; Sequence 55, Application US/09513783A
; Patent No. 6416959
; GENERAL INFORMATION:
; APPLICANT: Giuliano, Kenneth A.
; APPLICANT: Kapur, Ravi
; TITLE OF INVENTION: A System for Cell Based Screening
; FILE REFERENCE: 97-022-L1
; CURRENT APPLICATION NUMBER: US/09/513,783A
; CURRENT FILING DATE: 2000-02-25
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: proCaspase-1
; OTHER INFORMATION: substrate recognition sequence
US-09-513-783A-55

Query Match      11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 945 TGGTTTAATG 954
Db 1 TGGTTTAAG 10

RESULT 357
US-09-151-890B-39/c
; Sequence 39, Application US/09151890B
; Patent No. 6420109
; GENERAL INFORMATION:
; APPLICANT: Gary P. Schroth
; APPLICANT: Thomas Wayne Bruice
; APPLICANT: Young J. Suh
; TITLE OF INVENTION: Nucleic Acid Ligand Interaction Assays
; FILE REFERENCE: 4600-0128
; CURRENT APPLICATION NUMBER: US/09/151,890B
; CURRENT FILING DATE: 1998-09-11
; NUMBER OF SEQ ID NOS: 80
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc.binding
; LOCATION: (1)...(12)
; OTHER INFORMATION: synthesized test oligonucleotide for binding
; OTHER INFORMATION: studies
US-09-151-890B-39

Query Match      11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 945 TGGTTTAATG 954
Db 1 TGGTTTAAG 10
```

```
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 908 TTTTCTTTGG 917
Db 10 TTTTCTTTGG 1

RESULT 358
US-09-324-803C-7
; Sequence 7, Application US/09324803C
; Patent No. 6420547
; GENERAL INFORMATION:
; APPLICANT: MAITI, Indu B.
; APPLICANT: DEY, Nrisingha
; APPLICANT: SHEPHERD, Robert J.
; TITLE OF INVENTION: USE OF THE FULL LENGTH TRANSCRIPT (FLT) FROM
; TITLE OF INVENTION: MIRABILIS MOSAIC CAULIMOVIRUS TO EXPRESS CHIMERIC GENES IN PLANT
; FILE REFERENCE: 50229-148
; CURRENT APPLICATION NUMBER: US/09/324,803C
; CURRENT FILING DATE: 1999-06-03
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 7
; LENGTH: 12
; TYPE: DNA (promoter)
; ORGANISM: mirabilis mosaic caulimovirus
US-09-324-803C-7

Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 931 TCCTCTCTCT 940
Db 3 TCCTCTCTCT 12

RESULT 359
PCT-US94-02471-20/c
; Sequence 20, Application PC/TUS9402471
; GENERAL INFORMATION:
; APPLICANT: Draper et al.
; TITLE OF INVENTION: Oligonucleotide Therapies for
; TITLE OF INVENTION: Modulating the Effects of Herpesviruses
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02471
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION NUMBER: 485,297
FILING DATE: February 26, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 852,132
FILING DATE: April 28, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 954,185
FILING DATE: September 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
```

```
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0469
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: yes
; PCT-US94-02471-20
Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 899 CCTGCTCAT 908
Db 11 CCTGCTCAT 2

RESULT 360
PCT-US95-05812-22
; Sequence 22, Application PC/TUS9505812
; GENERAL INFORMATION:
; APPLICANT: Wakita, Takaji
; APPLICANT: Wands, Jack
; TITLE OF INVENTION: ANTISENSE INHIBITION OF
; TITLE OF INVENTION: HEPATITIS C VIRUS
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 502 or 55SX
OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: Wordperfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/05812
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/240,382
FILING DATE: 10 May 1994
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Paul T.
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 00786/221001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US95-05812-22
Query Match 11.5%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 913 TTTGCTTTT 922
Db 11 TTTGCTTTT 12
```

[illegible]

US-08-859-954-285

Query Match 11.0%; Score 8; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 901 CTGGTCAT 908
|||||
Db 1 CTGGTCAT 8

RESULT 364

US-08-859-954-309
; Sequence 309, Application US/08859954
; Patent No. 6083695

; GENERAL INFORMATION:

; APPLICANT: Hardin, Susan H.

; APPLICANT: Homayouni, Ramin

; APPLICANT: Hardin, Paul E.

; TITLE OF INVENTION: Design and Optimized Primer Library for
; TITLE OF INVENTION: Gene Sequencing and Method Thereof

; NUMBER OF SEQUENCES: 566

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fulbright & Jaworski L.L.P.

; STREET: 1301 McKinney, Suite 5100

; CITY: Houston

; STATE: Texas

; COUNTRY: U.S.A.

; ZIP: 77010-3095

; COMPUTER READABLE FORM:

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/859,954

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/632,782

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Paul, Thomas D.

; REGISTRATION NUMBER: 32,714

; REFERENCE/DOCKET NUMBER: D-5900

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 713/651-5325

; TELEFAX: 713/651-5246

; INFORMATION FOR SEQ ID NO: 309:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 8 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: other nucleic acid

; DESCRIPTION: /desc = "oligonucleotide"

; HYPOTHETICAL: YES

; ANTI-SENSE: YES

US-08-859-954-309

Query Match 11.0%; Score 8; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 934 CTCCTCTT 941
|||||
Db 1 CTCCTCTT 8

RESULT 365

US-08-021-667A-4/c
; Sequence 4, Application US/08021667A
; Patent No. 5434049

; GENERAL INFORMATION:

; APPLICANT: Okano, Kazunori

; APPLICANT: Kambata, Hideki

; TITLE OF INVENTION: POLYNUCLEOTIDE CAPTURING TIP AND

; TITLE OF INVENTION: POLYNUCLEOTIDE PREPARATIVE METHOD AND DETECTION

; TITLE OF INVENTION: METHOD USING SAME

; NUMBER OF SEQUENCES: 18

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Antonelli, Terry, Stout & Kraus

; STREET: Suite 600, 1919 Pennsylvania Ave., NW

; CITY: Washington

; STATE: DC

; COUNTRY: USA

; ZIP: 20006

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/021,667A

; FILING DATE: 19930224

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Terry, David T.

; REGISTRATION NUMBER: 20,178

; REFERENCE/DOCKET NUMBER: 520.31930X00

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 202-828-0300

; TELEFAX: 202-828-0380

; TELEX: 440280/248545

; INFORMATION FOR SEQ ID NO: 4:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 9 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)

; HYPOTHETICAL: YES

; ANTI-SENSE: NO

US-08-021-667A-4

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 952 ATGTATCG 959
|||||
Db 9 ATGTATCG 2

RESULT 366

US-08-095-162-13/c

; Sequence 13, Application US/08095162

; Patent No. 551459

; GENERAL INFORMATION:

; APPLICANT: Wagner, Fred W.

; APPLICANT: Stout, Jay

; APPLICANT: Henriksen, Dennis

; APPLICANT: Partridge, Bruce

; APPLICANT: Manning, Shane

; TITLE OF INVENTION: Enzymatic Method for Modification of

; TITLE OF INVENTION: Recombinant Polypeptides

; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Merchant & Gould

; STREET: 3100 No. 5512459west Center

; CITY: Minneapolis

; STATE: MN

; COUNTRY: USA

; ZIP: 55402

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/095,162
FILING DATE: 20-JUL-1993
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, Albin J.
REGISTRATION NUMBER: 28,659
REFERENCE/DOCKET NUMBER: 8648.32-US01
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
IMMEDIATE SOURCE:
CLONE: Ubiquitin cleaving enzyme
US-08-095-162-13

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CCTCCTCT 940
DB 8 CCTCCTCT 1

RESULT 367
US-08-410-544-4/c
Sequence 4, Application US/08410544
Patent No. 5607646
GENERAL INFORMATION:
APPLICANT: Okano, Kazunori
APPLICANT: Kambara, Hideki
TITLE OF INVENTION: POLYNUCLEOTIDE CAPTURING TIP AND
TITLE OF INVENTION: POLYNUCLEOTIDE PREPARATIVE METHOD AND DETECTION
TITLE OF INVENTION: METHOD USING SAME
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Antonelli, Terry, Stout & Kraus
STREET: Suite 600, 1919 Pennsylvania Ave., NW
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER: US/08/410,544
APPLICATION NUMBER: 08/021,667
FILING DATE: 24-FEB-1993
ATTORNEY/AGENT INFORMATION:
NAME: Terry, David T.
REGISTRATION NUMBER: 20,178
REFERENCE/DOCKET NUMBER: 520.31930X00
TELEPHONE: 202-828-0300
TELEFAX: 202-828-0380
TELEX: 248545
INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: YES
ANTI-SENSE: NO
US-08-410-544-4

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 952 ATGTATCG 959
DB 9 ATGTATCG 2

RESULT 368
US-08-470-220A-13/c
Sequence 13, Application US/08470220A
Patent No. 5707826
GENERAL INFORMATION:
APPLICANT: Wagner, Fred W.
APPLICANT: Stout, Jay
APPLICANT: Henriksen, Dennis
APPLICANT: Partridge, Bruce
APPLICANT: Manning, Shane
TITLE OF INVENTION: Enzymatic Method for Modification of
TITLE OF INVENTION: Recombinant Polypeptides
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould
STREET: 3100 No. 5707826west Center
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/470,220A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER: US 08/095,162
APPLICATION NUMBER: 20-JUL-1993
FILING DATE: 20-JUL-1993
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, Albin J.
REGISTRATION NUMBER: 28,659
REFERENCE/DOCKET NUMBER: 8648.32-US01
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
IMMEDIATE SOURCE:
CLONE: Ubiquitin cleaving enzyme
US-08-470-220A-13

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CTTCTCT 940
Db 8 CTTCTCT 1

RESULT 369
US-08-728-785A-4/c
; Sequence 4, Application US/08728785A
; Patent No. 5917506
; GENERAL INFORMATION:
; APPLICANT: Okano, Kazunori
; APPLICANT: Kambara, Hideki
; TITLE OF INVENTION: POLYNUCLEOTIDE CAPTURING TIP AND
; TITLE OF INVENTION: POLYNUCLEOTIDE PREPARATIVE METHOD AND DETECTION
; TITLE OF INVENTION: METHOD USING SAME
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Antonelli, Terry, Stout & Kraus
; STREET: Suite 1800, 1300 No. 5817506th Seventeenth St.
; CITY: Arlington
; STATE: VA
; COUNTRY: USA
; ZIP: 22209
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/728,785A
; FILING DATE: 10-OCT-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,544
; FILING DATE: 21-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/021,667
; FILING DATE: 24-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Terry, David T.
; REGISTRATION NUMBER: 20,178
; REFERENCE/DOCKET NUMBER: 520.31930X00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-312-6600
; TELEFAX: 703-312-6666
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; TYPE: 9 base pairs
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ANTI-SENSE: NO
US-08-728-785A-4

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 952 ATGTATCG 959
Db 9 ATGTATCG 2

RESULT 370
US-08-680-350-2/c
; Sequence 2, Application US/08680350
; Patent No. 5955590
; GENERAL INFORMATION:
; APPLICANT: Levina, Asya
; APPLICANT: Zamecnik, Paul C
; TITLE OF INVENTION: Conjugates of Minor Groove DNA Binders
; TITLE OF INVENTION: with Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks PC
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/680,350
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Kindregan, Helen C

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 TGGTTTAA 952
Db 9 TGGTTTAA 2

RESULT 371
US-08-680-350-8/c
; Sequence 8, Application US/08680350
; Patent No. 5955590
; GENERAL INFORMATION:
; APPLICANT: Levina, Asya
; APPLICANT: Zamecnik, Paul C
; TITLE OF INVENTION: Conjugates of Minor Groove DNA Binders
; TITLE OF INVENTION: with Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks PC
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/680,350
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Kindregan, Helen C

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 TGGTTTAA 952
Db 9 TGGTTTAA 2

RESULT 371
US-08-680-350-8/c
; Sequence 8, Application US/08680350
; Patent No. 5955590
; GENERAL INFORMATION:
; APPLICANT: Levina, Asya
; APPLICANT: Zamecnik, Paul C
; TITLE OF INVENTION: Conjugates of Minor Groove DNA Binders
; TITLE OF INVENTION: with Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks PC
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/680,350
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Kindregan, Helen C

REGISTRATION NUMBER: 39,248
REFERENCE/DOCKET NUMBER: W0461/7040
TELEPHONE: 617-720-3500
TELEFAX: 617-720-2441
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Oligodeoxyribonucleotide
HYPOTHETICAL: YES
ANTI-SENSE: NO
US-08-680-350-8

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 TGGTTTAA 952
DB 9 TGGTTTAA 2

RESULT 372

US-08-680-350-13
Sequence 13, Application US/08680350
Patent No. 5955590
GENERAL INFORMATION:
APPLICANT: Levina, Asya
APPLICANT: Zamecnik, Paul C
TITLE OF INVENTION: Conjugates of Minor Groove DNA Binders
TITLE OF INVENTION: with Antisense Oligonucleotides
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wolf, Greenfield & Sacks PC
STREET: 600 Atlantic Avenue
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/680,350
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Kindregan, Helen C
REGISTRATION NUMBER: 39,248
REFERENCE/DOCKET NUMBER: W0461/7040
TELEPHONE: 617-720-3500
TELEFAX: 617-720-2441
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Oligodeoxyribonucleotide
HYPOTHETICAL: YES
ANTI-SENSE: NO
US-08-680-350-13

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 TGGTTTAA 952
DB 1 TGGTTTAA 8

RESULT 373

US-08-680-350-15/c
Sequence 15, Application US/08680350
Patent No. 5955590
GENERAL INFORMATION:
APPLICANT: Levina, Asya
APPLICANT: Zamecnik, Paul C
TITLE OF INVENTION: Conjugates of Minor Groove DNA Binders
TITLE OF INVENTION: with Antisense Oligonucleotides
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wolf, Greenfield & Sacks PC
STREET: 600 Atlantic Avenue
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/680,350
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Kindregan, Helen C
REGISTRATION NUMBER: 39,248
REFERENCE/DOCKET NUMBER: W0461/7040
TELEPHONE: 617-720-3500
TELEFAX: 617-720-2441
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Oligodeoxyribonucleotide
HYPOTHETICAL: YES
ANTI-SENSE: NO
US-08-680-350-15

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 TGGTTTAA 952
DB 9 TGGTTTAA 2

RESULT 374

US-08-967-374-13/c
Sequence 13, Application US/08967374
Patent No. 6037143
GENERAL INFORMATION:
APPLICANT: Wagner, Fred W.
APPLICANT: Stout, Jay
APPLICANT: Henriksen, Dennis
APPLICANT: Partridge, Bruce
APPLICANT: Manning, Shane
TITLE OF INVENTION: Enzymatic Method for Modification of
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould

STREET: 3100 No. 6037143west Center
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/967,374
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/520,485
FILING DATE: 29-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Carter, Charles G.
REGISTRATION NUMBER: 35,093
REFERENCE/DOCKET NUMBER: 8648.32-USD1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLSCULE TYPE: DNA (genomic)
IMMEDIATE SOURCE:
CLONE: Ubiquitin cleaving enzyme
US-08-967-374-13

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CCTCTCT 940
Db 8 CCTCTCT 1

RESULT 375
US-08-297-395-62
Sequence 62, Application US/08297395A
Patent No. 6039947
GENERAL INFORMATION:
APPLICANT: Howard L. Weiner
APPLICANT: David A. Hafler
TITLE OF INVENTION: PEPTIDES DERIVED FROM IMMUNODOMINANT
FILE REFERENCE: 1010/05723US3
CURRENT APPLICATION NUMBER: US/08/297,395A
CURRENT FILING DATE: 1994-08-11
EARLIER APPLICATION NUMBER: 08/059,189
EARLIER FILING DATE: 1993-05-06
EARLIER APPLICATION NUMBER: 07/502,559
EARLIER FILING DATE: 1990-03-30
EARLIER APPLICATION NUMBER: PCT/US88/02139
EARLIER FILING DATE: 1988-06-24
EARLIER APPLICATION NUMBER: 07/065,734
EARLIER FILING DATE: 1987-06-24
NUMBER OF SEQ ID NOS: 84
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 62
LENGTH: 9
TYPE: DNA
ORGANISM: Homo sapiens
US-08-297-395-62

Query Match 11.0%; Score 8; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 930 ATCCCTCC 937
Db 1 ATCCCTCC 8

RESULT 376
US-09-063-450-9
Sequence 9, Application US/09063450
Patent No. 6109776
GENERAL INFORMATION:
APPLICANT: Gene Logic, Inc.
TITLE OF INVENTION: Method and System for Computationally Identifying
FILE REFERENCE: 77001.002
CURRENT APPLICATION NUMBER: US/09/063,450
CURRENT FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 38
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 9
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: example
OTHER INFORMATION: sequence illustrating a computational methodology
US-09-063-450-9

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 955 TATCGCTA 962
Db 1 TATCGCTA 8

RESULT 377
US-09-505-991-13/c
Sequence 13, Application US/09505991
Patent No. 6403361
GENERAL INFORMATION:
APPLICANT: Wagner, Fred W.
Stout, Jay
Henriksen, Dennis
Partridge, Bruce
Manning, Shane
TITLE OF INVENTION: Enzymatic Method for Modification of
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould
STREET: 3100 No. 6403361west Center
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/505,991
FILING DATE: 17-Feb-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/520,485
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Carter, Charles G.

```
/
/ REGISTRATION NUMBER: 35,093
/ REFERENCE/DOCKET NUMBER: 8648.32-USD1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 612-332-5300
/ TELEFAX: 612-332-9081
/ INFORMATION FOR SEQ ID NO: 13:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 9 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ IMMEDIATE SOURCE:
/ CLONE: Ubiquitin cleaving enzyme
/ SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-505-991-13

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 CTTCTCTC 940
Db 8 CTTCTCTC 1

RESULT 378
US-09-989-789-537/c
/ Sequence 537, Application US/09989789
/ Patent No. 6588746
/ GENERAL INFORMATION:
/ APPLICANT: LIU, Qiang
/ TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
/ FILE REFERENCE: 8325-0011.20 / S11-US2
/ CURRENT APPLICATION NUMBER: US/09/989,789
/ CURRENT FILING DATE: 2002-03-25
/ NUMBER OF SEQ ID NOS: 4085
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 537
/ LENGTH: 9
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: example target
US-09-989-789-537

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 935 TCCTCTTC 942
Db 8 TCCTCTTC 1

RESULT 379
US-09-989-789-538/c
/ Sequence 538, Application US/09989789
/ Patent No. 6588746
/ GENERAL INFORMATION:
/ APPLICANT: LIU, Qiang
/ TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
/ FILE REFERENCE: 8325-0011.20 / S11-US2
/ CURRENT APPLICATION NUMBER: US/09/989,789
/ CURRENT FILING DATE: 2002-03-25
/ NUMBER OF SEQ ID NOS: 4085
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 538
/ LENGTH: 9
/ TYPE: DNA

/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: example target
US-09-989-789-538

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 935 TCCTCTTC 942
Db 8 TCCTCTTC 1

RESULT 380
PCT-US91-03680-85
/ Sequence 85, Application PC/TUS9103680
/ GENERAL INFORMATION:
/ APPLICANT: Matteucci, Mark D.
/ APPLICANT: Krawczyk, Steven
/ TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
/ TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
/ TITLE OF INVENTION: DUPLEX DNA
/ NUMBER OF SEQUENCES: 158
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Morrison & Forster
/ STREET: 545 Middlefield Road, Suite 200
/ CITY: Menlo Park
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94025
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US91/03680
/ FILING DATE: 19910524
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Murashige, Kate H.
/ REGISTRATION NUMBER: 29,959
/ REFERENCE/DOCKET NUMBER: 4610-0011.40
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-327-7250
/ TELEFAX: 415-327-2951
/ TELETYPE: 706141
/ INFORMATION FOR SEQ ID NO: 85:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 9 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: 5
/ OTHER INFORMATION: /mod_base= OTHER
/ OTHER INFORMATION: /note= "5-methylcytosine"
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: 9
/ OTHER INFORMATION: /mod_base= OTHER
/ OTHER INFORMATION: /note= "T-T, linking group o-xyloso (nucleotides
/ OTHER INFORMATION: that have xylose sugar linked via the o-xyloso
/ OTHER INFORMATION: ring)"
PCT-US91-03680-85

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 908 TTTTCTTT 915
Db 1 TTTTCTTT 8

RESULT 381
PCT-US96-01008-18/c
; Sequence 18, Application PC/TUS9601008
; GENERAL INFORMATION:
; APPLICANT: Hybridon, Inc.
; APPLICANT: Worcester Foundation for
; TITLE OF INVENTION: Experimental Biology
; TITLE OF INVENTION: Human Immunodeficiency Virus
; TITLE OF INVENTION: Transcription Inhibitors and Methods of Their Use
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/01008
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise

; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HYZ-037PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US96-01008-18

Query Match 11.0%; Score 8; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 945 TGGTTTAA 952
Db 9 TGGTTTAA 2

RESULT 382
US-08-088-658-4/c
; Sequence 4, Application US/08088658
; Patent No. 5641625
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter E.
; APPLICANT: Berg, Rolf H.
; APPLICANT: M. Illegard, Niels E.
; TITLE OF INVENTION: HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
; TITLE OF INVENTION: NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5641625ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/088,658
; FILING DATE: 19930702

; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/054,363
; FILING DATE: 26-APRIL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucci, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1052
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439

; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-08-088-658-4

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 10 TTTTCTTT 3

RESULT 383
US-08-088-658-43/c
; Sequence 43, Application US/08088658
; Patent No. 5641625
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter E.
; APPLICANT: Berg, Rolf H.
; APPLICANT: M. Illegard, Niels E.
; TITLE OF INVENTION: HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
; TITLE OF INVENTION: NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5641625ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/088,658
; FILING DATE: 19930702
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/054,363
FILING DATE: 26-APRIL-1993
ATTORNEY/AGENT INFORMATION:
NAME: LUCCL, JOSEPH
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-1052
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 43:
SEQUENCE CHARACTERISTICS:
LENGTH: 10
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-088-658-43

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0;

Qy 908 TTTTCTTT 915
Db 9 TTTTCTTT 2

RESULT 384
US-08-122-433-39/c
Sequence 39, Application US/08122433
Patent No. 5683985

GENERAL INFORMATION:
APPLICANT: Chu, Barbara C.F.
APPLICANT: Orgel, Leslie
TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES AND
TITLE OF INVENTION: OLIGONUCLEOTIDES USEFUL AS DECOYS FOR PROTEINS WHICH
TITLE OF INVENTION: SELECTIVELY BIND TO DEFINED DNA SEQUENCES
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESS: PRETTY, SCHROEDER, BRUGGEVANN & CLARK
STREET: 444 South Flower Street, Suite 2000
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/122,433
FILING DATE: 22-SEP-1993

CLASSIFICATION: 514
PRIOR APPLICATION NUMBER: US 07/687,337
APPLICATION NUMBER: US 07/687,337
FILING DATE: 18-APR-1991
ATTORNEY/AGENT INFORMATION:
NAME: Reiter, Stephen E.
REGISTRATION NUMBER: 31,192
REFERENCE/DOCKET NUMBER: P31 9308
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-546-1995
TELEFAX: 619-546-9392

INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLSCULE TYPE: other nucleic acid
US-08-122-433-39

Query Match 11.0%; Score 8; DB 1; Length 10;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 906 CATTTCCT 913
Db 8 CATTTCCT 1

RESULT 385

US-08-686-116A-49/c
Sequence 49, Application US/08686116A
Patent No. 5714331
GENERAL INFORMATION:
APPLICANT: Buchardt et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having Enhanced
TITLE OF INVENTION: Binding Affinity, Sequence Specificity
Patent No. 5714331
TITLE OF INVENTION: ans Solubility
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESS: Woodcock Washburn Kurtz Mackiewicz & No. 5714331 Iris LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/686,116A
FILING DATE: July 24, 1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/108,591
FILING DATE: 22-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Michael P. Straher
REGISTRATION NUMBER: 38,325
REFERENCE/DOCKET NUMBER: ISIS-2271
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-686-116A-49

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 10 TTTTCTTT 3

RESULT 386

US-08-686-116A-51/c
Sequence 51, Application US/08686116A
Patent No. 5714331
GENERAL INFORMATION:
APPLICANT: Buchardt et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having Enhanced
TITLE OF INVENTION: Binding Affinity, Sequence Specificity
Patent No. 5714331
TITLE OF INVENTION: ans Solubility
NUMBER OF SEQUENCES: 53

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5714331ris LLP
;; STREET: One Liberty Place - 46th Floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: WordPerfect 6.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/686,116A
;; FILING DATE: July 24, 1996
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/108,591
;; FILING DATE: 22-NOV-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Michael P. Straher
;; REGISTRATION NUMBER: 38,325
;; REFERENCE/DOCKET NUMBER: ISIS-2271
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 51:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 10 bases
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-686-116A-51

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 9 TTTTCTTT 2

RESULT 387
US-08-685-484-49/c
; Sequence 49, Application US/08685484
; Patent No. 5719262
; GENERAL INFORMATION:
; APPLICANT: Buchardt et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having Amino Acid
; TITLE OF INVENTION: Side Chains
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5719262ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/685,484
; FILING DATE: 24-JUL-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/108,591
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael P. Straher

;; REGISTRATION NUMBER: 38,325
;; REFERENCE/DOCKET NUMBER: ISIS-2270
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 49:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 10 bases
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-685-484-49

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 10 TTTTCTTT 3

RESULT 388
US-08-685-484-51/c
; Sequence 51, Application US/08685484
; Patent No. 5719262
; GENERAL INFORMATION:
; APPLICANT: Buchardt et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having Amino Acid
; TITLE OF INVENTION: Side Chains
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5719262ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/685,484
; FILING DATE: 24-JUL-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/108,591
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael P. Straher
; REGISTRATION NUMBER: 38,325
; REFERENCE/DOCKET NUMBER: ISIS-2270
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 51:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-685-484-51

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 9 TTTTCTTT 2

RESULT 389
US-08-847-108-49/c
; Sequence 49, Application US/08847108
; Patent No. 5736336
; GENERAL INFORMATION:
; APPLICANT: Buchardt et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having Enhanced
; TITLE OF INVENTION: Binding Affinity, Sequence Specificity
; Patent No. 5736336
; TITLE OF INVENTION: and Solubility
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5736336ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/847.108
; FILING DATE: 01-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/686,116
; FILING DATE: July 24, 1996
; APPLICATION NUMBER: 08/108,591
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael P. Straher
; REGISTRATION NUMBER: 38,325
; REFERENCE/DOCKET NUMBER: ISIS-2271
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-847-108-49
Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 908 TTTTCTTT 915
| | | | |
Db 10 TTTTCTTT 3
RESULT 390
US-08-847-108-51/c
; Sequence 51, Application US/08847108
; Patent No. 5736336
; GENERAL INFORMATION:
; APPLICANT: Buchardt et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having Enhanced
; TITLE OF INVENTION: Binding Affinity, Sequence Specificity
; Patent No. 5736336
; TITLE OF INVENTION: and Solubility
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5736336ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA

COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/847,108
FILING DATE: 01-MAY-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/686,116
FILING DATE: July 24, 1996
APPLICATION NUMBER: 08/108,591
FILING DATE: 22-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Michael P. Straher
REGISTRATION NUMBER: 38,325
REFERENCE/DOCKET NUMBER: ISIS-2271
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-847-108-51
Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 908 TTTTCTTT 915
| | | | |
Db 9 TTTTCTTT 2
RESULT 391
US-08-686-113A-56/c
; Sequence 56, Application US/08686113A
; Patent No. 5766855
; GENERAL INFORMATION:
; APPLICANT: Buchardt et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having Enhanced
; TITLE OF INVENTION: Affinity And Sequence Specificity
; Patent No. 5766855
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5766855ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/686,113A
; FILING DATE: July 24, 1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/108,591
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael P. Straher
; REGISTRATION NUMBER: 38,325
; REFERENCE/DOCKET NUMBER: ISIS-2273

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 215-568-3100
 TELEFAX: 215-568-3439
 INFORMATION FOR SEQ ID NO: 56:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 10 bases
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-686-113A-56

Query Match 11.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
 Db 10 TTTTCTTT 3

RESULT 392

US-08-686-113A-58/c
 Sequence 58, Application US/08686113A
 Patent No. 5766855

GENERAL INFORMATION:
 APPLICANT: Buchardt et al.
 TITLE OF INVENTION: Peptide Nucleic Acids Having Enhanced
 Affinity And Sequence Specificity

Patent No. 5766855

NUMBER OF SEQUENCES: 60

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5766855ris
 STREET: One Liberty Place - 46th Floor
 CITY: Philadelphia
 STATE: PA
 COUNTRY: U.S.A.
 ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WordPerfect 6.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/686,113A

FILING DATE: July 24, 1996

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/108,591

FILING DATE: 22-NOV-1993

ATTORNEY/AGENT INFORMATION:

NAME: Michael P. Straher

REGISTRATION NUMBER: 38,325

REFERENCE/DOCKET NUMBER: ISIS-2273

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 58:

SEQUENCE CHARACTERISTICS:

LENGTH: 10 bases

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-686-113A-58

Query Match 11.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
 Db 9 TTTTCTTT 2

RESULT 393

US-08-847-095A-49/c
 Sequence 49, Application US/08847095A
 Patent No. 5786461

GENERAL INFORMATION:

APPLICANT: Buchardt et al.

TITLE OF INVENTION: Peptide Nucleic Acids Having Amino Acid

TITLE OF INVENTION: Side Chains

NUMBER OF SEQUENCES: 53

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5786461ris LLP
 STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: U.S.A.

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch disk, 1.44 Mb

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WordPerfect 6.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/847,095A

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/685,484

FILING DATE: 24-JUL-1996

APPLICATION NUMBER: 08/108,591

FILING DATE: 22-NOV-1993

ATTORNEY/AGENT INFORMATION:

NAME: Michael P. Straher

REGISTRATION NUMBER: 38,325

REFERENCE/DOCKET NUMBER: ISIS-2270

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 49:

SEQUENCE CHARACTERISTICS:

LENGTH: 10 bases

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-847-095A-49

Query Match 11.0%; Score 8; DB 1; Length 10;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
 Db 10 TTTTCTTT 3

RESULT 394

US-08-847-095A-51/c

Sequence 51, Application US/08847095A
 Patent No. 5786461

GENERAL INFORMATION:

APPLICANT: Buchardt et al.

TITLE OF INVENTION: Peptide Nucleic Acids Having Amino Acid

TITLE OF INVENTION: Side Chains

NUMBER OF SEQUENCES: 53

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5786461ris LLP
 STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: U.S.A.

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch disk, 1.44 Mb

COMPUTER: IBM PC compatible

APPLICANT: Ecker, David J.
APPLICANT: Buchardt, Ole
APPLICANT: Egholm, Michael
APPLICANT: Nielsen, Peter E.
APPLICANT: Berg, Rolf H.
APPLICANT: M llegaard, Niels E.
TITLE OF INVENTION: HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
TITLE OF INVENTION: NUCLEIC ACIDS
NUMBER OF SEQUENCES: 56
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5986053ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,907A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/088,658
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Lucci, Joseph
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-1052
TELEPHONE: 215-568-3439
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 10
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-08-471-907A-4
Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 908 TTTTCTTT 915
Db 10 TTTTCTTT 3
RESULT 398
US-08-471-907A-43/C
Sequence 43, Application US/08471907A
Patent No. 5986053
GENERAL INFORMATION:
APPLICANT: Ecker, David J.
APPLICANT: Buchardt, Ole
APPLICANT: Egholm, Michael
APPLICANT: Nielsen, Peter E.
APPLICANT: Berg, Rolf H.
APPLICANT: M llegaard, Niels E.
TITLE OF INVENTION: HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
TITLE OF INVENTION: NUCLEIC ACIDS
NUMBER OF SEQUENCES: 56
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5986053ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,907A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/088,658
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Lucci, Joseph
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-1052
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 43:
SEQUENCE CHARACTERISTICS:
LENGTH: 10
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-471-907A-43
Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 908 TTTTCTTT 915
Db 9 TTTTCTTT 2
RESULT 399
US-08-388-353-181/C
Sequence 181, Application US/08388353
Patent No. 6010895
GENERAL INFORMATION:
APPLICANT: Deacon, Nicholas J.
APPLICANT: Learmont, Jennifer C.
APPLICANT: McPhee, Dale A.
APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 181:

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-181

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0;

Qy 934 CTCCTCTT 941
Db 10 CTCCTCTT 3

RESULT 400
US-08-388-353-227/c
; Sequence 227, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4366
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 227:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-228/c

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0;

Qy 914 TTGGTCTT 921
Db 9 TTGGTCTT 2

RESULT 402
US-08-388-353-231/c
; Sequence 231, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 231:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-231

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCATTGGT 948
DB 9 TCATTGGT 2

RESULT 403
US-08-388-353-232/c
; Sequence 232, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 232:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
```

```
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-232

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCATTGGT 948
DB 8 TCATTGGT 1

RESULT 404
US-08-388-353-273/c
; Sequence 273, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 273:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-273

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
DB 10 TTTTCTTT 3

RESULT 405
US-08-388-353-274/c
; Sequence 274, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
```

```

; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 274:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-274

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 9 TTTTCTTT 2

RESULT 406
US-08-388-353-308/c
; Sequence 308, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 309:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-309
```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 308:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-308

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 910 TTCTTTGG 917
Db 10 TTCTTTGG 3

RESULT 407
US-08-388-353-309/c
; Sequence 309, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 309:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-388-353-309
```

US-08-388-353-309

Query Match 11.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 910 TTCTTTGG 917
 |||||
 Db 9 TTCTTTGG 2

RESULT 408

US-08-488-551B-181/c
 ; Sequence 181, Application US/08488551B
 ; Patent No. 6015661
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas J. Deacon
 ; APPLICANT: Dale A. McPhee
 ; APPLICANT: David Cooper
 ; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
 ; NUMBER OF SEQUENCES: 841
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
 ; STREET: 400 GARDEN CITY PLAZA
 ; CITY: GARDEN CITY
 ; STATE: NEW YORK
 ; COUNTRY: U.S.A.
 ; ZIP: 11530-0299
 ; COMPUTER READABLE FORM:
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/488,551B
 ; FILING DATE: 07-JUN-1995
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PM3864 (AU)
 ; FILING DATE: 14-FEB-1994
 ; APPLICATION NUMBER: PM4002 (AU)
 ; FILING DATE: 21-FEB-1994
 ; APPLICATION NUMBER: PM0284 (AU)
 ; FILING DATE: 23-DEC-1994
 ; APPLICATION NUMBER: US 08/388,353
 ; FILING DATE: 14-FEB-1995
 ; APPLICATION NUMBER: PN3021/95
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: FRANK S. DIGIGLIO
 ; REFERENCE/DOCKET NUMBER: 9606Z
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (516) 742-4366
 ; TELEFAX: (516) 742-4343
 ; INFORMATION FOR SEQ ID NO: 181:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 10 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA
 ; US-08-488-551B-181

Query Match 11.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 CTCCTCTT 941
 |||||
 Db 10 CTCCTCTT 3

RESULT 409

US-08-488-551B-227/c
 ; Sequence 228, Application US/08488551B
 ; Patent No. 6015661
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas J. Deacon
 ; APPLICANT: Dale A. McPhee
 ; APPLICANT: David Cooper
 ; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
 ; NUMBER OF SEQUENCES: 841
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
 ; STREET: 400 GARDEN CITY PLAZA
 ; CITY: GARDEN CITY
 ; STATE: NEW YORK

Query Match 11.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 CTCCTCTT 941
 |||||
 Db 10 CTCCTCTT 3

RESULT 410

US-08-488-551B-228/c
 ; Sequence 228, Application US/08488551B
 ; Patent No. 6015661
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas J. Deacon
 ; APPLICANT: Dale A. McPhee
 ; APPLICANT: David Cooper
 ; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
 ; NUMBER OF SEQUENCES: 841
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
 ; STREET: 400 GARDEN CITY PLAZA
 ; CITY: GARDEN CITY
 ; STATE: NEW YORK

RESULT 410

US-08-488-551B-227/c
 ; Sequence 228, Application US/08488551B
 ; Patent No. 6015661
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas J. Deacon
 ; APPLICANT: Dale A. McPhee
 ; APPLICANT: David Cooper
 ; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
 ; NUMBER OF SEQUENCES: 841
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
 ; STREET: 400 GARDEN CITY PLAZA
 ; CITY: GARDEN CITY
 ; STATE: NEW YORK

; Sequence 227, Application US/08488551B
 ; Patent No. 6015661
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas J. Deacon
 ; APPLICANT: Dale A. McPhee
 ; APPLICANT: David Cooper
 ; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
 ; NUMBER OF SEQUENCES: 841
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
 ; STREET: 400 GARDEN CITY PLAZA
 ; CITY: GARDEN CITY
 ; STATE: NEW YORK
 ; COUNTRY: U.S.A.
 ; ZIP: 11530-0299
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/488,551B
 ; FILING DATE: 07-JUN-1995
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PM3864 (AU)
 ; FILING DATE: 14-FEB-1994
 ; APPLICATION NUMBER: PM4002 (AU)
 ; FILING DATE: 21-FEB-1994
 ; APPLICATION NUMBER: PM0284 (AU)
 ; FILING DATE: 23-DEC-1994
 ; APPLICATION NUMBER: US 08/388,353
 ; FILING DATE: 14-FEB-1995
 ; APPLICATION NUMBER: PN3021/95
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: FRANK S. DIGIGLIO
 ; REFERENCE/DOCKET NUMBER: 9606Z
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (516) 742-4343
 ; TELEFAX: (516) 742-4366
 ; INFORMATION FOR SEQ ID NO: 227:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 10 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA
 ; US-08-488-551B-227

Query Match 11.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 914 TTGGTCTT 921
 |||||
 Db 10 TTGGTCTT 3

RESULT 410

US-08-488-551B-228/c
 ; Sequence 228, Application US/08488551B
 ; Patent No. 6015661
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas J. Deacon
 ; APPLICANT: Dale A. McPhee
 ; APPLICANT: David Cooper
 ; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
 ; NUMBER OF SEQUENCES: 841
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
 ; STREET: 400 GARDEN CITY PLAZA
 ; CITY: GARDEN CITY
 ; STATE: NEW YORK

RESULT 410

US-08-488-551B-227/c
 ; Sequence 228, Application US/08488551B
 ; Patent No. 6015661
 ; GENERAL INFORMATION:
 ; APPLICANT: Nicholas J. Deacon
 ; APPLICANT: Dale A. McPhee
 ; APPLICANT: David Cooper
 ; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
 ; NUMBER OF SEQUENCES: 841
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
 ; STREET: 400 GARDEN CITY PLAZA
 ; CITY: GARDEN CITY
 ; STATE: NEW YORK

COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 228:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-228

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;
QY 914 TTGGTCTT 921
DB 9 TTGGTCTT 2

RESULT 411
US-08-488-551B-231/c
Sequence 231, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
FILING DATE: 14-FEB-1994

APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 231:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-231

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

QY 941 TCATTGGT 948
DB 9 TCATTGGT 2

RESULT 412
US-08-488-551B-232/c
Sequence 232, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343

```

; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 232:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-232

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 TCATTGGT 948
Db 8 TCATTGGT 1

RESULT 413
US-08-488-551B-273/c
; Sequence 273, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4366
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 273:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-273

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 10 TTTTCTTT 3

RESULT 414
US-08-488-551B-274/c
; Sequence 274, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4366
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 274:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-274

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 9 TTTTCTTT 2

RESULT 415
US-08-488-551B-308/c
; Sequence 308, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
```

APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PN3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 308:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-308

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 910 TTCCTTGG 917
|||
Db 10 TTCCTTGG 3

RESULT 416
US-08-488-551B-309/c
Sequence 309, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PN3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 309:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-309

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 910 TTCCTTGG 917
|||
Db 9 TTCCTTGG 2

RESULT 417
US-08-906-691-14/c
Sequence 14, Application US/08906691
Patent No. 6066452
GENERAL INFORMATION:
APPLICANT: Weissman, Sherman M.
APPLICANT: Nallur, Girish N.
APPLICANT: Kulkarni, Prakash
TITLE OF INVENTION: MULTIPLEX SELECTION TECHNIQUE FOR
IDENTIFYING PROTEIN-BINDING SITES FOR DNA-BINDING PROTEINS
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 981094
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/906,691
FILING DATE: 31-JUL-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: No. 6066452tenburg Ph.D., Carol
REGISTRATION NUMBER: 39,317
REFERENCE/DOCKET NUMBER: 390036.403C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-906-691-14

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 958 CGCTACCA 965
|||||
DB 9 CGCTACCA 2

RESULT 418

US-08-522-384-74
Sequence 74, Application US/08522384
Patent No. 6110667
GENERAL INFORMATION:
APPLICANT: LOPEZ-NIETO, CARLOS E
TITLE OF INVENTION: PROCESSES, APPARATUS AND COMPOSITIONS FOR
CHARACTERIZING NUCLEOTIDE SEQUENCES
FILE REFERENCE: 2458-4029
CURRENT APPLICATION NUMBER: US/08/522,384
CURRENT FILING DATE: 1996-11-15
NUMBER OF SEQ ID NOS: 122
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 74
LENGTH: 10
TYPE: DNA
ORGANISM: Unknown Organism
FEATURE:
OTHER INFORMATION: Description of Unknown Organism: Primer
US-08-522-384-74

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 901 CTGGTCAT 908
|||||
DB 2 CTGGTCAT 9

RESULT 419

US-08-522-384-102
Sequence 102, Application US/08522384
Patent No. 6110667
GENERAL INFORMATION:
APPLICANT: LOPEZ-NIETO, CARLOS E
TITLE OF INVENTION: PROCESSES, APPARATUS AND COMPOSITIONS FOR
CHARACTERIZING NUCLEOTIDE SEQUENCES
FILE REFERENCE: 2458-4029
CURRENT APPLICATION NUMBER: US/08/522,384
CURRENT FILING DATE: 1996-11-15
NUMBER OF SEQ ID NOS: 122
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 102
LENGTH: 10
TYPE: DNA
ORGANISM: Unknown Organism
FEATURE:
OTHER INFORMATION: Description of Unknown Organism: Primer
US-08-522-384-102

Query Match

11.0%; Score 8; DB 1; Length 10;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 901 CTGGTCAT 908
|||||
DB 3 CTGGTCAT 10

RESULT 420

US-08-088-661F-20/c
Sequence 20, Application US/08088661F
Patent No. 6228982
GENERAL INFORMATION:
APPLICANT: No. 6228982den, Bengt
APPLICANT: Wittung, Pernilla
APPLICANT: Buchardt, Ole
APPLICANT: Egholm, Michael
APPLICANT: Nielsen, Peter E.
APPLICANT: Berg, Rolf
TITLE OF INVENTION: Double-Stranded Peptide Nucleic Acids
FILE REFERENCE: ISIS1108
CURRENT APPLICATION NUMBER: US/08/088,661F
CURRENT FILING DATE: 1993-07-02
PRIOR APPLICATION NUMBER: 08/054,363
PRIOR FILING DATE: 1993-04-26
PRIOR APPLICATION NUMBER: PCT/EP92/01219
PRIOR FILING DATE: 1992-05-19
NUMBER OF SEQ ID NOS: 42
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 20
LENGTH: 10
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6228982el Sequence
US-08-088-661F-20

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
|||||
DB 10 TTTTCTTT 3

RESULT 421

US-08-088-661F-22/c
Sequence 22, Application US/08088661F
Patent No. 6228982
GENERAL INFORMATION:
APPLICANT: No. 6228982den, Bengt
APPLICANT: Wittung, Pernilla
APPLICANT: Buchardt, Ole
APPLICANT: Egholm, Michael
APPLICANT: Nielsen, Peter E.
APPLICANT: Berg, Rolf
TITLE OF INVENTION: Double-Stranded Peptide Nucleic Acids
FILE REFERENCE: ISIS1108
CURRENT APPLICATION NUMBER: US/08/088,661F
CURRENT FILING DATE: 1993-07-02
PRIOR APPLICATION NUMBER: 08/054,363
PRIOR FILING DATE: 1993-04-26
PRIOR APPLICATION NUMBER: PCT/EP92/01219
PRIOR FILING DATE: 1992-05-19
NUMBER OF SEQ ID NOS: 42
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 22
LENGTH: 10
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6228982el Sequence
US-08-088-661F-22/c

US-08-088-661F-22

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
| | | | |
Db 9 TTTTCTTT 2

RESULT 422

US-08-150-156A-2/c
; Sequence 2, Application US/08150156A
; Patent No. 6357163
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: THE USE OF NUCLEIC ACID ANALOGUES IN
; DIAGNOSTICS AND ANALYTICAL PROCEDURES
; NUMBER OF SEQUENCES: 40
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/150,156A
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0986/91
; FILING DATE: 24-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0987/91
; FILING DATE: 24-MAY-1991
; APPLICATION NUMBER: DK 0510/92
; FILING DATE: 15-APR-1992
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; PUBLICATION INFORMATION:
; DOCUMENT NUMBER: WO PCT/EP92/01220
; FILING DATE: 22-MAY-1992

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
| | | | |
Db 9 TTTTCTTT 2

RESULT 423

US-08-150-156A-5/c
; Sequence 5, Application US/08150156A
; Patent No. 6357163
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: THE USE OF NUCLEIC ACID ANALOGUES IN
; DIAGNOSTICS AND ANALYTICAL PROCEDURES
; NUMBER OF SEQUENCES: 40
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/150,156A
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0986/91
; FILING DATE: 24-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0987/91
; FILING DATE: 24-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0510/92
; FILING DATE: 15-APR-1992
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; PUBLICATION INFORMATION:
; DOCUMENT NUMBER: WO PCT/EP92/01220
; FILING DATE: 22-MAY-1992
US-08-150-156A-5

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
| | | | |
Db 10 TTTTCTTT 3

RESULT 424

US-08-150-156A-14
; Sequence 14, Application US/08150156A
; Patent No. 6357163
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: THE USE OF NUCLEIC ACID ANALOGUES IN
; DIAGNOSTICS AND ANALYTICAL PROCEDURES
; NUMBER OF SEQUENCES: 40
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/150,156A
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0986/91
; FILING DATE: 24-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0987/91
; FILING DATE: 24-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0510/92
; FILING DATE: 15-APR-1992
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; PUBLICATION INFORMATION:
; DOCUMENT NUMBER: WO PCT/EP92/01220

```
; FILING DATE: 22-MAY-1992
US-08-150-156A-14
Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      908 TTTTCTTT 915
DB      1 TTTTCTTT 8

RESULT 425
US-08-150-156A-16
; Sequence 16, Application US/08150156A
; Patent No. 6357163
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: THE USE OF NUCLEIC ACID ANALOGUES IN
; DIAGNOSTICS AND ANALYTICAL PROCEDURES
; NUMBER OF SEQUENCES: 40
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/150.156A
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0986/91
; FILING DATE: 24-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0987/91
; FILING DATE: 24-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0510/92
; FILING DATE: 15-APR-1992
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; PUBLICATION INFORMATION:
; DOCUMENT NUMBER: WO PCT/EP92/01220
; FILING DATE: 22-MAY-1992
US-08-150-156A-16

Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      908 TTTTCTTT 915
DB      2 TTTTCTTT 9

RESULT 426
US-08-150-156A-16
; Sequence 8, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids
; FILE REFERENCE: ISIS0540
; CURRENT APPLICATION NUMBER: US/08/108,591B
; FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6395474el Sequence

US-08-108-591B-8
Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      908 TTTTCTTT 915
DB      10 TTTTCTTT 3

RESULT 427
US-08-108-591B-9/c
; Sequence 9, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids
; FILE REFERENCE: ISIS0540
; CURRENT APPLICATION NUMBER: US/08/108,591B
; FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6395474el Sequence

US-08-108-591B-9
Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      908 TTTTCTTT 915
DB      10 TTTTCTTT 3

RESULT 428
US-08-108-591B-10/c
; Sequence 10, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids
; FILE REFERENCE: ISIS0540
; CURRENT APPLICATION NUMBER: US/08/108,591B
; FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6395474el Sequence
```

US-08-108-591B-10

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
|||||
Db 9 TTTTCTTT 2

RESULT 429

US-08-108-591B-12
; Sequence 12, Application US/08108591B
; Patent No. 6395474

; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids
; FILE REFERENCE: ISIS0540
; CURRENT APPLICATION NUMBER: US/08/108,591B
; CURRENT FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-12

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
|||||
Db 1 TTTTCTTT 8

RESULT 430

US-08-108-591B-14
; Sequence 14, Application US/08108591B
; Patent No. 6395474

; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids
; FILE REFERENCE: ISIS0540
; CURRENT APPLICATION NUMBER: US/08/108,591B
; CURRENT FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-14

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
|||||
Db 2 TTTTCTTT 9

US-08-108-591B-10

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
|||||
Db 9 TTTTCTTT 2

RESULT 429

US-08-108-591B-12
; Sequence 12, Application US/08108591B
; Patent No. 6395474

; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids
; FILE REFERENCE: ISIS0540
; CURRENT APPLICATION NUMBER: US/08/108,591B
; CURRENT FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-12

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
|||||
Db 1 TTTTCTTT 8

RESULT 430

US-08-108-591B-14
; Sequence 14, Application US/08108591B
; Patent No. 6395474

; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids
; FILE REFERENCE: ISIS0540
; CURRENT APPLICATION NUMBER: US/08/108,591B
; CURRENT FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-14

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
|||||
Db 2 TTTTCTTT 9

RESULT 431

US-08-686-114B-56/c
; Sequence 56, Application US/08686114B
; Patent No. 6414112

; GENERAL INFORMATION:

; APPLICANT: Buchardt et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having 2,6-Diaminopurine Nucleob
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6414112ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/686,114B
; FILING DATE: July 24, 1996
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/108,591
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael P. Straher
; REGISTRATION NUMBER: 38,325
; REFERENCE/DOCKET NUMBER: ISIS-2272
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439

; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 10 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-686-114B-56

Query Match 11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
|||||
Db 10 TTTTCTTT 3

RESULT 432

US-08-686-114B-58/c
; Sequence 58, Application US/08686114B
; Patent No. 6414112

; GENERAL INFORMATION:

; APPLICANT: Buchardt et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having 2,6-Diaminopurine Nucleob
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6414112ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1


```
; FILE REFERENCE: 00162/HG
; CURRENT APPLICATION NUMBER: US/09/508,753B
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: JP 9/270324
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 50
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-50

Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  922 TGCCTTTT 929
Db   8 TGCCTTTT 1

RESULT 437
US-09-508-753B-113/c
; Sequence 113, Application US/09508753B
; Patent No. 6544736
; GENERAL INFORMATION:
; APPLICANT: Akira SHIMAMOTO
; APPLICANT: Yasuhiro FURUICHI
; APPLICANT: Yuko SHIBATA
; APPLICANT: Hiroko FUNAKI
; APPLICANT: Eiichi OHARA
; APPLICANT: Masanori WATAHIKI
; TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
; CURRENT APPLICATION NUMBER: US/09/508,753B
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: JP 9/270324
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 113
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-113

Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  901 CTGGTCAT 908
Db   10 CTGGTCAT 3

RESULT 438
US-09-508-753B-440/c
; Sequence 440, Application US/09508753B
; Patent No. 6544736
; GENERAL INFORMATION:
; APPLICANT: Akira SHIMAMOTO
; APPLICANT: Yasuhiro FURUICHI
; APPLICANT: Yuko SHIBATA
; APPLICANT: Hiroko FUNAKI
; APPLICANT: Eiichi OHARA
; APPLICANT: Masanori WATAHIKI
; TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
; FILE REFERENCE: 00162/HG
; CURRENT APPLICATION NUMBER: US/09/508,753B
; CURRENT FILING DATE: 2000-06-15
```

```
; PRIOR APPLICATION NUMBER: JP 9/270324
; PRIOR FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 440
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-440

Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  954 GTATCGCT 961
Db   10 GTATCGCT 3

RESULT 439
US-09-924-346-5
; Sequence 5, Application US/09924346
; Patent No. 6555674
; GENERAL INFORMATION:
; APPLICANT: Jens Tornoe
; TITLE OF INVENTION: The Jet Promoter
; FILE REFERENCE: 19313-005
; CURRENT APPLICATION NUMBER: US/09/924,346
; CURRENT FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/224,087
; PRIOR FILING DATE: 2000-08-09
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Chemically
; OTHER INFORMATION: Synthesized
US-09-924-346-5

Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  924 CTTTAT 931
Db   1 CTTTAT 8

RESULT 440
US-09-337-304-56/c
; Sequence 56, Application US/09337304
; Patent No. 6613873
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter E.
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids Having 2, 6-Diaminopurine Nucleobases
; FILE REFERENCE: ISIS-3809
; CURRENT APPLICATION NUMBER: US/09/337,304
; CURRENT FILING DATE: 1999-06-21
; PRIOR APPLICATION NUMBER: 08/847,110
; PRIOR FILING DATE: 1997-05-01
; PRIOR APPLICATION NUMBER: 08/686,114
; PRIOR FILING DATE: 1996-07-24
; PRIOR APPLICATION NUMBER: 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: 986/91
; PRIOR FILING DATE: 1991-05-24
```

```

; PRIOR APPLICATION NUMBER: 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: 510/92
; PRIOR FILING DATE: 1992-04-15
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 56
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-09-337-304-56

```

```

Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      908 TTTTCTTT 915
        |||||
Db       10 TTTTCTTT 3

```

```

RESULT 441
US-09-337-304-56/c
; Sequence 58, Application US/09337304
; Patent No. 6613873
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter E.
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: Peptide Nucleic Acids Having 2, 6-Diaminopurine Nucleobases
; FILE REFERENCE: ISIS-3809
; CURRENT APPLICATION NUMBER: US/09/337,304
; CURRENT FILING DATE: 1999-06-21
; PRIOR APPLICATION NUMBER: 08/847,110
; PRIOR FILING DATE: 1997-05-01
; PRIOR APPLICATION NUMBER: 08/686,114
; PRIOR FILING DATE: 1996-07-24
; PRIOR APPLICATION NUMBER: 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: 986/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: 510/92
; PRIOR FILING DATE: 1992-04-15
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 58
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-09-337-304-56

```

```

Query Match      11.0%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      908 TTTTCTTT 915
        |||||
Db       9 TTTTCTTT 2

```

```

RESULT 442
US-08-246-373-6/c
; Sequence 6, Application US/08246373
; Patent No. 5550018
; GENERAL INFORMATION:
; APPLICANT: LEVENBOOK, Inessa

```

```

; APPLICANT: CHUMAKOV, Konstantin
; APPLICANT: POWERS, Laurie
; APPLICANT: RONINSON, Igor
; TITLE OF INVENTION: "TEST FOR VIRULENT REVERTANTS IN
; TITLE OF INVENTION: ATTENUATED LIVE VACCINES"
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIRCH, STEWART, KOLASCH & BIRCH
; STREET: 301 NO. 5550018th Washington Street
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: United States of America
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/246,373
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/607,742
; FILING DATE: NO. 5550018ember 6, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Gerald M. Murphy, Jr.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 1173-234P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 241-1300
; TELEFAX: (703) 241-0369
; TELEX: 248345
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE:
; DESCRIPTION: published sequence of nucleotides 439-446
; DESCRIPTION: of poliovirus type 3 genome
US-08-246-373-6

```

```

Query Match      11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      937 CTCCTCAT 944
        |||||
Db       8 CTCCTCAT 1

```

```

RESULT 443
US-08-173-489C-73/c
; Sequence 73, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT

```

```

;
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; DESCRIPTION: esterase D gene (Accession # M13450)
; DESCRIPTION: nucleotides 777 to 787
; HYPOTHEICAL: No
; ANTI-SENSE: No
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: chromosome 13
; MAP POSITION: 13q14.1-q14.2
; PUBLICATION INFORMATION:
; AUTHORS: Lee, E Y H P, Lee, W H.
; TITLE: Molecular cloning of the
; TITLE: human esterase D gene, a genetic marker of
; TITLE: retinoblastoma
; JOURNAL: Proceedings of the National Academy of
; JOURNAL: Sciences, USA
; VOLUME: 83
; PAGES: 6337-6341
; DATE: 1986
; RELEVANT RESIDUES IN SEQ ID NO: 73 :FROM 1 TO 11
;
US-08-173-489C-73
;
Query Match 11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 444
US-08-173-489C-74
; Sequence 74, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESS: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage

;
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 bases
; TYPE: Nucleic Acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from esterase D
; DESCRIPTION: sequence region in Seq ID No. 586124473
; HYPOTHEICAL: Yes
; ANTI-SENSE: No
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 74 :FROM 1 TO 11
;
US-08-173-489C-74
;
Query Match 11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 3 TTTTCTTT 10

RESULT 445
US-08-910-632-27
; Sequence 27, Application US/08910632B
; Patent No. 6077668
; GENERAL INFORMATION:
; APPLICANT: KOOL, ERIC T.
; TITLE OF INVENTION: HIGHLY SENSITIVE MULTIMERIC NUCLEIC ACID PROBES
; FILE REFERENCE: 220.00010130
; CURRENT APPLICATION NUMBER: US/08/910,632B
; CURRENT FILING DATE: 1997-08-13
; EARLIER APPLICATION NUMBER: 08/805,631
; EARLIER FILING DATE: 1997-02-26
; EARLIER APPLICATION NUMBER: 08/393,439
; EARLIER FILING DATE: 1995-02-23
; EARLIER APPLICATION NUMBER: 08/047,860
; EARLIER FILING DATE: 1993-04-15
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 27
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ligation adaptor
;
US-08-910-632-27
;
Query Match 11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 3 TTTTCTTT 10
```



```

RESULT 449
US-09-249-155A-18/c
; Sequence 18, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249,155A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-18

Query Match      11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      964 CAACGGTG 971
Db      11 CAACGGTG 4

RESULT 450
US-09-249-155A-31/c
; Sequence 31, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249,155A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-31

Query Match      11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      964 CAACGGTG 971
Db      11 CAACGGTG 4

RESULT 451
US-09-249-155A-191/c
; Sequence 191, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
; APPLICANT: Rodriguez, R.S. et al
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE CODING FOR AN
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249,155A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 191
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-191

Query Match      11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      932 CCCTCCTC 939
Db      2 CCCTCCTC 9

RESULT 452
US-09-249-155A-251
; Sequence 251, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249,155A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 251
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-251

Query Match      11.0%; Score 8; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      932 CCCTCCTC 939
Db      2 CCCTCCTC 9

RESULT 453
US-07-754-918A-4/c
; Sequence 4, Application US/07754918A
; Patent No. 5286484
; GENERAL INFORMATION:
; APPLICANT: Rodriguez, R.S. et al
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE CODING FOR AN
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/07/754,918A
; CURRENT FILING DATE: 1997-07-04
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Mus musculus
US-07-754-918A-4/c
```

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stanger, Michaelson, Spivak and Wallace, Esq.
; STREET: Parkway 109 Office Center, 328 Newman Springs
; CITY: Red Bank
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5 1/4" 360Kb IBM compatible diskette
; COMPUTER: IBM PS/2 Model 80
; OPERATING SYSTEM: MS-DOS 5.0
; SOFTWARE: Microsoft Word 5.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/754,918A
; FILING DATE: 19910905
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Michaelson, Peter L.
; REGISTRATION NUMBER: 30090
; REFERENCE/DOCKET NUMBER: Centro-2R
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908)530-6671
; TELEFAX: (908)530-6584
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 bases
; TYPE: NUCLEOTIDE
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-07-754-918A-4

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 925 CTTTATC 932
Db 11 CTTTATC 4

RESULT 454
US-08-115-497-11
; Sequence 11, Application US/08115497
; Patent No. 5514546
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
; TITLE OF INVENTION: PARALLEL AND ANTIPARALLEL BINDING DOMAINS
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/115,497
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8771
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366

; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-115-497-11

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTCTTT 915
Db 4 TTTCTTT 11

RESULT 455
US-08-363-475-27/c
; Sequence 27, Application US/08363475
; Patent No. 5516679
; GENERAL INFORMATION:
; APPLICANT: Chiang, Shu-Jen
; APPLICANT: Burnett Jr., William V.
; APPLICANT: Tonzi, Sean M.
; TITLE OF INVENTION: PENICILLIN V AMIDOHYDROLASE GENE FROM
; TITLE OF INVENTION: FUSARIUM OXYSPORUM
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Thomas R. Savitsky
; STREET: P.O. Box 4000
; CITY: Princeton
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 08543
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,475
; FILING DATE: 23-DEC-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Savitsky, Thomas R.
; REGISTRATION NUMBER: 31,661
; REFERENCE/DOCKET NUMBER: ON-0134
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 252 4956
; TELEFAX: (609) 252 4526
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-363-475-27

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 TTGCTTT 928
Db 11 TTGCTTT 4

RESULT 456
US-08-280-441-8

; Sequence 8, Application US/08280441
; Patent No. 5552278
; GENERAL INFORMATION:
; APPLICANT: Sydney Brenner
; TITLE OF INVENTION: DNA Sequencing by Stepwise Ligation and Cleavage
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevicz
; STREET: 21890 Rucker Drive
; CITY: Cupertino
; STATE: California
; COUNTRY: USA
; ZIP: 95014
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/280,441
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222,300
; FILING DATE: 04-APR-94
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevicz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: slc2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 638-5552
; TELEFAX: (510) 670-9302
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-08-280-441-8

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 935 TCCTCTTC 942
Db 5 TCCTCTTC 12

RESULT 457
US-08-214-603-11/c
; Sequence 11, Application US/08214603
; Patent No. 5596091
; GENERAL INFORMATION:
; APPLICANT: SWITZER, Christopher
; TITLE OF INVENTION: NOVEL ANTISENSE OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/214,603
; FILING DATE: 18-MAR-1994
; CLASSIFICATION: 536

; ATTORNEY/AGENT INFORMATION:
; NAME: Kezer, William B.
; REGISTRATION NUMBER: 37,369
; REFERENCE/DOCKET NUMBER: 2307E-0521000S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; DESCRIPTION: /desc = "Oligodeoxynucleotide"
; US-08-214-603-11

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 9 TTTTCTTT 2

RESULT 458
US-08-410-116B-26
; Sequence 26, Application US/08410116B
; Patent No. 5599675
; GENERAL INFORMATION:
; APPLICANT: Sydney Brenner, Glenn Albrecht, Andrew J. Blasband
; TITLE OF INVENTION: DNA Sequencing by Stepwise Ligation and Cleavage
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevicz, Lynx Therapeutics, Inc.
; STREET: 3832 Bay Center Place
; CITY: Hayward
; STATE: California
; COUNTRY: USA
; ZIP: 94545
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,116B
; FILING DATE: 24-MAR-95
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222,300
; FILING DATE: 04-APR-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/280,441
; FILING DATE: 25-JUL-94
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevicz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: slc3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 670-9365
; TELEFAX: (510) 670-9302
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-410-116B-26

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;


```
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 931 TCCCTCCT 938
Db 8 TCCCTCCT 1

RESULT 462
US-08-413-813-12/c
; Sequence 12, Application US/08413813
; Patent No. 5683874
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/413,813
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELEPHONE: (516) 742-4366
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-413-813-12

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 463
US-08-413-813-13/c
; Sequence 13, Application US/08413813
; Patent No. 5683874
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/413,813
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELEPHONE: (516) 742-4366
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-413-813-13

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 464
US-08-413-813-30
; Sequence 30, Application US/08413813
; Patent No. 5683874
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/413,813
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELEPHONE: (516) 742-4366
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-413-813-30
```

```

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 12.5%; Pred. No. 2.8e+02;
Matches 1; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTCTTT 915
Db 2 UUUUUUU 9

RESULT 465
US-08-667-689A-26
; Sequence 26, Application US/08667689A
; Patent No. 5714330
; GENERAL INFORMATION:
; APPLICANT: Sydney Brenner, Robert B. DuBridge
; TITLE OF INVENTION: DNA Sequencing by Stepwise Ligation and Cleavage
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevitz, Lynx Therapeutics, Inc.
; STREET: 3832 Bay Center Place
; CITY: Hayward
; STATE: California
; COUNTRY: USA
; ZIP: 94545
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/667.689A
; FILING DATE: 21-JUN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,116
; FILING DATE: 24-MAR-95
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222,300
; FILING DATE: 04-APR-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/280,441
; FILING DATE: 25-JUL-94
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevitz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: 801-06
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 670-9365
; TELEFAX: (510) 670-9302
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-667-689A-26

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTC 942
Db 5 TCCTCTTC 12

RESULT 466
US-08-662-335A-16
; Sequence 16, Application US/08662335A
; Patent No. 5792613
; GENERAL INFORMATION:
; APPLICANT: Schmidt,, Francis J.
; TITLE OF INVENTION: METHOD FOR OBTAINING

```

```

; TITLE OF INVENTION: RNA APTAMERS BASED ON SHAPE SELECTION
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth, P.A.
; STREET: P.O. Box 2938
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/662,335A
; FILING DATE: 12-JUN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: No. 5792613e
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Woessner, Warren D
; REGISTRATION NUMBER: 30,440
; REFERENCE/DOCKET NUMBER: 423.001US1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-339-0331
; TELEFAX: 612-339-3061
; TELEX:
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-662-335A-16

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 900 CCTGGTCA 907
Db 5 CCTGGTCA 12

RESULT 467
US-08-466-670-11
; Sequence 11, Application US/084666570
; Patent No. 5808036
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
; PARALLEL AND ANTIPARALLEL BINDING DOMAINS
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,670
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:

```

APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-11

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
|||||
Db 4 TTTTCTTT 11

RESULT 468
US-08-686-631-7
Sequence 7, Application US/08686631
Patent No. 5824318
GENERAL INFORMATION:
APPLICANT: Mohr, Ian J.
APPLICANT: Gluzman, Yakov
TITLE OF INVENTION: Avirulent Herpetic Viruses Useful as
TITLE OF INVENTION: Tumoricidal Agents and Vaccines
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: American Cyanamid Company
STREET: One Cyanamid Plaza
CITY: Wayne
STATE: New Jersey
COUNTRY: United States
ZIP: 07470-8426
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/686,631
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Barnhard, Elizabeth M.
REGISTRATION NUMBER: 31,088
REFERENCE/DOCKET NUMBER: 33,161-00
TELEPHONE: 201-831-3246
TELEFAX: 201-831-3305
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-686-631-7

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 924 CCTTTTAT 931
|||||
Db 2 CCTTTTAT 9

RESULT 469
US-08-712-011-26
Sequence 26, Application US/08712011
Patent No. 5831065
GENERAL INFORMATION:
APPLICANT: Sydney Brenner
TITLE OF INVENTION: Kits for DNA Sequencing by Stepwise Ligation and Cleavage
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Stephen C. Macevitz, Spectragen, Inc.
STREET: 3832 Bay Center Place
CITY: Hayward
STATE: California
COUNTRY: USA
ZIP: 94545

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 3.1/DOS 5.0
SOFTWARE: Microsoft Word for Windows, vers. 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/712,011
FILING DATE: 11-SEP-96
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/410,116
FILING DATE: 24-MAR-95
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/222,300
FILING DATE: 04-APR-94
APPLICATION NUMBER: 08/280,441
FILING DATE: 25-JUL-94
ATTORNEY/AGENT INFORMATION:
NAME: Stephen C. Macevitz
REGISTRATION NUMBER: 30,285
REFERENCE/DOCKET NUMBER: slc3c2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 670-9365
TELEFAX: (510) 670-9302
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-712-011-26

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 935 TCCTCTTC 942
|||||
Db 5 TCCTCTTC 12

RESULT 470
US-08-770-565-4
Sequence 4, Application US/08770565
Patent No. 5846723
GENERAL INFORMATION:
APPLICANT: Kim, Nam Woo
APPLICANT: Wu, Fred
APPLICANT: Kealey, James T.
APPLICANT: Pruzan, Ronald
APPLICANT: Weinrich, Scott L.

;; TITLE OF INVENTION: Methods for Detecting the RNA Component of
;; TITLE OF INVENTION: Telomerase
;; NUMBER OF SEQUENCES: 26
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: TOWNSEND and TOWNSEND and CREW LLP
;; STREET: Two Embarcadero Center, 8th Floor
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: USA
;; ZIP: 94111-3834
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/770,565
;; FILING DATE: 20-DEC-1996
;; CLASSIFICATION: 435
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Storella, John R.
;; REGISTRATION NUMBER: 32,944
;; REFERENCES/DOCKET NUMBER: 015389-002300US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 415-576-0200
;; TELEFAX: 415-576-0300
;; INFORMATION FOR SEQ ID NO: 4:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 12 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
;; US-08-770-565-4

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 935 TCCTCTTC 942
Db 4 TCCTCTTC 11

RESULT 471
US-08-478-239A-26
; Sequence 26, Application US/08478239A
; Patent No. 5856093
; GENERAL INFORMATION:
; APPLICANT: Sydney Brenner
; TITLE OF INVENTION: Method of Determining Zygosity
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevicz, Spectragen, Inc.
; STREET: 3832 Bay Center Place
; CITY: Hayward
; STATE: California
; COUNTRY: USA
; ZIP: 94545
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/478,239A
; FILING DATE: 07-JUN-95
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410,116
; FILING DATE: 24-MAR-95
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/222,300

;; FILING DATE: 04-APR-94
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/280,441
;; FILING DATE: 25-JUL-94
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Stephen C. Macevicz
;; REGISTRATION NUMBER: 30,285
;; REFERENCES/DOCKET NUMBER: slc3c1
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (510) 670-9365
;; TELEFAX: (510) 670-9302
;; INFORMATION FOR SEQ ID NO: 26:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 12 nucleotides
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-478-239A-26

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 935 TCCTCTTC 942
Db 5 TCCTCTTC 12

RESULT 472
US-08-173-489C-83/c
; Sequence 83, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCES/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 83:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
DESCRIPTION: retinoblastoma gene (Accession # M33647, J02994) nucleotides 1842 to 1853

;
; HYPOTHETICAL: No
; ANTI-SENSE: No
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME: Chromosome 13
; CHROMOSOME/SEGMENT: 13q14.2
; MAP POSITION: 13q14.2
; PUBLICATION INFORMATION:
; AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,
; AUTHORS: Wang X P, Bogenmann, E, Li, F P, Weinberg,
; AUTHORS: R A
; TITLE: Deletions of a DNA sequence
; TITLE: in retinoblastomas and mesenchymal tumors:
; TITLE: Organization of the sequence and its encoded
; TITLE: protein
; JOURNAL: Proceedings of the National Academy of
; JOURNAL: Sciences, USA
; VOLUME: 84
; PAGES: 9059-9063
; DATE: 1987
; RELEVANT RESIDUES IN SEQ ID NO: 83 :FROM 1 TO 12
US-08-173-489C-83

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 8 TTTTCTTT 1

RESULT 473
US-08-467-346-12/c
; Sequence 12, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/413,813
; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DiGiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8085ZYX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-467-346-12

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 474
US-08-467-346-13/c
; Sequence 13, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/413,813
; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: DiGiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8085ZYX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 475
US-08-467-346-30
; Sequence 30, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser

STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-30

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 12.5%; Pred. No. 2.8e+02;
Matches 1; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
Db 2 UUUCUUU 9

RESULT 476
US-08-232-081B-33/c
Sequence 33, Application US/08232081B
Patent No. 5886152
GENERAL INFORMATION:
APPLICANT: NAKATANI, TOMOYUKI
APPLICANT: GOMI, HIDEYUKI
APPLICANT: WIJDENES, JOHN
APPLICANT: NOGUCHI, HIROSHI
TITLE OF INVENTION: HUMANIZED B-B10
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: BIRCH, STEWART, KOLASCH AND BIRCH
STREET: PO BOX 747
CITY: FALLS CHURCH
STATE: VA
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/232,081B
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: SVENSSON, LEONARD R
REGISTRATION NUMBER: 30,330
REFERENCE/DOCKET NUMBER: 20-3484

TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 205-8000
TELEFAX: (703) 205-8050
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-232-081B-33
Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 948 TTTAATGT 955
Db 12 TTTAATGT 5

RESULT 477

US-08-663-823B-65
Sequence 65, Application US/08663823B
Patent No. 5972693
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
APPLICANT: Simpson, John
TITLE OF INVENTION: METHOD AND APPARATUS FOR IDENTIFYING
CLASSIFYING, OR QUANTIFYING DNA SEQUENCES IN A SAMPLE
TITLE OF INVENTION: WITHOUT SEQUENCING
NUMBER OF SEQUENCES: 77
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie and Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/663,823B
FILING DATE: 14-June-1996
CLASSIFICATION: 422
ATTORNEY/AGENT INFORMATION:
NAME: Misrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-033
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 65:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-663-823B-65

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 937 CTCTTCAT 944
Db 4 CTCTTCAT 11

RESULT 478

US-08-507-032-13/c
; Sequence 13, Application US/08507032
; Patent No. 5989810
; GENERAL INFORMATION:
; APPLICANT: Flanagan, William A.
; APPLICANT: Crabtree, Gerald R.
; TITLE OF INVENTION: Screening Methods for Immunosuppressive
; TITLE OF INVENTION: Agents
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/507,032
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/228,944

; FILING DATE:
; APPLICATION NUMBER: US 07/749,385
; FILING DATE: 22-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 5490A-89
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422

; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-507-032-13

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred.No.2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTC 942

Db 8 TCCTCTTC 1

RESULT 479

US-08-779-355-10
; Sequence 10, Application US/08779355
; Patent No. 6017701
; GENERAL INFORMATION:
; APPLICANT: Sorge, Joseph A.
; APPLICANT: Mullinax, Rebecca L.
; TITLE OF INVENTION: METHODS AND ADAPTORS FOR GENERATING
; TITLE OF INVENTION: SPECIFIC NUCLEIC ACID POPULATIONS
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Evenson, McKeown, Edwards & Lenahan P.L.L.C.
; STREET: 1200 G Street N.W., Suite 700
; CITY: Washington
; STATE: D.C.

COUNTRY: USA

ZIP: 20005

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/779,355

FILING DATE: 06-JAN-1997

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/775,993

FILING DATE: 03-JAN-1997

ATTORNEY/AGENT INFORMATION:

NAME: Kulik, David J.

REGISTRATION NUMBER: 36,576

REFERENCE/DOCKET NUMBER: 43092CP

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)628-8800

TELEFAX: (202)628-8844

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-779-355-10

Query Match

Best Local Similarity 11.0%; Score 8; DB 1; Length 12;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTC 942

Db 3 TCCTCTTC 10

RESULT 480

US-08-874-825-86

; Sequence 86, Application US/08874825

; Patent No. 6057101

; GENERAL INFORMATION:

; APPLICANT: Nandabalan, Krishnan

; APPLICANT: Rothberg, Jonathan

; APPLICANT: Yang, Meijia

; APPLICANT: Knight, James

; APPLICANT: Kalbfleisch, Theodore

; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF

; TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS

; TITLE OF INVENTION: AND IDENTIFICATION OF INHIBITORS OF THESE INTERACTORS

; NUMBER OF SEQUENCES: 122

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Pennie & Edmonds

; STREET: 1155 Avenue of the Americas

; CITY: New York

; STATE: NY

; COUNTRY: USA

; ZIP: 10036/2711

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSeq Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/874,825

; FILING DATE: 13-JUN-1997

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/663,824

; FILING DATE: 14-JUN-1996

; ATTORNEY/AGENT INFORMATION:

```
/ NAME: Misrock, S. Leslie
/ REGISTRATION NUMBER: 18,872
/ REFERENCE/DOCKET NUMBER: 7934-045
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212-790-9090
/ TELEFAX: 212-869-8864
/ TELEX: 66141 PENNIE
/ INFORMATION FOR SEQ ID NO: 86:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-874-825-86

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      937 CTCCTCAT 944
Db      4 CTCCTCAT 11

RESULT 481
US-08-874-825-87
; Sequence 87, Application US/08874825
; Patent No. 6057101
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; APPLICANT: Yang, Meijia
; APPLICANT: Knight, James
; APPLICANT: Kalbfleisch, Theodore
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF
; TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS
; NUMBER OF SEQUENCES: 122
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036/2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/874,825
; FILING DATE: 13-JUN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/663,824
; FILING DATE: 14-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Misrock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 7934-045
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-790-9090
; TELEFAX: 212-869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
```

```
US-08-874-825-87

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      937 CTCCTCAT 944
Db      4 CTCCTCAT 11

RESULT 482
US-08-874-825-112
; Sequence 112, Application US/08874825
; Patent No. 6057101
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; APPLICANT: Yang, Meijia
; APPLICANT: Knight, James
; APPLICANT: Kalbfleisch, Theodore
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF
; TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS
; NUMBER OF SEQUENCES: 122
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036/2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/874,825
; FILING DATE: 13-JUN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/663,824
; FILING DATE: 14-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Misrock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 7934-045
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-790-9090
; TELEFAX: 212-869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 112:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-874-825-112

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      937 CTCCTCAT 944
Db      4 CTCCTCAT 11

RESULT 483
US-08-938-835A-10
; Sequence 10, Application US/08938835A
```


Patent No. 6060245
; GENERAL INFORMATION:
; APPLICANT: SORGE, Joseph A.
; APPLICANT: MULLINAX, Rebecca L.
; TITLE OF INVENTION: METHODS AND ADAPTORS FOR GENERATING
; TITLE OF INVENTION: SPECIFIC NUCLEIC ACID POPULATIONS
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Parabow, Garrett &
; ADDRESSEE: Dunner, L.L.P.
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/938,835A
; FILING DATE: 26-SEPT-1997
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/775,993
; FILING DATE: 03-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/779,335
; FILING DATE: 06-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Barker, M. Paul
; REGISTRATION NUMBER: 32,013
; REFERENCE/DOCKET NUMBER: 04121.0044-02000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-938-835A-10

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 935 TCCTCTTC 942
Db 3 TCCTCTTC 10

RESULT 484
US-08-910-632-8/c
; Sequence 8, Application US/08910632B
; Patent No. 6077668
; GENERAL INFORMATION:
; APPLICANT: KOOL, ERIC T.
; TITLE OF INVENTION: HIGHLY SENSITIVE MULTIMERIC NUCLEIC ACID PROBES
; FILE REFERENCE: 220.00010130
; CURRENT APPLICATION NUMBER: US/08/910,632B
; CURRENT FILING DATE: 1997-08-13
; EARLIER FILING DATE: 1997-02-26
; EARLIER FILING DATE: 1995-02-23
; EARLIER FILING DATE: 1993-04-15
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 8
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: linear sequence
US-08-910-632-8

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 485
US-08-910-632-11/c
; Sequence 11, Application US/08910632B
; Patent No. 6077668
; GENERAL INFORMATION:
; APPLICANT: KOOL, ERIC T.
; TITLE OF INVENTION: HIGHLY SENSITIVE MULTIMERIC NUCLEIC ACID PROBES
; FILE REFERENCE: 220.00010130
; CURRENT APPLICATION NUMBER: US/08/910,632B
; CURRENT FILING DATE: 1997-08-13
; EARLIER FILING DATE: 1997-02-26
; EARLIER FILING DATE: 1997-02-26
; EARLIER FILING DATE: 1995-02-23
; EARLIER FILING DATE: 1993-04-15
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: desired oligomer
US-08-910-632-11

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 486
US-08-910-632-36/c
; Sequence 36, Application US/08910632B
; Patent No. 6077668
; GENERAL INFORMATION:
; APPLICANT: KOOL, ERIC T.
; TITLE OF INVENTION: HIGHLY SENSITIVE MULTIMERIC NUCLEIC ACID PROBES
; FILE REFERENCE: 220.00010130
; CURRENT APPLICATION NUMBER: US/08/910,632B
; CURRENT FILING DATE: 1997-08-13
; EARLIER FILING DATE: 1997-02-26
; EARLIER FILING DATE: 1997-02-26
; EARLIER FILING DATE: 1995-02-23
; EARLIER FILING DATE: 1993-04-15
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36
; LENGTH: 12
; TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-08-910-632-36

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      908 TTTTCTTT 915
DB      11 TTTTCTTT 4

RESULT 487
US-08-663-824-86
; Sequence 86, Application US/08663824
; Patent No. 6083693
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
; TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS
; FILE REFERENCE: 7934-006
; CURRENT APPLICATION NUMBER: US/08/663,824
; CURRENT FILING DATE: 1996-06-14
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 86
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-08-663-824-86

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      937 CTCCTCAT 944
DB      4 CTCCTCAT 11

RESULT 488
US-08-663-824-87
; Sequence 87, Application US/08663824
; Patent No. 6083693
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
; TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS
; FILE REFERENCE: 7934-006
; CURRENT APPLICATION NUMBER: US/08/663,824
; CURRENT FILING DATE: 1996-06-14
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 87
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-08-663-824-87

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      937 CTCCTCAT 944
DB      4 CTCCTCAT 11

RESULT 489
US-08-663-824-112
; Sequence 112, Application US/08663824
; Patent No. 6083693
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
; TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS
; FILE REFERENCE: 7934-006
; CURRENT APPLICATION NUMBER: US/08/663,824
; CURRENT FILING DATE: 1996-06-14
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 112
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-08-663-824-112

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      937 CTCCTCAT 944
DB      4 CTCCTCAT 11

RESULT 490
US-08-805-631A-8/c
; Sequence 8, Application US/08805631A
; Patent No. 6096880
; GENERAL INFORMATION:
; APPLICANT: UNIVERSITY OF ROCHESTER
; TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
; TITLE OF INVENTION: DNA
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MUETING, RAASCH & GEBHARDT, P.A.
; STREET: 119 No. 6096880th Fourth Street, Suite 201
; CITY: Minneapolis
; STATE: Minnesota
; COUNTRY: USA
; ZIP: 55401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/805,631A
; FILING DATE: 26-FEB-97
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/393,439
; FILING DATE: 23-FEB-1995
; APPLICATION NUMBER: US 08/047,860
; FILING DATE: 15-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDBERG, VICTORIA A.
; REGISTRATION NUMBER: 41,287
; REFERENCE/DOCKET NUMBER: 220,00010140
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-305-1226
; TELEFAX: 612-305-1228
; INFORMATION FOR SEQ ID NO: 8:
```

SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-805-631A-8

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
|||||
Db 11 TTTTCTTT 4

RESULT 491
US-08-805-631A-11/C
; Sequence 11, Application US/08805631A
; Patent No. 6096880
; GENERAL INFORMATION:
; APPLICANT: UNIVERSITY OF ROCHESTER
; TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESS: MUEITING, RAASCH & GEBHARDT, P.A.
; STREET: 119 No. 6096880th Fourth Street, Suite 201
; CITY: Minneapolis
; STATE: Minnesota
; COUNTRY: USA
; ZIP: 55401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 26-FEB-97
; CLASSIFICATION: 536
; PRIOR APPLICATION NUMBER: US 08/393,439
; FILING DATE: 23-FEB-1995
; APPLICATION NUMBER: US 08/047,860
; FILING DATE: 15-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDBERG, VICTORIA A.
; REGISTRATION NUMBER: 41,287
; REFERENCE/DOCKET NUMBER: 220.00010140
; TELEPHONE: 612-305-1226
; TELEFAX: 612-305-1226
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-805-631A-11

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
|||||
Db 11 TTTTCTTT 4

RESULT 492
US-08-805-631A-36/c
; Sequence 36, Application US/08805631A
; Patent No. 6096880
; GENERAL INFORMATION:
; APPLICANT: UNIVERSITY OF ROCHESTER
; TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESS: MUEITING, RAASCH & GEBHARDT, P.A.
; STREET: 119 No. 6096880th Fourth Street, Suite 201
; CITY: Minneapolis
; STATE: Minnesota
; COUNTRY: USA
; ZIP: 55401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 26-FEB-97
; CLASSIFICATION: 536
; PRIOR APPLICATION NUMBER: US 08/393,439
; FILING DATE: 23-FEB-1995
; APPLICATION NUMBER: US 08/047,860
; FILING DATE: 15-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDBERG, VICTORIA A.
; REGISTRATION NUMBER: 41,287
; REFERENCE/DOCKET NUMBER: 220.00010140
; TELEPHONE: 612-305-1226
; TELEFAX: 612-305-1226
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-805-631A-36

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 908 TTTTCTTT 915
|||||
Db 11 TTTTCTTT 4

RESULT 493
US-09-593-323-45/c
; Sequence 45, Application US/09593323
; Patent No. 6265213
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/593,323
; CURRENT FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; PRIOR FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 45
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-593-323-45

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 905 TCATTTC 912
DB 8 TCATTTC 1

RESULT 494
US-09-594-108-45/c
; Sequence 45, Application US/09594108
; Patent No. 628468
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/594,108
; PRIOR FILING DATE: 2000-06-13
; PRIOR APPLICATION NUMBER: 09/344,300
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 45
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-594-108-45

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 905 TCATTTC 912
DB 8 TCATTTC 1

RESULT 495
US-09-281-418-185/c
; Sequence 185, Application US/09281418
; Patent No. 6287769
; GENERAL INFORMATION:
; APPLICANT: Inoue, Takakazu
; TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F
; TITLE OF INVENTION: agent, Method of Assaying Microorganisms, Method of Analyzing Mi
; TITLE OF INVENTION: nisms and Method of Assaying Contaminant
; FILE REFERENCE: 9982-7
; CURRENT APPLICATION NUMBER: US/09/281,418
; CURRENT FILING DATE: 1999-03-30
; EARLIER APPLICATION NUMBER: JP/1998/87651
; EARLIER FILING DATE: 1998-03-31
; EARLIER APPLICATION NUMBER: JP/1999/69694
; EARLIER FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 216
; SEQ ID NO 185
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Primer
US-09-281-418-185

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 954 GTATCGCT 961
DB 11 GTATCGCT 4

RESULT 496
US-09-344-300-45/c
; Sequence 45, Application US/09344300B
; Patent No. 6297013
; GENERAL INFORMATION:
; APPLICANT: Morgan, Antony R.
; APPLICANT: Severini, Alberto
; TITLE OF INVENTION: Compositions and Methods for Determining the Activity
; TITLE OF INVENTION: of DNA-Binding Proteins and of Initiation of
; TITLE OF INVENTION: Transcription
; FILE REFERENCE: DNAB-02921
; CURRENT APPLICATION NUMBER: US/09/344,300B
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 45
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-344-300-45

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 905 TCATTTC 912
DB 8 TCATTTC 1

RESULT 497
US-09-354-231B-59
; Sequence 59, Application US/09354231B
; Patent No. 6342658
; GENERAL INFORMATION:
; APPLICANT: DeBonte, Lorin R.
; TITLE OF INVENTION: FATTY ACID DESATURASES AND MUTANT SEQUENCES THEREOF
; FILE REFERENCE: 07148-063002
; CURRENT APPLICATION NUMBER: US/09/354,231B
; CURRENT FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: US 08/874,109
; PRIOR FILING DATE: 1997-06-12
; NUMBER OF SEQ ID NOS: 69
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 59
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Phaseolus vulgaris
US-09-354-231B-59

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 915 TGGTCTTT 922
DB 1 TGGTCTTT 8

```

RESULT 498
US-09-569-344-8/c
; Sequence 8, Application US/09569344
; Patent No. 6368802
; GENERAL INFORMATION:
; APPLICANT: UNIVERSITY OF ROCHESTER
; TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
; DNA
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MUEITING, RAASCH & GEBHARDT, P.A.
; STREET: 119 No. 6368802th Fourth Street, Suite 201
; CITY: Minneapolis
; STATE: Minnesota
; COUNTRY: USA
; ZIP: 55401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/569,344
; FILING DATE: 11-May-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/805,631
; FILING DATE: 26-FEB-97
; APPLICATION NUMBER: US 08/393,439
; FILING DATE: 23-FEB-1995
; APPLICATION NUMBER: US 08/047,860
; FILING DATE: 15-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDBERG, VICTORIA A.
; REGISTRATION NUMBER: 41,287
; REFERENCE/DOCKET NUMBER: 220.00010140
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-305-1226
; TELEFAX: 612-305-1228
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-569-344-8

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 499
US-09-569-344-11/c
; Sequence 11, Application US/09569344
; Patent No. 6368802
; GENERAL INFORMATION:
; APPLICANT: UNIVERSITY OF ROCHESTER
; TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
; DNA
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MUEITING, RAASCH & GEBHARDT, P.A.
; STREET: 119 No. 6368802th Fourth Street, Suite 201
; CITY: Minneapolis
; STATE: Minnesota

```

```

; COUNTRY: USA
; ZIP: 55401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/569,344
; FILING DATE: 11-May-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/805,631
; FILING DATE: 26-FEB-97
; APPLICATION NUMBER: US 08/393,439
; FILING DATE: 23-FEB-1995
; APPLICATION NUMBER: US 08/047,860
; FILING DATE: 15-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDBERG, VICTORIA A.
; REGISTRATION NUMBER: 41,287
; REFERENCE/DOCKET NUMBER: 220.00010140
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-305-1226
; TELEFAX: 612-305-1228
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-569-344-11

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 500
US-09-569-344-36/c
; Sequence 36, Application US/09569344
; Patent No. 6368802
; GENERAL INFORMATION:
; APPLICANT: UNIVERSITY OF ROCHESTER
; TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
; DNA
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MUEITING, RAASCH & GEBHARDT, P.A.
; STREET: 119 No. 6368802th Fourth Street, Suite 201
; CITY: Minneapolis
; STATE: Minnesota
; COUNTRY: USA
; ZIP: 55401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/569,344
; FILING DATE: 11-May-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/805,631
; FILING DATE: 26-FEB-97
; APPLICATION NUMBER: US 08/393,439

```

```
/
/
/
/ FILING DATE: 23-FEB-1995
/ APPLICATION NUMBER: US 08/047,860
/ FILING DATE: 15-APR-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: SANDBERG, VICTORIA A.
/ REGISTRATION NUMBER: 41,287
/ REFERENCE/DOCKET NUMBER: 220.00010140
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 612-305-1226
/ TELEFAX: 612-305-1228
/ INFORMATION FOR SEQ ID NO: 36:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-569-344-36

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 11 TTTTCTTT 4

RESULT 501
US-09-231-303-86
/ Sequence 86, Application US/09231303
/ Patent No. 6395478
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
/ TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS AND
/ TITLE OF INVENTION: IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
/ FILE REFERENCE: 7934-087
/ CURRENT APPLICATION NUMBER: US/09/231,303
/ CURRENT FILING DATE: 1999-01-12
/ EARLIER APPLICATION NUMBER: 08/663,824
/ EARLIER FILING DATE: 1996-06-14
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 86
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-231-303-86

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 937 CTCCTTCAT 944
Db 4 CTCCTTCAT 11

RESULT 502
US-09-231-303-87
/ Sequence 87, Application US/09231303
/ Patent No. 6395478
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
/ TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS AND
/ TITLE OF INVENTION: IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
/ FILE REFERENCE: 7934-087
/ CURRENT APPLICATION NUMBER: US/09/231,303
/ CURRENT FILING DATE: 1999-01-12
/ EARLIER APPLICATION NUMBER: 08/663,824
/ EARLIER FILING DATE: 1996-06-14
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 87
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-231-303-87

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 937 CTCCTTCAT 944
Db 4 CTCCTTCAT 11

RESULT 503
US-09-231-303-112
/ Sequence 112, Application US/09231303
/ Patent No. 6395478
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
/ TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS AND
/ TITLE OF INVENTION: IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
/ FILE REFERENCE: 7934-087
/ CURRENT APPLICATION NUMBER: US/09/231,303
/ CURRENT FILING DATE: 1999-01-12
/ EARLIER APPLICATION NUMBER: 08/663,824
/ EARLIER FILING DATE: 1996-06-14
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 112
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-231-303-112

Query Match 11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 937 CTCCTTCAT 944
Db 4 CTCCTTCAT 11

RESULT 504
US-09-475-947A-19
/ Sequence 19, Application US/09475947A
/ Patent No. 6472154
/ GENERAL INFORMATION:
/ APPLICANT: Garner, Harold R.
/ APPLICANT: Wren, Jonathan D.
/ APPLICANT: Minna, John D.
/ TITLE OF INVENTION: Polymorphic Repeats in Human Genes
/ FILE REFERENCE: UTSD0667
/ CURRENT APPLICATION NUMBER: US/09/475,947A
/ CURRENT FILING DATE: 1999-12-31
/ NUMBER OF SEQ ID NOS: 346
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 19
```

```
; LENGTH: 12
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-19

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 4 TTTTCTTT 11

RESULT 505
PCT-US91-03680-93
; Sequence 93, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 2
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION:
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 3
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 6
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 8
; OTHER INFORMATION: /mod_base= OTHER

; LENGTH: 12
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-19

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 908 TTTTCTTT 915
Db 4 TTTTCTTT 11

RESULT 506
PCT-US95-03602-1
; Sequence 1, Application PC/TUS9503602
; GENERAL INFORMATION:
; APPLICANT: Research Corporation Technologies, Inc.
; TITLE OF INVENTION: STEM-LOOP AND CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03602
; FILING DATE: 21-MAR-1995
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9373
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 2
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION:
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 3
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 6
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 8
; OTHER INFORMATION: /mod_base= OTHER

; LENGTH: 12
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-19

Query Match      11.0%; Score 8; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 8; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 933 CCTCTCTTC 942
Db 2 MCTTCTCTTC 11

RESULT 507
PCT-US95-03602-2
; Sequence 2, Application PC/TUS9503602
; GENERAL INFORMATION:
; APPLICANT: Research Corporation Technologies, Inc.
; TITLE OF INVENTION: STEM-LOOP AND CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: Scully, Scott, Murphy & Presser
 STREET: 400 Garden City Plaza
 CITY: Garden City
 STATE: New York
 COUNTRY: U.S.A.
 ZIP: 11530-0299
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/03602
 FILING DATE: 21-MAR-1995
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Digiglio, Frank S.
 REGISTRATION NUMBER: 31,346
 REFERENCE/DOCKET NUMBER: 9373
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (516) 742-4343
 TELEFAX: (516) 742-4366
 TELEX: 230 901 SANS UR
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 PCT-US95-03602-2

Query Match 11.0%; Score 8; DB 1; Length 12;
 Best Local Similarity 62.5%; Pred. No. 2.8e+02;
 Matches 5; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 931 TCCTCTCT 938
 Db 5 UCCUCCU 12

RESULT 508
 PCT-US95-03602-3/c
 Sequence 3, Application PC/TUS9503602
 GENERAL INFORMATION:
 APPLICANT: Research Corporation Technologies, Inc.
 TITLE OF INVENTION: STEM-LOOP AND CIRCULAR OLIGONUCLEOTIDES
 NUMBER OF SEQUENCES: 8
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Scully, Scott, Murphy & Presser
 STREET: 400 Garden City Plaza
 CITY: Garden City
 STATE: New York
 COUNTRY: U.S.A.
 ZIP: 11530-0299
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/03602
 FILING DATE: 21-MAR-1995
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Digiglio, Frank S.
 REGISTRATION NUMBER: 31,346
 REFERENCE/DOCKET NUMBER: 9373
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (516) 742-4343
 TELEFAX: (516) 742-4366
 TELEX: 230 901 SANS UR
 INFORMATION FOR SEQ ID NO: 3:
 SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 PCT-US95-03602-3
 Query Match 11.0%; Score 8; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.8e+02;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 931 TCCTCTCT 938
 Db 8 TCCTCTCT 1

RESULT 509
 US-08-242-409-2
 Sequence 2, Application US/08242409
 Patent No. 5496831
 GENERAL INFORMATION:
 APPLICANT: Alexander-Bridges, Maria C.
 APPLICANT: Zhao, Hui-Pen
 TITLE OF INVENTION: INHIBITION OF INSULIN-INDUCED
 TITLE OF INVENTION: ADIFOSIS
 NUMBER OF SEQUENCES: 12
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson
 STREET: 225 Franklin Street
 CITY: Boston
 STATE: Massachusetts
 COUNTRY: U.S.A.
 ZIP: 02110-2804
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 COMPUTER: IBM PS/2 Model 502 or 55SX
 OPERATING SYSTEM: MS-DOS (Version 5.0)
 SOFTWARE: WordPerfect (Version 5.1)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/242,409
 FILING DATE:
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Clark, Paul T.
 REGISTRATION NUMBER: 30,162
 REFERENCE/DOCKET NUMBER: 00786/238001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (617) 542-5070
 TELEFAX: (617) 542-8906
 TELEX: 200154
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 11
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-242-409-2

Query Match 10.7%; Score 7.8; DB 1; Length 11;
 Best Local Similarity 81.8%; Pred. No. 2.8e+02;
 Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 929 TATCCCTCTCTC 939
 Db 1 TTTCGCGCTC 11

RESULT 510
 US-08-049-283A-2/c
 Sequence 2, Application US/08049283A
 Patent No. 5502176


```
; GENERAL INFORMATION:
; APPLICANT: Tenen, Daniel G.
; APPLICANT: Pahl, Helke L.
; APPLICANT: Burn, Timothy C.
; TITLE OF INVENTION: Cell Specific Promoter and Uses Thereof
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/049,283A
; FILING DATE: 14-APR-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/837,776
; FILING DATE: 13-FEB-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Brock, David E.
; REGISTRATION NUMBER: 22,592
; REFERENCE/DOCKET NUMBER: BIH91-03'A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-049-283A-2
;
; Query Match 10.7%; Score 7.8; DB 1; Length 11;
; Best Local Similarity 81.8%; Pred. No. 2.8e+02;
; Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
Qy 919 CTTTCCTTTT 929
Db 11 CTTTCCTTTT 1
;
RESULT 511
US-08-435-350-109/c
; Sequence 109, Application US/08435350
; Patent No. 5599704
; GENERAL INFORMATION:
; APPLICANT: James D. Thompson
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: TREATMENT OF BREAST CANCER
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
```

```
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,350
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936,531
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION/DOCKET NUMBER: 197/245
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 109:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-350-109
;
; Query Match 10.7%; Score 7.8; DB 1; Length 11;
; Best Local Similarity 81.8%; Pred. No. 2.8e+02;
; Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
Qy 916 GGTCTTGGCCT 926
Db 11 GGACTTGGCCT 1
;
RESULT 512
US-08-196-103A-13
; Sequence 13, Application US/08196103A
; Patent No. 5672472
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; APPLICANT: Anderson, Kevin
; APPLICANT: Bruice, Thomas A.
; APPLICANT: Davis, Peter
; APPLICANT: Driver, Vickie
; APPLICANT: Hanecak, Ronnie C.
; APPLICANT: Vickers, Timothy A.
; APPLICANT: Wyatt, Jacqueline
; TITLE OF INVENTION: Synthetic Unrandomization of Oligomer
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5672472ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/196,103A
; FILING DATE: February 22, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 749,000
; FILING DATE: 23-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
```

REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-0678
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA (genomic)
US-08-196-103A-13

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 54.5%; Pred. No. 2.8e+02;
Matches 6; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 932 CCCTCCTCTTC 942
DB 1 CCCUCCCUU 11

RESULT 513
US-08-314-309A-34/C
Sequence 34, Application US/08314309A
Patent No. 5677141
GENERAL INFORMATION:
APPLICANT: ISOGAI, TAKAO
APPLICANT: FUKAGAWA, MASAO
APPLICANT: IWAMI, MORITA
APPLICANT: IRAMORI, ICHIRO
APPLICANT: KOJO, HITOSHI
TITLE OF INVENTION: PROCESS FOR PRODUCING 7-AMINOCEPHM
TITLE OF INVENTION: COMPOUND OR SALTS THEREOF
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MATER & NEUSTADT,
ADDRESSEE: P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/314,309A
FILING DATE: 30-SEP-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/631,906
FILING DATE: 21-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Oblon, No. 5677141man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 18-863-0 CONT
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248655 OPAT UR
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid;
DESCRIPTION: synthetic DNA
US-08-314-309A-34

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 958 CGGTACCAACG 968
DB 11 CGGTACCAACG 1

RESULT 514
US-08-357-396-13
Sequence 13, Application US/08357396
Patent No. 5698391
GENERAL INFORMATION:
APPLICANT: Philip Dan Cook
APPLICANT: Ecker, David J.
APPLICANT: Anderson, Kevin
APPLICANT: Bruice, Thomas A.
APPLICANT: Davis, Peter
APPLICANT: Dreier, Vickie
APPLICANT: Freiler, Susan, M.
APPLICANT: Hanecak, Ronnie C.
APPLICANT: Vickers, Timothy A.
APPLICANT: Wyatt, Jacqueline
APPLICANT: Yogesh S. Sanghvi
TITLE OF INVENTION: Improved Methods for Synthetic Unrandomization
TITLE OF INVENTION: of Oligomer Fragments
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5698391iris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/357,396
FILING DATE:
CLASSIFICATION: 436
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 749,000
FILING DATE: 23-AUG-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 196,103
FILING DATE: 22-FEB-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ralph, Rebecca L.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1745
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA (genomic)
US-08-357-396-13

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 54.5%; Pred. No. 2.8e+02;
Matches 6; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 932 CCCTCCTCTTC 942
DB 11 CCCUCCCUU 11

Db 1 CCCUCCCUUC 11

RESULT 515
US-08-386-141-13
; Sequence 13, Application US/08386141
; Patent No. 5747253
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; APPLICANT: Davis, Peter
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: COMBINATORIAL OLIGOMER
; TITLE OF INVENTION: IMMUNOABSORBENT SCREENING ASSAY FOR TRANSCRIPTION
; TITLE OF INVENTION: FACTORS AND OTHER BIOMOLECULE BINDING
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESSEE: No. 5747253rls
; STREET: One Liberty Place - 46th Floor
; City: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/386.141
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/032.852
; FILING DATE: 16 MAR 1993
; APPLICATION NUMBER: US/07/749,000
; FILING DATE: 23-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-0653
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA (genomic)
US-08-386-141-13

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 54.5%; Pred. No. 2.8e+02;
Matches 6; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 932 CCCTCCTCTTC 942
|||:|:|:
Db 1 CCCUCCCUUC 11

RESULT 516
US-08-173-489C-60
; Sequence 60, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 932 CCCTCCTCTTC 942
|||:|:|:
Db 1 CTCTCCCTTC 11

RESULT 517
US-08-173-489C-138
; Sequence 138, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C

FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 138:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from Hepatitis B
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 138 :FROM 1 TO 11
US-08-173-489C-138

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 926 TTTTATCCCTC 936
DB 1 TTTTTCCTC 11

RESULT 518
US-08-173-489C-150
Sequence 150, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSER: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 150:

SEQUENCE CHARACTERISTICS:
LENGTH: 11 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from Hepatitis B
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 150 :FROM 1 TO 11
US-08-173-489C-150

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 931 TCCCTCCTCTT 941
DB 1 TCCCTCCTCTT 11

RESULT 519
US-08-173-489C-221/c
Sequence 221, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSER: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 221:

SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 23s tRNA gene from Escherichia coli
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Escherichia coli
STRAIN: MRE600

```

;      PUBLICATION INFORMATION;
;      RELEVANT RESIDUES IN SEQ ID NO: 226 :FROM 1 TO 11
US-08-173-489C-226

Query Match      10.7%;   Score 7.8;   DB 1;   Length 11;
Best Local Similarity 81.8%;   Pred. NO. 2.8e+02;
Matches 9;   Conservative 0;   Mismatches 2;   Indels

Qy      905   TCATTTTCCTT 915
      |||||
Db      1   TCCITTCCTT 11

RESULT 521
US-08-173-489C-265/c
Sequence 265; Application US/08173489C

```

; PATENT NO. 3861244
 ;
 ; GENERAL INFORMATION:
 ;
 ; APPLICANT: WANG, C. -G.
 ;
 ; APPLICANT: HEPBURN, A. G.

; TITLE OF INVENTION: GENETIC SEQUENCE ANALYSIS DATA
 ; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
 ; NUMBER OF SEQUENCES: 365
 ; CORRESPONDENCE ADDRESS:

CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:

NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9519-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 265:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 23s rRNA gene from Rhodobacter
DESCRIPTION: capsulatus (Accession # X06485) nucleotides
DESCRIPTION: 1038 to 1048
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Rhodobacter capsulatus
STRAIN: dsm 938

PUBLICATION INFORMATION:
 AUTHORS: Reenburger, A. Ludwig, W. Frank, R,
 Bloecker, H, Schleifer, K.H.
 TITLE: Complete nucleotide sequence
 of a 23S ribosomal RNA gene from Rhodobacter
 capsulatus
 JOURNAL: Nucleic Acids Research
 VOLUME: 16
 PAGES: 2343-2343

DATE: 1988
RELEVANT RESIDUES IN SEQ ID NO: 265 :FROM 1 TO 11
US-08-173-489C-265

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 929 TATCGCTCTC 939
DB 11 TTTCCCTCTC 1

RESULT 522
US-08-173-489C-295/c
Sequence 295, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 295:

SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 16s rRNA gene from Chlamydia psittaci
DESCRIPTION: (Accession # M13769) nucleotides 203 to 213
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Chlamydia psittaci
PUBLICATION INFORMATION:
AUTHORS: Weisburg, W G, Hatch, T P, Woese, C R.
TITLE: Bacterial Origin of
TITLE: Chlamydiae
JOURNAL: Journal of Bacteriology
VOLUME: 167
PAGES: 570-574
DATE: 1986
RELEVANT RESIDUES IN SEQ ID NO: 295 :FROM 1 TO 11
US-08-173-489C-295

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 935 TCCTCTTCATT 945
DB 11 TCCCTCTCTT 1

RESULT 523
US-08-282-383-2
Sequence 2, Application US/08282383
Patent No. 5864031
GENERAL INFORMATION:
APPLICANT: Sandra E. Russo-Rodriguez
APPLICANT: Tepper M. Koga
TITLE OF INVENTION: 5'-Dithio-Modified
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amgen Inc.
STREET: 1840 Dehavilland Dr.
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 in., DS, 1.4 MB
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh OS 7.0
SOFTWARE: Microsoft Word Version 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/282,383
FILING DATE: 29JUL1994
CLASSIFICATION: 536
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-282-383-2

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 911 TCTTGTCTT 921
DB 1 TTTATGTCTT 11

RESULT 524
US-08-227-180B-18
Sequence 18, Application US/08227180B
Patent No. 5866698
GENERAL INFORMATION:
APPLICANT: Ecker et al.
TITLE OF INVENTION: Modulation of Gene Expression
TITLE OF INVENTION: Through Interference with RNA Secondary Structure
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jane Massey Licata, Esq.
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM 486
OPERATING SYSTEM: WINDOWS FOR WORKGROUPS

;; SOFTWARE: WORDPERFECT 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/027,180B
;; FILING DATE: April 13, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/518,929
;; FILING DATE: May 4, 1990
;; APPLICATION NUMBER: PCT/US91/02588
;; FILING DATE: April 15, 1991
;; APPLICATION NUMBER: 07/801,168
;; FILING DATE: No. 5866698ember 20, 1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISIS-1420
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (215) 568-3100
;; TELEFAX: (215) 568-3439
;; INFORMATION FOR SEQ ID NO: 18:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 11
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; ANTI-SENSE: yes
US-08-227-180B-18

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 54.5%; Pred. No. 2.8e+02;
Matches 6; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 932 CCTCTCTCTTC 942
|||:|:|
Db 1 CCCUCCCUUC 11

RESULT 525
US-08-991-830A-6
; Sequence 6, Application US/08991830A
; Patent No. 6027892
; GENERAL INFORMATION:
; APPLICANT: Chang, Esther H.
; APPLICANT: Pirolo, Kathleen F.
; TITLE OF INVENTION: Compositions and Methods for Reducing Radiation and Drug Resis
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sana A. Pratt
; STREET: 10821 Hillbrooke Lane
; CITY: Potomac
; STATE: MARYLAND
; COUNTRY: USA
; ZIP: 20854
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 7.5
; SOFTWARE: Microsoft Word 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,830A
; FILING DATE: 16 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/034,160
; FILING DATE: 30 December 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Sana A. Pratt
; REGISTRATION NUMBER: 39,441
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (301) 294-9171
; TELEFAX: (301) 294-7357
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: Nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; MOLECULE TYPE: DNA
US-08-991-830A-6

;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 11 base pairs
;; TYPE: Nucleic acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; MOLECULE TYPE: DNA
US-08-991-830A-6

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 928 TTATCCCTCCT 938
|||||
Db 1 TTATACGTCT 11

RESULT 526
US-08-991-830A-7
; Sequence 7, Application US/08991830A
; Patent No. 6027892
; GENERAL INFORMATION:
; APPLICANT: Chang, Esther H.
; APPLICANT: Pirolo, Kathleen F.
; TITLE OF INVENTION: Compositions and Methods for Reducing Radiation and Drug Resis
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sana A. Pratt
; STREET: 10821 Hillbrooke Lane
; CITY: Potomac
; STATE: MARYLAND
; COUNTRY: USA
; ZIP: 20854
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 7.5
; SOFTWARE: Microsoft Word 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,830A
; FILING DATE: 16 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/034,160
; FILING DATE: 30 December 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Sana A. Pratt
; REGISTRATION NUMBER: 39,441
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (301) 294-9171
; TELEFAX: (301) 294-7357
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: Nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; MOLECULE TYPE: DNA
US-08-991-830A-7

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 928 TTATCCCTCCT 938
|||||
Db 1 TTATACGTCT 11

RESULT 527
US-09-105-515-3
; Sequence 3, Application US/09105515


```
US-09-157-257-39/c
; Sequence 39, Application US/09157257
; Patent No. 6375934
; GENERAL INFORMATION:
; APPLICANT: DUTTA, Sukanta K.
; APPLICANT: BISWAS, Biswajit
; APPLICANT: VEMULAPALLI, Ramesh
; TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
; TITLE OF INVENTION: POTOMAC HORSE FEVER
; FILE REFERENCE: 8172-9016
; CURRENT APPLICATION NUMBER: US/09/157,257
; CURRENT FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 60/059,252
; EARLIER FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Ehrlichia risticii
US-09-157-257-39

Query Match          10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 948 TTAAATGATC 958
Db 11 TTAAATTTATC 1

RESULT 532
US-09-748-044-3
; Sequence 3, Application US/09748044
; Patent No. 6458578
; GENERAL INFORMATION:
; APPLICANT: Brough, Douglas E.
; APPLICANT: Kovesh, Imre
; TITLE OF INVENTION: Recombinant Cell Line
; FILE REFERENCE: 207952
; CURRENT APPLICATION NUMBER: US/09/748,044
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: PCT/US99/14333
; PRIOR FILING DATE: 1999-06-24
; PRIOR APPLICATION NUMBER: US 09/105,515
; PRIOR FILING DATE: 1998-06-26
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Adenovirus type 5
US-09-748-044-3

Query Match          10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 902 TGTGATTTTC 912
Db 1 TTGTCAGTTTC 11

RESULT 533
US-09-475-947A-167/c
; Sequence 167, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667

US-09-157-257-39/c
; Sequence 39, Application US/09157257
; Patent No. 6375934
; GENERAL INFORMATION:
; APPLICANT: DUTTA, Sukanta K.
; APPLICANT: BISWAS, Biswajit
; APPLICANT: VEMULAPALLI, Ramesh
; TITLE OF INVENTION: A SIZE-VARIABLE STRAIN-SPECIFIC PROTECTIVE ANTIGEN FOR
; TITLE OF INVENTION: POTOMAC HORSE FEVER
; FILE REFERENCE: 8172-9016
; CURRENT APPLICATION NUMBER: US/09/157,257
; CURRENT FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 60/059,252
; EARLIER FILING DATE: 1997-09-18
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Ehrlichia risticii
US-09-157-257-39

Query Match          10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 948 TTAAATGATC 958
Db 11 TTAAATTTATC 1

RESULT 532
US-09-748-044-3
; Sequence 3, Application US/09748044
; Patent No. 6458578
; GENERAL INFORMATION:
; APPLICANT: Brough, Douglas E.
; APPLICANT: Kovesh, Imre
; TITLE OF INVENTION: Recombinant Cell Line
; FILE REFERENCE: 207952
; CURRENT APPLICATION NUMBER: US/09/748,044
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: PCT/US99/14333
; PRIOR FILING DATE: 1999-06-24
; PRIOR APPLICATION NUMBER: US 09/105,515
; PRIOR FILING DATE: 1998-06-26
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Adenovirus type 5
US-09-748-044-3

Query Match          10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 902 TGTGATTTTC 912
Db 1 TTGTCAGTTTC 11

RESULT 533
US-09-475-947A-167/c
; Sequence 167, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667

US-09-475-947A-231
; Sequence 231, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 231
; LENGTH: 11
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-231

Query Match          10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 905 TCATTTTCITT 915
Db 11 TAAATTTTITT 1

RESULT 534
US-09-475-947A-231
; Sequence 231, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 231
; LENGTH: 11
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-231

Query Match          10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 905 TCATTTTCITT 915
Db 11 TAAATTTTITT 1

RESULT 535
US-09-373-129A-14
; Sequence 14, Application US/09373129A
; Patent No. 6518481
; GENERAL INFORMATION:
; APPLICANT: Wimmer, Ernest A.
; APPLICANT: Berghammer, Andreas J.
; APPLICANT: Klingler, Martin
; TITLE OF INVENTION: Universal markers of Transgenesis
; FILE REFERENCE: EX-W199-0014
; CURRENT APPLICATION NUMBER: US/09/373,129A
; CURRENT FILING DATE: 1999-08-12
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-09-373-129A-14

Query Match          10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 941 TCATTGGTTA 951
Db 1 TAATTGGGTTA 11

RESULT 536
US-09-395-017B-48
; Sequence 48, Application US/09395017B
; Patent No. 6642014
; GENERAL INFORMATION:
; APPLICANT: Pedersen, Henrik
; APPLICANT: Holder, Sven
; APPLICANT: Kjems, Jorgen
; APPLICANT: Lund, Mette
; TITLE OF INVENTION: Enzyme Activity Screen With Direct
; TITLE OF INVENTION: Substrate Reloading
; FILE REFERENCE: 5654.204-US
; CURRENT APPLICATION NUMBER: US/09/395,017B
; CURRENT FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PA 1998 01044
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: PA 1998 01106
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: PCT/DK99/00441
; PRIOR FILING DATE: 1999-08-19
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-395-017B-48

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 935 TCCTCTTCATT 945
Db 1 TGCCCTTCATT 11

RESULT 537
US-09-529-812A-5/c
; Sequence 5, Application US/09529812A
; Patent No. 6682930
; GENERAL INFORMATION:
; APPLICANT: LU, CHANGDE
; TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN
; FILE OF INVENTION: ANTI-HBV
; FILE REFERENCE: 017227/0160
; CURRENT APPLICATION NUMBER: US/09/529,812A
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/CN98/00248
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: CN 97106667.1
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Triplex
; OTHER INFORMATION: forming oligonucleotide
; OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
US-09-529-812A-5

Query Match 10.7%; Score 7.8; DB 1; Length 11;

QY 941 TCATTGGTTA 951
Db 1 TAATTGGGTTA 11

RESULT 536
US-09-395-017B-48
; Sequence 48, Application US/09395017B
; Patent No. 6642014
; GENERAL INFORMATION:
; APPLICANT: Pedersen, Henrik
; APPLICANT: Holder, Sven
; APPLICANT: Kjems, Jorgen
; APPLICANT: Lund, Mette
; TITLE OF INVENTION: Enzyme Activity Screen With Direct
; TITLE OF INVENTION: Substrate Reloading
; FILE REFERENCE: 5654.204-US
; CURRENT APPLICATION NUMBER: US/09/395,017B
; CURRENT FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PA 1998 01044
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: PA 1998 01106
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: PCT/DK99/00441
; PRIOR FILING DATE: 1999-08-19
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-395-017B-48

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 935 TCCTCTTCATT 945
Db 1 TGCCCTTCATT 11

RESULT 537
US-09-529-812A-5/c
; Sequence 5, Application US/09529812A
; Patent No. 6682930
; GENERAL INFORMATION:
; APPLICANT: LU, CHANGDE
; TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN
; FILE OF INVENTION: ANTI-HBV
; FILE REFERENCE: 017227/0160
; CURRENT APPLICATION NUMBER: US/09/529,812A
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/CN98/00248
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: CN 97106667.1
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Triplex
; OTHER INFORMATION: forming oligonucleotide
; OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
US-09-529-812A-5

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 935 TCCTCTTCATT 945
Db 1 TCCTCTCTCTT 1

RESULT 538
PCT-US95-05835-2
; Sequence 2, Application PC/TUS9505835
; GENERAL INFORMATION:
; APPLICANT: Alexander-Bridges, Maria C.
; APPLICANT: Zhao, Hui-Fen
; TITLE OF INVENTION: INHIBITION OF INSULIN-
; TITLE OF INVENTION: INDUCED ADIPOSIS
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/05835
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA: 08/242,409
; APPLICATION NUMBER: 08/242,409
; FILING DATE: 13 May 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/238001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US95-05835-2

Query Match 10.7%; Score 7.8; DB 1; Length 11;
Best Local Similarity 81.8%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 929 TATCCCTCTCTC 939
Db 1 TTTCCTCTCTC 11

RESULT 539
PCT-US95-09475-2
; Sequence 2, Application PC/TUS9509475
; GENERAL INFORMATION:
; APPLICANT: Angen Inc.
; TITLE OF INVENTION: 5'-Dithio-Modified
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Angen Inc.
; STREET: 1840 Dehavilland Dr.
; CITY: Thousand Oaks
```

Query Match	Best Local Similarity	Score	DB 1;	Length	Indels	Mismatches	Conservative	Gaps
Query Match	81.8%	10.7%	DB 1;	Length 12;	2	0	0	0
Best Local Similarity	81.8%	10.7%	DB 1;	Length 12;	2	0	0	0
Mismatches	9	Conservative	0	Mismatches	2	Indels	0	Gaps
QY	950	TAATGTCGTCGC	960					
DB	12	TACGGTATCGC	2					
RESULT 541								
US-08-242-409-1/c								
Sequence 1, Application US/08242409								
Patent No. 5496831								
GENERAL INFORMATION:								
APPLICANT: Alexander-Bridges, Maria C.								
APPLICANT: Zhao, Hui-Pen								
TITLE OF INVENTION: INHIBITION OF INSULIN-INDUCED								
TITLE OF INVENTION: ADIPOSIS								
NUMBER OF SEQUENCES: 12								
CORRESPONDENCE ADDRESS:								
ADDRESSEE: Fish & Richardson								
STREET: 225 Franklin Street								
CITY: Boston								
STATE: Massachusetts								
COUNTRY: U.S.A.								
ZIP: 02110-2804								
COMPUTER READABLE FORM:								
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb								
COMPUTER: IBM PS/2 Model 50Z or 55SX								
OPERATING SYSTEM: MS-DOS (Version 5.0)								
SOFTWARE: WordPerfect (Version 5.1)								
CURRENT APPLICATION DATA:								
APPLICATION NUMBER: US/08/242,409								
FILING DATE:								
CLASSIFICATION: 514								
PRIOR APPLICATION DATA:								
APPLICATION NUMBER:								
FILING DATE:								
ATTORNEY/AGENT INFORMATION:								
NAME: Clark, Paul T.								
REGISTRATION NUMBER: 30,162								
REFERENCE/DOCKET NUMBER: 00786/238001								
TELECOMMUNICATION INFORMATION:								
TELEPHONE: (617) 542-5070								
TELEFAX: (617) 542-8906								
INFORMATION FOR SEQ ID NO: 1:								
SEQUENCE CHARACTERISTICS:								
LENGTH: 12								
TYPE: nucleic acid								
STRANDEDNESS: single								
TOPOLOGY: linear								
US-08-242-409-1								
Query Match	81.8%	10.7%	DB 1;	Length 12;	2	0	0	0
Best Local Similarity	81.8%	10.7%	DB 1;	Length 12;	2	0	0	0
Mismatches	9	Conservative	0	Mismatches	2	Indels	0	Gaps
QY	929	TATCCCTCCTC	939					
DB	11	TTTCCCGCTC	1					
RESULT 542								
US-08-235-503B-22/c								
Sequence 22, Application US/08235503B								
Patent No. 5563036								
GENERAL INFORMATION:								
APPLICANT: Peterson, Michael G								

Query Match	Best Local Similarity	Score	DB 1;	Length	12;
Query Match	81.8%;	10.7%;	DB 1;	Length 12;	
Best Local Similarity	81.8%;	10.7%;	DB 1;	Length 12;	
Matches	9; Conservative	0; Mismatches	2; Indels	0; Gaps	0;
QY	950 TAAATGTCGC 960				
DB	12 TACGGTATCGC 2				
RESULT 541					
US-08-242-409-1/c					
Sequence 1, Application US/08242409					
Patent No. 5496831					
GENERAL INFORMATION:					
APPLICANT: Alexander-Bridges, Maria C.					
APPLICANT: Zhao, Hui-Pen					
TITLE OF INVENTION: INHIBITION OF INSULIN-INDUCED					
TITLE OF INVENTION: ADIPOSIS					
NUMBER OF SEQUENCES: 12					
CORRESPONDENCE ADDRESS:					
ADDRESSEE: Fish & Richardson					
STREET: 225 Franklin Street					
CITY: Boston					
STATE: Massachusetts					
COUNTRY: U.S.A.					
ZIP: 02110-2804					
COMPUTER READABLE FORM:					
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb					
COMPUTER: IBM PS/2 Model 50Z or 55SX					
OPERATING SYSTEM: MS-DOS (Version 5.0)					
SOFTWARE: WordPerfect (Version 5.1)					
CURRENT APPLICATION DATA:					
APPLICATION NUMBER: US/08/242,409					
FILING DATE:					
CLASSIFICATION: 514					
PRIOR APPLICATION DATA:					
APPLICATION NUMBER:					
FILING DATE:					
ATTORNEY/AGENT INFORMATION:					
NAME: Clark, Paul T.					
REGISTRATION NUMBER: 30,162					
REFERENCE/DOCKET NUMBER: 00786/238001					
TELECOMMUNICATION INFORMATION:					
TELEPHONE: (617) 542-5070					
TELEFAX: (617) 542-8906					
INFORMATION FOR SEQ ID NO: 1:					
SEQUENCE CHARACTERISTICS:					
LENGTH: 12					
TYPE: nucleic acid					
STRANDEDNESS: single					
TOPOLOGY: linear					
US-08-242-409-1					
QY	929 TATCCCTCCTC 939				
DB	11 TTCCCGCCTC 1				
RESULT 542					
US-08-235-503B-22/c					
Sequence 22, Application US/08235503B					
Patent No. 5563036					
GENERAL INFORMATION:					
APPLICANT: Peterson, Michael G					

APPLICANT: Baichwal, Vijay R
APPLICANT: Scrulovici, Beta
TITLE OF INVENTION: TRANSCRIPTION FACTOR-DNA ASSAY
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSES: FLHR, HOBBACH, TEST, ALBRITTON & HERBERT
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/235,503B
FILING DATE: 29-APR-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: A-59332/RAO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-235-503B-22

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 54.5%; Pred. No. 3e+02;
Matches 6; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 915 TGGTCTTTGCC 925
Db 11 TGRMCYTWGCM 1

RESULT 543
US-08-242-664-13/c
Sequence 13, Application US/08242664
Patent No. 5571937
GENERAL INFORMATION:
APPLICANT: Watanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Weil, Roger
TITLE OF INVENTION: Complementary DNA and Toxins
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSES: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/242,664
FILING DATE: May 12, 1994
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:

NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-242-664-13

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 932 CCCTCTCTTC 942
Db 12 CCTTCTCTTC 2

RESULT 544
US-08-110-158-13
Sequence 13, Application US/08110158
Patent No. 5605821
GENERAL INFORMATION:
APPLICANT: McEvey, Rodger P.
APPLICANT: Pan, Junliang
TITLE OF INVENTION: Expression Control Sequences of the
TITLE OF INVENTION: P-Selectin Gene
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Patrea L. Pabst
STREET: 1100 Peachtree Street, Suite 2800
CITY: Atlanta
STATE: GA
COUNTRY: USA
ZIP: 30309-4530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/110,158
FILING DATE: 19930820
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/320,408
FILING DATE: 08-MAR-1989
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404)-815-6508
TELEFAX: (404)-815-6555
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-110-158-13

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 944 TTGGTTTATG 954

Db 2 TTGGTTTAAAG 12
RESULT 545
US-08-147-696E-24/c
; Sequence 24, Application US/08147696E
; Patent No. 5648267
; GENERAL INFORMATION:
; APPLICANT: REFF, Mitchell E.
; TITLE OF INVENTION: IMPAIRED DOMINANT SELECTABLE MARKER
; TITLE OF INVENTION: SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT
; TITLE OF INVENTION: OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR
; TITLE OF INVENTION: SYSTEMS COMPRISING SAME
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/147,696E
; FILING DATE: 03-NOV-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US 07/977,691
; FILING DATE: 13-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-010
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-147-696E-24
Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2;
QY 949 TTAATGATATCG 959
Db 12 TTAATTAATCG 2
RESULT 546
US-08-484-138-13/c
; Sequence 13, Application US/08484138
; Patent No. 5652350
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Wei, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York

STATE: New York
COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44MB
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,138
FILING DATE: June 7, 1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-Z/JPW/MJG
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-484-138-13
Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2;
QY 932 CCTCTCTCTTC 942
Db 12 CCTCTCTCTTC 2
RESULT 547
US-08-586-120-5/c
; Sequence 5, Application US/08586120
; Patent No. 5656740
; GENERAL INFORMATION:
; APPLICANT: GROSZ, RONALD
; APPLICANT: JENSEN, MARK A.
; TITLE OF INVENTION: SELECTION OF DIAGNOSTIC
; TITLE OF INVENTION: GENETIC MARKERS IN
; TITLE OF INVENTION: MICROORGANISMS AND USE
; TITLE OF INVENTION: OF A SPECIFIC MARKER
; TITLE OF INVENTION: FOR DETECTION OF
; TITLE OF INVENTION: SALMONELLA
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: E.I. DU PONT DE NEMOURS
; ADDRESSEE: AND COMPANY
; STREET: 1007 MARKET STREET
; CITY: WILMINTON
; STATE: DELAWARE
; COUNTRY: U.S.A.
; ZIP: 19898
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: MACINTOSH
OPERATING SYSTEM: MACINTOSH SYSTEM 6.0
SOFTWARE: MICROSOFT WORD 4.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/586,120
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: GEIGER, KATHLEEN W.
REGISTRATION NUMBER: 35,880
REFERENCE/DOCKET NUMBER: MD-1068
TELECOMMUNICATION INFORMATION:

TELEPHONE: 302-892-8112
TELEFAX: 302-892-7949
TELEX: 835420
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-586-120-5

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 950 TAATGTATCGC 960
DB 12 TACGGTATCGC 2

RESULT 548
US-08-254-355-5/c
Sequence 5, Application US/08254355
Patent No. 5660981
GENERAL INFORMATION:
APPLICANT: GROSZ, RONALD
APPLICANT: JENSEN, MARK A.
TITLE OF INVENTION: SELECTION OF DIAGNOSTIC
TITLE OF INVENTION: GENETIC MARKERS IN
TITLE OF INVENTION: MICROORGANISMS AND USE
TITLE OF INVENTION: OF A SPECIFIC MARKER
TITLE OF INVENTION: FOR DETECTION OF
TITLE OF INVENTION: SALMONELLA
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. DU PONT DE NEMOURS
ADDRESSEE: AND COMPANY
STREET: 1007 MARKET STREET
CITY: WILMINTON
STATE: DELAWARE
COUNTRY: U.S.A.
ZIP: 19898

COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: MACINTOSH
OPERATING SYSTEM: MACINTOSH SYSTEM 6.0
SOFTWARE: MICROSOFT WORD 4.0
CURRENT APPLICATION DATA:
FILING DATE: US/08/254,355
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: GRIGER, KATHLEEN W.
REGISTRATION NUMBER: 35,880
REFERENCE/DOCKET NUMBER: MD-1068
TELEPHONE: 302-892-8112
TELEFAX: 302-892-7949
TELEX: 835420
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-254-355-5

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 950 TAATGTATCGC 960
DB 12 TACGGTATCGC 2

RESULT 549
US-08-314-309A-28
Sequence 28, Application US/08314309A
Patent No. 5677141
GENERAL INFORMATION:
APPLICANT: ISOGAI, TAKAO
APPLICANT: FUKAGAWA, MASAO
APPLICANT: IWAMI, MORITA
APPLICANT: ARAMORI, ICHIRO
APPLICANT: KOJO, HITOSHI
TITLE OF INVENTION: PROCESS FOR PRODUCING 7-AMINOCEPHEM
TITLE OF INVENTION: COMPOUND OR SALTS THEREOF
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
ADDRESSEE: P.C.
STREET: 1755 S. Jefferson Davis Highway, Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/314,309A
FILING DATE: 30-SEP-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/631,906
FILING DATE: 21-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Oblon, No. 5677141man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 18-863-0 CONT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid;
DESCRIPTION: synthetic DNA
US-08-314-309A-28

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCAT 944
DB 1 CTCCTCTTCAT 11

RESULT 550
US-08-336-132-9/c
Sequence 9, Application US/08336132
Patent No. 5693508
GENERAL INFORMATION:
APPLICANT: CHANG, LUNG-JI
TITLE OF INVENTION: RETROVIRAL VECTORS
NUMBER OF SEQUENCES: 27

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HAVERSHOCK, MEDLEN & CARROLL
; STREET: 220 MONTGOMERY STREET, SUITE 2200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/336,132
; FILING DATE: 07-NOV-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: CARROLL, PETER G.
; REGISTRATION NUMBER: 32,837
; REFERENCE/DOCKET NUMBER: CHANG-00817
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-336-132-9

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 954 GTATCGCTACC 964
Db 11 GTACCGCTAGC 1

RESULT 551
US-08-411-727-5
; Sequence 5, Application US/08411727
; Patent No. 5705161
; Patent No. 5705161 5683703
; GENERAL INFORMATION:
; APPLICANT: VAN DER LEY, Peter Andre
; APPLICANT: POOLMAN, Jan Theunis
; APPLICANT: HOOGERHOUT, Peter
; TITLE OF INVENTION: IMMUNOGENIC MENINGOCOCCAL LPS AND OTHER
; TITLE OF INVENTION: MEMBRANE VESICLES AND VACCINE THEREFROM
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: YOUNG & THOMPSON
; STREET: 745 South 23rd Street, Suite 200
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,727
; FILING DATE: 01-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: NL 9201716
; FILING DATE: 02-OCT-1992
; APPLICATION NUMBER: WO PCT/NL93/00163
; FILING DATE: 30-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: PATCH, Andrew J.
; REGISTRATION NUMBER: 32925
; REFERENCE/DOCKET NUMBER: BO 38275
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-521-2297
; TELEFAX: 703-685-0573
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs

; APPLICATION NUMBER: WO PCT/NL93/00163
; FILING DATE: 30-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: PATCH, Andrew J.
; REGISTRATION NUMBER: 32925
; REFERENCE/DOCKET NUMBER: BO 38275
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-521-2297
; TELEFAX: 703-685-0573
; TELELEX: 248425 EMBON
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-411-727-5

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 959 GCTACCAACGG 969
Db 1 GGTACGACGG 11

RESULT 552
US-08-411-727-6/c
; Sequence 6, Application US/08411727
; Patent No. 5705161
; Patent No. 5705161 5683703
; GENERAL INFORMATION:
; APPLICANT: VAN DER LEY, Peter Andre
; APPLICANT: POOLMAN, Jan Theunis
; APPLICANT: HOOGERHOUT, Peter
; TITLE OF INVENTION: IMMUNOGENIC MENINGOCOCCAL LPS AND OTHER
; TITLE OF INVENTION: MEMBRANE VESICLES AND VACCINE THEREFROM
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: YOUNG & THOMPSON
; STREET: 745 South 23rd Street, Suite 200
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,727
; FILING DATE: 01-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: NL 9201716
; FILING DATE: 02-OCT-1992
; APPLICATION NUMBER: WO PCT/NL93/00163
; FILING DATE: 30-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: PATCH, Andrew J.
; REGISTRATION NUMBER: 32925
; REFERENCE/DOCKET NUMBER: BO 38275
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-521-2297
; TELEFAX: 703-685-0573
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-411-727-6

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 959 GCTACCAACGG 969
Db 12 GGTACCAACGG 2

RESULT 553

US-08-484-334-24/c
Sequence 24, Application US/08484334
Patent No. 5733779
GENERAL INFORMATION:
APPLICANT: REF. Mitchell E.
TITLE OF INVENTION: IMPAIRED DOMINANT SELECTABLE MARKER
TITLE OF INVENTION: SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT
TITLE OF INVENTION: OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR
TITLE OF INVENTION: SYSTEMS COMPRISING SAME
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,334
FILING DATE: 07-JUN-1995

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/147,696
FILING DATE: 03-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/977,691
FILING DATE: 13-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-162
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021

INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-484-334-24

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 949 TTAATGATCG 959
Db 12 TTAATGATCG 2

RESULT 554

US-08-608-881A-18/c
Sequence 18, Application US/08608881A
Patent No. 5747257
GENERAL INFORMATION:
APPLICANT: JENSEN, MARK A

TITLE OF INVENTION: GENETIC MARKERS AND METHODS FOR
TITLE OF INVENTION: THE DETECTION OF E. COLI
TITLE OF INVENTION: SEROTYPE-0157:H7
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. DU PONT

STREET: 1007 MARKET STREET
CITY: WILMINGTON
STATE: DELAWARE
COUNTRY: U.S.A.
ZIP: 19898

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/608,881A
FILING DATE:
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: FLOYD, LINDA A
REFERENCE/DOCKET NUMBER: MD1062
TELECOMMUNICATION INFORMATION:
TELEPHONE: 302-892-8112
TELEFAX: 302-892-5374
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-608-881A-18

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 950 TAATGTATCGC 960
Db 12 TACGGTATCGC 2

RESULT 555

US-08-360-125-41/c
Sequence 41, Application US/08360125
Patent No. 5767246
GENERAL INFORMATION:
APPLICANT: Saiko HOSOKAWA

APPLICANT: Toshiaki TAGAWA
APPLICANT: Yoko HIRAKAWA
APPLICANT: No. 5767246hiko ITO
APPLICANT: Kazuhiro NAGAIKE
TITLE OF INVENTION: Human Monoclonal Antibody
TITLE OF INVENTION: Specifically Binding to Surface Antigen of Cancer
TITLE OF INVENTION: Cell Membrane
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wenderoth, Lind & Ponack
STREET: 805 Fifteenth Street, N.W., #700
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 500 kb

COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/360,125
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/905,534
FILING DATE: June 29, 1992
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: Warren M. Cheek, Jr.
REGISTRATION NUMBER: 33,367
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-8850
TELEFAX:
TELEX:
INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL:
ANTI-SENSE:
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM:
STRAIN:
INDIVIDUAL ISOLATE:
DEVELOPMENTAL STAGE:
HAPLOTYPE:
TISSUE TYPE:
CELL TYPE: Hybridoma producing human antibody 1-3-1
CELL LINE:
ORGANELLE:
IMMEDIATE SOURCE:
LIBRARY:
CLONE:
POSITION IN GENOME:
CHROMOSOME/SEGMENT:
MAP POSITION:
UNITS:
FEATURE:
NAME/KEY:
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION:
PUBLICATION INFORMATION:
AUTHORS:
TITLE:
JOURNAL:
VOLUME:
ISSUE:
PAGES:
DATE:
DOCUMENT NUMBER:
FILING DATE:
PUBLICATION DATE:
RELEVANT RESIDUES IN SEQ ID NO:

US-08-360-125-41

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 905 TCATTTCCTT 915
Db 11 TCACGTCTTT 1

RESULT 556
US-08-545-785-2
; Sequence 2; Application US/08545785
; Patent No. 5770713
; GENERAL INFORMATION:
; APPLICANT: Imbach and Rayner
; TITLE OF INVENTION: Phosphorothioate Triester Oligonucleotides
; TITLE OF INVENTION: And Method Of Preparation
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5770713ris LLP
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA: US/08/545,785
; APPLICATION NUMBER: US/08/545,785
; FILING DATE: 17-JAN-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2114
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-545-785-2

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 926 TTTTATCCCTC 936
Db 1 TCCTTCCCTC 11

RESULT 557
US-08-441-887A-71
; Sequence 71; Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipschutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California

; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/082,937
; FILING DATE: 25-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joseph O.
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-0041600S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-326-2400
; TELEFAX: 650-326-2422
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (probe)
; US-08-441-887A-71

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 961 TACCACGGTG 971
Db 1 TAGACGGGTG 11

RESULT 558
US-08-441-887A-91/c
; Sequence 91, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/082,937
; FILING DATE: 25-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joseph O.
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-0041600S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-326-2400
; TELEFAX: 650-326-2422
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (probe)
; US-08-441-887A-91

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 927 TTTATCCCTCC 937
Db 11 TTTTCCCTCC 1

RESULT 559
US-08-441-887A-103/c
; Sequence 103, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

```
/ APPLICATION NUMBER: US 08/082,937
/ FILING DATE: 25-JUN-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Liebeschuetz, Joseph O.
/ REGISTRATION NUMBER: 37,505
/ REFERENCE/DOCKET NUMBER: 018547-004160US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 650-326-2400
/ TELEFAX: 650-326-2422
/ INFORMATION FOR SEQ ID NO: 103:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (probe)
/ US-08-441-887A-103

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      956 ATCGCTACCAA 966
DB      12 ATCTGTGCAA 2

RESULT 560
US-08-441-887A-135/c
/ Sequence 135, Application US/08441887A
/ Patent No. 5837832
/ GENERAL INFORMATION:
/ APPLICANT: Chee, Mark
/ APPLICANT: Cronin, Maureen T.
/ APPLICANT: Fodor, Stephen P.A.
/ APPLICANT: Huang, Xiaohua X.
/ APPLICANT: Hubbard, Earl A.
/ APPLICANT: Lipshutz, Robert J.
/ APPLICANT: Lobban, Peter E.
/ APPLICANT: Morris, Macdonald S.
/ APPLICANT: Sheldon, Edward L.
/ TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
/ TITLE OF INVENTION: Biological Chips
/ NUMBER OF SEQUENCES: 360
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Townsend and Townsend and Crew LLP
/ STREET: Two Embarcadero Center, 8th Floor
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94111
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/441,887A
/ FILING DATE: 16-MAY-1995
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/143,312
/ FILING DATE: 26-OCT-1993
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/082,937
/ FILING DATE: 25-JUN-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Liebeschuetz, Joseph O.
/ REGISTRATION NUMBER: 37,505
/ REFERENCE/DOCKET NUMBER: 018547-004160US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 650-326-2400
/ TELEFAX: 650-326-2422
/ INFORMATION FOR SEQ ID NO: 334:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (probe)
```

```
/ TELEFAX: 650-326-2422
/ INFORMATION FOR SEQ ID NO: 135:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (probe)
/ US-08-441-887A-135

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      950 TAATGATATCCG 960
DB      11 TTATTATATCCG 1

RESULT 561
US-08-441-887A-334/c
/ Sequence 334, Application US/08441887A
/ Patent No. 5837832
/ GENERAL INFORMATION:
/ APPLICANT: Chee, Mark
/ APPLICANT: Cronin, Maureen T.
/ APPLICANT: Fodor, Stephen P.A.
/ APPLICANT: Huang, Xiaohua X.
/ APPLICANT: Hubbard, Earl A.
/ APPLICANT: Lipshutz, Robert J.
/ APPLICANT: Lobban, Peter E.
/ APPLICANT: Morris, Macdonald S.
/ APPLICANT: Sheldon, Edward L.
/ TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
/ TITLE OF INVENTION: Biological Chips
/ NUMBER OF SEQUENCES: 360
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Townsend and Townsend and Crew LLP
/ STREET: Two Embarcadero Center, 8th Floor
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94111
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/441,887A
/ FILING DATE: 16-MAY-1995
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/143,312
/ FILING DATE: 26-OCT-1993
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/082,937
/ FILING DATE: 25-JUN-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Liebeschuetz, Joseph O.
/ REGISTRATION NUMBER: 37,505
/ REFERENCE/DOCKET NUMBER: 018547-004160US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 650-326-2400
/ TELEFAX: 650-326-2422
/ INFORMATION FOR SEQ ID NO: 334:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (probe)
```

US-08-441-887A-334

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 934 CTCCTCTTCAT 944
Db 12 CTCCTCAGCAT 2

RESULT 562

US-08-450-578-41/c
; Sequence 41, Application US/08450578
; Patent No. 5837845
; GENERAL INFORMATION:
; APPLICANT: Saiko HOSOKAWA
; APPLICANT: Toshiaki TAGAWA
; APPLICANT: Yoko HIRAKAWA
; APPLICANT: No. 5837845hiko ITO
; APPLICANT: Kazuhiro NAGAIE
; TITLE OF INVENTION: Human Monoclonal Antibody
; TITLE OF INVENTION: Specifically Binding to Surface Antigen of Cancer
; TITLE OF INVENTION: Cell Membrane

NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wenderoth, Lind & Ponack
; STREET: 805 Fifteenth Street, N.W., #700
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005

COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 500 kb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1

CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/450,578

; FILING DATE: May 25, 1995

CLASSIFICATION: 435

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/360,125

; FILING DATE: December 20, 1994

PRIOR APPLICATION DATA: 07/905,534

; FILING DATE: June 29, 1992

ATTORNEY/AGENT INFORMATION:
; NAME: Warren M. Cheek, Jr.

REGISTRATION NUMBER: 33,367

REFERENCE/DOCKET NUMBER:
; TELEPHONE: 202-371-8850

TELEFAX:
; TELEX:

INFORMATION FOR SEQ ID NO: 41:

SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: cDNA

ANTI-SENSE:

FRAGMENT TYPE:

ORGANISM:

STRAIN:

INDIVIDUAL ISOLATE:

DEVELOPMENTAL STAGE:

HAPLOTYPE:

TISSUE TYPE:

CELL TYPE: Hybridoma producing human antibody 1-3-1

CELL LINE:
; ORGANELLE:
; IMMEDIATE SOURCE:
; LIBRARY:
; CLONE:
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT:
; MAP POSITION:
; UNITS:
; FEATURE:
; NAME/KEY:
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION:
; PUBLICATION INFORMATION:
; AUTHORS:
; TITLE:
; JOURNAL:
; VOLUME:
; ISSUE:
; PAGES:
; DATE:
; DOCUMENT NUMBER:
; FILING DATE:
; PUBLICATION DATE:
; RELEVANT RESIDUES IN SEQ ID NO:
; US-08-450-578-41

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 905 TCATTTTCITT 915
Db 11 TCACTGTCITT 1

RESULT 563

US-08-661-330A-14/c
; Sequence 14, Application US/08661330A
; Patent No. 5849485
; GENERAL INFORMATION:
; APPLICANT: Sladek, Frances M.
; APPLICANT: Zhong, Weimin
; APPLICANT: Darnell, Jr., James F.
; TITLE OF INVENTION: LIVER ENRICHED TRANSCRIPTION FACTOR
; NUMBER OF SEQUENCES: 17

CORRESPONDENCE ADDRESS:
; ADDRESSEE: David A. Jackson, Esq.

STREET: 411 Hackensack Ave, Continental Plaza, 4th

CITY: Hackensack

STATE: New Jersey

COUNTRY: USA

ZIP: 07601

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.30

CURRENT APPLICATION DATA: US/08/661,330A

APPLICATION NUMBER: 14-JUN-1996

FILING DATE: 14-JUN-1996

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.

REGISTRATION NUMBER: 26,742

REFERENCE/DOCKET NUMBER: 600-1-030A

TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-487-5800

TELEFAX: 201-343-1684

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:

```

; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "HNF-4 Consensus"
; HYPOTHETICAL: YES
US-08-661-330A-14

Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 54.5%; Pred. No. 3e+02;
Matches 6; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 915 TGTCTTTGCC 925
DB 11 TGTCTTTGCC 1

RESULT 564
US-08-173-489C-84
; Sequence 84, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 84:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 bases
; TYPE: Nucleic Acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from
; DESCRIPTION: retinoblastoma sequence region in Seq ID No. 586124483
; HYPOTHETICAL: Yes
; ANTI-SENSE: No
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 84 :FROM 1 TO 12
US-08-173-489C-84

Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-08-173-489C-84
```

```

QY 909 TTTCTTTGGTC 919
DB 1 TTTCTTTTTC 11

RESULT 565
US-08-173-489C-119
; Sequence 119, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 119:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: beta-globin gene (accession # V00499)
; DESCRIPTION: nucleotides 1284 to 1295
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; PUBLICATION INFORMATION:
; AUTHORS: Lawn, R M, Efstratiadis, A, O'Connell,
; AUTHORS: C, Maniatis, T.
; TITLE: The nucleotide sequence of
; JOURNAL: Cell
; VOLUME: 21
; PAGES: 647-651
; DATE: 1980
; RELEVANT RESIDUES IN SEQ ID NO: 119 :FROM 1 TO 12
US-08-173-489C-119

Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-08-173-489C-119

QY 905 TCATTTCCTTT 915
DB 1 TCATTTCCTTT 11
```

RESULT 566
US-08-173-489C-219/c
; Sequence 219, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 219:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: 23s rRNA gene from Escherichia coli
; DESCRIPTION: (Accession # M25458) nucleotides 785 to 796
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Escherichia coli
; STRAIN: MRE600
; PUBLICATION INFORMATION:
; AUTHORS: Branlant, C, Krol, A, Machatt, M, A,
; AUTHORS: Pouyet, J, Ebel, J P, Edwards, K, Koessel,
; AUTHORS: H.
; TITLE: Primary and secondary
; TITLE: structures of Escherichia coli MRE 600 23S
; TITLE: ribosomal RNA Comparison with models of
; TITLE: secondary structure for maize chloroplast 23S
; TITLE: rRNA and for large portions of mouse and human
; TITLE: 16S mitochondrial rRNAs
; JOURNAL: Nucleic Acids Research
; VOLUME: 9
; PAGES: 4303-4324
; DATE: 1981
; RELEVANT RESIDUES IN SEQ ID NO: 219 :FROM 1 TO 12
US-08-173-489C-219
Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; Indels 0;
Matches 9; Conservative 0; Mismatches 2; Gaps 0;
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.

Db 12 CCTTTCACCCC 2
RESULT 567
US-08-173-489C-246
; Sequence 246, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 246:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 bases
; TYPE: nucleic acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from M. luteus
; DESCRIPTION: 23s region in Seq ID No. 5861244245
; HYPOTHETICAL: yes
; ANTI-SENSE: no
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 246 :FROM 1 TO 12
US-08-173-489C-246
Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; Indels 0;
Matches 9; Conservative 0; Mismatches 2; Gaps 0;
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.

Qy 905 TCATTTCTTT 915
Db 1 TCCTTCTCTT 11
RESULT 568
US-08-173-489C-292
; Sequence 292, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.

NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESS: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44Mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 292:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: third strand derived from C.
DESCRIPTION: pasteurianum 16s region in Seq ID No. 5861244291
HYPOTHETICAL: yes
ANTI-SENSE: no
PUBLICATION INFORMATION:
RELEVANT RESIDUES IN SEQ ID NO: 292 :FROM 1 TO 12
US-08-173-489C-292

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 935 TCCTCTTCATT 945
Db 1 TCCTCTCTCTT 11

RESULT 569
US-08-547-214-13
Sequence 13, Application US/08547214
Patent No. 5871697
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
APPLICANT: Deem, Michael
APPLICANT: Simpson, John
TITLE OF INVENTION: Method for the Determination and
TITLE OF INVENTION: Classification of DNA Sequences in a Sample Without
TITLE OF INVENTION: Sequencing
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSES: Pennie and Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/547,214
FILING DATE: 24-OCT-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mirock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-015-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-547-214-13

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 943 ATGGGTTTAAT 953
Db 1 AGTGGCTTAAT 11

RESULT 570
US-08-761-243C-27/c
Sequence 27, Application US/08761243C
Patent No. 5879879
GENERAL INFORMATION:
APPLICANT: Kamal D. Mehta
TITLE OF INVENTION: No. 5879879el Cis-Acting Element In The Human LDL Receptor Pro
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSEE: Benjamin Aaron Adler, Ph.D., J.D.
STREET: 8011 Candle Lane
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77071

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh
SOFTWARE: Microsoft Word for Macintosh
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/761,243C
FILING DATE: December 6, 1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Benjamin Aaron Adler, Ph.D., J.D.
REGISTRATION NUMBER: 35,423
REFERENCE/DOCKET NUMBER: D5956
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713-777-2321
TELEFAX: 713-777-6908
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bp
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
MOLECULE TYPE:
DESCRIPTION: other nucleic acid
HYPOTHETICAL: No
ANTI-SENSE: No

```

; ORIGINAL SOURCE:
; US-08-761-243C-27
;
; Query Match          10.7%; Score 7.8; DB 1; Length 12;
; Best Local Similarity 81.8%; Pred. No. 3e+02;
; Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 923 GCCTTTTATCC 933
Db 11 GCTTTTAAAC 1

RESULT 571
US-08-766-439-4/c
; Sequence 4, Application US/08766439
; Patent No. 5922538
; GENERAL INFORMATION:
; APPLICANT: HAZEL, JAMES WILLIAM
; APPLICANT: JENSEN, MARK ANTON
; TITLE OF INVENTION: GENETIC MARKERS AND METHODS FOR
; TITLE OF INVENTION: THE DETECTION OF LISTERIA
; TITLE OF INVENTION: MONOCYTOGENES AND LISTERIA SPP.
; NUMBER OF SEQUENCES: 110
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: E. I. DU PONT DE NEMOURS AND COMPANY
; STREET: 1007 MARKET STREET
; CITY: WILMINGTON
; STATE: DELAWARE
; COUNTRY: U.S.A.
; ZIP: 19898
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.50 INCH DISKETTE
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: MICROSOFT WINDOWS 3.1
; SOFTWARE: MICROSOFT WORD 2.0C
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/766,439
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/745,228
; FILING DATE: NOVEMBER 8, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: FLOYD, LINDA AXAMETHY
; REGISTRATION NUMBER: 33,692
; REFERENCE/DOCKET NUMBER: MD-1065-A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 302-892-8112
; TELEFAX: 302-773-0164
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-766-439-4

; Query Match          10.7%; Score 7.8; DB 1; Length 12;
; Best Local Similarity 81.8%; Pred. No. 3e+02;
; Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 950 TAATGTATCGC 960
Db 12 TACGGTATCGC 2

RESULT 572
US-08-663-823B-13
; Sequence 13, Application US/08663823B
; Patent No. 5972693
; GENERAL INFORMATION:
; APPLICANT: Rothberg, Jonathan
;
; Query Match          10.7%; Score 7.8; DB 1; Length 12;
; Best Local Similarity 81.8%; Pred. No. 3e+02;
; Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 943 ATTGGTTTAAAT 953
Db 1 AGTGGCTTAAAT 11

RESULT 573
US-09-017-628-41/c
; Sequence 41, Application US/09017628
; Patent No. 5990287
; GENERAL INFORMATION:
; APPLICANT: HOSOKAWA, Saiko
; APPLICANT: TAGAWA, Toshiaki
; APPLICANT: HIRAKAWA, Yoko
; APPLICANT: ITO, No. 5990287ihiko
; APPLICANT: NAGAIKE, Kazuhiko
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO
; TITLE OF INVENTION: SURFACE ANTIGEN OF CANCER CELL MEMBRANE
; FILE REFERENCE: 177/527361KH
; CURRENT APPLICATION NUMBER: US/09/017,628
; CURRENT FILING DATE: 1998-02-02
; EARLIER APPLICATION NUMBER: 08/360,125
; EARLIER FILING DATE: 1994-12-20
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 41
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Hybridoma producing human antibody 1-3-1

```


US-09-017-628-41

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 905 TCATTTCTTT 915
Db 11 TCACGTCTTT 1

RESULT 574

US-09-014-880-41/C
; Sequence 41, Application US/09014880
; Patent No. 5990297
; GENERAL INFORMATION:
; APPLICANT: SAIKO HOSOKAWA et al.
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODY SPECIFICALLY
; BINDING TO SURFACE ANTIGEN OF CANCER CELL MEMBRANE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wenderoth, Lind & Ponack, L.L.P.
; STREET: 2033 K Street, N.W., #800
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 inch, 1.44 mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: MS-DOS

SOFTWARE: Wordperfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/014,880

FILING DATE: January 28, 1998

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/450,578

FILING DATE: May 25, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/360,125

FILING DATE: December 20, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/905,534

FILING DATE: June 29, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warren M. Cheek, Jr.

REGISTRATION NUMBER: 33,367

REFERENCE/DOCKET NUMBER:

TELEPHONE: 202-721-8200

TELEFAX: 202-721-8250

TELEX:

INFORMATION FOR SEQ ID NO: 41:

SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: CDNA

ORIGINAL SOURCE:

CELL TYPE: Hybridoma producing human antibody 1-3-1

US-09-014-880-41

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 905 TCATTTCTTT 915
Db 11 TCACGTCTTT 1

RESULT 575

US-08-822-586-51
; Sequence 51, Application US/08822586
; Patent No. 6015890
; GENERAL INFORMATION:
; APPLICANT: WILLIAM R. JACOBS, JR., JAMES M. MUSSER AND
; APPLICANT: AMALIO TELENTO
; TITLE OF INVENTION: AN EMBCAB OPERON OF MYCOBACTERIA AND
; TITLE OF INVENTION: MUTANTS THEREOF
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: AMSTER, ROTHSTEIN & EBERSTEIN
; STREET: 90 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 10016

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 INCH 1.44 Mb STORAGE

MEDIUM TYPE: DISKETTE

COMPUTER: IBM PC COMPATIBLE

OPERATING SYSTEM: MS-DOS

SOFTWARE: ASCII

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/822,586

FILING DATE: MARCH 20, 1997

ATTORNEY/AGENT INFORMATION:

NAME: ELIZABETH A. BOGOSIAN

REGISTRATION NUMBER: 39,911

REFERENCE/DOCKET NUMBER: 96700/437

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 697-5995

TELEFAX: (212) 286-0854 or 286-0082

TELEX: TWX 710-581-4766

INFORMATION FOR SEQ ID NO: 51:

SEQUENCE CHARACTERISTICS:

LENGTH: 12

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

HYPOTHETICAL: NO

US-08-822-586-51

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 915 TGGTCTTTGCC 925
Db 1 TGGGCATTGCC 11

RESULT 576

US-09-013-092-24/c
; Sequence 24, Application US/09013092
; Patent No. 6017733
; GENERAL INFORMATION:
; APPLICANT: REPP, Mitchell E.

TITLE OF INVENTION: IMPAIRED DOMINANT SELECTABLE MARKER

TITLE OF INVENTION: SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT

TITLE OF INVENTION: OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR

TITLE OF INVENTION: SYSTEMS COMPRISING SAME

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS

STREET: P.O. Box 1404

CITY: Alexandria

STATE: Virginia

COUNTRY: United States

ZIP: 22313-1404

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/013,092
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/147,696
FILING DATE: 03-NOV-1993
APPLICATION NUMBER: US 07/977,691
FILING DATE: 13-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-010
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
MOLECULE TYPE: linear
TOPOLOGY: DNA (genomic)
US-09-013-092-24

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 949 TTAATGATCG 959
DB 12 TTAATTAATCG 2

RESULT 577
US-09-038-217A-14/c
Sequence 14, Application US/09038217A
Patent No. 6025196
GENERAL INFORMATION:
APPLICANT: Sladek, Frances M.
APPLICANT: Zhong, Weimin
APPLICANT: Darnell, Jr., James F.
TITLE OF INVENTION: LIVER ENRICHED TRANSCRIPTION FACTOR
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: David A. Jackson, Esq.
STREET: 411 Hackensack Ave, Continental Plaza, 4th
STREET: Floor
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM: disk
MEDIUM TYPE: Floppy
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,217A
FILING DATE: March 11, 1998
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-0308
TELEPHONE: 201-487-5800
TELEFAX: 201-343-1684
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "HNF-4 Consensus"
HYPOTHETICAL: YES
US-09-038-217A-14

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 54.5%; Pred. No. 3e+02;
Matches 6; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 915 TGCTCTTTGCC 925
DB 11 TGRMCYTWCMM 1

RESULT 578
US-08-874-825-84
Sequence 84, Application US/08874825
Patent No. 6057101
GENERAL INFORMATION:
APPLICANT: Nandabalan, Krishnan
APPLICANT: Rothberg, Jonathan
APPLICANT: Yang, Meijia
APPLICANT: Knight, James
APPLICANT: Kalbfleisch, Theodore
TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF
TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS
TITLE OF INVENTION: AND IDENTIFICATION OF INHIBITORS OF THESE INTERACTORS
NUMBER OF SEQUENCES: 122
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036/2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/874,825
FILING DATE: 13-JUN-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/663,824
FILING DATE: 14-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Misrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-045
TELEPHONE: 212-790-9090
TELEFAX: 212-869-8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 84:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-874-825-84

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCAT 944

Db	1	CGCGTCTTCAT	11
RESULT 579	US-08-874-825-85	US-08-874-825-85	
	Sequence 85, Application US/08874825	Sequence 85, Application US/08874825	
	Patent No. 6057101	Patent No. 6057101	
	GENERAL INFORMATION:	GENERAL INFORMATION:	
	APPLICANT: Nandabalan, Krishnan	APPLICANT: Nandabalan, Krishnan	
	APPLICANT: Rothberg, Jonathan	APPLICANT: Rothberg, Jonathan	
	APPLICANT: Yang, Meijia	APPLICANT: Yang, Meijia	
	APPLICANT: Knight, James	APPLICANT: Knight, James	
	APPLICANT: Kalbfleisch, Theodore	APPLICANT: Kalbfleisch, Theodore	
	TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF	TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF	
	TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS	TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS	
	TITLE OF INVENTION: AND IDENTIFICATION OF INHIBITORS OF THESE INTERACTORS	TITLE OF INVENTION: AND IDENTIFICATION OF INHIBITORS OF THESE INTERACTORS	
	NUMBER OF SEQUENCES: 122	NUMBER OF SEQUENCES: 122	
	CORRESPONDENCE ADDRESS:	CORRESPONDENCE ADDRESS:	
	ADDRESSEE: Pennie & Edmonds	ADDRESSEE: Pennie & Edmonds	
	STREET: 1155 Avenue of the Americas	STREET: 1155 Avenue of the Americas	
	CITY: New York	CITY: New York	
	STATE: NY	STATE: NY	
	COUNTRY: USA	COUNTRY: USA	
	ZIP: 10036/2711	ZIP: 10036/2711	
	COMPUTER READABLE FORM:	COMPUTER READABLE FORM:	
	MEDIUM TYPE: Diskette	MEDIUM TYPE: Diskette	
	COMPUTER: IBM Compatible	COMPUTER: IBM Compatible	
	OPERATING SYSTEM: DOS	OPERATING SYSTEM: DOS	
	SOFTWARE: FastSeq version 2.0	SOFTWARE: FastSeq version 2.0	
	CURRENT APPLICATION DATA:	CURRENT APPLICATION DATA:	
	APPLICATION NUMBER: US/08/874,825	APPLICATION NUMBER: US/08/874,825	
	FILING DATE: 13-JUN-1997	FILING DATE: 13-JUN-1997	
	CLASSIFICATION: 435	CLASSIFICATION: 435	
	PRIOR APPLICATION DATA:	PRIOR APPLICATION DATA:	
	APPLICATION NUMBER: 08/663,824	APPLICATION NUMBER: 08/663,824	
	FILING DATE: 14-JUN-1996	FILING DATE: 14-JUN-1996	
	ATTORNEY/AGENT INFORMATION:	ATTORNEY/AGENT INFORMATION:	
	NAME: Misrock, S. Leslie	NAME: Misrock, S. Leslie	
	REGISTRATION NUMBER: 18,972	REGISTRATION NUMBER: 18,972	
	REFERENCE/DOCKET NUMBER: 7934-045	REFERENCE/DOCKET NUMBER: 7934-045	
	TELEPHONE: 212-790-9090	TELEPHONE: 212-790-9090	
	TELEFAX: 212-869-8864	TELEFAX: 212-869-8864	
	TELEX: 66141 PENNIE	TELEX: 66141 PENNIE	
	INFORMATION FOR SEQ ID NO: 85:	INFORMATION FOR SEQ ID NO: 85:	
	SEQUENCE CHARACTERISTICS:	SEQUENCE CHARACTERISTICS:	
	LENGTH: 12 base pairs	LENGTH: 12 base pairs	
	TYPE: nucleic acid	TYPE: nucleic acid	
	STRANDEDNESS: single	STRANDEDNESS: single	
	TOPOLOGY: linear	TOPOLOGY: linear	
	MOLECULE TYPE: DNA	MOLECULE TYPE: DNA	
	US-08-874-825-85	US-08-874-825-85	
Query Match	10.7%;	Score 7.8; DB 1; Length 12;	
Best Local Similarity	81.8%;	Pred. No. 3e+02;	
Matches	9; Conservative	0; Mismatches	2; Indels
	Gaps	0; Gaps	0;
Qy	934	CTCCTCTTCAT	944
Db	1	CTAGTCTTCAT	11
RESULT 580	US-08-884-324-6/c	US-08-884-324-6/c	
	Sequence 6, Application US/08884324	Sequence 6, Application US/08884324	
	Patent No. 6060283	Patent No. 6060283	
	GENERAL INFORMATION:	GENERAL INFORMATION:	
	APPLICANT: Takatori OKURA	APPLICANT: Takatori OKURA	
	APPLICANT: Kakuji TORIGOE	APPLICANT: Kakuji TORIGOE	
	APPLICANT: Masahi KURIMOTO	APPLICANT: Masahi KURIMOTO	
	TITLE OF INVENTION: GENOMIC DNA ENCODING A POLYPEPTIDE CAPABLE	TITLE OF INVENTION: GENOMIC DNA ENCODING A POLYPEPTIDE CAPABLE	
	TITLE OF INVENTION: OF INDUCING THE PRODUCTION OF INTERFERON-	TITLE OF INVENTION: OF INDUCING THE PRODUCTION OF INTERFERON-	
	NUMBER OF SEQUENCES: 56	NUMBER OF SEQUENCES: 56	
	CORRESPONDENCE ADDRESS:	CORRESPONDENCE ADDRESS:	
	ADDRESSEE: Popovich & Wiles, P.A.	ADDRESSEE: Popovich & Wiles, P.A.	
	STREET: 80 S. 8th Street, Suite 1902	STREET: 80 S. 8th Street, Suite 1902	
	CITY: Minneapolis	CITY: Minneapolis	
	STATE: MN	STATE: MN	
	COUNTRY: USA	COUNTRY: USA	
	ZIP: 55402	ZIP: 55402	
	COMPUTER READABLE FORM:	COMPUTER READABLE FORM:	
	MEDIUM TYPE: Floppy disk	MEDIUM TYPE: Floppy disk	
	COMPUTER: IBM PC compatible	COMPUTER: IBM PC compatible	
	OPERATING SYSTEM: PC-DOS/MS-DOS	OPERATING SYSTEM: PC-DOS/MS-DOS	
	SOFTWARE: Patent in Release #1.0, Version #1.30	SOFTWARE: Patent in Release #1.0, Version #1.30	
	CURRENT APPLICATION DATA:	CURRENT APPLICATION DATA:	
	APPLICATION NUMBER: US/08/884,324	APPLICATION NUMBER: US/08/884,324	
	FILING DATE:	FILING DATE:	
	CLASSIFICATION: 435	CLASSIFICATION: 435	
	PRIOR APPLICATION DATA:	PRIOR APPLICATION DATA:	
	APPLICATION NUMBER: JP 185,305/96	APPLICATION NUMBER: JP 185,305/96	
	FILING DATE: 27-JUN-1996	FILING DATE: 27-JUN-1996	
	ATTORNEY/AGENT INFORMATION:	ATTORNEY/AGENT INFORMATION:	
	NAME: BROWDY, Roger L.	NAME: BROWDY, Roger L.	
	REGISTRATION NUMBER: 25,618	REGISTRATION NUMBER: 25,618	
	REFERENCE/DOCKET NUMBER: OKURA=1	REFERENCE/DOCKET NUMBER: OKURA=1	
	TELEPHONE: 202-628-5197	TELEPHONE: 202-628-5197	
	TELEFAX: 202-737-3528	TELEFAX: 202-737-3528	
	INFORMATION FOR SEQ ID NO: 6:	INFORMATION FOR SEQ ID NO: 6:	
	SEQUENCE CHARACTERISTICS:	SEQUENCE CHARACTERISTICS:	
	LENGTH: 12 base pairs	LENGTH: 12 base pairs	
	TYPE: nucleic acid	TYPE: nucleic acid	
	STRANDEDNESS: double	STRANDEDNESS: double	
	TOPOLOGY: linear	TO	

```
/ APPLICATION NUMBER: US/08/480,173A
/ FILING DATE: 07-JUN-1995
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Popovich, Thomas E
/ REGISTRATION NUMBER: 30,099
/ REFERENCE/DOCKET NUMBER: MED1003USD4
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 612-334-8991
/ TELEFAX: 612-334-8994
/ INFORMATION FOR SEQ ID NO: 15:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (synthetic)
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: 1..12
/ OTHER INFORMATION: /note= "Adapter sequence results
/ OTHER INFORMATION: from oligonucleotide duplex formation with nucleotides 5-16 c
/ OTHER INFORMATION: SEQ ID NO: 16"
US-08-480-173A-15

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 912 CTTTGCTCTTT 922
Db 1 CTTAGTCTTT 11

RESULT 582
US-08-881-037-79
/ Sequence 79, Application US/08881037
/ Patent No. 6080588
/ GENERAL INFORMATION:
/ APPLICANT: Klick, Gary D.
/ APPLICANT: Swanson, Patrick C.
/ TITLE OF INVENTION: DNA BINDING ANTIBODIES
/ NUMBER OF SEQUENCES: 113
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Morrison & Foerster
/ STREET: 755 Page Mill Road
/ CITY: Palo Alto
/ STATE: CA
/ COUNTRY: USA
/ ZIP: 94304-1018
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/881,037
/ FILING DATE: 23-JUN-1997
/ CLASSIFICATION: 530
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/443,540
/ FILING DATE: 18-MAY-1995
/ CLASSIFICATION: 530
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kanski, Antoinette F.
/ REGISTRATION NUMBER: 34,202
/ REFERENCE/DOCKET NUMBER: 203442110710
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (650) 813-5600
/ TELEFAX: (650) 494-0792
/ TELE:
/ INFORMATION FOR SEQ ID NO: 79:
/ SEQUENCE CHARACTERISTICS:
```

```
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: 4..9
/ OTHER INFORMATION: /note= "Portion of the germline
/ OTHER INFORMATION: gene incorporated into the CDR3 construct"
US-08-881-037-79

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 955 TATCGGTACCA 965
Db 1 TAGGGCTACCA 11

RESULT 583
US-08-663-824-84
/ Sequence 84, Application US/08663824
/ Patent No. 6083693
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
/ INTERACTIONS THAT OCCUR IN POPULATIONS
/ FILE REFERENCE: 7934-006
/ CURRENT APPLICATION NUMBER: US/08/663,824
/ CURRENT FILING DATE: 1996-06-14
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 84
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: linker
US-08-663-824-84

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCAT 944
Db 1 CGGCTCTTCAT 11

RESULT 584
US-08-663-824-85
/ Sequence 85, Application US/08663824
/ Patent No. 6083693
/ GENERAL INFORMATION:
/ APPLICANT: Nandabalan, Krishnan
/ APPLICANT: Rothberg, Jonathan
/ TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
/ INTERACTIONS THAT OCCUR IN POPULATIONS
/ FILE REFERENCE: 7934-006
/ CURRENT APPLICATION NUMBER: US/08/663,824
/ CURRENT FILING DATE: 1996-06-14
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 85
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: linker
US-08-663-824-85
```

```
Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCAT 944
   ||| |||||
Db 1 CTAGTCTTCAT 11

RESULT 585
US-08-959-853-8/c
; Sequence 8, Application US/08959853
; Patent No. 6090553
; GENERAL INFORMATION:
; APPLICANT: Robert S. Matson
; TITLE OF INVENTION: USE OF URACIL-DNA GLYCOSYLASE
; TITLE OF INVENTION: IN GENETIC ANALYSIS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Beckman Instruments, Inc.
; STREET: 2500 Harbor Boulevard
; CITY: Fullerton
; STATE: California
; ZIP: 92834-3100
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: WINDOWS 95 - WORDPERFECT 7.0
; SOFTWARE: ASCII (DOS) TEXT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/959,853
; FILING DATE: herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: P.R. Harder
; REGISTRATION NUMBER: 20,022
; REFERENCE/DOCKET NUMBER: 45D-1566
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (714) 773-6929
; TELEFAX: (714) 773-7936
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-959-853-8

Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 914 TTGGTCTTTCG 924
   ||||| |||
Db 12 TTGGTGTTC 2

RESULT 586
US-08-484-408A-15
; Sequence 15, Application US/08484408A
; Patent No. 6117653
; GENERAL INFORMATION:
; APPLICANT: Thoma, Hans A
; TITLE OF INVENTION: HEPATITIS B SURFACE ANTIGEN VACCINE
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Popovich & Wiles, P.A.
; STREET: 80 S. 8th Street, Suite 1902
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402

Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCAT 944
   ||| |||||
Db 1 CTAGTCTTCAT 11

RESULT 585
US-08-959-853-8/c
; Sequence 8, Application US/08959853
; Patent No. 6090553
; GENERAL INFORMATION:
; APPLICANT: Robert S. Matson
; TITLE OF INVENTION: USE OF URACIL-DNA GLYCOSYLASE
; TITLE OF INVENTION: IN GENETIC ANALYSIS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Beckman Instruments, Inc.
; STREET: 2500 Harbor Boulevard
; CITY: Fullerton
; STATE: California
; ZIP: 92834-3100
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: WINDOWS 95 - WORDPERFECT 7.0
; SOFTWARE: ASCII (DOS) TEXT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/959,853
; FILING DATE: herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: P.R. Harder
; REGISTRATION NUMBER: 20,022
; REFERENCE/DOCKET NUMBER: 45D-1566
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (714) 773-6929
; TELEFAX: (714) 773-7936
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-959-853-8

Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 912 CTTTGGTCTTT 922
   ||||| |||
Db 1 CTTAGATCTTT 11

RESULT 587
US-08-942-406-13
; Sequence 13, Application US/08942406
; Patent No. 6141657
; GENERAL INFORMATION:
; APPLICANT: Rothberg, Jonathan
;               Simpson, John
;               Deem, Michael
; TITLE OF INVENTION: Method for the Determination and
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie and Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/942,406
; FILING DATE: 01-Oct-1997
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/547,214
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Misrock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 7934-015-999
```

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,408A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Popovich, Thomas E
REGISTRATION NUMBER: 30,099
REFERENCE/DOCKET NUMBER: MED1003USD4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-334-8991
TELEFAX: 612-334-8994
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
FEATURE:
NAME/KEY: misc feature
LOCATION: 1.12
OTHER INFORMATION: /note= "Adapter sequence results
from oligonucleotide duplex formation with nucleotides 5-16 o
OTHER INFORMATION: SEQ ID NO: 16"
US-08-484-408A-15

Query Match          10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 912 CTTTGGTCTTT 922
   ||||| |||
Db 1 CTTAGATCTTT 11

RESULT 587
US-08-942-406-13
; Sequence 13, Application US/08942406
; Patent No. 6141657
; GENERAL INFORMATION:
; APPLICANT: Rothberg, Jonathan
;               Simpson, John
;               Deem, Michael
; TITLE OF INVENTION: Method for the Determination and
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie and Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/942,406
; FILING DATE: 01-Oct-1997
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/547,214
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Misrock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 7934-015-999
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE

INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-08-942-406-13

Query Match 10.7%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 943 ATTGGTTTAAAT 953
Db 1 AGTGGCTTAAT 11

RESULT 588

US-09-280-999-24/c

Sequence 24, Application US/09280999
Patent No. 6159730

GENERAL INFORMATION:

APPLICANT: REFF, Mitchell E.

TITLE OF INVENTION: IMPAIRED DOMINANT SELECTABLE MARKER

TITLE OF INVENTION: SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT

TITLE OF INVENTION: OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR

TITLE OF INVENTION: SYSTEMS COMPRISING SAME

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS

STREET: P.O. Box 1404

CITY: Alexandria

STATE: Virginia

COUNTRY: United States

ZIP: 22313-1404

COMPUTER READABLE FORM:

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/280,999

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/013,092

FILING DATE:

APPLICATION NUMBER: US/08/147,696

FILING DATE: 03-NOV-1993

APPLICATION NUMBER: US 07/977,691

FILING DATE: 13-NOV-1992

ATTORNEY/AGENT INFORMATION:

NAME: Teskin, Robin L.

REGISTRATION NUMBER: 35,030

REFERENCE/DOCKET NUMBER: 012712-010

TELECOMMUNICATION INFORMATION:

TELEPHONE: (703) 836-6620

TELEFAX: (703) 836-2021

INFORMATION FOR SEQ ID NO: 24:

SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-09-280-999-24

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 949 TTAATGTATCG 959
Db 12 TTAATTAATCG 2

RESULT 589

US-09-322-617-13

Sequence 13, Application US/09322617

Patent No. 6231812

GENERAL INFORMATION:

APPLICANT: Rothberg, Jonathan

APPLICANT: Deem, Michael

APPLICANT: Simpson, John

TITLE OF INVENTION: Method for the Determination and

TITLE OF INVENTION: Classification of DNA Sequences in a Sample Without

TITLE OF INVENTION: Sequencing

NUMBER OF SEQUENCES: 59

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie and Edmonds

STREET: 1155 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10036-2711

COMPUTER READABLE FORM:

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/322,617

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/547,214

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Misrock, S. Leslie

REGISTRATION NUMBER: 18,872

REFERENCE/DOCKET NUMBER: 7934-015-999

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212)-790-9090

TELEFAX: (212)-869-8864

TELEX: 66441 PENNIE

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

US-09-322-617-13

Query Match

10.7%; Score 7.8; DB 1; Length 12;

Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 943 ATTGGTTTAAAT 953
Db 1 AGTGGCTTAAT 11

RESULT 590

US-09-281-418-71/c

Sequence 71, Application US/09281418

Patent No. 6287769

GENERAL INFORMATION:

APPLICANT: Inoue, Takakazu

TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F

```
; TITLE OF INVENTION: agent, Method of Assaying Microorganisms, Method of Analyzing Microorganisms, Method of Assaying Contaminant
; FILE REFERENCE: 9982-7
; CURRENT APPLICATION NUMBER: US/09/281,418
; EARLIER FILING DATE: 1999-03-30
; EARLIER FILING DATE: 1998-03-31
; EARLIER FILING DATE: 1998-03-31
; EARLIER FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 216
; SEQ ID NO 71
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-281-418-71

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 929 TATCCCTCCTC 939
   |||||
Db 11 TATTCCTGCTC 1

RESULT 591
US-09-417-455-28/c
; Sequence 28, Application US/09417455
; Patent No. 6294655
; GENERAL INFORMATION:
; APPLICANT: Ford, John
; APPLICANT: Pace, Ann
; TITLE OF INVENTION: A NOVEL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF
; FILE REFERENCE: 28110/36328
; CURRENT APPLICATION NUMBER: US/09/417,455
; CURRENT FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: US 09/348,942
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: PCT/US99/04291
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: US 09/287,210
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: US 09/251,370
; PRIOR FILING DATE: 1999-02-17
; PRIOR APPLICATION NUMBER: US 09/229,591
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 09/127,698
; PRIOR FILING DATE: 1998-07-31
; PRIOR APPLICATION NUMBER: US 09/099,818
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: US 09/082,364
; PRIOR FILING DATE: 1998-05-20
; PRIOR APPLICATION NUMBER: US 09/079,909
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: US 09/055,010
; PRIOR FILING DATE: 1998-04-03
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: TBD
US-09-417-455-28

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTTTGCTTTT 929
```

```
Db 12 CCTTACCTTTT 2

RESULT 592
US-09-580-923-28
; Sequence 28, Application US/09580923
; Patent No. 6319672
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 03804.0138-01
; CURRENT APPLICATION NUMBER: US/09/580,923
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; PRIOR FILING DATE: 1995-11-08
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide
US-09-580-923-28

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 925 CTTTATCCCT 935
   |||||
Db 2 CTTTATCCCT 12

RESULT 593
US-08-849-567A-42
; Sequence 42, Application US/08849567A
; Patent No. 6326174
; GENERAL INFORMATION:
; APPLICANT: Joyce, Gerald F.
; APPLICANT: Breaker, Ronald R.
; TITLE OF INVENTION: ENZYMAIC DNA MOLECULES
; FILE REFERENCE: SCRI9438
; CURRENT APPLICATION NUMBER: US/08/849,567A
; CURRENT FILING DATE: 1997-08-25
; PRIOR APPLICATION NUMBER: PCT/US95/15580
; PRIOR FILING DATE: 1995-12-01
; PRIOR APPLICATION NUMBER: 08/472,194
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/349,023
; PRIOR FILING DATE: 1994-12-02
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: substrate
; OTHER INFORMATION: binding region
US-08-849-567A-42

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
```

```
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 952 ATGTATCGCTA 962
    |||||
Db 2 ATGTGACGCTA 12

RESULT 594
US-09-311-079-6/c
; Sequence 6, Application US/09311079
; Patent No. 6331618
; GENERAL INFORMATION:
; APPLICANT: Bloch, William
; APPLICANT: Werner, William E.
; APPLICANT: Egholm, Michael
; APPLICANT: Myers, Rene L.
; TITLE OF INVENTION: Compositions of Solvents and High
; FILE REFERENCE: 4444
; CURRENT APPLICATION NUMBER: US/09/311,079
; CURRENT FILING DATE: 1999-05-13
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Test Sequence
US-09-311-079-6

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 907 ATTTCTTTGG 917
    |||||
Db 11 ATCATCTTTGG 1

RESULT 595
US-09-348-942-28/c
; Sequence 28, Application US/09348942
; Patent No. 6337072
; GENERAL INFORMATION:
; APPLICANT: John Ford
; TITLE OF INVENTION: A NOVEL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF
; FILE REFERENCE: 28110/35801
; CURRENT APPLICATION NUMBER: US/09/348,942
; CURRENT FILING DATE: 1999-07-07
; EARLIER APPLICATION NUMBER: PCT/US99/04291
; EARLIER FILING DATE: 1999-04-05
; EARLIER APPLICATION NUMBER: US 09/287,210
; EARLIER FILING DATE: 1999-04-05
; EARLIER APPLICATION NUMBER: US 09/251,370
; EARLIER FILING DATE: 1999-02-17
; EARLIER APPLICATION NUMBER: US 09/229,591
; EARLIER FILING DATE: 1999-01-13
; EARLIER APPLICATION NUMBER: US 09/127,698
; EARLIER FILING DATE: 1998-07-31
; EARLIER APPLICATION NUMBER: US 09/099,818
; EARLIER FILING DATE: 1998-06-19
; EARLIER APPLICATION NUMBER: US 09/082,364
; EARLIER FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: US 09/079,909
; EARLIER FILING DATE: 1998-05-15
; EARLIER APPLICATION NUMBER: US 09/055,010
; EARLIER FILING DATE: 1998-04-03
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
; LENGTH: 12
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: TBD
US-09-348-942-28

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTTTGCCTTTT 929
    |||||
Db 12 CCTTACCTTTT 2

RESULT 596
US-09-203-231B-17
; Sequence 17, Application US/09203231B
; Patent No. 6355423
; GENERAL INFORMATION:
; APPLICANT: Rothberg, Jonathan M
; APPLICANT: Nallur, Girish N
; APPLICANT: Hu, Xinghua
; TITLE OF INVENTION: Methods and Devices for Measuring
; FILE REFERENCE: 7934-052
; CURRENT APPLICATION NUMBER: US/09/203,231B
; CURRENT FILING DATE: 1998-12-02
; PRIOR APPLICATION NUMBER: 60/105,305
; PRIOR FILING DATE: 1997-12-03
; NUMBER OF SEQ ID NOS: 88
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-203-231B-17

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 943 ATTGGTTTAAT 953
    |||||
Db 1 AGTGGCTTAAT 11

RESULT 597
US-09-231-303-84
; Sequence 84, Application US/09231303
; Patent No. 6395478
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
; TITLE OF INVENTION: INTERACTIONS THAT OCCUR IN POPULATIONS AND
; TITLE OF INVENTION: IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
; FILE REFERENCE: 7934-087
; CURRENT APPLICATION NUMBER: US/09/231,303
; CURRENT FILING DATE: 1999-01-12
; EARLIER APPLICATION NUMBER: 08/663,824
; EARLIER FILING DATE: 1996-06-14
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 84
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-231-303-84
```


Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCAT 944
Db 1 CGCGTCTTCAT 11

RESULT 598

US-09-231-303-85
; Sequence 85, Application US/09231303
; Patent No. 6395478
; GENERAL INFORMATION:
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Rothberg, Jonathan
; TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF PROTEIN-PROTEIN
; INTERACTIONS THAT OCCUR IN POPULATIONS AND
; TITLE OF INVENTION: IDENTIFICATION OF INHIBITORS OF THESE INTERACTIONS
; FILE REFERENCE: 7934-087
; CURRENT APPLICATION NUMBER: US/09/231,303
; CURRENT FILING DATE: 1999-01-12
; EARLIER APPLICATION NUMBER: 08/663,824
; EARLIER FILING DATE: 1996-06-14
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 85
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: linker
US-09-231-303-85

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 934 CTCCTCTTCAT 944
Db 1 CTAGTCTTCAT 11

RESULT 599

US-08-927-165A-16/c
; Sequence 16, Application US/08927165A
; Patent No. 6410226
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Holloman, William K.
; APPLICANT: Rice, Michael C.
; APPLICANT: Smith, Sheryl T.
; APPLICANT: Shu, Zhigang
; TITLE OF INVENTION: Mammalian and Human Rec2
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESS: Kimeragen, Inc.
; STREET: 300 Pheasant Run
; CITY: Newtown
; STATE: PA
; COUNTRY: USA
; ZIP: 18940
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/927,165A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:

; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansburg, Daniel
; REGISTRATION NUMBER: 36156
; REFERENCE/DOCKET NUMBER: 7991-010-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-504-4444
; TELEFAX: 215-504-4545
; TELEX:
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-927-165A-16

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 926 TTTTATCCCTC 936
Db 12 TTTTCTCTC 2

RESULT 600

US-09-751-561-13
; Sequence 13, Application US/09751561
; Patent No. 6418382
; GENERAL INFORMATION:
; APPLICANT: Rothberg, Jonathan
; APPLICANT: Deem, Michael
; APPLICANT: Simpson, John
; TITLE OF INVENTION: Method for the Determination and
; TITLE OF INVENTION: Classification of DNA Sequences in a Sample Without
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie and Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/751,561
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/547,214
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mirock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 7934-015-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)-790-9090
; TELEFAX: (212)-869-8864
; TELEX: 66441 PENNIE
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-09-751-561-13

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 943 ATTGGTTTAAAT 953
Db 1 AGTGGCTTAAAT 11

RESULT 601
US-09-457-626-28/c
Sequence 28, Application US/09457626
Patent No. 6426191
GENERAL INFORMATION:
APPLICANT: Ford, John
APPLICANT: Pace, Ann
TITLE OF INVENTION: A NOVEL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF
FILE REFERENCE: 28110/36010
CURRENT APPLICATION NUMBER: US/09/457,626
CURRENT FILING DATE: 1999-12-08
EARLIER APPLICATION NUMBER: US 09/417,455
EARLIER FILING DATE: 1999-10-13
EARLIER APPLICATION NUMBER: US 09/348,942
EARLIER FILING DATE: 1999-07-07
EARLIER APPLICATION NUMBER: PCT/US99/04291
EARLIER FILING DATE: 1999-04-05
EARLIER APPLICATION NUMBER: US 09/287,210
EARLIER FILING DATE: 1999-04-05
EARLIER APPLICATION NUMBER: US 09/251,370
EARLIER FILING DATE: 1999-02-17
EARLIER APPLICATION NUMBER: US 09/229,591
EARLIER FILING DATE: 1999-01-13
EARLIER APPLICATION NUMBER: US 09/127,698
EARLIER FILING DATE: 1998-07-31
EARLIER APPLICATION NUMBER: US 09/099,818
EARLIER FILING DATE: 1998-06-19
EARLIER APPLICATION NUMBER: US 09/082,364
EARLIER FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: US 09/079,909
EARLIER FILING DATE: 1998-05-15
EARLIER APPLICATION NUMBER: US 09/055,010
EARLIER FILING DATE: 1998-04-03
NUMBER OF SEQ ID NOS: 30
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 28
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: TBD
US-09-457-626-28

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 919 CTTTGCTTTT 929
Db 12 CCTTACCTTTT 2

RESULT 602
US-09-724-385-13
Sequence 13, Application US/09724385
Patent No. 6432361
GENERAL INFORMATION:
APPLICANT: Rothberg, Jonathan
Deem, Michael
Simpson, John
TITLE OF INVENTION: Method for the Determination and
NUMBER OF SEQUENCES: 59
CURRENT APPLICATION DATA:
CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie and Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/724,385
FILING DATE: 28-No. 6432361-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/322,617
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7934-015-999
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)-790-9090
TELEFAX: (212)-869-8864
TELEX: 66441 PENNIE
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-724-385-13

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 943 ATTGGTTTAAAT 953
Db 1 AGTGGCTTAAAT 11

RESULT 603
US-08-450-363-41/c
Sequence 41, Application US/08450363
Patent No. 6438434
GENERAL INFORMATION:
APPLICANT: Saiko HOSOKAWA
APPLICANT: Toshiaki TAGAWA
APPLICANT: Yoko HIRAKAWA
APPLICANT: No. 6436434ihiko ITO
APPLICANT: Kazuhiro NAGAIKE
TITLE OF INVENTION: Human Monoclonal Antibody
SPECIFICALLY BINDING TO SURFACE ANTIGEN OF CANCER
TITLE OF INVENTION: Cell Membrane
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wenderoth, Lind & Ponack
STREET: 805 Fifteenth Street, N.W., #700
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 500 kb
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/450,363

;; FILING DATE: May 25, 1995
;; CLASSIFICATION: 530
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/360,125
;; FILING DATE: December 20, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/905,534
;; FILING DATE: June 29, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warren M. Cheek, Jr.
;; REGISTRATION NUMBER: 33,367
;; REFERENCE/DOCKET NUMBER:
;; TELEPHONE: 202-371-8850
;; TELEFAX:
;; TELEX:
;; INFORMATION FOR SEQ ID NO: 41:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 12 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
;; HYPOTHETICAL:
;; ANTI-SENSE:
;; FRAGMENT TYPE:
;; ORIGINAL SOURCE:
;; ORGANISM:
;; STRAIN:
;; INDIVIDUAL ISOLATE:
;; DEVELOPMENTAL STAGE:
;; HAPLOTYPE:
;; TISSUE TYPE:
;; CELL TYPE: Hybridoma producing human antibody 1-3-1
;; CELL LINE:
;; ORGANELLE:
;; IMMEDIATE SOURCE:
;; LIBRARY:
;; CLONE:
;; POSITION IN GENOME:
;; CHROMOSOME/SEGMENT:
;; MAP POSITION:
;; UNITS:
;; FEATURE:
;; NAME/KEY:
;; LOCATION:
;; IDENTIFICATION METHOD:
;; OTHER INFORMATION:
;; PUBLICATION INFORMATION:
;; AUTHORS:
;; TITLE:
;; JOURNAL:
;; VOLUME:
;; ISSUE:
;; PAGES:
;; DATE:
;; DOCUMENT NUMBER:
;; FILING DATE:
;; PUBLICATION DATE:
;; RELEVANT RESIDUES IN SEQ ID NO:
US-08-450-363-41

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 905 TCATTTCCTT 915
Db 11 TCACGTCTTT 1

RESULT 604
US-09-757-528-13

;; Sequence 13, Application US/09757528
;; Patent No. 6453245
;; GENERAL INFORMATION:
;; APPLICANT: Rothberg, Jonathan
;; Deem, Michael
;; Simpson, John
;; TITLE OF INVENTION: Method for the Determination and
;; NUMBER OF SEQUENCES: 59
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Pennie and Edmonds
;; STREET: 1155 Avenue of the Americas
;; CITY: New York
;; STATE: New York
;; COUNTRY: USA
;; ZIP: 10036-2711
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/757,528
;; FILING DATE: 10-Jan-2001
;; CLASSIFICATION: <Unknown>
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/547,214
;; FILING DATE: <Unknown>
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Mirock, S. Leslie
;; REGISTRATION NUMBER: 18,872
;; REFERENCE/DOCKET NUMBER: 7934-015-999
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212)-790-9090
;; TELEFAX: (212)-869-8864
;; TELEX: 66441 PENNIE
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 12 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
;; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-757-528-13

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 943 ATTGGTTTAA 953
Db 1 AGTGGCTTAA 11

RESULT 605
US-09-059-625-31/c
;; Sequence 31, Application US/09059625
;; Patent No. 6486303
;; GENERAL INFORMATION:
;; APPLICANT: Moyle, William R
;; TITLE OF INVENTION: Improved Method For Making Hormone
;; TITLE OF INVENTION: Heterodimers
;; NUMBER OF SEQUENCES: 90
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Richard R. Muccino
;; STREET: 758 Springfield Avenue
;; CITY: Summit
;; STATE: NJ
;; COUNTRY: US
;; ZIP: 07901
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/059,625
; FILING DATE: 14-APR-1998
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Muccino, Richard R.
; REGISTRATION NUMBER: 32,538
; REFERENCE/DOCKET NUMBER: UMD1-040
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908-273-4988
; TELEFAX: 908-273-4679
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-09-059-625-31

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      948 TTTAATGATC 958
Db      11 TTTAAGGATC 1

RESULT 606
US-09-447-034-14/c
; Sequence 14, Application US/09447034
; Patent No. 6500672
; GENERAL INFORMATION:
; APPLICANT: Sladek, Frances M.
; Darnell, Jr., James F.
; Zhong, Weimin
; TITLE OF INVENTION: LIVER ENRICHED TRANSCRIPTION FACTOR
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David A. Jackson, Esq.
; STREET: 411 Hackensack Ave, Continental Plaza, 4th
; Floor
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/447,034
; FILING DATE: 22-NOV-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,217
; FILING DATE: March 11, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-030B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-487-5800
; TELEFAX: 201-343-1684
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "HNF-4 Consensus"
; HYPOTHETICAL: YES
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-447-034-14

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 54.5%; Pred. No. 3e+02;
Matches 6; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      915 TGGTCTTTGCC 925
Db      11 TGRMCYTWGCM 1

RESULT 607
US-09-576-008-28/c
; Sequence 28, Application US/09576008
; Patent No. 6541623
; GENERAL INFORMATION:
; APPLICANT: Ford, John
; APPLICANT: Ho, Alice Suk-Yue
; APPLICANT: Pace, Ann
; TITLE OF INVENTION: A NOVEL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF
; FILE REFERENCES: 28110/36456
; CURRENT APPLICATION NUMBER: US/09/576,008
; CURRENT FILING DATE: 2000-05-22
; PRIOR APPLICATION NUMBER: US 09/523,552
; PRIOR FILING DATE: 2000-03-10
; PRIOR APPLICATION NUMBER: US 09/457,626
; PRIOR FILING DATE: 1999-12-08
; PRIOR APPLICATION NUMBER: US 09/417,455
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: US 09/348,942
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: PCT/US99/04291
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: US 09/287,210
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: US 09/251,370
; PRIOR FILING DATE: 1999-02-17
; PRIOR APPLICATION NUMBER: US 09/229,591
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 09/127,698
; PRIOR FILING DATE: 1998-07-31
; PRIOR APPLICATION NUMBER: US 09/099,818
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: US 09/082,364
; PRIOR FILING DATE: 1998-05-20
; PRIOR APPLICATION NUMBER: US 09/079,909
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: US 09/055,010
; PRIOR FILING DATE: 1998-04-03
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: TBD
; US-09-576-008-28

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      919 CTTTGCTTTT 929
Db      12 CCTTACCTTT 2
```

RESULT 608

US-09-512-563C-57/C
; Sequence 57, Application US/09512563C
; Patent No. 6579969
; GENERAL INFORMATION:
; APPLICANT: Saus, Juan
; TITLE OF INVENTION: Goodpasture Binding Protein
; FILE REFERENCE: 98-723-A
; CURRENT APPLICATION NUMBER: US/09/512,563C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: 60/121,483
; PRIOR FILING DATE: 1999-02-24
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 57
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-512-563C-57

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 955 TATCGCTACCA 965

Db 11 TAGGGCTACCA 1

RESULT 609

US-09-874-601-136
; Sequence 136, Application US/09874601
; Patent No. 6632057
; GENERAL INFORMATION:
; APPLICANT: LEWIN, ALFRED S.
; APPLICANT: SHAW, LYNN C.
; APPLICANT: GRANT, MARIA B.
; TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
; FILE REFERENCE: 4300.014100
; CURRENT APPLICATION NUMBER: US/09/874,601
; CURRENT FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 09/063,667
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/046,147
; PRIOR FILING DATE: 1997-05-09
; PRIOR APPLICATION NUMBER: 60/044,492
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 136
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(7)
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-136

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 63.6%; Pred. No. 3e+02;
Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 961 TACCAACGGTG 971

Db 2 UGCUACGGUG 12

RESULT 610

US-09-874-601-137

; Sequence 137, Application US/09874601
; Patent No. 6632057
; GENERAL INFORMATION:
; APPLICANT: LEWIN, ALFRED S.
; APPLICANT: SHAW, LYNN C.
; APPLICANT: GRANT, MARIA B.
; TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
; FILE REFERENCE: 4300.014100
; CURRENT APPLICATION NUMBER: US/09/874,601
; CURRENT FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 09/063,667
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/046,147
; PRIOR FILING DATE: 1997-05-09
; PRIOR APPLICATION NUMBER: 60/044,492
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 137
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(7)
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-137

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 63.6%; Pred. No. 3e+02;
Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 961 TACCAACGGTG 971

Db 2 UGCUACGGUG 12

RESULT 611

PCT-US93-11702-4/C
; Sequence 4, Application PC/TUS9311702
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: IMPROVED METHOD FOR
; TITLE OF INVENTION: AMPLIFICATION OF
; TITLE OF INVENTION: TARGETED SEGMENTS OF
; TITLE OF INVENTION: NUCLEIC ACID USING
; TITLE OF INVENTION: NESTED POLYMERASE CHAIN
; TITLE OF INVENTION: REACTION
; NUMBER OF SEQUENCES: 22
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch,
; MEDIUM TYPE: 1.0 MB
; COMPUTER: Macintosh
; OPERATING SYSTEM: Macintosh 6.0
; SOFTWARE: PATENTIN RELEASE #1.0,
; SOFTWARE: VERSION #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/11702
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US93-11702-4

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 950 TAATGTATCGC 960

Db || |||||
 12 TACGGTATCGC 2

RESULT 612
PCT-US95-05265-22/c
; Sequence 22, Application PC/TUS9505265
; GENERAL INFORMATION:
; APPLICANT: TULARIK, INC.
; TITLE OF INVENTION: TRANSCRIPTION FACTOR-DNA BINDING ASSAY
; NUMBER OF SEQUENCES: 74
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOEACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/05265
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/235,503
; FILING DATE: 29-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Osman, Richard A.
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: FP-59232-PC/RAO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
PCT-US95-05265-22

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 54.5%; Pred. No. 3e+02;
Matches 6; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 915 TGGTCTTTGCC 925
Db 11 TGRMCYTWGM 1

RESULT 613
PCT-US95-05835-1/c
; Sequence 1, Application PC/TUS9505835
; GENERAL INFORMATION:
; APPLICANT: Alexander-Bridges, Maria C.
; APPLICANT: Zhao, Hui-Fen
; TITLE OF INVENTION: INHIBITION OF INSULIN-
; TITLE OF INVENTION: INDUCED ADIPOSIS
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/05835
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/242,409
; FILING DATE: 13 May 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/238001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US95-05835-1

Query Match 10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 929 TATCCCTCCTC 939
Db 11 TTCCCGCCTC 1

RESULT 614
PCT-US95-06379-13/c
; Sequence 13, Application PC/TUS9506379
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Weil, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch 1.44Mb
; COMPUTER: IBM PC
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/06379
; FILING DATE: May 13, 1994
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 44683-PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-278-0400
; TELEFAX: 212-391-0526
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double

```
;
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US95-06379-13

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 932 CCTCTCTCTTC 942
   |||||
Db 12 CCTTCTCTTC 2

RESULT 615
PCT-US95-06704-5/c
; Sequence 5, Application PC/TUS9506704
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: SELECTION OF DIAGNOSTIC
; TITLE OF INVENTION: GENETIC MARKERS IN
; TITLE OF INVENTION: MICROORGANISMS AND USE
; TITLE OF INVENTION: OF A SPECIFIC MARKER
; TITLE OF INVENTION: FOR DETECTION OF
; TITLE OF INVENTION: SALMONELLA
; NUMBER OF SEQUENCES: 22
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.50 INCH
; COMPUTER: MACINTOSH
; OPERATING SYSTEM: MACINTOSH, 6.0
; SOFTWARE: MICROSOFT WORD, 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/06704
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: GEIGER, KATHLEEN W.
; REGISTRATION NUMBER: 35,880
; REFERENCE/DOCKET NUMBER: MD-1068
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US95-06704-5

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 950 TAATGTAATCGC 960
   |||||
Db 12 TACGGTATCGC 2

RESULT 616
5212296-13/c
; Patent No. 5212296
; APPLICANT: DEAN, CAROLINE; HARDER, PATRICIA A.; LETO, KENNETH
; J.; O'KEEFE, DANIEL P.; OMER, CHARLES A.; ROMESSER, JAMES A.
; TEPPERMAN, JAMES M.
; TITLE OF INVENTION: EXPRESSION OF HERBICIDE METABOLIZING
; CYTOCHROMES
; NUMBER OF SEQUENCES: 19
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/569,781
; FILING DATE: 23-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 464,499
; FILING DATE: 12-JAN-1990
; APPLICATION NUMBER: 405,605
; FILING DATE: 11-SEP-1989
```

```
;SEQ ID NO:13:
; LENGTH: 12
5212296-13

Query Match      10.7%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 3e+02;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 900 CCTGGTCATTT 910
   |||||
Db 12 CATGGTCATGT 2

Search completed: October 18, 2004, 14:27:52
Job time : 3 secs
```

This Page Blank (uspio)